<SEC-DOCUMENT>0000950170-24-021183.txt : 20240227
<SEC-HEADER>0000950170-24-021183.hdr.sgml : 20240227
<ACCEPTANCE-DATETIME>20240227161901
ACCESSION NUMBER:		0000950170-24-021183
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240227
DATE AS OF CHANGE:		20240227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822933343
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38792
		FILM NUMBER:		24687037

	BUSINESS ADDRESS:	
		STREET 1:		131 OYSTER POINT BLVD., SUITE 600
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		131 OYSTER POINT BLVD., SUITE 600
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alec-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:alec="http://alector.com/20231231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_f6e80797-f1a0-4a3f-b7ac-8a6d73737f9e" name="dei:EntityCentralIndexKey" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c">0001653087</ix:nonNumeric><ix:nonNumeric id="F_d66bfc5f-9520-4474-a1d5-a87a8fdf835d" name="dei:CurrentFiscalYearEndDate" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric><ix:nonNumeric id="F_212f573b-a35a-4193-8109-9d7f4ed630b3" name="us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend" contextRef="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_2243f1f8-6c2e-4253-84c7-bee7a5b60294" name="dei:DocumentFiscalPeriodFocus" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c">FY</ix:nonNumeric><ix:nonNumeric id="F_8f6db90f-54b3-4b0b-85ee-d8cd007a1398" name="dei:AmendmentFlag" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_59739cf5-7c7b-4790-81b7-25249697bc0e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_24681dae-d59f-43a3-ad73-dee32de8893e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_94e46f7d-4030-4cdd-937b-79e7aa9936e8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_60750fab-7364-4d16-b450-a83cad11cc9e">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alec-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_0b316b30-6fe6-45ed-a034-7a7078c020a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11e15bef-5569-498f-9263-fd8668b4e72c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-22</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0af91d08-2797-49ba-a679-a9d25bb3512d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:AdimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cce98dde-1d02-4f46-a623-794fa3f11385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be19a186-b61e-4093-842b-37a052d70447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_063d5b29-5b06-4630-b2ef-ae848097335d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56217c44-9068-48a9-bd55-ca120578b623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a83cdc-0b37-49af-9a68-60f9ffb64987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb09fe55-8ca8-43e2-8bb6-54b263316207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b15d294-93bc-4f21-877c-2a47962db58d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_340e1b04-fc2d-4614-bea3-759221ffd38e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b63dbca3-4067-43b5-ab54-c12f0d45646c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6321c67-3454-46af-9d81-b479594892c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a89ff33-c725-4439-ad8e-bf3568d41b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90f3186a-3a7c-4ce6-bbc4-af5ab058188b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec43ac9d-d355-4fa2-9bd9-cf8e37006808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5b6de0c-0735-4356-9282-a70e9141c22d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc9dc938-5e3b-488d-998b-8e76468ef770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34b1db7c-6e16-43d3-bd5b-68502507a278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbfb3835-28fe-4139-9939-85de4a95d6c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd74e1af-61b1-488d-8031-e66435e39cdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fcade9bc-91eb-4e33-86f9-9e6dd66a7393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_939b60bd-dbba-49f8-810d-9f58546ab346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ba9b64f-d373-4d84-929c-816017c4d96c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eeb6d5e-07f7-4d7a-9ae5-040a3397c88c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79cee874-ca87-430e-8f98-93d2c63bf411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e1505fa-8544-4458-96c7-53104f4fe63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef477b10-b2f5-419c-9069-8dd0afc677f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95c548cd-02a1-4c12-93cb-ea44937aa4a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_536c635f-d92f-46c9-b598-60cb1e600887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_331414b3-e237-427f-b014-b2fbd7be148d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_799c46d0-304e-442b-87b3-67e31110ef56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0628b57-6af6-4f3a-a678-5f72c4012bd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf80a4f5-ee57-4865-a16e-612cda395dcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bb5d2cb-8240-469c-b215-b0ef522ac46c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe95f1f3-8845-4196-a35b-577d8188b3b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3aa9e816-d1a0-4625-9af0-5128da3a9209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18e12969-87bd-493d-8d25-859c9cbffa99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7151cd96-2161-4092-af10-bd88188169e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1cbc65c-39be-40d5-94a2-085b20c52e97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8df4e45d-5ccf-4447-ac9d-b88b2629cca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6938cb01-3217-495c-940e-68f940751ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c6c34c3-6684-47c0-932c-32afe31b92fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce453676-bced-4bc7-adfc-3a7dc2104ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72e522a3-5366-4e26-836a-dbe1abd68f5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baab8074-6a4c-411b-b481-b273fda9f214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_618c715a-60ae-467c-8c7b-117bc9bc8695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5380031-3260-4626-aa94-6be4667cd0d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53a5db9e-db92-4bd5-a460-a20781d98b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CertificateOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c758acc5-763d-4c36-99d6-c281cf90a70f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a6ec65-ac34-40f3-95e7-bfa2ffab6462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab5bd7aa-9449-45ef-913b-7842f838798d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_781e8b1b-18da-4c56-a6df-8621e45c8fde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e123b7a5-e275-4b05-8fa9-5b78e2f38cf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17714c29-f0b8-4a31-9e58-2bb7319ace3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2ced522-2924-4199-8e43-04ab2c397ba4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e7b91da-0112-404f-9acb-f761639a66b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5221b583-972a-4325-9c52-a770e32fec78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5faa559f-1d59-40e4-a7d3-52eebb14274c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d28c5140-6e95-49fb-9fb1-c9575190d7b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">alec:ChangeInEstimateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3cdfe83-caeb-4047-a450-8e67619a35be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_762e850e-ccde-406e-bb94-80d9fd84a94a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a780de0c-7437-4cda-82c1-96d14ee7da1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb621957-f8bc-47e9-9219-b82401bc112f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a10ce102-5713-4bf0-a2c5-da99484f0103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:UnderwritingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5a08e1c-7661-4242-afc0-5a1579c71846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:UnderwritingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c39aa66-67a0-4bc2-bb2d-dfaf63ec336a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f68b6d3e-af72-4397-a93c-d21976f8b5eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5787191-0ee2-419a-98e0-6bb30e57cb15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e332595b-2812-42e7-8164-9333c6cb735f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_875c92eb-4727-4d07-8257-01fde8082811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd35894d-35dd-488a-bba1-d0a7f771501b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4aa98c31-3185-40ce-8dd2-7ce79a8cd6e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-30</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1f0c7a7-e180-4765-8b37-912035434a8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4fbee25-c222-4832-b8a1-0ed2b6aff01f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52035361-b24c-4755-ad7a-e82a0d8ebc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_666e3ab2-8e5f-48ca-8ffa-0360410c200c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0a79701-f609-4f39-8ea8-fa90332bbbba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eba99dec-98b2-45c0-9d27-7d9f74ea5672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f63097f-fc67-43ad-b6f8-799a51185227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_906aea5b-0c93-441f-993c-a2359ebc1e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d7c568c-73b0-4659-933e-e70332ce56ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0b6fc05-c1a0-4504-91f0-023a1f8c2514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6997d26-1cd1-493e-9c86-be8ab9f39310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e926ae33-adab-44c6-9813-d90466e7d1d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_324a6c7e-62a2-4eaf-a1db-f175723903c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db20ea7a-0049-46f5-a310-e578628c49ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f97232c-f60b-4a4b-b51b-6d2e65356471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52dc5672-fc66-4cee-a898-4ecac0b3d0bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4cbf91d-96bc-43ff-ae3a-304b48be2025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f69c2b26-8b9d-489b-a357-6baf4bc970c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbbafbf6-6ed4-4a1e-81cd-8fc78087cc1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d58b91a6-8565-488e-b02e-ec025dddbb45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3eeb729-bc22-498d-881c-1db3ed88b394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fddc05c2-32c9-4c4e-b1bc-8af85e42859f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88135be7-53d0-4cfa-bfc7-18676d65fe75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16787d87-ace1-4e09-9ce1-9264b6480e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44344e5d-5a1c-404e-8607-c5de69163711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_958166bd-8c6f-438a-9963-ca72620d9960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdbff2fe-671a-4c39-9142-ff03f354ebbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24dffb2c-e6de-4b86-a1a9-787450030b02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85f03d7f-58f4-427b-a31f-ee0c4a55e9ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d33b68e-2d8d-4bba-8c12-cc5befb5c40e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60750fab-7364-4d16-b450-a83cad11cc9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5b536d9-fa13-474e-a41d-356bbdb5ca40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2bb0f40-e78b-430e-9753-abc94b48fdb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67c1d049-46bc-4a4e-bfb5-f558c76ed8e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2f18b21-9cde-4c57-b478-19cc995431ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acc458ea-fb09-43a4-ace2-5afee4642294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7296cb0-df0b-44d4-8629-0d1f54c91d3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ac7c560-3741-425b-922a-fa6377eceda5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b441b445-cd74-4873-a003-e91cd23b0590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54cb7dea-1f14-46b8-a85c-4dea206dca63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:AdimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b020fee9-3aeb-4b54-9981-194d9a106693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef725d3-1855-48f2-ad32-868fd7a56f60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ea8a13b-a850-4902-bc14-e2a26e047915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19b8748c-94f6-4009-ae46-72a683ffb30c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0b4d8d2-f8bb-40b4-9f9f-b389737a0383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_758a9e1c-3654-4bc4-a4b7-e7f816f49088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a87639f8-76eb-442c-be84-1c45bb446983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99484b82-1134-42a5-ab27-b25e9ac34512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb3c4f20-3132-4502-b703-ab8173a141fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc034315-cf03-4581-b437-e478d0086352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70243292-8d4b-4f56-b852-1e89e77c7444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a26230e7-fd18-41d7-8d63-f51a79aa854b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2576a651-9ed1-4183-b092-abc05d49d737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ad7b64a-0330-47d7-be46-238226e3cd18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f007740c-c40f-4489-8fb4-025d2bc6fa15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0473103a-2c31-4a58-83e1-238b77fc08f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46e9ae40-b4f7-48d6-998a-fdae75e33340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c0dae0-748f-402b-8e0c-a163a0ca3e35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AlectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7db9d754-8d91-4ea6-9ab3-778ba4a2b5f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employees"><xbrli:measure>alec:Employees</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:14pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23bad412-c194-449a-a60e-538e93d13a94" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_7e0bc482-fc9e-4c88-be3e-00731abac25d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbfcd3ff-cb28-4742-87a2-1743549de7c0" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76a14c40-1ad1-4c2f-9f98-bdae00bdc32a" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_7cdf628a-1470-4e56-b684-c7f373265c56" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">                     </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23e49932-075e-4808-849d-0323614d039c" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">001-38792</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_175e5d43-d313-45d3-9cc7-e9dd1a1e6d64" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.44%;"/>
    <td style="width:3.74%;"/>
    <td style="width:31.78%;"/>
    <td style="width:2.5%;"/>
    <td style="width:32.54%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0e3abff1-bd69-4555-9df8-2631972b39ec" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_846d2315-632e-4c8c-a68a-cb6a80c7a1b5" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-38792</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_16a72581-0332-4581-b942-ecef2c91a013" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">82-2933343</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(State or other jurisdiction of incorporation)</span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc13c219-323b-4075-9a84-5694465a3c2f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">131 Oyster Point Blvd</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ceb05ba-761c-463d-961d-31054bd12502" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Suite 600</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c034698-0684-47f6-81c6-0cfc9da0e783" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_441d0c45-f743-48cc-8247-5425b51f9389" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b16f006-acc8-4688-b7f6-f54b97602971" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">94080</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dd6265a-e091-4edc-9d0d-da87ef335dc0" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_034353ad-33f8-40f4-9005-9f5ffe3559d4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">231-5660</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> (Former name or former address, if changed since last report)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.5%;"/>
    <td style="width:26.22%;"/>
    <td style="width:40.28%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_dbb56710-bbb0-4377-b18a-f3e5fa77426d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a6901e52-1095-495b-b32e-dfcd86ad70e8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ALEC</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ca6bac6a-da7b-418f-9297-b5e6fc6b8cb8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b1cbbd3-5ef5-4f23-9f4f-404abd5d0861" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb4b5d34-7011-4703-8adb-84803959c0ad" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b50d448-cee2-4cd5-b761-9914f9cf3279" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f75bff1-da7c-4b72-b984-b52cc44df192" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.996%;"/>
    <td style="width:2.14%;"/>
    <td style="width:54.389%;"/>
    <td style="width:1.06%;"/>
    <td style="width:18.996%;"/>
    <td style="width:2.34%;"/>
    <td style="width:2.08%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_648b7a45-3a3b-41f5-afa5-9df471f9e9cb" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_6a221e1e-b513-4536-8d29-1e1d3a70f021" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntitySmallBusiness" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#61608;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_37f073c1-e45f-43ca-9baf-477547e09778" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#61608;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under section 404(b) of the Sarbanes-Oxley Act(15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report </span><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_eabcf272-d632-46f5-95b1-9ff1ee28853c" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_1f82a363-f36a-4b82-b311-2cd4aa0daf42" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#168;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#168;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_809c3285-1e73-441d-a4f4-24de23900c91" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61608;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61560;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2023 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf79698-5a0f-4bbf-8318-5cc7e577aac7" contextRef="C_8df4e45d-5ccf-4447-ac9d-b88b2629cca6" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">383.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the closing price of the registrant&#8217;s common stock, as reported by the Nasdaq Global Select Market on June 30, 2023 of $6.01 per share.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of the registrant&#8217;s Common Stock outstanding as of February 22, 2024 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d0c87d-cc0a-4435-a179-1ea151034e40" contextRef="C_0e7b91da-0112-404f-9acb-f761639a66b5" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">95,749,259</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29a48823-5326-492e-9ce4-5f6fbf1c9450" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s 2023 fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.94%;"/>
    <td style="width:83.76%;"/>
    <td style="width:1%;"/>
    <td style="width:6.3%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_re_foreign_jurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans relating to the development and manufacturing of our product candidates and research programs, including additional indications that we may pursue;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of the number of patients in the United States and the European Union who suffer from the diseases we are targeting and the number of patients that will enroll in our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and focus of our future clinical trials, and the reporting of data from those trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the market opportunity for our product candidates in each of the diseases we are targeting; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to expand our product candidates into additional indications and patient populations; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing therapies that are or may become available; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">existing regulations and regulatory developments in the United States and other jurisdictions; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our continued reliance on third parties to conduct clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to hire additional personnel and our ability to attract and retain such personnel, especially in light of a competitive hiring and compensation environment; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and additional financing needs;</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance, including potential volatility in our stock price;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of worldwide economic conditions, including macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the coronavirus (COVID-19) pandemic and geopolitical events, on our business; </span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of inflation; and</span></div></div>
  <div style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5356267702001714%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sufficiency of our existing cash, cash equivalents, and marketable securities to fund our future operating expenses and capital expenditure requirements.	</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">siness.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Supporting our scientific approach, our research and drug discovery platform enables us to identify targets and advance a broad portfolio of product candidates, validated by human genetics, which we believe may improve the probability of technical success over shorter development timelines. Three product candidates, latozinemab (also referred to as AL001), AL002, and AL101, are in clinical development. We continue to develop our preclinical and research pipeline, and we are developing our proprietary blood brain barrier technology (Alector Brain Carrier) to potentially apply to next generation product candidates. We are focusing our development resources on latozinemab in frontotemporal dementia (FTD) and AL002 and AL101 in Alzheimer&#8217;s disease (AD). We are advancing our clinical product candidates and research pipeline with our existing resources and in collaboration with our partners, Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK) and AbbVie Biotechnology, Ltd. (AbbVie).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we entered into a Collaboration and License Agreement with GSK (GSK Agreement) to collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Latozinemab modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. Latozinemab is in development as a potential treatment for FTD, a severe, rapidly progressing neurodegenerative disorder that affects 50,000 to 60,000 people in the United States and approximately 110,000 people in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Latozinemab is currently being studied in a global pivotal Phase 3 trial, INFRONT-3, for the potential treatment of adults at risk for or with symptomatic FTD due to mutation in the progranulin gene (FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). In 2023, we and GSK held a Type C meeting with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA) regarding the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in participants with frontotemporal dementia due to FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We and GSK previously aligned with the FDA and EMA to conduct the primary analysis on symptomatic participants in INFRONT-3. The companies performed a sample size re-estimation that supported enrollment of approximately 90-100 symptomatic participants for a treatment duration of 96 weeks. In October 2023, we achieved target enrollment in INFRONT-3 with 103 symptomatic and 16 at-risk participants enrolled. Target enrollment was based on feedback from the FDA and EMA. Enrollment completion is subject to revised protocol approval in countries outside the United States. In February 2024, the FDA granted Breakthrough Therapy Designation to latozinemab for the treatment of FTD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">-GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The FDA's Breakthrough Therapy Designation is granted to expedite the development and review of drugs in the United States that are intended to treat a serious condition, when preliminary clinical evidence indicates the drug or vaccine may demonstrate substantial improvement over available therapy on clinically significant endpoint(s). In prior clinical studies in FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients, latozinemab demonstrated elevation of progranulin levels to the normal range and early signals of exploratory biomarker and clinical activity. Latozinemab has been well tolerated in healthy volunteers and FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients in our Phase 1a and Phase 1b clinical trials, and in our open label Phase 2 clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AL101, the second product candidate in our PGRN portfolio, is designed to elevate progranulin levels, similar to latozinemab, and is currently being investigated for the potential treatment of Alzheimer&#8217;s disease and potentially other indications, including Parkinson's disease. In May 2023, we and GSK amended the GSK Agreement (the GSK Amendment). Under the terms of the GSK Amendment, we are responsible for funding and sharing in GSK&#8217;s and our development costs up to $140.5 million for the conduct of the initial Phase 2 trial of AL101 in AD. In August 2023, GSK received FDA clearance of the Investigational New Drug (IND) application for AL101 in the treatment of early AD. In February 2024, GSK dosed the first participant in the PROGRESS-AD global Phase 2 clinical trial of AL101/GSK4527226 in early AD.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our AL002 product candidate targets Triggering Receptor Expressed on Myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation. We are currently developing AL002 for the treatment of Alzheimer&#8217;s disease in collaboration with AbbVie.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the first patient was enrolled and dosed in a long-term extension (LTE) of our INVOKE-2 Phase 2 clinical trial. In February 2023, we and AbbVie amended the AbbVie agreement (the AbbVie Amendment), which resulted in our receiving a $17.8 million milestone payment in March 2023 for the dosing of the first patient in the LTE trial. Under the terms of the AbbVie Amendment, we were eligible to earn up to an additional $12.5 million to support the enrollment of additional patients in the ongoing INVOKE-2 trial to replace discontinuations and we received the total of $12.5 million in 2023. We completed enrollment of 381 patients in the INVOKE-2 clinical trial in the third quarter of 2023, with data expected in the fourth quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our efforts to advance our programs through clinical development and execute on the strategic approach outlined in the section titled &#8220;Business &#8211; Our Strategy,&#8221; Alector from time to time may execute partnerships with other biopharmaceutical companies. To date we have two active licensing, co-commercialization, or co-development agreements for certain programs in our pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Immune System is Central to Neurodegeneration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. As a result of these genetic mutations, the brain&#8217;s immune function deteriorates and subsequently would fail to carry out critical activities, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clearing or counteracting pathological neurodegenerative proteins such as amyloid beta, tau, alpha-synuclein, and TDP-43; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">providing metabolic and functional support to nerve cells; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulating synaptic connections; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that restoring the immune system&#8217;s ability to perform all of these vital functions in the brain is crucial to addressing neurodegeneration given that past approaches focusing on single degenerative pathologies have had limited or no impact on disease progression.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The brain&#8217;s immune system undergoes gradual deterioration of its functionality as part of normal biological aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration, with the goal of slowing or reversing the deterioration of the brain&#8217;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent pathologies responsible for neurodegeneration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to develop therapies that harness the immune system to combat neurodegenerative diseases. The key tenets of our business strategy to achieve this goal include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Building a leading, fully-integrated company focused on delivering innovative immunotherapies, validated by human genetics, for the treatment of neurodegeneration. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that building a fully integrated research, development, and ultimately commercial company will enable us to develop therapies more rapidly and efficiently for patients and realize the full potential of our immuno-neurology approach and discovery capabilities. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applying our proprietary capabilities to rapidly advance our product candidates through clinical proof-of-concept studies and beyond.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focused on maximizing the probability of success of our product candidates by leveraging immunology, neurobiology, and human genetics, as well as our state-of-the-art bioinformatics, to enable better and earlier target selection. In addition, we are also focused on a biomarker-driven approach, including proprietary tools and assays, to confirm target engagement, inform patient selection, and follow clinical outcomes. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maximizing the therapeutic potential of our targets and product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the central physiological roles played by the distinct targets of our product candidates, we believe that there is significant potential for us to address multiple indications with single targets. Our goal is to expand the therapeutic and commercial potential of our targets and product candidates to additional indications. We will remain disciplined about advancing this strategy, leveraging our discovery capabilities to inform expansion areas of maximum value and highest probability of success. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continuing to focus on discovering new targets and product candidates, validated by human genetics, to fulfill the full potential of our insights and platform. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our discovery capabilities are central to our efforts to rapidly identify new product candidates with compelling clinical promise. We will continue to invest in our research and discovery efforts, including evolving our proprietary analytical tools and assays, to validate our identified immune system targets and generate additional targets and product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Approach</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Role of the Innate Immune System and Microglia in Neurodegeneration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant evidence in the last decade has shown that neurodegenerative diseases, such as Alzheimer&#8217;s disease, Parkinson&#8217;s disease, FTD, and amyotrophic lateral sclerosis (ALS), are linked to a dysfunctional brain immune system. In contrast to the dual adaptive and innate components that characterize the broader human immune system, the brain&#8217;s immune system consists primarily of innate immune cells, known as microglia. These brain resident macrophages account for 10% to 15% of all cells found within the brain and are responsible for many aspects of brain health and maintenance. As the key innate immune cells in the brain, microglia respond to infection and damage, clear cell debris and pathological proteins, nurture neurons and the brain support cells, and control the number and functionality of inter-neuronal connections. Microglia have been our focus and new scientific advances have made it possible to understand how these key innate immune cells in the brain represent a crucial focal point for potentially treating or preventing neurodegenerative diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_0.gif" alt="img43903234_0.gif" style="width:362px;height:312px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1. Our clinical stage neurodegenerative disease programs pathways</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Scientific Data Support Our Hypothesis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Understanding how the brain&#8217;s immune cells affect its structure and function, in both normal and diseased states, is in our view, the key to understanding many neurological diseases. Human genetic evidence has supported the importance of the interactions between the brain and the innate immune system. For example, most of the top risk genes for Alzheimer&#8217;s disease, identified using genetic linkage studies, candidate gene analysis, genome-wide association studies (GWAS), and whole-genome or whole-exome sequencing, regulate immune function in the brain. Many of these risk genes have been shown to express predominantly in microglia and to control the function of these cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Microglia have been shown to be key cells in overall brain maintenance, health, and function and are the brain&#8217;s first line of immune defense. These innate immune cells are tooled with &#8220;microglial sensomes&#8221; which enable them to constantly survey brain cells to identify and respond to subtle signs of pathology or dysfunction. Microglia scavenge the brain for toxic misfolded proteins, cell debris, damaged or unnecessary nerve cells, dysfunctional or aged synapses, and infectious agents. In addition, microglia support the generation of new neurons and synapses and remodel neuronal circuits. Microglia also control the survival and function of astrocytes and oligodendrocytes, the main brain support cells which control brain metabolism and blood supply and replenish aged or damaged nerve fibers after injury. Further, microglia have been shown to modulate the permeability of the blood brain barrier allowing peripheral immune cells to access the brain and assist against infection or injury. Microglia can also change their morphology, functionality, and number in response to changing brain environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analysis of gene transcription at the single-cell level in microglia from normal and diseased brains revealed that multiple microglia subtypes exist which may respond to specific disease pathologies in the brain. Our product candidates are designed to recruit microglia subtypes by targeting microglia check-point proteins that control their survival, proliferation, migration, and function. This allows us to differentially modulate microglia activity as needed to counteract a given degenerative brain disorder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Findings in the fields of human genetics, immunology, and neuroscience have indicated that as a result of normal aging or genetic mutations, the beneficial functions of the microglia deteriorate leading to dysfunction of neuronal connections, massive death of neurons, and neurodegeneration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our therapies that focus on harnessing the power of microglia may improve neurodegenerative disease outcomes either as standalone therapies or in combination with anti-amyloid beta targeted therapies. Anti-amyloid beta antibodies mark misfolded aggregates and recruit microglia to remove them. Our therapies, including those in our progranulin franchise, are expected to enhance microglia&#8217;s ability to remove misfolded proteins in conjunction with anti-amyloid beta antibodies that tag these proteins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_1.gif" alt="img43903234_1.gif" style="width:519px;height:303px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2. Our checkpoint therapies are anticipated to act independently and in combination</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Research and Discovery Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to: (1) identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases, and rapidly develop antibody therapeutics to these targets, (2) interrogate and prioritize those targets for activity using biomarkers and related proprietary assays and preclinical models, and (3) clinically test product candidates, including in genetically defined patient populations that may be most likely to respond to treatment. We believe that these platform capabilities provide us with the tools to solve the conceptual and technical challenges associated with development of drug candidates for neurodegeneration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on proprietary immuno-neurology bioinformatics algorithms and methodologies to analyze large genetic datasets from diseased and healthy individuals, brain-based gene expression profiling and proteomics, and human pathology. These proprietary capabilities allow us to rapidly identify tractable targets, pharmacodynamic biomarkers, and patient populations associated with aberrant immune function which lead to neurodegeneration. Specifically, the priorities of our platform efforts are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Target Selection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our target selection capabilities address a wide array of factors that we believe inform efficient, optimized therapeutic outcomes, including genetic and mechanistic rationale. We leverage our bioinformatics expertise to identify genetic mutations in the brain immune system that we believe increase the risk of disease onset and progression. We combine our bioinformatic approaches with in-house functional genomics to discover and validate genetic mutations and targets of interest. We utilize state of the art techniques such as CRISPR Activation and Inhibition, single cell transcriptomics, proteomics, metabolomics, microscopic and biochemical readouts in relevant in vitro systems such as hiPSC microglia and in vivo systems such as mouse/rat models to elucidate the immune dysfunction caused by these mutations. We then seek to engineer immune modulating antibody product candidates to functionally counteract the harmful consequence of these genetic mutations. We leverage in vitro and in vivo functional tools to validate the activity of our product candidates and their ability to cross the blood brain barrier enough to be therapeutically effective.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biomarker Selection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are able to identify and employ molecular biomarkers, assays, and imaging techniques that are tailored to our product candidates to confirm target engagement and quantify their impact, allowing us to potentially interpret the clinical impact of our compounds earlier than would be expected using traditional clinical measures. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patient Selection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize genetic screening and biomarkers in certain orphan disease programs to better align a patient&#8217;s specific diagnosis with the targeted intervention in our clinical studies. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biologics Discovery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We pursue a comprehensive antibody discovery strategy using in vivo (multiple species, hybridoma and single B cell technology) and in vitro directed evolution (phage and yeast display) approaches. We leverage our advanced antibody engineering capabilities to design and optimize biotherapeutics.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We employ gene expression profiling, proteomics, brain imaging, and data on disease pathology as well as our own preclinical and clinical data to continually refine our proprietary immuno-neurology algorithms and methodologies. Using our drug discovery platform capabilities to identify targets that are validated by human genetics, disease biomarkers, and responsive patient populations, we believe that we are positioned for greater probability of technical success on more efficient timelines relative to historical drug development in neurodegeneration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proprietary Blood Brain Barrier Technology</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing our proprietary blood brain barrier (BBB) technology as a platform to support selected next-generation product candidates. We refer to our BBB technology as &#8220;ABC,&#8221; for &#8220;Alector Brain Carrier.&#8221; The goal of our technology is to deliver therapeutic antibodies and proteins at a lower dose and provide deeper blood brain barrier penetration while maintaining efficacy and decreasing costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3. The following table highlights our clinical programs, preclinical and research programs, BBB technologies, and IP portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_2.gif" alt="img43903234_2.gif" style="width:624px;height:313px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:14pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical programs include latozinemab, AL101, and AL002. In addition, we continue to pursue a number of preclinical and research programs in our pipeline for indications including Alzheimer&#8217;s disease and Parkinson&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Progranulin Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first development program is focused on modulating levels of PGRN, a key regulator of microglia function in the brain with strong genetic links to FTD and other neurodegenerative disorders. Individuals carry two copies of the GRN gene that function together to produce healthy levels of PGRN throughout the body. Mutations in both copies of the GRN gene, resulting in homozygous loss-of-function, lead to a neurodegenerative disease called neuronal ceroid lipofuscinosis, which is typified by childhood dementia, vision loss, epilepsy, and death. Mutations in a single copy of the GRN gene result in a drop of between 50% and 70% in the level of PGRN and consequently lead to development of FTD with about 90% penetrance by 75 years of age. Moreover, large scale human genetic studies suggest that regulatory mutations in GRN, the gene encoding PGRN, can increase the risk for Alzheimer&#8217;s disease and Parkinson&#8217;s disease, making GRN a risk gene for these disorders as well.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthy levels of PGRN are associated with many cellular processes that include normal microglial activities, neuronal survival, and lysosome function. PGRN deficiency disrupts microglia-neuronal homeostasis in the brain and promotes neurodegeneration through the release of cytotoxic cytokines and complement factors by dysfunctional microglia. Moreover, these microglia activate astrocytes, which in turn, damage neurons. Thus, lack of PGRN leads to disrupted health and function of both neurons and microglia and if not corrected, leads to rapid neurodegeneration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_3.gif" alt="img43903234_3.gif" style="width:529px;height:229px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 4. PGRN deficiency disrupts homeostasis between microglia and neurons and promotes neurodegeneration during aging.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SORT1 Controls PGRN Levels in the Body</span></p>
  <p style="text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human and mouse genetic studies have identified the PGRN degrading receptor Sortilin (SORT1) as a major negative regulator of PGRN levels in plasma and the brain. SORT1 is a sorting receptor on the cell surface and on the endoplasmic reticulum-Golgi apparatus within the cell. SORT1 binds to extracellular PGRN in the plasma and brain and transports it into cells for degradation by the lysosome resulting in decreasing levels of extracellular PGRN. SORT1 deficiency increases PGRN plasma and brain levels by two to three-fold in mouse models, while variants that modestly reduce expression of SORT1 increase the level of PGRN in humans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, genetic loss of SORT1 in mice does not lead to the adverse effects associated with genetic loss of PGRN, and PGRN continues to carry out its neurotrophic functions as expected in the absence of SORT1. These studies and others have indicated to us that blocking SORT1 with a pharmacological agent could be a safe and effective approach in increasing the level of functional PGRN in the brain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed two distinct product candidates that target SORT1, latozinemab and AL101, designed to increase PGRN levels in the brain of patients to counteract the damage sustained due to low PGRN levels in neurodegenerative disorders. Our first product candidate, latozinemab, is intended to treat orphan disorders, including genetic forms of FTD such as in patients that are missing a functional copy of the GRN gene (FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). Our second PGRN product candidate, AL101, is intended to treat widely prevalent neurodegenerative disorders such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. We have partnered with GSK to develop and commercialize our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGRN product candidates. For more information on our collaboration with GSK see the section titled &#8220;Business&#8212;Strategic Alliance with GSK.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Latozinemab received orphan drug designation from the FDA for the treatment of FTD, as well as Fast Track designation and Breakthrough Therapy designation for the treatment of patients with FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Generally, if a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other new drug application (NDA) or biologics license application (BLA) application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even though the FDA has approved orphan drug status for latozinemab for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and additionally, a rolling submission of the marketing application. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Latozinemab for the Treatment of FTD</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of PGRN in the brains of FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients. Administered via intravenous peripheral infusion, latozinemab functions by blocking the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. We are initially developing latozinemab for the treatment of symptomatic FTD due to a progranulin gene mutation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of FTD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FTD is a rapidly progressing and severe degenerative brain disease with no approved treatment. FTD is a form of dementia found most frequently in individuals less than 65 years old at time of diagnosis. Patients with FTD exhibit a range of personality-related symptoms, including compulsive behavior, lack of restraint, apathy, and anxiety as well as language and behavioral problems. The rate of disease progression in FTD is faster than in Alzheimer&#8217;s disease. Average life expectancy in FTD patients is seven to 10 years after the start of symptoms. FTD symptoms have an insidious onset with clinical symptoms usually appearing between 45 to 65 years of age at an average age of 58. Hence, FTD is considered an early-onset dementia as compared to late-onset Alzheimer&#8217;s disease and is more common than Alzheimer&#8217;s disease in early-onset dementia under the age of 60 years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_4.gif" alt="img43903234_4.gif" style="width:245px;height:198px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 5. MRI of frontal and temporal atrophy in FTD.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although FTD was poorly understood and thought to be rare, over the past decade the scientific community has gained knowledge about the biology of FTD as well as an awareness of disease prevalence. FTD affects 50,000 to 60,000 people in the United States and approximately 110,000 in the European Union. There are multiple heritable forms of FTD; to date, researchers have identified over 70 inherited loss of function mutations in GRN that lead to FTD. FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients represent 5% to 10% of all people with FTD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_5.gif" alt="img43903234_5.gif" style="width:591px;height:261px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 6. Mutations in a single copy of GRN result in a 50% or greater decrease in the level of PGRN and result in a greater than 90% probability of developing FTD. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends in Pharmacological Sciences. 2022 Aug; 43(8):641-652. DOI: 10.1016/j.tips.2021.11.015. PMID: 35039149. (2) Meeter L et al Progranulin Levels in Plasma and Cerebrispinal Fluid in Granulin Mutation Carriers. Dement Geriatr Cogn Disord Extra 2016;6:330-340. DOI: 10.1159*000447738</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients, inhibition of SORT1 through latozinemab represents a potential mechanism to compensate for the over 50% reduction of PGRN. Latozinemab is intended to reduce the ability of SORT1 to bind to and degrade PGRN, leading to increases in the levels of PGRN by increasing its circulating half-life. We have tested our PGRN program antibodies in various animal models, healthy volunteers, and FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients and have achieved significantly elevated, long-lasting levels of PGRN in the brain after intravenous administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_6.gif" alt="img43903234_6.gif" style="width:352px;height:284px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 7. Mechanism of action for our PGRN programs. Latozinemab (referred to as AL001) binds to SORT1 and prevents degradation of PGRN, increasing its circulating half-life significantly. A similar mechanism of action is also applicable for AL101.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our PGRN Product Candidates&#8217; Development Plan and Clinical Trial Results to Date</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Latozinemab is currently being studied in a global pivotal Phase 3 trial in both at-risk and symptomatic participants with FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, named INFRONT-3. The randomized, double-blind, placebo-controlled trial previously planned to enroll up to 180 FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mutation carriers across approximately 50 clinical sites in the United States, Canada, Europe and Australia. Symptomatic and at-risk participants were randomized to receive latozinemab or placebo intravenously every four weeks. Participants are also given the option to continue receiving treatment in an open-label extension (OLE) study. In June 2022, the first participant from the INFRONT-3 study was enrolled in the optional OLE designed to assess the long-term safety, tolerability, and efficacy of latozinemab in participants who have completed 96 weeks in the INFRONT-3 study, and enrollment in the OLE continues. The primary endpoint of our pivotal Phase 3 trial is to measure the effect of latozinemab on clinical decline by utilizing the CDR&#174; plus NACC FTLD-SB assessment, which evaluates clinical impairments in behavior, language, memory, judgment, and functional activities in trial participants. In addition, our Phase 3 trial will assess secondary clinical endpoints, multiple biomarkers, and safety. We and GSK held a Type C meeting with the FDA and received scientific advice from the EMA regarding the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in participants with frontotemporal dementia due to FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We and GSK previously aligned with the FDA and EMA to conduct the primary analysis on symptomatic participants in INFRONT-3. The companies performed a sample size re-estimation that supported enrollment of approximately 90-100 symptomatic participants for a treatment duration of 96 weeks. In October 2023, we achieved our target enrollment in INFRONT-3 with 103 symptomatic and 16 at-risk participants enrolled. Target enrollment was based on feedback from the FDA and EMA. Enrollment completion is subject to revised protocol approval in countries outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we presented data for latozinemab from our ongoing open-label Phase 2 INFRONT-2 clinical trial. INFRONT-2 was designed to establish the safety and tolerability of chronic administration of latozinemab at therapeutic doses, and the study also measured biomarkers of disease and clinical outcomes. Results from up to 12 symptomatic FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients treated over 12 months in an open-label study showed that latozinemab was well tolerated. Treatment with latozinemab restored PGRN in both plasma and CSF to levels seen in healthy volunteer age-matched controls for the duration of treatment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_7.gif" alt="img43903234_7.gif" style="width:526px;height:202px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 8. Latozinemab restores PGRN in plasma and CSF of FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants to levels seen in healthy volunteer age-matched controls.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to assessing PGRN levels in plasma and CSF, we evaluated disease-associated proteins, including lysosomal (e.g., CTSD, LAMP1), complement (C1QB), and astrogliosis (GFAP) biomarkers along with NfL. In our Phase 2 trial results presented in 2021, many of these disease-relevant biomarkers of lysosomal function, complement activation, astrogliosis, and neuronal health trended toward normalization or remained stable over 12 months of treatment compared to baseline and age-matched controls.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_8.gif" alt="img43903234_8.gif" style="width:505px;height:198px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 9. Latozinemab treatment normalizes lysosomal and complement biomarkers in CSF symptomatic FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients enrolled in our open label Phase 2 trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (1) The control group included N = 44 age-matched procured control samples, (2) at Baseline N = 11 FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants, (3) at 6 months treatment with latozinemab N = 9 FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants, and (4) at 12 months treatment with latozinemab N = 10 FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_9.gif" alt="img43903234_9.gif" style="width:500px;height:180px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 10. Latozinemab treatment decreases Glial Fibrillary Acidic Protein (GFAP) levels towards normal levels in plasma and CSF of asymptomatic FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants enrolled in our Phase 2 trial, suggesting a reduction in astrogliosis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_10.jpg" alt="img43903234_10.jpg" style="width:475px;height:180px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 11. NfL levels in plasma and CSF are stable over 12 months in latozinemab-treated symptomatic FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants enrolled in our Phase 2 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To provide context for the clinical outcomes observed in the open-label INFRONT-2 trial, a matched control cohort of ten FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> participants from the GENFI2 consortium was created using the propensity score matching technique. These ten GENFI2 patients were identified based on the CDR&#174; NACC FTLD SB at baseline and further</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refined by matching based on age, NfL levels, and clinical diagnosis at baseline, all done on a blinded basis without access to longitudinal results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Using volumetric MRI, we found a greater than 10% reduction in the atrophy rates in favor of the latozinemab treated FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patient population for the whole brain and frontotemporal cortex measures, and an approximately 50% reduction in the rate of ventricular enlargement, relative to the matched control GENFI2 cohort of FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_11.gif" alt="img43903234_11.gif" style="width:550px;height:201px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 12. vMRI data suggest slowing of ventricular enlargement and brain atrophy in latozinemab treated FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients enrolled in our open label Phase 2 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our Phase 2 trial, we also assessed clinical outcomes using the CDR&#174; plus NACC FTLD-SB scale. The CDR&#174; plus NACC FTLD-SB is the Clinical Dementia Rating Scale plus National Alzheimer&#8217;s Coordinating Center frontotemporal lobar degeneration sum of boxes rating scale developed for patients with FTD. Latozinemab treatment was estimated to slow disease progression by 48% in 12 FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients at 12 months relative to matched GENFI2 controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_12.gif" alt="img43903234_12.gif" style="width:553px;height:214px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 13. Treatment with latozinemab showed a slowing of clinical progression in FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients enrolled in our open label Phase 2 trial relative to matched GENFI2 controls. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Random Coefficient Model with Repeated Measurements including baseline and all available post-baseline measurements up to 12 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In prior clinical trials, latozinemab was well tolerated and demonstrated proof of mechanism. In our Phase 1a trial (n=50) in healthy volunteers, latozinemab was well tolerated. In our Phase 1b portion of the trial (n=14) in FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients, there was a statistically significant increase in PGRN levels relative to baseline when compared to pooled placebo in plasma and in CSF at the pre-specified follow-up time point. In addition, results from these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 studies showed that latozinemab was generally well tolerated, with no drug-related serious adverse events or dose-limiting adverse events reported in the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_13.jpg" alt="img43903234_13.jpg" style="width:490px;height:242px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 14. Latozinemab restores PGRN levels in symptomatic and asymptomatic FTD-</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> patients back to the normal range as seen in healthy volunteers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following their completion of the Phase 2 study or Phase 3 OLE study, we plan to give participants the option of enrolling in a continuation study, which will continue to assess the long-term safety of latozinemab and to enable participants to remain on study drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential Additional Applications for Latozinemab</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to treat any other neurodegenerative diseases including FTD patients other than those with </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations with latozinemab, we will be required to conduct additional clinical studies to obtain the applicable approvals for those specific patient populations. For example, excess aggregation of TDP-43 in brain cells is thought to lead to neuronal cell death and is associated with multiple neurodegenerative diseases, including both FTD and ALS. We enrolled an additional genetic subset of FTD patients (FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) in our open-label Phase 2 clinical trial of latozinemab and we will need to conduct an appropriate Phase 3 clinical trial to potentially obtain approval for treatment of FTD in the genetic subset of patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we initiated a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of latozinemab in people with ALS who carry a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mutation. In preclinical studies using multiple models of acute and chronic neurodegeneration, increasing progranulin levels has been shown in the literature to reverse and be protective against TDP-43 pathology. In light of the evolving ALS landscape, we closed that Phase 2 study to additional enrollment, and we and GSK continue to evaluate plans for development of latozinemab in ALS.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AL101 for the Treatment of Alzheimer&#8217;s Disease and Parkinson&#8217;s Disease</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a second product candidate in our PGRN programs, AL101, a human recombinant monoclonal antibody that also targets SORT1 and is designed to elevate progranulin levels similar to latozinemab. We are developing AL101 to target large chronic neurodegenerative diseases, such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. Excess aggregation of TDP-43 in brain cells is thought to lead to neuronal cell death and is associated with Alzheimer&#8217;s disease and Parkinson&#8217;s disease.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Polymorphic mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer&#8217;s disease and Parkinson&#8217;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, GSK dosed the first participant in the PROGRESS-AD global Phase 2 clinical trial of AL101/GSK4527226 in early AD.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, we presented interim data from our Phase 1 clinical trial testing the safety, tolerability, pharmacokinetics, pharmacodynamics, and bioavailability of single doses of intravenously or subcutaneously administered AL101 in healthy volunteers. AL101 increased progranulin levels in the periphery and the brain persisting for one month. AL101 was found to be well tolerated at all doses administered. We completed enrollment of additional cohorts to test multiple doses of AL101 administered intravenously and subcutaneously. AL101 was well tolerated and increased PGRN levels in plasma and CSF in a dose-dependent manner. In the two multiple dose (MD) cohorts, 27 healthy volunteers received either AL101 30 mg/kg IV every four weeks (q4w) for a total of four doses [n=11] or AL101 300 mg subcutaneously (SC) every two weeks (q2w) for a total of seven doses [n=13]. Three volunteers received MD IV placebo. AL101 was found to be generally well tolerated following MD IV (q4w) and SC (q2w) administrations. Consistent with previously presented data following single doses, AL101 was measurable in the CSF following multiple IV and SC doses. MD administration of AL101 increased plasma and CSF PGRN levels, with a higher elevation observed in the AL101 30 mg/kg MD IV group than in the AL101 300 mg MD SC group. Multiple IV doses of AL101 at 30 mg/kg increased and maintained the levels of PGRN at approximately 160% to 200% (2.6- to 3-fold) above baseline in plasma and approximately 80% (1.8-fold) above baseline in the CSF. The PK and PD profile of AL101 following single and multiple IV doses support future development in chronic neurodegenerative conditions such as AD and PD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_14.gif" alt="img43903234_14.gif" style="width:520px;height:193px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 15. AL101 treatment increased PGRN levels in healthy volunteers enrolled in our Phase 1 trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview of Alzheimer&#8217;s Disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alzheimer&#8217;s disease is a chronic neurodegenerative disease that usually starts slowly in people over 65 years of age and worsens over time. It is the most common cause of dementia, accounting for 60% to 70% of all cases. The most common early symptom of Alzheimer&#8217;s disease is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, failure to manage self-care, and behavioral issues. As a person&#8217;s condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is eight to ten years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While estimates of the prevalence of Alzheimer&#8217;s disease vary, the Alzheimer&#8217;s Association estimates that in 2022, there were more than 6.5 million Americans ages 65 and older suffering from Alzheimer&#8217;s disease and that number is projected to nearly triple by 2060. Alzheimer&#8217;s disease is the sixth leading cause of death in the United States and the fifth-leading cause of death for those ages 65 and older.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to its debilitating effect on patients&#8217; cognition and day-to-day functioning, Alzheimer&#8217;s disease places a significant burden on the healthcare system. According to the Alzheimer&#8217;s Association, the aggregate cost of care in 2023 for patients with Alzheimer&#8217;s disease and other types of dementia in the United States was estimated to be $345 billion, approximately 64% of which is borne by the Medicare and Medicaid systems. Total payments for health care, long-term care, and hospice care for people with Alzheimer&#8217;s and other dementias in the United States are projected to increase to nearly $1.0 trillion in 2050.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TREM2 Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TREM2 is a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia in the brain. TREM2 on microglia cells is thought to promote improved cell migration to the site of injury, improved cell survival, increased phagocytosis, and increased cell proliferation. Rare individuals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with homozygous TREM2 mutations, or mutations on both chromosomal copies, may develop neurodegeneration by the age of 40 with an average lifespan of 10 years following diagnosis. A gene variant in one of the two copies of TREM2 is found to increase the risk of Alzheimer&#8217;s disease by three-fold. Not only do mutations in a single copy of TREM2 increase the risk of Alzheimer&#8217;s disease significantly, but Alzheimer&#8217;s disease patients with TREM2 mutations also exhibit an earlier onset of symptoms by three years and an increased rate of brain volume loss compared to individuals without such mutations. Evidence also suggests that a gain of function mutation leading to increased expression of TREM2 confers a protective phenotype against Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The discovery of strong genetic linkage of TREM2 to Alzheimer&#8217;s disease in 2013 was one of the first examples in which large scale genomic analyses were used to identify a rare gene variation and link it to an increase in the risk of late-onset Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TREM2 binds to membrane lipids and lipoproteins such as Apolipoprotein E (ApoE) which are normally found in the brain. Polymorphisms in the gene for ApoE are also known to significantly increase the risk of development of Alzheimer&#8217;s disease and are the single highest risk factor for Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AL002 for the Treatment of Alzheimer&#8217;s Disease</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidate, AL002, is a humanized, TREM2 activating, monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion. AL002 is a microglia cell regulator that modulates the TREM2 receptor</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and is being developed for the treatment of Alzheimer&#8217;s disease in collaboration with AbbVie. For more information on our collaboration with AbbVie see the section titled &#8220;Business&#8212;Strategic Alliance with AbbVie.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_15.gif" alt="img43903234_15.gif" style="width:275px;height:327px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 16. Mechanism of action of our TREM2 activating product candidate AL002.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no cures for Alzheimer&#8217;s disease. Two therapies directed at the underlying pathology of the disease have been approved by the FDA with evidence of reduction of amyloid beta plaques and potential clinical benefit. Both aducanumab and lecanemab received accelerated approval from the FDA based on a surrogate endpoint, the reduction of amyloid beta plaque in the brain. The FDA subsequently granted full approval of lecanemab based on the cognitive endpoint. Other classes of approved therapies are for symptomatic treatment including, acetylcholinesterase inhibitors and glutamatergic modulators. Drugs for symptomatic treatment are intended to help preserve neuronal communication, but only provide temporary benefit and do not slow or halt neuronal death. In addition, antidepressants and antipsychotics are often prescribed off-label to treat the symptoms of severe Alzheimer&#8217;s disease in patients suffering from agitation, aggressive behaviors, psychosis, and depression.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent drug candidates under development for Alzheimer&#8217;s disease include those focused on blocking synthesis, enhancing clearance or disaggregating misfolded amyloid beta or tau proteins in the brain, reversing chronic inflammation, and repairing vascular dysfunction, metabolic dysregulation, as well as neurotoxicity. Almost all of these candidates were designed to target just one of the multiple Alzheimer&#8217;s disease pathologies, and most of these drug candidates have so far failed to demonstrate significant benefit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although amyloid beta plaques and tau protein in the brain represent physical pathologies of the disease and are believed to cause a loss of neuronal connectivity in the brain and neuronal death, recent scientific data paints a more complex picture. We believe more efficacious therapies will likely require addressing multiple pathologies including those associated with microglial failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our TREM2 Clinical Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we initiated INVOKE-2, our Phase 2 trial in Alzheimer&#8217;s disease patients in early stages of the disease. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 trial was intended to enroll approximately 265 participants with early AD at up to 90 sites globally, and in 2023 we added additional participants in the ongoing INVOKE-2 trial to replace discontinuations, including APOE e4/e4 participants, from the study. The primary endpoint of our Phase 2 trial will measure disease progression utilizing the Clinical Dementia Rating Sum of Boxes (CDR-SB). The trial will also measure multiple fluid and imaging biomarkers, and assess several secondary clinical, pharmacokinetic and pharmacodynamic endpoints, as well as safety to generate data enabling pivotal Phase 3 studies. In January 2023, the first participant from the INVOKE-2 study was enrolled and dosed in an LTE of our Phase 2 clinical trial. In the third quarter of 2023, we completed enrollment of 381 patients in the INVOKE-2 clinical trial, with data expected in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment-emergent MRI findings resembling amyloid related imaging abnormalities (ARIA) have been observed in the INVOKE 2 study. ARIA are MRI findings that may include vasogenic edema, sulcal effusions, microhemorrhages and/or superficial siderosis. The incidence of ARIA has been shown to increase in Alzheimer&#8217;s disease patients with the administration of certain Alzheimer&#8217;s disease therapeutics, namely anti-&#946;-amyloid antibodies. We do not yet know whether the biological mechanism(s) causing these MRI changes are the same as that associated with the ARIA that has been described with anti-amyloid beta antibodies. In our INVOKE-2 Phase 2 clinical trial, most cases resembling ARIA were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred early in the trial in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, at that time we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, and are following recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we completed the Phase 1a portion (n=56) of a clinical trial in healthy volunteers with AL002. AL002 was well tolerated in the single ascending dose part of our Phase 1 trial. In addition, a dose dependent and statistically significant change in both soluble TREM2 (sTREM2) and downstream biomarkers for microglia functionality in CSF were observed upon treatment, indicating both target engagement and proof-of-mechanism in healthy volunteers. Based on the tolerability observed in our Phase 1a healthy volunteer trial, as well as encouraging biomarker data, we initiated the Phase 1b portion of the trial with AL002 in participants with Alzheimer&#8217;s disease. However, based on the data collected to date in preclinical studies as well as in healthy volunteers, and in alignment with our partner AbbVie, we closed enrollment in the Phase 1b trial, which was impacted by the COVID-19 pandemic, and shifted to initiating our Phase 2 trial. In our Phase 1 clinical trial, AL002 demonstrated tolerability, target engagement, and proof-of-mechanism in the central nervous systems of healthy volunteers and Alzheimer&#8217;s disease patients.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_16.gif" alt="img43903234_16.gif" style="width:490px;height:216px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 17. In healthy volunteers, a dose dependent decrease in sTREM2 and an increase in CSF-1R, a biomarker of microglial activation was observed in our AL002 Phase 1 clinical trial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CSF samples were taken from the five highest dose cohorts. The data shown are derived from analysis of CSF samples from 34 healthy volunteers (* denotes p&lt;0.05 by T-test, *** denotes p&lt;0.001 by T-test).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our TREM2 Preclinical Data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AL002 binds to TREM2 on the surface of microglia and is designed to optimize microglial activity through the phosphorylation of Spleen Associated Tyrosine Kinase. With prominent academic collaborators, we demonstrated that AL002s, an antibody that is functionally similar to AL002 but cross-reacts with mouse TREM2, can normalize gene expression signatures associated with Alzheimer&#8217;s disease and reduce pathology in a mouse model of Alzheimer&#8217;s disease. Furthermore, AL002c, a form of AL002 with a murine Fc region, was shown to induce microglial proliferation and amyloid plaque compaction and decrease dystrophic neurites associated with damaged neurons in a severe amyloid mouse model that expresses either the normal or genetic risk variant of the human TREM2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43903234_17.jpg" alt="img43903234_17.jpg" style="width:285px;height:217px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 18. AL002s significantly improves cognitive deficit in a mouse model of Alzheimer&#8217;s disease. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(**** indicates p&lt;0.0001 by T-test)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Add-on and Potential Combination Use of Our Product Candidates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our therapies are also likely to act in conjunction with each other or with other experimental drugs that are designed to remove pathological proteins. Therapies such as antibodies against amyloid-beta, tau filaments or misfolded alpha-synuclein protein are designed to tag the pathological proteins and recruit microglia to dispose of the drug/pathological protein complex. Aging microglia are less likely to perform this function effectively, and our immuno-neurology therapies could ameliorate this deficiency. We intend to explore various combination strategies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in preclinical models and will, in the future, consider moving this strategy into the clinic based upon results from preclinical models.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic Alliance with GSK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we entered into a Collaboration and License Agreement with GSK, pursuant to which we and GSK will collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101. The GSK Agreement became effective on August 17, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we may be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments, including $160 million for the first commercial sale in the United States and $90 million for the first commercial sale in at least two of the following countries: France, Germany, Italy, Spain, or the United Kingdom. In the United States, the parties will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, we will be eligible for double-digit tiered royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The parties will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#8217;s disease and Parkinson&#8217;s disease and other non-orphan indications. GSK will also conduct the initial Phase 2 trial for AL101 in Alzheimer&#8217;s disease. Development costs will be shared 60% by GSK and 40% by us, except that we will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we and GSK amended the GSK Agreement. Under the terms of the GSK Amendment, we are responsible for funding and sharing in GSK&#8217;s and our development costs up to $140.5 million for the conduct of the initial Phase 2 trial for AL101 in Alzheimer&#8217;s disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the parties will be jointly responsible for commercialization of latozinemab and AL101, with us leading the commercialization for orphan indications and GSK leading the commercialization for Alzheimer&#8217;s disease and Parkinson&#8217;s disease and other non-orphan indications. Outside of the United States, GSK will be solely responsible for commercialization of latozinemab and AL101 for all indications. We may opt out of the sharing of development costs and of profit and losses from commercialization in the United States on a product-by-product basis. In such case, we will no longer conduct development or commercialization of that product and the Company will receive tiered royalties on net sales in the United States instead of a share of profits or losses. GSK may terminate the agreement with 180 days&#8217; notice at any time, but we would not need to repay any portion of the payments received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the GSK Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the term of the GSK Agreement, each of Alector and GSK are subject to exclusivity requirements prohibiting certain activities outside of the GSK Agreement directed to targets under the GSK Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ownership of intellectual property created in connection with the GSK Agreement is generally determined on the basis of inventorship. Generally, we have the first right to control prosecution and maintenance of licensed patents, including patents developed solely by us or jointly by the parties, in the United States, and GSK has the first right to control prosecution and maintenance of such patents outside the United States. GSK has the first right to prosecute infringement of such patents by certain third-party products. The parties shall mutually agree on which party shall control the defense against claims that a product developed under either of the programs that are the subject of the GSK Agreement infringes third-party intellectual property rights, with the party against whom such claims have been filed having the first right to defend in the absence of such mutual agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At any point during the term of the GSK Agreement, after a specified notice period, GSK can terminate the GSK Agreement in its entirety for convenience. Additionally, GSK or we can terminate the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK Agreement in connection with a material breach of the GSK Agreement by the other party that remains uncured for a specified period of time.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Alliance with AbbVie</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2017, we entered into the Co-Development and Option Agreement with AbbVie. The primary goal of our global strategic collaboration with AbbVie is to co-develop and commercialize therapeutics to treat Alzheimer&#8217;s and other neurodegenerative diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the AbbVie Agreement, we granted AbbVie an exclusive option to global development and commercialization for our TREM2 and SIGLEC 3 programs. The terms of the AbbVie Agreement included initial upfront payments of $205.0 million and $20.0 million from the sale of shares of our stock. We are responsible for the design and execution of Phase 1 and Phase 2 studies. In June 2022, AbbVie provided notice of termination with respect to the SIGLEC 3 program. In February 2023, we and AbbVie amended the AbbVie agreement, which resulted in our receiving a $17.8 million milestone payment for the dosing of the first patient in a long-term extension (LTE) study and a $12.5 million payment for the enrollment of additional patients. If AbbVie exercises its option for the TREM2 program, we will receive $250.0 million. Additionally, under the terms of the AbbVie Agreement, we will be eligible to earn up to an additional $225 million in milestone payments related to the regulatory approval for up to three indications. Following AbbVie&#8217;s option exercise for the TREM2 program, AbbVie would be responsible for certain development activities and global commercialization, taking advantage of its global clinical trial expertise and commercialization networks. Additionally, following AbbVie's option exercise, we may opt out of sharing development costs and profits and instead receive a tiered royalty on sales of products. Through this partnership, we aim to leverage the strengths of both organizations efficiently to best achieve the desired outcome.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise of option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> AbbVie may exercise its option for the TREM2 program at any time until the expiration of the option term. The option term ends following a fixed period after AbbVie receives our data package resulting from our TREM2 research and development program. If AbbVie does not exercise its option during the option term for a product candidate, we will retain all rights to the TREM2 program. If AbbVie exercises its option for the TREM2 program, then AbbVie will lead development and commercialization activities worldwide. After AbbVie opts in, AbbVie must use commercially reasonable efforts to develop and commercialize AL002 globally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the AbbVie Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the term of the AbbVie Agreement, we and AbbVie are subject to exclusivity requirements prohibiting certain activities outside of the AbbVie Agreement directed to TREM2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ownership of intellectual property created in connection with the AbbVie Agreement is generally determined on the basis of inventorship. Generally, each party has the first right to prosecute and maintain its own patents. We generally have the first right to prosecute and maintain joint patents prior to AbbVie&#8217;s exercise of its option for the program relating to such patents, and AbbVie has the right following its exercise of such option. AbbVie has the first right to prosecute any infringement of jointly held patents developed under the AbbVie Agreement and our patents that are licensed under the AbbVie Agreement. Additionally, AbbVie has the sole right to prosecute its own patents. AbbVie has the first right to defend against claims that a product developed under the TREM2 program that is the subject of the AbbVie Agreement infringe third-party intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At any point during the term of the AbbVie Agreement, including during the research, development, and clinical trial process, AbbVie can terminate the AbbVie Agreement for convenience. In that event, all rights related to the TREM2 program revert to us. Additionally, AbbVie or we can terminate the AbbVie Agreement in connection with a material breach of the AbbVie Agreement by the other party that remains uncured for a specified period of time.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adimab Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview &#8211; 2014 Adimab Collaboration Agreement (2014 Adimab Agreement)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2014, we entered into the 2014 Adimab Collaboration Agreement (the 2014 Adimab Agreement). Under the 2014 Adimab Agreement, we are required to fund, and we and Adimab LLC (Adimab) are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We are developing antibodies discovered by Adimab in our latozinemab and AL101 product candidates, and we are developing an antibody optimized by Adimab in our AL002 product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee prioritizes among research programs and prepares and finalizes new proposed research plans, among other activities. If the research committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then either party may seek arbitration of the matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to the 2014 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. For example, patent rights relating to improvements to Adimab&#8217;s background platform technology that are invented in the course of the research are assigned to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research; and except for Adimab&#8217;s retained rights to continue using and licensing its own libraries, each party agrees not to practice or license the patents arising out of the research that it owns for any purpose other than to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise of Options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The 2014 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extended to ownership of patent rights specifically covering the sequences of such antibodies, and the right to obtain worldwide, royalty-bearing, sublicensable licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. These licenses are exclusive, except as to Adimab background and platform technology and Adimab&#8217;s retained rights to continue using and licensing its own libraries, as to which the licenses are non-exclusive. We have confirmed with Adimab in writing that key patents we have filed relating to the programs partnered with AbbVie claim inventions owned solely by us, and do not include any such background or platform technology of Adimab. All of our options under the 2014 Adimab Agreement have either expired, are in the process of being exercised, or, with respect to multiple targets and hundreds of antibodies (including the target programs partnered with AbbVie), have already been exercised. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. The assigned and licensed patent rights we obtained from these option exercises are described in more detail above under the section titled &#8220;Business&#8212;Intellectual Property.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We fund Adimab&#8217;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2014 Adimab Agreement. We also have potential milestone payments per program for use of antibodies and low- to mid-single digit royalty payments for commercial sales of products incorporating such antibodies. However, if we enter into any transaction granting rights to the inventions or sell products created as a result of a collaboration with a third party, we have a choice to pay a share of the resulting revenue instead of royalties from such sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are able to terminate the 2014 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on three months prior written notice to Adimab. In addition, either party can terminate the 2014 Adimab Agreement in its entirety, or, subject to certain limitations, with respect to specific optioned rights, for material breaches that remain uncured after 90 days&#8217; notice to the breaching party. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the case of a termination before expiration of the 2014 Adimab Agreement, we would have certain continuing payment obligations to Adimab, or would be required to adhere to certain restrictions as to the fruits of the collaboration. The 2014 Adimab Agreement expires on the twelfth anniversary of the first commercial sale of the products created under the collaboration, on a product-by-product and country-by-country basis. The licenses we and Adimab granted to each other do not survive, subject to certain limitations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview&#8212;2019 Adimab Collaboration Agreement (2019 Adimab Agreement)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we entered into another Adimab collaboration agreement (the 2019 Adimab Agreement). Under the 2019 Adimab Agreement, we are required to fund, and we and Adimab are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We have not yet identified any research programs under the 2019 Adimab Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee facilitates communication regarding research under the 2019 Adimab Agreement and has the limited authority to amend a research plan in a manner not substantially affecting the resources required from a party. If the research committee is unable to make a decision by consensus, no decision will be taken.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to the 2019 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. Certain intellectual property relating to Adimab&#8217;s background platform technology including any improvements thereto that are invented in the course of the research are assigned to Adimab. Patents covering antibodies that are the subject of the collaboration are owned by us; however, prior to our exercise of the option described below, we are prohibited from practicing such patents for any purpose other than to perform our research obligations under the 2019 Adimab Agreement. Upon the expiration of the option term described below, in the event we elect not to exercise our option right with respect to an antibody, ownership of such patents is transferred to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise of Options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The 2019 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extends to ownership of the applicable optioned antibody, and the right to obtain worldwide, royalty-bearing, sublicensable non-exclusive licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We fund Adimab&#8217;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2019 Adimab Agreement. We are also responsible for certain development fees and, in the event we exercise the option right, we are obligated to pay an option fee. We also have potential milestone payments per product for use of antibodies, subject to certain limitations on total payments owed on any given target, and low-single digit royalty payments for commercial sales of products incorporating such antibodies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are able to terminate the 2019 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on 60 days&#8217; prior written notice to Adimab. In addition, either party can terminate the 2019 Adimab Agreement in its entirety for material breaches that remain uncured after 90 days&#8217; notice to the breaching party. In the case of a termination before expiration of the 2019 Adimab Agreement, we would be prohibited from using the fruits of the collaboration. The 2019 Adimab Agreement expires, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and expiration of the last patent covering such product in such country, or, in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the event no product is optioned under the 2019 Adimab Agreement, upon the last to expire option period. Upon expiration, the licenses Adimab granted to us with respect to products for which we have exercised our option will continue on a non-exclusive, royalty-free basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview&#8212;2021 Adimab Collaboration Agreement (2021 Adimab Agreement)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we entered into another Adimab collaboration agreement (the 2021 Adimab Agreement). Under the 2021 Adimab Agreement, we were required to fund antibody engineering research programs with respect to targets selected by us. The 2021 Adimab Agreement also granted us an exclusive option to obtain a specified number of engineered sequences discovered or optimized by Adimab and directed against the targets that we selected. We selected one target, which was the subject of a research program conducted by the parties. We did not exercise our option to obtain any engineered sequences in connection with that research program, and we did not nominate any additional targets for additional research programs. The 2021 Adimab Agreement expired at the end of the option period for the research program that was conducted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must manufacture our product candidates for clinical trial use in compliance with cGMP regulations. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA or comparable foreign regulatory authority&#8217;s satisfaction before any product is approved for human clinical trial use. Our third-party manufacturers will also be subject to periodic inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of our products to assess compliance with applicable regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture our product candidates for use in clinical trials and commercialization. We rely, and expect to continue to rely, on third-party cGMP manufacturers or our collaboration partners for the production of our products for human clinical trials in compliance with FDA and other foreign authority regulations for such products. We rely on contract development and manufacturing organizations (CDMOs) to manufacture and supply our preclinical and clinical materials to be used during the preclinical and clinical development of our product candidates. As part of our broad manufacturing strategy to expedite the manufacturing of our product candidates and minimize manufacturing risk, we currently have established relationships with several CDMOs for the manufacturing of our drug substance or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have long-term supply agreements and we purchase our required drug product through development manufacturing services agreement. We expect to continue to rely on third-party manufacturers or our collaboration partners for the commercial supply of any of our product candidates for which we obtain marketing approval. We have personnel with significant technical, manufacturing, analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have any approved drugs, and we do not expect to have any approved drugs in the near term. Therefore, we have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing drugs. When, and if any of our product candidates are approved for commercialization, we intend to develop a commercialization infrastructure for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also rely on partnerships, such as our AbbVie and GSK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations, to provide commercialization infrastructure, including sales and marketing and commercial distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to enforce our proprietary rights against infringers. Our strategy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and related components, their methods of use and processes for their manufacture, our proprietary reagents, assays and platforms, and any other inventions that are commercially important to our business. We also rely on trademarks as well as trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms, methods and product candidates. We believe that we have substantial know-how and trade secrets relating to our technology and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our patent portfolio contains over 50 families, which include 79 issued patents and over 500 pending patent applications that are directed to over 20 different targets and/or technologies and that are solely owned or we have rights to exclusive licenses by us. For our product candidates, we generally pursue multilayered patent protection covering the composition of matter based on binding epitopes of the product candidates on the target protein, functional characteristics of the product candidates, degenerative sequence of the product candidates, and/or specific sequence of the product candidates. In addition to composition of matter coverage, we also generally pursue claims directed to methods of making, nucleic acids, formulations, and methods of using the product candidates. The method of use claims further include claims directed to methods of treatment, patient selection criteria, biomarkers, disease subgroups, pharmacodynamic and clinical end-points, and dosage regimes. As further described below, we intend to strengthen the patent protection of our product candidates and technologies through additional patent application filings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PGRN Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own six patent families directed to our PGRN programs, latozinemab and AL101, which include seven issued U.S. patents, covering the compositions and uses of our PGRN program product candidates. The first two patent families are expected to expire in 2036, the third patent family is expected to expire in 2039, the fourth patent family is expected to expire in 2040, the fifth patent family is expected to expire in 2041, and the sixth patent family is expected to expire in 2042, in all cases excluding any patent term adjustments and any patent term extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TREM2 Program</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own seven patent families directed to the TREM2 program, which include two issued U.S. patents, covering the compositions and uses of our TREM2 program product candidates. The first patent family is expected to expire in 2035, the second patent family is expected to expire in 2036, the third patent family is expected to expire in 2038, the fourth patent family is expected to expire in 2040, the fifth and sixth patent families are expected to expire in 2041, and the seventh patent family is expected to expire in 2043, in all cases excluding any patent term adjustments and any patent term extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in force. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it, may be extended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors. Expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Some of the pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and ALS, include large companies with significant financial resources, such as Biogen, Eli Lilly, Merck, Roche Holding AG, and Eisai. Some of these companies are pursuing product candidates for the same or similar indications to ours and in some cases acting on the same targets or through comparable mechanisms of action. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, method of administration, cost, time to market, level of promotional activity and intellectual property protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate our product candidates will compete with therapies approved for treating the symptoms of neurodegenerative diseases and therapies approved or currently in clinical studies intended to halt or slow the progression of neurodegenerative disease that are being developed by a number of companies and institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA) and biologics under the FDCA and the Public Health Service Act (PHSA). Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future product candidates must be approved by the FDA through either a BLA or NDA process before they may be legally marketed in the United States. The process generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval by an independent Institutional Review Board (IRB), or ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Submission to the FDA of an NDA or BLA; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality, and purity; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA or BLA; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The data required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory requirements for approval of therapies for the treatment of neurodegenerative diseases are evolving. For example, two agents, aducanumab and lecanemab, received accelerated approval from the FDA based on a surrogate endpoint, the reduction of amyloid beta plaque in the brain. The FDA subsequently granted full approval of lecanemab based on the cognitive endpoint. Under the FDA&#8217;s accelerated approval pathway, a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients may serve as the basis for an accelerated approval, subject to subsequent confirmatory studies. By contrast, the FDA declined to grant accelerated approval for another product, donanemab, in AD, based on an insufficient number of patients with at least 12 months of drug exposure. FDA also recently granted accelerated approval for sodium phenylbutyrate/taurursodiol for treatment of ALS, based on efficacy data from a single 24-week Phase 2 study. The FDA advisory committee that voted in favor of approval was presented with survival data for the drug in that Phase 2 study as well as biomarker data from the drug in a separate Phase 2 AD study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a recent publication of disease progression models for genetically inherited forms of FTD, including FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, may help inform the design of clinical trials for such forms of FTD based on more accurate estimations of sample size and the potential use of biomarkers as surrogate endpoints to reduce sample size. We and GSK held a Type C meeting with the FDA and received scientific advice from the EMA regarding the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in participants with frontotemporal dementia due to FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We and GSK previously aligned with the FDA and EMA to conduct the primary analysis on symptomatic participants in INFRONT-3. The companies performed a sample size re-estimation that supported enrollment of approximately 90-100 symptomatic participants for a treatment duration of 96 weeks.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2, and Phase 3, and may overlap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug or biologic, findings from animal or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NDA/BLA Review Process</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity, and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#8217;s 2024 fee schedule for prescription drug user fees, which became effective on October 1, 2023, and will remain in effect through September 30, 2024, the user fee for an application requiring clinical data, such as an NDA or BLA, is approximately $4.0 million. PDUFA also imposes an annual program fee for each marketed human drug or biologic ($416,734 in 2024) and an annual establishment fee on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drugs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other NDA or BLA application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Latozinemab has been granted orphan drug designation by FDA for treatment of FTD, and AL101 also had orphan drug designation until we withdrew the IND for FTD and decided to pursue larger indications, such as AD and PD, for that product candidate. Despite latozinemab's orphan drug designation, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication for which it has not been granted orphan drug designation, it will not have orphan drug exclusivity in that non-orphan indication. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In litigation in 2021, a court disagreed with the FDA&#8217;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease, and not to all uses or indications within the entire designated disease or condition. This appellate court decision created uncertainty in the application of orphan drug exclusivity. In January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the applicable court ruling, it intends to continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved. This permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that has not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA approval, but ideally no later than the pre-NDA or pre-BLA meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, a drug or biologic may be eligible for designation as a Breakthrough Therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the Breakthrough Therapy program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the filing of the IND for the product candidate. The benefits of Breakthrough Therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. The FDA must determine if the product candidate qualifies for Breakthrough Therapy designation within 60 days of receipt of the sponsor&#8217;s request. The receipt of a Breakthrough Therapy designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures, and it would not assure ultimate approval by the FDA. The FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened. Fast track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for FDA approval, but may expedite product development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product. The Food and Drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Omnibus Reform Act (FDORA) reformed the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements. It is unclear how these proposals, future policy changes, and changes in FDA regulations will impact new drug applications in the treatment of Alzheimer&#8217;s disease and our clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, or ACA, signed into law in 2010, includes the BPCIA, which created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">animal studies (including the assessment of toxicity); and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate safety, purity, and potency in one or more conditions for which the reference product is licensed and intended to be used. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, an application must include information demonstrating that: </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.66525540221037%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proposed product is biosimilar to the reference product; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#8217;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#8212;laboratory, preclinical and/or clinical&#8212;required to demonstrate biosimilarity to a licensed biological product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity and recommends that sponsors use a stepwise approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in active ingredients do not affect the safety, purity, or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product&#8217;s safety, purity, and potency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The submission of a biosimilar application does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12 years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: one year after the first commercial marketing of the first interchangeable product; 18 months after resolution of a patent infringement against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; 42 months after approval of the first interchangeable product, if a patent infringement suit against the applicant that submitted the application for the first interchangeable product is still ongoing; or 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#8220;off-label use&#8221;, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters, or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other U.S. Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state and local governments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations and statutes could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. Likewise, the interpretation of federal law by regulatory agencies may change if judicial deference to such agencies&#8217; interpretation is limited or eliminated. The judiciary may change the agencies&#8217; interpretation of federal law in a way that has a negative impact on the operation of our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Patent-Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office (USPTO), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA), and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Clinical Trials Regulation EU No 536/2014, which replaced the Clinical Trials Directive and entered into application on January 31, 2022, is intended to simplify the current rules for clinical trial authorization and is aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Review and Approval</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP), of the EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare and Medicaid Services have proposed to expand Medicaid rebate liability to the territories of the United States as well.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices, including U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, from 2016-2020, HHS and Centers for Medicare and Medicaid Services (CMS) issued various rules that were expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of these rules. Some rules have since been delayed in their implementation or have been rescinded.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The American Rescue Plan Act of 2021 eliminated the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of approved products, which could have a material impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. In March 2023, the Centers for Medicare and Medicaid Services (CMS) published its first guidance on how negotiations will be conducted, starting in 2026 for high expenditure drugs as determined and selected by Health and Human Services. In June 2023, CMS issued a revised guidance for the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. Various industry stakeholders, including pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the Inflation Reduction Act are unconstitutional. The impact of these judicial challenges as well as future legislative, executive, and administrative actions and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, many states have proposed or enacted legislation, administrative actions, and government programs that seek to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. Recently, the FDA authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. Additionally, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products candidates. Such initiatives, state drug importation programs, and legislation may affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the demand for any such product candidate, if approved. The full impact of the state importation program on our industry and our business is unclear.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we expect will continue to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scientific Advisory Board</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have assembled a highly qualified scientific advisory board comprised of advisors who have, collectively, deep expertise in neurodegenerative diseases, genomics, protein engineering, drug development, and drug discovery as well as translational medicine. Our scientists work in collaboration with these advisors to identify new disease targets, develop a biomarker strategy, and accelerate discovery and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37%;"/>
    <td style="width:63%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Affiliated Entity</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adam Boxer, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Department of Neurology at University of California, San Francisco</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen Hauser, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Department of Neurology at University of California, San Francisco</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Heneka, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Luxembourg Centre for Systems Biomedicine at University of Luxembourg</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Martin Kampmann, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Department of Biochemistry and Biophysics, University of California, San Francisco Weill Institute for Neurosciences</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard Scheller, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">National Academy of Sciences and National Institute of Medicine</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thomas Christian S&#252;dhof, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Departments of Molecular and Cellular Physiology and Neurosurgery at Stanford University</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources are a key factor in our ability to achieve our mission. We believe that our future success depends, in part, on our ability to continue to identify, recruit, retain, incentivize, and integrate our employees, advisors, and consultants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Profile</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 244 full-time employees, 76% of whom were engaged in research and development activities. The majority of our employees work out of our headquarters location in South San Francisco; we have a second, smaller location &#8211; Anderson-Simonsen Labs &#8211; located in Newark, CA; and the remainder of our team members work remotely. None of our employees are represented by a labor union or party to a collective bargaining agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diversity and Inclusion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees represent a broad range of backgrounds and bring a wide array of perspectives and experiences to the company. We are committed to building an open, diverse, and inclusive environment for everyone, as we believe this fosters greater innovation and furthers our mission. We have made efforts to ensure that our job postings, hiring process, and people programs are unbiased and are fair and equitable to all. As of December 31, 2023, approximately 62% of our workforce, 63% of Research &amp; Development, and 58% of people managers were female. As of December 31, 2023, ethnic or racial minorities represented approximately 53% of our workforce, 56% of Research &amp; Development, and 43% of our people managers.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not tolerate discrimination or harassment of or retaliation against our employees, job applicants, contractors, consultants, interns, or volunteers, and we have a longstanding anti-harassment policy. We have created multiple safe avenues for employees to submit concerns, including an anonymous hotline that goes directly to our head of compliance. We have a formal process and policy for the submission and treatment of complaints.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Compensation and Benefits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal purpose of our compensation program is to attract, retain, and reward employees who share our vision and are deeply connected to our mission. We achieve this purpose through the granting of cash-based and stock-based compensation awards and the provision of meaningful benefits. Our compensation and benefits include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitive employee base salaries and short-term incentive bonus opportunity;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation awards to encourage an ownership mindset and align employees to Alector&#8217;s long-term success;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retirement savings options and matching contributions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare and other benefits for all full-time employees and their dependents, including dedicated mental health, fertility, and caregiving programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generous paid time off for all full-time employees; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parental leave and other leave options available to all employees</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Growth and Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are committed to employee growth and development, and we support this in a variety of ways, including through a seminar program of visiting academics, in-house training programs (for all employees and specifically for people managers to ensure quality management of their direct reports and teams), and quarterly employee/manager check-ins to discuss career development goals and success. Additional opportunities are available to employees, including opportunities to attend external conferences or receive training. We encourage ongoing feedback, improvement, and growth for our employees, and we have incorporated those principles into our values, particularly the value &#8220;Embrace Feedback &#8211; and a growth mindset.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Wellness, Health, and Safety</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The well-being of Alector&#8217;s employees is critical to our business success, and we have designed our health and safety programs to reflect our commitment to a safe working environment that is in-line with regulatory standards. We mandate Environmental Health and Safety (EH&amp;S) training for all new employees and annual refresher training to ensure awareness of current policy and procedures. Additionally, we require job-specific technical and safety training for employees in laboratories and specialized work environments. We conduct internal safety inspections to ensure a continued safe working environment and to monitor employee adherence to policies and procedures. In addition, we engage with third-party EH&amp;S providers to review our programs and ensure compliance with regulatory health and safety standards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Flexible Work Options</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global pandemic taught us that great work can be accomplished in a variety of work environments. We embraced the principle of flexibility and moved to a hybrid working model for all whose roles allow for it. We empower our people to deliver great results by giving team members choice and flexibility about their work environment where possible, so that our employees can contribute productively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a Delaware corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080. Our telephone number is 415-231-5660. Our website address is www.alector.com. Information contained on, or that can be accessed through, our website is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the Securities and Exchange Commission (SEC).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended (Exchange Act).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use Alector, the Alector logo, and other marks as trademarks in the United States and other countries. This report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report, including logos, artwork, and other visual displays, may appear without the </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Channels for Disclosure of Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investors.alector.com), SEC filings, webcasts, press releases, corporate decks provided on our website, and conference calls. We use these mediums, including our website, to communicate with our members and the public about our company, our products, and other issues. It is possible that the information that we make available may be deemed to be material information. We therefore encourage our investors and others interested in our company to review the information that we make available on our website.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ris</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">k Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other public filings, in evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company, as more fully described below. The principal factors and uncertainties that make investing in our company risky include, among others:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are in various stages of drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant net losses in each year since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful development of our product candidates, which are in various stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they may be commercialized.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our research and drug discovery platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our research and drug discovery platform, our commercial opportunity may be limited.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in our efforts to carry out our obligations under our collaborations for our product development and research programs; for instance, without limitation, we may not complete in a timely manner or at all our contractual obligations to GSK and AbbVie.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in our efforts to obtain approval for additional or expanded indications for any product candidates that receive approval for a given indication.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen both limited success in drug development and evolving standards for regulatory approval. Further, our product candidates are based on new approaches and novel technology, and we must identify and develop new biomarkers that are signs of a disease or condition and that can measure impact on disease progression of our product candidates, which makes it difficult to predict the time and cost of product candidate development and subsequent regulatory approval.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations and financial results could be adversely impacted by the effects of worldwide economic conditions, including macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the COVID-19 pandemic and geopolitical events.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, including as a result of layoffs and furloughs, pausing of recruiting efforts, or regrettable employee attrition, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock may continue to be volatile, which could result in substantial losses for investors and could negatively impact our ability to conduct additional fundraising in the public markets.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business, Financial Condition, and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are in various stages of drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company with a limited operating history, focused primarily on developing therapeutics for neurodegenerative diseases, including FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and ALS. We commenced operations in May 2013. To date, we have financed our operations primarily through the sale of equity securities and upfront payments received in connection with our collaboration arrangements with AbbVie and GSK. We have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are in Phase 2 and Phase 3 clinical trials for one product candidate, latozinemab; we are in a Phase 2 clinical trial for one product candidate, AL002; and we are in a Phase 2 clinical trial for AL101. In the third quarter of 2023, we inactivated the IND for AL101 in FTD, given that we and GSK plan to develop AL101 for the potential treatment of larger indications, including Alzheimer&#8217;s disease and Parkinson&#8217;s disease. We previously decided to close the Phase 1 clinical trial for our AL044 product candidate based on initial PK and tolerability data. We inactivated the IND for AL044 in the third quarter of 2023. In addition, in 2022, AbbVie decided to terminate our CD33 collaboration program, after we and AbbVie concluded that further development of AL003, the asset being developed under that program, was not warranted. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will encounter risks and difficulties frequently experienced by clinical-stage biotechnology companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant net losses in each year since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses in almost every reporting period since our inception. We incurred net losses of $130.4 million, $133.3 million, and $36.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023, we had an accumulated deficit of $710.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have invested significant financial resources in research and development activities, including for our preclinical and clinical product candidates. We do not expect to generate revenue from product sales for several years, if at all. The revenue we currently generate from our collaboration arrangements with AbbVie and GSK is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variable and limited in amount. For our collaborations with AbbVie and GSK, we recognize collaboration revenue by measuring the progress towards complete satisfaction of the performance of obligation measured as the program costs are incurred. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2021, we entered into an agreement with GSK to collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101. Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments for latozinemab and AL101.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing our product candidates is expensive, and we expect to continue to spend substantial amounts as we fund our early-stage research projects and continue to advance our programs through preclinical and clinical development. Even if we are successful in developing our product candidates and obtaining regulatory approvals, launching and commercializing any product candidate will require substantial additional funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses and increasingly higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our research and discovery activities; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance our research and drug discovery platform, including our target, patient, and biomarker selections; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">progress our current and any future product candidates through preclinical and clinical development; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">work with our CDMOs to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">change or add contract manufacturers or suppliers; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals and marketing authorizations for our product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish sales, marketing, and distribution infrastructure to commercialize any products for which we obtain approval; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make milestone, royalty, or other payments due under any license or collaboration agreements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">take steps to seek protection of our intellectual property and defend our intellectual property against challenges from third parties; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property obtained through license and collaboration agreements;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract, hire, and retain qualified personnel, especially in light of a competitive hiring and compensation environment; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">implement additional internal systems and infrastructure related to cybersecurity; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">meet the requirements and demands of being a public company; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withstand periods of rising rates of inflation; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defend against any product liability claims or other lawsuits related to our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and achieve profitability depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completing research and preclinical and clinical development of our product candidates;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing a sustainable and scalable manufacturing process for our product candidates;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, assessing, acquiring, and/or developing new product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, whether alone or in collaboration with a partner, including the establishment of any necessary sales, marketing, and distribution infrastructure; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining adequate reimbursement for our product candidates from payors; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining market acceptance of our product candidates as viable treatment options; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving milestones and other payments under our current and any future collaboration arrangements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing impacts on our clinical trials resulting from factors related to the effects of worldwide economic conditions, including macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the COVID-19 pandemic and geopolitical events;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attracting, hiring, and retaining qualified personnel in a competitive compensation environment. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, clinical development of two of our product candidates has been terminated. AbbVie decided to terminate our CD33 collaboration program, after we and AbbVie concluded that further development of AL003, the asset being developed under that program, was not warranted. Additionally, we decided to close the Phase 1 clinical trial for our AL044 product candidate based on initial PK and tolerability data. Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our current or future collaborators&#8217; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and upfront payments received in connection with our collaboration arrangements with AbbVie and GSK. Developing our product candidates and conducting clinical trials for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#8217;s disease, ALS, and Parkinson&#8217;s disease, will require substantial amounts of capital. We will also require a significant amount of capital for the further development of our product candidates, and if any of such product candidates are approved, to commercialize any approved products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $548.9 million. In January 2024, we announced the closing of an underwritten public offering and the net proceeds from the offering were approximately $71.1 million. Our cash, cash equivalents and marketable securities as of December 31, 2023 plus the net proceeds from the offering total $620.0 million, which we anticipate provides runway through 2026. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may prove to be inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances, including periods of rising inflation, may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to grow more rapidly than we presently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global markets recently have experienced volatility and instability in connection with macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the COVID-19 pandemic and geopolitical events, including the ongoing conflict between Russia and Ukraine, and associated sanctions targeting Russia, and the ongoing conflict between Israel and Hamas, among other matters. In addition, the public market for and stock prices of biotechnology companies have experienced a significant downturn over the last few years. Our ability to raise money in the public markets may be severely impacted for the foreseeable future due to these factors. Additional capital may not be available when we need it, on terms acceptable to us, or at all. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder. Debt financing, if available, may be on unfavorable terms, including interest rates, and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing or other transactions, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified over 100 potential immune system targets. Three of our product candidates, latozinemab, AL002, and AL101 are in clinical development, and we continue to develop our research pipeline. Together, the development of these programs and product candidates requires significant capital investment. Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to obtain approval in other indications, and we may expend significant resources in seeking such approvals. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, such events could have a material adverse effect on our business, financial condition, and results of operations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. Our reliance on genetic screening and use of biomarkers to align patient risk profiles with targeted intervention may eventually require us to develop and use companion diagnostics, which could impact product development costs and timelines depending on the specific diagnostic test and any applicable regulatory requirements that would need to be met to enable its use.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful development of our product candidates, which are in various stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are in the clinical stages of development of many of the product candidates currently in our programs. To date, we have invested substantially in our efforts and financial resources to identify, procure intellectual property for, and develop our programs and product candidates, and provide general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may not successfully complete preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product candidates that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product candidates that we develop may be covered by third parties&#8217; patents or other intellectual property or exclusive rights; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may not be capable of being produced in sufficient quantities for development or commercialization at an acceptable cost, or at all; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors, if applicable. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Most of our product candidates are in the early stages of development, and all will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never completed a clinical development program. We are in Phase 2 and Phase 3 clinical trials for one product candidate, latozinemab, we are in Phase 2 clinical development for one product candidate, AL002, we are in a Phase 2 clinical trial for one product candidate, AL101. Further, we cannot be certain that any of our product candidates will be successful in clinical trials. For any product candidates that have advanced into clinical trials, we may terminate such trials or the clinical program prior to their completion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled, or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or partners will conduct these activities or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdiction. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or other diseases, we cannot be assured that any such product candidate will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our research and drug discovery platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our research and drug discovery platform, our commercial opportunity may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of our strategies is to identify and pursue clinical development of additional product candidates. Identifying, developing, obtaining regulatory approval, and commercializing additional product candidates for the treatment of neurodegenerative and other diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop, or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to obtain approval for additional or expanded indications for our approved product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. Conducting clinical trials for additional indications for our product candidates requires substantial technical, financial, and human capital resources and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be successful in our effort to obtain regulatory approval for our product candidates for additional indications even if we obtain approval for an initial indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, and we must identify and develop new biomarkers that are signs of a disease or condition and that can measure impact on disease progression of our product candidates, which makes it difficult to predict the time and cost of product candidate development and to subsequently obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focusing our research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are limited currently approved therapeutic options available for patients with FTD, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, ALS, and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our product candidates for treating neurodegenerative diseases. Developing product candidates and, if approved, commercializing our products for treatment of neurodegenerative diseases subjects us to a number of challenges, including obtaining disease modifying activity and efficacious dose in target tissue and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach to the treatment of neurodegenerative diseases aims to identify and select targets enriched in microglia and other myeloid immune cells which are genetically associated with neurodegenerative diseases. We identify and develop product candidates that are designed to cross the blood brain barrier in sufficient quantity and potency to enable efficacious dosing in the brain and engage the intended target, and we must be able to identify and develop biomarkers and biomarker assays that can accurately identify signs of a disease or condition, assist us in selecting the right patient population, demonstrate target and pathway engagement, and measure the impact on disease progression of our product candidates. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an IND or a clinical trial application (CTA) will result in the FDA or EMA, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in identifying, recruiting, and training suitable clinical investigators; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining required IRB/EC approval at each clinical trial site; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of delays to clinical trials, including as a result of temporary or permanent clinical hold by regulatory agencies for a number of reasons (see for example our discussions of ARIA in other risks described in this &#8220;Risk Factors&#8221; section), including:</span></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.759008424780358%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; </span></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.759008424780358%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as a result of a new safety finding that presents unreasonable risk to clinical trial participants; </span></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.759008424780358%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as a result of modifications to clinical trial protocols or related documentation; </span></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.759008424780358%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a negative finding from an inspection of our clinical trial operations or study sites; or </span></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.759008424780358%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials, or failing to return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty collaborating with patient groups and investigators; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by our CROs, other third parties, or us to adhere to clinical trial protocols and other requirements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current good clinical practices (cGCPs) requirements, or applicable EMA or other regulatory guidelines in other countries; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do or sooner than anticipated, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. For example, we had been developing AL003 with AbbVie to treat patients with Alzheimer&#8217;s disease but on June 30, 2022, AbbVie provided written notice to us formalizing the decision to terminate the CD33 collaboration program under which AL003 was being developed. AbbVie, or any other collaboration partner may, in the future decide to terminate collaboration programs based on, among other things, our clinical trial data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA, or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, and impacts of worldwide economic conditions, including the COVID-19 pandemic and other geopolitical events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, which could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We pursued measures to enroll our Phase 3 INFRONT-3 and Phase 2 INVOKE-2 trials, for example, by opening additional clinical trial sites and expanding recruitment efforts to enroll the INFRONT-3 trial. We completed enrollment in those trials in the second half of 2023. Target enrollment of our Phase 3 INFRONT-3 trial was based on feedback from the FDA and EMA. However, we may experience difficulties in patient enrollment in other clinical trials for a variety of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to a trial site; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrolling patients in our clinical trials caused by worldwide economic conditions, including the COVID-19 pandemic and other geopolitical events; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability of approved products that target the patient populations that we are seeking to enroll;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will not complete such trials or that we may not be able to collect data from such patients for any reason. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment of patients in our clinical trials and maintaining patients in our ongoing clinical trials have been, and may continue to be, delayed or limited due to the effects of worldwide economic conditions, including the COVID-19 pandemic and other geopolitical events. While the impact of the COVID-19 pandemic is lessening, the effects resulting from the COVID-19 pandemic or other public health concerns could continue to delay or prevent the anticipated readouts from our clinical trials. On May 11, 2023, the federal government ended the COVID-19 public health emergency which ended a number of temporary changes made to federally funded programs while others continue to be in effect. The full impact of this termination of the national emergency and such policy changes on FDA and other regulatory policies and operations remain unclear.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our partners may encounter difficulties or delays in enrollment of our clinical trials, due to the availability of newly approved therapies and competing products. For example, lecanemab has received FDA approval for the treatment of Alzheimer&#8217;s disease, and donanemab, an investigative drug for the treatment of Alzheimer&#8217;s disease, may receive FDA approval in 2024. As a result, our or our partners&#8217; ability to enroll participants in clinical trials for Alzheimer&#8217;s disease may be hampered if potential participants choose to instead avail themselves of approved therapies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in healthy volunteers or one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocol elements, and the rate of dropout among clinical trial participants. Open-label or long-term extension studies may also extend the timing and cost of a clinical program substantially. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, in our ongoing INVOKE-2 Phase 2 clinical trial in Alzheimer&#8217;s disease, treatment-emergent MRI findings resembling ARIA have been observed. ARIA are MRI findings that may include vasogenic edema, sulcal effusions, microhemorrhages and/or superficial siderosis. The incidence of ARIA has been shown to increase in Alzheimer&#8217;s disease patients with the administration of certain Alzheimer&#8217;s disease therapeutics, namely anti-&#946;-amyloid antibodies. We do not yet know whether the biological mechanism(s) causing these MRI changes are the same as that associated with the ARIA that has been described with anti-amyloid beta antibodies. In our INVOKE-2 Phase 2 clinical trial, most cases resembling ARIA were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred early in the trial in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, at that time we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, and are following recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations. If these measures are not successful in managing the ARIA in our trials, then the FDA, EMA or other regulatory authority may suspend clinical trials, delay or deny approval, or require a more restrictive label or box warning on an approved product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential. Further, even if regulatory approval is secured for any of our product candidates, we cannot be assured that a federal court will not modify, invalidate, or revoke such approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations and financial results could be adversely impacted by the effects of the COVID-19 pandemic or other global health concerns in the United States and the rest of the world.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 11, 2023, the federal government ended the COVID-19 public health emergency, which ended a number of temporary changes made to federally funded programs while some continue to be in effect. The full impact of this termination of the national emergency and the wind-down of the public health emergency on the FDA and other regulatory policies and operations is unclear. To the extent the COVID-19 pandemic or other disease outbreaks continue to pose a threat to our ability to conduct our business operations as planned, there can be no assurance that we will be able to avoid a material impact on our business from the pandemic or its consequences. Additionally, a resurgence of the COVID-19 pandemic or other public health concerns could adversely impact economic and market conditions and lead to an extended period of rapid inflation and global economic slowdown.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020 and 2021, the FDA issued a number of COVID-19 related guidance documents for manufacturers and clinical trial sponsors, many of which have expired or were withdrawn with the expiration of the COVID-19 public health emergency declaration on May 11, 2023, although some COVID-19 related guidance documents continue in effect. Should the FDA issue additional guidance that mandates material changes to our clinical trials in response to a pandemic or other public health outbreak, the costs of such clinical trials may increase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The spread of COVID-19 and subsequent variants has caused us to modify our business practices including by employing more remote workers and operating under a hybrid work model. In addition, we may take actions as required by government authorities and regulations or that we determine are in the best interests of our employees, customers, partners, and suppliers. We continue to maintain both a remote and hybrid work force, with many employees continuing to work remotely.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent the ongoing COVID-19 pandemic or other public health concerns adversely affect our operations and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change. Some competitors have achieved, and there is a possibility that other competitors will achieve regulatory approval before us. Our competitors&#8217; therapies may be safer, more advanced, or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#8217;s disease, Parkinson's disease, and ALS. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. For example, in January 2023, FDA granted accelerated approval, and in July 2023, FDA granted full approval to lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer&#8217;s disease developed by Eisai Co., Ltd. (Eisai) and Biogen Inc. (Biogen). Eisai has also filed marketing authorization applications for lecanemab in Japan and Europe. Eisai further announced that they expect to initiate a Phase 1 clinical trial with a TREM2 agonist in Alzheimer&#8217;s disease in 2024. Additionally, in July 2022, Biogen announced that the FDA accepted an NDA for tofersen, a drug for ALS associated with mutations in superoxide dismutase 1 (SOD1), and in September 2022, Amylyx Pharmaceuticals, Inc. announced that the FDA approved RELYVRIO&#153; (sodium phenylbutyrate and taurursodiol) for the treatment of adults with ALS. The FDA granted accelerated approval to tofersen in April 2023, to be marketed as QALSODY&#153;. In seeking accelerated approval, Biogen pointed to biomarker data and the slowing of disease progression in a longer-term follow-up in their study. In addition, companies such as Prevail Therapeutics, Inc. (Prevail) and Passage Bio, Inc. (Passage Bio) have developed gene therapy based products (PR006 and PBFT02, respectively) for the treatment of FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Vigil Therapeutics has developed small molecule (VG-3927) and antibody (iluzanebart) candidates targeting TREM2. There are also pharmaceutical and biotechnology companies, such as Denali Therapeutics, Inc. (Denali), F. Hoffman La Roche Ltd. (Roche), and Aliada Therapeutics, Inc. (Aliada), that are developing technologies for the transport of products across the blood-brain barrier. Other competitors are pursuing product candidates that act on the same targets or through comparable mechanisms of action.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, including through fast track designation, priority review, accelerated approval or breakthrough therapy designation, and may obtain orphan drug exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#8217; products, and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of our product candidates is complex, and we may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products, if approved, for patients, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The processes involved in manufacturing our product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in large quantities. Our CDMOs may be unable to successfully produce or increase the manufacturing scale or capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If any of the foregoing occurs, the development, testing, and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained in any or all jurisdictions in which such approval or launch is intended, which could significantly harm our business. The same risk would apply to our internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design, and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA, and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA, and foreign regulatory authority requirements, including complying with current good manufacturing practices (cGMPs) on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in commercial activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists are expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may inhibit our efforts to commercialize any approved product on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability, and our ability to recognize revenue from such prices; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent commercialization organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of any of our products will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety as demonstrated in clinical trials and published in peer-reviewed journals; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sufficient third-party coverage or reimbursement; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to offer appropriate patient access programs, such as co-pay assistance; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which physicians recommend our products to their patients; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convenience and ease of dosing and administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product candidate is approved by FDA, EMA, or other regulatory agencies; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA, EMA, or other comparable foreign regulatory authorities, including any limitations, contraindications, or warnings contained in a product&#8217;s approved labeling; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on how the product is distributed; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publicity concerning our products or competing products and treatments; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any products we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulations that govern marketing approvals, pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted or potential future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continued governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or render commercially inviable our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid, and Veterans Affairs hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors, and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA, or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current and future CMS coverage restrictions on classes of drugs that encompass our product candidates, including our candidates for treating Alzheimer&#8217;s disease, could have a material adverse impact on our ability to commercialize our product candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates for which we intend to seek approval may face biosimilar competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products entitled to the 12-year period of exclusivity, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is analogous to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get it on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, such product candidates may become subject to competition from such biosimilars, with the attendant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any legal proceedings or claims involving or against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become subject to legal proceedings and claims that arise in the ordinary course of business, including intellectual property, data privacy, product liability, employment, class action or derivative, whistleblower and other litigation claims, and governmental and other regulatory investigations and proceedings. Such matters can be time-consuming, divert management&#8217;s attention and resources, cause us to incur significant expenses or liability, or require us to change our business practices. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change, and could adversely affect our financial condition and results of operations. Because of the potential risks, expenses, and uncertainties of litigation, we may, from time to time, settle disputes, even where we have meritorious claims or defenses, by agreeing to settlement agreements. Any of the foregoing could adversely affect our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection acts or in countries outside the United States under the applicable legal regimes. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense or negotiations of a settlement would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased or interrupted demand for our products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exhaustion of any available insurance and our capital resources; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any product candidate. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not submitted an application for or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, the U.S. federal government has experienced and may in the future experience shutdown or budget sequestration, which could result in significant reductions to the FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. To the extent FDA and other regulatory authorities experience any delays or limited resources in reviewing our regulatory applications or requests for meetings and/or guidance, and inspection of manufacturing facilities prior to regulatory approval, e.g., due to the effects of worldwide economic conditions, including the COVID-19 pandemic or other geopolitical events, or other reasons, we may experience significant delays in our anticipated timelines for our clinical studies and/or for seeking regulatory approvals, which could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or the interpretation of the results of our clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately or insufficiently effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio, on its own or when compared to the standard of care, is acceptable; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval or resulting in delays in our regulatory approval, including, for example, in connection with the FDA&#8217;s approval of </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biogen&#8217;s Aduhelm in Alzheimer&#8217;s disease amid questions regarding the underlying data, as well as the government investigation of the FDA&#8217;s approval process for Aduhelm.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, any of which could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any regulatory approvals we may have obtained. If the Supreme Court reverses or curtails the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chevron</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> doctrine, which gives deference to regulatory agencies such as FDA to interpret relevant statutes, more companies may bring lawsuits against FDA to challenge longstanding FDA decisions and policies which could undermine FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt FDA&#8217;s normal operations, which could delay FDA&#8217;s review of our regulatory submissions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment-emergent MRI findings resembling ARIA have been observed. in our INVOKE-2 Phase 2 clinical trial. ARIA are MRI findings that may include vasogenic edema, sulcal effusions, microhemorrhages and/or superficial siderosis. The incidence of ARIA has been shown to increase in Alzheimer's disease patients with the administration of certain Alzheimer&#8217;s disease therapeutics, namely anti-&#946;-amyloid antibodies. We do not yet know whether the biological mechanism(s) causing the MRI changes in INVOKE-2 are the same as that associated with the ARIA that has been described with anti-amyloid beta antibodies. In INVOKE-2, most cases resembling ARIA were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred early in the trial in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, at that time we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, and are following recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw approvals of such product and cause us to recall our products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way the product is administered, monitor patients over the course of treatment, or conduct additional clinical trials or post-approval studies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, pre-prescription screening or ongoing monitoring for ARIA and/or other adverse events, and/or other elements, such as boxed warning on the packaging (for example, as required for lecanemab), to assure safe use; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently are and may continue in the future to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently are and may continue in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe, Latin America, Asia, or Australia. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, as regulatory authorities in different jurisdictions may impose different requirements for approval, including requirements with respect to trial design or trial diversity. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. Our reliance on genetic screening and use of biomarkers to align patient risk profiles with targeted intervention may eventually require us to develop and use companion diagnostics, which could result in additional regulatory requirements that would need to be met to enable its use.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fails to comply with the regulatory requirements in international</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">markets or fails to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive post-marketing requirements and regulatory scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA, or marketing authorization application (MAA). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including any requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to ensure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning letters that would result in adverse publicity; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approvals; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any of our ongoing clinical trials; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products; or </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require a product recall. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have orphan drug designation from the FDA for latozinemab for treatment of FTD and may seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. While latozinemab has (and AL101 previously had) orphan drug designation for treatment of FTD, we may be unable to reap the benefits associated with orphan drug status. In addition, we may be unable to obtain orphan drug designation for any additional product candidates, if we seek such designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other NDA or BLA application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even though the FDA has approved orphan drug status for latozinemab for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, in litigation in 2021, a court disagreed with the FDA&#8217;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease, and not to all uses or indications within the entire designated disease or condition. This appellate court decision created uncertainty in the application of orphan drug exclusivity. In January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the applicable court ruling, the FDA intends to continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that has not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have obtained Fast Track designation and Breakthrough Therapy designation from the FDA, for latozinemab for the treatment of patients with FTD carrying specific genetic mutation in the granulin gene, but we may be unable to obtain or maintain the benefits associated with the Fast Track designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product and the specific indication for which it is being studied.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FDA granted Fast Track designation for latozinemab, and in January 2020, the FDA granted Fast Track designation for AL101, each for the treatment of patients with FTD carrying specific genetic mutations in the granulin gene. If our clinical development program does not continue to meet the criteria for Fast Track designation, or if our clinical trials are suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we may not realize all the benefits associated with the Fast Track program. For example, we inactivated the AL101 IND for FTD in the third quarter of 2023, and therefore Fast Track designation no longer applies. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the FDA granted Breakthrough Therapy Designation to latozinemab for the treatment of FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, in 2010, the Patient Protection and Affordable Care Act, or Affordable Care Act (ACA) was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by administrative or legislative action will impact our business, financial condition, and results of operations. Complying with any new legislation or changes in healthcare regulation could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of approved products, which could have a material impact on our business. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. In March 2023, the CMS published its first guidance on how negotiations will be conducted, starting in 2026 for high expenditure drugs as determined and selected by Health and Human Services. In June 2023, CMS issued a revised guidance for the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. Various industry stakeholders, including pharmaceutical companies, the U.S. Chamber of Commerce, the National Infusion Center Association, the Global Colon Cancer Association, and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the Inflation Reduction Act are unconstitutional. The impact of these judicial challenges as well as future legislative, executive, and administrative actions and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products candidates. Such initiatives and legislation may affect the prices we may obtain or demand for any of our product candidates for which we may obtain regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, in April 2022, CMS released a national policy for coverage of aducanumab and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer&#8217;s disease. CMS reiterated this policy in January 2023 in connection with the accelerated approval of lecanemab. According to the two-part National Coverage Determination (NCD), Medicare will cover monoclonal antibodies that target amyloid (or plaque) for the treatment of Alzheimer&#8217;s disease that receive traditional approval from the FDA under coverage with evidence development. Following full approval of lecanemab in July 2023, CMS reiterated that it would broadly cover the medication while continuing to gather data. Additionally, for drugs that FDA has not determined to have shown a clinical benefit or that received an accelerated approval, Medicare will provide coverage in FDA or National Institutes of Health approved clinical trials. In February 2023, CMS again reiterated these policies in rejecting a petition from the Alzheimer&#8217;s Association to provide wider coverage for lecanemab. In June 2023, CMS announced that Medicare will cover new Alzheimer&#8217;s drugs with traditional FDA approval when a physician and clinical team participate in CMS&#8217; registry to collect evidence on how these drugs work in the real world. Current and future CMS coverage restrictions on classes of drugs that encompass our product candidates could have a material adverse impact on our ability to commercialize our product candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance requirements and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. Further, FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for our product if we obtain regulatory approval; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to receive or set a price that we believe is fair for our products; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the above healthcare reform measures and others that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. This could lower the price that we receive for any approved product. There may be further federal and state legislation and regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our product candidates, if approved. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">comply with the laws of the FDA, EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide true, complete, and accurate information to the FDA, EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">comply with clinical or manufacturing standards; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">report financial information or data accurately or to disclose unauthorized activities to us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations, and financial conditions could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among other things the federal Anti-Kickback Statute, prohibits, persons from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, impose criminal and civil penalties, including through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require applicable manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments and other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as nurse practitioners and physician assistants, among others) and teaching hospitals, and information regarding ownership and investment interests held by physicians (as defined by law) and their immediate family members. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, and unfair competition laws may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements, as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State laws also require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration, and items of value provided to healthcare professionals and entities. </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign laws also govern the privacy and security of health information in certain circumstances, such as Washington&#8217;s My Health, My Data Act, which, among other things, provides for a private right of action. Many of these laws differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to security, privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A wide variety of state, national, and international laws and regulations apply to security and cybersecurity requirements and the collection, use, retention, protection, disclosure, transfer, and other processing of personal data, including the data obtained in our clinical trials. These laws and regulations include the General Data Protection Regulation (GDPR) in the European Union and similar requirements in other jurisdictions, as well as state privacy laws within the United States. These security and data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. We are continually working to comply with these laws, and we have devoted, and anticipate needing to continue to devote significant additional resources to our compliance efforts. It is possible that new legislation or regulations may impose new obligations and requirements on similarly situated companies, and these laws or regulations may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction, that can result in new or modified compliance obligation or that may be inconsistent with our policies and practices. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or perceived failure to adequately comply with applicable laws and regulations relating to security, privacy, and data protection, or to protect our systems, personal data, and other data we process or maintain, could result in regulatory fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, and could impact our ability to use, process, disclose, or transfer data obtained in our clinical trials, any of which could materially affect our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In the past, the U.S. government has experienced budgetary shutdowns and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business activities may be subject to the Foreign Corrupt Practices Act (FCPA), similar anti-bribery and anti-corruption laws, and other regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations, or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who engage in our clinical trials or prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these investigators, prescribers and purchasers are subject to regulation under the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently use and expect to continue to use third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop, including our arrangements with AbbVie, GSK, and Adimab. As discussed previously, GSK can terminate its GSK Agreement with us, subject to certain notice provisions, in its entirety and for convenience at any time. Similarly, AbbVie can terminate the AbbVie Agreement for convenience at any point during the term of the agreement, including the research, development, and clinical trial process. Adimab can terminate its agreements with us in the event of uncured materials breaches, and subject to certain notice requirements. In the event that one of our current third-party collaborators discontinues its collaboration with us, we may not be able to find a suitable alternative collaboration partner or partners, or we may need to obtain and expend additional and unanticipated capital to maintain our current development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our likely collaborators for any other collaboration arrangements include large and mid-sized pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and academic institutions. Such arrangements with any third parties, generally provide us with shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of our current collaborations or any collaboration that we may enter into.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations involving our research programs, or any product candidates we may develop, pose risks to us, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs, for example, based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, the collaborator&#8217;s assessment regarding the commercial viability of the product candidate, or external factors such as an acquisition that diverts resources or creates competing priorities or collaborators may elect to fund or commercialize a competing product; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, provide insufficient quantities of materials for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity, and enforceability of our intellectual property; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may own or co-own intellectual property covering our product candidates or research and development programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and maintain regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may restrict us from researching, developing, or commercializing certain products or technologies without their involvement; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators with manufacturing, marketing, or distribution rights to one or more product candidates may not commit sufficient resources to the manufacture, marketing, or distribution of such product candidates; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control, and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how, or intellectual property of the collaborator relating to our products, product candidates, or research programs; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if our collaborators do not satisfy their obligations under our agreements with them, if they terminate our collaborations with them, or if we fail to satisfy our obligations to our collaborators, we may not be able to develop or commercialize product candidates as planned; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of a collaboration agreement may be amended in a manner that could negatively impact us;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control, and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished, or terminated.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, AbbVie, after reviewing the CD33 collaboration program with us, decided to terminate the CD33 collaboration program, under which AL003 was being developed. Additionally, GSK is conducting the PROGRESS-AD Phase 2 trial with AL101/GSK4527226, and Alector is responsible for up to $140.5 million of the costs of such study. As such, the timing at which such costs are incurred, and the day-to-day operations of conducting such study are not within Alector&#8217;s control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face significant competition in seeking appropriate collaborations. For example, business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not realize the benefit of collaborations if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. For example, AbbVie may decide not to exercise its exclusive option to develop and commercialize our TREM2 program, and in that case, we would not receive a $250.0 million milestone payment for such opt-in or any future payments, and all rights to the TREM2 program would revert back to us. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#8220;Risk Factors&#8221; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. For example, if our CROs or clinical sites deviate from the clinical protocol or cGCPs, then such deviations could have serious negative impacts on our trials, including exclusion of patients or sites from our trials, which could put patients at risk or make assessment of the clinical endpoints infeasible or inconclusive. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on government-sponsored databases within certain timeframes. We may also be exposed to additional liabilities if our contracted third parties engage in activities associated with improper use of information obtained in the course of patient recruitment for our clinical trials, cGCP noncompliance or noncompliance under applicable privacy laws, which could result in regulatory sanctions and cause serious harm to our reputation and business operations. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, clinical data to advance development of any of our product candidates or to achieve marketing approvals for any of our product candidates and we will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of materials for our research programs, preclinical studies, clinical trials, and for commercialization of any product candidates that we may develop. Additionally, GSK, and AbbVie, have certain product manufacturing rights under their respective agreements. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any manufacturing facilities. We currently rely on CDMOs for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacture of each of our product candidates, as well as with GSK for latozinemab and AL101, and with AbbVie for AL002. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to produce required volume in a timely manner and to quality standards. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our CDMOs or collaboration partners, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures, or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We, and the CDMO partners on which we rely, depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and the CDMO partners on which we rely depend on third-party suppliers for the supply of the raw materials required for the production of our product candidates, and we expect to continue to depend on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Their dependence on these third-party suppliers and the challenges faced in obtaining adequate supplies of raw materials involve several risks, including supply chain issues caused by the effects of worldwide economic conditions, including the COVID-19 pandemic, national security concerns, export or import restrictions, trade tariffs, or other geopolitical events, limited control over pricing, the availability of such materials, the quality of such materials, and delivery schedules. To the extent our business relies on customers, vendors, or suppliers in countries where the U.S. government has imposed any of these or other trade restrictions, our business may experience a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">material adverse effect. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We do not have long-term supply agreements, and we purchase our required drug product on a development manufacturing services agreement or purchase order basis. We cannot be certain that suppliers will continue to provide the quantities of these raw materials that are required or satisfy the anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials, including those caused by the effects of worldwide economic conditions including the COVID-19 pandemic or other geopolitical events, could materially harm our ability to manufacture our product candidates until a new source of supply, if any, can be identified and qualified. In such an event, we may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of the suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. As our product candidates enter and progress through clinical development, we continue to pursue intellectual property protection with respect to certain aspects of those product candidates. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in cases in which we have only filed provisional patent applications on certain aspects of our technology and product candidates, each of those provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our patent applications, or those of our collaborators, do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents or those of our collaborators with respect to our product candidates. With respect to both our intellectual property and that of our collaborators related to our product candidates, we cannot predict whether the patent applications we and our collaborators are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we or our collaborators may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our collaborators were first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our or our collaborators&#8217; pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we or our collaborators license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we or our collaborators have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our collaborators may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or foreign patent offices or become involved in opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, inventorship dispute, or interference proceedings or other similar proceedings challenging our or our collaborators&#8217; patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us. Moreover, we, or any one of our collaborators, may have to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, in which a third party challenges the features of patentability with respect to our or our collaborators&#8217; patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other inventorship dispute, we may be required to obtain and maintain licenses from third parties. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with rights to exclude others for sufficient period of time from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our patents and patent applications may be co-owned with third parties. In addition, collaborators or future licensors may co-own their patents and patent applications with other third parties with whom we do not have a direct relationship. Our rights to certain of these patents and patent applications may be dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our collaborators or future licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology to the extent such products and technology are not also covered by our intellectual property. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize are subject, in part, to the terms and conditions of agreements with others, including terms and conditions regarding intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our product candidates, and development and commercialization of our product candidates are subject to the terms and conditions of certain collaboration agreements with third parties. For example, in 2014 we entered into the Adimab Collaboration Agreement with Adimab. Under the 2014 Adimab Collaboration Agreement, we are developing antibodies discovered by Adimab in our latozinemab and AL101 product candidates, and we are developing an antibody optimized by Adimab in our AL002 product candidate. In August 2019, we entered into a new collaboration agreement with Adimab for development of antibodies for use in future programs. In 2021, we entered into another collaboration agreement with Adimab, which granted us an exclusive option to obtain a specified number of engineered sequences discovered or optimized by Adimab and directed against targets that we select. Additionally, in October 2017, we entered into an agreement with AbbVie to co-develop and commercialize medicines with AbbVie to treat Alzheimer&#8217;s disease and other neurodegenerative diseases. In July 2021, we entered into the GSK Agreement to collaborate on the global development and commercialization of the progranulin-elevating monoclonal antibodies, latozinemab and AL101.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our agreements with Adimab, AbbVie, GSK, and other agreements we enter into in the future may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilize technology retained by such collaborators to the extent such products are not also covered by our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, subject to the terms of any such agreements, we may not have the right to control the preparation, filing, prosecution, and maintenance, and we may not have the right to control the enforcement and defense of certain patents and patent applications relating to or affecting our development candidates. For example, the GSK Agreement provides GSK with certain rights with respect to preparation, filing, prosecution, maintenance, enforcement, and defense of certain patents and patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that patents and patent applications as to which preparation, filing, prosecution, maintenance, enforcement, or defense are controlled by our collaborators will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our collaborators fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, our rights to such patents may be reduced or eliminated, our right to develop and commercialize any of our product candidates that are the subject of such rights could be adversely affected, and we may have a reduced ability to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to control prosecution of patent applications we have licensed to and from collaborators, we may still be adversely affected or prejudiced by actions or inactions of our collaborators that took place prior to the date upon which we assumed control of patent prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our or our collaborators&#8217; patents may be subject to a reservation of rights by one or more third parties. For example, we received an award from the National Institute of Health in support of our research into the production and characterization of novel therapeutic antibodies against the neurotrophic factor PGRN degrading receptor SORT1. As a result, the U.S. government may have certain rights to resulting intellectual property. When</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements for public use under federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in facilities in the United States in certain circumstances and if the U.S. government does not waive this requirement. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the government may implement new policies and guidelines that impose certain risks on our intellectual property. On July 28, 2023, President Biden issued an Executive Order that emphasized a preference for domestic manufacturing for subject inventions under the Bayh Dole Act. On December 7, 2023, the National Institutes of Science and Technology (NIST) published a draft framework for expanding the use of the government&#8217;s march-in rights under Bayh Dole. To date, the government has not exercised its march-in rights against any federal funding recipient (assignee or exclusive licensee). However, the framework proposes using the price of pharmaceuticals as a factor in determining whether a federally funded drug is sufficiently accessible to the public and as a basis for the exercise of the government&#8217;s march-in rights. If the final framework applies to certain inventions developed with government funding and no waivers or exceptions apply, the U.S. government could exercise its march-in rights for these subject inventions under the new framework, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we option or license intellectual property rights from our collaborators or future licensors or otherwise experience disruptions to our business relationships with our collaborators or future licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into agreements with our collaborators to option or license certain intellectual property and may need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain additional intellectual property rights at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, each of our agreements with collaborators do, and we expect our future agreements will, impose various economic, development, diligence, commercialization, and other obligations on us. Certain of our collaboration agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. In spite of our efforts, our collaborators might conclude that we have materially breached our obligations under such agreements and might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these agreements. If termination of these agreements causes us to lose the rights to certain patents or other intellectual property, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of the option or license rights granted under the agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the collaborator that is not subject to the option or license rights granted under the agreement; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our collaborators and us and our other partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we currently have rights to option or license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in or into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert counterclaims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we, our collaborators, or any of our future licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our collaborators or licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We also are dependent on our collaborators or licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ongoing conflict between Russia and Ukraine, including the sanctions targeting Russia, could interfere with filing of patent applications, prosecution of applications, and maintenance of issued patents in Russia, Ukraine, and via the Eurasian Patent Office. For example, the conflict and sanctions could interfere with payment of filing fees, extension fees, and annuities. The conflict and sanctions could also interfere with enforcement or defense of patents issued in Russia, Ukraine, and via the Eurasian Patent Office. Similarly, the ongoing conflict between Israel and Hamas could interfere with our ability to prosecute, maintain, enforce and defend patents in Israel. These conflicts and associated sanctions could therefore increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents Act (the America Invents Act), the first inventor to file a patent application in the United States is entitled to the patent on an invention regardless of whether another party was the first to invent the claimed invention. Therefore, a third party that filed a patent application in the USPTO after March 2013, but before us, could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This possibility requires us to be cognizant of the time from invention to the time of filing a patent application. Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to file any patent application related to our product candidates or other technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain procedures at the USPTO under the America Invents Act could affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Rulings from the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have narrowed the scope of patent protection available in certain circumstances and weakened the rights of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent owners in certain situations. For example, in the recent Supreme Court decision, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amgen Inc. v. Sanofi, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">143 S.Ct. 1243 (2023)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Court affirmed a Federal Circuit decision and held that patent claims reciting a genus of antibodies defined by a functional property were invalid because the specification did not provide sufficient teaching to make and use the full scope of the claimed genus. These rulings have created uncertainty with respect to the validity and enforceability of patents, once obtained, for example, with respect to written description and enablement requirements. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, or enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Protection Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate and academic collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining, through acquisitions or otherwise, necessary rights to our product candidates or other technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many pharmaceutical companies, biotechnology companies, and academic institutions that are competing with us in the field of neurodegeneration therapy may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owners&#8217; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any rights to compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement, misappropriation, or other violation against us or our collaborators may prevent or delay the development and commercialization of our product candidates and other technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The field of discovering treatments for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by various companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. Additionally, the technology used in our product candidates is still in development and no products utilizing similar technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our and our collaborators&#8217; ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, and we may become subject to, or threatened with, such actions in the future, regardless of their merit. In addition, we may undertake costly administrative proceedings for challenging third party patents, including post-grant, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot be assured that our product candidates and other technologies that we have developed, are developing, or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing product candidates, and other technologies might assert are infringed by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our product candidates or other technologies infringes upon these patents. In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable, and infringed by our product candidates or other technologies. In this case, the holders of such patents may be able to block our ability to manufacture or commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates or other technologies, which could harm our business significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights or to defend against allegations of patent infringement, which could be expensive, time consuming, and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our future licensors or collaborators, might not have been the first to invent the claimed inventions covered by the issued patents or pending patent applications that we license in the future; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may harm our business; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our leadership, including our Chief Executive Officer, Dr. Arnon Rosenthal. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to either find suitable replacements in the event of such loss or to attract senior management personnel to fill open positions could result in delays in the development of our product candidates and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct our operations at our facility in South San Francisco, California, a region that is headquarters to many other biotechnology companies as well as many academic and research institutions, which may limit our ability to hire competitively and retain highly qualified personnel from or outside of our region.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided and will continue to provide restricted stock units, stock option grants, and other equity awards that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to effectively manage the size and capabilities of our organization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 244 full-time employees. As our development plans and strategies develop, and as we progress development of our product candidates and move towards commercialization, we will be required to add additional managerial, operational, financial, and other personnel. We will need to effectively manage the size and capabilities of our organization and any future growth through significant responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, retaining, and motivating additional employees; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to collaborators and other third parties; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanding our operational, financial and management controls, reporting systems, and procedures; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing increasing operational and managerial complexity. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our near-term financial performance and development plans also require that we manage our personnel, and we recently committed to a plan to reduce our workforce to better align our resources with our current strategic priorities. We initiated a reduction in force impacting approximately 30 employees across the organization effective March 2023. One-time restructuring charges associated with the reduction in force were approximately $1.7 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits. Most cash payments related to these expenses were paid out during the first half of 2023. Any future reductions in or restructurings of our workforce, whether due to market downturns, uncertainty in capital markets, other macroeconomic changes or any other reason, may generate severance and other costs that may cause our business and operating results to suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively manage or expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates, and accordingly, may not achieve our research, development, and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have engaged in strategic collaborations and may in the future engage in acquisitions, collaborations, or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have engaged in strategic collaborations in the past, such as our strategic collaborations with AbbVie and GSK, and we may engage in various acquisitions, collaborations, and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition, collaboration, or strategic partnership may entail numerous risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">volatility with respect to the financial reporting related to such arrangements, such as our expected variability in the recognition of revenue each quarter from the AbbVie and GSK Agreement based on the percentage-of-completion basis under the applicable accounting rules; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assumption of indebtedness or contingent liabilities; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential goodwill impairment resulting from such acquisitions;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issuance of our equity securities which would result in dilution to our stockholders; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property, products, and product candidates of an acquired company by our partners, including difficulties associated with integrating new personnel; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition, collaboration or strategic partnership; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals, that may impact their ability to fulfill their obligations under such transaction;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks that the other party to such a transaction may exercise its rights under the applicable agreement in a way that negatively impacts us; and</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired or partnered intellectual property, technology, and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have experienced cyber-attacks in the past, and our internal computer systems, or those used by third parties with which we engage, such as research institution collaborators, clinical trial sites, and CROs or other vendors, contractors or consultants, may fail or suffer other breakdowns, cyberattacks, or information security breaches or sensitive data loss that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced cyberattacks in the past that have not had a material effect on our business operations, and we face the risk of future cyberattacks that may or may not have a material effect. Despite the implementation of security measures, our internal computer systems and those of third parties with which we engage, such as research institution collaborators, clinical trial sites, and CROs and other vendors, contractors and consultants, may be vulnerable to damage, interruption, or other disruption from various causes, including computer viruses and other malicious code, and may be vulnerable to unauthorized access. Likewise, data privacy or security breaches or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets, or personal information of our employees, patients, customers, or other business partners, may be exposed to unauthorized persons or to the public or may otherwise be misused. As the cyber-threat landscape evolves, especially as certain of our employees have engaged in remote or hybrid work, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect, mitigate, and defend against. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. During times of war and other conflicts, we and our business counterparties, including third parties upon which we rely, may be vulnerable to a heightened risk of these attacks. Such attacks might involve the use of sophisticated malware, including ransomware or various types of service denial tactics. They can be initiated through harmful websites or by leveraging phishing strategies, social engineering tactics, or credential stuffing. This might also include brute force attacks, along with other contemporary malicious methods which are always changing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a breakdown, cyberattack, or other information security breach or incident occurs, it could cause damage to or interruptions or other disruptions in our operations or those of third parties with which we engage, and could result in damage to, the loss or unavailability of, or misappropriation or other unauthorized use or processing of, sensitive data, including personal information and confidential information, such as our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss or unavailability of, or damage to, clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third-party research institution collaborators, clinical trial sites, and CROs and other vendors, consultants and contractors for research and development of our product candidates, and we rely on other third parties, such as CDMOs and CROs, to manufacture our product candidates and to conduct clinical trials, respectively. Supply-chain attacks against third-party actors like these have increased in frequency and severity, and we cannot guarantee that third-party infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. Cyberattacks, security breaches and incidents, and disruptions, interruptions, and similar events relating to their computer systems and operations could also have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our business counterparties, including third parties on which we rely, may be unable to anticipate or prevent techniques used to obtain unauthorized access to or to compromise our or our business counterparties&#8217; systems because such techniques change frequently and are generally not detected until after an incident has occurred. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions or other disruptions, attacks, or compromises of, or security breaches or incidents impacting, systems that could adversely affect our business and operations and/or result in the loss or unavailability of, or damage to, critical or sensitive data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any disruption or security breach or incident resulting in loss or unavailability of, or damage to, our data or systems, or those of third parties on which we rely, or inappropriate use, disclosure, or modification of personal, sensitive, confidential or proprietary information, could result in our being subject to claims, demands, and litigation, investigations and other regulatory proceedings, and fines and other liabilities, as well as in delays to further development and commercialization of our product candidates. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, there can be no assurance that our efforts will prevent service disruptions, or prevent or identify vulnerabilities or security breaches or incidents, that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">could adversely affect our business and operations or result in the loss, unavailability, or corruption of, or inappropriate access to or use of, confidential, personal, or other sensitive information or company resources. Any such interruptions, breaches or incidents, or the perception that any have occurred, could result in financial, legal, business, or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other privacy and security breaches or incidents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions, including as a result of global pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to pandemic events and other events beyond our control, such as the spread of disease, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political unrest, including the ongoing conflicts between Russia and Ukraine and between Israel and Hamas, and other natural or man-made disasters or business interruptions, for which we are either totally or partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster, global pandemics, or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of our operations including our corporate headquarters are located in a facility in South San Francisco, California. Damage or extended periods of interruption to our corporate, development, or research facilities due to fire, natural disaster, global pandemics, power loss, communications failure, unauthorized entry, earthquakes or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances, and our business may be seriously harmed by such delays and interruption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to economic, political, regulatory, and other risks associated with international operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to risks associated with conducting business internationally. Some of our CDMOs and clinical trial sites, for example, are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular in non-U.S. economies and markets; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing and changing regulatory requirements in non-U.S. countries;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in compliance with non-U.S. laws and regulations; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in non-U.S. regulations and customs, tariffs, and trade barriers; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in non-U.S. currency exchange rates and currency controls; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in a specific country&#8217;s or region&#8217;s political or economic environment; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shipping of biologics/drugs; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or non-U.S. governments; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative consequences from changes in tax laws; (including the provisions of the recently enacted federal tax legislation titled the Inflation Reduction Act);</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the FCPA, UK Bribery Act, or comparable foreign laws; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, droughts, extreme temperatures, and fires. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal and state net operating loss (NOL) carryforwards of approximately zero and $202.2 million, respectively. Federal NOL carryforwards have an indefinite life but cannot offset more than 80% of taxable income. Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. As a result of our initial public offering in February 2019 and follow-on public offering in January 2020, and other transactions that have occurred since our incorporation, we may have experienced such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. Additionally, our NOLs may also be subject to limitations under state law.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are or may become subject to income and non-income taxes in the United States under federal, state, and local jurisdictions and in certain foreign jurisdictions in which we operate. Tax laws, regulations and administrative practices in these jurisdictions may be subject to significant change, with or without advance notice. For example, on January 1, 2022, a provision of the TCJA went into effect that eliminates the option to deduct domestic research and development costs in the year incurred and instead requires taxpayers to amortize such costs over five years for domestic costs and 15 years for foreign costs. As a result, the Company recognizes taxable income earlier than anticipated. Also, the United States recently enacted the Inflation Reduction Act of 2022 (the IRA), which introduced a 15% minimum tax on book income and a 1% excise tax on certain stock buybacks. Changes in tax laws (including provisions of the IRA), regulations, or rulings, changes in interpretations of existing laws and regulations, or changes in accounting principles could negatively or materially affect our financial position, cash flows and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock may continue to be volatile, which could result in substantial losses for investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although our common stock is listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">beyond our control. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. Some of the factors that may cause the market price of our common stock to fluctuate or decline include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of existing or new competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to achieve development, regulatory, or commercialization milestones under our collaborations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure or discontinuation of any of our product development and research programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to develop additional product candidates or products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders, or other stockholders, such as if we use our at-the-market facility; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expiration of market standoff or lock-up agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, political, industry, and market conditions, including a rising rate of inflation or a period of economic recession; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors, such as inflationary concerns, may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business cease to cover us or downgrade their evaluations of our stock or if we fail to meet their operating results estimates for us, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock could decline significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain holders of shares of our common stock have rights may, in the future, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We have an omnibus shelf registration statement on Form S-3 with the SEC, which became effective on May 1, 2023, which permits us to issue up to $400 million in common stock, other equity securities and/or debt securities. On November 7, 2023, we entered into an at-the-market sales agreement with Cowen and Company, LLC (TD Cowen) pursuant to which we may offer and sell from time to time through TD Cowen up to $125,000,000 of shares of our common stock, in such share amounts as we may specify by notice to TD Cowen. On January 17, 2024, we entered into an underwriting agreement with Cantor Fitzgerald &amp; Co. (Cantor), pursuant to which we offered and sold 10,869,566 shares of the Company&#8217;s common stock at a price per share of $6.57 paid by Cantor. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own 40.9 percentage of our outstanding common stock as of February 22, 2024. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred and will continue to incur significant additional costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform, and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and expect that we will need to continue to hire, additional accounting, finance, and other personnel in connection with our being, and our efforts to comply with the requirements of being, a public company, and our management and other personnel have devoted and will continue to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of Sarbanes-Oxley Act Section 404(a), which require annual management assessments of the effectiveness of our internal control over financial reporting. Section 404(b) of the Sarbanes-Oxley Act also requires our independent auditors to attest to, and report on, this management assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm are unable to attest to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ, the SEC, or other regulatory authorities, which would require additional financial and management resources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations are subject to the effects of a rising rate of inflation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States has recently experienced historically high levels of inflation. According to the U.S. Bureau of Labor Statistics, the annual consumer price index increase for the United States was approximately 3.4% for the 12 months ended December 31, 2023. If the inflation rate continues to increase, it will affect our expenses, such as employee compensation and research and development charges. Research and development expenses account for a significant portion of our operating expenses. Such increased charges may not be readily recoverable during the period of time that we are bringing the product candidates to market. Additionally, the United States is experiencing an acute workforce shortage, which in turn, has created a very competitive wage environment that may increase the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company&#8217;s operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our consolidated financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March 10, 2023, Silicon Valley Bank (SVB), where we maintained certain immaterial deposit accounts at the time, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. If other banks and financial institutions with whom we have banking relationships enter receivership or become insolvent in the future, we may be unable to access, and we may lose, some or all of our existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC. In addition, in such circumstances we might not be able to timely pay key vendors and others. We regularly maintain cash balances that are not insured or are in excess of the FDIC&#8217;s insurance limit. Any delay in our ability to access our cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on our operations and cause us to need to seek additional capital sooner than planned.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish that our board of directors is divided into three classes, Class I, Class II, and Class III, with each class serving staggered three-year terms; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that our directors may only be removed for cause; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminate cumulative voting in the election of directors; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit stockholders from calling a special meeting of stockholders; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors, by a majority vote, to amend the bylaws; and </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction):</span></p>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim of breach of fiduciary duty; </span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and</span></div></div>
  <div style="margin-left:6.796%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5760267799665257%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolved</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, using widely recognized industry frameworks. We use risk management strategies that focus on vital areas such as data protection, access control, incident response, and vulnerability management, and we have integrated these processes into our overall risk management program. We routinely assess risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented a multi-faceted cybersecurity program in accordance with globally recognized standards to protect the confidentiality, integrity, and availability of our information assets. The primary aims of this program are to devise, initiate, and maintain a cybersecurity approach that safeguards our systems, services, and data from unauthorized access, outages, exposure, modification, damage, and loss.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented a range of logical and technical controls to appropriately restrict physical and logical access. We maintain authentication controls in line with industry-recognized standards, including audit trails and logs for access. Access privileges are updated following any change in personnel or system, and are reviewed periodically, with the frequency determined by the associated risk of the application or system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We engage the expertise of third-party organizations to assist us to design and implement our cybersecurity procedures, as well as to monitor and test our safeguards in the context of recognized industry standards and practices. This process aims to confirm that our security infrastructure is robust and efficient, and that it is designed to resist diverse security threats. We use the critical insights gained from these third-party assessments to continue to improve our security controls and protect our systems and data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate potential cybersecurity risks associated with third-party service providers, including through a periodic vendor security review process overseen by our Head of Cybersecurity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not encountered any cybersecurity threats or incidents to date that have materially affected, or that are reasonably likely to materially affect, our business, strategy, results of operations or financial condition. For additional information regarding cybersecurity risks and their potential impacts on our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A, &#8220;Risk Factors,&#8221; in this annual report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Vice President, Technology and Digital Health, serves as our Head of Cybersecurity and is responsible for developing and executing our cybersecurity strategy and program. We also maintain a team of cybersecurity professionals who are responsible for security operations and report to the Head of Cybersecurity, who has more than 20 years&#8217; experience in cybersecurity and information technology infrastructure and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Head of Cybersecurity is regularly informed about developments in cybersecurity, including potential threats and innovative risk management techniques in the interest of effective prevention, detection, mitigation, and remediation of cybersecurity incidents. The Head of Cybersecurity oversees the processes for monitoring our information systems, including periodic system audits to identify potential vulnerabilities and third-party audits and evaluations. In the event of a cybersecurity incident, the Head of Cybersecurity implements an incident response plan. This plan includes immediate actions to mitigate the impact of incidents and strategies for remediation of future incidents. The Head of Cybersecurity is responsible for reporting information about cybersecurity risks and incidents to our Chief Financial Officer and other members of executive management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors oversees our enterprise risk management, including our management of cybersecurity risks. The audit committee of our board of directors has primary responsibility for the oversight of risks from cybersecurity threats. The Head of Cybersecurity, or a delegate, provides quarterly reports to the audit committee on the effectiveness and overall status of our cybersecurity program, and is responsible for reporting to the audit committee information about our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are currently located in South San Francisco, California, where we lease approximately 105,000 square feet of office and laboratory space. The term of the lease agreement expires in May 2029, with an option to extend the term of the lease for an additional 10 years. The lease agreement also provides us a right of first offer to expand into available office space in the building. We subleased approximately 7,100 square feet of our corporate headquarters in November 2021 with a lease term that expired in December 2022. Additionally, we subleased approximately 13,150 square feet of our corporate headquarters in May 2022 with a lease term that expired in November 2023. We also subleased approximately 13,250 square feet of the Headquarters in November 2023 with a lease term that will expire in November 2024. We also subleased approximately 9,300 square feet of our corporate headquarters in February 2023 with a lease term that will expire in February 2025. We lease approximately 18,700 square feet of additional office and laboratory space in Newark, California. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation, or other legal proceedings can have an adverse impact on us because of legal fees and settlement costs, diversion of management resources, and other factors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is publicly traded on the Nasdaq Global Select Market under the symbol &#8221;ALEC.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 22, 2024, there were approximately 6 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This graph is not &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Alector, Inc. under the Securities Act of 1933, as amended (the Securities Act), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on February 7, 2019 (the first day of trading of our common stock) and its relative performance is tracked through December 31, 2023. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img43903234_18.gif" alt="img43903234_18.gif" style="width:624px;height:339px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> [Reserved].</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled &#8220;Special Note Regarding Forward Looking Statements.&#8221; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled &#8220;Risk Factors&#8221; included elsewhere in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Supporting our scientific approach, our research and drug discovery platform enables us to identify targets and advance a broad portfolio of product candidates, validated by human genetics, which we believe may improve the probability of technical success over shorter development timelines. Three product candidates, latozinemab (also referred to as AL001), AL002, and AL101 are in clinical development. We continue to develop our preclinical and research pipeline, and we are developing our proprietary blood brain barrier technology to potentially apply to next generation product candidates. We are focusing our development resources on latozinemab in FTD and AL002 and AL101 in Alzheimer&#8217;s disease. We are advancing our clinical product candidates and research pipeline with our existing resources and in collaboration with our partners, GSK and AbbVie.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have been financed primarily through our collaborations with AbbVie and GSK and the issuance and sale of convertible preferred stock and of common stock upon the completion of our initial public offering (IPO) and follow-on offerings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one of our product candidates. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We have incurred net losses in each year since inception and we expect to continue to incur net losses for the foreseeable future. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $130.4 million, $133.3 million, and $36.3 million for the years ended December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023, we had an accumulated deficit of $710.1 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance product candidates through preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursue regulatory approval of product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire, discover, validate, and develop additional product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the manufacture of supplies for our preclinical studies and clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain, maintain, expand, and protect our intellectual property portfolio. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2023, we committed to a plan to reduce our workforce by approximately 11% to better align our resources with our previously announced strategic prioritization of our late-stage progranulin and TREM2 immuno-neurology programs. We initiated such reduction in force impacting approximately 30 employees across the organization, effective March 29, 2023. As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $548.9 million. In January 2024, we announced the closing of an underwritten public offering and the net proceeds from the offering were approximately $71.1 million. Our cash, cash equivalents and marketable securities as of December 31, 2023 plus the net proceeds from the offering total $620.0 million, which we anticipate provides runway through 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any revenue from product sales and do not expect to do so in the near future. Our revenue to date has been primarily related to the AbbVie Agreement and GSK Agreement for the license and co-development of product candidates with those parties. We recognize revenue from the upfront payments and the milestone payment received from AbbVie over time as services are provided. We recognize revenue from the upfront payments from GSK at a point in time for a development license and over time for research and development services. Revenues for research and development services are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the AbbVie Agreement, in addition to receiving the upfront payments from AbbVie, we may also be entitled to development and regulatory milestone payments, an opt-in payment for continued development of AL002, and other future payments from profit sharing or royalties after commercialization of product candidates from such program. Under the terms of the AbbVie Amendment signed in February 2023, the Company received a $17.8 million milestone payment in March 2023 for the dosing of the first patient in the LTE trial and $12.5 million payment in the second half of 2023 for the enrollment of additional patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payments for latozinemab and AL101. Alector and GSK are jointly developing latozinemab and AL101. In May 2023, we and GSK amended the GSK Agreement. Under the terms of the GSK Amendment, we are responsible for funding and sharing in GSK&#8217;s and our development costs up to $140.5 million for the conduct of the initial Phase 2 clinical trial of AL101 in AD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, Alector and GSK will equally share profits and losses from commercialization of latozinemab and AL101. We may opt out of the sharing of development costs and of profit and losses from commercialization in the United States on a product-by-product basis. In such case, we will no longer conduct development or commercialization of that product and we will receive royalties on net sales of the product in the United States instead of a share of profits. Outside of the United States, GSK will be responsible for commercialization of latozinemab and AL101 for all indications, and we will be eligible for double-digit tiered royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our revenue for the next several years will be derived primarily from the AbbVie and GSK Agreements. The balance of deferred revenue was $293.8 million as of December 31, 2023, related to the AbbVie and GSK Agreements. The deferred revenue is expected to be recognized over the research and development period of the programs through proof-of-concept for AL002 and the completion of the initial Phase 2 clinical trials for specified indications for latozinemab and AL101.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses account for a significant portion of our operating expenses. We record research and development expenses as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of our product candidates, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with third-party contract organizations, preclinical testing organizations, and consultants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to production of clinical materials, including fees paid to contract manufacturers; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to the preparation of regulatory submissions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party license fees; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense, and other supplies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators, and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specific program expenses include expenses associated with the development of our most advanced product candidates: latozinemab, which is being studied in a pivotal Phase 3 clinical trial, INFRONT-3, and which has an ongoing Phase 2 clinical trial; AL002, which is being studied in a Phase 2 clinical trial; and AL101, which has an ongoing Phase 2 clinical trial. We also have expenses related to the discovery and development of future product candidates and separately tracked expenses related to programs that we expect to move out of preclinical studies and into Phase 1 clinical trials. These expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses, including depreciation, and lab consumables.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where we share costs with our collaboration partners, such as in our GSK Agreement, research and development expenses may include cost sharing reimbursements from, or payments to, our partner.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, information technology, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, consulting, and tax services, insurance costs, and facility costs not otherwise included in research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net consists primarily of interest earned on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Income tax expense consists of federal and state income tax provisions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth selected consolidated statements of operations data for the fiscal years indicated and the percentage change in such data from year to year. These historical operating results may not be indicative of the results for any future period. A discussion of our results of operations for the comparison of the years ended December 31, 2022 and 2021 can be found on page 102 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on February 28, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Dollar</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,062</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,617</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,555</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,115</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,418</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,303</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,687</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,033</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,346</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">248,802</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271,451</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,649</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(151,740</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(137,834</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,906</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,561</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,778</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,783</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(125,179</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(130,056</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,877</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,212</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,254</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,958</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(130,391</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(133,310</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,919</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue was $97.1 million for the year ended December 31, 2023, compared to $133.6 million for the year ended December 31, 2022. The decrease of $36.6 million was mainly due to $68.9 million of collaboration revenue recognized in the second quarter of 2022 due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program and a $27.0 million decrease in revenue recognized for the latozinemab programs. This was offset by a $30.6 million increase in revenue recognized for the AL101 programs, including a cumulative non-cash revenue adjustment due to contract modification to have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK operationalize the AL101 Phase 2 study and a $29.0 million increase to collaboration revenue for the AL002 program due to the addition of AL002 LTE and patient replacement revenue in 2023. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $192.1 million for the year ended December 31, 2023, compared to $210.4 million for the year ended December 31, 2022. The decrease of $18.3 million was mainly due to the Company&#8217;s strategy to prioritize late-stage programs, higher cost share amounts with GSK for the latozinemab programs that are recorded as contra expense, less manufacturing expense due to the timing of production, and the Company's funding to GSK on the AL101 AD program being recorded as a reduction of our refund liability to collaboration partner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Dollar</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Direct research and development expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Latozinemab</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,511</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,118</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,607</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AL101</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,751</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,348</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AL002</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,490</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,805</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,685</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,096</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,931</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,835</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Indirect research and development expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel related (including stock-based<br/>&#160;&#160;&#160;compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,956</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,063</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">893</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities and other unallocated research and<br/>&#160;&#160;&#160;development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,659</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,091</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,115</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,418</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,303</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $56.7 million for the year ended December 31, 2023, compared to $61.0 million for the year ended December 31, 2022. The decrease of $4.3 million was mainly driven by a decrease in consulting expenses related to accounting, recruiting, IT, and other general expenses, plus a decrease in insurance costs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net was $26.6 million for the year ended December 31, 2023, compared to $7.8 million for the year ended December 31, 2022. The increase of $18.8 million was due to higher investment yields on our marketable securities compared to the prior year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense was $5.2 million for the year ended December 31, 2023, compared to $3.3 million for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception through December 31, 2023, our operations have been financed primarily by our collaborations with AbbVie and GSK and the issuance and sale of convertible preferred stock and of common stock upon the completion of our IPO and follow-on offering.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $548.9 million of cash, cash equivalents, and marketable securities. As of December 31, 2023, we had an accumulated deficit of $710.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs, and to a lesser extent, general and administrative expenditures. We expect our expenses to continue to increase in connection with our ongoing activities, in particular as we continue to advance our product candidates and our discovery programs. In addition, we expect to incur additional costs associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $548.9 million. In January 2024, we announced the closing of an underwritten public offering and the net proceeds from the offering were approximately $71.1 million. Our cash, cash equivalents and marketable securities as of December 31, 2023 plus the net proceeds from the offering total $620.0 million, which we anticipate provides runway through 2026. We reduced our workforce to better align our resources with our current strategic priorities and maintain our expectations with respect to our ability to fund our operations. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We may also choose to seek additional financing opportunistically. We may seek to raise capital through public equity or debt financings, license agreements, collaborative agreements or other arrangements with other companies, asset sales, or through other sources of financing. We have an omnibus shelf registration statement on Form S-3 with the SEC, which became effective on May 1, 2023, which permits us to issue up to $400 million in common stock, other equity securities and/or debt securities. On November 7, 2023, we entered into an at-the-market sales agreement with TD Cowen pursuant to which we may offer and sell from time to time through TD Cowen up to $125,000,000 of shares of our common stock, in such share amounts as we may specify by notice to TD Cowen. On January 17, 2024, we entered into an underwriting agreement with Cantor, pursuant to which we offered and sold 10,869,566 shares of the Company&#8217;s common stock at a price per share of $6.57 paid by Cantor. The Company also granted Cantor an option exercisable for 30 days from the date of the underwriting agreement to purchase up to an additional 1,630,434 shares of common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to obtain substantial additional funding in the future for our research and development activities and continuing operations. If we were unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; including, without limitation, our collaboration efforts with AbbVie and GSK; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if our product candidates are approved, commercial manufacturing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain our current research and development programs and establish new research and development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addition and retention of key research and development personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our efforts to enhance operational, financial, and information management systems, and hire additional personnel, including personnel to support development of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with workforce reductions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and amount of milestone and other payments we may receive under our collaboration arrangements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of regulatory approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our eventual commercialization plans for our product candidates; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of inflationary pressures; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>&#160;December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash provided by (used in) operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(184,162</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,329</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,551</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,918</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(159,014</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(49,663</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,550</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,514</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,295</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, cash used in operating activities was $184.2 million. This was mainly due to the net loss of $130.4 million. We also had a decrease in deferred revenue of $66.8 million and a decrease in refund liability of $24.5 million. This was offset by a non-cash charge of $42.8 million for stock-based compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, cash used in operating activities was $20.3 million. This was due to the net loss of $133.3 million offset by an increase in deferred revenue of $66.4 million from the $200 million upfront payment received less revenue recognized. In addition, we had non-cash charges of $46.1 million for stock-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2021,cash provided by operating activities was $298.6 million. This was due to the net loss of $36.3 million offset by an increase in deferred revenue of $292.9 million from the $500 million upfront payment received in the third quarter of 2021 from GSK. In addition, we had non-cash charges of $40.8 million for stock-based compensation and $6.3 million for depreciation and amortization expense.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, cash provided by investing activities of $101.9 million was primarily related to the maturities of marketable securities of $652.5 million offset by purchases of marketable securities of $551.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, cash used in investing activities of $159.0 million was primarily related to the maturities of marketable securities of $402.0 million offset by purchases of marketable securities of $556.9 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2021, cash used in investing activities of $49.7 million was primarily related to the maturities of marketable securities of $286.3 million offset by purchases of marketable securities of $343.4 million and sales of marketable securities of $10.7 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, cash provided by financing activities of $2.6 million was primarily from the exercise of options to purchase common stock and the issuance of stock from the 2019 Employee Stock Purchase Plan.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, cash provided by financing activities of $4.5 million was primarily from the exercise of options to purchase common stock.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2021, cash provided by financing activities of $30.3 million was primarily from the exercise of options to purchase common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under arrangements, we perform the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligations. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. We recognize collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in our forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of our clinical trials. We have had changes to the overall expected costs to satisfy the performance obligations from period to period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, we accrue expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation is measured at the date of grant, based on the estimated fair value of the award and recognized as expense over the employee&#8217;s requisite service period (usually the vesting period). We estimate the grant date fair value for options to purchase common stock, and the resulting stock-based compensation, using the Black-Scholes option-pricing model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;We have limited information on the volatility of our stock as shares of our common stock were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry. These companies are considered to be comparable to our business over a period equivalent to the expected term of the stock-based awards. In 2020, we began giving weight to our own historical volatility in the determination of expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The expected dividend rate is zero because we have not historically paid and do not expect for the foreseeable future to pay a dividend on our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of our common stock on the grant date, which equals the closing price of our common stock on the grant date. We recognize expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also granted RSUs with market conditions to certain executives. The fair value of the RSUs with market conditions are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and the estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for forfeitures as they occur for all awards.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and generally short-term duration, invested in compliance with our policy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had cash, cash equivalents, and marketable securities of $548.9 million as of December 31, 2023, which consisted primarily of bank deposits, money market funds, and government marketable securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the generally short-term maturities of our cash equivalents and marketable securities, and the low risk profile of our marketable securities, an immediate 100 basis point increase or decrease in interest rates would cause a change in fair value of approximately $2.1 million as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We deposit cash and cash equivalents with high credit quality financial institutions to minimize risk with respect to any amounts in excess of insurance limitations. Cash and cash equivalents held at these deposit accounts are currently insured by the Federal Deposit Insurance Corporation (FDIC) up to a maximum of $250,000. As of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, approximately $3.9 million exceeded the FDIC limit, and the significant majority of the Company&#8217;s operating cash is held at JPMorgan Chase &amp; Co.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services with payments denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:94%;"/>
    <td style="width:1.12%;"/>
    <td style="width:4.88%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:5.75pt;vertical-align:top;text-align:left;"><p style="margin-left:5.75pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Audited Consolidated Financial Statements</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reprt_of_indepdnt_registred_public_acctg"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_24556ad3-bc7c-4b6b-b0a9-fcd71bd32add" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statement_convertible_prefe"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financials"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="reprt_of_indepdnt_registred_public_acctg"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Alector, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Alector, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 27, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.84%;"/>
    <td style="width:76.16%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description of the Matter</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;min-width:fit-content;">The Company recorded collaboration revenue of $97.1 million for the year ended December 31, 2023. As described in Note 2, collaboration revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. In order to recognize collaboration revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations. Revenues are recognized as the program costs are incurred</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditing collaboration revenue was challenging as it involves assessing highly judgmental estimates with respect to the Company&#8217;s determination of the total expected costs to satisfy the performance obligations.</span></p></td>
   </tr>
   <tr style="height:99.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that address the identified risks related to the Company&#8217;s process used to determine total expected costs to satisfy the performance obligations, including management&#8217;s controls over updates to the budget for the relevant research and development programs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test collaboration revenue, our audit procedures included, among others, obtaining an understanding of the Company&#8217;s estimated costs to satisfy the performance obligations, as well as assessing management&#8217;s updates to the budget for the relevant research and development programs. We also tested a sample of expenses recorded to the development program, evaluated the historical accuracy of management&#8217;s budget estimates for the relevant research and development programs, and inquired of Company personnel directly involved with supervising the development programs.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b5bbe73-4967-4369-b729-8a94ec6f34e2" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2017.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cce2a5d4-08af-44b7-9235-262479330bc8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">LECTOR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">NC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Ba</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.92%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.82%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.82%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e12ccd7-99bb-41a7-a3bc-ac850754db01" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa26a672-f2a6-47a2-a539-60099c3748ed" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,323</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ac761dd-5a7e-4610-8f35-d982ee50ce30" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474,306</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a331e5d-9f62-4e6b-840c-75b9203133ce" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">558,528</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivable from collaboration partner</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f34a99df-0d07-4869-8adb-406e1cef19ff" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fd0664b-7cba-4009-b24b-92d676116e09" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3faa984d-f0de-4997-acbd-737decaf4579" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_787e0788-554d-4f4d-9345-d01e1bbb52bf" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,997</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_817f4965-18a1-4dc6-a1a2-f0ad4a931a91" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_316f383d-4c8e-4485-bfdb-136e9b083a26" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b082b5c-d039-476e-a7ad-bec295f633ab" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,861</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_887f511a-d9dc-444b-bfed-bc8c71f0800c" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b85e34b6-cfa4-4d80-98a0-06db67f0e03b" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,195</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79fda727-e307-4832-b82a-f0fae4f00912" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4290cb-d73a-4485-9f85-d4e8c01c3fa0" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_251fcf61-3de5-46f6-b889-f7e5153d2974" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a44fc565-b9da-4a52-9a77-8a8e573a5c90" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,418</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23689ab0-1fb0-4e53-bb5d-00313f5b8da9" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,409</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc05f178-17c3-41a2-b2af-29abd0b94be5" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,827</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9192f934-dd78-413f-bd0b-8aac9d7365c2" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b87b9e89-13c0-4aed-aef8-f3ea877c2183" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9fdb16c-7a95-4cbb-9699-7ccdbe5b71c5" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical supply costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0f0c43b-2492-4a42-a8da-c6ce27a03980" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:AccruedClinicalSupplyCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9853de11-a791-494d-aa60-86cc9093d2da" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:AccruedClinicalSupplyCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30ac3b0a-9590-4250-bf39-362987ee7544" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,378</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2506f646-05dd-4073-a539-684ed9a26c26" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,771</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b9ccff-7590-4896-ba6f-ca76d83e91a2" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,975</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a346d3bb-7694-4e26-ab76-3b2eea0a1660" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,231</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payable to collaboration partner</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23f51ff8-49bb-425b-af76-25990c2f2566" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:CollaborationPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59940351-d522-4f1d-a014-e1f29e63c102" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:CollaborationPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability to collaboration partner, current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9165586b-a096-4b50-9ba3-976dda0c7a45" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b6f756-d60f-489d-8ed7-52ac0b525d96" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c63b528-c964-4584-be33-fef8db61cd67" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_608d4442-bcf4-4068-aef4-8b21ec1e1304" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0e87293-adf9-4254-a656-e7fcab78fc9a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,948</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b682690c-04e3-454a-a064-6e7adf34936a" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue, long-term portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35477d85-30ea-45e8-b7d0-048fa4386f4b" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,845</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa7fea58-c97c-424d-9f24-03ba916c7d3a" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">443,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability to collaboration partner, long-term portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3716784-4774-4abd-8e61-65adb54066f0" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:ContractWithCustomerRefundLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,047</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4efef2b-9885-444f-8d53-2967d5850aa3" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:ContractWithCustomerRefundLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, long-term portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c900572-3cca-4471-b106-9637fae13fb4" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,456</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4714a6ae-96d7-455d-9c3e-075e6fa3ebdc" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cdba768-ff11-40fc-a7c8-2a1ea5f14af7" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f183b6a-69f4-4a73-9761-94b8e3e49c37" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65b55762-bea9-41af-85ef-d0277188515a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">487,669</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee70bfb-83e4-44c1-847b-46e6cb0dedeb" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">573,206</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_59739cf5-7c7b-4790-81b7-25249697bc0e;"><span style="-sec-ix-hidden:F_24681dae-d59f-43a3-ad73-dee32de8893e;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 4)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7773acb-c880-4bcd-908e-7d97498ca59b" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_b0eda075-565b-4156-bc7d-0571e92cba92" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22bb368b-79d8-4137-8ebd-a62be00afd59" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7eb2c3ef-8026-4fa1-ba9a-32c0fc4c80ff" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb732526-17ce-40a6-84c0-422a544bd316" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_843e8bde-f4de-45a4-88df-9b980c0fdaf2" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,879,693</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb1c2c7f-3caa-40e1-b416-e9878dc4b925" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7430ada1-1048-4dfd-aa72-fe8025e2463c" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,895,718</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of<br/>&#160;&#160;&#160;December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_692db0c7-d617-44c0-8aee-486fc16b772a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff35057-3a12-478f-bc4b-0bed91b62567" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f441331f-511c-4dd1-a342-16d9b56f5c2d" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">844,044</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3310a614-5b4f-460d-a39b-6354bfdb66ca" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c67c580-99a3-4fb2-a19e-f4a7211c7ef2" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2df049db-8049-4162-9e75-3568ca8ff0dc" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe258f4b-c30d-412d-87c3-d7f1e9d4b2c5" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">710,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b4bda11-bc3f-492b-9693-205397dfc6cb" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">579,687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1beb8619-0bd9-4814-956b-c4db8b7c3fe3" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,158</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c6496f6-3a47-44f4-84fe-55e80208de73" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22330cdb-074b-462d-9f5e-7eabcff6d83d" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">621,827</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_753281ac-3a1a-41e2-b209-e3633ecf96b2" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">LECTOR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">NC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Oper</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb37ec45-8068-4830-9d00-202fbcd15250" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_146d3bdb-aae3-4d0f-a7aa-e964235dd578" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07629a50-fa60-4b52-aa7e-059d65d8d51c" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9843e3a-724f-4dba-bf96-f5fe7c776ab5" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f0dce83-5a0f-4270-8e64-e0087a2f8390" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,418</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_739c4e06-f713-44b1-a5fe-7797362a584f" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189,407</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5955004-b947-4ad9-bd5b-db808b446a39" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_760ad245-4381-4e77-8aef-1be5521e8a14" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,033</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4e1200b-d2ad-4109-a8fc-c2ef5f638eb7" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fd820b7-a17f-4ee1-bc72-ada20c50d3de" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">248,802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ca26822-ca5b-4867-8ee3-2aa0586ebd2c" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,451</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3523ebcd-c6df-43fd-a033-369d67911dbd" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e18115b-cbb0-480d-b7c9-8fdc2349d3e8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,740</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f097d312-a649-4f25-9d4d-3ffabece2641" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">137,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e31a27e-65ff-46b3-b681-7200073b02f6" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f1e3129-4f2a-4951-906f-d60b16aef6b0" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e74aedfc-d04f-4748-9211-08f455f2e1ed" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,778</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99b04500-226c-4fc3-8b10-1e24676c0d9b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,031</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cab72aad-c851-4c00-a540-159863aae049" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c23c6ef-9ef4-478c-99a6-d0e167296e69" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b91055b-8cd1-4850-aa64-0df58c0a7f92" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fbc1f1a-9fc6-4600-8fe5-04e79e25ad2d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7a55848-7caf-47dd-ac43-57e766f9b682" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf1888aa-85c1-43b0-b3af-052d1b285104" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_658ed8ef-dd9c-45b4-9d61-b6dd27a90e12" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb6a1a6-432a-4f0f-b8c6-58493eecc3e4" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56463d9d-8906-46ae-978a-ceff580a11b4" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd556dd2-6967-476c-a6c9-844d2edd801f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2fb5434-9dc1-486b-9a30-23ca64dd4ea6" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ba29a9e-82c0-404a-9022-1ee10d123204" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,557</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3143f2c8-b13a-45c4-9e84-7c402e1579c2" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d638ac4-37ac-4b55-8321-564145dda3a2" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">136,942</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115e2f9a-47da-4879-b576-96793c1a023b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fd1469-76de-4a9b-8fb2-4e8d7d454563" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_561b2ed0-9c2a-459a-a59b-612351a4b8c4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33fa8c86-a003-4424-8fd0-cc253b2d2832" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7dbd2cbe-f489-4e7d-a5aa-a6e7ede87502" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c37496d4-415e-411f-a25c-6ebf185c91ac" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2efb31e9-0a67-41a3-b9d6-d51fcf440b37" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares used in computing net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_982323ac-219a-449b-81bf-734843c3bdc6" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a4d17398-c219-48e2-bef3-9a5543b5e411" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">83,733,730</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47c6b958-7ff3-43c4-9efb-b6e2424898be" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6703d295-e2ab-4400-9857-3ce25e46690c" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">82,467,587</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4093381-38f9-47ab-9844-0d79e554c33a" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5ea5fb0d-4e97-488a-a0c4-5c74e4786c6d" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">80,416,936</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statement_convertible_prefe"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.284%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.722%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.340999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:8.322000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:11.922%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:11.922%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:11.922%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional <br/>Paid-In</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive <br/>Income (Loss)</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance &#8212; December 31, 2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89a71f4c-b3a4-416c-ab2d-cf73933e6088" contextRef="C_6938cb01-3217-495c-940e-68f940751ad7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">79,316,261</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbe0c3f2-e702-458f-9aef-12a0dabd11f6" contextRef="C_6938cb01-3217-495c-940e-68f940751ad7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb260673-91c2-4304-bcc7-5a34e50843a7" contextRef="C_b020fee9-3aeb-4b54-9981-194d9a106693" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9af1ebb-5632-4a43-bed4-7fd1589694fd" contextRef="C_0b316b30-6fe6-45ed-a034-7a7078c020a5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c5396a9-321a-4938-9e20-4f2589e3a264" contextRef="C_fc9dc938-5e3b-488d-998b-8e76468ef770" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">410,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ec6ecb1-6eca-42e1-b18a-9314cd481185" contextRef="C_db20ea7a-0049-46f5-a310-e578628c49ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2375c45-5d93-4aa8-8702-bf4330bf339b" contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,395,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75dee3d5-56f6-453c-ac21-949cdc15a643" contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f436230b-41d6-4d56-b6fd-cb82f3f26a12" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c522a70d-316d-40ec-a668-f81dea3b11ff" contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">156,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of common stock<br/>&#160;&#160;under employee stock purchase<br/>&#160;&#160;plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d88a084c-a91e-48da-a6d5-066e458cb2aa" contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">136,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17c5a9e5-4200-4a49-884e-0bac0fadb952" contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e51ec8bd-7e41-407e-9cf2-e8d973a1e753" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeiture of restricted common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d14fab2-c0f3-429c-8abe-9f220d8fdc1e" contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,043</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7713203-5e9a-4e9a-a978-3a2c84c9dfa3" contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,785</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fa00289-46fd-4946-8c48-de58d9239c37" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,785</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable<br/>&#160;&#160;&#160;securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a997ceb-1e3b-430c-842f-c6d77c0b6b1b" contextRef="C_e332595b-2812-42e7-8164-9333c6cb735f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,557</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4fb746f-00ae-4f12-9e57-5e0241c5be7a" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,557</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_677e9c46-f466-46c6-8435-553a8a0d001f" contextRef="C_67c1d049-46bc-4a4e-bfb5-f558c76ed8e0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_674ceacd-909e-442a-884b-7031e81a335a" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance &#8212; December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b42bbe16-0611-468b-94f0-ebd618548039" contextRef="C_e3cdfe83-caeb-4047-a450-8e67619a35be" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,986,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e60de40e-fe72-4d81-a408-6e9029d9fc31" contextRef="C_e3cdfe83-caeb-4047-a450-8e67619a35be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87774d0-05f7-49dd-a869-055366e4e726" contextRef="C_f5380031-3260-4626-aa94-6be4667cd0d5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748,036</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60d0e700-2431-44a2-9249-6fbad4090e2c" contextRef="C_a7296cb0-df0b-44d4-8629-0d1f54c91d3d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">943</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0c77875-ccc9-4e89-b933-10eceaac29e0" contextRef="C_875c92eb-4727-4d07-8257-01fde8082811" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">446,377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_260e0f74-eb82-458b-a752-c52f0353b834" contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,724</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5454935f-9866-42e3-8cf1-584b9d6efb3d" contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">298,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43eae9d1-8d57-491c-b33b-e55aa5b08986" contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0de19483-3749-4730-87db-67a7e83f714a" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9de6e14-7a64-4329-bcd4-0b3f4dbacfe8" contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">414,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of common stock<br/>&#160;&#160;under employee stock purchase<br/>&#160;&#160;plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed78956a-5231-49cc-89b6-2209079b1b58" contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">196,710</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17d41d98-4652-4e29-b69f-fc259123ca00" contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d8edbfb-8149-4813-b45f-1c742083b039" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2795bec0-3641-406a-bb05-4a0770fffd40" contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5292a7b-366b-484c-9ca2-3ede713d0071" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable<br/>&#160;&#160;&#160;securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_689a7ca8-860e-47b0-ac4d-a520e3ef88fa" contextRef="C_fdbff2fe-671a-4c39-9142-ff03f354ebbc" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_296ccc15-58c3-4d57-b21e-b590eda438b4" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89d4e29d-4c70-4cd7-aa08-e9d85fa5ab8a" contextRef="C_2d7c568c-73b0-4659-933e-e70332ce56ef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8dfd9ed-cccb-46fd-aa0a-7f4677fc7ec5" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance &#8212; December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d60486b5-f0e4-4073-a2a6-798aa3a4ccfe" contextRef="C_24dffb2c-e6de-4b86-a1a9-787450030b02" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">82,895,718</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_789aba50-31a6-4323-9e02-9024bf20b0c0" contextRef="C_24dffb2c-e6de-4b86-a1a9-787450030b02" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5f667ea-6605-4264-8d55-910ec23a1950" contextRef="C_7db9d754-8d91-4ea6-9ab3-778ba4a2b5f8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc683075-6ecf-48b6-9065-9fcb40945b82" contextRef="C_799c46d0-304e-442b-87b3-67e31110ef56" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b99d8b9e-38ca-414c-8fbb-29bf09388634" contextRef="C_e123b7a5-e275-4b05-8fa9-5b78e2f38cf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">579,687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3438ecb6-87bb-4a73-ae19-334db6d3bba9" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2603f8db-afc4-44b9-b6a6-cbcb88255d00" contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">132,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a733172a-7684-40d5-a5c0-243bc0083bd3" contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a9dc9a4-d893-46a5-ac54-094261fa7ecb" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48a8391d-1800-4530-af01-9c6f352e2859" contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,584,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of common stock<br/>&#160;&#160;under employee stock purchase<br/>&#160;&#160;plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2829e5e-67ff-4fbf-b23e-5cd96809b56a" contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">267,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b289fd92-0960-4a3d-b23a-4503e84a32c2" contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f52371f-b28c-428b-b67f-cc31c0ddfb7d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cec69ce9-cafc-4887-8ad1-5cac9d29743e" contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_885f81f2-d0a2-480d-825c-8af6e6481b92" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable<br/>&#160;&#160;securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21ecc3e3-e0c4-4bcd-b766-0acbf275f9c4" contextRef="C_17714c29-f0b8-4a31-9e58-2bb7319ace3f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1543d6c3-789d-4835-bf58-54696072614b" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aab59ef-e720-4b46-bb89-199045171604" contextRef="C_5221b583-972a-4325-9c52-a770e32fec78" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bd324c0-02a1-4d2b-981f-9909c7a70551" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance &#8212; December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f9c4712-a522-411c-9067-0e2d5431ef56" contextRef="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,879,693</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_070afa72-a2ad-4abc-aebe-055d1ed7c9fd" contextRef="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cab15996-0e3e-42d6-9ee6-ed8cbe8c36b4" contextRef="C_8f63097f-fc67-43ad-b6f8-799a51185227" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">844,044</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_527cd34e-3f65-4601-8c4b-eb5b024bc347" contextRef="C_0af91d08-2797-49ba-a679-a9d25bb3512d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9fe204b-f121-473f-bc8f-3a5fe3e78bf5" contextRef="C_7b15d294-93bc-4f21-877c-2a47962db58d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">710,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_595a6bab-6d15-455b-aa1a-1f8e1c31ae55" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,158</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">LECTOR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">NC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ccdf488-4ff9-4c4b-bb1e-ac8217d81f1f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8066da3-e6d3-4aa2-b307-1f4108aa3588" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0499cd6b-b02f-46b3-a9d8-1eaa6c20d789" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating<br/>&#160;&#160;&#160;activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b667dc5-d4f8-4bf5-9c34-2c733aa85f1d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1e41235-3da4-4f83-9357-5292e1fa5633" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5a1ffc3-b9fb-404e-8106-671d026e6e9b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8de54e2b-8ced-4cbd-9a63-bc27a04ac4fd" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34dbe482-15b1-4881-b6ef-1e8dc5f51016" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b23249-cb06-440f-91df-3c5d3fb615ca" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,785</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premiums and accretion of discounts on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79493c60-4f4e-4a50-adea-636492db52b8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1b9d42-9e96-4d04-88f6-5a17ebdd2df2" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38746072-38ba-4e40-928f-8b0e9c97487c" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58212fc5-1b73-449f-8d32-2680e59eae78" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,123</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddcaa4c3-9f41-486c-9b19-0758ed3ac9f9" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4aa9a7e2-51c8-44ba-9aae-93fe56c0f358" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,986</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from disposal of fixed assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce99ee9d-df15-498c-b058-becd08bc1d70" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e933801-3a7a-4af1-b4be-8a93d0e529f8" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbc44363-58e4-418c-918b-c1999f2055cb" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivable from collaboration partner</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da22529d-38c9-4552-a9bf-f87a5a220b79" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_894b68b3-f761-4319-b7e3-f89808c67f94" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0214440-0c3b-466c-aa47-2827d667c427" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4500530e-acae-41d1-b1c9-16b7a39dac27" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43abb429-5f34-4a1b-8fee-9f564bc15002" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2936eb32-d429-4a02-8f74-386756a8acbc" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1c823c6-af64-4a94-a008-1fddf65a1d71" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ed627dd-08a1-4f4a-8871-3dea06c82381" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">835</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7e827e-5c48-4204-a258-24d66c5f9e5e" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,957</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab81c89f-53b9-499d-8722-934605e60d63" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebb7dd95-73dc-401a-8939-39c4e524f620" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4065c572-ecf5-4490-ab4d-14ce27e948d3" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities and accrued clinical supply costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63029f4f-0170-4699-a401-4c3d5bcf817f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6601855-508f-4614-9b3f-8f575edda85c" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7815497c-1d1a-411c-bd74-4afcdfe150a2" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payable to collaboration partner</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cb013db-a5d8-435e-8272-ff36e41dab5d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncreaseDecreaseInPayableToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dc09f2c-c422-4819-b1d1-f4144b05a793" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncreaseDecreaseInPayableToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630143e9-447d-4d39-8234-1d5493f4ae1e" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncreaseDecreaseInPayableToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b00b539d-fdee-4246-83c4-035d886de26c" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,782</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6b81cfc-2d90-4f4a-8607-6e4b41d1777d" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,383</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6379ab3-86af-46b1-9eda-6fd2edd4d42c" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability to collaboration partner</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28437145-e24f-4824-94de-48b0dd1d9dc2" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,512</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21565a69-731c-44f6-b355-a6e855f17772" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a038bd4-3b20-4d0a-901e-7f61d084fb1b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71657a7-86c9-4e54-8d05-18666cf21bb7" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cf4d983-8ac0-4a28-95a6-e0c2a27105c2" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,274</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63b627eb-ce9e-4daa-b99b-539a86977e95" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de63a8a-b433-4f16-95b5-484cce9b944a" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d05a9e15-9b83-4c14-957b-4836e9f7fa7c" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">601</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4add56ea-f099-4e1b-9938-7da3132bb9e6" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">314</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d62bd23e-0473-4d43-9b9e-047e4fe72d22" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c71b4ab-7661-4b7a-a597-5cfb9a557473" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49400022-d30c-420a-8224-e2b00410e213" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da4d1564-4e1f-4cfb-9a66-c877002117ff" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17865ea7-a3fc-4c93-9a27-bc01ba5d012a" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,117</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d63ab3c2-6e10-4f07-a568-3c2360c721c7" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,247</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_253592e8-c68a-466b-9053-bec97ca92d4a" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">551,729</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0e51c80-23d2-4c22-b833-7ef9f1a1651a" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556,898</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff1df14-493e-44d9-84a4-98ff26db7ed5" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8a28599-a1fa-44c1-bfaa-16c44a1ba579" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faf4f04c-6b82-4302-bce5-9fa74e6d7aab" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa35b5d2-e6ae-4f2d-b942-88b896dbf8b1" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286,290</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee320d33-aea3-445a-8cc0-82e34ad480ea" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,505</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd8566eb-8b43-417d-8bc0-c7b5ebef000d" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db9ee585-e032-48c5-a4dd-db33a589349d" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19dbb324-87ae-4333-9d3f-e733569fd920" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,918</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcbdd5bd-947a-46c2-a0e9-41c67cee55ce" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,014</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e855c9f-d6df-4fd6-aca2-5b2b732ddc76" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,663</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the exercise of options to purchase common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47ca048d-3bbb-4578-8e81-9632b4427e17" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef019227-8362-413d-a0b6-19dbeb27da56" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a317aec-f5f1-43e9-9308-6051b741b82a" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of stock from employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7652a356-a523-4c60-8f26-71c78457308d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fff3cb2b-7c98-4603-a91f-5a5f0a8c3301" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e49340-546f-46d6-a07b-d1c192d66d67" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80973364-0207-4b81-a282-7a733f0efaf7" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,550</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1f7053f-d33d-4ef2-863e-2a3691712ecb" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,514</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_448c638f-df0e-4ff0-a547-5a03dcdeb14b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,295</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59a5efa7-43b8-4705-b7e8-76da9088bd13" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">79,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_538393e1-ebc1-464c-b162-0dc7875bfbb5" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2197cca-c8f2-416e-a1dd-218aff3d2121" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">279,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_049c6ca2-d3d5-425b-ad5b-08b213bdb8ca" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e61865fc-0293-4fb9-9bd9-ba632ba83e27" contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,624</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08c0ac35-3388-45f0-8bf7-82e0efed7224" contextRef="C_db20ea7a-0049-46f5-a310-e578628c49ec" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eca9342-398a-48aa-9c32-a3cca1b6594e" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,101</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3e779e5-8c07-4a0f-8eea-e994b241c832" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,795</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0def6870-8814-4035-8155-258a2eade9ba" contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,624</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment purchases included in accounts<br/>&#160;&#160;&#160;payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a33a5fff-9e9e-4845-a9e9-9e2451344843" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61b31a2d-5cab-4738-8551-5f6ee34c1797" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a5b8379-822b-428c-aeea-bd1aa6a2a018" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;" id="notes_to_consolidated_financials"><span><ix:nonNumeric id="F_067ae176-3211-4f4f-b1a2-725efa44204f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_067ae176-3211-4f4f-b1a2-725efa44204f_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company  </span></ix:nonNumeric></span></div></div>
  <div><ix:continuation id="F_067ae176-3211-4f4f-b1a2-725efa44204f_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb6b64c9-61d9-4ec0-bc3d-59835ddd520e" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4509f94-f937-4c2b-b286-344c85dd26b0" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_e4509f94-f937-4c2b-b286-344c85dd26b0_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e4509f94-f937-4c2b-b286-344c85dd26b0_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6449e70b-2b97-4914-b03b-36946703b473" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef9b94cf-37a3-4d16-a2bb-ea5991896068" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34600bd0-81af-4447-b6a6-35c8dce80ce4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df8cfb06-c58c-45a0-8916-2fcbac684c49" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"/>
          <td style="width:1.72%;"/>
          <td style="width:1%;"/>
          <td style="width:12.92%;"/>
          <td style="width:1%;"/>
          <td style="width:1.72%;"/>
          <td style="width:1%;"/>
          <td style="width:12.92%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c76b3522-47dc-4a63-aad1-caf579cd613f" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,555</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ac91760-30c5-40c5-b17e-293be8c24cfb" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,323</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be2815d6-86d4-453b-ab6f-541925cc3449" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,546</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07c741ec-2c74-48b0-a1e3-2ccd46928b71" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,472</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a9fa028-3f41-485e-9448-43649321307e" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,101</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c96ac5b1-66bd-4e42-80c0-f8158029d55e" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,795</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9859be16-07f0-4be0-ad8a-3ffc4f3a3d0f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68c1b1cd-f633-4272-b052-2e9ecc220cdd" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:MarketableSecuritiesGainLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, certificates of deposit, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5007a151-c732-43ae-bd5c-4d20a27d07c7" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_5007a151-c732-43ae-bd5c-4d20a27d07c7_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#8217;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5007a151-c732-43ae-bd5c-4d20a27d07c7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad53a419-270b-46dc-93c7-ddabe5ff0488" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_ad53a419-270b-46dc-93c7-ddabe5ff0488_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_ad53a419-270b-46dc-93c7-ddabe5ff0488_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_94e46f7d-4030-4cdd-937b-79e7aa9936e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3e6532d-389d-4c38-9b8b-7e60f52eee7d" contextRef="C_d4fbee25-c222-4832-b8a1-0ed2b6aff01f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_def8c72c-9cf2-49c7-a7af-d58500ae5dcf" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a7f91cd-01ea-44f3-9753-9721a828e500" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fdde6bf-01fc-46f2-8662-8469bbd28a5d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5ea0053d-9267-49ab-9941-47a6910efe97" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize an impairment loss on its long-lived assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c69f94f2-1ada-4542-8def-1cc2e8036fb2" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each performance obligation is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the performance obligation.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5a02afe-0e9f-4f57-95f0-fbb2a429dd50" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e32b1df1-2e01-493d-97c1-87427b7872a2" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7c5b459-5ee2-400f-97f7-4336251ffa21" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8aab1f09-d55b-44de-99a5-72d669b579ff" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits within the provision for taxes in the consolidated statements of operations. The Company accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f5cda2c-7ae5-41c4-92c7-a4dd26571a48" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and penalties for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a4c3e52-8d2f-437b-824f-b48f14061516" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:PostemploymentBenefitPlansPolicy" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the Code) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60fe571a-ea15-48a9-94cb-475298e88bb9" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021, the Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b778e06-b2a5-4bb4-ab02-692057b21770" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b4fe8e-47b7-4be3-ba00-9c73d44bc98a" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2101c9d0-b44a-464f-9d4a-b950db5a13a1" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be805052-491a-4de0-adec-51c7a3eb13db" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_be805052-491a-4de0-adec-51c7a3eb13db_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_be805052-491a-4de0-adec-51c7a3eb13db_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dac47de6-75bf-4f08-ac7c-b874b3685626" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the Company&#8217;s consolidated financial statements and disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55d1b004-c7a6-4a64-a093-d560ac9d0ec6" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ab2cd1f-1adb-46f2-afe4-ce29589d0337" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.5%;"/>
        <td style="width:1.16%;"/>
        <td style="width:9.94%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:7.9399999999999995%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:7.9399999999999995%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:7.9399999999999995%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:7.9399999999999995%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8e4d053-8693-4ac6-bf0c-0137d2fa747c" contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,101</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92566bf1-8bc1-41bb-83a9-1858280c3812" contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19d82f43-1ca8-48c3-81df-27bf350856a9" contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8f2e8b0-28f9-49c0-a32d-ef06244ae4e0" contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,101</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e44150f2-bb0e-4bfc-8f1d-8bf887465ca3" contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd1f64bf-71f0-4bf6-8d55-0c9dbd42f065" contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85b58a64-fb85-4b19-b332-439c41cfb4f3" contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b540933f-3993-4454-837e-777c5d839a16" contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,206</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2182e88d-bd1b-43c3-ba20-9bda1601cea2" contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,086</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32462008-ad86-4d59-b397-efb49ccb62cf" contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caf0db5c-a348-402f-8a4a-a51238f37dd6" contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcf733d2-1634-44ec-8de5-9e40d1ea26cb" contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80179b07-43a5-4787-98e8-7f254c52996a" contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,082</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efa54071-4ff7-407b-8ff4-b9917f857e36" contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_461a831a-54c0-42b4-89ec-3a8f0a393a88" contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c23e0ac0-429a-4403-aae1-bced7a2b9c0d" contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ae67773-76b7-4899-a760-589e7426d49b" contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8caa9bd8-764b-40d3-ad7b-24722b60b5af" contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_258e02d6-dd4b-43dd-b618-f5a565ffa392" contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce22a0de-af9f-4286-8b2c-a38d111a1cbd" contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc291efb-fb7a-43f9-a54d-d6a853691870" contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">543,975</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97cd7dbc-837f-4891-9e68-07348372b9e7" contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1eceaa7-b8b4-403b-aed4-8bc6d843da2a" contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec258786-f8f0-4089-b7cb-4ef2e816e948" contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">544,158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af61037f-847e-46eb-84cf-aae9522b04cc" contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c5b3c56-7709-4e09-b43c-484368a29519" contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d4c5df0-3a5d-426e-a26a-a25d32e67f58" contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0934a569-6801-47e4-82b2-3962dae198ec" contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e345f2e-91b4-42e5-b649-62249127df6d" contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee710cd1-532b-4743-ae48-c46faee09848" contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a3f87d4-e116-41df-aefe-a153243c4da2" contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c94754f1-6832-49c1-8d51-a33859952519" contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501,810</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0da221c3-d4e5-4fc3-bf8a-f7f90de5d162" contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5219443a-54fb-419c-9d91-69c33c5c98cb" contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce52de30-9202-4da8-baea-3742a461359c" contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_495a6bfb-25d3-482f-ba74-fe035a565275" contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,432</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecb36fbd-c546-48d6-a401-57d054afba7b" contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34ee1e27-d734-4894-b711-bfe7bcfaac2d" contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5929663f-4bcc-467e-bb59-0ce1e010203b" contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce28f990-104c-4826-9efb-a80f96c34033" contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,346</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afb72212-68cb-487c-90a4-3a63984e0eb5" contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">655,010</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0202a6ed-706e-4e9e-b4f7-be9d15d0c53c" contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f00a9e1-ffc7-4877-9344-a7a2ad9d8661" contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,587</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62b4cdd2-9bf4-43c5-9b56-51e3447d6182" contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">650,436</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the remaining contractual maturities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1f95814-0433-4c02-a571-98bfbc146b79" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">503.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of investments were less than one year and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc605ad2-118d-4376-b7c0-a9585d125485" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were after one year through two years. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. For the year ended December 31, 2023 and 2021, the Company sold marketable securities for the total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_878223b6-4c85-4d7e-8fbb-31bdcca50c6d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a6c0eff-8a4f-40cb-9717-0ae158efb066" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for an immaterial realized loss and gain based on the specific identification method. The Company did not sell any marketable securities for the years ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_430ec06c-3606-4fbf-905a-809cc966ff2c" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.     Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2023, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into customary indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for certain losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_578aaf34-1e1b-4471-92ea-802f2f9c3fd4" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:IndemnificationAgreementLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded a liability related to such indemnification agreements as of December 31, 2023. As permitted under Delaware law, the Company has entered into indemnification agreements with its directors and officers that requires it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by law. The Company also has directors&#8217; and officers&#8217; insurance.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6910cd3a-782b-49b7-be68-179d29561daf" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.     Collaboration Agreements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab, and AL101 (GSK Agreement). The GSK Agreement became effective on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_894bdc0a-cfbe-476f-9890-7632c0d9abc7" contextRef="C_d58b91a6-8565-488e-b02e-ec025dddbb45" name="alec:CollaborationAndLicenseAgreementEffectiveDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 17, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the GSK Agreement, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a828e820-3370-47d5-ae83-1f5a06b5030b" contextRef="C_99484b82-1134-42a5-ab27-b25e9ac34512" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_470ba5f8-8f17-4200-a3c2-74c8d21f85e5" contextRef="C_d58b91a6-8565-488e-b02e-ec025dddbb45" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was received in August 2021 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fe48808-7ef7-47c2-89a8-7efc74574f4b" contextRef="C_f007740c-c40f-4489-8fb4-025d2bc6fa15" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f09668e-a0b7-493d-b389-c37bc134e774" contextRef="C_cd35894d-35dd-488a-bba1-d0a7f771501b" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#8217;s disease, Parkinson&#8217;s disease and other non-orphan indications. GSK will also conduct the initial Phase 2 trial for AL101 in Alzheimer&#8217;s disease. Development costs will be shared </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc162dcc-44ea-4135-b283-a85ead5f7955" contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c" name="alec:PercentageOfDevelopmentCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by GSK and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72aabac8-c882-45c3-bcaa-4db3646effcd" contextRef="C_a3c0dae0-748f-402b-8e0c-a163a0ca3e35" name="alec:PercentageOfDevelopmentCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by the Company, except that subject to the GSK Amendment (defined below), the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company and GSK amended the GSK Agreement (GSK Amendment). Under the terms of the GSK Amendment, the Company is responsible for funding and sharing in GSK&#8217;s and the Company&#8217;s development costs up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc39b075-0114-4b63-ad7f-f756b05741f2" contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d" name="alec:CompanyMaximumFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the conduct of the initial Phase 2 trial for AL101 in Alzheimer&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disease. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the GSK Amendment in accordance with ASC 606 and concluded that the GSK Amendment was a contract modification to the GSK Agreement. Accordingly, the transaction price as of May 2023, was updated from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc046671-54f8-415b-8772-da08c615ca66" contextRef="C_b63dbca3-4067-43b5-ab54-c12f0d45646c" name="alec:TransactionsPrice" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_797aaa32-05a5-43c3-b1fe-c304a85d51fa" contextRef="C_0c6c34c3-6684-47c0-932c-32afe31b92fb" name="alec:TransactionsPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">571.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the difference of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a02787ce-8e1c-44d9-b3cd-fe698972f988" contextRef="C_fe95f1f3-8845-4196-a35b-577d8188b3b5" name="us-gaap:ContractWithCustomerRefundLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">128.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as refund liability to collaboration partner for the expected cost reimbursement to GSK. The refund liability is an estimate of variable consideration calculated as the difference between the Company&#8217;s maximum funding of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3b3188-c44b-4e0f-9db8-c82d065b5ee4" contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d" name="alec:CompanyMaximumFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company&#8217;s cost budget estimated using the expected value method. The Company determined that the modified performance obligation for the AL101 Alzheimer&#8217;s disease program is performing development activities to support the initial Phase 2 trial, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fecb209b-ee2a-4c5c-ae3b-7ebfb7d4845e" contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the modification date relating to the performance obligation which was satisfied in prior periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023, as a result of the planned closure of the latozinemab Phase 2 trial and concurrent agreement by the Company to cost-share additional R&amp;D, the Company determined there was a modification of the GSK Agreement, resulting in a decrease of the scope of the performance obligation associated with the latozinemab FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Phase 2 trial and an increase in the amount of R&amp;D cost-shared by the Company in future periods. The impact of this additional cost share was accounted for as a refund liability, which reduced the transaction price for the GSK Agreement by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da629269-a443-44f0-b158-340516816328" contextRef="C_4e1505fa-8544-4458-96c7-53104f4fe63f" name="alec:ReductionInTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The refund liability is an estimate of variable consideration. The Company determined that the modified performance obligation for the latozinemab FTD-C9orf72 indication is performing the first Phase 2 development activities, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68d9cfdc-9a7c-43eb-84f0-0dcb95b4c3bb" contextRef="C_eba99dec-98b2-45c0-9d27-7d9f74ea5672" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the modification date relating to the performance obligation that was satisfied in prior periods.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of latozinemab and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to latozinemab FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction price at inception included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72eab347-0817-4479-a99a-29590036ba2e" contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was decreased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53e9608b-4ced-4f49-992b-bbd513e9c8a0" contextRef="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4" name="alec:TransactionsPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">569.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million due to the estimated refund liabilities created from the contract modifications. The Company reassessed the estimated refund liabilities to collaboration partner as of December 31, 2023 to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90aeab9c-becb-4d2c-a89c-b60b3005ff29" contextRef="C_d28c5140-6e95-49fb-9fb1-c9575190d7b4" name="us-gaap:ContractWithCustomerRefundLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of latozinemab and AL101 and estimated research and development costs to be incurred by the Company in each of the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management&#8217;s assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue under the GSK Agreement during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae43c79-41e9-4d24-8aae-870ebbf28d37" contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">66.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_391b344d-5128-4eb5-8e98-95b8711be736" contextRef="C_c5787191-0ee2-419a-98e0-6bb30e57cb15" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, the entire amount of which was included in deferred revenue at the beginning of the period. The deferred revenue related to the GSK Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d51efe6b-6891-4bac-87be-656cfd524738" contextRef="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">247.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01e39f59-eba3-4919-a102-374efaf7cb01" contextRef="C_dc034315-cf03-4581-b437-e478d0086352" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">444.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company recognized a reduction of research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dc2375f-a006-490f-9d54-40fddc002ab0" contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fbddcfe-df11-4937-91ca-1f8de6f0da4a" contextRef="C_c5787191-0ee2-419a-98e0-6bb30e57cb15" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the GSK Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AbbVie</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7295bd1-c7ad-4a77-b1c0-4b3b3a43dc1f" contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">205.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45f77712-f606-4bf0-8180-1ff53b07f23b" contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e170a36-a929-454f-85c9-d839a5f3d2d7" contextRef="C_c1f0c7a7-e180-4765-8b37-912035434a8f" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector concluded that further development of AL003, the asset being developed under that program, was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. Accordingly, the Company is no longer developing that program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06c24adb-6191-43e0-b521-3f6a16bf77cb" contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9" name="alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. If AbbVie exercises its option for the AL002 program, AbbVie would take over development of the product candidate, and the program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. Alternatively, following AbbVie&#8217;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9690e958-133d-4ec1-a7d3-a083cf09dbad" contextRef="C_f69c2b26-8b9d-489b-a357-6baf4bc970c6" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company and AbbVie amended the AbbVie Agreement (AbbVie Amendment), which resulted in the Company receiving a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06f1ea26-de03-458b-a2d6-07116241e31c" contextRef="C_cf80a4f5-ee57-4865-a16e-612cda395dcc" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment in March 2023 for the dosing of the first patient in a long-term extension (LTE) trial. In addition, under the terms of the AbbVie Amendment, the Company was eligible to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_221ee0d0-8f44-45a5-a743-9bd0a74d8e1d" contextRef="C_5eeb6d5e-07f7-4d7a-9ae5-040a3397c88c" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to support the enrollment of additional patients to replace discontinuations. The performance obligations to conduct the LTE trial and enroll additional patients are not considered distinct from the AL002 program performance obligation. The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a07abf71-8d95-47a4-a60c-8a8a758e6e23" contextRef="C_19b8748c-94f6-4009-ae46-72a683ffb30c" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the enrollment of additional patients from AbbVie in the third quarter of 2023 and received the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23b14fd5-b799-4b1e-a710-81b549d9ee26" contextRef="C_7151cd96-2161-4092-af10-bd88188169e1" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the fourth quarter of 2023. The transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74425371-1699-4e8a-9edd-480d6f9d6f2a" contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">205.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f30db99-8427-4319-88eb-2282b78dab82" contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million LTE milestone payment, and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae54ea44-1a97-46c2-aad7-300d69c6bf43" contextRef="C_7151cd96-2161-4092-af10-bd88188169e1" name="alec:CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment for enrollment of additional patients.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b06e8f-0a7c-435f-a5a2-01417c02e55e" contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_515e87ae-0611-4d26-bfee-65a59e8c26f7" contextRef="C_95c548cd-02a1-4c12-93cb-ea44937aa4a8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was included in deferred revenue at the beginning of the period. Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_feafd067-1e21-478b-a8f8-0ca28e56a974" contextRef="C_85f03d7f-58f4-427b-a31f-ee0c4a55e9ed" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371db0b9-e291-4bdc-877f-fd9c23694bdc" contextRef="C_e926ae33-adab-44c6-9813-d90466e7d1d6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The deferred revenue related to the AbbVie Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b046a4-f5ad-46c4-a0c9-3f8858daa631" contextRef="C_7151cd96-2161-4092-af10-bd88188169e1" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e61967c-04e9-4a36-9e29-ed39e8205b73" contextRef="C_79cee874-ca87-430e-8f98-93d2c63bf411" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively. The deferred revenue is expected to be recognized over the research and development period of the AL002 program through the completion of the ongoing Phase 2 and the Phase 2 LTE clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb2ceb58-993f-4c64-971f-3a45bbb0805a" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.       Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cf6f6ed-166e-49d1-a2eb-69243a54220d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.333%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:13.503%;"/>
        <td style="width:1%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1%;"/>
        <td style="width:13.523%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c7897be-12ed-415f-9b04-cd135d251916" contextRef="C_758a9e1c-3654-4bc4-a4b7-e7f816f49088" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95f2529e-f5fb-4aae-befb-88cc708cc202" contextRef="C_b2f18b21-9cde-4c57-b478-19cc995431ea" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6728873e-7f16-44d7-a5e3-068bd859c3f8" contextRef="C_f5b536d9-fa13-474e-a41d-356bbdb5ca40" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb53466a-6cfe-45c8-9cd9-57ec71e4fdea" contextRef="C_f68b6d3e-af72-4397-a93c-d21976f8b5eb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_451fa208-dd18-413a-acb3-56eeb89768a2" contextRef="C_fddc05c2-32c9-4c4e-b1bc-8af85e42859f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_beaf7c1b-c34e-449d-9657-5f1ab3e47a85" contextRef="C_6d33b68e-2d8d-4bba-8c12-cc5befb5c40e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f2d33a9-6e5d-46a3-bf1e-a9654182e564" contextRef="C_2576a651-9ed1-4183-b092-abc05d49d737" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,616</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_830d65ec-7e82-441a-a9f8-9d5ba885252f" contextRef="C_f0628b57-6af6-4f3a-a678-5f72c4012bd8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,228</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a744f03b-fdcd-4316-8068-2d334121371a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,911</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3985ab15-d9c9-469a-8706-dd1205229d79" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f87e00-6e7f-4d85-9975-c12c78b55835" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,050</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7c2eb27-ba74-4355-b7c9-91b2ff7377f5" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0676479-5ce0-4395-9a22-6f213ac2c0cc" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,861</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98b88ff3-444b-47e5-9a48-b73eba727d04" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc9dcf3c-2386-4a95-a26b-0f4bdc997085" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c90006-3cd1-48ce-998d-52e539d4e8b2" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,539</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea6bcf5e-7f14-4363-84b2-7bd7d3563658" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,321</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13cdf8a2-a8e1-49b1-9ae1-7c06879c3dfa" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd0912bb-2bc6-40ec-81ff-10e37c72b2fd" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9584ed5-0707-4e46-8caa-3cf79a476fb6" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_292ddcce-d126-4e4a-bcef-a317b7226815" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,983</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_344ad03e-4877-4a2c-a32c-384e973fe458" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77eeb080-14be-4029-9cc2-f0c0c1284dad" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65c71b88-21f6-4644-a2b8-03126e1a01f9" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,378</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be175ab1-2187-4938-9854-84bce9db0e10" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76903a84-9baf-44d9-9bda-ab53e7d26324" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.      Leases</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, the Company signed a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52f2f1f9-9134-4d6a-bbaa-70de9b7d6cd7" contextRef="C_4aa98c31-3185-40ce-8dd2-7ce79a8cd6e4" name="alec:AreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in office and laboratory space in South San Francisco which serves as the Company&#8217;s headquarters (the Headquarters). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53d34142-8702-4156-a042-b2693ebb016c" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a358262-0d14-4257-9fb3-cb9034a11bae" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:LeaseExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to renew for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5f4b335-f768-436d-842e-ecfbce3522d3" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The landlord paid for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1fe80a5-d87a-40ec-b74d-f0123fe19940" contextRef="C_acc458ea-fb09-43a4-ace2-5afee4642294" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a592cf4d-5bd2-49f3-b156-93e62c8123f1" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d042c5df-1e07-4909-924e-8431fed8f88f" contextRef="C_56217c44-9068-48a9-bd55-ca120578b623" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company signed a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1db2aee0-0eab-4898-a64d-ce0edf9ab4ad" contextRef="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">18,700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in Newark, California. The lease term ends on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40d930f7-a3d2-4caa-b7cd-d4bb60378ead" contextRef="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 6, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c33028d-69c5-48bc-bc3c-6040d40fa9ab" contextRef="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The landlord is obligated to pay for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff9ff4a-c71c-4dd0-8112-1e05fbbeb0ce" contextRef="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tenant improvements.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">measurement of the lease liabilities for the leases excludes the options to extend the term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#8217;s leases consist of operating expenses for the spaces.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2019, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78da1d95-2b6f-4d21-9493-df4c5a317c3d" contextRef="C_d3eeb729-bc22-498d-881c-1db3ed88b394" name="alec:AreaOfPropertyInSubleaseAgreement" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters, which was amended to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_731c68a2-fa14-4b19-a4de-c733e70f1c3b" contextRef="C_e0b4d8d2-f8bb-40b4-9f9f-b389737a0383" name="alec:AreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">23,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in December 2020. This Sublease expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad8ddee3-5a1a-4fa2-9677-dab8a9da534c" contextRef="C_340e1b04-fc2d-4614-bea3-759221ffd38e" name="alec:SubleaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24705bf3-888c-45da-81a0-d26dc8634e01" contextRef="C_762e850e-ccde-406e-bb94-80d9fd84a94a" name="alec:AreaOfPropertyInSubleaseAgreement" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">7,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters, which was amended in May 2022 to include an additional space of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccff41ee-5bce-4a32-a046-39c7bdce5972" contextRef="C_536c635f-d92f-46c9-b598-60cb1e600887" name="alec:AdditionalAreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">13,150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. The 7,100 square feet of space subleased expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70d92b72-f4a7-420d-b9c8-c11e455abbdb" contextRef="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160" name="alec:SubleaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the additional space of 13,150 expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9e1f96e-b5f3-4559-902e-2be2889a57df" contextRef="C_e1cbc65c-39be-40d5-94a2-085b20c52e97" name="alec:AdditionalAreaSubleaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In October 2023, the Company entered into a second amendment to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d35bcc1f-a4ff-457e-9ff6-31f4bd0a8165" contextRef="C_fcade9bc-91eb-4e33-86f9-9e6dd66a7393" name="alec:AdditionalAreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">13,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters. This sublease will expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_751e73a7-cb2f-4cfe-808e-c49eaec68888" contextRef="C_18e12969-87bd-493d-8d25-859c9cbffa99" name="alec:SubleaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c38c6ec-0efc-4e23-adf9-7b96b9b8536e" contextRef="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53" name="alec:AreaOfPropertyInSubleaseAgreement" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">9,300</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters. This sublease will expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37e97f10-2923-4ff5-bdae-4735d552da31" contextRef="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53" name="alec:SubleaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The sublessee pays its proportionate share of operating expenses for the space.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b6a2d95-c49f-405d-bc8b-10a3ccb93377" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.91%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.957%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.957%;"/>
        <td style="width:1%;"/>
        <td style="width:1.74%;"/>
        <td style="width:1%;"/>
        <td style="width:12.957%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359f2657-f92d-4b63-9532-0056e144ce85" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,626</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7817613e-98f4-43c4-9376-edba9abe1b24" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,638</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76d1e43b-2dc9-4beb-a0bb-e6261bc274ff" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2569333e-f406-4387-b85c-108b903be4a4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f88ff287-9f52-44f9-b8be-51a9a45fa3e9" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1febc256-e6f4-4f30-b2bd-7fc758d82538" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,046</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb274a5-3163-4649-acc9-a86d6627a964" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,482</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c3091aa-f43f-4a2d-9f69-c7966027f818" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3659c93c-8dd0-46c0-975a-26ac59198316" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,141</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad0bc337-076c-46ab-8478-08705de1899e" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,293</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d690518-e084-4ab3-aed2-f04476941a2e" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,551</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4c77a8b-c012-4320-b773-d158a3af03c6" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted-average remaining lease term for operating leases was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c61c54be-0ff5-4522-9928-4e4ca68d11bd" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f6edc5a-19d3-4679-9c64-dbed4b7c4fce" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Cash paid for amounts included in the measurement of lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5432ed7e-28a7-47a8-86de-2470e38fcfb7" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e717465f-27c7-41f2-80a0-47f8f50540bd" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07876fb8-9bd2-4cdf-925b-dbeb6c4d1f35" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_166a2b71-2e10-49c4-bc73-ef42d8533228" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following are the lease payments owed under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:18.36%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b415f72-b9b9-4d10-afcc-ce96214ae2ba" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8c537a4-f357-4024-896b-f676d4acdeb5" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af4f04f7-4817-4d33-8bd6-a2f4190469d7" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66c687e5-4b99-452d-8020-e3f46ece59cf" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e867a85-6d07-4abe-99cb-54c00e7e69b7" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4f90432-6168-4765-88d2-8004439b0b0a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c462149-ddb9-4834-802c-e144c091904c" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfb0db10-d4b3-4df0-adcc-16bb558ce122" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,557</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d25b719-2bf6-48d8-b718-4c784377c16c" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ad8c8a5-1f74-4fff-8712-455b0bd9c304" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.       Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d4074a4-78bf-4850-823a-161d249f9c88" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1%;"/>
        <td style="width:10.84%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9371c98-d392-4917-bcda-53f5176d1bf8" contextRef="C_a6997d26-1cd1-493e-9c86-be8ab9f39310" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9c64394-f107-44df-b49f-84d02a98ca9f" contextRef="C_21a83cdc-0b37-49af-9a68-60f9ffb64987" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,895</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf34ee28-476b-4af2-95fc-83d3d106ab70" contextRef="C_88135be7-53d0-4cfa-bfc7-18676d65fe75" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,443</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b389493e-0ab3-4b1d-b2fe-66e5790befe4" contextRef="C_d2bb0f40-e78b-430e-9753-abc94b48fdb0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,391</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d85be3f5-50c2-4a08-b72f-5705e2e86aef" contextRef="C_70243292-8d4b-4f56-b852-1e89e77c7444" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2ba09ab-ff75-436c-ad65-b680a25f31b0" contextRef="C_44344e5d-5a1c-404e-8607-c5de69163711" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,342</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d5987b-0dfe-42e0-8e37-0b7ba8941bcf" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,798</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76e0683d-f25c-40a7-b662-f87258c34072" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b8dcac8-16e8-4771-88ad-383459fdc7f4" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c20ad7d3-6143-445c-a305-27fff31c85e8" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.022%;"/>
        <td style="width:1.2%;"/>
        <td style="width:16.793%;"/>
        <td style="width:1.2%;"/>
        <td style="width:16.793%;"/>
        <td style="width:1.2%;"/>
        <td style="width:16.793%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e71bbef9-8ff6-4894-8270-41777d39eb6e" contextRef="C_52035361-b24c-4755-ad7a-e82a0d8ebc06" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211; </span><span><ix:nonNumeric id="F_a63e3016-0ca3-4257-824f-e0c33db8d22b" contextRef="C_5faa559f-1d59-40e4-a7d3-52eebb14274c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a47ff1ab-a858-474a-b3e8-e2317f116a17" contextRef="C_ef477b10-b2f5-419c-9069-8dd0afc677f6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_3bb86d5c-a534-4e6b-a48f-e54e82c41d90" contextRef="C_a10ce102-5713-4bf0-a2c5-da99484f0103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dc96d455-b615-46e5-8ed3-562e320ad116" contextRef="C_6ac7c560-3741-425b-922a-fa6377eceda5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_b875a4be-8c0c-4402-8662-6514d6e4a9bc" contextRef="C_3aa9e816-d1a0-4625-9af0-5128da3a9209" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57c6547-fd79-499a-88e4-c07bdae11bd4" contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e658f85-6d94-49a9-b164-8bbdc97a1f78" contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7147aee6-f6a5-4c6a-9fb8-0cbb1416136d" contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d13b8a-2a4c-4d2f-8adb-75fb9287c031" contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eeec05e-3cc6-403e-a488-d633b77f4b49" contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0564cccc-8f74-4557-9452-77b75ca0ce5c" contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25ad1593-d703-4e7c-abda-a1620622255f" contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba352a2e-c3e8-49a1-a0a5-4386bc2f4394" contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28add35c-ceb7-43a5-bfc4-962624680c2e" contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a366774e-8b2c-4aab-aa4f-1867448b08cd" contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59caf9c3-c559-41a4-8811-b28bde935e1f" contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36569415-07da-4648-89f6-8bd231dd107b" contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67f118be-89d5-4995-9d85-345ef811774f" contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc95fc4-b148-40ea-8f25-930cac41e903" contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f7f4795-2d62-4434-8fe6-c0ee9458bb7c" contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan and 2022 Inducement Plan</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#8217;s employees, directors, and consultants. The Company&#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14863f8-d714-41ff-89c8-6831783adbff" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="alec:PercentageOfStockOwnedByIndividual" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57fc2588-32ee-41d7-84cc-ee29a8644826" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value and the term of the award shall not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ae5b1cc-15a9-4a87-bc65-3a36d61dadb0" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9f103fb-a0c5-4d75-ace4-4dedb773d407" contextRef="C_ce453676-bced-4bc7-adfc-3a7dc2104ba3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The stock options generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_591f2fa3-a532-4734-9c8d-7707cf55e6ed" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period with one forty-eighth of the shares vesting each month or over a four-year period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df539d5a-9488-480e-9a74-e8c34aefb07f" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting at the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5b51a69-e8a0-47c8-8177-e1e8e707ae85" contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2023, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15249694-9da6-4bde-a964-9ca14a80ea65" contextRef="C_b5b6de0c-0735-4356-9282-a70e9141c22d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,144,785</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_500ae604-5792-4b6e-aa8b-747ea6107654" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,018,705</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the 2019 Plan, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70f566c9-b685-46c2-9fe6-84f6cc373afd" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,579,341</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were available for issuance of future awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1f7074b-8cbd-4f45-a801-fc13272058fc" contextRef="C_0ea8a13b-a850-4902-bc14-e2a26e047915" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,630,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13aff6b6-eaa0-4b49-9462-27ecf1cfd0d8" contextRef="C_11e15bef-5569-498f-9263-fd8668b4e72c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44ec9075-56f6-4bf8-b50c-368f22614fed" contextRef="C_324a6c7e-62a2-4eaf-a1db-f175723903c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,407,389</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were available for issuance of future awards under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a31533b7-ef61-46b9-9310-1a6ff8c2c1e6" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option activity is shown below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.36%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.82%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:10.14%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.82%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:10.34%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bde0e80-e9d0-46d7-9bc8-7c2aceb07745" contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,644,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5267021b-ffa9-49eb-bce0-8b1d5ae1fa0a" contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e875346-d0d2-4c2e-b85e-5f59417fa233" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,996,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea514d8-224c-43ea-bd19-0dfbec1eae2a" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a585ee61-b1cf-4afc-8453-f9b540f6ed5e" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">298,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c26fc4a-082e-46af-90af-f2af25de3e67" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2219b036-8c25-4690-8210-95b9ecfcacd9" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,628,925</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53b0d008-a6f8-4e4b-888e-dfe204a610c3" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32ac6b07-f732-44f7-b4ec-568afe18340f" contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,713,272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3eafcec-ef3a-41eb-8830-224e90022460" contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb35172c-ae81-4fd0-b60c-801d4e54d5e4" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">572,538</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc31a705-474e-4a13-8777-c3967b0508e9" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cb011f0-c081-4d95-b9a7-0bab7e008cc0" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">132,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_732c39e8-6f6d-4fd4-ab7c-6c3766029356" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d37bc6cb-4ecc-485d-ad57-ae3f7b249338" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,057,381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_125cdc61-8f42-4f96-9b8c-0d524464fae3" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1b1c8c3-05a7-4eae-bf75-d6c4524f7742" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,096,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9360d1bd-c9e0-40e2-b1d2-0ec5741c04e5" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b94bfa86-dc4c-49ac-a299-d99562db1281" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0692fbe-3ddb-40e9-bf81-550db86196b9" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1c39194-0e59-465f-881d-37dd7a7f9183" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,467,987</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9afe53-47b8-4a70-aaa9-709150165afc" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c3741878-4b21-4534-bb06-d3138585575c" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8ba0c04-d791-429b-a614-8374f7d1b53a" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31,<br/>&#160;&#160;&#160;2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0967323-2f79-47c7-8ce6-dccb02a2242f" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,096,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5890d10-30ef-4265-aa87-4dc2a246d20d" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_937088a3-2e40-41a7-9fba-7e66f58fe9df" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_885ea291-db9a-47ac-851b-78d5566f6ec3" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afcc776a-0712-400a-894d-c955165af361" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44be298f-fcc7-4553-b453-3195d8eb5327" contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f623c0b-03d0-49ad-92b9-bc4dc3f58c23" contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021, respectively. The weighted-average grant-date fair value per share of options granted was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aaffc3c9-35ab-424b-bce7-982d835078dd" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1881b278-8cd2-4d09-834b-fc9b90842500" contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eca23d4-e5b7-4c08-a2b1-05d305fa58c8" contextRef="C_18a6ec65-ac34-40f3-95e7-bfa2ffab6462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f07f965-9b03-43e3-aded-38ff7fb20653" contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72bc0670-7242-4018-90ab-ac0221db2c9a" contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Activity</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcd8a87e-0a2b-4881-8d93-48685b0c6528" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_fcd8a87e-0a2b-4881-8d93-48685b0c6528_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity for the RSUs is shown below.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the Company&#8217;s stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">model </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1b23363-4ab5-4f05-ad36-3d666ff3e260" contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be amortized over an estimated weighted average service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36e9de4c-5187-4f93-941c-22f2ca58ca7c" contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fcd8a87e-0a2b-4881-8d93-48685b0c6528_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.38%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45509eb7-98ef-4074-8b80-1fc53e998ae8" contextRef="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,373,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b95ee8-a302-49fb-a885-2f295dec4eb8" contextRef="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.35</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8e8b702-af49-473a-bfe3-8733ed612653" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,539,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4427e129-3741-492e-930e-47c488b00865" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.02</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5866d90-e8e7-45a5-afe4-b1c4b29eb1a2" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">414,577</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aad39f61-f654-4d48-91f1-af84975f7fb5" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0313a14-5be5-447c-8145-34c5188adae9" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">453,693</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdbbec87-8b5d-474a-88b2-d7e482911b17" contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91da485e-3a9c-4bdf-93f1-db10c27b5b9c" contextRef="C_6ad7b64a-0330-47d7-be46-238226e3cd18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,044,618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b05a0046-a799-4a09-8d26-e4c763d5aa56" contextRef="C_6ad7b64a-0330-47d7-be46-238226e3cd18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad14e123-f550-4a7b-995a-1a62b0136408" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,142,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_239a0e6d-f194-4d9f-874f-6f9bc15bed17" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1a7a1cc-72c8-4a97-895f-2590fe2ee99d" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,584,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce7da579-0cf4-404a-b3ed-aa9e9230f7e1" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.41</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff683623-1055-49bf-8435-8959105b3576" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">510,513</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8a3ca39-bbe0-4afd-b5d3-3d02bfafd37c" contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.03</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of<br/>December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_329d428a-3d80-44f8-9d78-fb1b7c55ebe1" contextRef="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,092,101</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4fd32f3-d439-4d1d-bc2e-13903cd6649f" contextRef="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_743b9d24-b706-43e5-b41a-2a1ef9cb11d2" contextRef="C_cbbafbf6-6ed4-4a1e-81cd-8fc78087cc1b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e131c88c-5373-44fe-b74d-828bd25dc5a7" contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d4b7a1d-421a-49e0-b62f-fc4335800a6d" contextRef="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b" name="alec:SubsequentOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62ae0bfc-b7ba-4b45-970c-01353afc63ae" contextRef="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26ae0800-6fa6-4718-98fb-9b12e26f52f5" contextRef="C_063d5b29-5b06-4630-b2ef-ae848097335d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">591,397</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a36f1b09-157c-4c30-9b0b-745683e844cd" contextRef="C_fb621957-f8bc-47e9-9219-b82401bc112f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unrecognized compensation expense related to the 2019 ESPP expected to be recognized over five months.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ac1e8bd-195b-4e2f-8ba9-50596e0b5d22" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.       Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af71143c-7f8d-4f5b-9ee2-3fe1e9889925" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal and state income tax provision for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.509%;"/>
        <td style="width:1.98%;"/>
        <td style="width:1%;"/>
        <td style="width:15.183%;"/>
        <td style="width:1%;"/>
        <td style="width:1.98%;"/>
        <td style="width:1%;"/>
        <td style="width:15.183%;"/>
        <td style="width:1%;"/>
        <td style="width:1.98%;"/>
        <td style="width:1%;"/>
        <td style="width:15.183%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c893011-286a-4400-aedc-ff2bcd19d0d4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,178</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_584f3e08-f0c2-44c3-b8a9-2e957f238443" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,209</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b4b2135-af23-4912-af7b-daec3a0eb09f" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fb86099-a868-4036-a58a-2f86f6a47151" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,034</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12bbb2b2-2a97-4e6f-a273-cf2506f94a24" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1f1c4ce-e83e-4023-8645-2dc732e13601" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_976ad369-ba03-4e8c-9354-ce1143895dff" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28f6c77-1730-4a30-b847-b6037cb26a45" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e178c1f1-296d-47f1-ab07-95675739d4e9" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3891a55-8cd2-4444-a504-677030f4ed98" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f948a70-f8d2-46ac-9673-0fda707b958f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8b6e810-cc1d-4177-a434-d1f3ae69b17f" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c8753e6-3afe-4cee-81cd-1590df2f6ffe" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,627</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_203dc7d0-24f0-4dcf-8f0e-03c5dec7f346" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a70cab-d261-483a-b58b-3d8c7281c2fb" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3b757cc-2c14-4a17-b569-5b17b4c9554c" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits, net of uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf4e8231-5830-4970-a36e-25eba37f6d37" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a2644f7-f3b8-49ac-bc81-f301b6c84b01" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfe5ee43-90c4-4821-bc6c-e179bf60340d" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,042</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d6ffa4b-21b4-4be5-b3cf-77e3a5a41f90" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="alec:IncomeTaxReconciliationUncertainTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cf674ba-90e9-434f-b055-6d01257be7d6" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:IncomeTaxReconciliationUncertainTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3314d3d5-7ccd-4b48-b2d9-cd13a82ff7a7" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="alec:IncomeTaxReconciliationUncertainTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0541edaa-c682-4d4a-8bfb-a8cd2f758044" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,842</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16e90e7e-082f-4f0d-9b6b-f1d22f29ed0c" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a44266e-b61d-4797-b7f6-693be1da699e" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,368</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51411f6-e689-481d-b5d7-b96eb6ab9b05" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,661</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f6be071-bb8f-4bd3-8318-9a805af3302d" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,421</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17bfd310-257b-4376-9d4a-efcb5720e9d2" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dd7cd25-d1ff-4146-8b2a-6fbdd32a8fd9" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8db7dae-1e76-4f9d-88df-ce10d6fbcf2e" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a42ce9-cdf5-4460-ae4f-4dd9c7aff67b" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49fbc02b-5b1b-428f-aa16-691663715002" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6309b11e-c8ec-4997-86d0-4df1eedfde0a" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d73495-3177-4ec8-9dc5-7365b3a792fa" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed2e7f8c-edd0-4479-9329-76a315d3df6f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.569%;"/>
        <td style="width:2.46%;"/>
        <td style="width:1%;"/>
        <td style="width:19.256%;"/>
        <td style="width:1%;"/>
        <td style="width:2.46%;"/>
        <td style="width:1%;"/>
        <td style="width:19.256%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccc1fe73-8840-43ab-91c1-db1f4e6f8da3" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,448</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a24b11a8-4453-4bfc-ab41-9ab03041a587" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,963</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf82c8cc-7a99-4452-9301-2d1a7071d89a" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">931</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75fe4d04-7234-4a31-9b86-6529d44aae02" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b36ae368-cde4-4bf3-bcbf-daa2b7169af7" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a4117e1-d3e1-4cf9-93e0-3409f6ae3cc1" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b40deffa-575d-4f63-99f4-015cf332a187" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,311</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1246c3ba-3c5a-4ace-9276-65d3d86a757b" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fce968f-daec-4c6b-a73e-ccb4cd8f905d" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_127d006b-1225-4ff2-ba15-f1cdf81afe25" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,673</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d1d27fa-30f7-4e12-919c-599d07e4a942" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,030</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32820d41-71d5-4e2a-a383-5291a3fb3389" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71657bf4-cf31-468e-8f65-734f978b0ca8" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75a8cb70-51f1-4f33-9633-bb6ec606634b" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ada38543-67de-4d4f-9c00-12461b404177" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:DeferredTaxAssetsRefundLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3429d53d-401a-449a-b61b-d6cb2c630d25" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:DeferredTaxAssetsRefundLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d143fa75-ea34-47f8-8f35-9eba036bc8ce" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd44ae9e-0401-4e67-bbbe-3a8f04abc772" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,608</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1e971aa-34c8-4eca-940d-adb5cfdf8c2b" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,939</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_778d7cb6-11c7-4e07-a2fd-c71c1298ae35" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,925</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef2d38b6-fa29-4b99-86fc-66e38a6380d6" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,550</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45d6b27a-a52b-499c-b24f-1985afea3fb8" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,316</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a4e553-cd6a-4787-82d4-d1ddb0665232" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9113c251-75f5-4c16-8a3d-18ea2b71f195" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b954c45-b4b6-4c30-a80a-6cd8f1e524ff" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,544</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcb30d16-5e35-40b7-a433-ae6fdbbda96c" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aee303c-fd98-4cf3-ac7d-a8f32ffdfc74" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="alec:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,845</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcacf778-eb5f-4855-a337-c3825e0c6633" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="alec:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fbfb0b9-cffd-473e-af93-07364d0ca07d" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8acaea28-2f77-442f-841d-2423671081c4" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1ce4303-d243-46ba-a8cc-f0709b3639ba" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd5d271b-ebd5-49a6-83ae-bfcd1b1e797d" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69442b42-0daa-45e6-8771-9db18cebf564" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal and state net operating loss (NOL) carryforwards of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_374aad23-a28d-4100-ba5f-f0ee94c0560c" contextRef="C_958166bd-8c6f-438a-9963-ca72620d9960" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84c3f9e5-c438-419a-b3ec-4abda3a36199" contextRef="C_f0b6fc05-c1a0-4504-91f0-023a1f8c2514" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">202.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71be9af3-3e3b-407d-9999-d702f510e054" contextRef="C_6c39aa66-67a0-4bc2-bb2d-dfaf63ec336a" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income. State NOL carryforwards will begin to expire as early as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21c53523-136f-489a-b16a-d382223368c0" contextRef="C_fb09fe55-8ca8-43e2-8bb6-54b263316207" name="alec:OperatingLossCarryforwardsBeginningExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if not utilized, or have an indefinite life. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had federal and California tax credit carryforward of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edf00e51-9673-4002-a9ef-a759c771a7f8" contextRef="C_958166bd-8c6f-438a-9963-ca72620d9960" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb4651d7-c3e5-49b6-8b37-3a43c6eac7ea" contextRef="C_906aea5b-0c93-441f-993c-a2359ebc1e69" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal tax credits will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26059e8d-21de-4269-8eb4-1afffd02b0b3" contextRef="C_cce98dde-1d02-4f46-a623-794fa3f11385" name="alec:TaxCreditBeginningExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2041 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">while the California tax credits have no expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_808a1ccf-b5b8-4ddd-8941-2ed115fcbb81" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f6919fc-48ed-4332-bd31-e2d0fc3e841b" contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,939</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dd5aee9-9a3b-46b4-acce-ad33a1048a99" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d70bf1a-a02b-4d46-b3c0-1912b25ab5be" contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,138</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f933ec57-05dd-4bc0-b86c-8b41e24cbda4" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf9d970a-9983-473c-80af-0f79cfdb8686" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,588</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_006d27a1-e176-4592-ab83-4f49243236da" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,071</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_baf2ccbd-f3a5-4d9c-851d-d317117ce8ef" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a36d2b98-9ad7-4d5c-8fda-b4e7eb0f279b" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and penalties for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company recorded an uncertain tax position of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_860a356d-773c-4ffd-af09-0d78fd5f9968" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_305071be-25f8-444a-9a42-26d6bbbd26ef" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The income tax provision for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, included changes to reserves related to prior year uncertain tax provisions of an increase of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb88892c-387d-4fc4-a721-7b6effcb06bb" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and decrease of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46cd614a-a385-4a02-b3b4-95a3f4eefe79" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The income tax provision for the years ended December 31, 2022, included changes to reserves of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf6d61b6-6c27-47c3-ad59-3e6a282f0181" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="alec:ReversalReservesOnUncertainTaxProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bcbdd19d-eca8-472c-87b2-543a9002068d" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.    Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#8217;s development of antibodies optimized by Adimab in its AL003 program, which was terminated in June 2022. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies, the term of which was extended effective August 2022 (2019 Adimab Agreement). In December 2021, the Company signed another</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab Agreement expired and the Company did not exercise any option to carry forward any of the results. Tillman Gerngross, Ph.D, the Executive Chairman of the board of directors of Adimab is a co-founder and former director of Alector. Dr. Gerngross resigned as a member of the Company&#8217;s board of directors, effective June 15, 2023. For the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22a3a975-5093-4dbe-bec1-f7baffca9eb6" contextRef="C_d6321c67-3454-46af-9d81-b479594892c1" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any expenses related to Adimab. For the years ended December 31, 2022, and 2021, the Company incurred expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83924d49-c748-480e-bd83-fc743b172102" contextRef="C_1ef725d3-1855-48f2-ad32-868fd7a56f60" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed9f82e-d6ea-4652-9e7e-3161305c657d" contextRef="C_eb3c4f20-3132-4502-b703-ab8173a141fb" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76de3884-676b-4159-9882-fc06a2211843" contextRef="C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f831a205-ef98-443c-a4d6-aca2b8a10775" contextRef="C_54cb7dea-1f14-46b8-a85c-4dea206dca63" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued liabilities due to Adimab as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of any covered product candidates.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07a39965-c852-4478-81e7-bf2e5f1034ee" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11.     Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85843a4b-f449-480b-9c95-91613d8c8d2e" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.22%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:13.645%;"/>
        <td style="width:1%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:13.645%;"/>
        <td style="width:1%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1%;"/>
        <td style="width:13.645%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>&#160;December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f36b8e6-8660-441e-854b-7689df154a47" contextRef="C_b441b445-cd74-4873-a003-e91cd23b0590" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,092,101</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbac6a61-ae95-4e80-bdcb-dea375cd3a4c" contextRef="C_666e3ab2-8e5f-48ca-8ffa-0360410c200c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,044,618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04f97d04-14a1-4f4c-b1c1-e9e952d627fe" contextRef="C_be19a186-b61e-4093-842b-37a052d70447" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,373,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af8e79ba-acba-4704-a2fe-6b6691375b62" contextRef="C_c2ced522-2924-4199-8e43-04ab2c397ba4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,096,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_470e6e5c-dddf-4d7f-b0c3-4fbd1a12ae84" contextRef="C_0a89ff33-c725-4439-ad8e-bf3568d41b8b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,713,272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2c6a884-02ec-4697-859f-0f6dfc09e36a" contextRef="C_ec43ac9d-d355-4fa2-9bd9-cf8e37006808" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,644,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc24859a-f601-4274-bfba-ef87f8989989" contextRef="C_52dc5672-fc66-4cee-a898-4ecac0b3d0bc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">160,356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d67a4ff-b12a-4253-9051-f06b9b9238f7" contextRef="C_90f3186a-3a7c-4ce6-bbc4-af5ab058188b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">167,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_023ea247-76dd-4fca-b847-72a2a49b5254" contextRef="C_3bb5d2cb-8240-469c-b215-b0ef522ac46c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">70,406</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e068c4a6-fd25-4c44-90ab-f21c2484c842" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,348,694</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c83fae40-3529-4412-811a-20a517d144c2" contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,925,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d62760c-8333-430b-8a4d-f69a0c1c1125" contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,088,350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c82f8732-c50e-416f-a3d0-14e95ba8841f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12.     Restructuring</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2023, the Company committed to a plan to reduce its workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03f3cd3e-b2d1-48e0-814d-1d4e1c7ff828" contextRef="C_c0a79701-f609-4f39-8ea8-fa90332bbbba" name="alec:PercentageOfReductionInWorkforce" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to better align the Company&#8217;s resources with its previously announced strategic prioritization of its late-stage progranulin and TREM2 immuno-neurology programs. The Company initiated a reduction in force impacting approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_962306b4-1956-458a-a328-879460dda14a" contextRef="C_c4cbf91d-96bc-43ff-ae3a-304b48be2025" name="alec:NumberOfReductionInWorkforce" unitRef="U_Employees" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees across the organization effective March 29, 2023. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred restructuring costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00dc3abe-097f-40ee-9a74-496f69e18d0f" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, primarily consisting of one-time charges related to the reduction in force, including personnel expenses such as salaries, one-time severance payments, and other benefits, which were included in operating expenses. Accrued liabilities associated with restructuring costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4dccc74-9bcf-4bb5-82f2-b689160fd479" contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d" name="us-gaap:RestructuringReserve" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d6e7f34-0662-4884-98cb-08ff341ff60e" contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_7d6e7f34-0662-4884-98cb-08ff341ff60e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13.     Subsequent Events</span></p></ix:nonNumeric></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_7d6e7f34-0662-4884-98cb-08ff341ff60e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_898c754e-5974-46b2-9323-2434aef21382" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 17, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co. (Cantor), relating to the issuance and sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9281cfb7-de61-4573-a3f0-d7fedf1220c8" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,869,566</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c5d5fb5-ea48-46b6-860a-7f13a95e4777" contextRef="C_e5a08e1c-7661-4242-afc0-5a1579c71846" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">6.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> paid by Cantor. The Company also granted Cantor an option exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2178ea3d-8ad8-4c98-b74a-1de7f1e5ee08" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="alec:SaleOfStockOptionTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of the underwriting agreement to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9afda212-2338-476b-968f-825528bc1742" contextRef="C_a26230e7-fd18-41d7-8d63-f51a79aa854b" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,630,434</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Aggregate gross proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_582042ca-2d84-4079-8127-57f7c29b6b3c" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d7be343-2bbc-478c-9d73-fd7f5d73cca0" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="alec:AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4155abf3-8183-49b3-b8bf-63049460bc6b" contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2" name="alec:SaleOfStockClosingDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 19, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The option to purchase additional shares was not exercised by Cantor</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of December 31, 2023, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control&#8212;Integrated Framework&#8221; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Alector, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited Alector, Inc.&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Alector, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes, and our report dated February 27, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Mateo, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)	 None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f), </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56e2aac4-a0a2-4993-afc8-8ad09a3d06b6" contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_3eccdb5b-00cf-4251-96eb-73886f1fcddf" contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10ef04ec-6e15-4b71-892c-89c05a58883f" contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6690e603-1e1d-486e-b0f8-6cea73c83e8a" contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated </span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Regulation S-K Item 408.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_re_foreign_jurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in our definitive proxy statement on Schedule 14A for the 2023 Annual Meeting of Stockholders (the Proxy Statement) in connection with the Proxy Statement to be filed with the SEC within 120 days of December 31, 2023, and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees, which is available on our website (</span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">https://investors.alector.com/corporate-governance/governance-overview</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) under &#8220;Governance Documents.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on the website address and location specified above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2023, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2023, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2023, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ting Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2023, and is incorporated herein by reference.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statement Schedules.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following documents are filed as part of this report: </span></div></div>
  <div style="margin-left:8.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.974562519187754%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="margin-left:8.8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements of Alector, Inc. are filed as part of this report on Form 10-K under Item 8. Financial Statements and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:8.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.974562519187754%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:8.8%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All other schedules have been omitted because they are not required, not inapplicable, or the required information is included in the consolidated financial statements or notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:8.796%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.974562519187754%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></div></div>
  <p style="margin-left:8.8%;text-indent:-0.308%;padding-left:0.28%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit Index</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.091%;"/>
    <td style="width:48.384%;"/>
    <td style="width:5.616%;"/>
    <td style="width:12.121%;"/>
    <td style="width:6.061%;"/>
    <td style="width:10.545%;"/>
    <td style="width:8.182%;"/>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:21.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:4.4pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing</span></p><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed</span></p><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519033930/d702882dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/11/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312523167891/d515127dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/15/2023</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen common stock certificate of the Registrant</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="alec-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of securities of the Registrant.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:25.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2017 Stock Option and Grant Plan as amended and forms of agreement thereunder</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.8pt;text-align:left;"><a href="alec-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Employee Stock Purchase Plan and form of agreement thereunder.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312522000212/d160293dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2022 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1//3/2022</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter dated November 30, 2021 by and between Alector, LLC and Saraswati (Sara) Kenkare-Mitra, Ph.D.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">135</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.091%;"/>
    <td style="width:48.384%;"/>
    <td style="width:5.616%;"/>
    <td style="width:12.121%;"/>
    <td style="width:6.061%;"/>
    <td style="width:10.545%;"/>
    <td style="width:8.182%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-8+</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter dated February 4, 2022 by and between Alector, LLC and Marc Grasso, M.D.</span></a></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022004925/alec-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter dated January 31, 2022 by and between Alector, LLC and Gary Romano, M.D., Ph.D.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">03/29/2022</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Incentive Compensation Plan.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Outside Director Compensation Policy.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:26.65pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12+</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:26.65pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease between the Registrant and HCP Oyster Point III, LLC, dated June 27, 2018.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:38.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14#</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September 19, 2016, as amended.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:38.15pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15#</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October 16, 2017.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-229152</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16#</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000156459019042920/alec-ex1017_159.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/12/2019</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17#</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017021000725/alec-20210630ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Collaboration and License Agreement, dated July 1, 2021, by and between Glaxo Wellcome UK Limited and Alector, Inc.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/3/2021</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18#</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017023005111/alec-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment Number One to the 2019 Collaboration Agreement between the Registrant and Adimab, LLC, effective August 16, 2022</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/28/23</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19#</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017023038023/alec-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement Amending the 2021 Collaboration and License Agreement between the Registrant and Glaxo Wellcome UK Ltd. dated May 19, 2023.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/3/2023</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20#</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017023017874/alec-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment Number One to Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology Ltd., effective February 13, 2023.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/4/2023</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21&#916;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312523272546/d565120dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sales Agreement, dated November 7, 2023, by and between Alector, Inc., and Cowen and Company, LLC</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">  </span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/7/2023</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Alector Inc. Insider Trading Policy</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of subsidiaries of Registrant.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:28.8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">136</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.091%;"/>
    <td style="width:48.384%;"/>
    <td style="width:5.616%;"/>
    <td style="width:12.121%;"/>
    <td style="width:6.061%;"/>
    <td style="width:10.545%;"/>
    <td style="width:8.182%;"/>
   </tr>
   <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97&#916;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Compensation Recovery Policy</span></a></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:right;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:4.4pt;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.4pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:1.1pt;vertical-align:middle;border-bottom:0.75pt solid #000000;text-align:left;"><p style="margin-left:1.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#916; Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit or schedule will be furnished to the SEC or its staff upon request.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.39%;"/>
    <td style="width:1%;"/>
    <td style="width:4.221%;"/>
    <td style="width:46.389%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ALECTOR, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Arnon Rosenthal</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arnon Rosenthal, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Co-founder and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Arnon Rosenthal, Ph.D., Sara Kenkare-Mitra, Ph.D., and Marc Grasso, M.D. as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his capacity as a director and/or officer of Alector, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.42%;"/>
    <td style="width:42.2%;"/>
    <td style="width:20.38%;"/>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Signature</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;min-width:fit-content;">Title</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Date</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Arnon Rosenthal</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Arnon Rosenthal, Ph.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Co-founder, Chief Executive Officer, and Director<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marc Grasso</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marc Grasso, M.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Lou J. Lavigne, Jr.</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Louis J. Lavigne, Jr.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairperson of the Board</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Elizabeth Garofalo</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elizabeth Garofalo, M.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paula Hammond</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paula Hammond, Ph.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Terry McGuire</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Terry McGuire</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard Scheller</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard Scheller, Ph.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.42%;"/>
    <td style="width:42.2%;"/>
    <td style="width:20.38%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David Wehner</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">David Wehner</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">s/ Kristine Yaffe</span></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Kristine Yaffe, M.D.</span></p></td>
    <td style="text-indent:6.55pt;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 27, 2024</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>alec-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 4.3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="c3"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following description summarizes certain important terms of the capital stock of Alector, Inc. (the &#x201c;company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to this Annual Report on Form 10-K, as well as by the applicable provisions of the Delaware General Corporation Law.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorized Capital Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of convertible preferred stock, par value $0.0001 per share. All of our outstanding shares of common stock are fully paid and non-assessable.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;ALEC.&#x201d; The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#x2019;s address is 6201 15</font><font style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Avenue, Brooklyn, New York 11219.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to preferences that may be applicable to any then-outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event of our liquidation, dissolution, or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of convertible preferred stock.</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights and Preferences</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock have no preemptive, conversion, subscription, or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred stock that we may designate in the future.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing change in our control or other corporate action.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain provisions of Delaware law and certain provisions that are included in our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences, or relative, participation, optional, and other special rights, if any, and any qualifications, limitations, or restrictions, of the shares of such series.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Classified Board of Directors</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class I, Class II, and Class III. Each class is an equal number of directors, as nearly as possible, consisting of one-third of the total number of directors constituting the entire board of directors. The term of initial Class I directors shall terminate on the date of the 2022 annual meeting, the term of the initial Class II directors shall terminate on the date of the 2020 annual meeting, and the term of the initial Class III directors shall terminate on the date of the 2021 annual meeting. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Removal of Directors</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Vacancies</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Cumulative Voting</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Special Meetings of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provides that, except as otherwise required by law, special meetings of the stockholders may be called only by the Chairperson of our board of directors, the Chief Executive Officer, the President, or our board of directors acting pursuant to a resolution adopted by a majority of the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance Notice Procedures for Director Nominations</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders must provide timely notice thereof in writing. To be timely, a stockholder&#x2019;s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Action by Written Consent</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amending our Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the Delaware General Corporation Law (&#x201c;DGCL&#x201d;). Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for any amendment of certain provisions set forth in the bylaws, which would require the approval of a two-thirds majority of our then outstanding common stock. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered, or repealed by the board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorized but Unissued Shares</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger, or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware, or if the Court of Chancery does not have jurisdiction, another state court in Delaware or the federal district court for the District of Delaware, is the exclusive forum for (i) any derivative action or proceeding brought on behalf of us, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee to the us or our stockholders, (iii) any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as either may be amended from time to time), or (iv) any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A) any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than such court, or (C) for which such court does not have subject matter jurisdiction. Additionally, unless we consent to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of our securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant. Although our amended and restated bylaws contain the exclusive of forum provisions described above, it is possible that a court could find that such provision is inapplicable for a particular claim or action or that such provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations with Interested Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We are governed by Section 203 of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an &#x201c;interested stockholder&#x201d; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i) prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A) by persons who are directors and also officers of such corporation and (B) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii) at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#x2019; and officers&#x2019; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>alec-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.3</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">alector, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 EQUITY INCENTIVE PLAN</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:24pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purposes of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The purposes of this Plan are: </font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to attract and retain the best available personnel for positions of substantial responsibility,</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to provide additional incentive to Employees, Directors and Consultants, and </font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to promote the success of the Company&#x2019;s business.</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As used herein, the following definitions will apply:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board or any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the legal and regulatory requirements relating to the administration of equity-based awards and the related issuance of Shares thereunder, including but not limited to U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any non-U.S. country or jurisdiction where Awards are, or will be, granted under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan.  The Award Agreement is subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence of any of the following events:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A change in the ownership of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">which occurs on the date that any one person, or more than one person acting as a group (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, however, that for </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">purposes of this subsection, (A) the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control, and (B) if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#x2019;s voting stock immediately prior to the change in ownership, the direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (i).  For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities; or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12)-month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A change in the ownership of a substantial portion of the Company&#x2019;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)&#x2011;month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#x2019;s assets: (A) a transfer to an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (2) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).  For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Section 409A.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the state of the Company&#x2019;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.  Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or a duly authorized committee of the Board, in accordance with Section 4 hereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Stock of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Alector, Inc., a Delaware corporation, or any successor thereto.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render bona fide services to such entity, provided the services (i) are not in connection with the offer or sale of securities in a capital&#x2011;raising transaction, and (ii) do not directly promote or maintain a market for the Company&#x2019;s securities, in each case, within the meaning of Form S-8 promulgated under the Securities Act, and provided, further, that a Consultant will include only those persons to whom the issuance of Shares may be registered under Form S-8 promulgated under the Securities Act.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means total and permanent disability as defined in Section 22(e)(3) of the Code, provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company.  Neither service as a Director nor payment of a director&#x2019;s fee by the Company will be sufficient to constitute &#x201c;employment&#x201d; by the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is increased or reduced.  The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, the value of Common Stock determined as follows:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of any Awards granted on the Registration Date, the Fair Market Value will be the initial price to the public as set forth in the final prospectus included within the registration statement in Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Company&#x2019;s Common Stock.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of any Awards granted on any other date, the Fair Market Value will be the closing sales price for Common Stock as quoted on any established stock exchange or national market system (including without limitation the New York Stock Exchange, NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market) on which the Common Stock is listed on the date of determination (or the closing bid, if no sales were reported), as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable.  If the determination date for the Fair Market Value occurs on a non-trading day (i.e., a weekend or holiday), the Fair Market Value will be such price on the immediately preceding trading day, unless otherwise determined by the Administrator.  In the absence of an established market for the Common Stock, the Fair Market Value thereof will be determined in good faith by the Administrator. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The determination of fair market value for purposes of tax withholding may be made in the Administrator&#x2019;s discretion subject to Applicable Laws and is not required to be consistent with the determination of Fair Market Value for other purposes.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fiscal Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the fiscal year of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a stock option granted pursuant to the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Director who is not an Employee.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;parent corporation,&#x201d; whether now or hereafter existing, as defined in Section 424(e) of the Code.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the holder of an outstanding Award.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award denominated in Shares which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine pursuant to Section 10.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="width:100%;display:inline;" id="ole_link4"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; </font><font id="ole_link3"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means an Award which may be earned in whole or in part upon attainment of performance goals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or other securities or a combination of the foregoing  pursuant to Section 10.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Period of Restriction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture.  Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this 2019 Equity Incentive Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act, with respect to any class of the Company&#x2019;s securities.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Shares issued pursuant to a Restricted Stock award under Section 7 of the Plan, or issued pursuant to the early exercise of an Option.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 8.  Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 16(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;  means Section 16(b) of the Exchange Act.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(jj)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(kk)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Employee, Director or Consultant.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ll)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a share of the Common Stock, as adjusted in accordance with Section 14 of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(mm)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award, granted alone or in connection with an Option, that pursuant to Section 9 is designated as a Stock Appreciation Right.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(nn)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;subsidiary corporation,&#x201d; whether now or hereafter existing, as defined in Section 424(f) of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Subject to the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="ole_link22"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Subject to the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font id="ole_link23"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to the provisions of Section 14 of the Plan and the automatic increase set forth in Section 3(b) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan is 7,688,156 Shares, plus (i) any Shares that, as of the date of stockholder approval of this Plan, have been reserved but not issued pursuant to any awards granted under the Company&#x2019;s 2017 Stock Option and Grant Plan (the &#x201c;Existing Plan&#x201d;) and are not subject to any awards granted thereunder, and (ii) any Shares subject to stock options or similar awards granted under the Existing Plan that, after the date of stockholder approval of this Plan, expire or otherwise terminate without having been exercised in full and Shares issued pursuant to awards granted under the Existing Plan that, after the date of stockholder approval of this Plan, are forfeited to or repurchased by the Company, with the maximum number of Shares to be added to the Plan pursuant to clauses (i) and (ii) equal to 5,184,750 Shares.  The Shares may be authorized, but unissued, or reacquired Common Stock. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Automatic Share Reserve Increase</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the provisions of Section 14 of the Plan, the number of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2020 Fiscal Year, in an amount equal to the least of (i) 7,096,760 Shares, (ii) five percent (5%) of the outstanding Shares on the last day of the immediately preceding Fiscal Year or (iii) such number of Shares determined by the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Lapsed Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to or repurchased by the Company due to failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated).  With respect to Stock Appreciation Rights, only Shares actually issued (i.e., the net Shares issued) pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated).  Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company, such Shares will become available for future grant under the Plan.  Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan.  To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan.  Notwithstanding the foregoing and, subject to adjustment as provided in Section 14, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section 3(a), plus, to the extent allowable under Section 422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to Sections 3(b) and 3(c).  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Multiple Administrative Bodies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Different Committees with respect to different groups of Service Providers may administer the Plan.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which committee will be constituted to satisfy Applicable Laws.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Powers of the Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the Fair Market Value;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to select the Service Providers to whom Awards may be granted hereunder;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the number of Shares to be covered by each Award granted hereunder;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to approve forms of Award Agreements for use under the Plan;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder.  Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to institute and determine the terms and conditions of an Exchange Program;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable non-U.S. laws or for qualifying for favorable tax treatment under applicable non-U.S. laws;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ix)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to modify or amend each Award (subject to Section 19 of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards (subject to Section 6(b) of the Plan regarding Incentive Stock Options);</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to allow Participants to satisfy tax withholding obligations in such manner as prescribed in Section 15 of the Plan;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award; and</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xiii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to make all other determinations deemed necessary or advisable for administering the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Administrator&#x2019;s Decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator&#x2019;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Eligibility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Service Providers.  Incentive Stock Options may be granted only to Employees.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option.  However, notwithstanding such designation, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such options will be treated as nonstatutory stock options.  For purposes of this Section 6(a), incentive stock options will be taken into account in the order in which they were granted.  The fair market value of the shares will be determined as of the time the option with respect to such shares is granted.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The term of each Option will be stated in the Award Agreement.  In the case of an Incentive Stock Option, the term will be ten (10) years from the date of grant or such shorter term as may be provided in the Award Agreement.  Moreover, in the case of an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award Agreement.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Exercise Price and Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The per share exercise price for the Shares to be issued pursuant to exercise of an Option will be determined by the Administrator, subject to the following:</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the case of an Incentive Stock Option</font></div></div>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(A)	granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant.</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(B)	granted to any Employee other than an Employee described in paragraph (A) immediately above, the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></p>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Options may be granted with a per Share exercise price of less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiting Period and Exercise Dates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form of Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment.  In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant.  Such consideration may consist entirely of: (1) cash; (2) check; (3) promissory note, to the extent permitted by Applicable Laws, (4) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (5) consideration received by the Company under a broker-assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (6) by net exercise; (7) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (8) any combination of the foregoing methods of payment.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Procedure for Exercise; Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">conditions as determined by the Administrator and set forth in the Award Agreement.  An Option may not be exercised for a fraction of a Share.</font></div></div>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An Option will be deemed exercised when the Company receives: (i) a notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes).  Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan.  Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse.  Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option.  The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised.  No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14 of the Plan.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font></p>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Relationship as a Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant ceases to be a Service Provider, other than upon the Participant&#x2019;s termination as the result of the Participant&#x2019;s death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement).  In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant&#x2019;s termination.  Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.  If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant ceases to be a Service Provider as a result of the Participant&#x2019;s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement).  In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following the Participant&#x2019;s termination.  Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.  If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Death of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant dies while a Service Provider, the Option may be exercised following the Participant&#x2019;s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement), by the Participant&#x2019;s designated beneficiary, provided such beneficiary has been designated prior to Participant&#x2019;s death in a form acceptable to the Administrator.  If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#x2019;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#x2019;s will or in accordance with the laws of descent and distribution.  In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant&#x2019;s death.  Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan.  If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.  </font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tolling Expiration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A Participant&#x2019;s Award Agreement may also provide that:</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the exercise of the Option following the termination of Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would result in liability under Section 16(b), then the Option will terminate on the earlier of (A) the expiration of the term of the Option set forth in the Award Agreement, or (B) the tenth (10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) day after the last date on which such exercise would result in liability under Section 16(b); or</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the exercise of the Option following the termination of the Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (A) the expiration of the term of the Option or (B) the expiration of a period of thirty (30) days after the termination of the Participant&#x2019;s status as a Service Provider during which the exercise of the Option would not be in violation of such registration requirements. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine.  Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in this Section 7 or the Award Agreement, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Removal of Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided in this Section 7, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine.  The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dividends and Other Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise.  If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Return of Restricted Stock to Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator.  After the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Criteria and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant.  The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the Administrator in its discretion.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Earning Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator.  Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form and Timing of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined by the Administrator and set forth in the Award Agreement.  The Administrator, in its sole discretion, may only settle earned Restricted Stock Units in cash, Shares, or a combination of both.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cancellation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have complete discretion to determine the number of Stock Appreciation Rights granted to any Service Provider.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The per share exercise price for the Shares to be issued pursuant to exercise of a Stock Appreciation Right will be determined by the Administrator and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.  Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Right Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expiration of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A Stock Appreciation Right granted under the Plan will expire ten (10) years from the date of grant or such shorter term as may be provided in the Award Agreement, as determined by the Administrator, in its sole discretion.  Notwithstanding the foregoing, the rules of Section 6(d) relating to exercise also will apply to Stock Appreciation Rights.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment of Stock Appreciation Right Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The number of Shares with respect to which the Stock Appreciation Right is exercised.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Units and Performance Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Performance Units/Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Performance Units and Performance Shares may be granted to Service Providers at any time and from time to time, as will be determined by the Administrator, in its sole discretion.  The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Value of Performance Units/Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant.  Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Objectives and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will set performance objectives or other vesting provisions (including, without limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers.  The time period during which the performance objectives or other vesting provisions must be met will be called the &#x201c;Performance Period.&#x201d;  Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine.  The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Earning of Performance Units/Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved.  After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form and Timing of Payment of Performance Units/Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment of earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period.  The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cancellation of Performance Units/Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Director Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No Outside Director may be paid, issued or granted, in any Fiscal Year, cash compensation and equity awards (including any Awards issued under this Plan) with an aggregate value greater than $750,000, increased to $1,000,000 in the Fiscal Year of his or her initial service as an Outside Director (with the value of each equity award based on its grant date fair </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">value (determined in accordance with U.S. generally accepted accounting principles)).  Any cash compensation paid or Awards granted to an individual for his or her services as an Employee, or for his or her services as a Consultant (other than as an Outside Director), will not count for purposes of the limitation under this Section 11.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Leaves of Absence/Transfer Between Locations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence.  A Participant will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary.  For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed by statute or contract.  If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6) months following the first (1st) day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transferability of Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant.  If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments; Dissolution or Liquidation; Merger or Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, and the numerical Share limits in Section 3 of the Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction.  To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of a merger of the Company with or into another corporation or other entity or a Change in Control, each outstanding Award will be treated as the Administrator determines subject to the restriction in the following paragraph, including, without limitation, that each Award be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor corporation.  The Administrator will not be required to treat all Awards or Participants similarly in the transaction.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the successor corporation does not assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, unless specifically provided otherwise under the applicable Award Agreement, a Company policy applicable to the Participant, or other written agreement between the Participant and the Company, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met.  In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a Change in Control, the Administrator will notify the Participant in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such period.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit or Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Change in Control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything in this Section 14(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#x2019;s consent; provided, however, a modification to such performance goals only to reflect the successor corporation&#x2019;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Director Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  With respect to Awards granted to an Outside Director, in the event of a Change in Control,  the Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award, including those Shares which would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, unless specifically provided otherwise under the applicable Award Agreement, a Company policy applicable to the Participant, or other written agreement between the Participant and the Company, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy U.S. federal, state, or local taxes, non-U.S. taxes, or other taxes (including the Participant&#x2019;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Shares having a fair market value not in excess of the maximum statutory amount required to be withheld, or (iii) delivering to the Company already-owned Shares having a fair market value not in excess of the maximum statutory amount required to be withheld.  The fair market value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance With Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A, except as otherwise determined in the sole discretion of the Administrator.  The Plan and each Award Agreement under the Plan is intended to meet the requirements of Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator.  To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A.  In no event will the Company (or any Parent or Subsidiary of the Company, as applicable) reimburse a Participant for any taxes imposed or other costs incurred as a result of Section 409A.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Effect on Employment or Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant&#x2019;s relationship as a Service Provider, nor will they interfere in any way with the Participant&#x2019;s right or the right of the Company (or any Parent or Subsidiary of the Company) to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator.  Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Section 23</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Plan, the Plan will become effective upon the later to occur of (i) its adoption by the Board or (ii) the business day immediately prior to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Date.  It will continue in effect for a term of ten (10) years from the date adopted by the Board, unless terminated earlier under Section 19</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator may at any time amend, alter, suspend or terminate the Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Amendment or Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No amendment, alteration, suspension or termination of the Plan will materially impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company.  Termination of the Plan will not affect the Administrator&#x2019;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conditions Upon Issuance of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Legal Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Shares will not be issued pursuant to an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investment Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inability to Obtain Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The inability of the Company to obtain authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any U.S. federal or state law, any non-U.S. law, or the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#x2019;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clawback</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.   The Administrator may specify in an Award Agreement that the Participant&#x2019;s rights, payments, and/or benefits with respect to an Award will be subject to reduction, cancellation, forfeiture, and/or recoupment upon the occurrence of certain specified events, in addition to any applicable vesting, performance or other conditions and restrictions of an Award.  Notwithstanding any provisions to the contrary under this Plan, an Award granted under the Plan shall be subject to the Company&#x2019;s clawback policy (if any) as may be established and/or amended from </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">time to time.  The Board may require a Participant to forfeit or return to and/or reimburse the Company all or a portion of the Award and/or Shares issued under the Award, any amounts paid under the Award, and any payments or proceeds paid or provided upon disposition of the Shares issued under the Award, pursuant to the terms of such Company policy or as necessary or appropriate to comply with Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will be subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan is adopted by the Board.  Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Alector, Inc. 2019 Equity Incentive Plan (the &#x201c;Plan&#x201d;) will have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the &#x201c;Notice of Grant&#x201d;), the Terms and Conditions of Stock Option Grant attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Exercise Notice attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and all other exhibits and appendices attached hereto (all together, the &#x201c;Option Agreement&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF STOCK OPTION GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant:				</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:				</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The undersigned Participant has been granted an Option to purchase Common Stock of Alector, Inc. (the &#x201c;Company&#x201d;), subject to the terms and conditions of the Plan and this Option Agreement, as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Number: 			_____________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant:				_____________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Commencement Date:          _____________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares Granted:		_____________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price per Share (in U.S. Dollars): $________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Exercise Price(in U.S. Dollars): $____________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type of Option:			___ Incentive Stock Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">					___ Nonstatutory Stock Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term/Expiration Date: 	   	______________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to accelerated vesting as set forth below or in the Plan, this Option will be exercisable, in whole or in part, in accordance with the following schedule:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Twenty-five percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date.]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Option will be exercisable for [three (3) months] after Participant ceases to be a Service Provider, unless such termination is due to Participant&#x2019;s death or Disability, in which case this Option will be exercisable for [twelve (12) months] after Participant ceases to be a Service Provider.  Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 14 of the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature and the signature of the representative of the Company below, Participant and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan and this Option Agreement, including the Terms and Conditions of Stock Option Grant, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, all of which are made a part of this document.  Participant acknowledges receipt of a copy of the Plan.  Participant has reviewed the Plan and this Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option Agreement, and fully understands all provisions of the Plan and this Option Agreement.  Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and the Option Agreement.  Participant further agrees to notify the Company upon any change in the residence address indicated below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">					</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________				__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________				__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">							__________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">							</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF STOCK OPTION GRANT</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby grants to the individual (&#x201c;Participant&#x201d;) named in the Notice of Stock Option Grant of this Option Agreement (the &#x201c;Notice of Grant&#x201d;) an option (the &#x201c;Option&#x201d;) to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the &#x201c;Exercise Price&#x201d;), subject to all of the terms and conditions in this Option Agreement and the Plan, which is incorporated herein by this reference.  Subject to Section 19(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Option Agreement, the terms and conditions of the Plan will prevail.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For U.S. taxpayers, the Option will be designated as either an Incentive Stock Option (&#x201c;ISO&#x201d;) or a Nonstatutory Stock Option (&#x201c;NSO&#x201d;).  If designated in the Notice of Grant as an ISO, this Option is intended to qualify as an ISO under Section 422 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;).  However, if this Option is intended to be an ISO, to the extent that it exceeds the $100,000 rule of Code Section 422(d) it will be treated as an NSO.  Further, if for any reason this Option (or portion thereof) will not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the Plan.  In no event will the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For non-U.S. taxpayers, the Option will be designated as an NSO.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in Section 3, the Option awarded by this Option Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant.  Shares subject to this Option that are scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in accordance with any of the provisions of this Option Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Option at any time, subject to the terms of the Plan.  If so accelerated, such Option will be considered as having vested as of the date specified by the Administrator.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Right to Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option is exercisable by delivery of an exercise notice (the &#x201c;Exercise Notice&#x201d;) in the form attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to the Notice of Grant or in a manner </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and pursuant to such procedures as the Administrator may determine, which will state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the &#x201c;Exercised Shares&#x201d;), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan.  The Exercise Notice will be completed by Participant and delivered to the Company.  The Exercise Notice will be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares and of any Tax Obligations (as defined in Section 6(a)).  This Option will be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment of the aggregate Exercise Price will be by any of the following, or a combination thereof, at the election of Participant:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cash in U.S. dollars; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">check designated in U.S. dollars; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if Participant is a U.S. employee, surrender of other Shares which have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares and that are owned free and clear of any liens, claims, encumbrances, or security interests, provided that accepting such Shares, in the sole discretion of the Administrator, will not result in any adverse accounting consequences to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Responsibility for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant&#x2019;s employer (the &#x201c;Employer&#x201d;) or Parent or Subsidiary to which Participant is providing services (together, the Company, Employer and/or Parent or Subsidiary to which the Participant is providing services, the &#x201c;Service Recipient&#x201d;), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Option, including, without limitation, (i) all federal, state, and local taxes (including the Participant&#x2019;s Federal Insurance Contributions Act (FICA) obligation) that are required to be withheld by the Company or the Service Recipient or other payment of tax-related items related to Participant&#x2019;s participation in the Plan and legally applicable to Participant, (ii) the Participant&#x2019;s and, to the extent required by the Company (or Service Recipient), the Company&#x2019;s (or Service Recipient&#x2019;s) fringe benefit tax liability, if any, associated with the grant, vesting, or exercise of the Option or sale of Shares, and (iii) any other Company (or Service Recipient) taxes the responsibility for which the Participant has, or has agreed to bear, with respect to the Option (or exercise thereof or issuance of Shares thereunder) (collectively, the &#x201c;Tax Obligations&#x201d;), is and remains Participant&#x2019;s responsibility and may exceed the amount actually withheld by the Company or the Service Recipient.  Participant further acknowledges that the Company and/or the Service Recipient (A) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends or other distributions, </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and (B) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant&#x2019;s liability for Tax Obligations or achieve any particular tax result.  Further, if Participant is subject to Tax Obligations in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the Company and/or the Service Recipient (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.  If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. When the Option is exercised, Participant generally will recognize immediate U.S. taxable income if Participant is a U.S. taxpayer.  If Participant is a non-U.S. taxpayer, Participant will be subject to applicable taxes in his or her jurisdiction.  Pursuant to such procedures as the Administrator may specify from time to time, the Company and/or Service Recipient shall withhold the amount required to be withheld for the payment of Tax Obligations.  The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Participant to satisfy such Tax Obligations, in whole or in part (without limitation), if permissible by applicable local law, by (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a fair market value equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences), (iii) withholding the amount of such Tax Obligations from Participant&#x2019;s wages or other cash compensation paid to Participant by the Company and/or the Service Recipient, (iv) delivering to the Company already vested and owned Shares having a fair market value equal to such Tax Obligations, or (v) selling a sufficient number of such Shares otherwise deliverable to Participant through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences).  To the extent determined appropriate by the Company in its discretion, it will have the right (but not the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant.  Further, if Participant is subject to tax in more than one jurisdiction between the Date of Grant and a date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges and agrees that the Company and/or the Service Recipient (and/or former employer, as applicable) may be required to withhold or account for tax in more than one jurisdiction.  If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the Option exercise, Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such amounts are not delivered at the time of exercise.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Disqualifying Disposition of ISO Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Date of Grant, or (ii) the date one (1) year after the date of exercise, Participant will immediately notify the Company in writing of such disposition.  Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by Participant.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Under Code Section 409A, a stock right (such as the Option) that vests after December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per share exercise price that is determined by the Internal Revenue Service (the &#x201c;IRS&#x201d;) to be less than the fair market value of an underlying share on the date of grant (a &#x201c;discount option&#x201d;) may be considered &#x201c;deferred compensation.&#x201d;  A stock right that is a &#x201c;discount option&#x201d; may result in (i) income recognition by the recipient of the stock right prior to the exercise of the stock right, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges.  The &#x201c;discount option&#x201d; may also result in additional state income, penalty and interest tax to the recipient of the stock right.  Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the fair market value of a Share on the date of grant in a later examination.  Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the fair market value of a Share on the date of grant, Participant shall be solely responsible for Participant&#x2019;s costs related to such a determination.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account).  After such issuance, recordation, and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Guarantee of Continued Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER, WHICH UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW IS AT THE WILL OF THE COMPANY (OR THE SERVICE RECIPIENT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER.  PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#x2019;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE SERVICE RECIPIENT) TO TERMINATE PARTICIPANT&#x2019;S RELATIONSHIP AS A SERVICE PROVIDER, SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nature of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In accepting the Option, Participant acknowledges, understands and agrees that:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past; </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all decisions with respect to future option or other grants, if any, will be at the sole discretion of the Company; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant is voluntarily participating in the Plan; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Option and any Shares acquired under the Plan are not intended to replace any pension rights or compensation;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Option and Shares acquired under the Plan and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the future value of the Shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the underlying Shares do not increase in value, the Option will have no value; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if Participant exercises the Option and acquires Shares, the value of such Shares may increase or decrease in value, even below the Exercise Price;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for purposes of the Option, Participant&#x2019;s engagement as a Service Provider will be considered terminated as of the date Participant is no longer actively providing services to the Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and unless otherwise expressly provided in this Option Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, (i) Participant&#x2019;s right to vest in the Option under the Plan, if any, will terminate as of such date and will not be extended by any notice period (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">., Participant&#x2019;s period of service would not include any contractual notice period or any period of &#x201c;garden leave&#x201d; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or Participant&#x2019;s employment or service agreement, if any, unless Participant is providing bona fide services during such time);  and (ii) the period (if any) during which Participant may exercise the Option after such termination of Participant&#x2019;s engagement as a Service Provider will commence on the date Participant ceases to actively provide services and will not be extended by any notice period mandated under employment laws in the jurisdiction where Participant is employed or terms of Participant&#x2019;s engagement agreement, if any; the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of his or her Option grant (including whether Participant may still be considered to be providing services while on a leave of absence and consistent with local law);</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">unless otherwise provided in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this Option Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the following provisions apply only if Participant is providing services outside the United States:</font></div></div>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) the Option and the Shares subject to the Option are not part of normal or expected compensation or salary for any purpose;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) Participant acknowledges and agrees that no Service Recipient shall be liable for any foreign exchange rate fluctuation between Participant&#x2019;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise; and	</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii) no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from the termination of Participant&#x2019;s engagement as a Service Provider (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and in consideration of the grant of the Option to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against any Service Recipient, waives his or her ability, if any, to bring any such claim, and releases each Service Recipient from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Advice Regarding Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#x2019;s participation in the Plan, or Participant&#x2019;s acquisition or sale of the underlying Shares.  Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant&#x2019;s personal data as described in this Option Agreement and any other Option grant materials by and among, as applicable, the Employer or other Service Recipient, the Company and any Parent or Subsidiary for the exclusive purpose of implementing, administering and managing Participant&#x2019;s participation in the Plan.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not limited to, Participant&#x2019;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#x2019;s favor (&#x201c;Data&#x201d;), for the exclusive purpose of implementing, administering and managing the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that Data will be transferred to a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration, and management of the Plan.  Participant understands that the recipients of the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data may be located in the United States or elsewhere, and that the recipient&#x2019;s country of operation (e.g., the United States) may have different data privacy laws and protections than Participant&#x2019;s country.  Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local People representative.  Participant authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purposes of implementing, administering and managing Participant&#x2019;s participation in the Plan.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#x2019;s participation in the Plan.  Participant understands that if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local People representative.  Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her engagement as a Service Provider and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing Participant&#x2019;s consent is that the Company would not be able to grant Participant Options or other equity awards or administer or maintain such awards.  Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#x2019;s ability to participate in the Plan.  For more information on the consequences of Participant&#x2019;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local People representative.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address for Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given to the Company under the terms of this Option Agreement will be addressed to the Company at Alector, Inc., 151 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080, or at such other address as the Company may hereafter designate in writing.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Transferability of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Option Agreement to single or multiple assignees, and this Option Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this Option Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.  The rights and obligations of Participant under this Option Agreement may only be assigned with the prior written consent of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Conditions to Issuance of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or non-U.S. law, the tax code and related regulations or under the rulings or regulations of the United States Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the United States Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as a condition to the purchase by, or issuance of Shares, to Participant (or his or her estate) hereunder, such purchase or issuance will not occur unless and until such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company.  Subject to the terms of the Option Agreement and the Plan, the Company shall not be required to issue any certificate or certificates for Shares hereunder prior to the lapse of such reasonable period of time following the date of exercise of the Option as the Administrator may establish from time to time for reasons of administrative convenience.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Language</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Participant has received this Option Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have the power to interpret the Plan and this Option Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Option have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons.  Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery and Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may, in its sole discretion, decide to deliver any documents related to the Option awarded under the Plan or future options that may be awarded under the Plan by electronic means or request Participant&#x2019;s consent to participate in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement Severable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any provision in this Option Agreement will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  By accepting this Option, Participant expressly warrants that he or she has received an Option under the Plan, and has received, read, and understood a description of the Plan.  Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option Agreement will be governed by the laws of California, without giving effect to the conflict of law principles thereof.  For purposes of litigating any dispute that arises under this Option or this Option Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the courts of San Mateo County, California, or the United States federal courts for the Northern District of California, and no other courts, where this Option is made and/or to be performed.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provisions in this Option Agreement, this Option shall be subject to any special terms and conditions set forth in an appendix (if any) to this Option Agreement for any country whose laws are applicable to Participant and this Option (as determined by the Administrator in its sole discretion) (the &#x201c;Country Addendum&#x201d;).  Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Country Addendum (if any) constitutes a part of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">24.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications to the Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option Agreement constitutes the entire understanding of the parties on the subjects covered.  Participant expressly warrants that he or she is not accepting this Option Agreement in reliance on any promises, representations, or inducements other than those contained herein.  Modifications to this Option Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company.  Notwithstanding anything to the contrary in the Plan or this Option Agreement, the Company reserves the right to revise this Option Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Code Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code in connection with the Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">25.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Either party&#x2019;s failure to enforce any provision or provisions of this Option Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Option Agreement.  The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#x2019;s right to assert all other legal remedies available to it under the circumstances.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">26.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant has reviewed with his or her own tax advisors the U.S. federal, state, local and non-U.S. tax consequences of this investment and the transactions contemplated by this Option Agreement.  With respect to such matters, Participant relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral.  Participant understands that Participant (and not the Company) shall be responsible for Participant&#x2019;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Option Agreement.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COUNTRY ADDENDUM</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TERMS AND CONDITIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum includes additional terms and conditions that govern the Option granted to Participant under the Plan if Participant works in one of the countries listed below.  If Participant is a citizen or resident of a country (or is considered as such for local law purposes) other than the one in which he or she is currently working or if Participant relocates to another country after receiving the Option, the Company will, in its discretion, determine the extent to which the terms and conditions contained herein will be applicable to Participant.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certain capitalized terms used but not defined in this Country Addendum shall have the meanings set forth in the Plan, and/or the Stock Option Agreement to which this Country Addendum is attached.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NOTIFICATIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum also includes notifications relating to exchange control and other issues of which Participant should be aware with respect to his or her participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries listed in this Country Addendum, as of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Participant not rely on the notifications herein as the only source of information relating to the consequences of his or her participation in the Plan because the information may be outdated when Participant exercises the Option or sells Shares acquired under the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition, the notifications are general in nature and may not apply to Participant&#x2019;s particular situation, and the Company is not in a position to assure Participant of any particular result.  Accordingly, Participant is advised to seek appropriate professional advice as to how the relevant laws in Participant&#x2019;s country may apply to Participant&#x2019;s situation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Finally, if Participant is a citizen or resident of a country other than the one in which Participant is currently working (or is considered as such for local law purposes) or if Participant moves to another country after the Option is granted, the information contained herein may not be applicable to Participant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXERCISE NOTICE</font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">151 Oyster Point Blvd., Suite 300</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">South San Francisco, CA 94080</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention:  Stock Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Effective as of today, ________________, _____, the undersigned (&#x201c;Purchaser&#x201d;) hereby elects to purchase ______________ shares (the &#x201c;Shares&#x201d;) of the Common Stock of Alector, Inc. (the &#x201c;Company&#x201d;) under and pursuant to the 2019 Equity Incentive Plan (the &#x201c;Plan&#x201d;) and the Stock Option Agreement, dated ________ and including the Notice of Grant, the Terms and Conditions of Stock Option Grant, and exhibits attached thereto (the &#x201c;Option Agreement&#x201d;).  The purchase price for the Shares will be $_____________, as required by the Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Delivery of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Purchaser herewith delivers to the Company the full purchase price of the Shares and any Tax Obligations (as defined in Section 6(a) of the Option Agreement) to be paid in connection with the exercise of the Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representations of Purchaser</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Purchaser acknowledges that Purchaser has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the Shares, no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option.  The Shares so acquired will be issued to Purchaser as soon as practicable after exercise of the Option.  No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance, except as provided in Section 14 of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consultation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Purchaser understands that Purchaser may suffer adverse tax consequences as a result of Purchaser&#x2019;s purchase or disposition of the Shares.  Purchaser represents that Purchaser has consulted with any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that Purchaser is not relying on the Company for any tax advice.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan and Option Agreement are incorporated herein by reference.  This Exercise Notice, the Plan and the Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Purchaser with respect to the subject matter </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">hereof, and may not be modified adversely to the Purchaser&#x2019;s interest except by means of a writing signed by the Company and Purchaser.  This Option Agreement is governed by the internal substantive laws, but not the choice of law rules, of California.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Submitted by:						Accepted by:</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PURCHASER						ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_____________________________			_____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature						Signature</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_____________________________			_____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name						Print Name</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:						_____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">							Title</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_____________________________	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">							_____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">							Date Received</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 Equity INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF RESTRICTED STOCK UNIT GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Alector, Inc. 2019 Equity Incentive Plan (the &#x201c;Plan&#x201d;) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restricted Stock Unit Grant (the &#x201c;Notice of Grant&#x201d;), the Terms and Conditions of Restricted Stock Unit Grant attached hereto as Exhibit A, and all other exhibits and appendices attached hereto (all together, the &#x201c;Award Agreement&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant:				</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:				</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The undersigned Participant has been granted the right to receive an Award of Restricted Stock Units, subject to the terms and conditions of the Plan and this Award Agreement, as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Number: 				______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant:					______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Commencement Date: 		______________________________	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Number of  Restricted Stock Units:		______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to any acceleration provisions contained in the Plan or set forth below, the Restricted Stock Units will vest in accordance with the following schedule:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Twenty-five percent (25%) of the Restricted Stock Units will vest on the one (1) year anniversary of the Vesting Commencement Date, and one sixteenth (1/16th) of the Restricted Stock Units will vest quarterly thereafter on the same day as the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date.]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event Participant ceases to be a Service Provider for any or no reason before Participant vests in the Restricted Stock Units, the Restricted Stock Units and Participant&#x2019;s right to acquire any Shares hereunder will immediately terminate</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature and the signature of the representative of Alector, Inc. (the &#x201c;Company&#x201d;) below, Participant and the Company agree that this Award of Restricted Stock Units is granted under and governed by the terms and conditions of the Plan and this Award Agreement, including the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, all of which are made a part of this document. Participant acknowledges receipt of a copy of the Plan. Participant has reviewed the Plan and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Award Agreement, and fully understands all</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provisions of the Plan and this Award Agreement. Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and the Award Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By accepting this Award Agreement, Participant expressly consents to the sale of Shares to cover the Tax Withholding Obligations (as defined in the Terms and Conditions of Restricted Stock Unit Grant) arising from the Restricted Stock Units and any associated broker or other fees and agrees and acknowledges that Participant may not satisfy them by any means other than such sale of Shares, unless required to do so by the Administrator or pursuant to the Administrator&#x2019;s express written consent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________________			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature							Signature</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________________			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Print Name							Print Name</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">								_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">								Title</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________________</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_______________________________<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company hereby grants to the individual (the &#x201c;Participant&#x201d;) named in the Notice of Grant of Restricted Stock Units of this Award Agreement (the &#x201c;Notice of Grant&#x201d;) under the Plan an Award of Restricted Stock Units, subject to all of the terms and conditions in this Award Agreement and the Plan, which is incorporated herein by reference.  Subject to Section 19(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Obligation to Pay.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Each Restricted Stock Unit represents the right to receive a Share on the date it vests.  Unless and until the Restricted Stock Units will have vested in the manner set forth in Section 3 or 4, Participant will have no right to payment of any such Restricted Stock Units.  Prior to actual payment of any vested Restricted Stock Units, such Restricted Stock Unit will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in Section 4, and subject to Section 5, the Restricted Stock Units awarded by this Award Agreement will vest in accordance with the vesting schedule set forth in the Notice of Grant, subject to Participant continuing to be a Service Provider through each applicable vesting date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4. Payment after Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="ole_link35"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) General Rule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Section 8, any Restricted Stock Units that vest will be paid to Participant (or in the event of Participant&#x2019;s death, to his or her properly designated beneficiary or estate) in whole Shares.  Subject to the provisions of Section 4(b), such vested Restricted Stock Units shall be paid in whole Shares as soon as practicable after vesting, but in each such case within </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">sixty (60) days following the vesting date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In no event will Participant be permitted, directly or indirectly, to specify the taxable year of payment of any Restricted Stock Units payable under this Award Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b) Acceleration.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) Discretionary Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Restricted Stock Units at any time, subject to the terms of the Plan.  If so accelerated, such Restricted Stock Units will be considered as having vested as of the date specified by the Administrator.  If Participant is a U.S. taxpayer, the payment of Shares vesting pursuant to this Section 4(b) shall in all cases be paid at a time or in a manner that is exempt from, or complies with, Section 409A.  The prior sentence may be superseded in a future agreement or amendment to this Award Agreement only by direct and specific reference to such sentence.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything in the Plan or this Award Agreement or any other agreement (whether entered into before, on or after the Date of Grant), if the vesting of the balance, or some lesser portion of the balance, of the Restricted Stock Units is accelerated in connection with Participant&#x2019;s termination as a Service Provider (provided that such termination is a &#x201c;separation from</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="ole_link31"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">service&#x201d; within the meaning of Section 409A, as determined by the Company), other than due to Participant&#x2019;s death, and if (x) Participant is a U.S. taxpayer and a &#x201c;specified employee&#x201d; within the meaning of Section 409A at the time of such termination as a Service Provider and (y) the payment of such accelerated Restricted Stock Units will result in the imposition of additional tax under Section 409A if paid to Participant on or within the six (6) month period following Participant&#x2019;s termination as a Service Provider, then the payment of such accelerated Restricted Stock Units will not be made until the date six (6) months and one (1) day following the date of Participant&#x2019;s termination as a Service Provider</font><font id="ole_link32"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, unless Participant dies following his or her termination as a Service Provider, in which case, the Restricted Stock Units will be paid in Shares to Participant&#x2019;s estate as soon as practicable following his or her death</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="ole_link6"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font id="ole_link5"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is the intent of this Award Agreement that it and all payments and benefits to U.S. taxpayers hereunder be exempt from, or comply with, the requirements of Section 409A so that none of the Restricted Stock Units provided under this Award Agreement or Shares issuable thereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to be so exempt or so comply.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Each payment payable under this Award Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).  However, in no event will the Company reimburse Participant, or be otherwise responsible for, any taxes or costs that may be imposed on Participant as a result of Section 409A.  For purposes of this Award Agreement, &#x201c;Section 409A&#x201d; means Section 409A of the Code, and any final Treasury Regulations and Internal Revenue Service guidance thereunder, as each may be amended from time to time.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forfeiture Upon Termination as a Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any contrary provision of this Award Agreement, if Participant ceases to be a Service Provider for any or no reason, the then-unvested Restricted Stock Units awarded by this Award Agreement will thereupon be forfeited at no cost to the Company and Participant will have no further rights thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant has reviewed with his or her own tax advisors the U.S. federal, state, local and non-U.S. tax consequences of this investment and the transactions contemplated by this Award Agreement.  With respect to such matters, Participant relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral.  Participant understands that Participant (and not the Company) shall be responsible for Participant&#x2019;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Death of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any distribution or delivery to be made to Participant under this Award Agreement will, if Participant is then deceased, be made to Participant&#x2019;s designated beneficiary, or if no beneficiary survives Participant, the administrator or executor of Participant&#x2019;s estate.  Any such transferee must furnish the Company with (a) written notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Tax Obligations</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) Responsibility for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.    Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant&#x2019;s employer (the &#x201c;Employer&#x201d;) or Parent or Subsidiary to which Participant is providing services (together, the Company, Employer and/or Parent or Subsidiary to which the Participant is providing services, the &#x201c;Service Recipient&#x201d;), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Restricted Stock Units, including, without limitation, (i) all federal, state, and local taxes (including the Participant&#x2019;s Federal Insurance Contributions Act (FICA) obligation) that are required to be withheld by the Company or the Employer or other payment of tax-related items related to Participant&#x2019;s participation in the Plan and legally applicable to Participant, (ii) the Participant&#x2019;s and, to the extent required by the Company (or Service Recipient), the Company&#x2019;s (or Service Recipient&#x2019;s) fringe benefit tax liability, if any, associated with the grant, vesting, or settlement of the Restricted Stock Units or sale of Shares, and (iii) any other Company (or Service Recipient) taxes the responsibility for which the Participant has, or has agreed to bear, with respect to the Restricted Stock Units (or settlement thereof or issuance of Shares thereunder) (collectively, the &#x201c;Tax Obligations&#x201d;), is and remains Participant&#x2019;s responsibility and may exceed the amount actually withheld by the Company or the Service Recipient.  Participant further acknowledges that the Company and/or the Service Recipient (A) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Restricted Stock Units, including, but not limited to, the grant, vesting or settlement of the Restricted Stock Units, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends or other distributions, and (B) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Restricted Stock Units to reduce or eliminate Participant&#x2019;s liability for Tax Obligations or achieve any particular tax result.  Further, if Participant is subject to Tax Obligations in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the Company and/or the Service Recipient (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.  If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">b) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding and Default Sell-to-Cover Method of Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  When Shares are issued as payment for vested Restricted Stock Units, Participant generally will recognize immediate U.S. taxable income if Participant is a U.S. taxpayer.  If Participant is a non-U.S. taxpayer, Participant will be subject to applicable taxes in his or her jurisdiction.   Subject to Section 8(c), the minimum amount of Tax Obligations which the Company determines must be withheld with respect to this Award (&#x201c;Tax Withholding Obligation&#x201d;) will be satisfied by Shares being sold on Participant&#x2019;s behalf at the prevailing market price pursuant to such procedures as the Company may specify from time to time, including through a broker-assisted arrangement (it being understood that the Shares to be sold must have vested pursuant to the terms of this Award Agreement and the Plan) (the &#x201c;Sell-to-Cover Method&#x201d;).  The proceeds from the Sell-to-Cover Method will be used to satisfy Participant&#x2019;s Tax Withholding Obligation arising with respect to this Award.  In addition to Shares sold to satisfy the Tax Withholding Obligation, additional Shares will be sold to satisfy any associated broker or other fees.  Only whole Shares will be sold through the Sell-to-Cover Method to satisfy any Tax Withholding Obligation and any associated broker or other fees.  Any proceeds from the sale of Shares in excess of the Tax Withholding Obligation and any associated broker or other fees generated through</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Sell-to-Cover Method will be paid to Participant in accordance with procedures the Company may specify from time to time.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By accepting this Award, Participant expressly consents to the sale of Shares to cover the Tax Withholding Obligation (and any associated broker or other fees) through the Sell-to-Cover Method and agrees and acknowledges that Participant may not satisfy them by any means other than such sale of Shares, unless required to do so by the Administrator or pursuant to the Administrator&#x2019;s express written consent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding the foregoing Sections 8(a) and 8(b), if the Administrator determines it is in the best interests of the Company for Participant to satisfy Participant&#x2019;s Tax Withholding Obligation by a method other than through the default Sell-to-Cover Method described in Section 8(b), it may permit or require Participant to satisfy Participant&#x2019;s Tax Withholding Obligation, in whole or in part (without limitation), if permissible by Applicable Laws, by (i) paying cash, (ii) withholding the amount of such Tax Withholding Obligation from Participant&#x2019;s wages or other cash compensation paid to Participant by the Company and/or the Service Recipient, (iii) delivering to the Company Shares that Participant owns and that have vested with a fair market value equal to the amount required to be withheld (or such greater amount up to the maximum statutory rate applicable to the Participant if permitted by the Administrator and provided such greater amount would not result in adverse financial accounting consequences to the Company as determined by the Administrator), (iv) by having the Company withhold otherwise deliverable Shares having a fair market value equal to the amount required to be withheld (or such greater amount up to the maximum statutory rate applicable to the Participant if permitted by the Administrator and provided such greater amount would not result in adverse financial accounting consequences to the Company as determined by the Administrator) or (v) such other means as the Administrator deems appropriate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Obligation to Deliver Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For clarification purposes, in no event will the Company issue Participant any Shares unless and until arrangements satisfactory to the Administrator have been made for the payment of Participant&#x2019;s Tax Withholding Obligation. If Participant fails to make satisfactory arrangements for the payment of such Tax Withholding Obligations hereunder at the time any applicable Restricted Stock Units otherwise are scheduled to vest pursuant to Sections 3 or 4 or Participant&#x2019;s Tax Withholding Obligations otherwise become due, Participant will permanently forfeit such Restricted Stock Units to which Participant&#x2019;s Tax Withholding Obligation relates and any right to receive Shares thereunder and such Restricted Stock Units will be returned to the Company at no cost to the Company.  Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares if such Tax Obligations are not delivered at the time they are due.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account).  After such issuance, recordation, and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Guarantee of Continued Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE RESTRICTED STOCK UNITS PURSUANT TO THE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER, WHICH UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW IS AT THE WILL OF THE COMPANY (OR THE SERVICE RECIPIENT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS RESTRICTED STOCK UNIT AWARD OR ACQUIRING SHARES HEREUNDER.  PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AWARD AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#x2019;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE SERVICE RECIPIENT) TO TERMINATE PARTICIPANT&#x2019;S RELATIONSHIP AS A SERVICE PROVIDER, SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant is Not Transferable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except to the limited extent provided in Section 7, this grant and the rights and privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale under execution, attachment or similar process.  Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this grant, or any right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process, this grant and the rights and privileges conferred hereby immediately will become null and void.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12. Nature of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In accepting the grant, Participant acknowledges, understands, and agrees that:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) the grant of the Restricted Stock Units is voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b) all decisions with respect to future Restricted Stock Units or other grants, if any, will be at the sole discretion of the Company;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c) Participant is voluntarily participating in the Plan;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d) the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not intended to replace any pension rights or compensation;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e) the Restricted Stock Units and the Shares subject to the Restricted Stock Units, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f) the future value of the underlying Shares is unknown, indeterminable and cannot be predicted;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g) for purposes of the Restricted Stock Units, Participant&#x2019;s status as a Service Provider will be considered terminated as of the date Participant is no longer actively providing services to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later to be found invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and unless otherwise expressly provided in this Award Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, Participant&#x2019;s right to vest in the Restricted Stock Units under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant&#x2019;s period of service would not include any contractual notice period or any period of &#x201c;garden leave&#x201d; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any, unless Participant is providing bona fide services during such time); the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of the Restricted Stock Units grant (including whether Participant may still be considered to be providing services while on a leave of absence and consistent with local law);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h) unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Award Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) the following provisions apply only if Participant is providing services outside the United States:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not part of normal or expected compensation or salary for any purpose;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) Participant acknowledges and agrees that none of the Company, the Employer or any Parent or Subsidiary shall be liable for any foreign exchange rate fluctuation between Participant&#x2019;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii) no claim or entitlement to compensation or damages shall arise from forfeiture of the Restricted Stock Units resulting from the termination of Participant&#x2019;s status as a Service Provider (for any reason whatsoever whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and in consideration of the grant of the Restricted Stock Units to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Parent or Subsidiary or the Service Recipient, waives his or her ability, if any, to bring any such claim, and releases the Company, any Parent or Subsidiary and the Service Recipient from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13. No Advice Regarding Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#x2019;s participation in the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan, or Participant&#x2019;s acquisition or sale of the underlying Shares.  Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.  Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant&#x2019;s personal data as described in this Award Agreement and any other Restricted Stock Unit grant materials by and among, as applicable, the Employer or other Service Recipient, the Company and any Parent or Subsidiary for the exclusive purpose of implementing, administering and managing Participant&#x2019;s participation in the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that the Company and the Service Recipient may hold certain personal information about Participant, including, but not limited to, Participant&#x2019;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#x2019;s favor (&#x201c;Data&#x201d;), for the exclusive purpose of implementing, administering and managing the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that Data will be transferred to a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration, and management of the Plan.  Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#x2019; country of operation (e.g., the United States) may have different data privacy laws and protections than Participant&#x2019;s country.  Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local People representative.  Participant authorizes the Company, any stock plan service provider selected by the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#x2019;s participation in the Plan.  Participant understands if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local People representative.  Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her status as a Service Provider and career with the Service Recipient will not be adversely affected; the only adverse consequence of refusing or withdrawing Participant&#x2019;s consent is that the Company would not be able to grant Participant Restricted Stock Units or other equity awards or administer or maintain such awards.  Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#x2019;s ability to participate in the Plan.  For more information on the consequences of Participant&#x2019;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local People representative.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address for Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given to the Company under the terms of this Award Agreement will be addressed to the Company at Alector, Inc., 151 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080 or at such other address as the Company may hereafter designate in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Electronic Delivery and Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Stock Units awarded under the Plan or future Restricted Stock Units that may be awarded under the Plan by electronic means or request Participant&#x2019;s consent to participate in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Either party&#x2019;s failure to enforce any provision or provisions of this Award Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Award Agreement.  The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#x2019;s right to assert all other legal remedies available to it under the circumstances.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Award Agreement to single or multiple assignees, and this Award Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this Award Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.  The rights and obligations of Participant under this Award Agreement may only be assigned with the prior written consent of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Additional Conditions to Issuance of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or non-U.S. law, the tax code and related regulations or under the rulings or regulations of the United States Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the United States Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the issuance of Shares to Participant (or his or her estate) hereunder, such issuance will not occur unless and until such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company.  Subject to the terms of the Award Agreement and the Plan, the Company shall not be required to issue any certificate or certificates for Shares hereunder prior to the lapse of such reasonable period of time following the date of vesting of the Restricted Stock Units as the Administrator may establish from time to time for reasons of administrative convenience.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Language</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Participant has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Restricted Stock Units have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">upon Participant, the Company and all other interested persons.  Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  By accepting this Award, Participant expressly warrants that he or she has received an Award of Restricted Stock Units under the Plan, and has received, read, and understood a description of the Plan.  Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications to the Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Award Agreement constitutes the entire understanding of the parties on the subjects covered.  Participant expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations, or inducements other than those contained herein.  Modifications to this Award Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company.  Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A in connection with this Award of Restricted Stock Units.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">25. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Governing Law; Venue; Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Award Agreement and the Restricted Stock Units are governed by the internal substantive laws, but not the choice of law rules, of California.  For purposes of litigating any dispute that arises under these Restricted Stock Units or this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of San Mateo County, California, or the United States federal courts for the Northern District of California, and no other courts, where this Award Agreement is made and/or to be performed.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Award Agreement shall continue in full force and effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">26.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan is incorporated herein by reference.  The Plan and this Award Agreement (including the appendices and exhibits referenced herein) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant&#x2019;s interest except by means of a writing signed by the Company and Participant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">27.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provisions in this Award Agreement, the Restricted Stock Unit grant shall be subject to any special terms and conditions set forth in an appendix (if any) to this Award Agreement for any country whose laws are applicable to Participant and this Award of Restricted Stock Units (as determined by the Administrator in its sole discretion) (the &#x201c;Country Addendum&#x201d;).  Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">necessary or advisable for legal or administrative reasons.  The Country Addendum constitutes part of this Award Agreement.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2019 EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COUNTRY ADDENDUM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TERMS AND CONDITIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum includes additional terms and conditions that govern the Award of Restricted Stock Units granted to Participant under the Plan if Participant works in one of the countries listed below.  If Participant is a citizen or resident of a country (or is considered as such for local law purposes) other than the one in which he or she is currently working or if Participant relocates to another country after receiving the Award of Restricted Stock Units, the Company will, in its discretion, determine the extent to which the terms and conditions contained herein will be applicable to Participant.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Certain capitalized terms used but not defined in this Country Addendum shall have the meanings set forth in the Plan, and/or the Restricted Stock Unit Agreement to which this Country Addendum is attached.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NOTIFICATIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum also includes notifications relating to exchange control and other issues of which Participant should be aware with respect to his or her participation in the Plan.  The information is based on the exchange control, securities and other laws in effect in the countries listed in this Country Addendum, as of [DATE].  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Participant not rely on the notifications herein as the only source of information relating to the consequences of his or her participation in the Plan because the information may be outdated when Participant vests in the Restricted Stock Units and acquires Shares, or when Participant subsequently sell Shares acquired under the Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition, the notifications are general in nature and may not apply to Participant&#x2019;s particular situation, and the Company is not in a position to assure Participant of any particular result.  Accordingly, Participant is advised to seek appropriate professional advice as to how the relevant laws in Participant&#x2019;s country may apply to Participant&#x2019;s situation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Finally, if Participant is a citizen or resident of a country other than the one in which Participant is currently working (or is considered as such for local law purposes) or if Participant moves to another country after receiving the Award of Restricted Stock Units, the information contained herein may not be applicable to Participant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>alec-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.4</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2019 EMPLOYEE STOCK PURCHASE PLAN</font></p>
  <div style="margin-left:0.796%;text-indent:5.914%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:5.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.41925728801258%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions.  The Company intends for the Plan to have two components: a component that is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Code (the &#x201c;423 Component&#x201d;) and a component that is not intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Code (the &#x201c;Non-423 Component&#x201d;).  The provisions of the 423 Component, accordingly, will be construed so as to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code.  An option to purchase shares of Common Stock under the Non-423 Component will be granted pursuant to rules, procedures, or sub-plans adopted by the Administrator designed to achieve tax, securities laws, or other objectives for Eligible Employees and the Company.  Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board or any Committee designated by the Board to administer the Plan pursuant to Section 14.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any entity, other than a Subsidiary, in which the Company has an equity or other ownership interest.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where options are, or will be, granted under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence of any of the following events:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, however, that for purposes of this subsection, the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#x2019;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event shall not be considered a Change in Control under this subsection (i). For this purpose, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities; or</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12)-month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or </font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A change in the ownership of a substantial portion of the Company&#x2019;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)&#x2011;month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection, the following will not constitute a change in the ownership of a substantial portion of the Company&#x2019;s assets: (A) a transfer to an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (2) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3).  For purposes of this subsection, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. </font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase, or acquisition of stock, or similar business transaction with the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final U.S. Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the jurisdiction of the Company&#x2019;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.  Reference to a specific section of the Code will include such section, any valid regulation or other official applicable guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a committee of the Board appointed in accordance with Section 14 hereof.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Stock of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Alector, Inc., a Delaware corporation, or any successor thereto.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; includes an Eligible Employee&#x2019;s base straight time gross earnings, but excludes payments for incentive compensation, bonuses, payments for overtime and shift premium, equity compensation income and other similar compensation.  The Administrator, in its discretion, may, on a uniform and nondiscriminatory basis, establish a different definition of Compensation for a subsequent Offering Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the payroll deductions and other additional payments that the Company may permit to be made by a Participant to fund the exercise of options granted pursuant to the Plan. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Designated Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Subsidiary or Affiliate that has been designated by the Administrator from time to time in its sole discretion as eligible to participate in the Plan.  For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies, provided, however that at any given time, a Subsidiary that is a Designated Company under the 423 Component will not be a Designated Company under the Non&#x2011;423 Component.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Eligible Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any individual who is a common law employee providing services to the Company or a Designated Company and is customarily employed for at least twenty (20) hours per week and more than five (5) months in any calendar year by the Employer, or any lesser number of hours per week and/or number of months in any calendar year established by the Administrator (if required under Applicable Laws) for purposes of any separate Offering or the Non-423 Component.  For purposes of the Plan, the employment relationship will be treated as continuing intact while the individual is on sick leave or other leave of absence that the Employer approves or is legally protected under Applicable Laws.  Where the period of leave exceeds three (3) months and the individual&#x2019;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship will be deemed to have terminated three (3) months and one (1) day following the commencement of such leave.  The Administrator, in its discretion, from time to time may, prior to an Enrollment Date for all options to be granted on such Enrollment Date in an Offering, determine (for each Offering under the 423 Component on a uniform and nondiscriminatory basis or as otherwise permitted by Treasury Regulation Section 1.423 2) that the definition of Eligible Employee will or will not include an individual if he or she: (i) has not completed at least two (2) years of service since his or her last hire date (or such lesser period of time as may be determined by the Administrator in its discretion), (ii) customarily works not more than twenty (20) hours per week (or such lesser period of time as may be determined by the Administrator in its discretion), (iii) customarily works not more than five (5) months per calendar year (or such lesser period of time as may be determined by the Administrator in its discretion), (iv) is a highly compensated employee within the meaning of Section 414(q) of the Code, or (v) is a highly compensated employee within the meaning of Section 414(q) of the Code with compensation above a certain level or is an officer or subject to the disclosure requirements of Section 16(a) of the Exchange Act, provided the exclusion is applied with respect to each Offering under the 423 Component in an identical manner to all highly compensated individuals of the Employer whose Eligible Employees are participating in that Offering.  Each exclusion will be applied with respect to an Offering under the 423 Component in a manner complying with U.S. Treasury Regulation Section 1.423 2(e)(2)(ii).  Such exclusions may be applied with respect to an Offering under the Non-423 Component without regard to the limitations of U.S. Treasury Regulation Section 1.423 2.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the employer of the applicable Eligible Employee(s).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Enrollment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the first Trading Day of an Offering Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the last Trading Day of the Purchase Period.  Notwithstanding the foregoing, in the event that an Offering Period is terminated prior to its expiration pursuant to Section 20(a), the Administrator, in its sole discretion, may determine that any Purchase Period also terminating under such Offering Period will terminate without options being exercised on the Exercise Date that otherwise would have occurred on the last Trading Day of such Purchase Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, the value of a share of Common Stock determined as follows:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the Enrollment Date of the first Offering Period under the Plan, the Fair Market Value will be the initial price to the public as set forth in the final prospectus included within the Registration Statement.</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For all other purposes, the Fair Market Value will be the closing sales price for Common Stock as quoted on any established stock exchange or national market system (including without limitation the New York Stock Exchange, NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market) on which the Common Stock is listed on the date of determination (or the closing bid, if no sales were reported), as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable.  If the determination date for the Fair Market Value occurs on a non-trading day (i.e., a weekend or holiday), the Fair Market Value will be such price on the immediately preceding trading day, unless otherwise determined by the Administrator.  In the absence of an established market for the Common Stock, the Fair Market Value thereof will be determined in good faith by the Administrator.  </font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The determination of fair market value for purposes of tax withholding may be made in the Administrator&#x2019;s discretion subject to Applicable Laws and is not required to be consistent with the determination of Fair Market Value for other purposes.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fiscal Year</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a fiscal year of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a new Exercise Date if the Administrator shortens any Offering Period then in progress.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Offering</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an offer under the Plan of an option that may be exercised during an Offering Period as further described in Section 4.  For purposes of the Plan, the Administrator may designate separate Offerings under the Plan (the terms of which need not be identical) in which Eligible Employees of one or more Employers will participate, even if the dates of the applicable Offering Periods of each such Offering are identical and the provisions of the Plan will separately apply to each Offering.  To the extent permitted by U.S. Treasury Regulation Section 1.423&#x2011;2(a)(1), the terms of each Offering need not be identical provided that the terms of the Plan and an Offering together satisfy U.S. Treasury Regulation Section 1.423&#x2011;2(a)(2) and (a)(3).  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Offering Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the periods of approximately six (6) months during which an option granted pursuant to the Plan may be exercised, commencing on the first Trading Day on or after June </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1 and December 1 of each year and terminating on the last Trading Day on or before December 1 and June 1, approximately six (6) months later; provided, however, that the first Offering Period under the Plan will commence with the first Trading Day on or after the date on which the Securities and Exchange Commission declares the Company&#x2019;s Registration Statement effective and will end on the last Trading Day on or before December 1, 2019, and provided, further, that the second Offering Period under the Plan will commence on the first Trading Day on or after December 1, 2019.  The duration and timing of Offering Periods may be changed pursuant to Sections 4, 20 and 30.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;parent corporation,&#x201d; whether now or hereafter existing, as defined in Section 424(e) of the Code.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Eligible Employee that participates in the Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Alector, Inc. 2019 Employee Stock Purchase Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purchase Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the approximately six (6) month period commencing after one Exercise Date and ending with the next Exercise Date, except that the first Purchase Period of any Offering Period will commence on the Enrollment Date and end with the next Exercise Date.  Unless the Administrator provides otherwise, the Purchase Period will have the same duration and coincide with the length of the Offering Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an amount equal to eighty-five percent (85%) of the Fair Market Value on the Enrollment Date or on the Exercise Date, whichever is lower; provided however, that the Purchase Price may be determined for subsequent Offering Periods by the Administrator subject to compliance with Section 423 of the Code (or any successor rule or provision or any other Applicable Law, regulation or stock exchange rule) or pursuant to Section 20.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the effective date of the Registration Statement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the registration statement on Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Common Stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;subsidiary corporation,&#x201d; whether now or hereafter existing, as defined in Section 424(f) of the Code.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a day on which the national stock exchange upon which the Common Stock is listed is open for trading.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury Regulations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Treasury regulations of the Code.  Reference to a specific Treasury Regulation will include such Treasury Regulation, the section of the Code under which such regulation was promulgated, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such Section or regulation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Eligibility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">First Offering Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any individual who is an Eligible Employee immediately prior to the first Offering Period will be automatically enrolled in the first Offering Period.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Offering Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any Eligible Employee on a given Enrollment Date subsequent to the first Offering Period will be eligible to participate in the Plan, subject to the requirements of Section 5.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Non-U.S. Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Eligible Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or residents of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an Offering if the participation of such Eligible Employees is prohibited under the laws of the applicable jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code.  In the case of the Non-423 Component, Eligible Employees may be excluded from participation in the Plan or an Offering if the Administrator determines that participation of such Eligible Employees is not advisable or practicable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limitations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any provisions of the Plan to the contrary notwithstanding, no Eligible Employee will be granted an option under the Plan (i) to the extent that, immediately after the grant, such Eligible Employee (or any other person whose stock would be attributed to such Eligible Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company or any Parent or Subsidiary of the Company and/or hold outstanding options to purchase such stock possessing five percent (5%) or more of the total combined voting power or value of all classes of the capital stock of the Company or of any Parent or Subsidiary of the Company, or (ii) to the extent that his or her rights to purchase stock under all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent or Subsidiary of the Company accrues at a rate, which exceeds twenty-five thousand dollars ($25,000) worth of stock (determined at the Fair Market Value of the stock at the time such option is granted) for each calendar year in which such option is outstanding at any time, as determined in accordance with Section 423 of the Code and the regulations thereunder.</font></div></div>
  <div style="margin-left:0.796%;text-indent:5.914%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:5.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.41925728801258%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Offering Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will be implemented by consecutive Offering Periods with a new Offering Period commencing on the first Trading Day on or after June 1 and December 1 each year, or on such other dates as the Administrator will determine; provided, however, that the first Offering Period under the Plan will commence with the first Trading Day on or after the Registration Date and end on the last Trading Day on or before December 1, 2019, and provided, further, that the second Offering Period under the Plan will commence on the first Trading Day on or after December 1, 2019.  The Administrator will have the power to change the duration of Offering Periods (including the commencement dates thereof) with respect to future Offerings without stockholder approval if such change is announced prior to the scheduled beginning of the first Offering Period to be affected thereafter; provided, however, that no Offering Period may last more than twenty-seven (27) months.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">First Offering Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  An Eligible Employee will be entitled to continue to participate in the first Offering Period pursuant to Section 3(a) only if such individual submits a subscription agreement authorizing Contributions in a form determined by the Administrator (which may be similar to the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) to the Company&#x2019;s designated plan administrator (i) no earlier than the effective date of the Form S-8 registration statement with respect to the issuance of Common Stock under this Plan and (ii) no later than ten (10) business days following the effective date of such Form S-8 registration statement or such other date as the Administrator may determine (the &#x201c;Enrollment Window&#x201d;).  An Eligible Employee&#x2019;s failure to submit </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the subscription agreement during the Enrollment Window will result in the automatic termination of such individual&#x2019;s participation in the first Offering Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Offering Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  An Eligible Employee may participate in the Plan pursuant to Section 3(b) by (i) submitting to the Company&#x2019;s stock administration office (or its designee) a properly completed subscription agreement authorizing Contributions in the form provided by the Administrator for such purpose or (ii) following an electronic or other enrollment procedure determined by the Administrator, in either case on or before a date determined by the Administrator prior to an applicable Enrollment Date.</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">At the time a Participant enrolls in the Plan pursuant to Section 5, he or she will elect to have Contributions (in the form of payroll deductions or otherwise, to the extent permitted by the Administrator) made on each pay day during the Offering Period in an amount not exceeding fifteen percent (15%)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the Compensation that he or she receives on the pay day (for illustrative purposes, should a pay day occur on an Exercise Date, a Participant will have any Contributions made on such day applied to his or her account under the then-current Purchase Period or Offering Period).  The Administrator, in its sole discretion, may permit all Participants in a specified Offering to contribute amounts to the Plan through payment by cash, check or other means set forth in the subscription agreement prior to each Exercise Date of each Purchase Period.  A Participant&#x2019;s subscription agreement will remain in effect for successive Offering Periods unless terminated as provided in Section 10 hereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event Contributions are made in the form of payroll deductions, such payroll deductions for a Participant will commence on the first pay day following the Enrollment Date and will end on the last pay day on or prior to the last Exercise Date of such Offering Period to which such authorization is applicable, unless sooner terminated by the Participant as provided in Section 10 hereof; provided, however, that for the first Offering Period, payroll deductions will commence on the first pay day on or following the end of the Enrollment Window.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All Contributions made for a Participant will be credited to his or her account under the Plan and Contributions will be made in whole percentages of his or her Compensation only.  A Participant may not make any additional payments into such account.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A Participant may discontinue his or her participation in the Plan as provided under Section 10.  Unless otherwise determined by the Administrator, during a Purchase Period, a Participant may not increase the rate of his or her Contributions and may only decrease the rate of his or her Contributions one (1) time and such decrease must be to a Contribution rate of zero percent (0%).  Any such decrease during a Purchase Period requires the Participant (i) properly completing and submitting to the Company&#x2019;s stock administration office (or its designee) a new subscription agreement authorizing the change in Contribution rate in the form provided by the Administrator for such purpose or (ii) following an electronic or other procedure prescribed by the Administrator, in either case on or before a date determined by the Administrator prior to an applicable Exercise Date.  If a Participant has not followed such procedures to change the rate of Contributions, the rate of his or her Contributions will continue at the originally elected rate throughout the Purchase Period and future Offering Periods and Purchase Periods (unless the Participant&#x2019;s participation is terminated as provided in Sections 10 or 11).  The Administrator may, in its sole discretion, amend the nature and/or number of Contribution rate changes that may be made by Participants during any Offering Period or Purchase Period </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and may establish other conditions or limitations as it deems appropriate for Plan administration.  Any change in the rate of Contributions made pursuant to this Section 6(d) will be effective as of the first (1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) full payroll period following five (5) business days after the date on which the change is made by the Participant (unless the Administrator, in its sole discretion, elects to process a given change in payroll deduction rate earlier.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Section 3(d), a Participant&#x2019;s Contributions may be decreased to zero percent (0%) at any time during a Purchase Period.  Subject to Section 423(b)(8) of the Code and Section 3(d) hereof, Contributions will recommence at the rate originally elected by the Participant effective as of the beginning of the first Purchase Period scheduled to end in the following calendar year, unless terminated by the Participant as provided in Section 10.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any provisions to the contrary in the Plan, the Administrator may allow Participants to participate in the Plan via cash contributions instead of payroll deductions if (i) payroll deductions are not permitted under Applicable Law, (ii) the Administrator determines that cash contributions are permissible under Section 423 of the Code; or (iii) the Participants are participating in the Non-423 Component.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">At the time the option is exercised, in whole or in part, or at the time some or all of the Common Stock issued under the Plan is disposed of (or any other time that a taxable event related to the Plan occurs), the Participant must make adequate provision for the Company&#x2019;s or Employer&#x2019;s federal, state, local or any other tax liability payable to any authority including taxes imposed by jurisdictions outside of the U.S., national insurance, social security or other tax withholding obligations, if any, which arise upon the exercise of the option or the disposition of the Common Stock (or any other time that a taxable event related to the Plan occurs).  At any time, the Company or the Employer may, but will not be obligated to, withhold from the Participant&#x2019;s compensation the amount necessary for the Company or the Employer to meet applicable withholding obligations, including any withholding required to make available to the Company or the Employer any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Eligible Employee.  In addition, the Company or the Employer may, but will not be obligated to, withhold from the proceeds of the sale of Common Stock or any other method of withholding the Company or the Employer deems appropriate to the extent permitted by U.S. Treasury Regulation Section 1.423&#x2011;2(f).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Grant of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period will be granted an option to purchase on each Exercise Date during such Offering Period (at the applicable Purchase Price) up to a number of shares of Common Stock determined by dividing such Eligible Employee&#x2019;s Contributions accumulated prior to such Exercise Date and retained in the Eligible Employee&#x2019;s account as of the Exercise Date by the applicable Purchase Price; provided that in no event will an Eligible Employee be permitted to purchase during each Purchase Period more than 2,000 shares of Common Stock (subject to any adjustment pursuant to Section 19) and provided further that such purchase will be subject to the limitations set forth in Sections 3(d) and 13 and in the subscription agreement.  The Eligible Employee may accept the grant of such option (i) with respect to the first Offering Period by submitting a properly completed subscription agreement in accordance with the requirements of Section 5 on or before the last day of the Enrollment Window, and (ii) with respect to any subsequent Offering Period under the Plan, by electing to participate in the Plan in accordance with the requirements of Section 5.  The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that an Eligible Employee may purchase during each Purchase Period.  Exercise of the option </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">will occur as provided in Section 8, unless the Participant has withdrawn pursuant to Section 10.  The option will expire on the last day of the Offering Period.</font></div></div>
  <div style="margin-left:0.796%;text-indent:5.914%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:5.87%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.41925728801258%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless a Participant withdraws from the Plan as provided in Section 10, his or her option for the purchase of shares of Common Stock will be exercised automatically on each Exercise Date, and the maximum number of full shares subject to the option will be purchased for such Participant at the applicable Purchase Price with the accumulated Contributions from his or her account.  No fractional shares of Common Stock will be purchased; any Contributions accumulated in a Participant&#x2019;s account, which are not sufficient to purchase a full share will be retained in the Participant&#x2019;s account for the subsequent Purchase Period or Offering Period, as applicable, subject to earlier withdrawal by the Participant as provided in Section 10.  Any other funds left over in a Participant&#x2019;s account after the Exercise Date will be returned to the Participant.  During a Participant&#x2019;s lifetime, a Participant&#x2019;s option to purchase shares hereunder is exercisable only by him or her.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which options are to be exercised may exceed (i) the number of shares of Common Stock that were available for sale under the Plan on the Enrollment Date of the applicable Offering Period, or (ii) the number of shares of Common Stock available for sale under the Plan on such Exercise Date, the Administrator may in its sole discretion (x) provide that the Company will make a pro rata allocation of the shares of Common Stock available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and continue all Offering Periods then in effect or (y) provide that the Company will make a pro rata allocation of the shares of Common Stock available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all participants exercising options to purchase Common Stock on such Exercise Date, and terminate any or all Offering Periods then in effect pursuant to Section 20.  The Company may make a pro rata allocation of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional shares for issuance under the Plan by the Company&#x2019;s stockholders subsequent to such Enrollment Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as reasonably practicable after each Exercise Date on which a purchase of shares of Common Stock occurs, the Company will arrange the delivery to each Participant of the shares purchased upon exercise of his or her option in a form determined by the Administrator (in its sole discretion) and pursuant to rules established by the Administrator.  The Company may permit or require that shares be deposited directly with a broker designated by the Company or to a designated agent of the Company, and the Company may utilize electronic or automated methods of share transfer.  The Company may require that shares be retained with such broker or agent for a designated period of time and/or may establish other procedures to permit tracking of disqualifying dispositions of such shares.  No Participant will have any voting, dividend, or other stockholder rights with respect to shares of Common Stock subject to any option granted under the Plan until such shares have been purchased and delivered to the Participant as provided in this Section 9.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A Participant may withdraw all but not less than all the Contributions credited to his or her account and not yet used to exercise his or her option under the Plan at any time by (i) submitting to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s stock administration office (or its designee) a written notice of withdrawal in the form determined by the Administrator for such purpose (which may be similar to the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">), or (ii) following an electronic or other withdrawal procedure determined by the Administrator.  The Administrator may set forth a deadline of when a withdrawal must occur to be effective prior to a given Exercise Date in accordance with policies it may approve from time to time.  All of the Participant&#x2019;s Contributions credited to his or her account will be paid to such Participant promptly after receipt of notice of withdrawal and such Participant&#x2019;s option for the Offering Period will be automatically terminated, and no further Contributions for the purchase of shares will be made for such Offering Period.  If a Participant withdraws from an Offering Period, Contributions will not resume at the beginning of the succeeding Offering Period, unless the Participant re-enrolls in the Plan in accordance with the provisions of Section 5.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A Participant&#x2019;s withdrawal from an Offering Period will not have any effect on his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or in succeeding Offering Periods that commence after the termination of the Offering Period from which the Participant withdraws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon a Participant&#x2019;s ceasing to be an Eligible Employee, for any reason, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to such Participant&#x2019;s account during the Offering Period but not yet used to purchase shares of Common Stock under the Plan will be returned to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section 15, and such Participant&#x2019;s option will be automatically terminated.  Unless otherwise provided by the Administrator, a Participant whose employment transfers between entities through a termination with an immediate rehire (with no break in service) by the Company or a Designated Company will not be treated as terminated under the Plan; however, if a Participant transfers from an Offering under the 423 Component to the Non-423 Component, the exercise of the option will be qualified under the 423 Component only to the extent it complies with Section 423 of the Code, unless otherwise provided by the Administrator.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No interest will accrue on the Contributions of a participant in the Plan, except as may be required by Applicable Law, as determined by the Company, and if so required by the laws of a particular jurisdiction, will apply to all Participants in the relevant Offering under the 423 Component, except to the extent otherwise permitted by U.S. Treasury Regulation Section 1.423&#x2011;2(f).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to adjustment upon changes in capitalization of the Company as provided in Section 19 hereof, the maximum number of shares of Common Stock that will be made available for sale under the Plan will be 1,478,492 shares of Common Stock.  The number of shares of Common Stock available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2020 Fiscal Year equal to the least of (i) 591,397 shares of Common Stock, (ii) one percent (1%) of the outstanding shares of Common Stock on the last day of the immediately preceding Fiscal Year, or (iii) an amount determined by the Administrator no later than the last day of the immediately preceding Fiscal Year.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Until the shares of Common Stock are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), a Participant will have only the rights of an unsecured creditor with respect to such shares, and no right to vote or receive dividends or any other rights as a stockholder will exist with respect to such shares.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Shares of Common Stock to be delivered to a Participant under the Plan will be registered in the name of the Participant or in the name of the Participant and his or her spouse.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will be administered by the Board or a Committee appointed by the Board, which Committee will be constituted to comply with Applicable Laws.  The Administrator will have full and exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to delegate ministerial duties to any of the Company&#x2019;s employees, to designate separate Offerings under the Plan, to designate Subsidiaries and Affiliates as participating in the 423 Component or Non-423 Component, to determine eligibility, to adjudicate all disputed claims filed under the Plan and to establish such procedures that it deems necessary for the administration of the Plan (including, without limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees who are foreign nationals or employed outside the U.S., the terms of which sub-plans may take precedence over other provisions of this Plan, with the exception of Section 13(a) hereof, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan will govern the operation of such sub-plan).  Unless otherwise determined by the Administrator, the Eligible Employees eligible to participate in each sub-plan will participate in a separate Offering or in the Non-423 Component.  Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding eligibility to participate, the definition of Compensation, handling of Contributions, making of Contributions to the Plan (including, without limitation, in forms other than payroll deductions), establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of stock certificates that vary with applicable local requirements.  The Administrator also is authorized to determine that, to the extent permitted by U.S. Treasury Regulation Section 1.423&#x2011;2(f), the terms of an option granted under the Plan or an Offering to citizens or residents of a non-U.S. jurisdiction will be less favorable than the terms of options granted under the Plan or the same Offering to employees resident solely in the U.S.  Every finding, decision, and determination made by the Administrator will, to the full extent permitted by law, be final and binding upon all parties.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Designation of Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any shares of Common Stock and cash, if any, from the Participant&#x2019;s account under the Plan in the event of such Participant&#x2019;s death subsequent to an Exercise Date on which the option is exercised but prior to delivery to such Participant of such shares and cash.  In addition, if permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any cash from the Participant&#x2019;s account under the Plan in the event of such Participant&#x2019;s death prior to exercise of the option.  If a Participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Such designation of beneficiary may be changed by the Participant at any time by notice in a form determined by the Administrator.  In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#x2019;s death, the Company will deliver such shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All beneficiary designations will be in such form and manner as the Administrator may designate from time to time.  Notwithstanding Sections 15(a) and (b) above, the Company and/or the Administrator may decide not to permit such designations by Participants in non-U.S. jurisdictions to the extent permitted by U.S. Treasury Regulation Section 1.423&#x2011;2(f).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Contributions credited to a Participant&#x2019;s account nor any rights with regard to the exercise of an option or to receive shares of Common Stock under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 15 hereof) by the Participant.  Any such attempt at assignment, transfer, pledge or other disposition will be without effect, except that the Company may treat such act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Use of Funds</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may use all Contributions received or held by it under the Plan for any corporate purpose, and the Company will not be obligated to segregate such Contributions except under Offerings or for Participants in the Non-423 Component for which Applicable Laws require that Contributions to the Plan by Participants be segregated from the Company&#x2019;s general corporate funds and/or deposited with an independent third party.  Until shares of Common Stock are issued, Participants will have only the rights of an unsecured creditor with respect to such shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Individual accounts will be maintained for each Participant in the Plan.  Statements of account will be given to participating Eligible Employees at least annually, which statements will set forth the amounts of Contributions, the Purchase Price, the number of shares of Common Stock purchased and the remaining cash balance, if any.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adjustments, Dissolution, Liquidation, Merger, or Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Stock or other securities of the Company, or other change in the corporate structure of the Company affecting the Common Stock occurs, the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will, in such manner as it may deem equitable, adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share, the class, and the number of shares of Common Stock covered by each option under the Plan that has not yet been exercised, and the numerical limits of Sections 7 and 13.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of the proposed dissolution or liquidation of the Company, any Offering Period then in progress will be shortened by setting a New Exercise Date, and will terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Administrator.  The New Exercise Date will be before the date of the Company&#x2019;s proposed dissolution or liquidation.  The Administrator will notify each Participant in writing or electronically, prior to the New Exercise Date, that the Exercise Date for the Participant&#x2019;s option has been changed to the New Exercise Date and that the Participant&#x2019;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 10 hereof.  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Merger or Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of a merger or Change in Control, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation.  In the event that the successor corporation refuses to assume or substitute for the option, the Offering Period with respect to which such option relates will be shortened by setting a New Exercise Date on which such Offering Period will end.  The New Exercise Date will occur before the date of the Company&#x2019;s proposed merger or Change in Control.  The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#x2019;s option has been changed to the New Exercise Date and that the Participant&#x2019;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in Section 10 hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment or Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason.  If the Plan is terminated, the Administrator, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Exercise Date (which may be sooner than originally scheduled, if determined by the Administrator in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 19).  If the Offering Periods are terminated prior to expiration, all amounts then credited to Participants&#x2019; accounts that have not been used to purchase shares of Common Stock will be returned to the Participants (without interest thereon, except as otherwise required under Applicable Laws, as further set forth in Section 12 hereof) as soon as administratively practicable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Without stockholder consent and without limiting Section 20(a), the Administrator will be entitled to change the Offering Periods or Purchase Periods, designate separate Offerings, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit Contributions in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&#x2019;s processing of properly completed Contribution elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with Contribution amounts, and establish such other limitations or procedures as the Administrator determines in its sole discretion advisable that are consistent with the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequence including, but not limited to:</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">amending the Plan to conform with the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto), including with respect to an Offering Period underway at the time;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">altering the Purchase Price for any Offering Period or Purchase Period including an Offering Period or Purchase Period underway at the time of the change in Purchase Price;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">shortening any Offering Period or Purchase Period by setting a New Exercise Date, including an Offering Period or Purchase Period underway at the time of the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> action;</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">reducing the maximum percentage of Compensation a Participant may elect to set aside as Contributions; and</font></div></div>
  <div style="text-indent:23.333%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:23.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.867%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">reducing the maximum number of shares of Common Stock a Participant may purchase during any Offering Period or Purchase Period.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Such modifications or amendments will not require stockholder approval or the consent of any Participants.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  All notices or other communications by a Participant to the Company under or in connection with the Plan will be deemed to have been duly given when received in the form and manner specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conditions Upon Issuance of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Shares of Common Stock will not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including, without limitation, the U.S. Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and will be further subject to the approval of counsel for the Company with respect to such compliance.</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The 423 Component of the Plan is exempt from the application of Code Section 409A and any ambiguities herein will be interpreted to so be exempt from Code Section 409A.  In furtherance of the foregoing and notwithstanding any provision in the Plan to the contrary, if the Administrator determines that an option granted under the Plan may be subject to Code Section 409A or that any provision in the Plan would cause an option under the Plan to be subject to Code Section 409A, the Administrator may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Administrator determines is necessary or appropriate, in each case, without the Participant&#x2019;s consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Code Section 409A, but only to the extent any such amendments or action by the Administrator would not violate Code Section 409A.  Notwithstanding the foregoing, the Company, and any Parent, Subsidiary or Affiliate will have no liability to a Participant or any other party if the option to purchase Common Stock under the Plan that is intended to be exempt from or compliant with Code Section 409A is not so exempt or compliant or for any action taken by the Administrator with respect thereto.  The Company makes no representation that the option to purchase Common Stock under the Plan is compliant with Code Section 409A.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">24.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will become effective upon the later to occur of (i) its adoption by the Board or (ii) the business day immediately prior to the Registration Date.  It will continue in effect for a term of twenty (20) years, unless sooner terminated under Section 20.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">25.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will be subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan is adopted by the Board.  Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">26.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will be governed by, and construed in accordance with, the laws of the State of California (except its choice-of-law provisions).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">27.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Right to Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Participation in the Plan by a Participant will not be construed as giving a Participant the right to be retained as an employee of the Company or a Subsidiary or Affiliate, as applicable.  Further, the Company or a Subsidiary or Affiliate may dismiss a Participant from employment at any time, free from any liability or any claim under the Plan. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">28.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction or as to any Participant, such invalidity, illegality or unenforceability will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as to such jurisdiction or Participant as if the invalid, illegal or unenforceable provision had not been included.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">29.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The terms of this Plan are intended to comply with all Applicable Laws and will be construed accordingly.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2019 EMPLOYEE STOCK PURCHASE PLAN</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SUBSCRIPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_____ Original Application				Offering Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">				</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_____ Change in Payroll Deduction Rate</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">____________________ (&#x201c;Employee&#x201d;) hereby elects to participate in the Alector, Inc. 2019 Employee Stock Purchase Plan (the &#x201c;Plan&#x201d;) and subscribes to purchase shares of the Company&#x2019;s Common Stock in accordance with this Subscription Agreement and the Plan.  Unless otherwise defined herein, the terms defined in the 2019 Employee Stock Purchase Plan (the &#x201c;Plan&#x201d;) shall have the same defined meanings in this Subscription Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee hereby authorizes payroll deductions from each paycheck in the amount of ____% (from 0 to fifteen percent (15%)) of his or her Compensation on each payday during the Offering Period in accordance with the Plan.  (Please note that no fractional percentages are permitted.)</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee understands that said payroll deductions will be accumulated for the purchase of shares of Common Stock at the applicable Purchase Price determined in accordance with the Plan.  Employee understands that if he or she does not withdraw from an Offering Period, any accumulated payroll deductions will be used to automatically exercise his or her option and purchase Common Stock under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee has received a copy of the complete Plan and its accompanying prospectus.  Employee understands that his or her participation in the Plan is in all respects subject to the terms of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Shares of Common Stock purchased by Employee under the Plan should be issued in the name(s) of _____________ (Employee or Employee and Spouse only).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee understands that if he or she disposes of any shares that he or she purchased under the Plan within two (2) years after the Enrollment Date (the first day of the Offering Period during which he or she purchased such shares) or one (1) year after the applicable Exercise Date, he or she will be treated for federal income tax purposes as having received ordinary income at the time of such disposition in an amount equal to the excess of the fair market value of the shares at the time such shares were purchased over the price paid for the shares.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee hereby agrees to notify the Company in writing within thirty (30) days after the date of any disposition of such shares and to make adequate provision for federal, state or other tax withholding obligations, if any, that arise upon the disposition of such shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may, but will not be obligated to, withhold from Employee&#x2019;s compensation the amount necessary to meet any applicable withholding obligation including any withholding necessary to make available to the Company any tax deductions or benefits attributable to Employee&#x2019;s sale or early disposition of such shares.  Employee understands that if he or she disposes of such shares at any time after the expiration of the two (2)-year and one&#x2011;(1) year holding periods, he or she will be treated for federal income tax purposes as having received income only at the time of such disposition, and that such income will be taxed as ordinary income only to the extent of an amount equal to the lesser of (i) the excess of the fair market value of the shares at the time of such disposition over the purchase price paid for the shares, or (ii) fifteen percent (15%) of the fair market value of the shares on the first day of the Offering Period.  The remainder of the gain, if any, recognized on such disposition will be taxed as capital gain.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:8pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee hereby agrees to be bound by the terms of the Plan.  The effectiveness of this Subscription Agreement is dependent upon Employee&#x2019;s eligibility to participate in the Plan.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee&#x2019;s [Social</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Security Number]:			</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee&#x2019;s Address:				</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EMPLOYEE UNDERSTANDS THAT THIS SUBSCRIPTION AGREEMENT WILL REMAIN IN EFFECT THROUGHOUT SUCCESSIVE OFFERING PERIODS UNLESS TERMINATED BY EMPLOYEE.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dated: ______________________________                    _________________________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature of Employee</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2019 EMPLOYEE STOCK PURCHASE PLAN</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF WITHDRAWAL</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:1.3in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the 2019 Employee Stock Purchase Plan (the &#x201c;Plan&#x201d;) shall have the same defined meanings in this Notice of Withdrawal.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned Participant in the Offering Period of the Alector, Inc. 2019 Employee Stock Purchase Plan that began on ____________, ______ (the &#x201c;Offering Date&#x201d;) hereby notifies the Company that he or she hereby withdraws from the Offering Period.  He or she hereby directs the Company to pay to the undersigned as promptly as practicable all the payroll deductions credited to his or her account with respect to such Offering Period.  The undersigned understands and agrees that his or her option for such Offering Period will be terminated automatically.  The undersigned understands further that no further payroll deductions will be made for the purchase of shares in the current Offering Period and the undersigned will be eligible to participate in succeeding Offering Periods only by delivering to the Company a new Subscription Agreement.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name and Address of Participant:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_______________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_______________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_______________</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:<br>            _____________________________</font></p>
  <p style="margin-left:40%;text-indent:11.111%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: 	______________________</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>alec-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10.11</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.11</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OUTSIDE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(As amended on December 5, 2023)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) believes that providing cash and equity compensation to members of its Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and members of the Board, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Outside Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This Outside Director Compensation Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) formalizes the Company&#x2019;s policy regarding cash compensation and grants of equity awards to its Outside Directors.  Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#x2019;s 2019 Equity Incentive Plan, as amended from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or if the Plan is no longer in use at the time of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted.  Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 9, this Policy will be effective as of the effective date of the registration statement in connection with the initial public offering of the Company&#x2019;s securities (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (such date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Compensation</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Cash Retainer</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Outside Director will be paid an annual cash retainer of $45,000.  There are no per&#x2011;meeting attendance fees for Board meetings.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee Annual Cash Retainer</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As of the Effective Date, each Outside Director who serves as the chairman of the Board, the lead Outside Director, or the chair or a member of a committee of the Board will be eligible to earn additional annual fees as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.487%;"></td>
    <td style="width:20.513%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-Executive Chairperson of the Board:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$30,000</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lead Independent Director:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairperson of Audit Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Audit Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:79.487%;"></td>
    <td style="width:20.513%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairperson of Compensation Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Compensation Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairperson of Nominating and Governance Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member of Nominating and Governance Committee:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$5,000</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarity, each Outside Director who serves as the chairperson of a committee will receive only the annual fee as the chairperson of the committee and will not also receive the additional annual fee as a member of the committee.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Payment</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each annual cash retainer under this Policy will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant capacity at any point during the immediately preceding fiscal quarter, and such payment shall be made no later than 30 days following the end of such immediately preceding fiscal quarter.  For purposes of clarification, an Outside Director who has served as an Outside Director, as a member of an applicable committee (or chairperson thereof) during only a portion of the relevant Company fiscal quarter will receive a pro-rated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during such fiscal quarter such Outside Director has served in the relevant capacities.  For purposes of clarification, an Outside Director who has served as an Outside Director, as a member of an applicable committee (or chairperson thereof), as applicable, from the Effective Date through the end of the fiscal quarter containing the Effective Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will receive a prorated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during the Initial Period that such Outside Director has served in the relevant capacities.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to the annual cash retainers described above, Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options, Performance Units or Performance Shares) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy.  All grants of Awards to Outside Directors pursuant to this Section of the Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Section 11 of the Plan, each individual who first becomes an Outside Director following the Effective Date will be granted a nonstatutory stock option to purchase 19,420 Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Option Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and 41,250 restricted stock units (the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and together with the Initial Option Award, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Initial Award will be made on the first trading date on or after the date on which such individual first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy.  If an individual was a member of the Board and also an employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to an Initial Award.  Each Initial Option Award will vest as to 1/48</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Shares subject to the Initial Option Award on the one-month anniversary of the date the applicable Outside Director&#x2019;s service as an Outside Director commenced and as to 1/48</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the Shares subject to the Initial Option Award each month thereafter, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.  Each Initial RSU Award will vest as to one-twelfth (1/12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) of the Shares subject to the Initial RSU Award on the first Quarterly Vesting Date (as defined below) that occurs on or following the date that is three (3) months after the date the applicable Outside Director&#x2019;s service as an Outside Director commenced, and as to one-twelfth (1/12th) of the Shares on each Quarterly Vesting Date thereafter, in each case subject to the Outside Director continuing to be a Service Provider through the applicable Quarterly Vesting Date.  &#x201c;Quarterly Vesting Date&#x201d; means each of March 1, June 1, September 1, and December 1.  Each Initial Option Award and Initial RSU Award will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider at the time of the Change in Control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to Section 11 of the Plan, on the date of each annual meeting of the Company&#x2019;s stockholders following the Effective Date (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), each Outside Director who, as of such annual meeting date, has served on the Board as a director for at least the preceding six months will be automatically granted a nonstatutory stock option to purchase 12,360 Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Option Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and 26,250 restricted stock units</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and together with the Annual Option Award, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Annual Option Award will vest as to one-twelfth (1/12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) of the Shares subject to the Annual Option Award on the one-month anniversary of the date the Annual Option Award is granted and as to one-twelfth (1/12</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) of the Shares subject to the Annual Option Award each month thereafter, provided that the Annual Option Award will vest in full on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the date of the next regularly scheduled Annual Meeting, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.  Each Annual Option Award will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Annual RSU Award will vest in full on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the date of the next regularly scheduled Annual Meeting, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.  Each Annual RSU Award will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Terms of Initial Option Awards and Annual Option Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The terms and conditions of each Initial Option Award and Annual Option Award will be as follows:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	The term of each Initial Option Award and Annual Option Award will be ten years, subject to earlier termination as provided in the Plan.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	Each Initial Option Award and Annual Option Award will have an exercise price per Share equal to 100% of the Fair Market Value per Share on the grant date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Policy, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the grant date fair value (determined in accordance with U.S. generally accepted accounting principles), or such other methodology the Board may determine prior to the grant of the Initial Option or Annual Award becoming effective, as applicable.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Change in Control, each Outside Director will fully vest in his or her outstanding Company equity awards, including any Initial Award or Annual Award, provided that the Outside Director continues to be an Outside Director through such date.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Compensation Limit</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Outside Director may be paid, issued or granted, in any fiscal year, cash compensation and Awards with an aggregate value greater than $750,000, increased to $1,000,000 in the fiscal year of his or her initial service as an Outside Director (with the value of each Award based on its Grant Value for purposes of the limitation under this Section 4).  Any cash compensation paid or Awards granted to an individual for his or her services as an Employee, or for his or her services as a Consultant (other than as an Outside Director), will not count for purposes of the limitation under this Section 4.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Travel Expenses</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Outside Director&#x2019;s reasonable, customary and documented travel expenses to Board meetings will be reimbursed by the Company.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Provisions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) the 15th day of the 3rd month following the end of the Company&#x2019;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) the 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#x201c;short-term deferral&#x201d; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply.  In no event will the Company reimburse an Outside Director for any taxes imposed or other costs incurred as a result of Section 409A.</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Revisions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason.  No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company.  Termination of this Policy will not affect the Board&#x2019;s or the Compensation Committee&#x2019;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>6
<FILENAME>alec-ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html>
 <head>
  <title>EX-19</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 19</font></p>
  <p style="margin-left:30.773%;text-indent:15.34%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.722%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ALECTOR, INC. INSIDER TRADING POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.63%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(As amended on March 2023)</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">INTRODUCTION AND POLICY OVERVIEW</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc. (together with its subsidiaries, collectively the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its own legal and reputational risk.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Insider Trading Prohibited</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The securities laws prohibit &#x201c;insider trading.&#x201d; As described below, this generally refers to trading securities (including the Company&#x2019;s and other companies&#x2019; stock) &#x201c;on the basis of&#x201d; material nonpublic information (as defined below). Transactions will be considered to be &#x201c;on the basis of&#x201d; material nonpublic information if the person engaging in the transaction was aware of the material nonpublic information at the time of the transaction. It is not a defense that the person did not &#x201c;use&#x201d; the information for the purposes of the transaction.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insider trading also includes &#x201c;tipping,&#x201d; when someone directly or indirectly discloses material nonpublic information to others who then trade based on that information or when someone makes recommendations or expresses opinions about transactions while aware of material nonpublic information. Both the person providing, and the person trading on, the information, recommendation or opinion may be liable for insider trading.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insider trading is illegal and a violation of this Policy. Your violation of the law could expose you, the Company, members of the Company&#x2019;s Board of Directors, and the Company&#x2019;s officers and supervisory personnel to civil or criminal liability.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Detection and Prosecution of Insider Trading</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sophisticated surveillance techniques are used to detect and investigate insider trading. The Securities and Exchange Commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the United States Department of Justice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DOJ</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) aggressively pursue insider trading violations. In addition to cases against individuals trading on their own behalf, the SEC and DOJ have successfully brought cases involving trading through foreign accounts, trading by family members and friends, trading only a small number of shares, and tipping (even where the person disclosing the information or recommending the transaction did not benefit from the other person&#x2019;s trading).</font></p>
  <p style="margin-left:0.96%;text-indent:7.359%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Even the appearance of insider trading can lead to government investigations or lawsuits that are time-consuming and expensive and can result in criminal and civil liability, including damages and fines, imprisonment and bars on serving as an officer or director of a public company, not to mention irreparable damage to both your and the Company&#x2019;s reputation.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Compliance Officers</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Policy, the Company&#x2019;s General Counsel and Chief Financial Officer serve as the Trading Compliance Officers and are generally responsible for administration of this Policy. Please direct any questions to them or their designees.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Your Responsibility</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">It is your responsibility to understand and follow this Policy and the securities laws and regulations. You should consult with your legal and financial advisors as needed. A violation of insider trading laws can result in severe consequences.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As set forth in more detail below: when you have material nonpublic information about the Company, you may not trade in the Company&#x2019;s securities, disclose material nonpublic information to others who trade in the Company&#x2019;s securities, or recommend/express opinions on transactions in the Company&#x2019;s securities; and when you have material nonpublic information about another company learned through your role at the Company, you may not trade in the securities of that other company.</font></p>
  <p style="margin-left:0.96%;text-indent:6.84%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, you must comply with this Policy as to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">when </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">how </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">you may trade. As described in more detail below, to reduce the risks of insider trading, the Company has established requirements and restrictions involving your trading, based on your role:</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.607220935518085%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employees at the level of Vice President or above, and other employees as may be designated by the Trading Compliance Officers from time to time, may only trade in the Company&#x2019;s securities in accordance with a 10b5-1 Trading Plan.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.607220935518085%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other employees may trade in the Company&#x2019;s securities (a) in accordance with a 10b5-1 Trading Plan or (b) if an employee has not established a 10b5-1 Trading Plan, at any time (i) when not in possession of material nonpublic information </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(ii) not subject to a blackout period. An employee who has established a 10b5-1 Trading Plan cannot trade outside of that plan.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.607220935518085%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Members of the Company&#x2019;s Board of Directors are encouraged to establish a 10b5-1 Trading Plan and may only trade in the Company&#x2019;s securities (a) in accordance with a 10b5-1 Trading Plan or (b) in accordance with the preclearance procedures set forth below.</font></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PERSONS AND TRANSACTIONS COVERED BY THIS POLICY</font></div></div>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Persons Covered by This Policy</font></p>
  <p style="margin-left:0.96%;text-indent:6.806%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to you if you are a director, officer, employee, consultant, contractor or advisor of the Company. This Policy also covers your immediate family members, persons with whom you share a household, persons who are your economic dependents and any entity whose transactions in securities you influence, direct or control (including, for example, a venture fund or other investment fund, if you influence, direct or control transactions by the fund). References in this policy to &#x201c;you&#x201d; should also be understood to include those other individuals and entities. You are responsible for making sure that these other individuals and entities comply with this Policy.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy continues to apply even if you leave the Company or are otherwise no longer affiliated with or providing services to the Company, for as long as you continue to possess material nonpublic information. In addition, if you are subject to a trading blackout under this Policy at the time you leave the Company, you must abide by the applicable trading restrictions until at least the end of the relevant blackout period.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Types of Transactions Covered by This Policy</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as discussed below, this Policy applies to all transactions involving the securities of the Company or other companies for which you possess material nonpublic information obtained in connection with your service with the Company. This Policy therefore applies to:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.602%;display:flex;margin-top:3.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any purchase, sale, loan or other transfer or disposition of any equity securities (including common stock, options, restricted stock units, warrants and preferred stock) and debt securities (including debentures, bonds and notes) of the Company and such other companies, whether direct or indirect (including transactions made on your behalf by money managers), and any offer to engage in the foregoing transactions;</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any disposition in the form of a gift of any securities of the Company;</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any distribution to holders of interests in an entity if the entity is subject to this Policy; and</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any other permitted arrangement that generates gains or losses from or based on changes in the prices of such securities and any offer to engage in such transactions.</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As described in more detail below, you may not engage in transactions involving trading in derivative securities (for example, exchange-traded put or call options, swaps, caps and collars, hedging and pledging transactions, short sales and certain arrangements regarding participation in benefit plans, and any offer to engage in the foregoing transactions with respect to the Company&#x2019;s securities.</font></p>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There are no exceptions from insider trading laws or this Policy based on the size of the transaction or the amount or type of value you obtain in the transaction.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">MATERIAL NONPUBLIC INFORMATION; TRADING RESTRICTIONS</font></div></div>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material Nonpublic Information</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Information</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">It is not possible to define all categories of &#x201c;material information.&#x201d; That said, information should be regarded as material if there is a reasonable likelihood that an investor (a) would consider the information to be important in making a decision to buy, sell or hold the Company&#x2019;s securities or (b) would view the information as significantly altering the total mix of information in the marketplace about the Company. In general, any information that could reasonably be expected to affect the price of the Company&#x2019;s securities is likely to be material. Either positive or negative information may be material.</font></p>
  <p style="margin-left:0.96%;text-indent:6.807%;font-size:10pt;margin-top:12.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered material. Examples of such information may include:</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial results</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Projections of future earnings or losses</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant clinical or regulatory developments</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:9.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant developments in research and development or relating to intellectual property</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Gain or loss of a substantial customer, supplier, vendor or partner</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New product announcements of a significant nature</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant product defects or modifications</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant changes in business plans, budgets or relationships</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Major personnel changes, such as changes in senior management</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Changes in independent auditors or notification that the Company may no longer rely on an audit report</font></div></div>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:10%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.602%;display:flex;margin-top:4.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New equity or debt offerings, stock splits and other major events involving the Company&#x2019;s securities</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant corporate events, such as a pending or proposed merger, joint venture or tender offer, a significant investment, the acquisition or disposition of a significant business or asset or a change in control of the Company</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Creation of significant financial obligations</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Updates regarding any prior material disclosure that has materially changed</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The existence of a special blackout period</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Data breaches or other cybersecurity events</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant pricing changes</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Significant litigation exposure due to actual or threatened litigation</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">News of the disposition of a subsidiary</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impending bankruptcy or financial liquidity problems</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Changes in dividend policy</font></div></div>
  <p style="margin-left:0.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material nonpublic information</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Material nonpublic information&#x201d; means material information that is not generally known or made available to the public. Even if information is widely known throughout the Company, it may still be nonpublic. Generally, in order for information to be considered public, it must be made generally available through media outlets or SEC filings. After the release of information, a reasonable period of time must elapse in order to provide the public an opportunity to absorb and evaluate the information provided. As a general rule, at least two full trading days must pass after the dissemination of information before such information is considered public.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As a rule of thumb, if you think something might be material nonpublic information, it probably is. You can always reach out to the Trading Compliance Officers if you have questions as to what constitutes material nonpublic information.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Trading on Material Nonpublic Information</font></p>
  <p style="margin-left:0.96%;text-indent:6.84%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You may not, directly or through others, engage in any transaction involving the Company&#x2019;s securities while you are aware of material nonpublic information relating to the Company. It is not an excuse that you did not &#x201c;use&#x201d; the information in your transaction. If you are in possession of material nonpublic information about the Company, you may not:</font></p>
  <div style="margin-left:10.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">use it to transact in securities of the Company;</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">disclose it to other employees, consultants, contractors, advisors, officers or directors whose roles do not require them to have the information;</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">disclose it to anyone outside of the Company, including family, friends, business associates (including entities under contracts with the Company), investors or consulting firms, without prior written authorization from the General Counsel; or</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">use it to express an opinion or make a recommendation about trading in the Company&#x2019;s securities.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, material nonpublic information about another company that you learn through your service with the Company is subject to these same restrictions around disclosure and trading, and you cannot use that information to trade securities. Any such action will be deemed a violation of this Policy.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Disclosure of Confidential Information</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You may not at any time disclose material nonpublic information about the Company or about another company that you obtained in connection with your service with the Company to friends, family members or any other person or entity that the Company has not authorized to know such information. You must continue to comply with all agreements you have with the Company, e.g., for employees, the At Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, and for others, the agreement(s) governing your relationship with the Company. In addition, you must handle the confidential information of others in accordance with any agreements and other obligations that the Company has with them, including any obligations of confidentiality and non-use under a confidentiality, master services or other agreement.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If you receive an inquiry for information from someone outside of the Company, such as a stock analyst, or a request for sensitive information outside the ordinary course of business from someone outside of the Company, such as a business partner, vendor, supplier or salesperson, then you should refer the inquiry to the Trading Compliance Officers. Responding to a request yourself may violate this Policy and, in some circumstances, the law. Please consult the Company&#x2019;s External Communications Policy for more details.</font></p>
  <div style="margin-left:4.259%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.04215539841865%;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TRADING: WHEN AND HOW TRADING IS PERMITTED AND RESTRICTED</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition to the above prohibitions on insider trading, you are also subject to trading restrictions that the Company has implemented to reduce the risk of insider trading. As described below, these restrictions affect </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">when </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">how </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">you may trade and depend on your role at the Company.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">10b5-1 Trading Plans</font></p>
  <p style="margin-left:0.96%;text-indent:6.84%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A 10b5-1 Trading Plan is a written plan for engaging in transactions in the Company&#x2019;s securities that (a) is made by an individual when not in possession of material nonpublic information and (b) meets all of the requirements established by the SEC. Transactions made pursuant to a properly established 10b5- 1 Trading Plan are not subject to the prohibitions on trading while aware of material nonpublic information or during blackout periods or the preclearance procedures under this Policy.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VPs or Above and Other Employees Designated by Trading Compliance Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">: Employees at the level of Vice President or above may only trade in the Company&#x2019;s securities in accordance with a 10b5-1 Trading Plan. Additionally, the Trading Compliance Officers may designate other employees from time to time who may only trade in the Company&#x2019;s securities in accordance with a 10b5-1 Trading Plan. For avoidance of doubt, these individuals may not trade in the Company&#x2019;s securities outside of a 10b5-1 Trading Plan, even when not subject to a blackout period.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">: Employees at levels below Vice President may trade in the Company&#x2019;s securities in accordance with a 10b5-1 Trading Plan. If an employee has not established a 10b5-1 Trading Plan, then he or she may trade in the Company&#x2019;s securities (i) when not in possession of material nonpublic information, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(ii) not subject to a blackout period. If an employee has established a 10b5-1 Trading Plan, he or she may not trade in the Company&#x2019;s securities outside of such 10b5-1 Trading Plan.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Board of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Members of the Company&#x2019;s Board of Directors are encouraged to establish and only trade in the Company&#x2019;s securities in accordance with 10b5-1 Trading Plans. Members of the Board of Directors may also trade in the Company&#x2019;s securities if they obtain preclearance in accordance with the procedures set forth below.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10b5-1 Trading Plans may only be established or modified outside of a blackout period and when the individual is not in possession of material nonpublic information. All proposed 10b5-1 Trading Plans must be approved by the Trading Compliance Officers or their designees, as appropriate, and must comply with the requirements set forth in the Requirements for 10b5-1 Trading Plans, attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If one of the Trading Compliance Officers is the requester, then either (a) the other Trading Compliance Officer or (b) Company&#x2019;s Chief Executive Officer or their delegate (other than the requesting Trading Compliance Officer) must approve the 10b5-1 Trading Plan.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The SEC requirements for 10b5-1 Trading Plans are complex and must be strictly complied with.</font></p>
  <p style="margin-left:0.96%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If you have any questions, please consult with your personal legal or financial advisor.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Blackout Periods</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Individuals who are not required to have 10b5-1 Trading Plans and who choose not to adopt a 10b5- 1 Trading Plan may only trade when (a) they do not possess material nonpublic information </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (b) they are not subject to a blackout period. To the extent applicable to you, blackout periods also cover your immediate family members, persons with whom you share a household, persons who are your economic dependents and any entity whose transactions in securities you influence, direct or control.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The prohibition against trading during the blackout period also means that brokers cannot fulfill open orders on your behalf or on behalf of your immediate family members, persons with whom you share a household, persons who are your economic dependents or any entity whose transactions in securities you influence, direct or control, during the blackout period, including &#x201c;limit orders&#x201d; to buy or sell stock at a specific price or better and &#x201c;stop orders&#x201d; to buy or sell stock once the price of the stock reaches a specified price. As a result, open orders should be cancelled prior to entering a blackout window. Failure to cancel before a blackout window may result in the execution of a trade at a time when you are aware of material nonpublic information or are otherwise not permitted to trade in the Company&#x2019;s securities and therefore may also result in inadvertent insider trading violations. If you are subject to blackout periods, at the time you place an open order, you should inform the broker that you are subject to blackout periods to address this issue.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Note that even when a blackout period is not in effect, you may be prohibited from engaging in transactions involving the Company&#x2019;s securities because you possess material nonpublic information.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Quarterly Blackout Periods</font></p>
  <p style="margin-left:0.96%;text-indent:6.731%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Quarterly blackout periods will start at the end of the fifth to last trading day of each fiscal quarter and will end at the start of the second full trading day following the Company&#x2019;s earnings release.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Special Blackout Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Either of the Trading Compliance Officers may decide to impose additional or longer trading blackout periods at any time on any or all of its directors, officers, employees, consultants, contractors and advisors. You will be notified by the General Counsel or his or her designee if you are subject to a special blackout period in writing or via email. If you are notified that you are subject to a special blackout period, you may not engage in any transaction involving Company&#x2019;s securities until the special blackout period has</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.96%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ended other than the transactions that are covered by the exceptions below. You also may not disclose to anyone else that the Company has imposed a special blackout period.</font></p>
  <p style="margin-left:8.133%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Regulation BTR Blackouts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:0.96%;text-indent:7.358%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.556%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Directors and officers may also be subject to trading blackouts pursuant to Regulation Blackout Trading Restriction (&#x201c;Regulation BTR&#x201d;) under U.S. federal securities laws. In general, Regulation BTR prohibits any director or officer from engaging in certain transactions involving the Company&#x2019;s securities during periods when 401(k) plan participants are prevented from purchasing, selling or otherwise acquiring or transferring an interest in certain securities held in individual account plans. Any profits realized from a transaction that violates Regulation BTR are recoverable by the Company, regardless of the intentions of the director or officer effecting the transaction. In addition, individuals who engage in such transactions are subject to sanction by the SEC as well as potential criminal liability. The Company will notify directors and officers if they are subject to a blackout trading restriction under Regulation BTR. Failure to comply with an applicable trading blackout in accordance with Regulation BTR is a violation of the law and this Policy.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pre-clearance of Trades</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company encourages members of its Board of Directors to establish 10b5-1 Trading Plans. Members of the Company&#x2019;s Board of Directors who do not have a 10b5-1 Trading Plan in place must obtain pre-clearance prior to trading the Company&#x2019;s securities. If you are subject to pre-clearance requirements, you must submit a pre-clearance request to the Trading Compliance Officers prior to your desired trade date on the form provided by the Trading Compliance Officers. The person requesting pre-clearance will be required to certify that he or she is not in possession of material nonpublic information about the Company and provide other information requested by the Trading Compliance Officers. The Trading Compliance Officers are under no obligation to approve a transaction submitted for pre-clearance and may decide not to permit the transaction.</font></p>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:12.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All trades must be executed within five business days of any pre-clearance.</font></p>
  <p style="margin-left:0.96%;text-indent:6.843%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.62%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Even after preclearance, a person may not trade in the Company&#x2019;s securities if they become aware of material nonpublic information prior to the trade being executed.</font></p>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may identify other persons who should be subject to the pre- clearance requirements set forth above, and the Trading Compliance Officers may update and revise the requirements as appropriate.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PROHIBITED TRANSACTIONS</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You may not engage in any of the following types of transactions, other than as noted below in Section F (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limited Exceptions to Trading Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">), regardless of whether you have material nonpublic information or not.</font></p>
  <div style="margin-left:7.602%;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. You may not engage in short sales (meaning the sale of a security that must be borrowed to make delivery) or &#x201c;sell short against the box&#x201d; (meaning the sale of a security with a delayed delivery) if such sales involve the Company&#x2019;s securities.</font></div></div>
  <div style="margin-left:7.602%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Derivative Securities and Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. You may not, directly or indirectly, (a) trade in publicly-traded options, such as puts and calls, and other derivative securities with respect to the Company&#x2019;s securities (other than stock options, restricted stock units and other compensatory</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.627%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">awards issued to you by the Company) or (b) purchase financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company equity securities either (i) granted to you by the Company as part of your compensation or (ii) held, directly or indirectly, by you.</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pledging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. You may not pledge the Company&#x2019;s securities as collateral for any loan or as part of any other pledging transaction.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Margin Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. You may not hold the Company&#x2019;s common stock in margin accounts.</font></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LIMITED EXCEPTIONS TO TRADING RESTRICTIONS</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There are no unconditional &#x201c;safe harbors&#x201d; for trades made at particular times, and all persons subject to this Policy should exercise good judgment at all times. Even when a quarterly blackout period is not in effect, you may be prohibited from engaging in transactions involving the Company&#x2019;s securities because you possess material nonpublic information, are subject to a special blackout period or are otherwise restricted under this Policy.</font></p>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following are certain limited exceptions to the quarterly and special blackout period restrictions and pre-clearance requirements imposed by the Company under this Policy:</font></p>
  <div style="margin-left:7.602%;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">stock option exercises where the exercise price is paid in cash and there is no other associated market activity (e.g., no sale of the stock after exercise; &#x201c;exercise and hold&#x201d;);</font></div></div>
  <div style="margin-left:7.602%;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">purchases pursuant to the employee stock purchase plan; however, this exception does not apply to subsequent sales of the shares;</font></div></div>
  <div style="margin-left:7.602%;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">receipt and vesting of stock options, restricted stock units, restricted stock or other equity compensation awards from the Company, provided that this exception does not apply to subsequent sales of the shares;</font></div></div>
  <div style="margin-left:7.602%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">net share withholding with respect to equity awards where shares are withheld by the Company in order to satisfy tax withholding requirements, (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">x</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) as required by either the Company&#x2019;s Board of Directors (or a committee thereof) or the award agreement governing such equity award or (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">y</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of material nonpublic information;</font></div></div>
  <div style="margin-left:7.602%;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">sell to cover transactions where shares are sold on your behalf upon vesting of equity awards and sold in order to satisfy tax withholding requirements, (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">x</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) as required by either the Company&#x2019;s Board of Directors (or a committee thereof) or the award agreement governing such equity award or (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">y</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is not in place and you are not in possession of material nonpublic information; however, this exception does not apply to any other market sale for the purposes of paying required withholding;</font></div></div>
  <div style="margin-left:7.602%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transactions made pursuant to a valid 10b5-1 trading plan approved by the Company (see Section I (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">10b5-1 Trading Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) below);</font></div></div>
  <div style="margin-left:7.602%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transfers by will or the laws of descent or distribution and, provided that prior written notice is provided to the Trading Compliance Officers, distributions or transfers (such as certain </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.602%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">tax planning or estate planning transfers) that effect only a change in the form of beneficial interest without changing your pecuniary interest in the Company&#x2019;s securities; and</font></div></div>
  <div style="margin-left:7.602%;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">changes in the number of the Company&#x2019;s securities you hold due to a stock split or a stock dividend that applies equally to all securities of a class, or similar transactions.</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.842%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If there is a Regulation BTR blackout (and no quarterly or special blackout period), then the limited exceptions set forth in Regulation BTR will apply. Please be aware that even if a transaction is subject to an exception to this Policy, you will need to separately assess whether the transaction complies with applicable law. Any other Policy exceptions must be approved by the Trading Compliance Officers, in consultation with the Company&#x2019;s Board of Directors or an independent committee of the Board of Directors.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SECTION 16 COMPLIANCE</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#x2019;s executive officers and directors and certain other individuals are required to comply with Section 16 of the Securities and Exchange Act of 1934 and related rules and regulations. To ensure timely reporting of transactions subject to Section 16, each person subject to these requirements must provide or must ensure that his or her broker provides the Company with detailed information (for example, trade date, number of shares, exact price, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">etc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) about his or her transactions involving the Company&#x2019;s securities, including gifts, transfers, pledges and transactions pursuant to a 10b5-Trading Plan, by no later than the end of the business day in which the transaction takes place.</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company is available to assist in filing Section 16 reports, but the obligation to comply with Section 16 is personal. If you have any questions, you should check with the Trading Compliance Officers.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">H.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VIOLATIONS OF THIS POLICY</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company directors, officers, employees, consultants, contractors and advisors who violate this Policy will be subject to disciplinary action by the Company, including ineligibility for future Company equity or incentive programs or termination of employment or an ongoing relationship with the Company. The Company has full discretion to determine whether this Policy has been violated based on the information available.</font></p>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There are also serious legal consequences for individuals who violate insider trading laws, including large criminal and civil fines, significant imprisonment terms and disgorgement of any profits gained or losses avoided. You may also be liable for improper securities trading by any person to whom you have disclosed material nonpublic information that you have learned through your position at the Company or made recommendations or expressed opinions about securities trading on the basis of such information.</font></p>
  <p style="margin-left:0.96%;text-indent:6.843%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.611%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Please consult with your personal legal and financial advisors as needed. Note that the Company&#x2019;s legal counsel, both internal and external, represent the Company and not you personally.</font></p>
  <p style="margin-left:0.96%;text-indent:6.84%;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.574%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">There may be instances where you suffer financial harm or other hardship or are otherwise required to forego a planned transaction because of the restrictions imposed by this Policy or under securities laws. If you were aware of the material nonpublic information at the time of the trade, it is not a defense that you did not &#x201c;use&#x201d; the information for the trade. Personal financial emergency or other personal circumstances are not mitigating factors under securities laws and will not excuse your failure to comply with this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.96in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, a blackout period will not extend the term of your options. As a consequence, you may be prevented from exercising your options by this Policy or as a result of a blackout or other restriction on your trading, and as a result your options may expire by their term. It is your responsibility to manage your economic interests and to consider potential trading restrictions when determining whether to exercise your options. In such instances, the Company cannot extend the term of your options and has no obligation or liability to replace the economic value or lost benefit to you.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PROTECTED ACTIVITY NOT PROHIBITED</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.839%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.565%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing in this Policy, or any related guidelines or other documents or information provided in connection with this Policy, shall in any way limit or prohibit you from engaging in any of the protected activities set forth in the Company&#x2019;s Compliance Procedures, as amended from time to time.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">J.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REPORTING</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.843%;font-size:10pt;margin-top:11.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.611%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If you believe someone is violating this Policy or otherwise using material nonpublic information that they learned through their position at the Company to trade securities, you should report it to the Trading Compliance Officers, or if a Trading Compliance Officer is implicated in your report, then you should report it in accordance with the Company&#x2019;s Compliance Procedures.</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">K.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENTS</font></div></div>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.593%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company reserves the right to amend this Policy at any time, for any reason, subject to applicable laws, rules and regulations, and with or without notice, although it will attempt to provide notice in advance of any change. Unless otherwise permitted by this Policy, any amendments must be approved by the Board of Directors of the Company.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.7in;min-height:0.83in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.9in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.63%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:11.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.63%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REQUIREMENTS FOR 10B5-1 TRADING PLANS</font></p>
  <p style="margin-left:0.96%;text-indent:6.841%;font-size:10pt;margin-top:12.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For transactions under a trading plan to be exempt from (A) the prohibitions in the Company&#x2019;s Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Alector, Inc. (together with its subsidiaries, collectively the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) with respect to transactions made while aware of material nonpublic information and (B) the pre-clearance procedures and blackout periods established under the Policy, the trading plan must comply with the affirmative defense set forth in Exchange Act Rule 10b5-1 and must meet the following requirements:</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan must be in writing and signed by the person adopting the trading plan.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan must be adopted at a time when:</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the person adopting the trading plan is not aware of any material nonpublic information; and</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">there is no quarterly, special or other trading blackout in effect with respect to the person adopting the plan.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan must be entered in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1, and the person adopting the trading plan must act in good faith with respect to the trading plan.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan must include representations that, on the date of adoption of the trading plan, the person adopting the trading plan:</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7422107449615454%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">is not aware of material nonpublic information about the securities or the Company; and</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7422107449615454%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">is adopting the trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The person adopting the trading plan may not have entered into or altered a corresponding or hedging transaction or position with respect to the securities subject to the trading plan and must agree not to enter into any such transaction while the trading plan is in effect.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The first trade under the trading plan for directors and officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) may not occur until the expiration of a cooling-off period consisting of the later of (a) 90 calendar days after the adoption of the trading plan and (b) two business days after the filing by the Company of its financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the trading plan was adopted (but, in any event, this required cooling-off period is subject to a maximum of 120 days after adoption of the trading plan). The first trade under the trading plan for all other persons (other than the Company) may not occur until the expiration of a cooling-off period that is 30 calendar days after adoption of the trading plan.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan must have a minimum term of one year (starting from the date of adoption of the trading plan).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.15pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All transactions during the term of the trading plan (except for the &#x201c;Exceptions to Trading Restrictions&#x201d; identified in the Policy and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">gifts) must be conducted through the trading plan. In addition, the person adopting the trading plan may not have an outstanding (and may not subsequently enter into any additional) trading plan, except that a trading plan may be adopted if it will not take effect until</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.56in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.96%;font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the outstanding trading plan has expired (i.e., the adopted trading plan and outstanding trading plan overlap solely to the extent of the adopted trading plan&#x2019;s cooling off period).</font></p>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any modification or change to the amount, price or timing of transactions under the trading plan is deemed the termination of the trading plan, and the adoption of a new trading plan (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Therefore, a Modification is subject to the same conditions as a new trading plan as set forth in Sections 1 through 8 herein.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Within the six months preceding the adoption or a Modification of a trading plan, a person may not have otherwise adopted or done a Modification to a plan more than once.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All 10b5-1 Trading Plans require a minimum of two orders.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the person that adopted the trading plan terminates the plan prior to its stated duration, he or she may not trade in the Company&#x2019;s securities until after the expiration of 30 calendar days following termination, and then only in accordance with the Policy.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must be promptly notified of any Modification or termination of the trading plan, including any suspension of trading under the trading plan.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.25pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must have authority to require the suspension or cancellation of the trading plan at any time.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the trading plan grants discretion to a stockbroker or other person with respect to the execution of trades under the trading plan:</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">trades made under the trading plan must be executed by someone other than the stockbroker or other person that executes trades in other securities for the person adopting the trading plan;</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the person adopting the trading plan may not confer with the person administering the trading plan regarding the Company or its securities; and</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.485544265424129%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the person administering the trading plan must provide prompt notice to the Company of the execution of a transaction pursuant to the plan.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All transactions under the trading plan must be in accordance with applicable law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The trading plan (including any Modification) must meet such other requirements as the Trading Compliance Officers may determine.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:11.9pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any trading plans adopted or modified prior to February 27, 2023 are permitted to continue in place until all trades are executed thereunder or they expire by their terms (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prior Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). If the person undertakes a Modification of a Prior Plan, then the Modification must meet all of the above requirements.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>alec-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.065%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(1) Registration Statement (Forms S-3 No. 333-238230 and No. 333-270126) of Alector, Inc.,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(2) Registration Statement (Forms S-8 No. 333-237369, No. 333-253524, No. 333-262990 and No. 333-270111) pertaining to the 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of Alector, Inc., and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(3) Registration Statement (Forms S-8 No. 333-261968 and No. 333-267597) pertaining to the 2022 Inducement Equity Incentive Plan of Alector, Inc.;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of our reports dated February 27, 2024, with respect to the consolidated financial statements of Alector, Inc. and the effectiveness of internal control over financial reporting of Alector, Inc. included in this Annual Report (Form 10-K) of Alector, Inc. for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">San Mateo, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">February 27, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>alec-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Arnon Rosenthal, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3%;"></td>
    <td style="width:44.96%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Arnon Rosenthal</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Arnon Rosenthal, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>alec-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Marc Grasso, certify that:</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and	</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.	</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3%;"></td>
    <td style="width:44.96%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marc Grasso</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marc Grasso, M.D.</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>alec-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.92%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Arnon Rosenthal</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Arnon Rosenthal, Ph.D.</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>alec-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.92%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 27, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marc Grasso</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marc Grasso, M.D.</font></p></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>alec-ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html>
 <head>
  <title>EX-97</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.65in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As adopted on September 27, 2023</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is committed to strong corporate governance. As part of this commitment, the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this clawback policy called the Compensation Recovery Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Policy is intended to further the Company&#x2019;s pay-for-performance philosophy and to comply with applicable law by providing for reasonably prompt recovery of certain executive compensation in the event of an Accounting Restatement. Capitalized terms used throughout the Policy are defined below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is intended to comply with Section 10D of the Securities Exchange Act of 1934 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), with Exchange Act Rule 10D-1 and with the listing standards of the national securities exchange (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on which the securities of the Company are listed. The Policy will be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, Exchange Act Rule 10D-1 and with the listing standards of the Exchange, including any interpretive guidance provided by the Exchange.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The application of the Policy to Executive Officers is not discretionary, except to the limited extent provided below, and applies without regard to whether an Executive Officer was at fault or committed any misconduct.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Persons Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is binding and enforceable with respect to all current and former Executive Officers, including Executive Officers who are no longer employed with the Company. &#x201c;</font><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer</font><font style="color:#262626;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each individual who is or was ever designated as an &#x201c;officer&#x201d; by the Board in accordance with Exchange Act Rule 16a-1(f). The Company shall require each current Executive Officer to sign and return to the Company an acknowledgement that such Executive Officer has read and understood the Policy and will be bound by the terms of and comply with the Policy. The failure to obtain such acknowledgement will have no impact on the applicability or enforceability of the Policy.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board has full delegated authority to administer the Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate or advisable for the administration of the Policy and in accordance with the requirements of the Exchange Act. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or a committee made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to the independent members of the Board or to such committee, as applicable. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Events Requiring Application of the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in a previously issued financial statement that is material to the previously issued financial statement, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Committee must determine what compensation, if any, must be recovered.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following is a non-exhaustive list of examples of changes to financial statements that would </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">not </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">trigger recovery of compensation:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective application of a change in accounting principle</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective revision to reportable segment information due to a change in the company&#x2019;s internal organizational structure</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective reclassification due to a discontinued operation</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective application of a change in reporting entity</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective adjustment to provisional amounts in connection with a prior business combination (IFRS filers only)</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Retrospective revision for stock splits, reverse stock splits, stock dividends, or other changes in capital structure</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Covered by the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy applies to certain </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that is </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), during the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> while the Company has a class of securities listed on a national securities exchange. Such Incentive-Based Compensation is considered &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Clawback Eligible Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; if the Incentive-Based Compensation is Received by a person after such person became an Executive Officer and the person served as an Executive Officer at any time during the performance period for the Incentive-Based Compensation. The Incentive-Based Compensation that must be recovered (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excess Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been Received had the latter been determined based on the restated amounts (such Excess Compensation being computed without regard to any taxes paid). The Excess Compensation is referred to in the listings standards as &#x201c;erroneously awarded incentive-based compensation.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received, and the Company must maintain documentation of the determination of that reasonable estimate in accordance with the Company&#x2019;s retention policy, and provide such documentation to the Exchange.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned for purposes of this Policy until the Company&#x2019;s right to recover under the Policy has lapsed.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The following are non-exhaustive examples of items of compensation that are not Incentive-Based Compensation under the Policy: salaries; bonuses paid solely at the discretion of the Compensation Committee or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure; bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period; non-equity incentive plan awards earned solely upon satisfying one or more strategic or operational measures; and equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure performance goal, and vesting is contingent solely upon completion of a specified employment period (e.g., time-based vesting equity awards) and/or attainment of one or more non-Financial Reporting Measures.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is a measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measure that is derived wholly or in part from such measure. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; under the Policy in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs before or after the end of that period. For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#x2019;s fiscal year. The Company&#x2019;s obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement Determination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earliest to occur of: (a) the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Repayment of Excess Compensation</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover Excess Compensation reasonably promptly, and Executive Officers are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover such Excess Compensation by requiring the Executive Officer to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Executive Officer). These means may include:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Executive Officer; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">cancelling outstanding vested or unvested equity awards; and/or </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">taking any other remedial and recovery action permitted by law, as determined by the Committee. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The repayment of Excess Compensation must be made by an Executive Officer notwithstanding any Executive Officer&#x2019;s belief (whether legitimate or non-legitimate) that the Excess Compensation had been previously earned under applicable law and therefore should not be subject to clawback.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce an Executive Officer&#x2019;s obligations to the Company or to discipline an Executive Officer, including (without limitation) termination of employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.65in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Limited Exceptions to the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that the conditions set forth below are met, and the Committee determines that recovery of the Excess Compensation would be impracticable:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange; or</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Important Information in the Policy</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements or rules, or the terms of any existing or future Company policy or agreement providing for the recovery of compensation applicable to Executive Officers or any employee of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the terms of any of the Company&#x2019;s organizational documents (including, but not limited to, the Company&#x2019;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify against or provide advancement to any Executive Officer for any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event the Company is required pursuant to the Policy to recover Excess Compensation from an Executive Officer who is no longer an employee, the Company will be entitled to seek such recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement such Executive Officer may have signed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Committee or Board may review and modify the Policy from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of the Policy or the application of any such provision to any Executive Officer is adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provisions to such Executive Officer or another Executive Officer, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Policy will terminate and no longer be enforceable if the Company ceases to be a listed issuer within the meaning of Section 10D of the Exchange Act.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.65in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGEMENT</font></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that I have received, read and understood the Compensation Recovery Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Alector, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and acknowledge that the Policy applies to me and all of my beneficiaries, heirs, executors, administrators or other legal representatives, during and after my employment with the Company in accordance with the terms of the Policy, and that the Company&#x2019;s right to recovery in order to comply with applicable law will apply regardless of the terms of any release of claims or separation agreement I have signed or will sign in the future.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I agree to be bound by and to comply with the Policy and understand that determinations of the Committee (as such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand and agree that my current indemnification rights, whether in an individual agreement or the Company&#x2019;s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that my failure to comply in any respect with the Policy is a basis for termination of my employment with the Company and any affiliate of the Company as well as any other appropriate discipline.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for good reason (or similar concept) by me under any applicable employment agreement or arrangement.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my responsibility to seek guidance from the General Counsel or Compliance Officer or my own personal advisers.</font></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Please review, sign and return this form to the General Counsel or Compliance Officer.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Executive</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">_________________________</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">print name</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">_________________________</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">signature</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">_________________________</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(date)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img43903234_0.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_0.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M.*@CIQ!&0)%Y'),Y[P8\]+%*! %GUE==G5=L"@=!&W0VRK"+JQ>,K*>(](@
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M%=LI/1]E':\;,8>U8B27>XN]00QH>O!#JZ:;&NS_?F:C>D$_$/3\WN\_:_=
MC^1X!V8SZT;4>IER1_M 7_.7:?HY)S"X*&=S>"_D]/BG<1W.4\ZF@-( 9#>)
MY?4E_X:2:Q&4PV<E<EP ]5\^H*;0NJ8*?[>.+M0R*N+ MLBPU ">F:GA#[^@
MS9G97OH+'J=&5CLNO/?0WIE,[[  @2#'/H(%"=8[2# :0H+*R(R!.$;-&#)I
M("XSF%'C1HX=/7X$&5+D2)(E39Y$F5+E2I8M7;Z$&1.DLE"@-(7"65/G3IR@
M<H+""!14-&7+:"H[M0RH2V(1QZ3_>5A1(D-]T39BW(=0$P('7+EV=1#6*]BQ
M8LF"-<M5!MJN.,CB6+A/7]:Y5N5J=/OU+%H<7Q&,]>N@;]JP:/4&1H!#V<:Y
M]: IW+?,\%Z_>2F?1=S6K(.U7P]H(DC/JF."C^EFA"K1Z4,UDV2^AAU;]FS:
MM6W?QIT;)#2EFWR>TNES62BEQ'4J+0ZT*+2BII9!"T4S%.B6J:,Z'4.]8+VY
MI^\2])$9[%JSY,^2YSKX<&' AC,EM)LUX;[%^[:^+9N_,%KTE[]VYFPS!'X@
M2!^$[,)*/H(R&6LPL2S;JS_- IM,O/0Z.M @T^JQ""+6(B*#&-U&)+%$$T]$
M,4454Z+I_R:?<*)IN.1^"B6:%W.J22BBC(KN%)J66HD2B"R2JB(R*"DH+H(2
ME,^J^\!2CS IUZLPRL0V>\N@[N2R:\M]H'&++?_4@S"P*"\;#RQZ(-MGS8*Z
M:XR]"M&L;,[$*+Q33K'J:_/- A5DR+ZH.C12HA4/131111=E-%'>0/$-1^F"
MDY2X&WWZ$48;GPN%MQAKBN^D:%1[B"(/QZ@/3BWW"36-]B:CTTHZY13/ =#B
M"_3 0.W[ZRTHJ6Q/OP?QG"R-CAJ+3Q-8\X3R5P'WVJR_S+PBD"$$Y_LRHXE
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MH.PQJ,^2P=Z^,[*9/5%6*/L@L-KB+19J\$VRH^;"T,)!!CTFK XP""<U L=
M@@TC;U #06@*%IU^$Z\ "Y60LO8A-7;7QC?NKA8]5S_!NJ0X1]')IH"9WDU)
M[12;<&5'D"E1K$%N59#A8,PF :N-S-"F-01;Y)0EW'WL<[2@[!Y8VBFSJH1F
MM=AZK0,:<"5%=I,P:6BG7>+2'81P\)F4P:LR[H,0.&;DN!D9C'^/6P_CI@4.
M!V'_H!NG)]<E[\Q?_\)QI"4M2SV_"#D\GDTT;I*3'Q/%=*A#3G)",@F[LI0,
M"CR(WAJ#R'U =2Q\_$%7D$M#@X0UR4E=TPQ%I G_0BLQ*4UT!M^ID65 M9*"
MR1Y@T!!#^2XNMUR:3U(1,^O#C!4L2*7U/@:T)LD@() S?4P,!=0 UVPGK@M&
M]%V*F,RH3-K=[VY?ID WNMOL\D934^R\#@M TO78(-8=4I.U$]U@LPFY__EJ
ME^.8X:Z$6ZTB7BM:[1,6L*H8>??4!T806<@"0==M"PR4,MZ0EP;XVC!KQ@&<
M38FMKIFP('";DZ WD\_JU>?/7<'@/K%-:[L$BSI>TGAD_^;CVH8,ZG$6H2B\
ME;YT<LE;*,+1#=+N%4;3E=0H\TNR1NJJM3-NQ$W158@;%T3E5F-&I\46#%@1
ML!@=[K&L#L@U5YC=;:6B.EM0]DCZZJ&,-.2 Y']9LP-.)IA^,H8J<JZS.^.C
MP]C*>N)[F2;$+1D9M<Z4K&5=CW9>NJMXHGGKYWL*TT4_>D:UB)?T)E&Z8)1>
M'Q%E1TA9ABFFDTM6060BCR8#=3CN=2':Y9F P6S9LA[Q6WV%(";N,ECLPGBT
M%>:1%DZU? ZY0%9#?TEZUD0FTJ#]3&B"&!S,H%VH0A5QWEUF\DR9S!'S U<N
MXW@(%6C)0'/G?/X3V6).G)+BL_^XW6:\Z(3J$(J8)M(CP *L-YY0"DU8!MJS
M#1TS'2*;%ZLKBEJBO<9ILGXY/%U!I%!YH^0!+8SAM23A.P!+JK$:,+'0J2U#
M#.@Q#6BP%IB"#WBZ"Z\Y-XY8-04I,ZZ:*[O0([T@(1'RBL +H2E!DZ_C&KK
ME1<KB)TYE6U).@.$PBB4"=/KJ!I1D7[K$7IQO=,9BIH8P'TPGVTIE2^$#(E9
MG"WA'8VIH& 9&]F"&+M+'&'[B)<BB=VZL)EQJ.%9$D12H60S+=-JL]G"G><S
M/S0#/]>"**@(P(=@-BETQ$=,B?J!D9K8!"5$D9M@#@CTM$V9P.'@B*9(#2,:
M@W R0R7_89LO@:ZRFQ#^$$1 _,/?L1NR6*.*D22"^1.Q:RWQFRMH8R$9=">O
M 3]U<\4P8T/  1PJX2<3FJY0*;,;9+!]L*OR(4-(I,9J+ CHV#3I*"-$V12H
M\13>8 [7ZT)0&#Y*:+*)<BF\*Y!P.L6M:)Z4.49X-+G?217$"[^-L$,Y\Q.J
MT#B:H:_R2[=F')Y H1A)\JP\^1U:\1WD08QY.INQN)5@)(U49$;?<XI5>@A_
ML\:-?$2?VK%M3!1,I(EP5"RCD)I+(R ^LCTFLP@U2+)=21\6XKC_,I/>"1R$
M@\5C,YQD'+HM,4*9B2?%>4'*0K,"B0N"'#J-<,%[1,6""(_DZ.F,C,G)*S$,
MKZK)Y1$>4R1*R4J(8K,KG6E$CA1+1]RET;$?C5P1'@/'D?I&J)D.C="$4)PQ
MK)K![YB+?SRESDLDYZFJWKH_"5,>Y9G&5<$5&&2UH N?I20V^5*(-0'&ZJ,V
M9YDM6"$3(J2I6/0+ CG"F)J/-8D&Q:'#(L(]B!C+THS"WK EJ .7J!DI4RA)
M,+J7U2F("_P09K-'+2E,!4D032@YNLD,J7H0>&29]%!#;Z*/ACB(QZ ^H?,.
MI@P4#HPGY23,K9J8W=N_C8@G?3A&"0*0(9Q,"&.V7 D5?83!^+"N,T+/433_
MS0(T"HXL&M03%[,D"G!,KR'#EW_3&O.!B%#I&?_K28U0E1PXI^9S0S%9)#;\
MBD["D*PR,S)CE4(B.@XZ2KEJ,)C$B-UB+8EAB"EK)(2;S&FA*I5ID*9ZR1N4
MOBY!B)X1$KF,B,%<ST@#A8VR1LR)ERKR&4W8PO/:PD<9H_C8NB)1@R0"/QFD
MGN/4H!0ZT&%,BYR<)ZM*C(XSMT7;QZ(4F6_2Q6SAN/2)B\\$T&#$%@0)D[HI
MT);QP0B2,.U@$DDRMR^%RS!<R5-[T=&+!B^L00*$E*8!&K-<RTT<J7J9C@1Q
MM&1"E5.<2([PFF8J"(Z1$ D!EKP(T7*JD.^QP[M[_\X34I6/HSU5VZ2$*+,*
M2[5\/,/GE"\&^2 QF<K!((_NA#!G(42GNLLB%39G*XB5%-2PC%-XV[24C$)Y
MHT1+#!=- S62!$>@2!U0:HI3Z1<XW<IW8@@68BWRB\Q5)1,/]4X+:=7SNT4T
MT\H91):-FP\O>48H+;C2R! @PA:8FQO!H<I:0=#"&,X["@U37)L&M4.)4=&(
MN#W6<-%;S3&?",$HU)RW'!I0$::J2R].*8I3H Y-((/T',.A^S@H/45?#10Z
MFB=V722KJJ2R$2M(FH_XT"VN-+A\I*R@([IT,[/LM#Y3=*9B9!F&%)N%?%2Q
MZ*1$BZLRRU8YC QV<PI^9?\Z34,7 ]2S&I5-H5' 89I/"%2O&!F5I\B:U$C3
MF;$6_EM3L N-A=18V8*6-=S8%DO%9FQ6/"R-L5607@R49?"229W(F&DY.<3%
M,^/,#VS#7OE0OC30OR#$=BK2B%7,*CU"M*V]([*.X?/92-,<PGVW=,$TD6#
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M:3 W86\ASJ":62,XT:KZA6#Q"6IO;HCL2P,?\#LV3X-^0EQ@) F]"13S]>-
M$<WT?.XGYRZ/1/ '+Y$%_PA/UXV8#LE@A< P>NLS\F3-\QJL_S##L&LJ\=8;
M;J50+XUT[/QC3 4?#<=2S(Z^NM02&O]U0B;TK!K*UM4(&%Z)$Y)UB64MYC3%
ME#I#Z6OLN2"&:/20W=;T6$K-GJ!I%"'UC[AR$UEEG_DE"%Q+YH"&-;:K&'*M
MT-[,%3[%0S[OL3U9D8ACZ9.NM2:_0O*W0N) H[3!,H^/@8%N(G?HE-5W8)32
MD9!T/#>X%'_C^B5SIB3?R # E6R$;;>Q\0J=H#41XUX)4<^->OF9T='1UUQ
M97 =EHS=.6,;%_?;> IT0Q:GO5'K98V^^;U+,W\IX1[/70%<RBKI_%X&8L"(
M=9=V0![BX%6\\"%//FE;3F7DIT[F#/^_=U=WIQVN&4L417SE>!M3O731!)*_
MC7#OB :W<EM?%-9,6F%U"!8ME8..[BR5JTK64GFG>NNS12-E$Q?>/>J.8@BM
M;BL]]NV(F7J  PLP@F6  R  @GI,DE3L80W="!C?/^BR[(]]5423Z@P!2 _7
M6?%+-+0&:QA\]C7VY#&0Z[#'*!<IK^  =9D0>93X8.)^#9/_&>1 K+<O25#
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M<603?MS,0X;W4@^!)9 ?*M%E<L.\%"+L0NL:CDMD516\"'&C!_G3DF02,H1
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M49GPS,6(DO % [Z5GG?_=%$ K45/0$0_%8TPM4P6_E(H)AR"#%BA%6/T691
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M%40%REC+;%1JF(\^W:2I7*AZ9I'ER .ZH?];.\BE6OE*M!X:$*@!6<B-,EA
M$/Z !9PI'.P$>!+C3\!G/)RB"^KJ@\YI:84KL=RJFBB&65D:)1(->'*,?Q%%
M:<J?NA#J95 COHZMA_R+OK;:Q#49R?&.'-;?Y.&AJ=+1/E)G;:945I+C/VZ&
MOGZ(E-&&-_$4* S'WMFJQ+)@4#A5KIQLAS$(,GYKG41+PBED^7 ;#Z8)P0U.
M0F0I7Q[##/4>A>:LSXJD&E0 '' M6ISI5X7)1Z&,#K9IH'G,FJS3ND;2R33M
MRC0N5?A*#QY'EI11C*P),>R=.,VK3!$OV1ZOWJ:7HSQ9,W$>'A;6ILYARE&J
M5MHF/R[#I[IAEA'_8F48D?%>HWME(/,8DJC\U(_,AHE9J5)M)^+XRNI:"?FP
MV7$@4)]<+9_-Q$D* YL^V!1A$BA,G[N-Q<Z^2'V.!1P ;<ZB1I4D1_[N+X1]
MZ<YTS$-U6J;=$Y.6CMNU22P5R+9B<.G41>"6+^SXU:* +?*>L(:X2*.R7&]:
MV<(.$@R;AD+L3I3%K3)L:E7F"\1>HW5TB :F<)F9Y4C$G].D@:TFF.0>'#3F
MY1=%UYG028"Q2J[*F_J]$T', RVV*6PQ')2@;NI6@!K@"1Q @+1R5=_5B>:B
MV^O6&RQN%"_Z4S"1Y,I.X@(=!LKNZJ9]VW+HUT $;[RVR[%]+PH/LG/"_R:)
ML/"RE=>RJ524;5,C+T_=@H25Y2T9VASNX..&< 20/L3/^<@D&"G)K@K :/#=
MZ"+2]%*WK$[+Q)(":>U?2JTJ.]HZ."9\!IK!H8>TUI9:<,_+@/'T(; :Y$V$
M) .;[F_S]0R[J>Q%I<D=IX:[4 _CPJ+5"E ]Y0WO#D1I*A)J$C(W)RH8SJ/E
M/=XV03+SF*5./00,8R\Z)UZRU<-"&%ZKNDRJDMF.[(9"^$@BI<%QL+&7\JD>
MMV Z?;#ZQ!BA"?2ZUF4E%4[8:>XL2U&A;5T%L(=]SL[3K<=]>C%710H]:"X[
M' ,[_-ZU"5>XE18\P6];Y),Y'<W_J!C\\END)?].E<"80 2OUTJ;('<S3@,6
M:X!SBMIMB0"2PM:P) =UX'4$\NP?Z+%)39CP8MTT0X!>/>X&&UF6<&26EX#R
M!#L+[]V=D^Z-G!%C6@D0@R%K?MV96VQN1YOBS%K.UGU5>EC &:N/5TFTSP;M
M=;SG+#_F0O *^M+/08^K*I6D\1F-6('=#<$TG/(741"##ER63Y%P3D>V:ZZS
MOL3H(M:C9!6U;$C6]98((_/K#I.')6]93?@H1F@"/]9S-(Q: ^W/\54F3Z@;
ME9@=<_E0HS$8WYQ8UDDI6QKVQ#AFMQ[#.BC</FR=!2!+>N2 W C=0QEFS@)!
M&MAG1L/$0F=QTOHE,MO_$&QKCI($!4O34WB \E+T]N* C-&RS+;F1(4*BE-+
MMGN;5!D:)2 =S"*J<R-?=O6R(\362'L[1$5PR 1^A$)TH==20A3_2M2"]<]X
M%-%XIW9JV)T42K3HDL1LIPG1<EZWKCJE1T'I['T:]ORDAB9$-!S$#[+\A0YB
MN X.0TU"9+]-L$PO<"79ST#7A[B-="CFTJ<!=HP30PN=9G&\MY![LY#9"PD=
MM4@$'H[,=]J0$"'I%*HYA.'MD#X:'E-'(VID]FX44_QE)R8=H[%!H9<("(K-
M,7)@=7?&4-) 5-@846T/!!:G,5_&)[2*+EJ0[K8QG4!L K((+0RU:99Z]#$,
M_Q\;$\86S9-!0.Z BO($#YV2;!M?BRL>8_.0HD1_#SFF)Q,VVFU])PRG+#D.
M*Z)\(8^09=DQLE=/7F"':#) $CCL%"3)+HA*?U)'M@FLQU-'.E*%F4F%;=1%
M=M-+!'J SG*3-%&\J8P55RV%^BP,U0.ZY35\5AWYM+3^H&(FULU#IM5,&(>_
M@?722:EEKD6S)"[7JI'\2<:59[JZ!Q:)7)RC*.R2[Q1O7&^L.OF(X(NIO_.E
M6Q,UTT97KLV/#X<:D,Q+E@<H(9P5ESGRA5$=DQ&K>H[CL&"N[X/^=BM?.F8R
MU(4RA$FE! ;,8<VEZ(.RLD/K,E_,$C9H>FYR5.ZS$O^.;?.0477IT=3=3<Q)
MG#5ZP^\#(IUF2J@!RZX[T&N<3W+JLRG#^*HS(Y=-J]GF0\PM"14EL>%.4Z Z
M;(C(2$C6,CAB"Z5$D1Z.0D$P$"VA1>&E=L)OA=L5?60'4C&S=K RRU-=BN=U
MMU['OY3=G$*'#-(#THH=WYLB$ED+E*I5*$5?FV$/-5G.1]5*^##H8;B'X6"P
ME.A5S[/+/ >]Y6?<4([ZU1<23]7[9JOPP5#J3W>0/'L(Z%'6QC\<>U>[=N>%
M>"($841F^'0.$#'I"394?SGKA8J\,0=H7[XN0ZP]^EYQZ^YOR7MTX=C'"7Z;
M['8WX201[B,<^6$,!*<@C1,(4$_P54VWT>7_=_\8'G+O7._F\\8@W<C!\$:G
MWZ&SW>-UF;XZ2]8A\95E!3GL(G@Q:K16:"9=#G90D35 Z-M7;Y_ @OL0THLV
M$.&^A?4>+CS8<!\]A 2C$=PW+]@Z9![7"0,I+%@[90@-,J1H4>5 @1+I<61W
MC%VPFO*"X627K*% C111-I38$BA+EC]A!H58<:C#B@BA 37X<JI#@<LN(LR8
M,NO#K/LHC4E#9DQ9LFE^ E6[EFU;MV_AQI4[EVY=NW?QYM6[EV]?OT"7@0*U
M+)2R4\J@+8,V&)HRQ<N414,<JO$RR<M,/1X<*G"HP7SU6;;\MRUAQXE1ARVK
M9@S9LEA=)I08=1_L_XD]A5+46"\JTH:[)QK4N) K0Z] CW/51Q#BRZ"W]XF4
M#M(FS9SS6"YSGMO@R97)@MD4KU,\.V0-84>[>A#C4X:TCSJE.-2GUK; ?U^D
MG='AS[03'S)HJY7L0T@9UUH;JRQ*2&O0P0<AC%#""2FL\*_ 0"DL,,@DZS R
M4!*+S#%3E!%1F<*B 46RPCP#Q3N\HL$*FO\@U"0:%$_3A P%Q6IM#$UT ^H_
MB6R#R+_B4.(OMH(D&HI&C.K1)RFH&F)).1I5@A(AV/19AR;K9KJIHV"$288E
M K]:"9F:UA&3O'B$B2<8*_/[33VIYJ,20(VRNTTC[5J2LJ#AA'PN-HF.;/_K
M1?8,4A#!-,9@T,))*:W4TDLQS12O93H+1;+# I,,,0Y+]/ PR4*$S%,-0]&D
ML$T=LDW"%#ED;!E-RO+QK!_UQ$VI^J!+2:(7TQ*P)3YG6[(MKP0UCM#:@I4O
MI>6B8S/.Z:IC9YV.A)G'S *=HD<?9=@AZ:9KMQ6339Z^FC;(_K[R+RNNFG*/
M*]K2NC/*M0@REJ7>D.N7*"4;.K!'LA &4M.%&6[8X8<A?@O##$\44441,PM1
M8U*C(5%4%@FCV*[(:JL7PDV@P5$R4';<U4>%A;*(OYG7 A1::G]KUCY"Z7S7
M/IP5NBBE_X2;J+FE]DT3I6OE=%,\D3XJ3QCSVEG_4QYAIOLHZI! ^@AJ=HP=
MR"N"%SK3*I1\*[C*KG;^JFREMXI[RV6=2[H]H<&MQZS5<H4YXK\!#USPP?,*
M&3-2'Q.Q,0\5,U&S& ]C\410L"S-H44CK/@RCXG)%6%(R5!88(JXBO)MNHQZ
MSMB?4IJ1[;7K%)0ED]G":+V&YLF::ZC7(0\GG+@6KR,XX=S]=_%":MJ@GF_#
MN2?8GJ76^9;NG)?T/-&&*[YC;Y/(IZ%25R9!'\=@S6_"T4]?_?4=OM6S4% $
ML?'#%Y]L\8U+-8PP^%VDO>:%9!4A6H7J-,I@S8[VUAK:Q"L_19,/0X!6MJ8T
M!3]"T9*O!H4<)J6)3_I1_\ERB(,GB7"D>"+Y4DUX-QVFB>1JXBF>=9*7PG7P
M9(+&40E,FN+ !^YP@7A3V\U^,KLE]6MT#:'-])CU0;9L8F^@*PLQV!=%*4Z1
MB@Y*D88R<YK$H49QD$'-8S(SF(IU9A.?@<M)8E2A#85H10=R(FO*EP;TZ"DT
MN4'3?L#%0+$5B%I'5,K<[%@;8&%O._-)"W[^(Q,PN9!-6AL)U[Q6PI%(,I+S
MB%=5BCBT^2S/A_O:#;6:5+GJ20M>"YR9W9PRR+!=A$@-P54"%13 *LZ2EK6T
MY99P ( #A*I_HZK,+^?7&#9>+'(K<A'FU&(9WE2(5IG)8C2@<<!<D<\V.DR(
M]?_T>*8S":HJ&:2@VWSER>* 4'I94H]&W/4S[RUE(QUQI-=R4AYN$4^%,=R=
M/44R#*D@2BW\28MWGC5'(P82G5)!I-+J9,BU5 ]Z!H*=05Z)0->0 9ET"4Q%
M;YE1C38, !WUZ V@R+ 8 . &G!D,K=C812[F,@;0A,Q+6<09_LD2/0M)(X4V
MQ#''3$*B/*+H0@_BO8A<[UW'V>.3A(6;G\B*G\O"H))FMCVB((0C]_R(T\@3
M0SGY+IXX>>$Z\A$S#4JIB*,LB@?_B"?V.,0BLO2C#_7$/-=E2:WWX='X=J27
M$W%FHWWUZ\(\&E@ B(%A'1V#8$Q*JOIQ<7$=C4%C1I7_,<HHAD5EK&AH %BA
MBH$J99&)J.<@%5(0$I%[4DF/1OQX3D.1-:BD9>T^YFHTH8#P*<R25SJ)NL&"
MP&8>D1P/\J1#SWO&";C#E5FAW/,LL]ELF<C-&\[N]M3M 6HVP''2/IMW5+3=
M"2OZ@*-$%Z07_OGOK^4U;X.&T=%,("03'L6HA8C1T9.\SS":D]\- ( &RR!&
MO9;YHF,VQ)G#G*)5)L-*1LA+FC4^!C4Z AVD7E;7$,(N:'"E:]N@]18:?2\X
M;#&;42_\)PZJA1Y>HTZ8%BDFX:Y0N,@H&BC7 BP0'W*4=71/DW[VG^:X!4OU
M(<Y!"=:3(*/'+$YLS?GHXBHS_YZ7R4W^2QKDVY#XYE=3[06 1B9G&E!%IJ-I
M$*9_&X>JR'B,,IMQ3*L<,Y\#OU?!*M+0Q0)#/H25!0Z A-=*<,R6V*H%MT$C
M8@X#RDJ&D-:"0;D3<83:/.\IJR"]35<\:U*3%>].DMBRI ;7%@V9%1%V9].-
M_U#IO-MQ$%^RW<>BC.4<Y0!Q+2PQ6!/+@F2Y=(K-3K;UK=TBAHX"I:.3:$@F
M=-UKBJ#!HYG [WKW(=^1^EH9P8[!E$.J#/P.5M<QD/)(\SL& +0TEX%-@S*@
M# !4:2+8)-4$@'6=B7 ?0!,J4AN"*S08G3;N++LBBZ36FL$' F=Z23+=4]I3
MP>T8I..'A'Y.GB=<V@KNYCBA?&")PY2M1=*SA!3/R7E^ ["DULPG.J-6<_-]
MW!<KU-0%EX]9M5O: =5PM^!ZY7<C/#+X>0;7-;<Y7$9Z UX#P-?[L')@T8"0
M<@?V),H0['JQ+5@#";:C.O<YTP<;C:2K-QIA(&ED?AY8%YEBI <(; S0K!4$
MWU1"O%Q18C)SUWJ/ =4%XO?!!P(PH"I+9_(:M*>) SU.7O.#.11ROQ:=5L&7
MV)Z_C?1O@U<NLZFE@TJL7(:=J[,;:J6@Q^FAS?P$6];Y:IWO.M/F-8*KB?9H
M##2%2V>6?/]SU:]>V%(6-K1AVU'"3IFP]< V>QU[ZGU,0KVGSOT^\*N"DU@9
MV;_O]AN6<8IJNQ0:76Z,8Q'#^_Q:QJ-IB,:T#2>VC.P90AEZZ65"Q!II^B@-
ML"F2ZIS"3D[S1]0DMR&,9UO:/!*EU$S9([\8N'>UJ.N$$I<T[Z+FTN(.@D[N
M.=*#PQ@M0.0C40(OH9RKT*9*\P3J3!H03=IE(" ,O/)*YOAG]33*1CQP+J8,
MV7 / #YA'X;.O5!PVQJ"V)Q.^EY$]AJBHX+.Z ! 86P0BF"P!#4A,$8*#1RC
M1-0+&L+M8J)!]J+!RKYM&7+I /3'568$@!+,+WHP91(#SJ!!1\K_ E*<R&\2
M3FEHZUV$!6>J:<)6+6ET@RL^+]$0RJ"R!T"V \= +AD>[?#((^(.+](P#GO0
MZ>WX1?+<8[N2RI/NKEGZ:'2.HBKT14B0)#[XPW5PK%DD8L[&IS7LXD8\@S!"
M\)8"8Q/CPLH6Q:,00K!B@+!&D><:8MD08J1,T?< P#MR</=VK001 K^<;@5;
MJMVZK$.L[-SPZ[$00Q,ZZ@W 3;XH8P4&ZQ1X:1,RJ];Z0D,0)V-$3U?ZY@WM
MZ'0,4+<"[GH.ZO[:YED2+FGJ YU.AQ 13N$02B, \,2.(?%.Z$O6P9(T#:[H
M)6>4*#_V+(#0<)-\)F!VZ/YL)VVB"SI(_^PK6*)S#F9O9.TME(SF/-&66N4A
M<VT62Y#9HDPM:! A8"_9 ( $-S+83D+Z4I$%<7'I2,HAX*"C>C#M.BHJ1JJE
M(H/87A$:EH_+ .#;9(HPSLTAIC 3!$ & D &?E( 8F H@5(HA;(HD?(G$4 &
M$* IH5(&G%(JJ;(II](I6: IC7(H8R KL5(KD1(KE;(IO1(!LM(KF3(KS?(I
M9> LS=(I8T KE=(MF1(L!: I#T HWQ(!F+(NV_( 6" IF1(PHY(HY9(IKQ(!
M).'1=.(=K65WA,%R,BP,DP7RQ@IN;LAL#'%+!@G/W&(>?<7/TD_?%@\H0($:
MR^>)ZJ(S]D<B;?\I0UQS+6S10)S-)(,.(P?KZ5K2%5_$!M=+)@$ (62R1+#-
M%%]R'XC! 'IO'R2AHT"A!T&A)O$+!HB!")M.,I13#%)$&&_P[&(**TR/-$Y*
M1&(D,20#CKY+01H&2=:'J^Y0GE LX@3P130S4"IH4%0KN28B$4<,*T2,(HZH
MB%*'(%T"Q/B.#>,F+53#R%K#&2EBKS($%&*SEJ*AW2:4(J#N)$=2L$)JZI1S
M!322(EW1HW(N1+^N(X7S1 $@I+(N^48*!R CW+ZN1&P0^:P3 #)D@#SE.3MD
M0C(1P$2$0^X*CLH"<]C34) 4_3IL29'D2 G226,,@]JBF_@,(4S(#OW_K_\.
M#TX*)80>SP+?(L^T(M4PR('N1I9:28B(@B!Z:)!HQ'4<12Q:9@RF$"@R,1,O
ME)9N)3Q#T 9)5 PPI]G^M&"4,P8F0==,420IPLJ>[=A:4/:48:1>!-O08,I^
M8]K$H#"<3S'$ -MB  BAB3N'(3&J[:4.YT2R;U9L!#-2Y.PX!5?&+V&2=$HA
MQ%]F59.HM)M*ITP?<$DUXFH*;R82[[=*2![FA>5ZHS?.20[Q<SU>:W32HC09
M+K<"IC,MS(^&@U#$L8A>C7QBC2XRA']"(4]K:1GLP$')52[PZS8S)1.5D5:8
MST.$25Y-!54'+# V 5TW93PYQ3$\A&6F"8'*_R<NCN)M$I2U3F(I1!,T3><_
MD0++!$U-1<QAD^BHCJ/";,Q(O)%W#.^WO$IW],GC/BD"+9!VBJ4KW-2A/*UA
MV8KOZC.H -0!5RN0C@,AT=-'\.WT,M'[TI66"JQG[V)%2U!?(P1#-@2EO(C!
MPDQ$)JM6."54\!1"*L93/F1%5H1O1@\M[ Q)ZK2N")(^I%0N4&MFL4M)82M*
MZZI<\&G2=$<D@D$ 238-";#3&H\]_ Y<>J@-L6<HS*^3 N64]$C^]F$:R0=2
MBD$N)F?FB!9H :=5^)1Q@<)//8I=%R8:RDARP*]QN$C,-N=PDD]_SDQ"I=93
M(.-4$ <:*,$U%$1!7O\$5\^*U8"&\;1"FQ@HJN8Q:&0F.P2B_K2DCC(6P0BB
MNYA#:/Q3D"20/Y"AQ:RJ:QY):XX5(X+F)*AK@S0V0.9Q(905/Q5"8RUBKM@4
M\!H66#Z/0 7-B(C&T#;H*@@.(6#.B<@@;]GB1C;#,[H6<@-G,=S-?N&BW$ J
M8KSO1DXDI8))L4PU1&0*@%_E030D,5[JF0J#<+UU(>],K<XQ>$V-AZB$'ER$
M&%Y*C(BA,#CXF):!@XE!&5SDW&@T%$I8&8JA1%:81H,P7TU8&<X-,F88,EK8
MA4\D#]MQA>K0ZB(!TH3AHEB81CE8&8[8,4JXA5]8AS5$B8O8A6W8ADM$0U;_
MN(9+6(R46$P#T67!5FG.I*'BEB#$!Z]R10WBHA["]7T>5W\'QW(UX4O=&'U:
MA#!2"E4T=VDE(XS*\V@=]T%RE#,RXS(Z),Y2$[S06&:OY_P@:'0V#G;P(QI:
M.# ^&(DKQC%<I(7S=3! 89*5(5_S555,>$.@LQA H9)/Y(A5N#!:&#H_>4.4
M84T@39X@R4L6 0 6 7F&H41,.94+@Y,KQI4+(U]7N6(^F!A<Y)=-^:(VV929
M>&HA@Y-'^)-GN _C+SWL<6["AFP,Q> &%T'63H(?=*8<<HZG2!GL8%S-F8H^
M.64(2&DWUY<XQ8 Y1$-. 01)HT(S-S(FBS%" 4'(_X\LTH9TBH6=N#9+NH,[
M(M>$/1DZ.1B+1;B$F;E$HOF8IWF*)9J77822@[ '@_"(.YF&^6\7SB ,%*&D
M(R$,PF 1PL & " ,Z D9;@63@Y")+YJAJUB)!T.B-[J(HWF$,?JG=]J2\U65
M*9J# :0?_7%HZF,J! 8V\"@E5 .<R^)PWR)<L;J-USEP;D6<;XF=O*.[M'JC
M.H.? SAI%XO!1H2R!DA%;J5!<HJ!MVR_+(.G5A=!0NHY/LRI,FR@G<MF@-I%
MQ.BE2F23(8.8<9JF0YE&!^/<#/N4"R.515F,(!NG-UJ6N<;J,M2C%D&%.IB$
M!?NB'CB:F5B+E1F)?QF9<\^XL2>ZB*4YIT^9FEUD 250KQG-KWG,;3 B5\:B
MMQ7H+2 T5;=ZBD AG6])TR:[W01#R<KH.3VCW1I2FA\#WCC1^X*4BQ)'5!@G
M<9*/4R@C@?WBI/@U,4PW,> @@7Q$#?SF\99">@HJ./YL;J<*DT$;F6?ZI>S;
MA2-;A4/:,4HYIW7:AF48IX_8HR]YA MC'2-ALST*IN,I&9#9M0^;EY%8P'-Z
MIFTZF2M<C%38ADW;OB7:HXU:B1OJ7NX/4;9#FX8*::(%G8B!$A528MY'7(?_
M>Y9:171G*3 TX0XRQ%5F[L?7^,??!Q0NM\=O'+KI*T;J-V(ZHYG@6:7.NK.H
M=K(2ZR_^=ZV5%E4-1D'0,Z_]4:GL")'J)26HJVBB@:<Q.8<IF;*7N; IFJ$W
M.,W=7(Q$O,.3.;]WNI./J1B0086" 0!@@*O8(1ZL3A$\NY+S/+"#693O6\,]
M&)9G>I1[L(1E6*B1&)@UN6*@XSZ3.JDW;TG#Q61>24[)1YP3US3XJL:IJ$)[
MD)8T(9UGG+Z&7%PC=.;V9^:"'-<]HXR0G&+(;G">DZZU*)X])',)^:S+>2_6
MB#/*DS-.I(]!@4@]1Q.(X0O#5& 0[3E8_!\'\-0H_UF44WFP#1S#PWV*.3F$
M[QO=QRBQ(>.8@]"_(6,=V<'J=B&>8NB6SP DCF&7<7B4<[J7*YJ%-UJB0?NB
MD)FG<WAJW;RH13F$9[C"=P;E+*(;L5V/MAV;EB%!5-='PC-DQ!6\57V*;@0.
M%O=O=/S&9WQ^474S-J36.5G79_S6A9S(G;O=IKMQ-\,* WC856JR],>M6:7D
MU\+[G)9#E#9&IO& TH 8J+U\P=QL6Z*:_@BZD,.HE[BG>]F_,9F()WS2:3H(
M+VJFLQBD9_K-?+F*@4<ZVO$&(J&612(28" 2/%NP"WR$![[##]Q%-OF2VSPP
M<GB8+;G-87N2=WH96CB!]_^QVR-Q3+MTH*!^6!)HSN2(+3IE?G$\Y-DY%.!@
MR=\X1H+YN5LE])V[UF-]LP(L0LOZ3F$^)3NRC"R#\TECI$AP'RAFOS+WE[3H
MNHT^,CZ7&>L"OR0!/4Y*-+X(5$Q#,ARLU(FAA5\7_RYPB%@N28PF-$RXA"5'
MX$?9W568P@=<J$GX@24<52OYB-N=FA->AJ?FA"AM.JQ#'K;E=X98X,-^H\]M
MHT]Y3ZV?PE%Y3X]I^P&BF#)0RT I4T8LE+)-R@0:U-30($%BR_99O%@OFKZ+
M%NEAM%C/8K1Z&_>5]/AQI$5E("U2&D,F#4R98\9HXLA16:A0!'>""H4SJ-"A
M1(O_&CV*-*G2I4R;.E5:$.+3J52;1ML7+1JT:,NX*ORJ# > L6-Q:/K)<]G.
M9:=V^EQF*I3:4V+&HCVK29/"BE652AH;<E^FN@ "H-&I+)JR-S'(QGBS#%IB
M963)XB"HJ;)F-!?_ B#&<1* &Q<51@L%K> RMLL21W[-50W,FFF*:2*FB2_1
MJR(#7\V(<V/@P/J&6]1=#Y1 A0(I@J*8\"#!@PP5ZDP8W7E!8LH*(H8^'?%S
ML =#16^(+!@[]<&"A;FT?KT\]<?B(ULG#+_WUM@7'FQM'F+2\:?0=,H9U)!_
MXK66H'D,7K?:0,M0-!!+)NU344D?=222AAJVQ%M&'UY4_Y(^LM54$QECR%:,
M4&JAQ5-:?<U(8XTVWHBC4*%H<H=N.?YXHV9CQ<#33Z <&2-B;NE$T V%G:)3
M6S[QI!=!0&(X5B86H2$D5]" TIB08BBF3&9"QA -ET*.!1HQ!I!EH46B 2"2
M)EQUYV5K=Y[2U5[0G"@;)1!MPAU.OUE4'$<EDHA58"9=)1QOB#+ZWW,2&N3=
M0<5,%-YYY2%DG7841H<I,<I%Q%]!FW979D'LL%.?>F$ L$@P\0AS*W[XQ1/,
MKL(@,V&!K3%H7H#;J=HJ=0@QN$QNF"HH$$,&^F?=<ZU))%!%DK:4(58X!<87
M<(XRND](^B!G$3&SR:9B36H(Q?^D7#^IY>.5]MZ+;[Y)[6B0OOXF11D 6NX3
MIH49 7C6)C^9Z58HC=WPUE=JN06*PF=U=6,F8ZTT%FG[I'% =V".=1@T9@(
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MX+0MMCA!:<9'$] ZY/^C?B6;)IBK$\%#'D45W'9W6IE3*]1[NN7R_%/Q57$
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M1:NW<M^RE?HDTI,835\]E3+WJ50YDZ5-F 7W":VG;U]+AA)7:B)&C&DQ3<5
M-46ZSZC!FQ.K5LV$P($#KU[!?AU+5FQ8L#C$ECT[%JW;KV??&%0*K>75A/*"
ML=L;;!<  ,&.K1.V[AA?P+OZLA-V4*+1H@MSE)41E^WEMF\O;W;;-FY!I72/
MKD2:E25>@_0,JAF3ALP8V*]A:])8V_9MW+EU[^;=VW?&@0)!/?Q]$2;,XLF5
MY_8()U3(DA]#II0NL9[-:/\T9=+$N9*[Q((XKXN7V'.G2X1*L:-7:?4@L5!-
MXS,EMHG@P:H)(Y=.G7!R6QQH0T@9M<!*0RB#E'D#+(6Z<B"-@W 8RZ TX$(
MPGU40PBFJY0J#)EU0!0&!L#"B"2272() S  Y!$FGA?G(2VAQZY+T"S+,#Q(
MF0J]P@&4JO31A$&$A SK( <=4(T8"P6$3"&CD-//IH,T@2TVU](8@PPU4%ON
M2S##%'-,,B=:!A3A[BMS)Y'6=!/,4-#TR*.03#))I#G/@TDI#LMK"3N=ZC*(
MIY;"R\XQ+^\:C33UB('**66@4J8^!*%<Z$^Z-"R0K4H/ FNNA;Q:2!D$0!TJ
M+@K_RR(K/X5:TG">Q0X+AD5:68RDL+X:NRHK@U@E%3-3$1K# 1P8$E4A)AU
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M,D V ]Q"7T/!L<HYGK,-CEB&4_@\S2.7E\BR8S,)K)@D^HD&8LBK-) Z"=1
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MFRUKFH6666B35?9E9Y<!-RXHVJ:VC"9,,N000_PYZ=%] 5XJ((DF*=8?56F
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MF?QL/+. BJ:KC<=K>:E$X?/;N^T2!6LME\'*;N4GW5KV2[#8FE:HO<"]F<
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MOO1H3(%/:E95N-DR'.Z4/>XCG_7TL90OT46)\X-L4=GT+5/>CR -&LS/5HG
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M2JQ^M4T^Y=ZT.J-N R'<D4[2AA@*=J)CU4>]TT>5^"Z;IF,_HKOJX:T? O1
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MR68DD'\&0E.@LF7UIXRUVTZ+44D'3NHK>,7:%Z!9%\IUX9WIVD=BAB-V&)9
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M1$H)./B!]P&>L-P7ZW&1C&&YH. CTYM&GJJ(U(,^99C!I((*,J"T?O^$3+1
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MB?=I5__7]$R.]0Z=I GUB<M6"I$QB=PKQY>0\1)7_#$HZ=#FY)%V_-FMTYS
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M&_8\]"N,A(A921-0@-9=H/*Y9U<^0:W2*:+IKDO$5/!S""5T!LZ!Z#0ADP!
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MOE$%4T!=U[!$2A!%J\0/@*2374W7"8+$ANC@1)$(#S($-.C,#PA<4M@( *R
MW!W<!87?W,W?W@G>VDW"^ % VNW##< =ZQG0FYE.XUF&;,U9#(609P"5D,W9
MRZ!%MO^P# .U1=#Y7VW4AA$BF0'51H$9V6I-6(=<4QCB2.+1A9?=H;"@WG?,
MFI?%WD+,B#=]D\XD70_^%B@(#0O.D23>14>L&_(QBTO !/'=V(>0D?(YHMQ1
MXJ:Y32$]1)R8W;/XUMR)'Q.& 4)T'Z$ P!/.W2O.G> A!!8R!/FU(C:Q'@/A
MGV--&V'M@^G 3FV0AY*ACYPUF(51WTTEX&#!&6B%6=K5#+$43[8QF%JLWEHT
M6Q018N595:0\D>3%2.0A$(.XH1;M3%B 8BCB#TJ8(B!!7T,PRSS9Q P^FOPP
MBZ;84SW"8T8 Y+V=4WT\A+<%''C=B,%)0D(P7%FLG]L)WL/_'=P3)L02KMD^
M=)]%)IXW2A2,_(1F"<=M3,*"253DC1*52! ;-E!A09O,"%B=U8-GN$MD?)[-
M&$J2V*'D_5&C0-C,'):2D4>I193*^!H@XES*W2%"?%IX)52X!:1<P0I><<H[
MCH0E7IV 2%W3^(=_5"6,12506"6FS0>P'%<TL,BWG4=2D!?YO1)&0AS"$8I;
M+H1=S%W?P2( 3*$TNAI[!2.4G9?<F8E..M)JB<>#)!B#/=@!RI"M-0J)T8,.
M44X9:ME4H"'I.5$&"EB>043M-="%=8C),9"A[$R*I(@.-&)8?I'^I.:%T)5$
MN U;K54HL)& %!]M<@I;WH]J/D0@_X5B'X58NO58 /680F#A5#2<%%)AVQWG
M([U?0F A7E92J2FE>%#9QI4DE\&99TB,S$688,U,S5 +HFCG0WU+Q\W0L[GD
M/L#<31&*?HT$.9*>D46>RL@(12'B'RJ0 I%97)!<:,H%4%K5A2U#J.E >*$<
M;U)/[VW$*%(%);+/J>0C2XC/I#6=/[Z8?"JHWH3BIY0B1'A;*H:%9<9E*\Z=
M 4B<7N[#+*96]T&<,E DPA6@?D9;9%2&?'&F1/E7F;C++23(WVA9?N*(GBV;
M0IC.8#;"7>S:7;A)>Z+4$[$6>1%BFD5@@D0*H]B?:87F'W:@ =D?;=E(.)5F
MM&PH.14D*/]PG6N"8MNDQ"FD$5M%S8&0S4#6TTB,)3S>:8?EBHE!!,XD5(JT
MID4D*% 8#\WI&5I060).0GYHBP+%'&Z,5@1&A=]8TWA0&#U\1I+<0L]4:AWZ
M%*%X%DXN91!.WB/QI6F]UM 9ED_.5A,)&#EFT4$E5".5Z1<IPR: 2IZ6"M9D
MQ5:&S[O)(&U.WZ:X(/#5*H(YHD< 2T00 ^ZEY1BT)&;F2'Y89:1HTY2>V6<
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MA+_I,VK%R7:V6]?352&7LX5=O;D%RO!<+(E:]33^O&R^?9F06?CE])*AE^3
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MLBHWRHEF,6$6Y3W>S=VTYR5$[*60C&R*Z=;.[0%WSTS2J")D,"43 U[H81C
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MHN&ZU+XZ:\%"Z;FGQ,Y=>T3-CXQFE*/Z9+DKU[R1G;%D&50UP74[ZX#77V/
M5"6QI]5*K>XYSBDRZXQ2Y.^FBC5>@JB1#K[;B$"0++_0"V5I.B\-1Z^X'"-)
MQ+G,,_"H3SUC\,:9E#IPC2Z_K)**9S;(*P3&SY(D)/\MOCS=SW(,?4.OW2\>
M$A$3P_:J3[[R#[08C5%FZU]"#&HS&HTG%D\RNBH,_%Q9;,Y',_/]ZIM(-E\>
MC9N?#!,?H_+7S_Z'%+P]-E=XJ99Q"L.O3C#V)Q#$'=9Z96P"#E@F6[N6=,)7
M>N%!'JBA$8ZV*^W7@ ZX$((1>_!G,8 A),;2,FA5:ZO#12;%&5,D5A1V7Y@V
M<920"93@:(XV<4&D#&/D)0_X@C#84A0Q&JT6-ML5@R)U@ZP#4ORW&*W"?#@8
MA$(X-AK8&7;F0"TVA!'1@ZL##?Z1?P1A']ZEA%18A0KQ1,B'$8FW358($?A7
M8.Z1A0P1,OO1A69HAJP'._]7$6YG&!F@D&T:A&U02!E V(9V"(.SAQ[C]E5W
MR!"*QSJ8(89-1C%0V(>&R%TNE1ZA=':'R%%P.'_^!WT8D26)V(B6F'IJI1Y9
MDF"7R%--%&M_^"IC!1B=\EB*@6=]ZV%@=6B*E[1!@:%@^M$8@LB*M)A5,WA2
MSB>)M?B)<G@1/UB(NQB,2Y0\]&%=J*9SPFA),949P0):%7-SR1B-F.6$LXA*
MA"B-&>5%+;@0L?*(V/B-^U-]TS<:-LB$X(A9QEB-Y[B./I=R\)%2M\B.F'4V
M\EB/IZ2+-&B,WFB/^O,_T,B/ )D_^#@:#C08 ;E19'20"ED\YF@\0:9$"WE-
M(161%+E*P/@09/AX%7E-X[:1'GDLL!(F-1<*X_B1^?.%)IF27Z)^0Z)=%ZF2
M0S)D,#F38%,D9J.#-)F3.HEU:X<@7K.30!F4PEB&0EF41$;9B%_G<$>YE$Q9
MA7:VCTT9E5(Y<'(VE59YE>S''U")E5S).L3PE1#9E5[8@6)9EJ=4#,3P#L20
..A&:I$"K5EG#)&0$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img43903234_1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M&1,-&18!Z1%"2(LNT8I#J!(+.1 /F1+* (16\8]&H5.UM7EV\W-'!&)N%$N
MR'9!A$8_!'/PTF351P_&A 8F @KTT(>)IPGZ@ ,F9CL;F E[XWK]@VX31Y1&
MAX@A!4=_EW/SI3-M$BK.,HD]F!4=F84W@(5>)0;[:! >B1,$J85#T80/0987
M883_%$D66)B6*H&6 [&6%O&5%@&762&7 F&6'.%5^A@2=GF5*^&6 D&7.00
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M\09B_U2.)YG07S1N"\E, #<3@CM(&M"0AJP(2[F81)M5M)()WV*$;VP!"PZ
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MR:F[N7 ^UMG"8D2'%G('85(,RTBFRVC&@_NWMH _2=&NU! 6@4/"5@0GJ#O
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MUGB=[=2V)X7)21 ELZA/C%P&-*#!L-C"T)B4]22&53$OO[P+3933&\U3P!A
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M(S2>44E#U#2>7X*&(9A8(I#2E9WAU> <D73/M/^H7/0-!G9H!W9@AWF 97F
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M&,2Q!2+)@,9LN4.DPN8B,@81_S%&Z&EJ\OE$M*WZ(.4X0(P90R;-/H,'$0)
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M,.E]^!.9QQQ3(HYEL7+M\$4[O*B_9.$J9J0IC<QZQ NP=$49N)F';H9!/;>
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M?^H5[OUT)WR)8?H8* /GO-/GZ[5\D$P05)\Q6/-"2)]/*O_<]*<_,WOKP58
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M_=KO39Z.)OXD$ $%4 @E*MA-4J E@_*FCN9H+0CMW93!!Y8A$WR 8+K.PMY
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M3K,04U&G?\K@H,86:,+LG*:$L$$(<?1G$WD)9!)<6XC_ M&B#&*42C?](X@
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M5$O8?4W8 +VX=M\'55"E>3!Q7>(')'WB5F#5)M5T7LV(7UUX#KP@ANAP#K8
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M&+6+:'R/BK;$@+:] 'T3FB<G(I5N*[6T84\^)2+\M&VXR6&I^(C2EB""6*>
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M.! Y'B)H4>NQ4T7*41DX34)H"(=7K'S0E#>*FU>:=<2!LPLEEE/ O8"=MW/
MM.L+]$16QT$,7F&B48:LM@-[L*0@4*9HVVEJ,4R7Q!7-Z8WC.:[CP[G> N(F
MM,I*KN2[4??  2J$28%U/<B.;FBZ4)F]BL@BDXK?<\>I1)"D'99RR/@ACX8)
M3/$AR_2N1O%@K&T@.#V*L'P\EHS'S2;=IVNQQ:#7!FS 'AT\D%7:D)E.F#U]
MA2U-V6FC7C=M$+FA+.46A6[HAX[H_XFNZ(O.Z(WNZ(\.Z9$NZ9-.Z95NZ9>.
MZ9FNZ9O.Z9WNZ9\.ZJ$NZJ-.ZJ5NZJ>.ZJFNZJO.Z"$UR(B(HH4<Z]+41OQ-
MSA@R@K%(NF]\(VYHW16'N]8)'\IP5 A^/!SHU0B1@?ML(@CN@5H=)!\W#$4<
M9-'0:29W8/"19"&MU[<PQJPD$6(2#>XPXK0["4DRNZLDT(Y:8<%[HQ3+72&-
ME3%*>SMN[_>.[S(-#4.F2H,<4REJO6#N&-^;CRVJVQM+P8@36$C<3\Y*6<9$
MMZRMP$IY',BH3)$%5%)GX;)((="@506RLDF1"83E$#TUP<30W$,B[K%TXJIT
M"PR60R=^XO_+0(S9;I$I IEVLM/.5J&]KB*T=%"(TF+Y3O1%;_1^:W@@ZR O
MA8@G[4J"*K4-DMB+:M+-L]- ;<4L[&W=)E#X#"% S;&J]VQX:(_:^2$)N;@%
MPEV3T*!K^H[UP,NH,T^"HR":T O$4/-)\J<GODJ&V%P3K.)MI(B#;9NYU(,A
M*,-'K_B+S_@O^S9JR<$GG,)RLUCN+75] [Y_@_%@*\4NOD^(\R?0H[UW*8H"
M\0.90(X]'8N9T.71)Q#), _[*H30Z7"!M>5O$OI6'.P ]CM>>AS43<73S6"0
M-;LU3XS_FD.@L$POWO%KJ\K=%N^VZ?!TK(J2V/C7C_W9'Z+:C,>Q)RSYQE<7
ME)I4IX9<"G_=G3^J%JI^@<J[V8,0;X &T3 /]<L@>/CGRE0Z+_<C+%*4 P$0
M^J+MJY>,WCYE]?8M7#APV;YH"NL1N]6+V+YERH@1ZV4Q%+%)%I6-!.F+F#)-
M&E6>?(BQH<*! ^L-A*A0F4N!&",RO-G2Y4)*8\:D&4,F#9F;#)4N9=K4Z5.H
M4:5.I5K5ZE6L6;5NY=K5ZU>P8<6.)5O6[%FT:=6N9=O6[5NX_W';UANY["0]
M91GSTHL8C=[#FSV5D1%Z5.@DFC0?TJRGK^7.G01WMH1&$"+#F0TE[SL8+:'?
MR] R.W:\4%/,?:$>"E2(<.'BA39K1J9Y4W3?U@/U;:QX\N1*2B(M^M;8RQ>H
MD<E_@^++\+'$?:)=)G[]<_;EGPZ)$B8\AI)<\.'%CR=?WOQY].G5KV??WOU[
M^''IZJ6;US%?NBY[3N(^E+#+S&J:3C.94,,.,@%A"[! S2Y;,,!E0(DP%,Y,
MBP:RAYXS<#,!J5LJH>)\L2@E8I#[C9AA@B/F(V60TV@2XE)*":669M*GP\L,
MS"S EZ*YT;+$&MM'DZ*&$HH,3>)3<O]))IMT\DDHHY1R2BJKM)(LE8JI:Z^(
M;OO+-4V,.E*H)&F2SD<&;X*)H,I6>PQ(!RO#2)_,''H).Y\.U 0.V**!HZ&,
M0!DHJ7WH[*O'!"7+Z,00851)(Q-)$K'%E40\"93?2!II,P0KFZFUFQ!T"3:=
M!$QJH*"$*NHH0J]T]5588Y5U5EIKM?567)U"Z;=E\,J+LXA(JV<9Q\8L4@U#
MUUQ3IM T@^G9R]3,*;O8\'0P2,@4"L6(TS1YR%N,- EEV)@^3:RY0M]$2"5,
M'\U$)!,C;5>37AP]Z2-[26H7.>SJE(BZQUB+CB%#G9MV)V)R($P-59/,]6&(
M(Y9X8HHKMOC_XB5+)(;$C/3J<EC7>@V3*(;)=+9<.%MZJ$[-!,Z1V@$'?+:T
M&Q4#15P^,1+T3S\' L4ZQ1@Z]*=%E1N)Q)4T53K$$RV]-%.-5':P03N=U2S#
MV7C,CDA5N;L(8[##%GMLLLLV^^PH[=)$X]_FPT\T+Z,AIL@QO]NLM(%IPG'4
MZBZKT6_);B2VI>90RZ@OODY;R X)HUE&$SMT7F@3YUZKF<?5NBP1TD>?;O$W
MI-N=Q%),2S)ZWIX6NHVUCU7_%/ &A>:[IL%6[4X-M'/7?7?>>_?]][)WE7%C
M3/7::T[ 7"IY8:&("3I'A;"^#%W!$?5WH9RT#E+P4/B$9IG%9LH(_PYE!H(#
M#L\H3^W[\LOO^[KL-/4\ZI&T;/=SDCC:B"21-B>F:/=99TU7DYW45&:G@\".
M2-TIDL. ]T (1E""$Z1@!=4B/&5D0F-KFU%&\*.FP""$&&(:4YGNM*9ID:I/
M.,%33M05/AQE)!2:B,.>[!"*\BW#,W%P22C>D)J?#2D.RE"-#OTEG0,IY%)*
M\QRC'M6YHKGH1)%*R(&@)R#8U:QFZ2H4:G8BIV6HRC!IP)T%S7A&-*91C6L<
M&S0VML%=8:IT';M(3TJ3GV481DR$N0C>#+0R'_4--UL$9+7LM*.JB4HI$8+#
M#"%RFE"A3URIT43C7%,M AWD,<3QWZY0<BRTY&B"1&E  RG%D(:D?9)=)RE0
M](BVQ0=-AD,K@U-F%D@W[[!1E[OD92]]^?]+]&B$@QO;E0;7EHGDV"=Y@P-3
MUXQTFID5$G!2(V!#JL<@B$P+C((+%49PV"7(#<D.X$-((_\$BCA<2"&*BT9E
M#C7 +B7S46F0!!J<*,IZ3D(EDQ"#/C.!3*1!$3);[&*/!$8JZBP(98,2X[%:
M!4R(1E2B$Z4H186I,4P9\Y,IT1)]_ *8>G@ICWLLT@JS"3O9E88VKF20"RTC
MS9A0SC.."P4H-@$*FS;.IG8X7VJ&*,-)[@21UH+(1N2HDE.*84;WR\0I[9E!
M'" S$S%86UUF-"/G56XZKV.6ZH $K><1"SMA*E)W[%91M*95K6ME:^XVMK:,
MGH1$PTQ.1F:"G]+_]&I.E&"@JBC!+%D*J2]^C(U#IC5+R[P,=H"A$#DA$J%-
MF&*F1&QDA(SP!E"<#Q04(E!!S54=3GZNJ4]EE";$@(9,+ ,-8CB)&)1J-*4I
M[D&&[-#0!H(N3P4R6PN9VQA*=I0TY*FMPR5N<8U[7"AYDH/">^/]\G(2A-S5
M+]/%HW]\6Z2OJ<M.0P,D0:LS$#DMM#.M60P1]U130D6HBRVJZ1W.E\-HS+ O
M:I*,0N14,'T,0[_#B*U<0:D<8IR2&*/E)T#_.Z,$"@Q-#KI<Y10D*NT.B6YF
M16Z%+7QA#&=X+<+<U2>(F1(#;VDOR[QKR!Q#5F/A+FB*%&1U/LLLZ;D3_X5Z
M<U]$E!&'RD;C9WK!Z6:[YQ P;O97!CI4T/@;RJ5UCGXW\*<8,C&)4NI3R5%+
M9'V]:%_KX B;H&G)W AC&-\^5,-C)G.9S3SF#3;WC0'-2UWP^A"^X"=Y= 'N
METW6G 9_S$PP8XP[%YE863Y$0A_!4TW%53[D@.(-<+AI*' L(:TM%C-%AI03
M#ZRIIB*3GZ-T\A0YYQ,&T>0@UT/-J6Z$2'CN8WE"8=A9S_QJ6,=:UA%=<S*&
MIXED\*K-RM!22'T]W;?Y>G"]+:MOGX6@6+;FGPC19U8KI[=H\/=K0H/),G*F
M-^1$(R5P6/2BNY?.!L&PB\=62D@S=555*CD-K/\-,!JF/",H9BV0RYJ:3,[$
MMP5?2XFL'I,:A#MK@ =<X /GG1OEN&9==\S-U/VH8VSBZY"I>E6J&H/#J)-"
MI0QD$CC8!S%N,"-[:@*9DLC$D.R9ADRD!.4PVP<<@J@S'.)TT3_X 1!"$0H[
M%$-"GZ&620=U&2HR*N4:BY!K6W1*V)86E <K;*)(?2?9 :DSKP$S"1VHE;OJ
MQ7C,)'C7O?YUL*L'X<XU'DEZQ<PX(X[A>#5-=XS2'36U$CNWL4Q3,RB&863:
MM)E N9/]_L]_BB$&8"SG^5R.G!F&PA2:> ,0B@"$"IB3AWZK\0 ;PU53>:Y=
M?'?R2#*MC (G;5^9LLLC2'9RJIH<;(L*[A%+-V-+9ZZJ-5'Q]:Z?J/ VESTC
M8>=][WW__WNQ:,S#'=Q2Q_Z25X=_C)D]0==")K'J(^U-E@/ZYR3X+G(Q+ 0-
M^\C^WO=1RB>C' <7&8BXED$A;6<6#HQCY \@4//-NA>'YW?Y8S3YLNQ5)\G$
M,.4DEE%@U6(M91@&46*BD1B]%Z(65).9H0DO>D.(%#,9J/B+NBJ^W!L)O- 2
M9?B+_Q&Q-@,^$ Q!$01!YJK 71L6UCF^Y(DSC& [IABAZZ(;AZ&[@4FB?4 E
M,0"]E)L$)D.#>FBJ'%RM?@H\,;B!QQ T"MDQ";&IFYNA];LY'*NL +(M%T,0
M&B.1^]$$24B#O+N!UA*#C!"Y?](\XE")%ALWHM(;&[F6S?"4__H"L^5QM46B
M0(73N@IDB5W+" U\KMS#"X\:04 ,1$$\,PY+B:W#"Q0<%DVBD\%)OC=C"M@;
M$\/HIBIT)2LJ-<,1B$D@I2!)"I_8,?%A"%"X Q^[N4WH'E)T.<<!'V^ANY#J
M+#@[E-)+NF**JA-Y,C9;HD_2H9/!O%<DFB1B/4XQ#6.!.Z40#7E*)I;X#0TT
MOK/CC,'Y"PI4B:U+ID&\1FS,1K:"H_KHM2Z9$SW##^G"#T@,)*HCJ:+XCA>S
MI@YIC=F#DYIX,O**.BJ\,FNKJ3C(+)X2-/7+K)H"C.=)M0HQ./]2,M?:1$G0
M)TT8AB:2GTVIK\/:,C2\C51CF5=4AO\BV0ZB<!@[K$->:[/\J(?+JQ#JHLB2
MG \^[$AJU$:6;$F77*,W,D%?$XW!^;5@0Z)RU*J.HYN2R0$'0B*IP;@+84 >
M(3+)F#J,V+V7<IQ]M(--T"&7TPD)R3C5>#W# I!2Z\!'83-YRI3E:!'[.8D%
M^2Y_F3YHJT)@418PFS#;,YYE;!_9&!S/P B:+(T06C[+F,;2(P8Z3(Z7_$O
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M1NF\7E@/C]9TALS:76294-O+:1TDSB"4B%\*WW(N1Z/BB\B%'6>]/N6326#
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M4.UI&B\'B0$H=\4AR7$X);06R9$1C27;!JC50@XJ-#(Q9"(C@DJ\)BDN4A3
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M'ROZL1\GT"Y9\!V(P15&DL T3.PDM.V^&#_:.;0CI&C#7T(1@ 3KSN:1-,F
M<Z>Q@-Z'TJ^S-LV%4)MTA,^5CNTG%<4=2<J3&D\X"?409%;2&HY ##LK[#I_
MMCO?\S[?IG'Z\]TJ6YLK]#^OBT:/=T:O2$-AUDM/%H+\]"K1\F11-.=J73#B
M?M0+("!NCP1*H.C\O=:-&PCJO9I@;OFXKTJ#W>6U?[$DH J9]?]#HSN.@8/O
M!39)&L\V1G(EUMYH4R<R\V'SC,\..#,C.H$ DC@5*V#'T$P47&$45O &C] 5
M=C<K^& &)F#WSMX/WCD?)FW(5>_V*Q3S!>'74>Y)V1Q;F/;J"OH3+_K'_C*7
MQ([7II^JP?(IDY9+IPP6@73T)?7"+IS /_QAD8S$7XZACNK'C_Q&O?. NOQ@
M(?S0'Q1*/_WL^?, U97S6,U"\P[8M8\&RC3=3.U/<Z_Y>C7^-/[)\=WX^O;G
M/!PN$I7RZ$D;0@_OU1RBHP9&<1W<$=\ L6]?/8$#]T4;B+">/H$,$>YC6%"A
M0((0D]%+ED_8.F'SV D+QBY8L'7!@)7__"B/Y#"5)4LF*RE,9+)YP>31"QE,
M8+!YR2!*%!BMXL&!$8'N6Q8T8D2A00L.?5C0X-1E:<B,&7,5*R6I^Y01 T5,
M$S%BRI8I0SOTJ$!Z49M*7;A,GURZ<>/N:]NVGMFT7?W^%0@ \&#"<!OY.DP,
ML2]<:@L_AAQ9\N3"8@ HHYQ9\V;.G34#  #-\VC2G"<!6-'5<HS2K5U#CB'X
M=69EH$7/QJVYMIC<O2-;SN3;MVSA@\^>18L6.=IBS.DI:RY6K";JTC.!'0MJ
M;/7M8S\1NZYI6/;QW:>+#=M=67;IZ<&.%PM_6%A0XY5E6I_\N'YB])8M%.JK
MK-+ RJHQDF*+_ZV',/,JJ(K40FBIIR24:J*B*,+PIZ?PHF<>>O1!1AZ!Y$%F
M'GU&XH@C>?39"$5A5"()&))R*BF8=C9*AAV(2*+H(8*,RE HA^AI*$$,HUGJ
MQZ[TJ4BT>AZ*4"!BLAK#*@,9]*HZ_)+CRS&"B(Q*(&A^#%.H,9/Z;ZX&ZQHS
MFN?,(B;,R8AS31E<>G&DEV4:Z8627N0L+M#,;@" &$$/150SX!)EE#!H0 ,@
MAAMB PW+1B\M*)/+,"W(,MXX%<XR4'M#;53.Z&14/[Z:@XZOK]9K;SNQDLE.
MUDS&NO4^3>HS3SNQPMMN/?AN+6\^L>YK;YAC@]4D/UG=XW*Y5C%+ZO_,N=3
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ME)N(MH-6;Z$J.XR**>F]-)C,9;+"BBD9 8.2R3$92I)6@7JLG6M5UUB&/EG
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M'9-2C$GOI;*HRI8IS6CUZD, 6+=RM5BOD:]&O9;U:D3L5M6N([LJ W C(P
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M%6Q99:,?R9BWTD*UK3"U:A8Q5[;*5E*?<=$T0_209V9:,9\^K4(2'2I04;;
M.D:UD"G,2%6E-D>G&E!"XDI+?EQDQ-V(4:L ."I7$*3$[EPPHH:]BDD/&T R
MY4E\XMM;,G04V;X=:4?RFXH^&N>FSXW)E"P!E>+XM#J5X%-.LWP()2IGDYLT
M[IY:(I-)W(1.=9:6)<(0B?C69#IV8J5U$V&)Z^21#-KY;E#2%!ZD&%5<135*
M(/387552XA  L@ZVZ/P2]?@$OXN EKL\,5TH9[N,U:K65J6:$BH]MRIA#LM]
M[ W6/]N+R64D:Y$N&N!6Z.$+_U^()!K[%6O;(E37.?ZG*F+H33V"QA<1F<8
M//&,:-(Z+]J(<(\4W8=FO,6NNEP0JKZ9BVJHBL;+C+A 5N,0V!)#,0X#AHBE
ML<N)'[("BM$5I18K:6]X>E(J>3B!(PZ141KFL!GRV)"0$4-1IJABUEPGQU(L
MK K5<T"+,L<T1.;97!144AI[F%M<,>('VZ,,TZ#5B@_9\B$'^1_NH)EE[!*P
MF>GHK1C8%$'F*A!'Z>RP2;14SA8QJWBJDN"2*>/*@DV14[>JV$4WA]%JZ5Q
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M-FP?"$U:YDNPHI!<&NX>2X@RMB-M5ZA8;:@][_$FXR6_M*@!4$XK+SWY!$\
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MQ8(IAT7 _-JUL-2#R;EU%'$.L3:C-JO:+*2ZYJ^G9SG>Y[-I)_ER-?\.]!I
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M98J:KA3_;$"0S)@Z;VONRB7FSQ85\'JZZ-2"01]$*6ARPZ  *N<XKQR3 S:
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M-R\\EV3FIV>$E3?L,G*V2'.9I705]T[*M6;[IQ=$1HF5F%G9]Y)PQBU:IY,
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MCGPB.:@[OIC2* D1A@2QI$O:OI_2C3B:&_]ZZH9HZ'O1L@S8*,:U;,NWC,M
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M>J>000B%ER:^TYT]9]9D.O6UO.DR5$S!=^.=M]Y[\]VWWX:V#2I22SW4<%
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M2825FUIIAIC5!F9F1L,4SIC57RG>WTM99,^%@A' P3Z$0EI% QPXRB;TXH\
M5<PUT@*F0;[!(:[ 'NRYI&',(:/]45:Y2K_%4Z;E6&@$A?\TI**,HG!(XKM<
MA_2LC3VZ@WN!IFA6GV@JY</YIG>MX$]NA]M5UY6LH _I9H9JZ(;F4F$<88((
M!WLU&#$0(VN897(*B0%97C55YY3H'X/I97;,PS LEZ( "!F*347@QS*  BC$
M 1SP!(_N Y 6Q'8F#[DU(8Q%BUBL4U2]Y^JY9)3.)(@]8ZQ$(Q[59&\E@^\=
MR;*A%F59US^Z2YO_^%7=A>(A#B4JH>;<30M#U)T[&B)Z@<>53.*8.F)/JLOD
M<>B>\FF?@H]@S @B.ISFR$]8N86.G.B0. HQC9)&^$\77N-.0@0[B)Y$T(,P
MI-&-FLM3A!. @,)LZ(=XCF=YA *;+2?2R=:S>%W+X)LR/MT&PM-CNJ2@6=T%
M015;?<G87:9'%=O*(83$ 9X/$:@1IM+T--G1%*A?-<3*<53S,8=T >AVM<WV
M !,M^>FU8FNV"HRF&>NVY%\R=956?,QR.@JE4,Y1 6<UZ1_PP6*=(0E;[D,R
M" ,]=!J9&04RS,-I%,G1#4:0TL;?R9$=&,1IP,%X]N)IB-ET#L?IP5@]_T%I
MB<%;BD'LJL:A!$T5.WV8!$60ZIQ.K&C"%CI76T9$+'$(R,'2]@RE<*CKS4W/
MF1*E.JH2(P# AX:4>977S76+E!74QG%2VM&2W6EKT KMT/;);BVE8'T,B0X7
M55""<02)J) 6&'(:M=E?F(E>-,P#IC:%,,B#,."K,(!*D,PK,AA'?X1")L !
M'&PD*%@&3T@'-,#!7Z;M:80"1A9#1F8DU2[#LC3-&*0(Q'H@-;Y3HKD>Q9[D
M-%:0'N76>/1.6_&$_SS*\B6<RA)##&3"=B1A8.U'G*P-NZ )NX N,>   *Q+
M#$Q"\5 EJL55*X%<]I127J&+;U:')!%M[=KN[?^J!^ZA!A*YUT4Z7JIP%AD=
MI\CZ%_U1FRT"'(-]#/!A1C+DZS[,0[[20]:R0S+8HCZP@]86BS(D0S0 I8]6
M",@9*6U\ZC[$07FD;0O]%TU9JB#A2%> +N*RY\,ZG:M()ANR4WT:K848A9Q8
M$L^)UC(8UA 1SSZ@ 0!H IAY9M<<'Z(P!X-6B%\80 PP1!H 0"80F=E=5R;J
M4/:H+B=%WYT0*^Z2< F;\$KL5F60IITDT\Y@1:*6QGY6K;6<5I!@$5H.A/\(
MCF;N0_4^A/;N0S#, S)4+[OJ0S#\Q&5%[T3T:,$.1$:&PD]H@AT,*4^()ZPA
M[%) Y$.<8B&M6^&BQJ#_02S$3N#\1JE5;>PSQI->A%;5QJ@#QUWRQ97Q6&()
M?AE22EPJ#26[ , 8 -&1-4_9@'#;V)J%NA"2A8=VS&ZTG7 C._(CP];5):AR
M?!&).(Z>PA7Q:A'8#&\L0LJ/*,,FI):0]IQQS&N\/B_T/N\09Z] 7"H[N&T/
M:2V/AD+>*@,H;"<N1X-WPH$=P %M%.S06))9OM?$,.Q8F=7H,*/7X2_%QJK$
MCA@TSX@?I7&_@0IM"%,V3\EKVHG*6DE!^>;)7D^(=I+"K1I0XDDF7'!1BO/)
M@IE<_6ILFO/ST"G;T-T]0G(^ZW,)ZX-B[-X1(MZ9B4@J1F30-04^)TYF+<5H
MM/#H,@AL1&Q">224"#=%]<X#+!N+,# %V0ZQ1B=#.V#O3[3(P?4$*&QD+6M"
MJ7JOVFJ"VNZ#+Q,-*&R"D8(ILAC%Z2D0&34IE+(J?:8D;RTC,Y?.''X=D,QP
M !$$#L3 ,,0   # ).C#)#CU#1"#4P! & "'Z#HU#@P#;0" )%@P /1&&JC
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M)T4FQJ6>,HERGQT;YCT&>1F9$EX5C>31=0 D^=FBC2GBJJ2KNH+)*R?'$BO
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M U(@!_^RTR8AK*)I&4-&BCC#'H?&G*IP*C9F:)3BY!@R<";"3J)!$ZY+-NY
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M-\[QCGO\XS!959B0>>C.FDC@[^62B(1\$;+!RMP*+@TT< T'7V,'#NVY:HN
M ,:M;0(4B-G',[3%%_G>@A>.<(1:K3TDNJ&%R<1H!"5ZT0LVT@,:^BBHHH52
M_R^)W)5C#T2YO,@M+A.-\CN)M@@Q(H=,?ML,<W4J'<7@GMMR:Z75 <^*@9FB
M5/(TF#M;$@]W&'WP^9@69MB)V?$:XLI))[[BD\(XGD!.^<I;_O*5'SEKU.#;
M08%[*EOZ4&4P9$V6F\5D+*-(OUU-U?Y 8S8,H6HFY,>D98@K1IFH'V$D$G5'
M4-T1O%!,7/#VEF ,HQ&XZ,4M&M$+K03]O7[<$KIIIU$8$HHS6=*:>U5>[NM
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M73@X#&/3%%1%1F#8'M]4@J!01KQ&';5QE<OV%%IAG_O@"_\[*'7,ES>-4)/
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M=;;#<EHA/CY9E%-TG,EI7]'_ 'ZLD1NP87[!Z5!]EUE5F6IEZ5M],I!LB(&
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M)N0E^S"H,<G0""5"H0E*1"T.!A+?J_;A*IN@)$_%N8I/</@Q]QG%(B?IUCX
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M:^D+P_ZBL'_A)8D@08P3"::\*5*Q9554ALK48('-9/$'$-"$33:Q&<RDC'U
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M.C2Y(/?)CZK@-/QJF:><8DJ3ZZZK!QJKZ%G&NV4TK<?34?,J52[REE%&$V)
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M/H025+12*H0PAT8X&@*J=O^C,"G1?_3!I'P$\A)O.<22ED V#N0B%-:N9.$
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M$=]\2V6X$#0QH8<34+7AE-Y.X-&VVD) [:0>4>05!Y-)N)U$3S3+"$2,<-$
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:[_$N[_-.[_5N[_>.[_FN[_O.[_W.%P$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img43903234_2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_2.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M71O!@7@.TT]L4C&=B*'UYF-VT=5EVS%>"!A08XR [B/RV7,^B!]EF:2U$33
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M8@M16.D7[F3G+6W1$=XHTZ0DM06AYB/&;DQ3(,V( 7NT64Q+%_.FE")I>P#
MG&-JYZ#.&4XN'GW<VM@IM(,>KV=J>1"S1(E$)C8$4PG$9%F!]4=4300D!WS)
MQS""$EO)X"<=7-G_1(*I3.XCCS:;6,Y$@A!7C:5C&U%AJ6 8%3,NJV0J@=4%
M*]44)<*0DQV9! L&2X^^\A4F6UG536+F/UE-=HP9@U:NJE7((>XDB0S9(D^(
M9;"V5A IRW#612@2DLJ>T2907"(7S>*2_?&)7GGM[1?%""J62%9?PC+(<P>&
ME(;M=7UF[&/ $-;)/Z+1M*W5$\8R!DC6_P:R(C]IE+SH*@,6-+*($OK?2HXB
M*!SBBV+-+2PI-YE?G2G.;CV-CH]T&1<=Z>5T\,/+Z5+I&.&DA3AM60QFX&FE
M910&-?T<$S$R6CFW&68VIA&#@SQJMY3*B$M*&]]BL.-*]HC)?$JK"V>$U]*E
MI<VA:E'E.6]4I*[BS3FS0=/@6"D8CT(H<6UZ,>XZPQF.0DY-U,PP0%-J3<Q(
M#: CKE&)?U,<O'TXQT*V:%\HNH]W#BF= >6F,@* EL>$J#7]E,L*M.0] M62
M=VAVS(Z!!QTT0:@MQ;L;ZNXFM_AP1@R@R">9>"D7-:_3>P!*:8WT(IS%>:@S
M 7IJAL+7'J4>M?\S8)I-7>8C'18K*3KC!!JJ!_.C^P76C\/EGUI_HEL9/%>"
MT4 KJW>[CR.RY%&'92P"Y"L4&,*$@?N@2@Z FE;.(H"^1.28Q* ]E Z.,E];
MH616!J*K/3:Q7BX!E#(LAI!.VBHL;Y5!1Q)6J4H%2ZTR6&PTQ(" ,=0C8;Z6
MHV/+_<%HYXM7AL49=J>E$MXJT:X,41>[#%*I_X&KV?5^MZVF"-ORRD!=G"7D
M<C&><964D5;#]50"O!M*D3RR3P%L" Y#(A%NS7L@8F"5"Q&%;2 JZ[L&D0@]
MQ!M&:HWW@@89I$A"+M[QHK$GN9VB2W[ROUP[I6 (0*P,0#3L>L$QN#G_! 6D
M *6)U0I7)ZYMB2G=J>J^G/K+@W9ET599X!:-31,W8%#MSE0,][C)09?+YVI0
M [L-$T-W /">-IFIGK0IHT9?>QM;:H268F@"#9A)LIW<(Z(7O>W,7R7P<=Q)
MT_JA-'BJ=@Y<K/-C^K$%QW8;C94?$PK)PVW->/][,=[L&?4AAG)XYUYW9)\=
M8F@Z<9L3 P[2PID"&=AW?!Z2F =L8[L,#LJ6YLT*6IH;Y40N+@R>JHM;;R)\
MJH5[-5;>=FYC\;3S!?P\AA!WXKD:JW9)P@<(*H$ZS4U]IGA$FIYSV?22G^51
M!CY5?G&1,)[Y4!-*V09=M%3:+4=8$9=8*5'._V!*RQT;7\4*'"E$PCB%0L30
MRI#$!.& '*6,K#%$#Q7* [E; O%<=^V<8$F*<C6@;.E+9?$+8]755<"$:*D5
M FP6!3H%)<#$9O5@!3)$ L$$"R320/3@!J)$!S:$#B;$?NV;2EQ$PGS<:5V+
MS[G$$<;+1:!7LKC5/KS<:^U#)E1@0BR2N7B$KGP<K(S+T+V:'^&72-!+:?W;
M(2D7OK!7$+5$=)V@02@=2@2 S%#1:"F,1Q2#GIRAJF1*?J%@%89$ AA& W(,
MUZE1I!3+Q!S%K93<L%$$0Z3<#>X#'_V+NQ4<4O#1=W$1Q9 52^Q,AN 8X0W/
M^0D/+,W28$B'<)B(XW8D"56UB-R42(3%V>)A2>58WV+0!S:!6))$CY.1F. M
MB?E 549Q26/\3GDX'X+("8<PQX]TWCL]R&Z4SIIL66A R2JE6ITTV8L)1HWD
MHO=\S=H,7^FXAS$FAHI@G_-\E(E\CF-X7T$!5)J8R JD16!PQXSL1H+!_Y3J
M< @XW@WYA(A@2!-;E(B(<!C/:$)IK 8.-%J2F8ACW,7]&1\JZ44Q],AT7%3I
MO9+/$*3^L4@,-$9*-49@D)J4N(7NN 7C!,#5(,;6K(7?&4;@R85I<-3K$0X
MK,^:T%\WA1.$[-@X!2!S9%%@!1<J&LL0]F%829(3&H3]R RO86!"Q) *K<1B
MH=7"&<0&;@06R0S-($"M[94=_E6K@<6TK94D_AJU]9H$>A)M69="K)!>?N5<
M>42W76"Z,02BP 1]!<L:QAP+@L18AL0:NAMKI>(, 59Y.6#-.,O$I4N>W-Q
M4%*M*5P>'HPRH)5T :;-1.8^H!?18285VB%*E/^1"TWF*=*E05C,30P$'8W$
M"89$59XA&+(5MXP-5^35#4)2ODB(M%2;S\$A=P&=!P7<(=:FP?D)$/T/'M'@
M"B' 6$)<0A #S4Q@5H8%"UB<I(#6%>J<*DKBFB7/=( D H8?@N5-? *88[3%
M&"[&"FC3@L13#* &FA2&XY2/B_"28GB:-,G%6?RD?^P.4'[/ZPF/)L03B-4%
M[+!&=R3-/YF(W+F/D*#3+0')G'QC*Y$.G^&=2\[(<UC(FCCDT51>1$99^QSC
MA?2CV<#8^:R'FKT),="=]'3',F&)WQD:\XC3\#S'Z20?CL@B.!G/-SG3XRR/
M2,I81ZK=DM[(5PE.8.#_6,_$E/+TV,^4'P&B78/8I^]XE3=6Z=D%CI3>THC4
M8I6*))L&CH#AR"V!7C>!F9ZNF\U93!]))]=A&QRFYY\"',\US':M)[6DHB+*
M!$*PILA]T'9-)4HD:DQ@6TAT$B49$@-N!*8BEU_AB\UQJJ@NUT_HRJ*V6M?I
MU[T<:@K"I0..G*N2EU]9G<GEH65ZD*NAT:3"97)-YQ(A';P,T*ET$G:UZJY.
M)ZA@3*&F47K6S*=:2Z("TFMR$G!1HIYLJGI:W:NI8$C$&<_H:9DI6)32F)!X
M!DUMV7+0Z9MV9)KR63<E)3H)6>>YJX.8J73,:[O"*]YT9&"8DZ!Y7BO=%.KL
M_\B,U>+[0*B%#$Y-9:-,W2N5XNO\J.F\[JF0E=F;SFN=SJE">A5PT!2'B-E_
M_:OKR,6)HE*<8*.3XLC(QD>=/NG\K%)U[!ZLI%JYYDT"9D?IE)F *>4WO5--
MD5[.<I6;_I<KM=.4:M7&LH6%-,>.7.PJ%</]-&M=1F>C6NVJ0B&_06$+0AM9
M:6W&<=U*",0.Q>49]5S6AFIA1:5J&2JLZFJS4J%8S$"[C.0%UJJJ*JNB/ENG
MPN:U:%S7HJW>M@MPR:;72B<&51NVEBIQ72W7YFT:U=>OZJJ\0*?C=NMX"5VK
M(BY=NN&SJBVENBWAYD_#? C2_H68FE/\R"R[L@X"GO^LP!Z8T#(I-UJ4Q>HL
ME=;8^\S-]Q7@\"C#<[BG\!3??R&'3#'/B!"8-IH3BC4:@($CT!XOF-FGTZ)3
MS (8W9AIP_Z7T:;I[);I*W:522:?1.D%S^B2\:+:.SFM8+#KS$)IG(X/G-3-
M\FRIX"#*?<;GX"A'F4(OR K/Z65C[Z(D_+(OTF8LG'C& 28@FT8INZ)KFN(4
ME!+'<S#+KW+N6ZKG&U*KQFV<&^YJKL($W0:25'+,J'Q=&VKPYD;NR.U<)!XN
M#%-NLC:G#.W:"X/J!9/PJ'I=VV:F86&NU\(M=TUEOLBAY KQ$8>J9>+MIY0P
MH.Z;*-EJ:_KPQ1P <@$KV#[_6^!.L6MI\5A]L=[2:A"[RTR^U- *I/OL"/LR
M7X/<B"L.VK\&< (.R8[P+]1RR.D!2;ZZQ8[Y;(W:;/U>J=H=K6.HTHXY,.W>
MB$G*$MRX9(_5:%>9C@##Z9,"E4O)V"4_&2RZDMUXAW08<*DMK>!(Q^915#2L
M[,V^A7<$<!O+R4*R*1LC[)YY%<.J;LA*RN,P+/0"6MGI4MG)Q8[M&"-;["*;
MZR?3YR:OZT498-"F'<JF\?%PZ8GJ6PB/A.:BQ @/+AAW%R-^;=BRZN1",;0Y
M#&Z&!0==\="M\*M2KL"=K=B6ZNAN:SAW\-/E)3S/,*N&;M6RK3:;;36_,&!-
MXL08_VXX4ZTZJZ#-D=<*RVVT5>N@IO#:Z@L K  *QT0Y>Q>Z['!$H[!S*JL8
M3>(;8O!&7+-!", I(4;JCIA\1JR/(,::+J1-G228I1+1\(SO3F_$YO&9NN>[
M>E7QPH]6Y4CTMH8PM^*4VN? .@CFU7)]IMUUN#0 [\5+E8Y)8BQ.%:_)KBGP
MGM-1VRP<IV_H#>R23O4;\YE[BMF-X7&@Y>GS%DTXE>AQ$ DX3>]#A1YB[%B=
MTO3-VE'MSO)V] 7@%+-?2+!TV/3[%@U!VO6=NC3(,O(B'[+J?>F%*-@RX+6)
M_K'<K(53RN*87>;;JO!#4QS?YFK1@?.K<BI.9+,+9\6H;/_M1PNNW$Z+P#FT
MKS+B(37BY(XNWEY$&M8EM^ZPM_(S#S^N;R_T/LN :F.MXGJ*'%[K"!/Q1OAI
M%?JSU0(T;88QQ1%=I"8K<H=7<.MJ<G>Q&H&PJLKJ=/^VGV@N-[]E3$A)(O-K
MYRVP4,-UOK(H9,]%FAYUZT@'<<#WD BS]R)@N"Y(.26/F YX6]"B@Z!QA4AU
ME!8D\NIW&_M,AJ3KTHQCT QR.I6C>;@/7:RH_3K(CQ0?R)89TAKD71RR.&6(
M5V'R<KPRJL&%F GOGM%TD24O2L.K>X+?YHGO?K/N@)DXAX0"26XX)><L'6OX
M^:&4<JSTN,9%6-./*_+Q(Z\N<K#_:%N;'Y#C[,$V\%TT)N3:YFKQ+0Z[L^/:
M9L=\W;,.<=Z:RCGO+9HW:G,J[@\?=&URL#RKLT:/1*4<$9^0]&S?9AV*JN>>
M=JIV;@[WL]]Z=$L0-+)&,:)K=PE'>@MS=ZP.]P8S+J2'A.6F.7,6=#ZO+4=[
M,42/.:A/NJE7A"F%ZQY?-313N$)&*1U/L@,C:2"3D]@-K 07H'V7;(CRZZRK
MG8"%]5X\J82STRSYS(@,^%]_:8+3+)92GDL*Y)85[]!@'G^7J3?>R%;7.H>0
M>"SIKI#_#(73<=D]^6;?LNJ4Z8[9,9FN[V2W]#3':RP',#A6.XB^DB\_AI?6
M<DD6,C>J_VY*<WF>CGL:3Z]=RZ+R%+A4NU,K-T>)ORYEX[?,)CLJ23 FTF%I
M'_JGZ[":RSG:QK:>7VN=+[$0@GD@7;1I@71 5[<5FNUT)RYH3S&A>UVTT#R;
MB[I"?S-Q%WJBA[%UQW!.2'>?&'$U[W,[,_%Z9S=I)RYZ>U V&T3(L434.^)Q
MGT4,8"8XQS/.(S3)^RJJ;W1(EWE()#<X[PPK'6 WME19VW+NS@WSTE+@/'M^
M![)*$Z";YGM<A^0X=?*->\?NROK;!VWV*@^#3W!3TVX#XS6$SC**\[0LYO@S
M3_*(<#M;U^Z'#D^VHRG/6+Y,USB>4%2ZF[6-$8>7NZ_JTN_!$O][^<)RBU<V
MF*4*JGWXDA\84W*U':^L'0,']W'>P9:CVF.RYV4R*X>D9-.-^IY:]+[I5CJ6
M9^NY#F_M=<LP0TO_T0-Q!K6Y2,SE>BI]GA,QH6[PHA]]GBMTV<>\>YFFTEM]
MI7N\UFI];9K\QYNYR\O U"LW(!&T0WN*=*<Z0,A ((/@0(("$1XT.'#A080,
M"SI\F!!BQ(D1&V*T6/&B18T;$0((H/!C1X,>+YZL>-)D0H\<76;L2+*DRX\J
M;<ILN#,B"P":E"U35DRHT%!!ARX#M4PHT:!"-Q4-6NSI4JJ;G@X-JJEHT:50
MEQ$K*E9LT[#+N")E&E2L6JI.X6J5^M98:U.U9:VJ+4JW+5.R<Y7"';O6;BB[
MA,\2.TJ8Z-*MA/\FWJM,$X!,5,^>#546*=;,RC8#1AIW+5'%?8MZ-BH6\U2Y
M9Y_^7:RUV%*Q7%L3?LJ5,V:QGK7N$_\^G/@^R,MRF^W[UW=FSGZ5(G<,'+EK
MS)A!-2^;%JWRKL^%,\WM]N[BP*+-L@T;NGO9VXBG1@>-^:C3ZJ&3C_[>59EZ
MNZ8->RXZUAQC*KW]].(-MF6,FPBGC#AZ,*>7;**H)9Q(XNE"AR+D$*0.:X)I
M)AG2V$>9"5GZT$,,8[J)IA9;9 DF#%E,B:89,W21PIB4V4<-&'&$<:8.901R
MQ0D]?+$E)5>R$$D5<\R)DGV(X:G(*%%*D<8*98I1(@F%!.G+&RM$\<@AE03@
M@#!!7')'"J],TDPQ<6RS23LE<I+-%P_X*2G]6 -T+:Q:HRLO^P9C+ZC0DA)0
MP*_4VNVPLW+_^PHUR>;RS[72C$HJ._XF0TRQ3)N"5%'-Y$+MS_$P.Y!1P_X,
M"X!)7E-//0%M/7"HV183J\#"^GHK*UVK"S6O]88%M5%*]7)/MV(6*ZZX>K2"
MU3O^*H6NL\,L#?4L2'6S5E=$78,UM[:$NPNZ5LN:5%-FX8MWV%VK5:]0\K2%
M+M!0I_JTMJ86 ]=6^V*3#+1]/<VOJ6BHW/)%,%-<LD@1E;0Q3C!#U)-+.+$<
M$2($&FD0S38WU)C%D]\<N>(FDV39XI7?S(C!-%(&L481)Q;30BV]+)GCC1_^
M><R+$<ID'TU0>KFD._64$$(LB0Q:8AN9[+FF.1\$8(496DS@S)R%_R29:9WF
MK#K+I".^\F,RK>8)@+ZX G7!=S\[;+18LS*-WS14 ,!O'-P3 X 8_$K#[\P.
M#^H&OS5I*P  %B7&[\E_NHUR  !?;QDQ^@1 #,YB " -K4(?PRC!"0_*\,EC
M>*-83.5ZM[YAXV9ML+N]5:^R3$K[=-/!1GV*JL5RNR[O=UL=EBQKX];/,8*)
M@HVTX(N:S:G9B*5*6N*BV0^O4A<L%CODI%I7KV2%;2Y]?*TC%:R@-@E/KM9X
M_<NZX^M:EK;[B^VKUKK_=3[5!.4KW/%=^1SUGT79ZW_'&LQG]'9 $^DL;'):
M&]L\YB"-Q,E-/.N8AJ@6)*B-J$3* !O1./]()I1!:4M@4Y':*FBVGVF(1L38
M!\W(!D.AR<!K(#02VI"4PS.5Z8([&^(&AZB2*1&C;4?481+'1,&R_1"#*ARA
M"WTF)#7Y\$E!XJ(//5BGH5F13B5SV0<S9I/'*4AZZH$4P5XW'^7I)BKVX]<R
M<' YQ@5E$@ P &;R:!FF9$)-20G=X)[BMU;ID7?%(.3E"">4/E+N,D$IW5,6
M)P:M&"X&21'<Y487OEI!#S:A$!9ACA(KS6UJ?P$277?*5[[FZ0M!VD)46TAY
MM]J0"X+*B(I^@/G @OU'>IG2V^SLLSWBV'%VQS$E 7MYF%DNRXY(,5<LR\5*
M80(P*.')G]YPE9S_Y3FG4]"1BK42>#M.X;*8_F$GWII3FO\-AGX/1(VO="/*
MW)BHA3LBV=+.YD$BAHEJ2@,H$,]6$JY%S$$E6@9""_HRBJ&L2V3+6(TZV#0C
M$O1F%.K1))XV0HVYZ: :/6$5Q9C!/6'QHA8Q&M+0E+2(6BE*>#)H03%&TRC"
MC&<8M1E!1)*G"_J4H!KL61'1Z,6OY:FD1AP(UV2J(XKXB3\#K,[PEF6;!?V&
M@'"LI1Q7EP:F3%(,3*G,3X0RN3$,17!EM>3@*K>,Q%&%<:!Z)%,^^930E543
M.  *4T*'ANJ$3JQ!$1P.BH(ZM(0NDNXZ%5;EZ3VS'"M7J"),92;!*:W4__$X
M:D$F5.:UGG;!3UWE(VTN[UB\JIRE>?9Y(VD)\[PY*G,X\&%7W8(Y6F(]9UBA
M<99\X&*]N82F5\LH+EO"$RBORB5NT8%LP:C)J_25,WGV$1;V4@/,XH**G<?=
MSU5B^4[JG$NT3.D6=.I!I9I)T:E)/9(0P]C%E5H0B4'$FE$/,H9]T$.G%>QH
MCI[V7XT>T6HQD]- 04@TB_3H1V1,(U+[6\8RKA!C*IW:U0)<-B4>3</UA5)"
M81;#!_OWP$-MKQ,][*2!J$FJ*HXI?M<K5)7)>*,<PUD5:ZI!J&XI=+B9U&FP
MA<!GE4^UPVO+,^VS5[6L#C-]RJSD'A?)Q5T&L/\_ < -F)*X+%N&-F$Y:U$.
M)Y;083E5R]AK463@N:1PLBV<5-W@0&O6NG$'4]E5Y[:>$T %2BX3R\GG89",
M6WE>95Z,@DY]? ='O/6O6'GY;&@WQ=NK_DX]1Z&M<' 3*][J[7]#^=1DKL=5
MV-G-M?%\C)#I.:QT@<IXD;4C:;!IOGQ>MU[2V4\;9SU'V9#J6/X+U309 QAE
M<1I4_.380E\(T:HQU&0Z$F+0<EJQC4*,Q@Z:1(/2-F"IC6BDU)YPAP%L8/BV
MC(4U+<8-Y2O0C1'UC"LT\!1-/& 9S8!E!J%W&A-BM"H!L4L9I6BXM=U3IK:[
MJ!QM*8)E<&^+!/7?99+_:H5IJ%*!G[&I3M,9A.GK,!D(X&W]*5:R?/VOL5C+
MET0^WW+/XK?,8N:NAL6<,@R'!K\%Q6]]Z7'?@'(XS%P.!T]I^1C\N!:@ T %
MH<3,(4&96#@C1^8RD)7G:NFNY"G0+,1;-+VNM9M904>K;?GEW$9^RNC8\ZOD
M4A]HV/),HZ!GT;CT9;/ HBIR H<HES9173A3'^#N!]ATAB=HRO=UU=I67=4%
M^6:\V1Q/KT9N?]KTL:8^/[A#-W>K](YK!HC.N0FF@+8D<G;DHM6NFS-2A.KF
M0XEJ\((HW*A1JW<,,TSN%"98Q"AT,4'T>R(/]S/V.1:IA!D:-8G#?MT2W@CK
M_PW2(YHU]=ZTC[9 71;M9A-8:L_&8$=I-"68[I[ _U5J%%]_8SS!,-X8]_>>
M$L[B;1^IA]L^J;0Q;E,8JP3YX$_XQ6O\1('TF'RO_3AG^0=VZ$)2GD.Y$DF0
MV.*L_JJ/"$=P-*''*B.2WDH3#*>L9@[,*$<&$I"16F-U]H@I%D>/-(DJW$PH
MAHZ2\N4PQ(XVS./OADS3X..7)*>PY.9>2J.93$XP8J=_U&Z80BORBF66TDE
M5G _/BU2/L[N6HV8_(.R!BUO"D25#+ N-J_+* TZ:B<PLF+5%H@QGL)@&L-
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MSTC$J/= 3/N\$B%F,;["<KXH"!7#+^.L2.,H42N!:DVJ+=V^S??$;]FJ;\8
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M3K?#ZE7<AE0O[>TP1^HQ,4)(FU>$B%=#.<)KSF]J; \C7/=&ZQ4G2G?@"@(
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M52KJI;711E_!N$63)9M"PA2CD'<^&:9+;%(,:)I^J@DCA6)NV,AP-G;99IV
M?KF3F8&^Z.%*$NM(9(LMBVP0,?M,0F6#97X\(LHA2APAGQF_^&)+=KJLX85=
M9K*/)C46R=#/'N.)L\5$)R@FR_]@]MPGSARR"4  &N]Y,D9J@ITUF&K?2&6'
M-&\]]) T.PV LY"Y2YN[X#EJ<'>)^AJ5=<?>>^AHX.'G;,"R#<YNJ)85/"KA
MR-EE<-_J68=L5)'GMLQ:G+_&VE;7W?5?*)=E0CCCF*O&7>B$=^L7@<@])QYI
MUNDWE\-\7R[64)O9A]R T6XW*K;"98>PJT-%7B^Y4G''6[7.$@\M>+&C)RS
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MUO;"M<GC;6PCA]Y._],.=91#'>JP(0A]6*MB)8M9VKE.=H %.0#@P#1_"QP
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M"@V5T+5(C&?S,Q"%R[+(C%_;T+Q@RP:UT#M;46NKE+*@T M=T!3U"; HT*P
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M'=97L(-8.J=SE@,Y>$,Y@$1S/J=9FB4[# 0]E"4YU.5&R,-9GN5W'N=+J
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M?9K!"$21'$?0HMMTR*I '2*1&,P^;:";)*V8-(S6[I0$B5;8E@GPJLA"P8C
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M]]Y]_QWXX(7_'Y[XXHT_'OGDE5^>^>:=?QYZ.F^8;;;I;XBA>BYNN$&&&\+
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M>#SH556/9>0VU*)WMV3)139C9_)&RB0,TH >>"2,)>8G9])D0QP@E.W+! "
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M8CHO_EC&D",TD63Y#&2/XT*K;(]E'Q7L&+T"!^1(07<AYO^Y9Y]_!CHR90
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MK; N,K*Z&X/J I7"[,P5K%X*,KKJJM84V ZM3I2E573?B[A/U0TP)&'-+!G
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MBJ2C'!@-%"T%.>APZFG7!W6'/ X-:GT>:E+(Y/(]C_@L?E(1X#Y64[8][2D
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M:U(9D]S )B1E2$P8\AD4KB8E40%+D@XZ2N35JR(%W(F()!(FGL[1(>J[:4^
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M>W[8B\_GIYKGAU[HGXKHCQZJ2A1Y)NBY\.S/D5OC$P+EJ;[JK?[JQS?W-KR
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M@G6L8BV_*UG/:M:THG6K*:7'4M\*U[C*]9X^K:M=[XK7O.IUKWSEJ53=.M?
M"G:PA%7>4]O1U',X%;'L4*PY&.M8R"XVL9-M;&4C2]G'9E:RFK5L9S'K6<Z*
M=K.D#6UI08O:RZKVLZL=K6E?FUK6RM:UL:5M:T][6].F]!PI94?\"@O<X IW
MN(%RZE./BUSC)E>ERFTN<Y_;6^@N-[K4G:YUG5M=[%Y7NMKM+G>_FUWP;C>\
MY!VO>;U;7O0NMZI!):Y[WPO_W_B*)J6(/:YQI6K?_$XUO_>-;G_WV]__XC?
MU!VP?PNL7P,#^,#\1;" $PSA!TO8P11NL(4)?&$&8WC#U'7L2MLKWQ"+>,0D
M5@MR'8MB^JK8'+QM;&)WZ]04:W;&+:XQC%D<XQ77U\8NQK&/>3OC';^XQRC.
M<9!W.V0@%YG%.D:RBXD<8R/75\A/5G*4F7QD)E?YQC*>LI-M_&,IKYC'5OYQ
MDWTLVQ*K><UL;O-*P(M?_5I8SABF,X/MO%\\Q_F_<^9SG?U\9T#G6=![)F^A
MIWMH["8:NHNN,(2AZ^9(2WK2E#9(5%O,7""CN;X][O&F>PMD3WN8TZ'6]*A!
MC>H;_\^XTZ8V+JE3_>D7RSK6K%;IJ64M:E>G.M<KKK6J7SWK6_N:UJ6VM:YQ
MK>E7.U>YE6ZVLY_]WN=B=M (ONJCK7KM!4<XV]9^<+>KC6UOAQO<VIZPN ]\
M[F]O.]WCWG9RP>Q8=D![WO2N]UO1C%UEQQK-F+XUOY_J;P_W^]C_OO*,"[YO
M@0.<X HW>'T1'G#C#GS%$&>XQ!=.\88G_.(.-[:3-VX.M[9CPBFUM\E/CG*%
M/IK;'"8W>O_,Z$#'G-HNA[/,:V[HF[L;T3HG.<]IOG-%,UBQ L$TLLV1\J0K
M'9;$(!%^BN/T6R[SHX5)I.+4 TQ6U<8 DZ!B29ZCO:3%0,L^43].>Z!!S"#A
MS^DW4,PH\5,1IR>D[&/_(S'K7I+HIOC)JNXWP%'=\1OS/>)#!OG@+5YXPA\^
MXY?&^,'C/?''-S[P/EZ\Y!./>,L_'/*.W_SD#5]R?>PZNDLOO>FWJ(RRHT8Q
MWB%.&<FI*.K4IIG$["-SIM.2N\<1;T%L??D$4@_?]_&H&RG5V\69KGHZ-&E
M(SXX13)KJ2:$'L=5R,KSK&>6$EK[.5_I]KW?_9G+N=KCSS[X?RY^/I-?_>9/
M?W69&U1W_)?3IZ^__?^?1R(Q=*4>F3  "#GR'%21'(5!+T62'-@!&]@!)9<C
M2"R1&@VX3'5"(H-A('<3+0LR@)2B?QZS$9.3').#/T 1$0["'4ZT3K94(L2
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M+*.7IKQWZJ&>EL)WMJ$/O*?5!5CU#-+_(?U>W2J1-:N6D6R_UG6_CBK1Y?K
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M3&32,83@*&/CH5T#'?A "$90@A.$"HM\,AE-\,0M%.*)7-3V)GPEK$5(.Q$
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M1Y@E1WDDD;F%49N55Z;L6;W__4BP75N7)%=S]%AV/%O"Y4W#?5FW35FXS5F
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M.7OVO"PSZM&@5R^C_-FPYL^D-1/^7!DWY-2.64<KO9MU[-22B>LVO3HX:=7
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M3WJ5H9^O@IFB]&TO.0,$80*',QGCN*<R,")@9](@!A:@3 R3T QQ"),)D\F
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M6,%C&.@^W)YLR)M85Y(IUML?=E0$YX!8FD 9B(.>8+*B;AEO4' .3);BL>,
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M!B(;$F;IBG,':_YEL=@0 FA"_-XK<>X00^AS<B,86C[U0-3I419$1)](&@@
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MT&LH)E-#B@4E3:IHD-B-C!T)BA'C<: D ,0(Q@"0,J%(@@!B$,P44B/'C,H
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MPD0$=1%Q4O;P KZ;7(8O!RJ0@^;#+*FT,8U^05XH.X0@%=C'C6_\8U]BPYM
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MH2;%7\5>JV 0))24N4N1;)Y@#V,D/9VW1WE3"'8W9)O;HIDJ8!(40FE%*_9
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I1WXD2(:D2!^.)$F6I$F>)$JFI$JN)$NVI$N^)$S&I$S.)$V^1$   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img43903234_3.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_3.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M0W/:5++:=+*/I[(FNS>/5[)<BG@=I$TQRTHO5[,SJUW2EK.)M+/A1;.48[-
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ML90TB#-%8K9 WN6;BA.GV-2_YJ-5BA/ W@5.I=E-TLA&T); #MS $&Q1$<S
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M,BL[-T,CHRLQMQEC[#2QWV:;;=?@OKONQ,3F6SCK=E,4K-8R,TRMU_0"M'#
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MXOBVL6Q*VKJV%1S'>!M'QYI L[2AKWQ ;534S:JM1!VMS9++$>S3/(V<W))
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MOP.BU4 4A Y%3S'8PY[\@G=F_>$A??S;GY3U#,$\(TY)A>U'X@@5BTAMZ84
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M328678NWZ4]LA(^9=='=&9=];)HRQ) :7*=HEDOTYCNV8&B&*:'*A$_(V4)
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M-X2A@@"G+#3/%@ 8H )$!K!0$DSF'H"#N0](2RT,$=D+$1#3*K("'(H H*X
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MJ%(R0'(E+%4Y8,O  @J5F84N+WL9(]TBE[O(["YE48Q:<"9)3=SL+H&Q"QQ
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MQWXJ<VV*=!8!^6UQD?]7 &@S![D)S95)AN%<#/D7SJ4)$$DT%<E)DJ1=4?.
M31->"=B1#;=-22,854,=_W8@&5B"^$8<$I=-)78Z"I:#K(&"P4%-]D:$7>,=
MM6%+$-:"Y3&$S[1Q*J<<^E%S#&)?C^,Z,?@VZO1>+.=,8_-+TR1-YM&!.\E?
M\(&#0'D@\@$>ZJ%@]+&41*B+O\@LP*.%34<)9VE0,B9C&N5D?'B'4M)1)&4C
MR3,EW3,)=T@E''6'-)(\+752229U4"8E(!)E.S)U-;*7-<((;[>'.X(+.9)W
M<B)FC9@#;G)WM#(&_I,_:0! AG)4(7-4D!)XAO<__!,I<D:6-40/R@!!9'7_
M>JK"B")D0FK%>9V" W'E>7S6*Q1D>K5H:+0(5)1G0H]FBG#"/_]4#W^1+"NV
MFC4$:J?E+(ME? B00\G0+<.W+?H !@"0C"81#"ZQ,!X!+KA7% WS:Y % RMP
M!Z%U --'!3PTG=>B#Y9U &H 9\I0+:I5#^&G$$R!;'!$%$\Q%3^Q6R2#H.P'
M?]D&D,8BD,,U%WD!H<6%?VF!;I1$- 9H;J4D7189;QM);Z84HB?679(A3!B6
M2SLH<^'E-&%C.+QD.2]7'B%WA,3!-:KQ'9]1&_:!'Q*W<C^G2CG:'137.$WX
M3*5#'N<A'=+T'"H7'@^F31=F.HXS'A1G8EB332.6_QX(ACDBR'!7"H,_6&$F
M^%T4)AC/.3L,I2&5T'1L&6-MNH4F<CO<XV0?XB,U CT?A5*#:"-'@H=]F252
MPB%D\CTT8H8N]3PUTCYVV)=I&*C1HW24T#W,@R,@\F2-,)F8F:EAEGHF$6>
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MYF&0>VJV/TF>B+OB=2Z$T"O(]_%=1>ZY62L>+"'C<03G')>1WQ)O'\+0&,*
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M?=5Q7$4=%E(#6+$U-;@_M0(/$O,U!?0%[WH'IM@(\!B)?2@&IFB(R?$0 [S
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M8M&YA3$F^K%<JQ0B%./VS2<XL(LEE>I3K_"&'OU30QRHIPE"(661C *D8-)
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M>[VKQ1QD0 -.I!CXZ0]=*?*. S6[(AZV\DS:,8EL1AL[O6!$S2R8:,Y$Z)Q
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M!35 LUV1 6\"YQQ) QI'$S>QH38+XCDM9V"SA',( AS51![:E%Z;@QSAI$W
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MJ9"! ,3' 9(Q4$&($'2H[M0'_42?7X6)3K$?%QL(M)#6_5E/##2Q]$&(JOC
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MKSY)"#AX)Q0\B,Z B"# (0'6A!D#@E/0!X DB1R  WI1AC&PP)+(J(!2 U
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M])T+H-OV]A78P'A)^%6&;08":GQ"]\8Z+H,,J]NZ^C:BRV [(Y*8B@W@Z3;
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MY/A<$)P 05?)3TJJR$(6Y$*VR9?HP*#MHX4(FND@FSTB7S  @ S88&TP&P(
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M7B4,K,!4K57_ %360NR""OBH8EU*NLB;"CB )*!!&@3J%0G 5-&"" Y$/L0
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M] -#8"2@#HY( HP_[J])'BSAJ*]U6H3@',H6(PIW%,IUY.G@6N3"Z(WYW&_
MUFE*;#%),H2C\$,5+>=*%/ 4R3%\]$&%/BY,_.0 6X/&1F[&ZD$?5NZG&M!5
MZ&$9H,%59L[ECL59_/$#'8):R&.JH.4GIF6KH&RKNDP3U&6KIL(.BD(CM@4B
M-X$B0T(B8J*LV@H'JT[-;G!?!*8SV(SKP,XCW BQ$BDSL,:ONO!D$ TJ5":S
M1B;R? 9EX.[5K% LRO!AVL@K_$PMPA H(TLOB+)E;D:4:(LM_US+*9)B9VK+
MU:J&9R;-[XSFT=:N+9 F*W:"+RY#[K)"CJZFC*H0";WB_\I1I(YKV'X#NH2-
MV8#)F9)-F*S++5\/;):AFKH+(A:'$JII$C+N+-5#&?*/Q([/G)P/GRZL1LHM
M=.+OH@C$_%SD^U;G&'\Q1&XD_AZ3O^QI2-8/1(J$G2"LHGZ$PG9Q13B3WR1S
MH,C/0*J1W.9O_"[J22ZGG"B.,&4@#0 S-\F1$Q-PQA*0IW1%'G5L."50'ET%
MYH(,J7XLR(*LJ8R*6@+2'T&A&"JB6G1(!('H!(6(RESP6M0*K. E6Z:B(*:B
M/,G3BM(L!J'N!O'J7MXJE3HBC#J)+_],8JX4;2,*1B :X[$ 9M%XLB<V)D#]
M9=;<8BE$TF04 [ FXR47-&E&R9#H<)720NS.KH]VTHQTX@LA+T'U2C-,(XQ(
MJ2>VIC3HRB\ :V)4<BRS1I((JS'XR- &3VCDL)#.#BO3@M.4XB]UL[C2\MB<
M;6Z4K3BL:Q)/#RXC44A?SVZBBSIH+S?,DCW,0_?2X!/? )MV-#W>8TOZ;S#M
M P<@[G<(JL-DIS&Q+W3(#W5P)QH[TT7Z:T<^K!:%9T7J"7G4[Y[4K7=89W>4
M)T.JCT\MY$CHS>'D"S3Y0TS=B0P^[ <\*DN^30:X!S>O-%)[C:7^;Z=8 ^42
ML#@E4,?PD0+_=>58^-$AG-.H!M+FJ/,#1U"K@.CGGFQ53[ HPA,H()*(6A B
MM4PAQ$P&IVR*U(6MKD@C"&,P0B8^K^Z-_F4CV$P)#W'24!*TA*:O *_2L/#Q
M4N:/$,D_]^YFRF4+/Z(+=U*U^!,K@RLQ+@TG<2L/)Y1%P1*4VJ*T.H^PQ&@Q
M@B8-4TE&O<*,3@WR.L8L8')%]3!B-B8K#I2-P.)));4 >S1)JT,34^]''['U
M>".Y+M&ZF+1A\2;UB($W*><BQF,\<,I@#W8UODG<R"D_2G8^S*T_I"1V,*JB
MCD1!".S?(NS[Y,D!^ LU*X1S"DK[Q%1YK _\-.3[7@?=#JK!(@P!_PS.0HP@
M <>@^]B/02Y*&#OGP\84XO8I22 D0^J#Q+*$-D\L9,&6FS36-6(LQE8CQWIL
M-7)JY3@U'S$053HU V4NR4+!YNP6(*%EA_!V.GV(J\;EYZXLR] E)&BP7;QJ
M/.F%/,GS6W[U6*OH<3M2"!%&("XI[$AC,5P4CN[HCA#"/TV4*+GR\6@&<UWM
MLI@2CZX0+#+4C:I0[VZ&+>3.:EQF(XQRDX#2#Q\F(5J+* 7-#.TH9?P.#3%+
MLIB&+18K)01FE98R:DR-,CXB-7CPC;J0MG!M*5J"63]WDTQB;,/VEG[-8A6V
M;Q@6N5QO]1SV+8EC8LV7F2#62'4CVD**>P&[_]<UO&V]"I,^<. QH_9J&:Y,
M$U.B*$HUZ$$82Q/]I,]%J*_?!D2^=&!'XJU%:-9"Y.MJ9S8'-@$:)J$T(R@!
MF24UPX]04U; AI'^2"2B\BE#&I4V1TP&='1^77AR@$PV_E(?O$;E=$Q7H(%3
M.17F+M"HBLS'FNK(9J@A=JB'M,H$5Q5=$A(\N:R'"'<&4]!<S%,FG,A>ZJ7I
M'+=A_L4)V0S-X*PC^,B3XK-%^Y,00X:63(;L(@;MQ$BWQ$X,(ZDI#\806=>P
M@N9U@VN68,9#'10J=3*1;JWKAC<I_<)=>9(RHG!:+29K5/)I>O<P#KDK^'5U
M":L/1XV+DD)EQC7D7O_XENCR?"]6;I()]<:7-Z@K.-0W?)6MDS<N%8FOQ+34
M<C[X3NG/WM"M>OQ7@@88PHKG-'GQ1RI,%WF$P21$,Q-*@QLJ:@L$,F< 1G!H
M'WCA=G(@#<: 1WYY&1DD2N(+OAP,3$NDX;Z)Q,"):[F$E<W9-FBX'6'#:W)8
MQAJP 4_%56AX'I.3'^'VQX"X'Z/%R(Q,AY2,;Z?EA["3.UUUB:Q%78QHZ1AW
MB'PB!A<WS9*.BCTB7LS,!BVZ) ;)U4@7CH1"CR'T)/"B*@0BC'A2DQ_K>0>T
M7#+&M*QP*\D0)UTT=QG48WSF09-W8UR+/Q-+0J>5E:H5T4R4C^4.CP@&CIG_
MTD!/(S,XS67@HNO\T*[\1;$ QF>N]9/R+F,&BV9,AB_.6:2^EWQ#^;F$@SB6
M#3I(>6'%&JU#.97AMZM73##!$4O8*QQC8!FGI!9SA&I9\YL!CC]T^48$SC/1
M3]^ 4:$&RD:$L;!_V8!SEI832GD.I1<6&^$$*L-(!_JJ9\/TFD1^)_J^;9S5
M2YS$P*U)NS;2F6S?\1W--K5OF!YACE--CH=%M3DU< /Y.6_].8E)<%MBXJL*
MPF_))5NL>"$C(KB1SHEZM7 3-ZW:LZ)G<%_N*@<]2:3'"%F]T)-2E'9I%ZD_
M264HM$'KCFHXYBQDJ;<<Z75)PLZ29EM75RM?MRD!_SD/U_#2="+K6,TM%-0K
M6:GSI)*E5[1##>^G8]1@HJ*ULI70>O<K<6*J2W<C(L,F@J:02CNDTM(1Y=)\
M*59N>DEOBBV5B^FL57ENGF/">:TVO78VD8]031@VV2F?^C<-M&QP<,H@HF]'
M5DIM,Z%.72<'X"!5Z$$9_%D3;D3+U'88I"\'O$,&@"!82$H-!.Q&J&7DB*&#
M.>?&@5P3<OP!D#S'Y70_)J4>E,%,+4H6Q<]_EZ]W@D=K,\?$+&X^MHW$K]3D
MP&8=U3D!70Y5A#/C&%#(V-;E(G#ERD,?FU-4]]FV[7:'JF5OA:A:M%,A$_+)
MK&7H@OM6VT43HCB*I&A7*?_:(ID;7ZZH7$ZBTP$/,T0R""7+NT5#TBJOCBB7
M9)B:-#")6Q=\9*(FTQ9KP5LB=)_:=25)UFD)#WWWTFR&1?]J=W-:\M1PE50=
MV*U0C2!9JD^W"0DI$)NWU?AJ>#D)9T#C<UNK#%7M)'("SKMI$2,Q.<X:F4!<
MF90+Q*TC;GY!?L6]VS@J2[%$A2]G1-[T,*$$L84Q:J%'@EZ#$OJCQEB#'CK8
M> +JF2VP-8BA/R8%A5:#'L: 19;6'88KXM5)!_0'S/-D$BKD%%Z#'BA$4"0^
M9Y?6-?3!R4=X=*K6=&;QG?"O:X^/_^!#N^(];/2!$6Y@##@93((!  0 Y-.C
MYRW_J.A;8Q=40  4Z !/[FR'3(<ED(>7 5AF>U27 5I,U6ZG*JL&&B%;U6^M
MY59;L-)_>R+4Q8J/SERB3JTH>BJJJ''+);H-(HU "^J(U9,N V1(K6)0]Y3R
M@HL-=+(&Z]8&CS+VGI$[9HWI+!#]HO*8^HX)#2HY=/)%@S :K2B]^]MM^B;*
M=;#R" Q5=R7J4"SY_NX"!K?\J/+7&R[,8@VK)M1P] P)'S!NOIM"3ZQ3F3=(
M#WPC=O660VV8C3JLXSDJ]FY MO;#)Q->>4L9=3YFF807L]^C%J^+ELCIX2^
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M=!(_L$T9D4W>Y!(ZT!;#D& )T'*GH ^4  K*H R9,!"N G2(@@-)Z"J)PB@
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M>%X1+UXQ#Y%7E^PB0;X"%+P  U$6%.QP.G*Q"VSV%B$$>&_Q#)$7!V9Q0LE
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M'4G  &,9Z<3[E9'^(8!]T(,,E8,!K( ! $ ,   B*W(,',%TJ, !3#( K
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MY<K48HT]MB:@+%C)*@3(.HD=& 08*A@5EHT3!A;6;$D?+1 04AX5YF0IF44
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M&&QLVE3$[4(%*DR)/"A"T2%=Y7B["$ ,;A!3%0  !\>CAS+220QBB,];Q3/
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M58EA#&F8A";X=]>MU&.#!-8P32+A0I70L(0?)N%0@&* %0 @ '@"DQ8 H((
M&"  H3 25N(4@YYP2Q(P\+"QZLJ2# [EAT-)5%*+B!;N^80>?3'R$@6+EV@
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M\&R*\LK_ E[8$3(9CBV0:(F2S.'N4>*BC,H4RS-#X?<BHXHL9HQ4M(PR!C-
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M)PW-AT_$F[%U?N5#J?&OAF5R 5=RT%+2N[04.M+:UCH1.OZXGEUP0MD$2,1
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MR',Z%R6N0V'PU4VR(SO64U]CLE_%\$UL\D,4H3WKPT'2,R<#YCLST4Y.EQP
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M:2\:2BYJ?844!CL3@XME:O-1-/E7'C Z&8K53U C-7Q35X(%6OO@E.:7?__
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M=!L<8K :8N"ID#$, R(#:0,ADO#5$K-&_ZG!&>V7#UBK',>1!KSAU06B"<G
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M01=G=;'B N5/L=BY?>=WWC=XON=\WN<J9N<K2@4'@ 8(6.B]Q#&76T@KM\K
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MYZ2S3CL12@[*.]D) *Z#M,IAJ%U@"""'3"2!00"=]%G$@ /2R"0,&!X8:B8
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M^G10>;[)X8G14[$:_1H5!9I9$IN6AYGE81!1.MLO$;3"-RM;E^3H6Z8)%Z8
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M48-$AP$CD]1"9@E!FDD^Y%&)OC2A"^WG2/OIG[3)@"?TX(G@:H$#.! #&L-
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MS>8-4"J]4I7:?$SAIDT]H<B&6?_L 9=7Y6RQ%UMD[^D&=TP';KEBJ%Y)E>"
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&C2L."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img43903234_4.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_4.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M2S#*RYH>JC[ZVPZU&'KZ17PF=;W2E%K/U4O;LED[RS8XHE>9&(&O29[( 85
MP&U<'"ZC^X*%&Q^L* DK<[L(_ZB ,ME]MT8S9)LC9F8O X:]:-9P?).HR_<=
MII*?RS:SHM."WGM;Q\&:U_JU@#PDL?>'G=H>/A!I^B1+-(J(!/*UBR"DTSFJ
MM,.6<B6@[09JNKLH%H@D'^@<N2RKLXIFVH(R\#H==[D+;[FUNJ()L'D#J=M&
MM!G%U1L#UGHXQ-&F=(3"Y[HQ;>@O-W>[L HF"[82+?E<U ?+-Q)$)-:ER8&
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MTHKJ93L-)N=;,MJ=D\9FE0WQ1C&,0<J('%2?L_$I/T:J4U"L_V1)K0DD$NH
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M87#*I(0598"&>KC-15F+:*@46($&1ZE-I(3*:1Q#+P(G-UNR,,/$I1(X1#)
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M[#CT-0OO)4J'1F/7+M\8GQ" 1WB\;!@94$;YWN3['4JH=MC")<[:]F@(.^0
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MT)V* [<T1QK=/&0.\&I4)&;#AXXCS-68J$6ANT^!>8,Z6?%)F%$*0;R7C'H
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M<.:FF0=AA-G@-0^.! FU#!!-_5AC\,HTL<WIY=D-'-=/C"%@3&/&"%F<$,^
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M14DG5VB!]DH;8]>&)C16DU-,E2;J+N\28B%4UH'\,22,3O=FJF^5)K$.4<#
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MM6KVADM-DJ@.3 J^O.&R8PL6WJQ;4R:XKKL/)+\37J+E]9I$OY$%@U4'#62
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M7XP7M5P:MJ29"*&*UI*/RVNEIBB8:2(*OV RUI"O0'LQ;WNOH4# T,"MSLC
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MG%9$D?6U8D,MXMJ\V2',8<CH3(@,6SY#9DD&424QCJBM (G?HE@I.UU8XZ-
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M"C9L*-%PPJL@;YB,1HRL 9ADU) 9(U-9)F7$,G&)\=&RR  B5_?=:SGHZK2
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MGVA0LP0CK0R&7625TSP/#AU9"TJ1==$(4Y102]8*MD'%^PQ,#+A0D5C%B0"
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MVD+6Q92]E20L15/TY72D28%BWSG_:0J=I9REY>0^"):]U8VBK&.:0,RX*%3
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MUE5DT?!=QB1TB)(RQ#3)A8Q<\*=5R>3MZ[@Q!*VT#[CJ<NATQ (2BAJV4#U
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MJ]_4V"JGAL:2:#<TAGFJGDQPL(HIW082**Z"]%)M.NE>4H\FQ@X[#/^A3-+
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MS)E]=OFBZ5Q'$\KX1$BDFICT6%6;!A(GG="PA65F""2]&L88;O"G>NJ.K3$
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M3!DX1AF$2GLV+?F!,SCX$.&$3IH2=GF&3CK66;WF/MZ" VDP<,,P2PPC&\.
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M.M$?]':/=3&B-7XPY=":^RS:^GP-.!5V%GLY!&9HX"5W81:2, EB_WTC(BK
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MY++5:1$8(OH),03@8LVG.:R7Y\*N8CT);1/68JV64'M^"!](2IGQC-7:_FN
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M^A1*G3+5KS,W2Y=:T+'_4:\E#PI?C'5J==[$"P/&X88;Q+B!"[,FR602--)
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MBTHGZAX%W?]8 >Q/NS,-$:>'-XS]24CP2AMW]DO1! +8V,=&MJ:.W24O(YO
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0*@DS@-.V+T/$@\B@@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img43903234_5.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_5.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
MS,R _\RJ ,RJ,\RJ9LRJF<RJS,RJ_\S5 ,S5,\S59LS5F<S5S,S5_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\K /\K,_\K9O\KF?\K
MS/\K__]5 /]5,_]59O]5F?]5S/]5__^  /^ ,_^ 9O^ F?^ S/^ __^J /^J
M,_^J9O^JF?^JS/^J___5 /_5,__59O_5F?_5S/_5____ /__,___9O__F?__
MS/___P               "'Y! $  /P +      7!3\"  C_ /<)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*Y*A,6;V:-G'>K+DS)T^=0'\*]4FTI]&@19$>';HT*5.E4)]*=4JUJ=6H
M5;%>G;HU*U>M8+^*]4JVJ]FP9=&>';LV+5NU<-_*=4NWK=VX=?'>G;LW+U^]
M@/\*]DNXK^' A1$?'KPX,6/%D!]+=DRYL65E XU"X[G99N=ZGT-S'NV9-&C3
MHDNK/KTZ->O7KF.CGMV:-FS;LFOKOKT[-^_?OH/C'MZ;.'#CPHLK/[X\.?/G
MSJ,CG]Z<.G3KTJMKO[X]._?OWL-C_Q_?G3QX\^++JS^_/CW[]^[CHY_?GCY\
M^_+K:Q^H#-KER?]5%IF   X8X($&)EC@@@0VB""##SJHH(003ACAA19F6.&&
M%':((8<?>JBAB"".&.*)0&5FXHHEMDCBBRBZ&".,+-(H8XTSYHCCCC?V:../
M.OH8)) \$BEDD4,FB1=_.6UVDY/]-2GEDU-&2>655F8)Y995<HFEEUIV*>:7
M8X9)YIEFI@GFFF6RB::;:K8IYYMSQDGGG7;F">>>=?*)IY]Z]BGHGX,&2NBA
MAB8*Z**%,HJHHXHV*NFCDT9*Z:669@KIII5RBJFGFG8JZJ>CADKJJ::F"BJ4
M*A[IJI&P*GSYJJRQ(FGKK+?6BNNNNO9*ZZ^Y LNKL+X&:^RP:/G$GW_'%HOL
ML\Y&2^RTS5(+K;725JOMM=MFR^VWWH:+[;@X8=9JJ:NBJRZJZ;*[KJKOM@NO
MN_3.:Z^\^,:K;[WY\KOOO?_V"["_! ]LL, (!ZQPP0DSO/#!I?:WTS[*_PH$
M+KD7=XNQN!IWG/'''(.\\<@>AVPRR2*7C#*LY=K4*K,IQWRRRC3+O/+--<]L
M<\XX[^RSSD#W'+3&G>5TT\06%Y7???HQ[?324.,G==-14SWUTU=7C;757&_M
MM=9@9RUVUV&3/?;79Y>-MMELK^VVVG"G+7?;017MY+E"Y\WSWC_KW3??0_\M
M>."$^UTXX(8GOB*41C=N+L4P%TU4N3U1WO)0EE]>.5*9M[PYYIR'#OKHDXM>
M.NF?GZYZZJQ?OKKKK6L.^^RRU^XY[;?;WOGNIL>>^^^\HXY[\*_KWOOPQQLO
MO/+% Y^\\\M#WSSQOE./?/36,U_]\]E+OSWVW/^'#_[XTXM?/OG?GZ]^^NQ?
MO[[[[6L/__SRU^\]_??;W_W^YL>?__\]D1SESO43UDA,-0<T(+,4>#2[-1 G
M"W0@ B,(P0?6A((7M& ")<C "6H0@QNLH ='V,$2<O"$(C1A"E&801*R,(0M
M5&$,7PC"&G[PABY<H0YGN$,8^M"&.>2A$'^(0QD2,8A'-"(0E5A$&C:QATMT
M(A*C",4G#I&*5[1B$J7(Q"EJ$8M;K*(7Q]C%,G+QC&(T8QK1F$4RLC&,;51C
M'-\(QCI^\8YN7*,>Y[A'&%;N:$:#&9, "11"%M!RAG3<(?\X.4 R\I&-C&0B
M)ZG(2CH2D9B$9"$EF4G_3&Y2DXOT9"@W^4E1-@Z4IS3E)4DYRD.6DI6IA.4J
M7=E*2]H2DJB<Y2TY^4I:QM*7NJ2D,#LIRUWV<I>Y-&8MAYG,81Z3F:I4YB^1
M&4UG+I.3S>3E-7%936U.$YK%M.8WL=G-;)JSG.@,IS>#24YUGM.=Z02F--G)
M37C:4Y[BI"<Q\;G.>?J3DJ2!X.7XLY//S&YSK4/H0>^G4-DU]'8/->7K(@K+
MB3+THM:CJ"\MFE&,'D^CE>3H1STJ/) F4J0E)2E*5YI0E;:THS =:4Q3.E.6
M+K2F+Y6I3FFZ4YLZU*4W[6E.>4I4GT(4J#_%:5"+.E2C2K2I4%VJ4RL:U:0*
MZE6J53VJ4JW*5*RZCB@4"^4EF=0X5@FT)A3#4EBCA-8JK;5H:<W26W$25[->
MD*YN/2MF\GK7MJI5KW7-R5S]*E? \I6M>_UK7Q-;V,4&]B:#9:Q=$?O8O3KV
ML'#%+%X52UG-$G:RF>5L:!O;6=%NEK2C!>UI5?M9P1K6M*V%[&M1NUK77A:V
MDK5M:6D;6\ONEK6YE>UM>1M<WZ96M\<5[F^16UOE)M>XS85N;R-;6>IZMKC6
MQ6UU9PO<[0ZWN]?U[G*=&]WL$E>\SS4O>+4;WO:R][WG=6]\X;O>^=JWOOAE
M[G2YZUHJ446 5O]2T5K)R<A2%EBLN[OD@5.Y8 4G>)P&?C [(\PY!U<8P@B^
M\(0SC#D+=QC##):P+2G\X0V'6,,CYC"!10Q0%7.SP2#V\(I1W.(3ESC%-I[Q
MC6LLXQ>S.)(DUK&0?4QC(+NXDS V<8^1_.,DXWC)02;RCHV<8RD/F<E%=C*/
M8\QE)7?YR5_>LI?'#&8RB[G,:#ZSFDNGT*:$&&D#=C/N4M<Y.F/EJW*VG9VG
M@F?3U?FK=YXSH/DLZ$'G^7=[IDJ?2?=G0_LYT'H>M*(+#>A#-[K2CR9TI!W-
M:$@C6M*6]O2E%ZVZ45.:U(D.M:8_S>E2B_K5JS;UIC'=Z5C#>M*S1C7_J#.-
M:U;3VM6V#G:O9>UK7;<ZU;Q6];!OK>QF)_O9M5ZVL)T=;6H#6Y&?>^OG!%B/
M0;:0L7&MZ\3Z*]EQR_;<!P0WN05);G$3-MQ-,K>ZGR1O>-/[W>NN=[[QC6YV
MH]O=\RXWOP4><(#;F^ '-WB[XSUPA?^;X06'>,(EOO![1]SB$\=XQ=.=<8YO
MW-\!!_G!1;[OBWO\X1I'^<E#KN]^MQSA'W^YPUG><(JKG.0NKWG*:6YRG,/\
MYC*W.<\[[O.9CSSH.S^ZSE>N])XCG>DE)_K3BR[TIDM]Z51/>M1CCO6I>[WK
M8'=ZV*\N]IZ/!MU!:>!8T6JQG21:>J26]+6)_Q?W7<L]VG1W7]U;+?>W\SKO
MS-O[K_M^=[S__?"&3_S<$;]XQ?O=\85OO.0?/_G(4_[REL]\X3&_><W?G?.?
M]SSA.T_ZT)=^]*9//>I7;W?5MY[U?'^][&-/^\'/WO:U%[SN]<[[P/<>[KU/
M)( 'FK0XOYG-QV?R21V\_.1'N/G,/ZJ,C]_F'%-?^M.\OO*1'_WM5W_ZT?]^
M]L./?5UJ__G<MS[YO5_^D*X?_>(W__L1#'WU.Y_^Z0?__<^/__B[?__SQW\"
M&( $"( &V'WPUW[UIW\(V'\*F'_C=X#VUX #*($,.($8>($:&($46( =:($<
MF($AN('R!X(EV'W1-_]::P=(9"4EBV4WZZ979N5?B#6#-2A0_2:#,?B".WB#
M.<B#/^B#N06$0RB$@46$1VB$+JB$- B#0>B$10B%22B%2TB%38B#48B%4ZB%
M5<B%5WA73^B%-PB&64B&6VB&78B&7UA8:VB#,*B&8\B&<>B&.AB&</B&<HB'
M=(B$:9B'=5B&?LB';=B#5CB'A"B&>GB(=_B'9QB(3&B(=NB(A9B(D;B'CTB)
M@&B)D\B(?:B)B,B)@UB)BBB)GRB(D)B)H^B)BVB*F-B(JDB*/+A80G%Y*G(4
M 9AV(86+)Z6+I>9VN3B+O^@3YL>+=.:+NPB,QRB,P6B,O5A+F3.,R-B,V4?_
MC(L&C<J8C,Q8C,Y(C;1CC=E8C<NXC=&HC=,XCN"(C>)XC=+HC>GXC=T8CN6H
MCN3(CO'HCK5#C_@(C_F(CO78CO[8CP"YC^NHCP3)CP(YCP4YD :9D BYD ZI
MD!#9D!%YCA/YC@\ID1A)D1G99^2G=C?&6 _$)##3>8;44H<V2R8Y4B>);0NU
MDB79DBH9DRGEDKV&DC YDS)I432YDSF9DCCYDSK9DS<9E$#IDT1YE$:9E$.I
ME#_%DT6YE%#9E$(IE4])E4@9E=A7E5EYE5;)E%OIE?L$EKTDEJU$EK]DEC;9
ME5@9EFLYEFU9EF]YEG&9EE\)DY2G.5R2);!#4(<$XV^)Q2P2U!EI!9@B))B>
MT83^-9B(R5:*68.)>9B.R9B0&9A^19@M9)B@L9B8:9D'M)F:69F?^9>AV9B4
M*9J1Z9FG"9JI:9JE29J%J9JM.9FOR9JSZ9J7"9NU*9NW29N[:9N=B9N]J9N_
MR9O#Z9N6:9R/F9FKB9R2J9RQZ9RY"9W!*9W%*9S':9W)R9G729W;J9W9.9K8
MV9S>*9[@R9W?N9SAB9K/.9[J&9WL"9S5:9[DB9[RV9[3^9[$V9WEB9_,:9_Q
MR9_I"9_Z29\ 6I\">I[KN9\*2J +ZH1.PBR-J9S'^)*0__DXY3)\HU-CT;14
MVKA@&\I5'4IW&EI,',J1(DIE'ZI5C#:B\E2B+@JB)NIG+(IC*5JC) JC+ZJB
MS>BA-ZJC(2JC*-JC-MJB.%JD/AJC*QJD1'JD.3JD-"JD4+JD3CJC5*JD3RJE
M47JE6EJE/(JE7KJE5LJE)]JE8$JF8@JD9AJF:IJF;#JFP.<Z"V1+C$-7?/F!
M#Z5_*I84)9BGMOA_?!ID>NJG]O>GA#JHAHJGAQJ!A8JHC*JHB;JGCRJHC0JI
MDRJICEJIS;>HE[JIE,JIEMJIH/JIHIJID4JJF(I\FAJJINJIJZJJJ%JJKWJJ
M=\JJL4JKL^JJMSJJM8JKG\:K?__FJU !K$\AK(&:J1?(?ML6:)"5-"T#A9L3
MIZX&K78FK8!&K5]EK7!*2-.JK=7*K=?JK=FJC-\JKN'JB^-JKN7::=AZ.>O:
MK.#*KN_JKN0*K_,JK^A*K_=JK^H:KQ?*KRFTK_7:KP'[K]'JKS$$L/DJL E+
ML-LZL =;L Z;0 @[L1"[L _;L!8KL15+L1C+L=T:L>VJL!Y[KB.;KAM[LAV+
MLA^;L2'+L"M;LO@*L_JJLB1+LR:;LCC[LC8;LR=;:2.Y47'X$W'E7YI14'PY
MM(H$H9,35@^*=FUE)4I;.4P+F7&%5U#KM);5M(QEM5I;M4_;M4L+AE%;+E.K
MG%Z;M53_&[97N[5?F[92*[986[9CR[5N2[9PR[9H:[9J"[9ON[9G*[=Q>[=_
M*[A[6[=TJ[=]R[=VZ[>%B[B+J[B'.[=MZ[B1&[B,F[B&.[F2F[>;"[AXZ[F#
M>[F/F[F<:[F0J[FF:[@SL;JLV[JN^[JP&[NR.[L+\;.D9+O+.F"XEW[&,Z$Z
M&CJ^*U&@$[P5-;SE0[Q R[O.@[R_6'V]>[S0NSW,.[W1BSS4*[W5^[S8N[W6
MF[W+Z[V\<[W=R[W:.[[FZSK$(+S*&[[@.T"T^[[P&[_R.[_T6[\Q4;R@U"H>
MJ9RCA+1:Y;^>!,"D),"N1,".8\"$A,#*DHL)S, +O(L-#,$/_WPZ$4S!$_PY
M%8S!%YQ4"BQO&NS!'.S (/R_(DQ8'VS"(2S!(QS )0R2*6S!*SS +=S!*$S"
M*ES#+'S#+FS#,(S#P$@,F3##0JS# LR,CV._2)S$2KS$3-S$LJM<O550@F4Q
MMDLY&,I5F.9WR?B[2.IH6KQX6ZR^6-S%61QZ7WS&9IS&A(?&:ZS&N\;&;^S&
M7BS'9=S&=AS'=SS'>5S'>-S'>MS'-Y$)0&Q\</S'?$>T3IS(BKS(C-S(CMP0
M5MQ0!D6G^U!@DS2V+$BXCM0941NGPJ6X%M3):R>ZH7QNGERZ+LP:HMPXH'M*
MG&S*HPS*JK'*F4S*LPS+K*S)@=1"$=)J6[*LRKA<R[_\RJ8IS'5;RL7LR\=\
MR\G\R<L,S,V,RD@+S;WLS(Z+S-4LS:[,RY!IS-?,S-G<RIO,S1*JS-\LSOU%
MS- @R(*L$\0<SKJ,S=TLFP8$9X]\S_B<S_J\SS)AO.;*C-Z6&K\(8-/*:]Q6
MK08-?$63: =]K0F==PLM:0T-IP_]:!$]:!/-KA6MKAL=K1U=T-&6T<WZT0@=
MT@I-T@YMTA"-TA2MTA;-TBU]EY-##$"L#)E IK+HT7@G.4VQ&?S\TT =U$(]
MU!&ACK(HQ6S_)Q!&?&&IY+7OUY'%*I=0[8 .^)(("-5]ZF%8G8!5'=4V.=7G
MM]54?7U6;6-B'=9DS=5IG=52C=97G=9C?=9/#==N7==:3==SK6"G+!1 W->T
M!-9YC=9]2=2$7=B&?=B,K%=]&<!4C$EA97R[)[!W-Z<8_7B4_;&3O7A5[-!^
MM]D4W=F6K=FA#=J%=]GCFMFDC=J3/=JK7=JB[=JI+7>F':ZJ+=NL;=NPW=JU
MK=& 1SM]_0E]+=*?K=LM76<\C=C(G=S*O=ROZ\HG[+YA14@8ZE][O<K^:]V.
M@]W2C<O7S=W9[=W;;9K=+=[?3=[AW9CCC=[EK=[GO<P'Q-X^H=WQ_PW>\VW>
M]0W?!47?^6W?^XW?Y(S)_XUN_>W>\CW@W_S>!*[? ;[#!;[@Z9W@_.W@ZPWA
M_IW.'N;?@XD3?<W.Z6O*JOG@!_[,8#7 S%WB)G[B*.X1=F9(@ EG\>U\S)M[
MO]?;-,YXH =[NQO9;[KC-0YYIW=[.M[CE??C,NY[1L[C-BYZ0#[C24[D.9[2
MG!UY0B'(P$WEZ7ODCG?%;#62 >0R*?[E8![F8EX0$@O%1D9680S9&?Z-J\3F
MCN/FWKI^<"ZN<D[5<_[/R7?GYMCF=M[GVJ?G\AA+@#[H?E[G?U[H>8[H**CH
M)T;HA_[HAA[IB0[ID\Y\IYR"U >MRK#AQ/]0Y5<^8A8&YS #Z(%ZQ&-^ZJB>
MZH3=Y;>S5D?!'[J+R\;+/)Q,/+5N.K=..KFN.KN>.KW>TCP-[+9^U,*.Z\3.
MV\&.[,..6+Q^["/-[+[N[!<J[6>5[,]N[=,.[<6NZ]3>5]A>[<O^[=X>[N1N
M[-JN[.8N[EM>[MQ^[E+.[!R-OAP^[['^7]W^:\,70-FFZOS>[_[^R AF[:R!
MYDDJM!"ESI9^F0G?F0O?X@R&\ ^O\!'/\!/O\'HM\1=/\1EO\=NL\1W/\>/L
M\2$/\KLL\B5/\LA\Z<RL\M#,\A"_\?<&\V5^\C'_\34_\C=/\S.?\@V?\SQ?
M\3Z_\CV_\T(/]$3[C]2/'4C15[7CMK67Q.E5;M-7[LQH>V(/.L_2K8Q./>*Y
M^^]>__5@+[^\34NN;J'[3:UY^=6/1J%!M>++QO96Y?:A!O<J*O=K__9X/_=Y
M?_=ZW_=\__>=1O>B9/>!O_>%[_>'#_BN)OBL1/B+;_B/;VF:#M):/J]=_MN<
MSLX_6]8\6SH1+6>XVS)A/_JD7_JK>W\'1O"YQNJAOT_^_*K.*'[L2ZJQOY6O
M3U&06ONN#X&S#_N.JOO'Q/O *ZC 7_R_?_RYC_S$K_RTS_R^G_S0O_S1W_RY
M[^;.C4!1D?DU+<A [*&R/_P:Y(*&E.&N9?KF?_[H3Q(T>%;R]M[_;6=02-VG
MRT_^\&^WJ@R,E=E7B43_^/^7 *%,&32!]909%*ALWT&" PL^%+BP7L.&!A%&
M9"BP(D2%&1T>!)E0(D6(%T=J?'BQXT24(4UZW*CRY$>$+UG2#(GQYL:<,V,F
M7$G2I4B8*8'Z+$ETIU&E0FLV;6GQ:-&A.IWF#!J5(U*0,JD^M:K5Z]*J67&.
MO=KS*U:N8,W^-$I0)="Y=+M2O$@LD[),Q#[I!?QW[TJF;Y.F;)A0JF*@'!TK
MW!=9\F3*E2U?QIQ9\V;.G3U_!AU:]&C2I4V?1IU:]6K6K5V_ACW9J%2#B1E'
MC'R;<>V"MNW6-BBQ\>*&PG]C'%B7N,[A_R$7)F_<M:7QW<BA*0]9'*OTCM";
M(]0^=_'SZ]&7$S[>O?SWZ=O':\0.GGEZ\O';BW<.WWSV^=75V_^(.J;JVT\^
M]/PCD+T W<O/N_3"4S#!!_L;4#\%(:3/P@D/K-!!_XC"";KR+I*+N_02ZBM%
M8O12!K"^ML.K0(C*LVVQA-:[2R6P@HNM1Q]_!#)((8<DLD@CCT3RR.A\D^XB
M'JF;2,><@C,QN@\?*ZRY++&LTJXMM_N2(QMU.U'++L$\4TPPZTISRC6M'-/+
M,]F,4[<ZZ4333>QDA/-*+NM4<T\%]_L23S;U)'10,^_L\U GW^0S448C7=0]
M',=\%+JY2GSNN/\4^7(Q,+U^VA%,GDPLT<9.-T0H25=?A35666>EM59;8P5)
M.-J *E&DW$[%LBZY1FS2KDYW'8Y8QZ0Z=DYEL6*V.N6>E9+*V<RC]KAF[\RV
MNFW7[-:H;Z>UL=KNBDVV7&VEQ59=;]E-U\UWKXTW4W'AI2M<Z<9M5]Y[Z<W7
MW7_1#=C???%53-]H 4X8TS(A-9BA.JD3;$45!0.UK_,<)1A:K(#5%26IBKNU
M9)-/1CEEE5=F^3,V$TMU*LGXLVBC59%=\D:/.$IL)#8[)4_.GB6V$NB6>&[J
M9Q!KU-DJI:T3.NFBEX[:Z:FAUFWH**]6K^J@GNXZ:ZFC,_HCI*TFFVK_L=%N
MK&RFC_:9ZZ#7_EKNHW/2&L>IL#Z[[K3YQGOLMM7N.^YX1=0/O(7]973,A2SV
MBT45)R<FL;GB%JJWEPI^5"5@]VTY=-%')[UTTT_'C-XXM\;M6SF)-CM'@HG#
M^3;6$55\3LWMY([8/6_O/+O:2[H47M\)!=[XX5TJGM[CM4S>^>5K:A[=Y[V,
MWOKI=P]4>-UAQSUQ2+-']GK;JR]_>_"#SWU2\GM7_WW:V[26=_SV&Q:YLYJ&
M*'+*/P4@,9+2N"X]:E4)BU2<4+= !C;0@0^$H&KN)AZ]Y2HW^.&-?0[UNF Q
MB'>)\I.4_D0ICXU0425$$X#(9"\.%E!.>#JA_PA32$(9PO!A->Q3#%^8PQON
M$(1;PN$/7?A!,X70AT4$XA%;N#HEDNE:&'0B2Y[R'+<$3V0=LUC&0%6QR:TG
M<X"*F4/,Y28!G2MF$41C&M6X1C:R3#J6JZ"J(M.^$'5,?%3*X/K,>)?;>)%Z
M!M19S?J8.SUV*E66L]!ZDF=(/LZ(D(L,Y,X(J<CB,5*0CK00)*]X$^]Y1Y-B
ME&0B_\@82X;2.Y0$Y"81><I1/J24G)QD*W,525B*DGNS5.4@,UE)6J[2C[>L
MWR%UZ4E>YA*3Q$QE[,+8&Z;8D(A,\4UY*,=%4>WE1>PR%Q-96$M>.4P^;01G
M.,4Y3G*R!HHG*L_, G6G(YCM;H,F3**]MME#>:Z0GD24H0OKN:Q[JHF?1MPG
M"O6)S]=IDZ#V/"?C"LJ@@.;3H/X4Z$,5BM!!!=1C";7H&#^4T7Y.E)^[(E$H
M5UE& ;6/:<A:$37[$KE0K;2"@<P<B+SRSRP]*R7EQ&E.=;K3<4+3IVS_F6.O
MK&C'_. L9+TBY>#4Q!.DNE*I;F(J@P[8K(=$%3]3Y9U5FX/5I<Y(JD]]E%:-
M!5;&B#6I>X.J5Z]*UJJJ=:ML!8E9G8K6L+IUK'0MJUW/"J*TTNRM>&VK7^_*
MU[H*=J_Z*ZQ\7G:8P_"&<]T$I:(2HY>+53-46GPB[A1Y1;NFLTRM.@I/13M:
MTI;6C6*Y$?5(F1OLF0U/-^.5$[?RSZ<@=:A4;&U<%;HY$=9VMS+-;1Z[AYS>
MMK6>O UN9!%%W.3:]D.XM9UQ[0?<Z.KVN-1MK')O2UOI#K<[Q;7N=)E;7>$N
M][O-_>UXL^O<PD!WO>DE3!63V"83#14N+=I+_TM#A;'),3)V>5IH&.]G%YZT
MRK0'1G""%2RD(4;7P+IZFQ0UY9N;/$7"N!Q*@2FL(<=FF'A:*MXJ':M:+X4X
MNAH&<6$]S+P4YS4I*"ZQBGW+XAB[>,4D'J9N7_SA&@?VQLSLL8Y_O+-C"GG&
M."YRAX\,Y!PK.;!([J21G\SD)+MVRD2.LI,CZ>.&3?!XW,1;[1"R7\GYKZ6@
MRFRYCM<LJ@[*<!][TH+E/&<ZUYDSMA&.@&.K3L1$\3A@>:G'WC; 52)JT$,!
M<_ .;>%"*WJAC?SMHOL,T9$]^I*1MK0I#9WI1%='TI"^[J<O'6I.-]K3I29H
MATLXZNF*6M..MB>H6_^-:DJ'=Z:R^W/.A%9>M.)7O_I5*8L.%2,K=="=D)54
M3^R\;&8W6\$-MK)%)',[\=+M,1OS3Z63K:%F"OF(<43T?R$*;@N+VU_DC@L/
M271.;5>*V]QI][?9[6TBHON-ZDZM@N)=[WFKFM_ZIO>X^VUN>]E[WP('N+\1
MGIZ#GWO $)V*L(KUGGI"22#^VV(U,U;FOL"LW)G"HU(BIBEI5021SD9YRE5.
MSMS&E\A\1I<A:_9QU((RGZA%5A[+W1A2P=OF7^KY8G0.]#1+=^>QG;B'A6ZJ
MHMN:Z$GW[=(E#G6C/QVD2@\WSYL^]#,%'>M';]K5HYYUI(N]ZEW?^L_13G7_
MIZ_=[&U7EW!M*O)A%YN%NOF?95VT\;\(4%6$ K?6*PP^>,IDY8='?.(7J.,+
M-PHR(2.XE3:,[5.'?+%'6ZSE)<^_S+M<UU;.F>8_7^C8BE[KF-^\Z9$.>L%[
M_O2L+[WK5T_Z2$+^];2_HNUG+UM0ZIY_N.]]FMK))4X)G_.IE_WO>5]\,!X_
M],D_&O![=:ILOFEK;^</AGW=%_[JM[(J*J+ IBQ^Z/7'*XI'?_K5?[*[A_N;
MK/U)29/.I/J29(-;"YGC"-^O_+-E__'J/[1X)_Q+.L&!$\^Z.@/DOP)DFP/4
M//VCM@5,P :4P(YY,P=T.0@,M"X+P(C;P-WI0 4$MD &]!N[0T +_+^""4$*
M',$)])M2Z:NP.Y=B:Z?!<Q?O(S-K8JF5LJ81B:ISF;E)$Y,UTPK"<H[U0\(D
M5,(B\2X:^8UIHY^ >Q<<8A\ HR$2+#: (JHL-*CEX4*&VD*[ T,O%$,H(D/'
MRS5 *4/V.,,K=,$LC*<P1$-LLD(=>D,X[$+Z<D,YW,,VU"'.PJOK@Q9B64%_
MRXOOTZ*\^SX!VB$GH;^_J4,F\K$EI,1*M,35,)M2@HA5_X$YDE.U72FCO7DI
M _DY4/2VJ2O%@_G$T:.Z/&NA&DPZ5Y0M6+PZ6<026BP66V2Z3<K%4V1%L]-%
M5(P94US%VVM%7S1&8$3&W5/&8F3&6%Q&Y6O&V!'&8W1&:83&:X2?&7RG.DRV
M2_.U8..BC..^EM*_1F0[&^206_((9KG$S!@#!!B#(]$$ 9 !!'A'TY@$!) !
MT2$&?B0&RR"&') !&="$>)S'TD#(R[A'36B-AI0,3;A'&7B\V*BOB7JP91JK
MD'HK\=.V76$2^F.=( 3)SRL8V2G)USM)DKPWE>PRE&S)U5M)HDE)F7Q)ECPX
MD=PL0<Q)#(3)GNR7GPPXG62TJ_\+29_$R:%$2IJ,2?Z929Y4RJ!,2H4C2L0P
M2I,\J\5YDYUL)+$C1-X;,QU<1!Z$'$5D1.T2J(]X1(43,R!LFTN<2'O$@4E8
MAL@@2#$P$F)(@X60@81,/$K  1D0@+FLR]2@A((L$HF4@8 <#64H2(>LC,"\
MQTP8 QG 2\U03,:DC+NT#,6L2, 43,*,C$DH2'EDS#2(RWN<A'U 31S(C7ET
MS!SXD8>[NX68&2EQ+SH,R<Y!)/OHP$V!0U7$PD><PN$,SFC!OKMQO-]T21EA
M3IMT3K9SRN643N6,SN0TMW7!3N*\E^T\SEGR3CP$3^,4SP?L$NX4SC=$3^3$
MPO^JOA+_\QKNM$';.#,5T;ARQ+ARS 3(4ZQS8<Y2(3':P\V*7,)_+,B)E '7
MW <QD '91!+'],N54P;)Y,?)5 W4Q$<BV4<9  72T 1^)-!],-!,J(=H$ -Y
MW(P-[=#*.-$(E8S6G!D*+<W]C$<$5=#*/%!^=$ABD $6(%#$])&Y,J/;8BT.
M^RL9(3\P"<7-*[J0"\YHR\8GA=):],8I[<5N1+UI?-+>C-(MI4/V]-(F74<:
M_-+Q#%.J<]+@Y%(JQ5(K)48I7=,KA=,R35,XC-,WE=+]P9D(C$EJ,SM!_"B!
MT,^]&U2SI)S/>S@RY:1WNR2+,[Q*=$P$6$W6U-%]6$@DD<B]_T2\RI34UYQ4
MU,@$?BP28@C,$/4,'C7(RG#,5+74!MT,4J5(RZA,!Z6,@J0$R>#4256&,:"$
M5=U+?3C(R C,#*U5!(#,R.!13>V1^_D[G+C-ZBDC GP^YN Z.D27-LVL:\W3
M LRY;4W ;LW3;_6Y<-76I2/7;C57*177='W2=2V+=BW7=_U.=)77\O0Y=IW7
M>ZW7+Z17MX#7?N62-10Z\SD]K%I4)CJ@[]2?A("<,A-'RZH8_L*^N(-)+92M
MN9$V2U1,R$35U:S,RSP25T4\9>!'96T-TNS'T)%(! C1E65,SBR-P'31A:A4
MONQ4ROC0Q:P,'+4,@HQ0')@!(*&0:O][/"EI*G^UUCSI3TX:&M?R.**!,/Z9
MFYWQ0<L;OK"AVB",6KC!O*<EP$MK6CC*MZ^E6L)A6JV%M+!%H,0Y0:8U6Z]M
MVZN=VK.%VK1]V[&-6ZGM6KRU6KUU6KZ-+[G=6[;M6Z[]6\(-7+\56\3=VDQ<
M/3RZ'HF*)Q\L%N<*2S,C2['$0<V])G$C"[?EH:]<*!AL'4HT4$U=V5L-3 <]
MR'MD 1PX5L LV;J,35A%T965@?T440PM2)-]7<4[3!^]#$W  01XW6.]1V*(
MQ]6,!I0US<A0@X8\41E05L'<U4YMWH(<3+I\S1Z%W<BH3$T@S9HEV5AU3!Q0
M7N--@\)L7>/__5Z^U-G)J-&)7%"1;5')4$V:C541+=[<C4>0C<A[E Q*,-X0
M154<*$S)($ABG0S25-!]",P@$<,VTP]U"B*A6K'%%3TS5!0U!+@L\6"&NY(0
MSK81KM)T]29U+8L4_E?OTL,2!N$37N&+4F'YTBA[-:\7[K88;E,4IN$6SF$2
MWN$J$>)Q->(O+!-AJJY$H3ZS^1^^N\_\)%2]R#\,KKX@#-CD,43ON$0>[=3K
MC=5+G=X#3=5,(./<W0?%+,TS+LV ?(,<+<A)Q8$'1KQAO8PT8($SALP*Y<?5
M'-;2Q &%0%D$I=[(@&,_)F04A6!^K%!A;5 R1H" ].* 5$P^+N0%_ZW0B:3D
MY*4,!D502U7D_\7?5)UD_5WCOJP,E)4,!F7@R9#,OES1^DU9RD#-E(U'!@-3
M($,6**P_NN%@XO,3(W*PCFF_XG+!8FZM8Y8M8R;F94[F9C:V 8)FB'$_(G;F
M86[+:*YFA]%FFN-F:O9F%!*4;19G$ KG(.*T:1[G<U:BI<6U/K5FX,@DO]J<
MAPB@<;3/S/TULN2A$SK ;-6/D]HJ2RS?4];4CXV,OH@&8>U4@E30-+A5 \T!
MA1C6,8B&2(WH3"C,64UCXYU(4V4VGE75QQQ-4=V' U6(9?!,\$5E.+C'>5R&
M S5D@-P'E29IUGQ,5 W("67I5%U5V719$?]]:87PY(0FAH6&X$)>U5B6# -]
M6<MD:;\LV33F9!RE9'ZDU1?]7? UZ9Y%4$U=X(EDV<A8V1;)Y$@.4EUKO]91
MR^'"-ALR.ZWA$-;Q(ACA*^<J&^4R7+3,ZZ9R7$"L'TWT6[Z^:[O6'[PN;. \
M;#)*[-<3[,#>LL%&[,56[#U*)L'>Z\FV;,>.;,@&Q,QF;,KF;,#VS\@&[<LV
M[;]6+M@*3HQ=6 ^IE,^Q(D/-03.+6(<=E7831+C=T^F\R(_,CDNLY((<@V-=
MW<B(AC'  1:HT'D<W^*>F8)DS U5X$M6@S'NZO1;X,YD9$*.C*GFZM1$454F
M:YH&;TRFU9A&@$Q&B(9[Q(%>K>X'KE'X50A0D&[H%>":KF6/WLN@I@S[YE"6
M=M#C-F09N-5558A[5%:$WDQ4MDL@O0R]U.16/6/&U&DF[+\A!/]%UJ(-8!'H
M><ZCJPUFOGHFW!HJ;KP2$T]Q= 2N$V?M*E'Q+'GQ<Z18$G?QPCA'%XYQ&&=Q
MYKIQHMWQ',_A(/<_(,?Q(M?Q([^U(5?R7OOQ&E_8)U^NXG'$#68L]V)))ANJ
MN8 <?)9B1=P^<_1G+VSB#K\Y G,E@NYC675P5L[1A*SE@E0( X7,PYQE!IW'
M.,]D)*SE$!UD.)[I3\714W;N_!;J "](W6U5 (YC_IU(3<5SR3#C?J1S$>7'
M%9UT1X;D>73JRBAE3$[(RI1J&7@#2T]56Y4, I\,!J75\07I !: _=QN5:W9
M(>$8V$:)VP0\%^2J[M'*V;!B.7GQ0;3_J(SP5W8J]@MS*/1)EG=%]F<R=IK2
MHVO#X!5B]GQQ]I.,&&4OJ&M'H&/7]KOC=FM/]FI?%F]G)G!_R6TW=V*']G$_
M]W+/=A_Z'"3^(*K<)V+K#LJ:8C#7SXT32\R*0'"$EQ#/0C;35E^I1"\^ULD@
M2-DTT$GEZ,A8ADF'>!"-# S%503 RY<NZ5E.OY6=68VW#%1WY*R6C#>>Y5#5
M67Y4@^K.:GN$@Z;&48>\5%"F=(S_=(WW8HEWU4AM63EGZ<MTZ%%>30-5B/,6
M]9WE^ !V\,Q ]:*NC)4F$J?J3ZNT(-BZ.7T?D^J98!D,2JY<VQE,*VNADZ;-
M*EPZ>Q(O^_/"_Q:VKRNS_^?7CGNW;W:ZSRNY?WN\EZ[<'/L#JGN_9S+ SWN[
MQW:^#R_!WQG"[_L_0?NNTON[)_O =WRX+WS%-YIY4L=<CI[)4ZC[.D3 V#@6
M$14<!+90 3?"ET7V*LJ1BZFL-]TUWUFH1E6'7%F\' --30-1C53&S'0!/VFE
M)DB03S_)U%2]I$OB7NAE2(.$Y,=2)^M$SXT<V,_#1%%EF $@;?2$-M[]I(?=
MI\B!#,AEJ%1.W4\#A4V2+E_&M'.J3E7B;?J-I756??B>5H@:??E5M7FASUDZ
M!HA]^S+)0"!0((Z"DZ+M4S9&3:8QR@021)!I7XZ"!S=.TKCQ(\B0(O]';E1F
M\J3)>LI4IH2&\N3!B2_K06.Y\J9*FS9QHFQHLJ%*H#=/YIPIT^C+GT-Y+E56
MDVC2E#)U#MWY5&K4H$N+-KW:%*56JBRM4LTZ%>I8E%YW@CTK->W)M5%O"GV+
MU:1<LW69DH6J=VM5M663AD5[U^E@HWNY]CW<=G'@N(D? X:+=S)4R)81^R7L
MMBM+KYV=1A5=F2GIG311WW2Y,A.Q3\1@TXX]^S9M9;!E9](]VW?MW;/3LN7:
MMKCGY$^+,E_I>B+)Z-*G4Z]N_3IVDIIDR% 3,F&.?=$*<B\_9M^8@BRXI]E'
M#($,Z&H\[DMX/J,, =SA9^_O_S^  0JD3'G_\,'GW1CPE2=#>_MP-\E!]>"@
M'WDR4+)/&@7NIXE !T:X7X7M$5,A=Q/A9V")^VR' #'NP0>*0!D:Y*""YKDH
M0XL?C8BC0.F=-Y""-5ZT8HLK+BC#CQMM%U],"U*8R20HZO=C>C*$E&%X F+G
M7%'/G9933%+YU):7G:UFEV,ON<06:H499M57:!Y%W%=KFF633W2R9:=G>&+5
MG%IQHI:G77L*:ARA/!G*YJ!_LI;:G3 Y:AQ>ARZ5**!Q6>IG8)1"VJ>DG=:Y
M::AZJDFJ4J(N&FFJI@;****3Q@E769D22E.FEY8V6J)M0<7;;;P!A]NPP>%F
M6V_&EM:E8<>1QF6E_SBYQFBD6EI[+;;7PG<12!G^J$Q&"*21!@+G.<0=#A<V
M5%".!%G98[D]HKMDMO7:>R](T8R1$))IZ"/0)&+ AT,:]2 D (<;I9$#?&(D
MK D"DVB2T S<.BB#Q3'BAT/" R54+G0).LS=& D3R.3)T-';4+ACD&MN0= I
M&;- :(A[T)(YS(; A2D+1 P.+!"L3+PZPM?Q/LNDP6\.[2E=7@X61_GN1QDE
MB6](L+8VJLQ?,:OHUE0])Q;8H>7TU+1)">6:G5PMA[9C=K(--F>X/KOJW("^
MK5+:KS[;]E![WWTJWY7J?7;AHR8.N-G0]JWIXG0+_KCA?TN.^.!^Y\W4Y/]Q
M;PVIVYA3#NGFH3ON>>2'GZZXY:K;/;K<E9O^.NJM?_XIG&;.113:5 EEG*>8
M\T0,L<8F.RRPR1\+VV_!%H;<F75+UI2G6RW'TY@I8;T]]]U[_SWXX8L_OD!B
M($F^]^S9N^WXA?J*9E #@NYLH&$WZYRFT8XV6O75"_JE4=A$+;)!+SD&S-6C
M_D?  !H0*72[W_YT%[Q9S66!]'N? Q'8OPJ^B8$.S."C-F@6]UTP@G?1( 5'
M^$ YF1" $%SAG'C")_?MY8-9\9+_7*.\V@"+A\LCGFR*AZQCG8J%J)GA_NQ6
MN-SA\"CH>R(4HRC%*5*QBAB109:L>*V7U6M)RVC_7_V.@I49Q@1.;/K=^VPR
MP^;D2G7.4LUGV!BJ-_8$@)RBHZ06>,<.YK&#>R2A4O0X1SX&TH^#!&0<'Y@]
M1&JF40S<22-C]<@Z"C)5>"RD^_ZXPDCJ:I)]S.0A-VG'4%)**Y[)GAKOLLA(
MJ9$Y3QG3V60WO!\FZS?&0U:QBA4L6\KQ62$\C9U6>4*ZG5&+QCPF,I.IS"FF
M1PS+!-"($" S:Z4'!^0["_!B**DPV2J!@$G;$G?7QR:V)'&9>TGVR%G._#DF
MG1BTF_Z^XD[^>46=EO0E]>J)03'B4S7ZW-\\#P//?J(SC/E,)4 -ZD^$ME.A
M8/EG0]EY4(FR): 3C6=%3QW*.X;*4Z/KQ&A!*?I0A!9PE7 <3%BN9]+_I<DX
M7L(E;'QSK-L,BY;-RXVR.)@XO@EPGXKDH&&>*=2A$K6H1B4)%X]JG82HZUKL
M(A^U% C_$_GYTE!T 4Q++P.MS[QE;'0,)ZUDN!FP726L71IK<\HJ*YXZ)JUA
M)2M:Q>HHN+95KI%Q:UW/.E>\>LVN9FU-7/5Z5[].4JVJXDQ?!?M7MB86L'LE
M+!T-:RK#=E"R[J/L9;O"1].$4YP;[>?U?-=8E=S2A\+!Z1"%9=I=PB:THD'.
M6:8%SL#I;B^QTYY2<ZO;W?*VM[Y=9E=C*:U8QF\?H9U?_UR3I^MEM8322I-?
MD%C5_+FM,]+U:K2J>Y?K6A=-V/T4.TE*V^UR;2FSG6[EPBC>T'37JN;U;GN+
M^%[.Q5>]U!WO>]V[7OVE4K_W92]Y_9M=_/97OOM%+WCY^U^0_V)SOH"!I2';
MZ,T41L\DQ^HA\FQZ6@W_4**MXJJ<.,HL-C&7*;\],8I3K.(5LW@ZGHWJ3ZC:
M0KM(%X3(>4Z):]NFZ4T0P#W6ZH\'5T#I#?F\S3HN_8SL713ZN+%$]J"2.<?D
M 1=YRD*&LI6C/#LG:SEP63;BEHL,9B__LLE5+C.5H1M9 O-.HF6RJN@PB5B;
MW+*'R_.-G5%;R]ZD]C>]W-T$:6CC8>:OQ88^-*(3K>@J0BNM9:.+0"2L1 0_
M>DTX)NX1?YH4N3"JAM7S]%Q ?4;JA9K4HX9C5$2M-E*GVM2K1O6KG<M5:JFZ
MH+"VM:Q!W>J3QKJ%M::D3^6<0%WWVO^(LRXUKW'M:U='5XX5%BB9#^O*1X,J
MV,2K99[Q3$MMUT:(J)V-,)V-OT+>UH.?*\MQ%ZWN=;.[W>Z^#J.^&\\PR=:<
M]ZO>X_QW02]!>#6302.//]L8,1VQ.#E^;8.U.E+04,:E!J<4P@&.6($+IN'F
M?3C#,U/PF1P<CA+G;,<MWDJ.0]SC&U_XP*_J<))GG. K1WG%-?YRBD]/YA?G
M. ;?'!G6]#2>^'QSC@F.IA^R]L["N8T0\VQ3H>/8OH-.2[[)-*MW4[WJ5K_Z
MBH,K9475I(P4%&Z $S[:JWJ2U9W4VJWOS5*R57O"IVF[OM]N[KBS?>YK?V&(
M[V[L'4>U[A?_I#O>^0[HP&>S[X27^P%1Y7:_J]WP>4?E<.M(NC1>I6_BUO<&
M74,,;@]QS\I NO%TJ>?.ZZ: X@9D1GVU%LK!$^NN?SWL8V],?!JP3%TC)&7V
M;CT *QCB^83*&M=I<,,@W*MN.O=SI6X7R,SVV>8L"O,+I7/C)[+YTP_J-Z5O
M%.I'G^O;Q[[8M*]\[&7?^^.'?OFG?7Z5 U_\[5]^^I/_?O*'W_SS1W_]36U[
M:*,%L]G<?YK1CMBIQ _96=%M6+;9TK617FWP2;Q]7W;)EK.L4=2IC>Q=( 9F
MH 9F"[7UFXE%6N6QG#^5W2*=GNW4'4K17FH@7()!GKTIG(,)CPQM_]I@&!^G
MJ6!>3-= ?4W,Q>!6S:":U&#_D8WMY: -$B$-=I?6T5@2DM<2 F$/,I0,\F#-
M^> .WDX52N$/4B$,:N$5ON#$"1=LJ1_C#5@:@1+O^=15;-[HM:$"[MD;7I@0
M$=$]-1C898J>?%<*/MD&]J$?_B$@@L2J[$\PR1CZJ= A_@UFZ)P&J1.$@=($
MFIUV_5GCC-5X42*0-5?S815S]=PFHAMC* <DDIDEFMF.24\*?6*S[5QTC6(E
M:J(K9F(JQB(J>B(M=J(H4ALIPJ(NPA8_C9ON4-_L/ <LS<TDA:)EE%8NE=8!
M9EBWH99LL-S@]=S@K:)4(-&:!*(V;B,W8@7=1UF7I_]X'=K9CT[Y!>8X&F%P
M6@5"%'P1VLW='1+5RIP-7CR:XSQR4#TZ"F9]'ZQ!G26V7S]>XS]>HR0*I)J1
M(Z$QEN'E8V#LH]0%I&/!8T%&Y$).I$+2HT7>HPK5Q0U>$(2-B3UETQN)!@"*
M1G!P'ARJ5APRSVI!X_)(F.!(H^ P1@XF!E=T(T[FI$X:6I\H&?3)SR8:HY](
MF(>Q4@-%VS!A&A^=R2/^R2O-%6V=R1@^Y<ZQEU0BA=U@2BM>I:]D)51:Y>-H
M A  @2;0PS+HPS+00S30@S(L Z%96EU!BU:.T;A-I2E9!EC>Q5AJPCK-952.
MSEA0)5X:#F#VY5<29EQZ957_(F9?R>5AKF!B"J9TH1M]N2/J-1#@X1^I'> "
M&HM-P53GK:2WZ5Q6U9"@[%_T- Y=3M5.MJ9KOF91_5)579HXLM,RB"40; );
MNJ4FZ !9-AVOR9%MR>(6OM,'F0;ES=@+IB!V]11IEA\K$B3OJ,%8YE\ITAYS
MW@1UJD$TH 1N @$TL*4RF*4RP %U H$:\*5-F.=8DJ5WMB<<H,1M D%\E@5[
M\N57: (<M"=]:D):MJ4RG"=_PH%;GB=YCI\[/E]6/:=U+B@(26=T8B%6W<YU
M,NC]-9?=T:6CO57%U1N0X9!K[4[?U!EK?5Y* A&'!9%IB5XB)EO%+=8*[2'8
MP":-_]:HC5)1FCW03<H8&K$E')#!;XYG>8XE')BED;HE5;*3[>4*9VD<, Z9
M8Z:@OP7=(=;DYP .]H7A?@(!,:3E,I3.28BE&L"!38RE&B3E"3J+3UBI21#I
M;FXI>@(!>;JE,O#G>?)E3>SG=A*I2HAIG/HG6^+F^^S#EG((5"S#>2;J7IJ$
M/M0I>NI HH[G?8[G?V:IE::.JZVIE*:II6XJF':J!'$J_(4A\<E2EDX>9FB6
M8Q7>/IF2469*B7J;T<VJTL'A2>(4/P)CT%W:IB59^#G?C0:KL [K]D#A4:Y$
MA @*;^XE>=;#?=(I2HAGA,D?!)E. %G:USC>0<+0A#H95/_JCC+@)GX*:?#@
M9GRV)3T8: 25$H8FAKBZ)3V@9V^.Y4D$*GH6Z7?VJ9F:A!I0)RB$*WK2@YX"
M*'5J@DA2@KR:Q%F:Q):FIX_>*;J:J4NPY6XZ*H&ZA)>FD-FQT'7R7[6V:ZNR
M&C6F';MJ+,G^GH).*-EXH&78$^*EQ7#ZG.AMFQO::HD:BTHJ"V38X[0"FRD]
M3E,^%[$.+=$6;7]TY5.R5>L-R&RAI8\F[$EL:9$V&KJF)0 R$$@F7_#!V"K2
MY';)D>V!&A*)K5\06WE"JB:L);3FD4MH0L$*J3*L9=S";5JJK;1:;=F26NRH
M!**BIY#"*S08J%MVY[ZF9:&>[9G_NN664L(R[&=\BF5\TH,1N&<5-BZSGL0R
M$,.^UFO#G@1Z)J[""NEVPNW$?B-"'AMVD2TDZ6W>PM'8LBY6J"ZP72CJ-H79
M1J=EC$FXT=XFCA/RA:RSN02*(F !)IT<*B-+=J:)+J^9D!,8.BFK%&1%&6U(
MB,$! , !0,ATW$  '$ 8?(0F&$  &$".Q,#UHL%!Q$ ,4*\RX0#V!D#&D(3Y
M @#Z;D0FC&\ 0$-#X*_% ( UV>C&OMA!>.G=OB=9GJ7AJH$.^&?4"B@<X*=;
MCB4QL"=91H/;$BE87+"9%JGA\N=>BFM.B"O#"NA8&@%+:/"8;D*8+FI;;N=3
MH+ *_PDH_Q1LPSXN'$!J?+H&!ILE;H)"/<3I6.I ?-XF!:<GOWHP$!1HP+HE
M$0.!;S[P3>"FY;)P6^JGF8ZK3<2KW\(K@,:ID-+#!4]MN+[M>9H$&%/GX_JM
MF )LXK*EGPALP1+PD(ZI5"@Q$$2L$)NQ,C2JXDHP@/(M-*SMA)HF$B:>L $3
M(GY2J*)F9Q!RJ1HRB UE3T(.S]:%J6"<<4J/5UVMA=&LK#)C+=V4;RSC2L*&
M)%4FS%+KG]W3R"D&^WX$&G"+ 2!-^DJ-,^U###2(0*S 1 S# >P#&M1O#&3"
M,@" )MS *R.3& Q#0\3 -!W$+!^$&-0O_,;$ =##0*SO#5R$,O\X,S$<0";<
M<HU*WK2R1)BT97B2:UL>[@K3IQO#J8 :+,#:J9EZL!J0YW<ZL$GXZ9^*Z;F6
M)W460^"V9Z*>Z9#:,U]:;GJF\^9^9WNJ9;W.\Y[6LYVJA!:#KI[R)473L4.W
MI\'J:9R>J1:?J\ 2M$<S;$@#<5FR,7^.H)N&+EL^-!.+\+*ZLYLBJ6^>*3^3
MY1KC!9WN1*&.S9T>*%L.M:.J0<;JL;BFLQZ[,?Y4:J4Z*<*Y$F/UE:9^5>\D
MT5%,=>3E(-,%I^-,QL\N%/*)9,Y!Z+IN+%A''CS-1L[.(9^=EHF*)O(V(_-\
M0GK=7-H9$?5UU6$ Q54D\T:(@?:*0?S_FN\TX0!TA#/.?*] '  QQ, 7 ?.W
MK*]@:Q$.<,L-Y,A!=.]'W,!DHX$N9T*#*$, ='/Z)@QC [ EXU?3Q9A0S"F
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MJC[P)AB&RIHO"F-EABI:6PY>,"!G@K("9AN);EB'!=^NY$^3_Z)0 _T3%,6
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MP)=Z86=67<I$SVAI%J0Q4=0Q!3E9I0:-=$UJ;N8-]_+2= CT[([SJA7:0G&
M@[2!S54,G ]=,<_U3M.2NW480M-O508[W@Y7I6H*09!1-_>*_R@.Y1KN2T<8
ME3\H3!%PS^#,5Y@W1)IK,(R0T;+RRUAXY2J5(]'S!PL-B]&2S[AKYYI2@7Z,
MAIVST99.E#932YFY=%/74VO8F75XA;,46>;SI."3H0C5Y88W/Q57H4CUSX:S
MN3P7F*VLBBME,+!8F(M*\8BH[2"R8TRTU&9UG]6H /7Y$6?(\-P86O%+B+JF
M3%'F?$,D6>>W\G2-,0'116FM:R$::9!H?->5?T-&+B]3J)XC@+=*-"?!1ST9
M;DPS&?S60,2UDU/:7*?0D_-R,M>V1TK6/;AC#/V,"%LV3_>C(L\,7J*3\+YR
MVVZRY7"9=VDX@UMC*K,SRZ"8/Y#%!Z(?%M#HTXF666,@Q8HMTD-R(P1[0Z@=
MM72+]^IJ,'JOV%4C%[^,HRQT#EXV]4UW]U\?;9B?MX37#M,(=4T;,96!MP59
MDE:?KM#RN:2X!HX]U#;U0['[%XW]*XK$EY$9U&4$:4*-*J#UERX]E*44<6LO
MY$4ONL&0=;0OCXR&9BZCE6G34(+Y\C9?AT<3.*9'S#0SN5PWF;9KFQA06I0G
M^)]9:CK_!F(DJ,S1RI"].,1YR%--?9DI!70\U^X"B_(%)5=,XQ-CB1<\PS*L
MS5EC)2M S@Z':"6N?TZ!N*TC?7*:&8HHA1ET,=4&#14-4S#C,'#21N0)YQL[
M43EB78[(HC) 1;;DTOI1DYD.X9DKD9>)#ZTP-=AI&7QZ.VFA"7/S3 3N))SS
M1E1]62U_U]9I011MTS ^TA=$/5K (AJCS<CQ;.)8AW6TZW=%Q;94?\9H Q<^
MZAC3@.TN GBV=1NLH %)6YJ!>]R2H-226UN\B%:JMHPI3_::&]J%&SSCJ'*H
M QMV*0H!?<Q2)$TKD:SLPN^\D?"[4W?JPI0J+_91R^.&?_AW_X'L[/S,S(;S
M. G\H73C"@UMRGD#/:69K$QP:=,@&6LZ.]I,TB!NNA3C!J** 7=Z59/#I[.S
MY""6NP16K6&VJT&0FXG0PR&<;%G[R4?DC"_*IWKUNSX4L_$2GR?T9.YYAF*&
M0SF;( :YHL]H:DZ<10&1UF$\UU1\?1\[B4;FGCTZLP$O#9F#1R>A;X<\V2\I
MMY6]V2]IL_7PE"?KS*PFB--,JVUPI79Z$L2OAY7A3/ (#?#G#\,O!I0-8C(A
M#,0O$\SRVV. &+J:YY0C_-"3.ZQ:S,E#!*WC"Q4(9T30+/UZ#'N70?9(<HTP
MX._G!F3@!F( _=C]=<&]X1<'W@^"V_^W@.&E+Q.V8AF\9 O2(*T)GF#&8Q+.
M1F.!N'C%K4ZE;L>J9!+BDP31N;US[N>"J'F=TX)IMF$SF"?)@^,F1B8SDH[V
M@Y2G]2VE-7LW\V<DC-<0+GP[*5675K-%)B+K2\)1EZWY0XM..\%:G'[;%Z,I
MVB#/2,6EYL(A6[V@?3!Y7=/KR%HSH<B=/>[MR*7E?JI"N8!U^0TE;*0I):??
MF[G3KM#"] /G/0;$[\QPP-PE@>0!/6)N( S2 /;$CR[$3Q/0X-V;HTK:!H7J
M.0F3;4J\;(P-6V0)ZDS5:RLX))9M$LEZLT_! P&YG9#@O*V/KBBJQ''.1 QB
M0!(V;AAPX/'_)R'RRT\ON%W9@I_ABV8XAF'A2QXA2#X3RLX\N%WCN=)C&HI4
M?6KEO"2JUFJ=(;8NH9"##_8XA/G[U1O!+QTMN9!ZL/JCSAA[X_BWS[[8X%\]
M.CP-@]W1B(W4NJ:? :*>,H'*E$$KB'"@0H$,%R(DEBD31(C*)%*4^&FB18D8
M-7K,5-%CR(\7B67L")+CQY <%284>%#@OH0N$=8[2%,FS8(S"2J<69!@0YG[
MBAH]BC2ITJ5,FSHM2FR2LJ=4JV8ZL,( CJJ:# 0X,/7H@0 &)A45<^! #*-H
MPU9]"S?NTFARZ]J]RQ0BWK>3O!H04Q4-V;5'H9$-D.FLUQM&<0#8_PLYLN3)
ME*N^K+DSL]&"RPS24_997^;/I)=!6T8OFK+.H'%"^QP4FD!B-\1DBB%&M>EZ
MMR6IKA@##6AE8F(06ZTLC''@Q#[' %DP>&:"KUE_%G-#8.=HI$&CWHZ<<_>$
M]&3O/'VY8/GNJ+TC--VY/6O.-A.:IA^_(/KXF7"(.0C-,#'@,,Q!M#W7&6P0
MD9;&<^IE(D,8[652FQABT'/?)#=DPMI\RDRRW'M3+?2:0[!A"-MWY2%TFU3Y
M65>?3MKEM)IY,]($FT\R#H>A:^UAB-R,,/VHC&[(66<==^UE1J)0#@6%D(U,
M-@EE0SSI]^1TF%7Y4VQ#U63>E%;Z5!.94O_J1!-.":G9TD83G321226E5!*<
M*J&D44AVDJ02G'O2:5.8F.V894-J>KD3F5!B25-ECC8543V/+I4)8/N(8592
M:5@Z4PST['/;4;;-!!:%9Z&Q3PR:Q.#6I*[N$XVDK\Y:%TBT[C,)JOMLJ-0-
MF8)*F!BZ%A7#,#,% ,TD6^UJU@'#'' KK?I$2RU<(_ITID,,'6240)\1E%]#
M,[TX'(_N?5<DD"R*,4P]M8V'W7$*%;<:A6F42Z%PD\APT#(Q2(*:A5#VA)"Z
M!$5#;XE YJ<>C\N(%I^42:*88)?J13Q?QMU]UIYHWHYX<6D;#_?Q9P**H= R
M:#PG$'92<8P>?9/_A($&N,HA1TP,DQ0'$H:2R)#)R#-IR"&4L-G'*,.K?=8O
ME+2]K(QHI2W-)(H#X72T0=Y1C%R_6>LWGY7AK5CNDO1M7)UG'NYV];:9J1F3
MUF+;2/?;-'(9Z%!P?SEEE(ER*:.:BE('4Y8Y94LP0<3$2>>??++$YW%M>O0G
M2WJ^N;B;'7DDZ**>KTDC3GPCZE/B<CLT4[65441M?T5E,NSK "1F%.Q%T0.6
M48^=5:DF1:UJ5.ZJ#T^\JWK1:OL^:?Q:5!@'$'-4&K0#7]0RC!$[# YA*7L[
MM,5_#_ZCBFZI-:-$S13SU5FO[&MK*1X9\]'RHUND,KCE1P]NI\&&W3 ?_SX'
M)-[(0 SZT)"\VG<;>1V.-<1@'[NP,Z,&*H=F2V,-&G 0@QLP0CT6JM2[.H.&
MXM1&@16QT W\XS!)8"<XQ.A7 V^00300(V,/:5]T)N%!' AG/D;2Q+O4HR&I
MT 9E!.E.$1LD%84,"#84F@0H<(,0#0V#8:P!D?_TL8QA7! WPA&());CK29B
M*!EBP,$6-)B0%J&G4@.RS8H>IJ+Z&21!\:$8Q\IG1(0HR6K?(L_#SM6CLED-
M.49RC]'Z]B6^.2D]6DJD2X!BIO'%*$VDTQ:5S*2E*!FJ3#2ZB22G!!$ZW0ES
MHH3<Y!KWN%'NR7&3JYQ*ZJ,?MUER6SJBI"0[Q__(\@TD?'B)R*>B52EBI<$H
M:2A+4B8QS*(<X)?*\-X^T* L8\WD>JEJ%2^OB4VF2.16FRH*8AH3 &M>BG;V
M,TK.&G.;L 235-ELISN=,K!'SK)1U2/9>[ZULN(X"#DS&5F*%J:N$@6E-E)3
MA@\OQ)EDJ8HX6]!$^=R%LB%FXHL&U5G<Q#8<&$(3._0J"&UN, 8VHLP@Q"@.
M&B0QAO9!PX1BD$02BR,&-S3B!C? &1=W5AO.2*(VD]A9T+)(TYZF=*2I*8T:
M!U(;GIKTD";+Z7:*X]#>=*9I4^V1AFH&#0]*938Q2(,^7'83$$&GJ,,A6F=H
M@P.7PK0@!WT/&AJJC"'_;C2GLVD?/6Z#@TE((JV=453%/J:>0R'ICK_9&DTB
M!J6,"70X?4T(=\RE+@Q!K'Z.9)0NR4>PBQK.LI_#V[4L-DF,^JUOFE6DX6JI
M$%S&*%N*T]R<3"FG.T&.E7):B4I2.2?;Y@DD!"'8W2[+2-..3ER<M-([WS(,
M#E'K63$X0.Q61KNCK',?PBLG[T:UCW,J4YS'[2[QCC>KJS0WNKMB55*P2QMS
M4E,,/H0>J):ECP!X=[[M[!MGN;09(,6-/BL,@PRV:I_]I M+L#$/:PAR/Y[<
M1@P5HT<:PB 5[&3"2C&04 EQ(Y$P_*=K""'8,L2*'!!E!S3Q"LIM?@I=@>A#
M_Q,3)DYM"DLTQ06'B3SJ*'%PD+7.E%%>]#"KB.[:OLYD,(G$8=4=^;.%W)@,
MB@ZVZS+$H!P8,A@T#5).!C%5OB;&E:;',6!XPF/%@I0X:D&\3DU1E%,7'\<T
M( :.BZ LGD.I^&(B$E+4AE/8F_118X_-XT'Z>,<9B<8@'R-70;!(GG+!;9Z%
MN]+@1GLZTS6:1+GLY*(OXTE&;_90KDD(4#HKS]&![B$<.<EL=ZO;4:+$E)=K
M96[QM&I53^10@#M=96-CM[_1^DJ:H2]36,S=26F"4YKZ)C%U9=U]+,.9..B/
M[]YK%//Z>MK #'9E<L64YK:JV:];UCZ>:)0;T,:]ZPML)K7//;RV:1J2Y?\S
MBL;$$S4HRP"&T#'LR(*$;U@BE8@>):C,VH<&+M1[*@,JEW;04-.2GA' :Z)7
M=["#G-ID(KD1Z:J8607OB].99YG01')K0\/.>/E2SXF;<VQ#\=ND060&ZBII
M:G,3U*1A"T4[-&@."DTTS)M#"@48:#*Q/ TA]$,\#?B&MJ:)+:R<Z%(1J\BN
MYF,,=SP3(/+-_Z22+!M*?.)4OX'/:;-TE1]-;-_!R8^PAA][TJ=A_71L>.CX
M8ZT=^7T-6T^']HQOT382TZ$EW]\^#5J]/5KPI+TO3)SDR%K>!%%^?Z@E,1<Y
MQL6VMBTIB>1%&3E9C^24J,Y(2"QIV4^*3E [(N[_XA$_*-2A^RC)_>6M7-<4
M[D'%O+(OBJ_V$=\"7@^[U+7VZG]O%_"^:KI+N7U1-'06YAT@,<2 U@6)]6S<
M 7_ZDQK?KC]WOJ@MZ8_A22F$4]NA(RE$?J(;3IAJPZ8$$T2L3]X08'$#)"8N
M1^)M;DC^;I ?A,5 (+>9][QC4&$78CUB4$1]M5(C=F@#L@49% ,R<$9]E"LF
MM$^TP05YQ2(WL( 8!( :]F6=H65"MF&?H2&:4!XW<AL5-B"2<!PB:$,5HPPO
M-A Z-PD'L6#S\8'V(VYOL%# !2+',0PPY%\,B$+T<% M(VYQ!8 W( ,9M(0$
MY&;(@1UII4"XA")493!E_Q,RWM$T>0=9-3)(C>6""6(>XX(<XW$?X_$24F(Z
M:;@FG_0E:ZAO<7@9@,<DDC9+<@8EUP=J;JAN5D)KK]9JN85;?4)*A?AYKH9Y
ML$9Y?,)IP]6'G?5)B&0^5V,^U,=BR] ZQ$85;[ ":D$LB=%,7R%-&'0 R])<
MG4A-U*>*<;%-M)(&L4,5:'$ EK)\V:46SV-[ 1 <RH05?[&*OX@7M48HL603
MW7)/\/8C[T8:"J,F2I)O7Y8J",40/U0B*U,@;796Z%<C69162%@TPK(E&+0Q
M$+=E*.=Q+'8<^J _ZL(9'?4=]*81$K$: H*!-(5A/L%&1Y@S[)5<$*$)S:%]
MI/^1=%X%&OYQ1VW6,+PA,&9S5AF$&@(5C; 11 H!8I^1,TD$9)@2!BWV)413
M4>S%=1.Q&E]UA#!7$2,T<1XG$=D(-5FT0KQ5:_4Q=LU8&K1&)%]#'ZK!C@,6
M6%2SDP63D^8"'FC").7';AA%2^6S:YJ5+<3H6VEX:Y2T=WLG2Y^%7Y2820TQ
M>8JHB'X"B+(&$JA&B&Z2:EMI.7<B:O5!:V&R2(2&.O-4:4]"?<GE>\!HEW?Y
M%,.@"=."EW%!%WUIEZ,VE8]4%'E(-7\F1Y*5=N%2$^-A'GUD/[F1$/22']CA
M@3K3&LO0(H.TD!3B/_0@,)H%<96Y%D@H@(R%'I09D"3_AH 7]VF+9Q!EI(*H
M 6)%!!S",409ESZL<8,@5U9'>"/  1CP-F@N<R0GIY,-(@F<(57UTC[:85+[
M9%D]6(X< QN(!AQ4-X%0)$\%<52,E9N"23_(,6CC=S9=\CZJD6DZ(3\C\D]U
M-$<AHR*=T78,4U#W]!U8Q#4XB255V7=C4I2;Y5F0]I:FY1)TXX=^(UITR'>P
M^3E@*3EEF1&95R<4ZDIB>7F1 R=X2)1/@BVXADE3$A-2(B4[88F3P)> J:(K
MBA2:D PL^A8I"J._IVE8>:"[5!0%.'9?1B8P<6] "1\U$39IAB)I8%=$-P:P
M<48X8V,%X67>V!DZ9#7]\D50_[-3&.=B08,<$O$9T*4@F7 :*W-G @$B7500
M>CD033IF=T0<(X4=)-@O\EB%7)5$$ 4S"%F"Y=@PXJ&97'!T=_1#3%<QQ4$,
MHB$@1*8,)^-^ED0TY<$S0*&9*PB"4$:?:H:8'6>1STDU+E9!=B1W?P10XE<>
M'G*<Y2(F'9A:6!@:I"I8YC(CC<6?>ZJ>H->@IVIK OHEY9=(>A@H6!F)M(HW
MAR>@E,8BI 1;I@:A=G*(J7:L@SAYR/JLF2.2F]2&N:1WB?>((OJ6<ZE<,^JM
M>*F7W^H4LB*NYS9IFF2M/%&8Z4,F7\B.,Z(;J>$2)[(TKT$,:2 )1HHI.(00
M5Y8K%?\F'@W24AH29!AR8N7204_J@A^U/#A0&Z5Y5VTT43R#&@>R/ CW,I;Y
M93? !<+RKTFT8/CJL @"#3( 37O%,L 1'#VE'"VT$UIV<HAII,<!+MZ)&TK2
M.1';L3FW!?Z1G.V#:#MU+YKI*P;F8@)W60<!(@YUDKC!LC? M%0&0TMGLTZ[
M*<6B&BTB9F+P!CN#F62C1SL)(S87629B=MHB,6J#AC-"=Z"Q1W$$,_.QC G5
M$.CB@IQ%*!PZHG(H.%:)A\#UGV[Y-[7&H%5R?8_VE%R2K)D7B)PWEJBVE14*
MEK#%>1M:JT+1MPVZE$R"K=11C-/'8JX'&2N&0Z4;$3ATNA'_076JB[JKR[JJ
M^[JI&[NN&[NFN[HX5*[4YG&4 3NF:[NMZ[JM*[RS"[S .[O!>[NWBP;DE;O3
M9KB/YI9DXFYJ]UE>@T=R6RX%UEB%Y9P9=$97IC@:PD5EZ)TK9!NF2C/:D1J5
MLG %TUC04%)75E(C91KSJU$M1E+]E093U*8.TZ4B=+[]]&!<-&Z@\592!ATW
M,;\Q!!V-1:><89(B5RR":Y$<:*+A$4(P= /0Y!X364,(=9%LEPE^RI$.X648
M8K\2MV?TZ#^-U:8TA0;\NV52\4PB% 8K]R*#E(5 XHQAPV%\6IYO8X8UXA,P
MXRWC>5B;BG=Q5#!J,EEO.+C4VJ-Y_S.L\22,JK5?J,=KP&5Z-)*X-DJ,9"(2
MFT.(EJ=*<>*5MT5;>])YD;L1FT<2 \JY<A,FM-:YY'.XA E\PT##DA$-_#HM
ML:(/L;(/LF+(A9RCN"<IOU0/^B IAPS)B8S(CYS(=.'(=%$1==F\O!2NDX%E
ML()[=!')B#S).2K*A7S*I5S*E*S*F @K@1S(/:7)FXQ-IWIZ:9)]^K4EBO>I
M J:^INJI7/.AX&*=]$',*6.TC-(C[>%7.7)G63A)6>P29$*J[3$N1P,>ILJ8
M.KPB7Y(U?Z:36,DTP1ES(SF?[4E'.BR4"Z.%(M+$9C,E#\FG-=(PZ(+-UHDD
M.%)!:,<T?/\:2'?;'9_61XCK$';KD^^!G=CLOF2E9_=46$&<,F5HSX#+Q-C'
M=XUW)KBD*';,EK@<7*"WEM=JE0!Z.A'Q:E]9B&N,H8[[6J.D6Q>*K*GZB.MI
MT7RSE@K*6@)JB6 Z&3W&O/,%$>1*R^]D*Y,!3><&3= PU+YVA^E!TV[APY[E
MH"F#-DB#Q#'S6)XUJI=1GCLY/UR#A?N3U=Q7075V-Q[B$_KI'6H]MO,*2$02
M,VF#Q.'QMG1&-4C<KID!AGB&- (1KXB)G8;E,9M:1W"$(EEM6(C)SO2Q/^3K
M.77;GNQ<T07S&Z\:*/-A<J2ZI^92$/'ZS@HA-=Q;S>4I'Y06&N1ZX\#FV30.
M^IHR[7AI.4F4&)53W*.92Z"P[9^#NR@6X3C*.KFRQ95MW":;=VJ8I]*:)X?V
MA<?37%I;<M.W.I>3(-1[\<?=RA1_6138#<K9;138[=W=W=TIJMU*D<E+?5S"
M!QD<7!?C?=U(,=[L?11"G2O3;=[N]*&Q_4G_FQ'8GT9ZJ(UO9/6I?%0V04P_
M?72VL*F?\.DA[#PU^N:'4[K6, +@<<,:W%O/9>T2\(P>[.'86]-G"\X:BW4?
MAI4NC-G09'-'WR(H"HV]U*$T9;A8.V'092V&G]%VU)'BY<<HLSI5G#U'GNH>
M"N."^WDV9>?7"J$;@_V>FSU8_KM]]VS5C0+:HP:?2Q[D?7=?V0IID@1XYM&W
ML.FYV(IIG0/%C2;&JD:YQHKFO^W&%.K2CQMKE&-Y9#[3GT4XIP5JPFCGH[73
MLUP5#O;32"&C,IIN>UG?[M2*DH$I[0W><D'H>Z'>AWY<T;O<LS2]D/G8-+%'
M?;9V6X/9:4?,[8$U_R->T<'IMF1;57Q-O5Z-UE^VV(6=:'84I/W,-$LB)9+=
M'13N=@XCGP?MXNT)T; >SA[RQ)"5S27CME/#-JBQ1W@D4&A(0XEU9_"I65G#
M-?$JZDB#A9.%O>1)8$ )I%(N[<G8V82DH!<S:*,Z,AAUS@^9GO.3D.2SJ^-#
MTXKRE&*3VZCWW+CFT?95.+-QQIMC:AHJ>=%Z>2,QH:LDN:Q&\+?5$H8KF%+I
MN7P;3[_:27Y^7'1)&3@DNHV^%RD*\DZAU.1=U))^31X'WW:1*VXQW8\NZ$81
M\N]=%'R)W32/>TPARR;_3F+2E'ZS&6-C-F#^F(>EV O^MNMQ&5Y3X/!<Q/]K
M[;Y 7ZIA$S^SZO3US#3^U.MIPN%LFW&)1MIE72(ED\V!G9D\6A\Y/-GO@W?F
MAS'9&WY4M-FFVJGD@NU/%]AE&T"')5D++O?G[);;QR,"!JFX?F!C4RA8LX58
M#]9R)*KUD\UY_F,,.5ED[VA):VESS*!37*LUC;:H5TMVB%J2*ZT0VKAG21+0
MRI5I#J%DS&JGQ-]Z?FMZ$Y,>G92B1M_G%KJ341&!WET&U?$Z7SS#  J4<=34
MA@:P"/R\5*!VDVDXJFRD45C."&JP:M!%I=GB!YOP[#GO.^-[S1Y7#Y2 %W_:
MGC*#]B+[$==+4]?;@<Y8F9]H?Y^&U/@Y7N#)[CG_!74TH_?+\AKO#080RN@I
M6Z:LGC)HR@0JT[=P8$.# @M.'*A0X4","Q,JBV:Q(,:"$@ENM'CPH,6*^P@2
MU%?PI,*$]$(B7):1XL*+*'%&1"AS8,&-+R/6C-AQXLJ9$D%F7)GQX4=H)J-&
ME(E0(=&/%B.J%!K1I%>M8+]J_:I28;V@/*V>72N49%B+)+O"C*M6629B>/'F
M)?:)KU^\@._RW:N7<-[!@ \?#LP7L=[!F2(K>_S7L5_+AMF.#;OQK5VRG]%^
M/?F9+LR3^U2O9MW:]6O8L67/7CTLTS+:N573FW1;]V_@P?/B#E[<^''DR96_
MUC1L.6M):90]ISY[TJ3I_]6U;^?>W?7<Z9OMIE9-<Z%0G^+I0:NH%>),GT0Q
MLF=[M>7ZD&C;5Z3?/N<R:&:JR:65E!J)()D:^LD_^1QR\"#_=&JOIHYVZHHI
MCQ!<Z3Z<;FJJ/@$K.NBHCCA#*<"+  R)O:-">B\^I&(,:1D%&4*P1(YB_&H@
MM*[JZ</XZ*DPIA8K\D_$H5*LJ*".VL.10"85,DNM 'E$B:B<-LJHQH:D\E$A
M''^2\4NXKK1)3/# *A,A$T_C:LV7#I(+M#C%LI,TU.Y4JQ["$F,LL\,$:TPR
MPPJ=;%#&(NOK3\4*_=-10HDQ34_22'I3J#;#&@M/SKSSE#5-,J&GNFAZ^W2[
MN_]&/7555EO=!R_MQ)C$5>6BB4Y56G/5M3HIZ7QKKM4@+)"H'@_,<*+[;GI*
M*Z-B9&M)!\&L:L"5+D41HV@B[&G&:)&J*,P#6QP6P0%;TE$G',^:BL3T!FI2
M*Q3U\_%;^PP$$R<,KX(QJY! RDE!#]>:SRGZCLU)JWP+U'#:@5#45"2!"CZ)
M0*-(LG)>C0;<CZZ+PU/RX0K#.VK$,9-:&,L"^W/0RH.XFBI&DB :#2Q+#9KJ
MI81:5I,L-5\6KR2?S3+M+:+K.XUGA1 U3+%& 86T3\@>#;0RPPY3%-%&_8Q4
M,SRGG+0D*G^VJJSQU@1[5^ILR^XY?7K#%>W?[B(.;KK_ZX9M&$WTJ0X-[.S6
M+0U)HO%[<,++>[BKDZ1JV7"H%LKOO/ 2=CQ&(9URJ*:-LEHIW9VTU2DIG2$L
MJ$:*"LYQPI@BXC)B_A".=ET+$5;Y*BU7&@O:+A?.D,T.15:=*(OU%:G?HS04
MCUIQ*6I03(U5I$H^+/M-"/K<?31WIBKQA1Q :26*%^2=(4XR_ 5SVF_VI])S
MV&8K)T+1^;7*K/&K@$_+%&S0Q!,:_YZ--KIK2NT,3SZ#!J,292A',8UJC]*:
MUJ86J:9AS6F+R=K1?D:VLN%,; ];RYO>9*G" 2=4:UM.2$(HF\6=4(6MTD0R
MM".E%;H&AC&DX:IH!C8Y6= @_\'"5Y1V8C(5Q<=</V+0YA16E88HZW/K2E:"
MJ*44(&K%?<RCBNTNM[OD!:E%5>J7OH"2).5!D26N*U!5PD*@C@5L0F8*XKT4
MDCLBK><B(6N=0V9'.V1I1"<Y,L_TUC,Q:"E,6#C9D1N+!SDQ'8PH4XK0$^T"
M$:O0B$ ^,LJTJN4LC+V$>RN[G!:U:"P'/2Y\/-$9G6Q6)B_Q)&?UN=G8S%87
ML^40:1'9BV*@9K7"+ HRCJJ, Y^V2ZD-ZFK$8*#2!M-*$Y6&?SX33U<NQ;O[
M@:6&LK%-/:9Y36Q>$V^?$EPVO?G-XQRN+7I:FWFZ6)5L0>XDGJ.?AH25$940
MCW56G,+D*RTRI8@)*W=,:1#&[D6\I71+=OE"9\/L9:3:[7% \6+1'-/SGLP]
MQ'%5F0H58]<^_I$K158D68LXA"'EF3&@5?$/(%6VR>(95%GR@=V\8 <MADG2
MH.KK:+OJ\DZ8)"PC\CI0NY*G,'MNSV$RXQW0ZM29-G%JEICR7YUFMBFOM'*<
MB5.7 ;=V2Z4=<($)G* "K_I+7>IRF$];D]?"%R=FTB6:<($J7<"Y&DU, AIO
MI6M=:04KY'33KGOEJVS"@[B@6O^S/,L[RI)0E#J7<%%;0\P<4,OGK3TJJ5S-
M:T\\#69$X%W2756TTO3H<A0/EDRD!9J8M,+X)+7H-"D>$AW,C,8]B1+(LSEQ
MZI4N8CHB[L2<G V+9?UINX2FE$8+L6Q6$ME8&S6HBTUQ$5QD^Z5\A=2<],B$
M#-#@K84*J(K:E:A$#Y*LOT[%MTZIYRS9DA83235^^/.9,ODG2UBFR95,?<O2
MK$J,L?+%3Y<I9I]PZ9A<-D8P^@4K7@X5ULV\#$^A\=]6;LB39W+F9:VLJ]KZ
M>F$,)R<ORM&;7EVCMPR'F(;PVMDS75;.GSA,CLNCW!X5BZ4@29:/QIN>N;*%
M.;-Y]B7_-K6<2-;YVT,*2UBX-9^-#+KC,HIO8V]$2;,(5*P$_;!U](@!&M(#
M-HQV""03CHB6-ME1L+B/LGJ,4DW$<(,?:[*B8 M30\ED$SZR;'(":18]SHRY
M_4CW3-![7TN&$0/)_%8,8D #(]()241*<5E4C.+!PL+HL-P8B6+3H%'A5:FV
MGE*:[U53#A5'2K#-Z2#$C.#53 U,!#Y04:7FJC ![+3);/6 ^'QE*??4951F
MU#.],B\)OQFJMXE8V,->C622(UC!LB;8Q&9VW7:6%ECV=K"T%9Z,,L)%*\:%
M6Q[)1 QNX.T8A $[*^[8#UE"V7[R1,PC<>3P>@<A:$SB!MB9_S$8]^6C>EIV
M('>N'8!(=N<D;2E#I;U)A09T S%X),I '0I]- <B\<G)2.N5W,B@L84;5 0-
M,?"(9P:);4?/1,A&W.GZR@@?CIQ91RHF2;.DJ+VDS;N*:IK$=0>>,G*]9Z*I
MDW-L.;JA><YL8^Z[)PY'N=9?9334IFPPIS>8%ZXN!M5AG7J!_?NT"/874L/T
MJJ)X]NF9+54T A2U &^=0G .8Q)S:W;;+[SAYZ@=#6G@&T?<?O==B;.V72O/
M$-^8GSM6TB*0C#)(<M<0><OJ.CCP]FU@BCS)O85)_+%<A%1"T137X\S0DO>X
MW;V3U.USEOA1Q@VX(,:-F3YBDRMLY_\60GBU;$$,Z<S00-XD1S&1GF1PYA!V
MP>+DR@D4!Z?/EAAPX-,U(IED(Z==*!W+/HB9T<PQ&.05-?;Z<BE$WIKP2K?I
M_;ZVH$$,A8RCYLRO<*"L"++:LB10*5*AG?*L:$</(+21"6V/\>]->\*_QPA,
M=;&R.E8+0+'2*D$!%*]ZH/N*E%?+!%NK-57:NYLR.CB9P ZBJU !,;S;P+?"
MJ^7(A    !4 @!@@!@X\01O*E+32E-5XG-T[ENS),XW"-^=2ADF( ;F"B4G@
M@AO KX?+DB?3$S3!+.Q*I-Q3")4#D(!JO2%JIZ3 D55Z'#,R#YLIK]*Y(AQQ
MLAF4"(33EW3_FD*#69+V2*+3>9B&B9 >(Q$UJ0@QX#@LNC*1@+](LH@OI)S^
M>*+B,1<.@88VK)G6>[G5BK<8& :M& :98[&3H+OX<21Z20F'4CAJ<Q(G$I)(
M-)"A RH)I"_W6B]*8RM.$QJFXC554HO'2+56(T!@RKJJL2^KJSJJ.3598\5%
MP9\(P[7_T:%;0RJSHZJMH"NU\S44#,85@KL/C $8B($ N(%,$$9F?*'34"]D
M.J75P(G4(1?+49Z$6C,Y$Y;.,Y ;M#(6$:\/X4180IG**YC:D<./.+/2@@FB
M(,.%H"-$0ADDFS+E.AA)4[0OVAB"49>/0+BN  HA@A[C>2(D:;<B_TDGHF,I
M-*PD=EPS')M!?V$I37H]&A08[,LU=DPMA_NK!\&)[9L6[VLL>92$\>,)(VD6
M@GLM.=K"\K(M9EF)]YF6^5$P.$FZ ,*G]F(F3^.@43RJG9$Z!53%"6)%!VH:
MQ=BOKP+ J\*,K%+%R&@O$J/ 6PR=HNL5"1/%^)HA<!JA9OS*$#*VO%J-&R1!
M$C1!L$Q+X[ 3JA2-U1C"Q+((-) !F>L<R,,WDLC+&Y0$D_FVH\B$-O0V>CN(
M&U0&\4.X85B&26C#,#"VE="$,Z/+M8N(PDR#,(@!,9 ,ZKH!NHP!;UL/8L!!
MBUC,&]@"'/ \,3$XA""&+IRC-DRY+9@)X_\+-RN#3:T@!C&XS!M  V*8ED%3
MALA$@]M(+8[ S*  S&\+ ^G0"L#TMLS,F<.L,DWHBMRY/&48AHV+@=/,B4D(
M V5(@S8\39^(AC;\B8VC0^343KYL&'FS01RX 7'S$<!DS-MH0V+@QA(LBB0[
MB#9$.-QT0X4@!DE@/.O:B>9\3WHC!L8#MQL@1-;L#<:<A(F<NRL!/]<#*211
M)GA[%D;,1\M)**#:"+,(.P?+GUP#2K.C2J!\"5H+T+#R"Z>,10=:E,H0RJ;$
MJ@4DIJR2Q?\3)D=1.@RRM*+RQ&6B2IM9,&#,IFI22R:%&V)4CFXS@!A0@1O0
MA":]4MH #WRBJOW_FT;:BYV-NTP<D Q_@Q<Q5*>AD DTD#D8R4U1N0O,S 32
MI#<;1#A9.3,<D 2$FP3&TTPXE163W,V?&- VG(0T\#9B6 9BZ$X<E%."R 29
MVX?$,]0P.,3<0I(S\T'*0#B5V+R:P($PX)NY1) [$Q)YFS?2K%*,,+X]/;.$
M6Y!^P4RBV#C%:\.$,XAN$P/ D16"6%- S4QH8KAER-5)"%3L*(@;/+/HN,Q
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MJ]<WX+<MT#3C4()]U;=^9\)[Q5=GJY=G.V)D,\XW-.DW,@Y-X7<N[!=]6?:
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M?^CU,!HWQ3J6F7*S7MCY.9OUTB?3&W:MU2;^.ZL\O'5WQ<TUJS9CW&0::59
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M.QVSW@2OB>L<WD; 83<MKE'3+_. 3Z#0%3!NA9VA=3/ZA[5A=R])8[S_((]
MM>',0='[T<+W<+^HMFC3A84SV[YPF!WKYMP-;)]H:X]Z\V*0K6FXH,Y,+\"M
M*=&'='[<2$>T/;RQ2P1!A&&&SWAM3Q7C$[_6U"(JZ6D\>E%3 5YC+QZ1PS?:
M,(MC%$:;KAA(,-XX')4<\8$\)DYWJ[B/"8)5[FL_QV&:N%;R%#M&L@S+F0
MH0)@$2^OE1YG74'GL+RS/^:DKX-, S'_D(2;&[H"[),#)$"E4*L"9, &5 JN
MRBRC&ZM ,CI],B?IVJ=K6QG$@Q!-JQGTJ:C"ZI#2R)!Y8B#3$(T_TZV**39Z
MX;_@>2>,J2T?XI /XKSH:!EO&@Z)V9X;>J;L8J;&N[UNRJ?5 "?7HJ\35 8@
M  (XR*?V@:T \1Z3P;WBT2W8^J<(LSK08"]I"0Q-8$)0*(S$FYX&21:'X965
MH:\\ZJ_^Z0UEH29[.AK/(#U.0XBXNY^C 1==*B?@"J$'JY;F$2[,4!<RS,,!
M489\8[&%TS"N@2J$LY*!T[<LNB*U&3%\\S>;JK'D8\0OBING:AHCLJKN\[@<
M0YS%$1PSVK$;_^L;-$(CO1&+.JJX,<FLD2.=&X"(H#B(3CF %>B_@RBYM8H&
M*;LD ("!25 &21B#04*#.(N+7S01/D$1JPB#EJ@DNW+  D2#C)@R \!&J)@L
MGCC!P=*<;#3'.E,3K]"SSOH*Q\FLQ!@0.  "'?@[.- !(""5\,@E9BNLKOL+
M0ONS@J$8"6.."*$.&QJ/?F$]'<P/B#I(Z2@V7 D6ZADIC9HH<VJI'BPOT^O'
MT[,MM% #)BP(O-C!G&FOACPM8>K %EP&, 2"@PE))KQ')LP598"#D-0!.$B*
MF)!')DR*TY+'I/@8L@!#>BRIZ7%))E0#.% :S5C"F9Q)3:B'9?!)Q?^(O LL
MK  2MY7*J.S2POS0&)ZY$-&X#F8SGK<;&0OJP6K#$-3 J![TK7Q!F>,R'F6S
MEP.Z$.Q8BV70*4RDQ.!3."BJ*4<,OB_RQ"*Z-^:SOBQ1Q![!D25IJJ9"ON-[
ML:=1Q59T$\RD.,$9B#O1L5C9N!O+$[%2LL;AS"_9.2]3"'I  Q60JQC8B$BQ
MI!@("F*0!#3 S4;@DW^C"BF#@8E 1AQP316@S3@[QZ#+A) XP#XI1Z<PE:48
MQY$ZSNFL,Z1+1SM3DW64D,&QP).X27R\GWUP23A "QX:#X-0RI/1R])ZR!V2
M$-NHC/!D*7/AF8':P-9KGH0QR%X9F?*I'X?_.2;UT*"T!!^*>A#)( :?U+83
M0@\@^ $U>)?OU 1KL<B0D2YWXL!X"<^YV(>8_ LUB,F8! +O$%$FQ$>#T(1[
MC,FD@ LP5 /A 1&7W$F7 840-=&J-(RD5,HFC V7% M=8:!>TACBZAF3RK:2
M A ;7)GF0(R5NKWUD:@!P942V2'Z.*&8R3SF8;R4&=(-+$_+>SKO"(^B,LQX
M@[%0-%,KZIHU=2KIX[<1DT1,G"HV%2,T'3Y.5%,GTAK!V8LAH[C,#)PDNQOO
M2Z.^.1/P0Q,\ZLPBVPJLL$4Y"\:$&$8#6(%)@0$5P8%*JB1-B!0 6 $5B$W:
ME)0 R"LQF!270 -E_Q"#2G*)EZ-..IL$0D*5&!FS5[55!GPE0G6ESG)'U'2P
M?>A))I71$6*P7KM')T0]M@#(0^,[9V$]'X3#&MRF>%DTT$ ,LTRO$$(0CBR8
ME:$\=FN/\I*@8=U2MGP+)G3"R A)-8B)'.PZ:R+!]$"9W',\90B%JHR-=?67
MB1G6! 4""+7)$PW)G_37QHN[GB0&05N&F&1*K$C*JMB'&CU1!*D'<F48CIK/
M_9 8KEP?WM E#[(G5YN6",H\<ML9/&Q!Z7&W^,#(8E)+8+,V!K&P<&(6W&(6
M6ED&IT*2.&4^L(&S@*N^%Y.I1J2^@_,:%6N^)D):)4(B)$J;#RO,IPE-Q/]!
M(S,J$[#R.*JEH[!"'*T:'//KS%FZ%3KS,F92"3&@5(E8@422E#:# ;:="-H<
MI(>PU$:Z@4KM1;BM)$JQJUJ]5<0BA@-0E2#AB?641HC]V\1-%1YKDS?)3L2M
MBS"1UK[0A(&]$!G=4-O*#J5<M:39H/:DM"=<#IDUGY'Q"]Q;GG9S/$##CQOB
MB^&R*&HUJ0(BQ%ZCCIB-(,FXUR9$&I.R3Q,]B=-U2Y=]3R1<#8H97E%SM<K%
MQ_R01PCE&;Y(3Q2M2LL%0V3U2=+KEN\40Y<9SX:LAYO,2<GX7AFBC'F$@V?U
MEHM!V0*CPW#9F9$L%A):F5S[0Q[LKOQ0R1U:GI__X5#.&S6:03WJ<HN%]!A,
MPQ=;^Y?R@,0RU40WG;$.6Y(V_2GGNT3'+#&"ZS</FZ(C69'$7,0H,:KKZYHB
MHS@RZDQ9(;_"R;[1=*44WAN[J3A;4=2=RQRXN@'7M*0#H-L5. #BS#^7Z!R)
M<$W/&6+:[,4>ME1)>8GB55S$0@,<D"FK*3.HX-2F8*08  HQL*OF?.(O5@HV
M2L<V$N/; 8OU6S#HL,<331=[7$H*D<<?^%=-H(P4-=%['$F)1==E2)>0U$D<
MU82>S $X@ .*T5$@&&10N,>?M IT;=$;_8%[!(Q GL<F))5Z (5Y%,IZ\-"3
MH&0=4 -2(9ISQ<>D+&1B_Y#'G!P3]/Q7$$GE@EC72@8"EBG1I&C)'0W##OU7
MDPGDF7SCQU#DE_Q.'4@* 0E84(8#NVB.?*7)U7!D^B!?=%V,GDP*R[7<JERW
M;T%8=U'*BN@>\9Q>YOW)9=-E-<"H*L2N9>N?W8C+'I284Z/7(<50B>PN8WFV
M=B&7S*N8 A8@7U.08J+6KN3#;9L>+%TTP;.*A;,Q+.HP#&X;J7)HA:Y,(BI:
MJ%&K?UL;Q;S@H06;%,O$@\L:.YT^@D@RL0U;S]2Q(8MA5G03H].C-1$YK#(Z
M6U$*7 2)CX (D B !%3 +P-&3P) 20C N)T(**--M14#'/A-(XXR2?EAN4T#
MO/\2@S20!"T#XU7RB#:;"(<X'8OP8IOP(J.@+#;3U!@PSBJ^ZK3F*\:50 EL
MU+8(D^JR"W&^7 4U"!M-3Q?]5R;<!'!6RIFL"'T T1U-YE 04350T>#8T8&-
MAIA4BV$]Y+T&CDVX41-]T9FS:WWH2>JM;'86TAN-Y1*ER<*81R.8"Y?<!,$&
M;2"8D\I&7[_>:R"HB)CTB\AN9:QP;4?6#%P&3]KST ^]T9P$A9-(T*6L;3^&
M;28,A>M]/-88">;MWK\P4=6Z:YKT:V2-$&8&@A!IJ-.*M/]]C31,']!CO4*D
M/9LA2^JYRVEY//,QPV8C.RP,M(<$(KKCP1W,'NIZ7<S_2!\AJ6CATS#EV^ 5
MJ[$X];>H\LL3$YNJ8=HD<6  I[ZN*1L;P4RK$CE:=)4R,0O!^2H=JY70M+,]
M.K+M4[(:-HJMZ!,_00/:Y&FC* FS!:1894:K<0D5 (F2<(G/T<T5U^(8Z.K!
M4FM4@@8$3/&;\]N<H%6FB)3A=-4@=_*U?MPR;B6L^ J6$9P+NHN>#&X330IZ
M>%XG#%C6)@MI!H]_9=>(1>Y]L.P95<J=I.;C<NQR%DK'UH?T5(8T7\)_+0CF
M%?-A-8N8[(OG+0A4EI!M4DJFS',]7P8W)A5DIHOG!044'5AXPL?-^&U]4-&#
M@ 8/A89B4,K=((:8# N]3@I_V850?1A6FRR&_L3M73Z/Y\5E/AY68*[*15]7
M37!1_^3OU%CCU X04 :"/YO)OLADQ+YC^0W6\$RGT" A:#U"UIJ[GPG!9<;R
M?JSO?#I";4I($?J5[)E#(#PW@=966O.5*=TF"V2.ZN-9QGQH-RWP=F_HRO1$
ML\%H?M.1%5F^"8=3WW-:X2.^3U015=R*0R4K116RS"*K+\':[+M.L?KP.8(*
M04&KKVX*3J5XA-A6V\2KV[2:,)"!,-!B1UG.0'KR;!2LG/!IG>B82/F<&S#.
MDH=YFJ@*[VMKK7#_:\B%>'7VZUC^:TV0C,V>:S\F[7]E"\KN[?"=Q\>04.H8
MSY315^$8SY/(<S#7UWVXQ^YUT3W'YNO6!\-N0K40WV@&@DU0!HQ*IGU( R;T
MBZ7W:Y^O\W\];;[.46D>2 CIR=NP\[KHR;G>^F&ERB9<^WF4C$U85[7X9L*K
M^H&4^A!%<\ W",(?>\<!EI!L288MB"#TZ^AF91W8)KR?1X/P=-<6P]CXSDW@
M%IY1&&BM9Y--'_SL#C2\3W?1#I0I+V!1)OM$F2>M&91)*?:I[_*ZKF8S'W*Z
M$ &KI0:_1'QO]^?[Z,-\JITEX=Y+\*0M3 D'!09_4\=\1*^93"[A:*<!_QR]
ML2JQ\#%9T5K01&FLHHJ.P]IVI I8S(HC<PIBD#(<>'E,*8D65PR9, O^  AZ
MR_81+&CP(,*$"A<R;.CP(<2($B<V5*;,H46*#HEETI@P4PP ,5;$Z$@PFL>4
M*E>R;.GRY<IZ%F<JDRG3(C2<-7=>)*B,7L:+T.KMBU8/#A UFO;I8ZH)")"E
M]:"J@6I5*4$=0.#L6Z8/3E6H6I,"(1B6*<&G6"\NHTI0IMNB]<(JVP1UJ;ZD
M:J(IJZK&+%2B%]4N?1J5Z;*S JTF[=E5;C2M</35BT;I;MJD7*=N;7H4*C&4
MA)E&TZ<I+)"Q^Z#MDTRP:5A]T<)&HR<:LUJN^__Z)FV:]ZI4?5Z-1G/;E#7*
M@:#([C.\=.CRP_6&HKRKC+$.32@O-ETV>BAEJKXK,R4K>W33@D21 E&&DAYB
MSZLA,YW^N#9*P6_C&Y5;/S]K\'4EFVV4^6<@44;)1UP]LA%%F8/YR46=<$7!
MQQI1%KZW6H/[)"A<>AG6AAA!0[$V$&6L>4A0@0,]Z!6*,@T#RC":S#@,1\34
MN".-FB1C8X\X9J),CC[:F../-2J328Y,.MEDDTM&.>233/X()958YICC)UHF
M:2.0.X)YXYAC!AEDF60.8]%-/[E)DVT"T9-3FSOE!)1,R_"T#%!W+I,333(!
M1=.?/[6DC!@&W$ ,3 W_:3))>HU*.BFEE5J:T"0'B#$D0DN*<8!),#'ITB0Q
MF&J &(SN=RFKK;KZZJ$[W02HK#SIE*&'RNBYGX+-8?:887!,5]4/8X6EB5=D
M"6A86*@Q=5:#WMV5H3Y5P3&<&E6!XF%3SH%5UD"&,:;=/F2IV%5J7!%S5W](
MY5#4;FI!M0F(^\!7;5*E^=K>0-=M55Y2N^WS+2B"I=N?N%?IL*)?;.T3UGIJ
M++PB*-;N"X> [%56V6E6:4=M@U!AW%^#';8&E3Z;6)NA)F1TAI*]3W&EUKX&
M#KCO4AZB1-= (P9K\%9$$75A/1TO=5%_1@UE;WV426BS?0/BMR*$4]N7X-6\
M_][;<X'V#7?OBM3=G"+3_G&[HGT]-2BATF43]35! UFX:H4:UOV@U9Z5!F8R
M7/K-I)B!@P)EET\6CN621 [)8XU?"BEEE5IF:3A'4AY>)>3$7%XYDX<WSKGD
M?V.YFT5 Z5F;GGD&:A%?;0KD7ND6\2G[ZZ7S.;N>N@H'U.LL?7I#SJ\.DXG<
M$!4/LX2P*K\\\YVB$<,! . 0!@[0!Q #&JHV6F.D*BD.IF.1POS6N<V;?S[Z
M$M%$9ZTTL<E30;$+7/5G[8TXL%8YZX56AS"[9I1ST.(9X;!'-IF)2FF6T9:
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M(.50QNNP39ZM:/RPK>%1>K*S/?9!1(,DF(I(',";A\17!H"0?F54-KK,?]<
MM_D OWG BK:D@Y,DF#:LI#/"W@#'3L_TF J<QX!D2S8!S^57PF@,W,#T6'T8
ML-X-<('58P^+!GW*:MZT[:1P\]X#LPG2,G@/>Z+<KN"J)+N(!^?4,&2-!F?<
M2O_=/QKG"(,IH.H+S:99.MH9'''WV=P-N4>NAJM(0/O'F564/[+WG?TL;DXP
M/EO6B=-' R+=:Q[QEKJ[J;/C70V6NV?JA)NJ&P,(=UKTVTTD*SJ&V;GG$'8D
MOB/2IXKM9[TWYBOQ4P]M0A>(VN71HPKGVZ:F?:BB#*K-#A-2V9BJFV&XW)%K
MZM+XWX4DPQ-YPN]XD(0U[T(R$XXACD<\XQUYJ=UX]C-)CBCOL"TYV4_'[[[/
M8(]R,E%Y\<Y$Y*U/1JS$_2.1-'T]5L8R0.P3.##3 14&5B",82!&PA@P8@2(
M<6-2)HMB8C14"", C!49<83!05'90),G4:94N9)E2Y?_+V'&E#ES7T$QPS01
MTZ2,&"AB)6G"))9)Y3)ZRY0IJ\<S&K&%*B)"]!@C$SU-80(@!'"#V-*ERI#2
M2RJV'K2@9]&F5;N6;5N97I4F3;H46MRY<?<!S5NR9+2R^^CM\QMMWS+!^^KI
M0ZP86F+$ATLV-JMOF;[!>??IJW>YGL#$?R/_I7>Y<N9H@1$3UDS9L]F^CPO#
M'OUXM>/9G0U[MCR:]6/#?LT:UFS6+V"!OSNOSKPY<&_ T2QW7DQX<VS7F9$K
M[EP\-F?%T4U6+M[;-F;-A*%#%\][NO33A',[3BXXL?K6W:6O%MX=M6C/V(\3
MC#?Y"%O..,WH&ZBRW'C[K3_H_Z3;KKS2K'.O.OD@T^VYVP8*K#'%D!/H0<<<
M-#"U?:XK+#KUM!/1)+TZ:^P_VGXS;CK63ELN.,1X^H08G(#4),AA0 E2F4R&
M(L9'))E,DDB<DDQ&2$VDA!+)*8<L4D@MA\1RRBJWQ G,,8=29L@DKZQ2IRZK
M+%+),IND<DHXX81&+*.4.4JLQNR2"ZFQDN)3KJ3"BJO00.4Z[4\]C6H4-;24
M"0 H' XPX   T'!+)4TF4>RD>C*19 PTT! C#(,6TNBA ,30:Q*$&(H!@(P,
M"("KI'[22]-=>>VUUTD."#952Q>:Q->:B)E)F1M6. "BCK**@2\QJ!6#I&.Q
MS5;;;0NS';2NK_J,JRZYI/_C<2X#<_QP.1!7E'"R^$#\3S'4]J-L-\+,BM"S
M IO;+$((&^,7Q0CMS9&Q"Z,CKCH/ZVMPH.3$4RXY"8T+;M[,NE,Q0,R <BPT
MC?O=MST6GU.N.<.$*^NOB57[J\8+9=3W,9@QH\WE@<<S3+K9^KU78P9%A) ^
M^\S#T+KG-ENQ:'7;TS!IZ4)3[++4Y%.LI-4&L]?=V#I,CT.#0:-O,I#1P\RL
MP+9#+>0*6<SMXX(=?FPV\78>VD7&T#SR3227=!)+-YG4^\F_@Y0RR;XST1M)
M+='L"2>]^P8SR!]S2KS)RP_/''.^Z=Q\33FS!))+I):I"RG3!Z4L+CVA00I<
M1L7_&DVN.V''<ZP_E1E7+K4FN6$@,=#@*9, LATF\9<FB>& A!Q2P=E6"4I5
M5C$2YTE7;K'/7GOMAZ+)^DQN<!ZB&)(5R"P9MT]?_?6WO0O<LN("-_ZD!KH+
M9P1/[.NOQ;!KL33]K6:WJZ%L1FA#D=D\-C2L#:AK"<),@=(VGGK$(%-URQ=U
M9M0PHFV'-0$S#P8!-)A^77!M*N(.!T]D&,E4C'_2R0W=X+.N^)CF:5SKF<%,
MV"#+[ 9C,;K9/JQ%(T_Y##\8)-!P[)8)JGP'8@%ZC[T>DR/:1+$Z)F2-SX3F
MP2:>;(?X$9EC8*,NB.&H,U!;3@QMIAV_Q,LX_RJ:W=9C_Z+\S#!?,_K? 3&T
M0MN0)B]=\F.80$<XS37NCX4CW"'_2*<O 7)REBO3E!27-\XA3I)TDMPB"YFG
M/.%I*609E%@&93NEZ*YUY )+[@;E)W'-#RZY00L.B"(0,1A+( >XWJXT4967
MH.$A&<G(K!)"/9X0@Y<KX @,H,<^92Z3F3(YWEF(<0.)J,!6PVCF-;&9S9<@
M:BZZ"Q1<!E4N<,T0.#;"T%].^"YY(<Q&0!N.$B?B2S&(+!,8B0'U$E3/B62"
M;OKH'3',8IR/G7$?][Q.<:X6-CW^YXE-;&%J[.5.-.ZG.GS134/-HT1:;F=D
M'T3-,&[@RQN(01,""<V1[#E22?_DB3!I$*D,T$",%CF%*F6490SJ>" @QH!A
M)N6:RBZ&1 \&ICC]4D8,)I$U>)GS85F\F;J0:%/R(*@W2-S/#%-V+ZO"S8D<
M4HX>J7,Q#Z),C?/"EW_X,[ 6X><Z*:OC"M6UU!(A9D<X#(PR&,DE+5U2=(6$
M).<<:;E(>JY)?5O28/=624H:MG&!;>P@ =NXPVXNDJ1+Y2E+N91H@(4RH!04
M6/2T25"*UBB*HH>="#5:;]UR)K,<""P'<@!K'FL8DW E2_"*$XN@81*\+55&
M0CK2-/@V$^72YG&Q:9&2#J1W:3A6]\ZR+  <9%;+1>YUL<L^N+QO?JC\RE[J
MQZ?^M1/_9V:3VP:#AB.&$2:AZ)%.\M)0D4Q4Y(#T<"GU)!%2HNA#&3*0!#'2
ML(62)$835+D/P;(FD'MV"&,GLAEUKH,_NO6OG ;T:5'7%9O2E&MN"O*487I7
MW+/5K#S<*8E+&6$11MP@#-9=2DBI-XE)C&2>@+%6129A+1EP-AKYO6=D"A/$
MFP$GB,5!GX<4=)@9/H=_: 2?L?"W0A4JE*-F3*&!%EJPV)RG;AI+*!M=N-8H
M]HRN<+RH5>D3U K9\#ZE05!Q&GJQ+9_HA_X24 CW2.(6<49X.AF3D/SVY[[N
M)$U>*F29Q 3(-A7.;X:$$B61]*3'!JY)DJ;TYR*)24,3.K%+_^+O43J[.DT"
MRD]'N9UJ3X>4O5SVE(<RK6E9*Y-2I212 ?55+FV-%EX"8 4 2.9 "I1=86]/
M#,LS0*;0$( #_)I72(+4).+KVU@/F]K59DLJY1=.;=//,[,32-:$)F>(<D>'
M)V3C@Q;S%VC\$W__658RB8&1SBBQ)/2@2'#"4.,!"\@^""H)!1.#G J7MZ<0
MW;!/YUR=%*T7/]]1X0/W2*\ MK! 4T;/R00RB3 X5R %]IWLPB"#6'KJ2-7A
M92QK0D'M9 *F,9#$&O?!2W:B1N8 *K/.BB;6_<T-:_H@AG_S-R,8[4LY'>/A
M>6IF\(<E3$<_<^+"2*;PL!7Q;N6)&?\&F>A>Z$R1YQ+,6GWV7%$#W9%_5Y/B
MPO!\474G$!J/M9*?$;GIT 72<)!V.Z ]QUC"=BZQA6T<XSB'R4#'77!X;]PI
M53DNTIG:4;,KW5U.(VK[S2]VF64UMR%U@/*9!"/%F\2CT)(\AJC@!M?SE+51
MWZMA'( H3L$!4D_O*^AJ2GX_2?WM<8_;NWP++WV"'UY,BA>P*=U!0BOXSE@$
M\V74,Q,!-*(2B7%6R=0C>=8L$"^CW[O#(!4Q:,"! 4<,F]<H>)Z$65MV?NJS
M".(/*%,6?X**OK$VHBLY,$<^OR7F(@E938DB3@P.MD X,((H_$5HEL-:DJ4D
MAB$&QD P_(G_?&X !\JG'H((Z>(CB+Q,0SH&/L C-=3F,,KHR?"(PL8(HRXC
M;E+F.*#(AW*JR@!$.4PFK&"N/])KCZI#X""JZ<CJ0'!#:?I#:N;CI\P+?\KI
M1#K,1LSK!G4NK*A(1')+KP;M[1P-"N6.2_Z*3B:KTR:M\ 9G</@J)WQ$<OQ,
MLLCPTB@)T'S$T< 033X-3SQ)+/@+4$SGLTR-U AEDRX+=?JD=O1D+=" ]8"B
MGC0O6W+IMH)"&=( *@P"!Z8M]QSQ+-( !P;"I1K1+9Y)4Y3!GC*"V1ZQ$ZN-
M+^X"E;#-E##O*RK#A0Y(&9+G!C*E/Q1F8 Z*8+AF66) Y(P#R4*,_ZEDJ?3H
M"E1N0!+V80'C@B)2+OH.*(5V*-XV\=WX1Q.L92* D:A\CI<F LH**@U BBK8
M2^,F0@P2$$7B+0RZ47^B8<4R @U^0Q\T@1IO !,,H\/,HL" <1^<@E."R[G.
MIS[F+0;2X/2LQ9J.:I[<[#%VY.0&(IK$ $'^*1.V  W^HN; QBPP0HJ("20D
M(3>L)4\\H_^L9@R"BQ&4(3V(8>,>0Q)>;Z24 >EDYLO(#6.FS%,XR(Q6*&Z(
M"N)DT(=B:*'LQF2:CLM:!B9CR  E3H1PAHN,B-_4!F#XA^?B8\0L,,,JS#[:
M#D@FK9(2!] TK0O=!$LBJ6_F)$X,)]&ZD/^1 HE-Y*XL-TU-]@Y)+HFON$1O
M+"MW<,>RRL)U1LU0<H?Q^*(.30UV]G"SN&EWUF(29D4B#L# BN<2T4(29$56
MPF#S/#$R::*>F$L2MV7VW"(39V5Z*E$R/7.9N,N4X(+WZ$<O\K(O5A"(8,S
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M [>&2[,8E&SP,K^!JEE>V%:[JA72*3)B46<.*8!EMUW.16E)3!A![#K;E#G
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M\/9!8PM-(OKL/A%C($D,,3@B)H9,%$-1HN]4,J@[\32:4225 ,RQ(^_H(7#
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M:B.6:@.*:F,+\VJ*!+*. ]/%P@ _T)RWA3(,:2%&C!B_]/N+_RC-V\ C PB
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MR@M?VI%@A/ 7@P/ (  '"(/^*/2O9C(PFM+D5R8".)X;/(@]F3@ -[.)!AE
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M-:[;G'$F2 (.4)I!3*<9ZUY#"/(Y.HBD(?$-A'%HB@%0N \ML@XQT*(F\ D
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M1"!73*'_3% X$6H32B4\GZY"@@S&"*KH_J0B"<N/5NI9H$+FEDA3F.:AQ,
MMG,%J AD#@ &   '_D53QZ3%.A4$HTYVJB2E'-+J[$<453'NA+4FLV.FN"YE
MQBOLJ-+Y2NF\;E2YM-)LM$[PQ$W6QO B%W$IZ\;N#M0F_4845X]M/NG>T Y*
M?_06RP9".4^2[#,M\\=%F67<Q(Z3GK584D:)E.\^9*B5H.\N,3(J<7 -Q75G
M,LGW\,8E;<4'9X-7CI(G/R,NA?"5: J7@@4F4$:2=) -73% SZ,0W\TO _%B
M,VE%A]5=N,UE?$5>RP:5!H0A>&E,,61']%1!VI3[QF+]@G$8_W])&1MD0@QL
M<]@4<H#11Y1Q%S4'X3KSX!@G(>@/271'=U!.PJ8/PKJ1G/J/2&S'G)XL=295
M>8QSI/01;">U?J#G4C50:81,.<]63DA1# !@@KPG!@P@!E1@5A-BQ&! 4\1@
M;*GG(F)U6I3A!K83*O QH1:*;75NR4RJ!<_S/+<B/>W3]U(1,5M)"=DRDCAC
M0G/P0G'%$*U,2-W#%D--!RF)]PSQ2]W3!M6F2>E2+]T%7Q;6UCI#8,E-=*&K
M$Y]OCL9-2L$T#0]1)P=M7!M)@#CW+M.5]V+)8.9CN(HO;%!Q)!%(,(WO7MU-
M;;R#B\P#>E]Q*LYF0!/6#K%219OO0O^[]UW5+O1^#WN!\EB#U5W0#3ALR3 #
MAT071MU2$6T&3;QR5V#NDR\7<7)XA'/N]$Z=L1GKJS1OMKXNTVC%PDTM1!?M
M-!<'C!J[Z>$:SDEN[_^VQ.0.=?Y89TI,[G92YW= CIY 6)X(<%+?1 %M3*%P
ME6QCC%)@&.DJ1,A 04\DM5&&87!EHCTR)08"  8.0"D20H<.P%4E*E.0>#;$
M CMY(V_:9%),)1V;3'\6\E4<$B+]1THE4CV-,#J.:TJQ;="HEUU<5_, RPWW
M,^N\KD1)<2HZIHW8K46-\HUNBFVP1BOVE3"[E/AH:?<N34K9DGGOQD6M\&^P
M]7XE8CQJ[Q/_@6,JS:Y$]Z-?(;FLP.XPU%.5;JV.84HN78-EZW46U]<'H[45
MTY4PBP4[!OG2DN\&M>MR-]E=:0A?_7+0[D9C46FZN @,\\TIW<B/559C!R]_
M#A,4EZ5CNN-EP\\QF=F K:]QHCE!H+E' B[\J/G]OH\9#>X9)XYR_"N:=W;Z
MT,E7.PP 59.$H?9V&I)/MQ8VR;F%TU%Y'C7&$#*&-S5Z0! Y.TJA$I=.D.T
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MXLD2&W+W\8A10[_<43 *=#'P98SGH5"/&%^W%Q_N]E$O$P Q<%\.H5_+S*4
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M.=#"96M!WXAC421R_6MF#FE9[,AD1$&1HH9^AA)I"(DX)W@W/VQ' :G5NX6
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M4UDN(,1@1!=\(0"Q;!@.%3'2U-N74.%"A@T90G.8,%I$B@L1[HM&KR+#94"
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M&+@UQVM$1ERF3)#$22@4Y=HE91@#&, 39BHMCZ $/DP( Q&UT=(E0UD-SC,
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M*SD<8'S2+H&O<9PW?QL,C(,[F4C'@&3-MH&> @VD@Z3'A'NT)!42?"S/RM+
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MV]7%QM=\ZC&N9U[N90WV'&4(1-46G(UHM;;\RF&(ADKQX(7@K=]V6<U^M3!
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M"?7032$1I>9;A\9Z($Z PJI?8&,]QM1C):'UTTU!&80J9SV===BF?J4U%4D
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MPK2F0"JA#CYJTPW!A4^'BQ6OVO\6-YZD)9=;"=S=_J-*4T)D6G/!8*LNDDM
M[8<T^,08V_JF*IL4*G?HHMS$P@<HHLPD=A"19FH0*1 ,?@5C70VH3P^4S K^
MDR/&:QNH3)))6!'24ZN<W69N1QL\>0QS;)'5&0^S5Y_ DGS8N\W'7(4]R7:+
MK@*]GEY.=Y>1<$]3SF-,GC)%U\(PA5&/FF:M> F\?AYVJ1C<;+G.RMDZ&F0X
M^V+/_?35/WQMQYST/"=P%2A/=:+G/ ACC\+0>1S<LM. TS%8.9^I%N2-3YG2
M,IQ1$]<3#9:O*3ME4@B_:T2SP:&D7ZJ+@Q;Z((Q6K8@)FL0!8@ V"LG, )-0
MKX/(I@/_*K%4O [RC7\7I(R9EK=,]6!O@)M$-B^J <$)AM 8V[;'.\9M=<,;
MI4@H.#XW0G(GSSIL]"KG5.W2A"^.G,M8$:E=$(\%K\.2)DI<IQ]^$JIBF4Q5
MK!PIF<:5$7N2RZ1-.AN^O"S2F%)=BV14LL<\#26@$SZKWLH7)T*R"3<'DAR2
M5_=:?F)J79,]5FL0!;F0?.^ZFPH7K6YRD\1@JZK'LMU61J.3Q^EFCFG1$YRM
MHD=PM=*RG9KQ8>PI,'WQEE\>I5<ZC^N<!1*7FX9.IW%\(QR$/<><U(G?<Q\H
MG  2][C"E1<=9_RKCF3E,L)"LTE8XV?*B&4O.GWP@A)J7ILZ_U1)6B.&@U6X
M4V7$2 5H0) ^;@0#'[4PBS-%&ZP9]-)D7VV__4WV01U*AA-"&\* !>7;'A(W
MC"T+F&=*JDXP&=<H5T_%:(R5[0CUMR<3[[!*S2"-_WA8L";OK-C3G#03MV$<
MGT3"_4[R6"6U$6:NJJZTTM-1+C4Z2+4D>L,DD":7JB[&:1?/J)3L1G)#U3Y3
M3IB!8BJ7/34G>H^F)& )I/A0E<O:P=@^<SU78;2UK*J^J7.AE.JBSHJX@==\
MKBA9S*RL&^ZR5,=?SL47H;V9='RY![?F&6!QYUF<>54ZZLB%=*.C_C[J'&^8
MYB(E5#[<;Y4 B*L\'AZ4CU+MABKTP?_+,!M-,>3>!]4#1D3+=4O3,*.=@6T9
M+*Q0)F;M4#5$;>T)>B*SX:Z&5X-(O5@TO(,TL<0D%1[R650W(+^-.D"JD%QG
ML9M6*LM&T2DK>X]IEM=13+YRZ[M8 U^+JL4W<9F0?31Q<A;,#]E&I/P.4HJI
M;,W%)?1_EHZVI/8V:@HN+(^X9"X\AF2Q-F,LUO*^<D*NV[GJ7)'IO>:NPB,7
MDT>W8V9=3_3=]K+NSF5)V7;JYX>,N6GWPTR+902U:)$QJ-9"=CN'6HZ&LF.R
MJ)H Y4N\+!T!D@<"[D]Q)9=Q0=H#>1/2P1,$[@\"YH]SS(=FS=CIE-B?V4UF
M"%_U4=6J<-#_65D>@R04X[74@'6(E>A4-& 11F%4R?":"F3"XPT)#;V@"L9(
MRR!1"N[#@DW1K"7;LD%;$&(-ECB'">:70UG)$)K@VF@>0KP-4\1-?1".5)36
M[Q2+N6 A96 *DKT8YCR3Y_T27HP27&&$PLW6]Y2:55%*21C(4D59&[8<^K">
M?N1'?D3,OQG&?R"5!E97^/E2F^$%Q0U<42Q5QEQ*\W#58]$9ATF63IP&H%S8
MB37*7:C:=3&</WT?1T#/6#1+&KZ8(S$&9GV+,J4)-!%53%35/BU2'5$+Y=R?
M9/F-HG29ID1&?BS%ZH$A[BW#;Y23=S@,=QS=!":=.PU1T4G'UB7@_],%AP0&
M3 62AV[MBP%&!_<\"]G9!VTY5IJHC[=Q4)&)W!)2R"3,78#!P4P]&XC44!K$
M0 S](!2ED$$0 ]Q("1#L5]R9(( 97A?EXQ<]H81$@R3@0+&5(Q N$94L'D)F
MD4>T#4+D!AFU28(H4^HD&4R 7JKMB085!9"UENJYU38>UD?>1!B"CV9L5C'Q
M1^I,BN1$E9O)'F-E'@<*AI0EBT4RSUODDCCB3=DQU9U,'\N1$M!MX5P@3U[T
MH5=!!6NPU2FQ"YMTW)_Y5?5]W++H6=A]7+DIEN@H!2B9A=T4ANTH4EV-GS'E
M'C4IBE&B! BR):BLAFG,6>KPBF<-94@VE?]!+*,QP@]O*<,Y@5/!"*, ":/4
MA1/^(!IQ' ?"[ LW55VD$0-S\<L CL7&;,Q6+ ;XK,[U8"%*5M-&]B'@(*2L
M5=N4B(D1S%>0\%J. $#@[0,Z'M3C <D*F@T[&AYPO":LE:87P8$\[L,/Q<P*
MR- 2+D,)>0C>(:1;I,::0*0I5E@;F5S]M84&H5R&98Y<G5OV,*+[%2*9_4FB
MN%N^Q9SLM23M[0WU@"></-.@!$M=:LKMH0M6ZHED9%)15N9G_I/&N%'A1.%9
MS%7PI5;PF2*X\!N?9*580D7Z?5Z4_<JIZ=M&KE6^X653D.6448I\.I_J,%+.
MZ=C]%<M/P4KS10[_&CF33)I9):;1'Z5*Z*"8XCCHA2[$P*2'!3:'H]'HPL1'
M.6G:,)*'UA5F _[6IO5E/,5+<0BF=]P/8RQ/-Y)9H\B%2;#G5/PA6@T=V?TA
M0H97M45#DE0)$!18D @;C@AG0R:D%W6I0$);< QGV1#8F2;->^'(CUB>,BAD
M/FI"FRZAYB6G+B&&FX"2G^+*0,G?QH4BS^6B3]!EBFGBH&3+[0 (>YY:6'U*
MXGQA4%HH[F$/\VW2N3TDY<3A]0C%DK*&3:Z82IX=8[A5Z^DI3\02I9@5Z@03
MZ^5D^HU?',D)QHD*B'XE(=Z;84V&!E5&-G96D-4)+[E:Z%%FSKF%)B9K_SZA
M7:$V4F-=T%UH89'=61Q194\%$S5]"VL ((X^9J'I3X\&UX\RS'#YUM49AXTF
MS+A^ZQ#)J&\TG<'<3[C:([+VHB^-7XO.C=Z(FI?E36\&V,C@5[6]'=PQ#)"P
M$,ZP4,!^$&XRX11U2,,&F&\<9[(1YQ3MEQH@K(00 P[(B(E,;+0E"9+4J<6.
MZ<*E4KID6]SX3=^8H2/BR9G$(A@*2V;^&8VUG&:BXC5]9X%(S*^$5DQ^RTIV
MV58*A9J CAK1S;9$4H*F#I-510ARH;DEA4!15?,L:2+^'T"E5:H>#FA(!5:
MRO(TBZ#J(8-RH[K4#L#BV,^IBB1B8JBHSN;I))7-F1+\L5_]"<A_@%;,$54?
M<I!:VB+KR!LJ3A"AJ&'_C4Z+SL;EZ)]/7)ITS!/6,>!SJ)/[V)/DYM:C0=T\
MP0N\ J9R#2EB8AV[@@=92(K=6"U2U,GNG-G8>5ZS1 RIB<J=/EB%0(,)UEI
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M-]VN#EP;G&;<RBE6>&5G<,QY!71S9B!*UE*9W.D$CN)04$]A.#N-^+XL)OR
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M*;UB\+^##RX8N(B PU@VAE[D$CMP?<Q6WH+][:_D%>7C>5O[NEQ007R'6_)
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MXA_"XNDPDM8G$>>FJ652]A+QE'.Z2DY#)0\NJ)6IJP81CFU/] 0#>XECLH
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M_P.*8C:$-(:-\&;_8I%#R)/%I*%200XY9>*")DXYV<=H<VKEGTIU2Y!%J2$
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M$Q08GDMQ>#A!1RW39S8)B/:*IM;!$!\: ZI1#RUZ$/*I&!(ZKA$1GS0Q##&
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MH[3*N=2)ERLI-/*::]I+Y,.1,LPVY&$(=,3 @U(+!RN*GA#'J5C K-C&;YS
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MLV<G%B/3]$PQQ$BG+D:\]O/HT^\#7V_ZI!B:U,N?3Q\['#5 X  !@G]__OH
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M<, 1WS[Z[;?,=)K@]^^^""=<'1KBB6'O@>8I#. D";J7K\0!ZJ?&/LL83%W
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MJ8S7ZN^=H&#GG3VVCX(Y4,^0ML[)^D3CE/^M#X5,%<YW+?T7E;Z4<+/B4F#
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M\D7LY2:B;^4"9F],VR=B3N@VTC6>UW?<S(W&5$87'PG(]"X5!U/(8#YMYCB
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M93,(89U(V'C<4EF@>K4G(ADP0X(D'$4F6\11&-7(_ I+HAQ.&DE%4(O*@IW
M6PRZX'O',Q10Z412;MR@WN7&?4.)^K+(6<3(&D39^IF95@4@-*H-I'7>YX7>
MZ!452#M/60*D7%7 ^%C)KM->\#@D]9PF?)+ ?U(OS]W8"@1=@.5'#)09;#J7
M.6689%$O0QO V!M602(=VRPLE8U3=>&/;K'2R%D2?P$6>!M,\G32Y/@/F*'_
M0/T!'8>I&=!XH/:(7*[*S85 7O)J1W])*6$#BD^4,G[B$*FAQ0HE+$ 3EZA+
M*@M"CL@KJ@04.%"2O)M9Q_39J9W:$ CIRZBS/JS,/*)[);]%7\W2M+Z,QE=T
M'_88H:"AV0]R$A/:O"ANT3I]S1P.$>[Q3>)H3E[-0PZ5WB\&XS!>3([Z$L%K
MVG_M)OH+2O7A,OA*EL9K+5S+$&3+Q*%<%OZE-+^RS7(SN]&<XF4TS];KGM2L
M)/B2F#?.VQ6CM_1IQW&#K@<$I/(1,,_)6#M>" HYU?<5NNSB#YS P;(MSXM\
MTYQ%I6(+GUR9MZ[4I B>UF?,%Z4;QE.J&0IZX)VJ_^30/4.2BLMY&1CKS4U0
M+J5XD35VPV4@]LZ6P2[JX3 +K$&B4U@A/F5S))\& XV->)+3$L('K5/0J WK
M@IX%4CSP>+XC@T^/B4<Q1N=T5F<X Q>?LU42-<,<*V "3@_TD$J (8VI:I\%
M\K]0F6?<>2J(\=/WW>$'-K&#GK*QTJ^:G(PVC5K%P=3D(5,9,:8W1CYJ;E>M
MTSI&:Z/F_%]H6]O1Z66VO#YW!397FTDCFS F]0T#NKF6+AG_^S839,81P>=-
M6Y.('8JGK)K<;<W <C09NAWWDRW\PU V+9GQ Z:4G#0EU=RIQ"P'J2IMD4D4
MM+O;L&294&#I."052A_5VO\2TEO0#0(XJRXU[1NP$0ZKX4E$SF6O=8;KN)9K
MX/.TO NPCQ)/&(4<_E2<=GF/+1Z[G?FI%GU7.S8<1UIJ0-26($.F,B+JR.$N
M@"G!WW#?!F.P?0TT^.#(Z&F8EE&55CQFO54J!I' -+%8^.*T8!QG?1+,EEM.
MV3E6%@-,1KWD!GPF^13!8<*F&AXKY35F%)%!RE%A0E,D@SG-LF(ZK<Y;VEPF
M:S-6GGLL &42 (72[(QE9-JF\$IA@TF2DC(I"5VCLK7F>/+4U&*G.D4V^"@J
M K'E]*&W>$G(-;U/ IGK^K;O^VXS0P2Q1R:DM8DYG'RK;8HQ8F75]!CJ\Y36
M_?/_S0.>MG?9D#YCO4.ZEDT"#=H!#QIQ2SDMR-ZHIGJE2B5%2Y$L*?T23P/\
M$>9V+SS<9$>*N6-".-PQ.J&R'J$[2>NMW);QGQF-O)^=X#U,7KU6DMFI;&[V
M6N><M%;#E=/Y%2%_&LM2PU->%7+5#O@.M.T;,DVFEJYL./ )76;]B<>QKIOC
MY3T[#6<4N^?45*,[7UC><>HD$I:(J;RTB- +/9\I(8U<0\TVEYN.;O<9Q<_V
MD 6C#_PF]$(W],< ,+MNM!,E5(X"P&$S:1;B0Y?]-C4WL2F^Q)DDS[0F2\ 4
M%SL"P38!K:N9U-WQZT>*Q)$<V1'SJ::22ZGM," )K15M_T01.\"[ML\/=G0"
M;!UZXN8.7LHRO9\?>Z_0ZN/[LU>5CM(]\Z,G!%+F@16@%.;U/#%621[Q5*O2
M,"!K/=L7J5)H3<)F+4 /5N8O3]&9,;S],C<RHD1=K/6I').AZ @. MXH!MZ?
M(C!)%B3.<LX_Y,<&8G8W.?2!)_B"7PM(LLR4_4>]8HXN"AF/;3>>:& !H;$7
MZSD'!Q>9I W!@C'ZS<#\_='X,);5,QEQFMJ!\T/[L97*,O>42Y>1Q37M-;=?
M2;%?4?/Y&IFRXF<K+2-7 SP 2>/TRGG\(YQD[T!9$1UF#CB.!/D(PI&I@2]O
M"J?B&1GVFC7EQO&@(VT?^;>S#$V@: $Z\L/4QE;$#-Q#:8E&:3Y<D>%E%PT7
MX:7?[%AK&B9JZMKZG<&)4,VWSAO'N6*[FSE5R#G6W;[B?EKA\QUT@U?\Q5?\
M^:B- ]D<J_]R6N%+6W@+4%F<RSD4EI7$-I"ZM?X6D$QV/R\7I7'GM4GW;I&O
MD8U^2RUF=@0SJP6+D*IRF,AZX7\"M#S7:O\A;E)DG<J)G3).U <7>Z![[7$7
M:6A--+%T,8M-G#4O]L%K;.]F0WAT7Y9K9ZC4MHJ)46ZU-,\P5VM,7.Q4N:^Z
M=9G'I@H.6]_ %[,#74T_^4.EW?/(14M[8-'.1*>DF19E;X@ "&*9!!(<F$S3
ML(+$/A%DF&F9LHCUE-&#-C$B1F40E]&CJ&Q?1(@4-V84J6QBQXX9-:8,J0R:
MQWTR9]*L:?,FSIPZ=_+LZ?,GT*!"AQ(M:O0HTJ1*ES)MZO0IU*C_-2/"O#CQ
MZLF352."G#FR(]:P'E4JB^92(U6L&RMF];B2I,F-T#BB54N69<:6)%&BC6B6
M+DR]:/5E9<L1XD6T>_N2I2<R<&&/$!TKIFAQK,>K,"57)GFWX^&4(N_F9>SV
M;=NO)+-.1,QYV=S2)K]BG#C7,6776$&"IER1;L7&&#F:Y7N7,.6LH=<"%^E<
M,7+@5,FZ;MG7;T:LV#$*=WGQ-MR(^NBRG'R8<7/<$&%"C :V;'GN%,U:=^_]
M8]W*+ME&!#W]-30=C4?=:9'5%6!VJ8%TWF3[I;8>9B@1AUMF^85T66MHJ220
M,@-ETB$Q"&D"HH<D$J/,@&?UMTR*!/:'_V"#A$TD(W:+\05;@QE*M2.//?KX
M(Y!!"CDDD44:::1VB:TDT9)>86362IO!U9)H(Y4V'$8+XH9@2@%*YQ]I[&VI
MT7AHT=>?:7R%E!MD_CFXV4O&6;8B6B"MF!Q[L8$Y9USZU>87E6[%5D]L'A6J
M'&L8ON0?<^\1AI=) F($V4M?9O57A=EMEAQ&CR[ITJ9],H>7?(JIE]=CI;[$
MF'UR7N<:8I=111*-$J:&8G/X$8<7@@8B!]^:DWXF*ZCR7?39I(C"N=:?*PF'
MW)FN0?F><X(Y]ZMK3W:T+(6A1ND?;]<12NU9LVV')I/.<H:B,@TIY.%"[PK$
M[5=0NN1>KFNQ]_\JFEV2M:]@;ATY,,$%&WPPP@DKO+#!GVIF59:LS8152V(%
MQVYXC_;&$KY5HA;>K!K>!AZ%PPFGTD3V+OBGG16V%[%*R\6\[WF_,CD:DX+Q
MQRR%DFI'GG.#NE7E:!QM"F=)>$EZ+ETL]H>I;A;Z.1:$$]EY7L[,#1A:8453
MN=FCX/7E:6"'E0V6T'PI296IN/)'6F1N.@@?IZ3*EEO2/ ,6'VP9TDEARG3&
M*K.QA6UVD8RRLAC>GOW:B]^V2I_6H'CDB54290BJ-7GE,:/IM*3OJ3TH9%AA
MNNZ[(#I$#$$<#L0UL-Q)E]&9,0?*%]2FTG71>A=UQ3#PP0L_//'%&W__/%!,
M@D1H@G$V*=.J)#WN4J2]PH7@]'1G%>[2ZJDD-WG: NU8;.2]]^)LF?<;&;-O
MB49:^^*U?1UAU4FVV>FK1DY7BJ^-;>5]HF8<FN7L5L'"C+HDPJ7EZ,]<*O&2
M80J4K*25J5+YB9K\,L0[MG&*<E):%6OBIB(& 8YZHO$4;&R7&I(Y4#47PQ*3
M$B.<U@3F@YSIU:<@LK*D)<9<X0M8;O!&F_M<*&I"4U%>.O8G"-U/;9@["Z/Z
MLBQTZ:=-NG(+,4"1$'C!RR$F^E!(HG,J[#S,A,,IE)@PL[1DJ:DOR'LC'.,H
MQSG2L8XZ^=0*4Z,=K\Q.+RVRDEP"A3.*78=Z__$IS;3"1S*3R:<C4*H67FSE
M,GY5CBM9J=]*EF>H$$+D45#:W,Q,(J?-W4@^TV(7WCH2+BHFBU9#%"5^CB67
MPVSM-F=DV\TJI$$8/HJ!8<$A;;J#JE(Y,3%MY-H8/_BR]Y"EEYN!S+X*:#>W
M*3(TI^/6XCPV'5C!B5'6R9?W[#-# UW&>\'"$9T0M"D]VHU[2V*+;T*XPX@5
MCG(:@8S1E':ZBH40DY;*4*0N9*+5K8Z+!.F?N>[TJ2Z123K:,5-E6E,RGGW$
MCA:]*$8SJM&-*H50EPMANBSI%<H4QS2&I)+TJ)81/<72(Y[JG&?$9<!\]LTT
M8Y*;!87XJW&EIFX-TO\D#W&YI\A]3HU]>B>6HAA%N\6%'G]QS-9Z=AU;5G E
MIX0;9XJ9+M# R7K\S.=_@JJDFD9M9>1#2S1K(Z62J8B9EM'FJ*AVJAMM"VOS
M9"2RO)=0[8'R3N<)Y5E'@S0LF0V7V9JJ,<>2R/@4JF7U\YP..3DV)M839=<Q
MS/F8!9@&_>:>.934RW!&+G%")%X#*:CJ7'>B8$%U5R*QRY22MA)7_8LZO\(4
M1W.KV]WRMK?'<QC2$D.LBNXCH-R!VM+R]\T_E3)OY>$4C"QCFZSUTCJ 7&):
MNO8?(5XV4KE"E5.I,T: 2K:SG8R,U913)D=BYKPWA5Q/\2C;B78NA-Z,FCW_
M9S-=!X&R?$\D[RK%UQVDB3="$ P6_BY)ET=VQF3J]%\./27#!&&E3!NQ, C_
M9$[/HNM0AK4N2CGF/1S^4H4T4B ,D_.]V34MJ07J)@"[EDH;!D>SC42:>5BK
MFI9"T:65L2+E""*B+<IK(/?T7%YPB$.;60EM6(DFH6#%5,SXMLI6OC*6L]P4
MEC$WNXGUBH5;BZ9>2HY\/+,/O2CDSFYB36YC#:F^8E2]M4GWLN74RF1DA4;3
MS5:")TM6XTR2O3[?#VC.+18-?UG&L[+OEFOJZ@,]4M*-Q3"ZLO'QL6SJG3N;
M#$=S+8NU9#N^\"7(7U3&D@87&-[P86V76$6@+N>#76362JN$O]0=1"5(6*SF
MN;L*Y=1=Y[<[&*4-I/0Y*@HO61FRC&M*R*33U.[BQ-74&%'K4L8P1'2086@1
M(=W>MI?(M.-1D?N052VU20T%.Y)HN=WN?C>\L6Q X<X[2_\RP9FS8AM*!,YF
MW1;<=6&9="89&JW @>Y7^AAD*+]=5J9#1#B>)/K4OUSF//9!;ZP]VA;_>DYT
M<GWXJQT6,K=.E%PD'(XG?:H231[[+!G")TLQ%UE6P@]8-3;UF;K\YO!X357G
M"MF$P?:DAJJG?#Y-*@0!)M\,#TVH37:-)N$9M52>)]S;&:Z3U3TG%\,MYE_I
M57H-7B=G 3-D$ J=TQ:SKS;%]#_KH8L6NYUMU2*$(/A.WR896BJK4R:]%Q*,
MEB:59U7&N_"&/SSB?VO)Q#(^8B-MSQ@Q8W2W7-B%0[_=G*1]FHASV#7UHU3!
M9ZD:&&L(33."E)LZR-U%&5>83>__/)8&JV&5B@9I]K*7E%>M5[8V]U#$XFRI
MG'; AY.Z,>0YFV@A;T_+9FO2#NT+XRS455IBYE>,-MNS"9E=_+)579$[_7NL
MGJYBIW=S@XN\S9=$$F!RB=#!M-P]^RT80LJ%D/YAGB&#BAUF\TTK]D>4N: $
MV$F&BIE03-G.D,E= F;;,*0+2I14N951F^&;TE";[&#<1B2>!FX@!W9@D-Q*
MRX345DC$3!2@[#A5?D#6<N%8[:U&_[48OC3+QT%1^XB6GRT.J409(YT=KEC&
M\77)0^G@8DB+A6P)5&6<5E#/H3R26SG1 ]7-2K%1[-F:AA5*#.9<BVU<K*S)
MJ)2- >W0__>$D0O654L\CG>A$N5]GWV52X,QB:<0B/Q57<BIQM9(#;4U58YL
MDGR]$&DH47),'6= 8'Z$(/[UV_J,2?R$$2N=%!?R4[<T6J:M4Q3*Q?H\E)_\
MD*=M79>TW4 P8-U]"!==S950RB(*%6Q(6NDEG-C(%IIXH"N^(BS&8O+(H"9M
MQ7?X#O2$F]'@'<JYQ5/M6,O88 B^E<]5%<-IQ?E@# &&!U %G^R\U*GT26^
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M%KI@7#R#P.Q,CU?XFAS+'/2IX^E&>7&QV:T469?=J&]6OK&/#5%BS'TE*F)
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K:\S&;>S&;PS'<2S'<TS'=6S'=XS'>:S'>\S'?>S'?PS(@2S(@QS( 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img43903234_6.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_6.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M=*:J[)#N+],C:1#X<*@L _DI$V;426V$-(R^*<^):%04G![FE^)@)SH>BI-
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M?E\8!S/7+JEZ@NJB4G'%AFXBWV] 3G&7,K.(4G"VHF1,SNC-:D2=, Y*)!$
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M3R:X[2Y+A!OS)=QBHWDX!1H*PK@"R[AL=#EE@!X 9Q_<< S!XI(J):^R1(L
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M8Q,M+\AL4>KJ:"FI=T('5PP'&-Z^BWL0=ESVD%SZ,7'U$V7-C&5'3BNX)/:
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'>^UR!P0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img43903234_7.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_7.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MW7AB)K1\(!D:0CD1;#8E*!**;JAMYQ0-Y-5JA5=$40E<N*$0/V-N$\4"RF!
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M[=N\W=R\70^9P-O#/=W'30S+?=WOG-W;/0G#S=W4K=S'K=W,/=X^A=[5'=[
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M03$,HXL[-* ;$UA'!]H1A/N 8QK$- DK[J-]8DHC^^#HPSD.0X[*&$8+H>A
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MZ'S+)&U=X>?!9T>:BI+)\^G$':G2.3R<8T7K?HL<"PF>4(F^N2$VS,$1*R-
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M9%*/;EE/U8@/PKG.W:@\V(HRY8!"=[N19>&Z7F.XQ=N46705=7S_$\J\DDD
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MD.J$D49?I@/#--T00[$@,1PXB$'#L2+-L&4WMF8*D.EF #&9Q!Q06[7@RIM
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MRB*:,-]YE *:-!@ 9SJ+1L?*DC/NX$0G?IQHQ\0B":<2AC2]65PQ@5E!?>
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M3=:<AH$81U ,!U;T47>Y3W]0#J^,244PS<K0S%KD6#O5PQN4!@Y(PH+P5,X
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M:P,G_[W-XUZMFF[MHZ]\R'WX2"LK5JB%()A;1#7;4C"&K'?"-)J3+'Q\WE+
MP,C 4EY41Y+(#._>844X63OIP]38A,RT1(4_28(+1ETXS8S0Y"(J\3Z('@'#
MF%HPAI8D4H_13 W3MSA;6O@T*P$OH^/0@W0@CCV+01BXR(0Q!F74RGF( ='
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MULC3;@U2?&-&Y 3L.F2?<*,11Z=23JT>[$S=,&R%9N2C]FBQLB\'8>6;;A!
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MS50?+FYW?$N,UH(Q<NXEQJDST@ &\.8K9*(C.,)EA4,P"4(&4L(C*L+EPO_
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M-88\MJ+%/&@MM6<F+"PY*D\=)F0&@2WZ>Q>M\A=NC%(Q%["SB!)Z9T]/]D7
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MRCSHV-+H+;>(*H[&Z-Y*J[;5'GJII^$:9/^+/=AF'*ZFFPQT$"WZ<F).R,#
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M,S11Q9GV@XF (#B92Z7(9[M9&REY9J_N_,=\Y;$6">\(*$8*4$H)96ACE &
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MP!=S4V*BOJ(<36 DE=STIWJ:4,RY,V%L4^0+&I$#CS=B$]#;C\9AQ6TKP:H
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ME8 %EIM@L3=[$=T:AV2[[!Q17FR+T# '*$,BEFZ I)$(U=0S-XY<%#\"!(P
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M42MVG ME%'&\4NNTFYLYR*<1$_HTR*[4"+$0RD@Y6Y_(W5B-T*1PU1W!Q\%
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MACYK/4S_$\/T2 (YI0&TNH0+'O)Y_XY)WV2>4W;#\XH(6SNVO2@Q4MW"_PI
MB=$L+TII(6*&[FV:N&DKBK$C@LFP#[$@^^CCL=>MLO/[#.VCJ56-T&9];& >
MEU;]I/>[F=!)Q6G7O!Q;3U[>]*#>&BF)?.]UC!6?L_C4&N2)>%?3%-#S_::*
M4)-5;SXF2R.5BC0B=70TE@]3#I*G+9VS_6,7U92^IVV$T_MDH(&AQT!**<,!
M#.J^K@NO)23[^%W5"K1\0+2D,A6&Z8:W:Y/1K=DV4U$,E:NV)$IAU,;[4OJB
MI9+LHLV2 X2^:/N6Z=M7C^"^??H*[J,W<)E">ON4[8.&\*+ _WH:]6TL&'%A
MO8'1$#X\2)!C/6@4#PY4J$E&3!DX-.V+]M"D1ILJ]VD:<W,@SH4D5SJTZ-&F
MR8TW$QH5.7&B0(4D%T9\R+"CP(DDHW7<J9$I5J90NR($R7-B1)%B)RH,Z5)K
M5Z =5U8LZ-)M7GK+E"DCEDG3I#1CQ.28*1-!S,0R%3-F3'C,&,& B1%3]M&@
M6X- $0X4R;/ST*U;-SHLJW!,&HD'&3;-^QIV;-FS:=>V?1MW[MR3AAE-R-0T
MU)T*GYYDN9HJ5I$GRQI$"!8A2ZD(*Q)7&/$NPK5F63X'W;QJ4ILG*T8'B=.S
MP9P>I6;,#E%]U[-NET]$NS XU;-:5_\GO#CUJN$.6JDS]DHSJ:763FK((*ND
M^VTCGDCJB"KAN#K*LPQ9 ZJEXPHT+:OY+B)PK*Z,4VNET?1;T,.+-+3/):5.
M\HJH[D8TSZ*0-/HOHP>KHRZ\Z[XJT:B5&KJO(JE,\^Y&A2JJ[CR(%&JP)9-0
MO ZKA*!TJSK=O/P23"[#')/,,MU*(P TT(@A$V)BB":3&[HL4YE)*IIPK*&>
MNXNUY2(T$3VO_JO13YOB4G"B'KF["L<JC9K0-..6"I"\HX2,J#FF7.).O0Y_
M)'$YEB#EJ:*'/HR*SZ;::@BD"TN+*".>"N*)1NVF9$J9,1A+([JV2H+4UTS$
M:#2AI0H-RKC_.S%"RD1,/Q.**@%/DZZS5?%3B[B1ADO1P[*X94ZESQK4SK-L
MC7-*H,TFS0NOJ1CJ2Q--,AF,,!QP<&RQF.Z5(5_&[AT#A\C2F$23RI0)-R3\
M$B2W5XFD]&\?R<9S-C,S+39SSGV&0:/=B[\$;+PDGXIVN[DP.NZC(4,#<3E8
MQ:W*JRN!'-&WI2@L#D20(HHY(=+H"JW'\K#DBEGB*+0NK _I8BE)3)V#+]IT
M1>7.9"=]0Q$T_N9TEEJ8F1)WK80:VNJD5>,;TCZ#FCX[.I&/<F\ZJJI&:;P5
M,S)Q67=!! Y!1EO#E3667%QRM5 5%9LX @=D$:5R41K;7$BQ[59(_Z32G9Q0
M\09/]#,0C6;5*T>MSC(ZCTWW<I+355==##04$B.-.!6*@9B+];'ST="P_>_7
M'$UB"B1PCW(N1:#L&\Y*(9,L-URU(_7,R)#J$J_2'^7+*O>O,%MR)%\5%QG1
MI,K-<.F'BQO\QY_/+K5#WZC:[G(%<]57ADD&^OLJN3];R:?KI<NN2'^ZG,-H
MQ)KSZ&AA_!&*RX0T*++8["["$0ZF%C:^Y;C-9R9CR]N6\Q^UZ(0K9CL2;9;!
M%V+(2S"#P4$.]K6OQ?3+,?RZ%P[$(+!) $83?;E,EO#S,,XY9Q]I4 VU=+(Z
M(\8&&F*(00Q<5Z<8'" &1]3-))+1I^08"O^ "1NAA[#7D%*5ZW"#,ER$"*0X
M'"EK<9G)HL@&\BW@@$0YB../H#KTP.:,#6JDR5;,^.B4Q1VLCJ+ID*R$%)5H
MG<4EV^/<;WPE/BJU)G0N TN60/(C\44'1TSY#X3<$JU$(?"";Q&.XMXG'ZNE
M!6E90V1_0#*X:AGJ,VU$RN,,\K.A;0A5JSE<=KAE)8-L[HY4:DET;D0\#[VE
M;')9D)+"-A>K,>PX4I1F7FHW36OF1@QB4,@-!*--9<0@8V-:!N[",JMT=08Z
MRVR;UQ;)E0(FR)S(6AJ5.)>AZ$S(6$&JSTX&ESCC2,F<.PO-/BG)D699JC6]
M:@YH#!B?1D9R.CO_0=;$G(?/E8A14OJ R4P24\WJ-')=0,P$#C"IH><032=F
M$2;\J**LD;QJ.,CZ6M+$ T9;18J"P"J+MP)();GD,T'O$Q J6:*4.4*J2@,I
M#QW; AL*T4,9Q8A7)B@A1( 9AE^-B6&^^I6#&J9F8)0H6%\4E)>&2*Q $[VF
M$3-Q !R@(0!BN,$!N!G.M>:E30]KC= 4VLRU5+)N>JS0:3+7(U.-!V4YNIM1
M&*6E&3$4G_Q<5EPJ54N=#0=R[OS0A7P5%/^%K:;[R]$][4A,F"[-ERPK7EM0
M2965\!$XXB+9]([66#RUI2*;/%1FUX6J+)EJ136R5JT:1Q:S?8AF9DL/_^#P
MJ-"G!HY;%3IFJQI[6,TF5*DYZA,G;Y8]G<4G*P@#D.-DY5#F38\] \)D0B^Z
ME*'<]8AVA2]\,Q$#'-P@KOB=EYQLEP9E1-(M:MEI5 2)12$-$CS[=)OV)#I,
M*@GTM?%\&6!OQA&C5">W!I(*80T4/>[4;%31>]LP-]7>RD'MKT TK$1SJ9V5
M"/5N8IG$8Y:7N[D@DB<^V1[[7&3(H(Y&>HL+&Y/RB5KJ^76G 5S<YH9'2+JM
M$KF_6B?OXH?33B%KDP(6K6_NU)WN99>!"LL+@?IRPGFEH3 XF,&^8L@8KCIF
MA34<V%@+DAK?):QC\S637!&2B0#$H"9ZELT- __HN R74:6^,0DJ(\0?$BDY
MRZMAW^)@9,#QP&^\]=$DSC:K'25AY\)!YHZB[A:5EEW9/#H16H]X=[U0!="!
M@_S*ASL'O>5@KSP_A:<:*]HHP5J+;LLB67@D-Y7.)55'YB0Q:8KGE>5DJ"WE
M-)<ET0B7*"5TM%)2J7L!RRT<%451VFHLD&39J?\,\)/6DEM"XIBS(E*PIZD>
MYA]5QAQZO%K0'LM$OO,M+#'$J74Q $#J+K8,2=R)4:Q.-'9>R226@1 MAQ2?
MSQH-/!U)7%7A^6*"'$RTZ7:R) LKRG#."1UNS:?=#$*8; UI:DLY-I2EX=3P
M<"EQZNB*H_8[L><T';I5>@B+/O?[8+%LF3>*N5:E7,,3PX[&1ACQC"<G^8[P
M)I(^P?5VW>V6D*TX1)J94CI'G>*D47:6)]_0R*BS.LG(7Z,2OR@C7D)4(0O=
MC)@V:_4P8^B0)/_Y;3%N*@0:;.H[;$!&\G5%JSJCXBS=NDPR(A79BX@5;8&6
MUM"]1RIAEW9+<C/5&J&\TT]26Z?FK]LR41_'MNLL('L<SU3_P0IF32X*4L[R
MG_QU=KCK<M&Z_@=;(D>OB\'!#\TLC9<0OA?8-@NUNL#24\MCG=SDTHGZHID<
MAJZE:BM?J.)@7YRT7OZD]@8/^VKERL0UCUFZ\^DGBQ4D1MVO=(,GT[[EWW>^
MF"X:=BKIGD073PIA!; "J4<$[+>,#9DT!$/6+J0H9BI"[3ZP+,!^:],\JU*J
M[O(^"9VN;M<XZ;7LZ9"F3^W."? :ATI"*6H>1!/$(%]JPCFRQ'JR NG_^(>D
MC&=&2.Y"?DGZ:H9 8!"!@*QXOH)%ADR3_.FC,L7'K&:VJ.9 Y(:RR()T1B<#
MA::44JS0].3RB&9:4H5FN$-HY"LOZJ',4,BJQ,!>\.7N-*%3CJ;^PF09WFH9
MZ($8#F#?^B+^\HTW_B>F<DF]=H3L FPU..?1K +I[.EG%"?AAJ-+(BA2D**8
M.,-</B1O_(/U%BF";&V.GFV49,N?]BG28N5[: [4,,EJ@G!0*@50(&78A"O8
MS.=:ENF?$JKY+,?TA$EHGBI&F*:'7(SQ,&LXBL-4GN;;&@A'-L,H1#!<\ *P
MFH8(I6YHB G\I"8MC$ED>LF4T.]2A.3XO ( _RMF%GM+/&HE2S8)C7AF#<G$
M"\MQ=93A)AKB=.CA#3(,!^]'3X@QT2A/I31E&#,/4YQP9]XPV0AH/Z[K^$(%
M8;ZN>?P0'X/$>MSB\WK1@_9H6NXCH<CHXHZGGW8/0[P#)>ZCYOP$3A@C!W(M
MZOSDT6#J)%+0K,"BGB8HC6))1EXL^K*K_6 0^W PF@2QCBP(.H1B4O#";:2+
M=Y#P1!+PKSK$T1JM6*0D1&+OA[S,V;K#D:XE,XZQ>;8G-L8%7N1E,-" A69H
M)D!M']$13,( BF[@B99HB?BK[PHO@8[$L\#1*!5)VP))012'^F8KICR-PGS-
ML_;/8?RF1)H.F<A% ?^- [? );*T+3,LD&Z4XK.:@D]PI#1P< M=4"^.H]5*
M<'H&4+ONPP+Q2%W0Z[V6L!658],N:?9:(R@=A,H\J<E^Z<!H:<3J,?;\$;CN
MD<CXH^->4K%D#KVXI01]R'$N:SB/)KO24-G<*7@B AZ]BWK"TI)&IABI4"S!
MI)JJTXBB08D.0 4.X   (-!,9Q)JQ_3Z!%LF9'O.Y]8&27UBJ0#G T\XR:BF
M!HA"+-1@:3P6R+%"9Y'.+?*Z!*4TI1"E3B9C:6]89-V$YK (YS/U2;*09R%P
M+B;\:W@&JXO.!C1]XDG"(_?TQBT7A['>QQ#Q+!/EQCY<3/7V<KDH#H2*:"__
M5(SUD@D6225AE@;Z8FK6@)-BON]#LHV2+$4[$$E&U/!25#,'9V,O_,+.;"9"
ML%,W,F$,T" -I)1*!T;^J*AJR@6/%H:?%E%(PC'4B@VX_/ JCF2.V'%+I$W(
MSK2LDH?TK*746&;BA)/ 7 1[HF=W)%-Q2' 1EV9Y8JDT@LI6;L0E5DT70>I+
MDZY#"E76HO,W ;5GHB6VBN@>K8@_CDX7E>ZP$JYTP,9D3(GCX(A)B2W*@%%Z
MM*/69&XC60QFC(6GR(\]V#%$2:R E$T002IZD@29,LN?9F]JIL5)O83^@O5T
M)L$ _DU>,F%8/489,@%\KHZGR*:!K(,E(.S2CC.3_]C):);0H!JF1K;D\OAH
M5O BO"1K?(!M<LS))-7N<W135RLMO6#0(KM#-U]L1JZ-'>-I'X@!JV8B/%_)
M@I),W?I,[SZ,#V.N'VG.0$^33\),*8O*4("#0QR.I5!4\[!M0R51\D1E1EAQ
M'RTH4>'&O2[O:I#S*(4,""'(>3:I3$,"5I'CL%+F%X,'-5*'E*B'6'.6-@!C
M_\1"F!J+,WL*\=H'IE#)H8ZI<0BS.'1J%X5,KXXQ<+Y(4%154["QJ:C%)3SN
M:+"EY; DZLK4V=*#:RK+55>N-Z/6.G@$&WF"\[8#\,CHI'@O/0T/-A4DCB;V
M4$R10/%#*2ZJ3YRG,$,E4/_6LT??;YU$-.-J"5Q>JRF<Z4=K;$N7$\\\#:"F
M,FF!\I7(YDJP)#(S PN#SZ+TDIF>)IITEC;.T72]A(:F"1KLI$:P9?4\0RA0
MJ4D()[TZ"V)E9'&<1;J2ZB#72X.X%)8 ,&1\0TXWS;+^[^B:"C-03LO:J \U
MMBC#;WHU<&H2U24T@<UH(E)9Z^HJ+)2P1WMII5K_<G1&93__A.-^Q=F"QC74
MCB@:QOS^!DB&ES-T\QOA)V7DU?K"L6&F,7M:<61P+;3@(P@M90#3J2FJ)3T@
ML\'&\2;?"V8B0HC4:9-2%X/=X@Z="5M89=JP%S*=9[+"TE!(K '!=NTJ-)E"
MKRG_T,BP%N^P\DF,OD79F(UA5BMWW-?#9!(]_TDHJH-_=>* ,J-)T E;,NR9
MN"4H0P/M9*TU$TT8?4H[%HT)*4_BNL0"3TZ7!K7]MC"8SFN8W-?ZO&UZ:JXR
M<D@1$TUHV@\XB"YQMP<T@3*IO") %$>,P.,3>6U_D#)Y:))1/XB7_"B#90-U
M!]DV)N$&IJD>*+1C\4?X'LWL9E/$G,6-P :]G,>RZ(9T'6N-3PWIB(OWLBO7
MLL?CIL62:/"$0;4 .^AX=3-Y%E0HP"X_HI$B9DPQQ@"(0X5KF/C4E' ?H!1Q
M2+/_IE6-\G,1/<S CHUX5S4C+0KUM$MH:%9!X'>?HF9L_Z$V/:1S103P94ZY
M<Q9M<E^+H6(-NB(.>PBI !4EG9X0#)O"("1&G+/6D/6"D05#$J:TD*T)9$SU
MG#:-AHF'6PESDV++]LKI@8J4,.NIEF288ND7SP[T.\[9@,$2H!F7ZYC9\>0T
MC" 6L1RZ=\5B9$I'$1LG;1NN7'*KR7;J9"?61'!QN")O6F:*)CEZ0YE'/.S"
M?,L.P/ZF;#JS1P[, NWF1!2$7V=B#*HI Q%).:+K(&&Z4&Q,_%R1I+D#85:Y
ME%#)+2N&=XN1:VRTAP+'/?/,D)=UGKWDF\1 A_QB=0Y. QWD./2C4S!Q:'%)
MU.*WEA+IO7!,'D%MJ9GC4'SS^__R!T6Q;7BN)!-'$6S3BBR6:978!UN\+P$9
M<YE9.II>;7ZRBN!J"WE3>CKO;"(T%(%VM"@<Q&V6 4D0"YPOV40H:T\VX[#$
MSJ:QAH#"Q8.45^PBSTSW-]0:0KHH$Z<V9,HJ;E>MVFEY!B.OIL$B,<S",I.7
MQ2[K@8)5(Z&-=Y[3 )P4 HJ@**ZN]!/8#2D:!CYA"E2"JGT1!I@,4)BRI$%(
MQY.PT-1<93J61A$'JS"/[S 7&JE$ZUE=;7KT*,M2BE4W-5-"*7!I:U'^TM8
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M:45-=8N8DI!2R%?ZT)>9#&1MENDE"692+P&CBY?N9+)C:L:11FJ:RA+$+.%
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M 9$!!"NF$#+%+*8_O,!$!YUW;Y)Z"\_S!)G:W0TN_TN7D?)&,[O9*2]OJ O
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MA1@<, (C, YHM9]-0C(\94I "E?HC%Q1 I]X]/!\&;Q4RO!5BSNQ;USLD5O
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M;PT8;1]E<-I"<9]LVB,]$*@D$1;NFQF9DEAI^QZ'2^2E]-$32^!OS-&AU.@
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MQ !TNH)]@Q$[.-,P7/<9)UA 7$%*9=853K=Y+M,CZE)FYA)QIF0F7=9%_A*
M-<A#G^4_<=%1ET%PS>8@HZA51?]SBM3H,H 4<:^C&@F5&8?H.L'S2))3(O<3
M2WU"3QU898LW:_>448DG+VSX.C-3)34D4VL&62ZX3<WX%?F8,> V/#+5%S4B
M(%*R44L5BXCC,>D%;F+"DC.A8I%#$1U7&RI23ZZH)\53<D^B>:P38"(4?'0U
M+^>A#&K5?)VQ00C !=;XC6>)EL74'/N@"0<@!M/D0;;"5SC2+W;4$)3 -LH
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MC22$.U:*>F9+?]=O3'AADV   5">RB&>V.%R#<9RQR0:Z-F_?>S'MG(# 0
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MHWX;&_S[,*;"QP8GO@SYL&!?L$A%^@2-\J/FQ!HG?GW[DB5-S1%#LHS:L:3
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MNW& )/2Y$R$F6Q^2>"2+"U0TQ&"<X;'II: QAE'*8 S#Y3?A"V]XZ4X"DS'
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M2),X_?P3T)*R-$T?99H#I<J'T$!.KT2-&S302"6=="%];I!RGYH(_-(R%A"
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M9A\F<3&5HT@F$>PZ1B?0PBE>1>'T,'[B<+O>\7HR)/5<+MJ@Q ?_>P/VF"\
M8@ P7I!J( TP+D,9].'39$\9^' ?AH'="K(A#C,BS)$.&4TC3:)O$) UO](>
M444P-:(=%ZXZ Q$'"@\U+V\J+_ --:).=BX[/R),1B-91 (4 ( L9)*,E@/F
M<"(X'O('E\/;Z',AX#,K;<(]]%,ALE$R9C-'Z&\2YB0GB(%;\K$IR)+C;J5,
MH&0][Y$8':(PC6-FZ.<2;P\-TC)R[@(-["0;S3$[TN!"FLT J,\96Z,GZ,%F
M;.8D0P;=@$8:W\TA4M%(>"_I@&X[1<(95P P*= >R2)7RK(J-U+=4%+EV"\D
M:H)LP$)I>B\CE+0A0":%?E,@-' ,40L _YHS(I2A3SH/+*PT).I!$U(+2M8,
M'8.T(\Q+^4*O)_KD SM"=FYE!6Q0(7SS(Z\C)SXQ+]Y@3M""&34J,F!.HT@J
M,,FR[%YS:](%[&P4?-ZN"2&J6GH1;DB32:,22GC2-]*C7IK#7I;KV2;B;*9O
M8] B +Z10"'B,C@..4-B&1J-),+O "AN]UQU52_B[G#B$_=!3T5"$P" :;S-
M%+TM5=E4(VX .:PN\-3&9L2 4VD" %)O2")#3FQF/#,B#5(/;4;3)E".'BUB
M^:H%4\P25C%R'\!N& ?N$Z63,W1.)-#R_)SU51>#,HWB,H@1&Z6$')73.,2@
M)J#'1Z0&6<!B0O_B!P&1522QA_+\\#**[P".+U)NI2DL:2%N!4T=)S3,XEXU
M DU3*S*B81@6ZHB4KV*AU$O-A -O11/@@V45+2+J 4W-0C/,"\T ;398MB>&
M :*.B!X8BC92BU>$K:'R))#Z*3@VMBD\U#CZ9&9GU452I6-+PE+EYC8K3^$N
M8Z%LKB;$H*$0 RR[;Q@VKJ%ZE @3,U>7!VB0%2B_1T%[P@+UX>[RPFS;SVZ9
M CL0U3B.=+^8$2S,!B\B0QFH@E?F=F^P,2T*#WQL9FE[PIC\[WNZKS5P8CN9
M]&XO5R6FME-G,7W0XALUY#(8%WS&$$PS<1_D31-@(&4QEW4M@FE;%X$6_!#=
M@!%V:U?8;'>)R")?(!5W>]=,?/\7>&>%<\_/8H-72U[7>)/7W=S(X?8M*YL7
M))8!#5+4(=-B!8Z4)&[MUH S<V<$4B56)+3W)S07;Y77?,TM6L6-&LL.-CQC
M<&^F3EJ##IVE"[-P83_"[*H29(A!'U2S(R8.5*"$6'U449L-#61 <3V"%P=B
M&>(7#7@WZ;Q-,D=B@24-Y@#G,A3D,ME6(^CW/FIF.I,N?M=1)7Q.*,/7A!-X
M_,Z7A>F#&6%.2B]BXEBTV1*G)J #:&Y",TYN-KPM5NHD # %<8>H_JB/"HDP
M;2,""EMC((A!^(BA3H9N^B3-/= 5)$[N)DXE1,6R@-U-;3I2W4ZN 213[F(
M?*>T3L+_$_1"V"+T@3,D<T7]+&HVKFY!XC)FXX)+XC(T05 %S7C<=S;(MX5/
M)A-2%(KKF#Z&TVPUL-G&=BM!)ER)=R2#XTD($>NJ$D<W$WLQ@H\MUP*=\/*D
ME_J<Z3E!XF<W3DKJ82H/%EC3Y09^TI1%(SE4T!_#MV5+633N#E9E68A# Y$Y
MH@7M<R0H+C 7R42D9$(@F#&JMCPF+CP%./32EW@&%R^\\FYKHB>@X2U];ROK
MI#9B;R$NPYH#U BAL(Q\@/K"X%0FF)M1,?$$(CP_PCXO=!'U,EV@Y(@*UC+"
MP"06[V+;<B3D-4\3$"0$%-S&62,Z)E7J%7]%;]Q((AJR\6U1_P-Y'2,T!$]-
MD2\485 AT2*)B8<>TF+Y(EEZZ@%C1P0*FZV4.6((Z2:>-W(T/+HBR'$2+#D0
M,9GZ#'HC6'F2B7#8_#7P5MJ+I02;4:LKPQ?FS$(@^4VGP\33B&,ASM,CR/$[
M1R(-#"  .-B.<^(NA'KL/&^)!3E\%T1IN"WS-D(I?RY38@ 5-QE[]! I$?8&
M9*!;140Y0.,ZQ57\$G8PP'D@T$2%&R)*+C9#18(363DB\>RN!8*81_*C*2([
MZ5DD3HXJ]#E3"MN(<FY"M'HC],$-_YDD]$%'%>*(1^*SV=(D^+#[.-LC+(X9
MW=//Y(3CQ/IV_P-9(H,>MODB&M X 'VZM,V'1&6/F?/F$AGY03*!$./CC%WW
M .P762T;%''3(JC:IH\&A,$TJ$7#FS^"IT62- T[2!]Z)"Q%2I1A!<;TESM"
MIX?ZGZ69(B)R-'09J<D&+$M"4=]NTJ!0F;F;H$ECN.EB&#(T&OR.(Z!!K5%3
MJJ_'$$,##^'G,.,CL/_YXS)S\ZA;&WXQVW($^A[S6@++F<,M8G9;(S?66.V@
M)$RYQ1PC?#/^1;++-),GD.I8^RN]NJ"-T!R7.R/F#T>V6R34^6)K!P5%CTQ-
M E[0(EM_L/(>FRYHNRIL RQH?+IS V3<$7YJ6FU>NGQ"5 @UG%*6&"?FY#@F
M5S,W\D2&I![:,UL8FB#F^C:Y!?1PPJU'0L7;!C-:HT,B.@9D8,SQ]R9$/*AC
M &K8V$PX(VU,L5;3PKW%#>;\''!LIM 3%<[WS"9NDTBTL\Z5?"ULAM(-/08
M@#\Y0G*7 ]-UE35D'#M=(\X?HZ(;XS+A0[<W! <J@Y[7&WQDJ<4/+>8P \>[
MX406J8D@$ 5?0(NN-.->AO<I[J5(HH&/L? MJ,W7,6ULPY>:>H)TNT?:NZ='
MB $4=GU*-<$XH9.N^ [8N<>(H.G9M/ NE:DEKDE0Q)+-J*UX0X(>'I#)?71!
MD@'(/_PA_C(3 ,/;>D[?H^<2Z2=?:@*A!QEWZWTIR,)U-H[CBN[\..Z$(Y5>
M%5YG$ASA@]?B:2U I+9^1C;\_COC=4WD1_YU>@XO-M[D-VG55][E7SYU5![F
M9Y[F2Z;D:S\>YW/>:&Y>YWO>YQOGYX->Z$&GY8?>Z(\>8'@>Z9>>Z4.EZ)L>
MZJ-^T:2>ZJO^8I3>ZK->ZT/DZ;?>Z[\^C\ _7NS'7G7(WNS/?GK07NW7'DED
MGNW?'NZ3HNOCGN[K'BZPWN[S7N^1PNWWWN__/B/F'O 'G_ II_ /'_'C0O 3
M.)_Q&W]#'!_R(Q\X))_R*_\G\-[R,__O]UOS.]_SE?CS0U_T[VCT2]_TL_#T
94W_T^U[U6U_G1]WU"F-_[Q=?]DTF(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img43903234_8.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_8.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M,P&Q@9PJ#9)@%71_%0T<LXJ"IK.GNNY3W_D.\'LL9*-\["/?N#Z0O@?;[WV
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MU-:C'I)O>8BQGU_O/0N^WFC$P)YP)QX&":;)9A77U]=* Z*KC7)[XI@>H
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M%[(Y/U& D:I#D^(^+?0^0D27H<9_F4@AK5,@"D$[B[4AWB,VLG-%>VIZ]?-
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M. D-]2/*IU[VFDSHB7/C"8X%.Y(&$.XD$P@<' O$1[[$F:Y[9>,6QU2XDVB
M:D\NP9( QX #PQ5QB#W+@1B2N$0EXD!Y)E+01GPX)JOL8U<*@6!#;FB23$@M
M31:<HD7J@4&K8=$ 'H/(_3 R0-\A  <&[!W7GM@1],%D+OL@QF*\.*<T$ ,:
M(,DBL&0@PQAN;72#+&36YJ@A>+50-'W\XT0"H!!H3'(?!\#@9'"%*SF!!5&,
MTIQ&'NG'B;S!,)J0T<LBLDEEH&&//?F>V,+G-;#)<FQ.X<DGMBB32"VR3^\;
M2NYL2;B9\<&P:PJ$$05M!<$#/"0&"HE!0@# D-9L2@SF:XK9ZK1#'"K/ '0Q
M@$(R&(/A5;-CN[3(  6@.!88[H#A0X O(:*)GZ6AGO:TYR32H$]\WM-SGUP/
MJ008.M"A86L(1"=IG$<LBCFLB@3!%1H9(HE(&NB56X*32@*0*F4< )K*B(8*
MDI)0BF0"?(@SH.ZTADV*'!)L[4PI^5*B_\VPK*IDD MB,&<IN&*>-(%*DI]D
M2@:Q):U @P19AAAPX"$UE@2@;J*=33E64H>Q1B'P408.1CI0@F;MC2I%'#(K
MDH99%FX,+.@:6G7'4CK*$RFYVL<RZ,%62I&4(H&3I2UQ<%#0V94RRF3(,EH5
MC83(M26=-!"F4C>1QQ VKG/-5!I@D :WA$H, DE*17_RO;)F[7""(V36)O79
MSJ94;+)TBE\;QT6WQH2-!!0?#!,G5A,ME%HQ:2I)GOK%7MTPMQ7!JT^_EM<#
MMO:J[]R:.VEXRY/L%E!]?(-Q)?);X*IT:P:%K=:*H22)8J0UJ.S>)#3;F_%^
M*93>G01KI'L15_\&J)9;(^TP94#7B(P/GC(0P!OC2+@9S%2U'^GA0FQK$542
MA1C$1:E/NP;,'0'690MQL*+^JQ%B7-1**F1<4.LJP!FT$;]??>_O-I*&#H-/
M!DDTL=9,MUZAT(-Q*J/N7;.V3M+%-[2*5-* (;(,))T0PNPJ3'DQ2E]5]3B
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MU(B>*C7P)$ZM.8SVC EZ%(IU_,X<,,D48U.(>,N= ,&3J0W-<K$2>AF!NP%
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M8]Q<!Y5)@?RZ..X)QW*_4'P\U\B$7F!?/7%GB8-:*(8M22Y ^Y6(*C;&146
M0%X(!WRIV>4K;@8)+?3G?5"1*KJBZ>!%B.A5DS!$*?6J*<5543H][XOFK-'"
M;4PR>-W8DK @:("*$E$E3:"-:,B$D9\^W^FHM*MXV=.-7B:&8IJ4XN+J,[Y2
M,ADJL5D&V_!-5HTN"DG8D^2-0[,%X*Z66JA%:G4E0V6$79H555KV85E$O+[D
MYXQ8*!#"ZF^M"$OJ**1U/(_>&#%@NYM YN[MMF>NU? %Y5H&8MR+J:2T:;=+
M+[F6I%2A!\=#E+N>3C0@.,T2(=]LV8FSV*G%N>%4'(+UWK\,V =\)Q^\U3"4
MI;;_-MS;U0@+&=W3]5.PGE[68.1AD"[A7+\W-D4JOL%!*MF%=4#PI- L'@,M
M?B>KWA"/@!2Y>0A>- QRIK16.M&!O,%KVPA:M6'QL3V3C>F<++J^M&E1V;2)
MB 'G<.YZ(.>@QJ)V9N)-J8K?%&A)(=+WPE[Y.F"(QDG#4TY%U>:NV64"$66B
M)F!WQHJ)1>7>:^D0H^>MRV^M06L]1BZ47J[_7J&*H.BD<*C8T-85$)!)N'"5
M@&9Y3C&T7!D;;#I%E>!*1!RTZAJ:?CK%H?#6CHFN].C80)L8Z/#)$ W5F-ZA
M)MV(N5@5F@0F(\ @]DN,,%/4)J#)XXCMENB^C/&>,(R-_YF_S=D.JC#=V%[?
M8,3-U?UBGH2A^^[MDIWHJ59R#VM2DH"_+AJJBEC% Y@8VKAK]?Z)(LW?/<N^
MXJN'T8Y& NSNY)I0"%T]6PKOD-@6 )R(D(-SA2@+?0#J3YZ,)-[L2CMHV);O
MC-7D,HRGINXL9V7&C3A-98V^-^YEF>B,P7(,NT$:>DC;^XMM][VI _=L#;R^
M5N9MV4K3_L5G2Z;*DRCU4R]?#3[!O9:,+/U25#XV13U&%[1=9X7@9*UFL$4I
M(C)7V<M,P8ER2M%5MUB?SK@=MMB6M1SHQ]WLJ%7<S$VD.,+A.T^ "/2=)N=+
MV4H U=X)J>%9DE8/MQ1HZ,W1J?]]885>Z&3-&H<6NDHN[#=>6, D\_!![@J?
MS1&LS6). Y(3 WR<>" EB:QM3L31\S:RMIX:S,$9[%5[K\',._ I]'Q;WMLD
MX(F3;3\E:&.=[[ICXUJ"74_W]/WVG1+K[8;/$>,#Z, B:LDM(4H :ZR0=5R/
MZJZ2+L#U].A[<(78;EZWKFQW:Z %9C6N-^'M:R4GG^);1\$A(L-6JAD8>\71
M0EO>^&BV>@)S._T8^0L,+"%]]2!M]1%"5$I!]^P^\HM(\I239/[BW(BVI76B
M]YGHJ !HV+A?-.O0$X(VZAPM:D;V\K<56S$OM3\+^=[Y<-DCKEQN-9_'B979
MUK3).<+_:"%0>1[#-%#R ?W#?Y1WFM#95Z(('9^OFP'&WP?[JF^<3W,KSPAE
MB $#&/X T#>V8-Z(8V?415O(#VM,YZO8=<1-_]"P'<@\EE9'[6W<&U]#QB$
M=F^!KHJ6?_Z,0/!2K%2$J_XQQ<FHWP<[S_2L&=R3L$5T$B^(.%2D9^(W$ ,3
M HAAFC(1'%AO'\*$"A<NDR$#@4.'$"=&C A11IJ%&A?6N^A0P,.0(2E&S+CQ
MY+X<(RN*M"@R!\J8"B?)U$BL)LZ-:>@IK)=IV,^@F8@1!#KPZ$]-RG(BU$3Q
MXM.6'I<QW3>FY4J2+F5$JRI1!HNO*RM"G#&F*MJJRM826YHV_^%0C4.#&LV$
M5!-0H$3;5M54,>Q8EA0U5:4D]2O)J#R9XA ;."I$'&\U2DH+K:VRFY-/3G*;
M$-2PO7/;2L+15B!JO)G0"G:,N.)9I@U?;_5(T213E61%1A6[&6$FSS@OL_TM
M5W@T@7;M#J-$T&ZOHIEZ#1PFO*9?L%NU;X=(F&D:E[;_:CV8>W=(P#) 0I4A
MV3C\?6B(H5&V>G-GCL^/YITNU/ES?#'EEU;B827##)KE=)5K+(FD7E=,C3'>
M5NI5!!-\8J0EAC+SW1<?0FB8EQ!114V"@Q@XW(!###B$@2(:0"VGUF-@%3C1
M#+CAI(QK%X757D5JH"5&8 ZZ]AY^B__EE$:'1(&(D"14)41/=9,\EY2,J@V4
MU'4R35+C4X!YU&5,5WEDHX%;19@3;6DZ&-N3;]6SU&H?OA670I?-%5TFDR!%
MB7)Z$:0@3MF]!E)K%(%257CC06:@E#DU]M"/O&4E4GPZXC3G/G7&N4]^"BF#
MUY:3H&'J)*BBD8:5U64R(DXSH.<@1(@Z!.>F9[8')&(T535A1>RM5^1%Q@7'
MU&6=*OMDJ @E-^AH!/EIE)4R"IB3)K)N1RMBA-84GIN.?@5K3;KM=N:E2'Z*
MUFJ:.+D9G@GYM!]J0CW77(!DHD2@D;VQY*U,X!X845@SH(N6M@VV%A&NFU7&
M[CY*:0K?)-#_+$1,EM"6*%J] ]&8V*7H31P3CX<Y*&Q):.F&+LLM80AOI#BU
MJXRO(.[4TW+2%B0C<\N1JN])F8PE[(T1Q5R3F5A1Z.":.+TF+KHSO+QN5?>M
M]=LDG\A%S"0E[A?MEG,!O9%?+#S:FK#?+2FK1T2/1='8&DVJJ]EC5:KN9FBD
M=1\Q^GS:+$+VJ<;S7%<6%!1KVR;ZU<@QM6U@RPG4O."YE8OID+%QXXP0,18_
M>6Q"^N U26K#^,E<M4)9U]>LBW^E-DYI)"R65A0E((.2.)G;.N0:4EW5,G;^
M%F_@5S8G$.E]$A1=O=<6:B1B=3NHN4(,%LEM1"J[6=M+F:(5_._[_T1Y\>&D
M7BD:4:0;))O2(3O6L$PE\TH[5HVCU%CM!YXY]5N3R_S[^!*RC+H8[R>G&XAS
M?E:8_)%$6PA0#_42DC2MJ.=V#DI<F!!C,.[<*GQ56965_(<6P"$D-??:DOG"
M-I (-N5I XL*[+ZEOTN-YV@RF9OKZ.8[XSSL@V.0UJ= EY#, (5/S3.<<@B"
M09'8"CT7L=]&.N*8!RY-)%#<B/6V!;)B#8^%\OFAE>($.-$9Q71$00I=A.(\
M["RL<MUB5+^&-A8;QF1WO'L-WCP8$WI$@X]>W)I^ F0\U02%.EQB'?2NYY $
MP;%-T/-(TVJ2,'^E26KQV>%&_*81/OKQ4_\W$Y7/=)8SHOCBA,, 7AMK-3#)
MT4AQNG)(W2BAO=ZT[$+&F43N:K(,?2P#&N0RSB<1$CSI;(EYH40@4.B($J$Q
M<%@-4N9))OA";BV1ED6RI!XW!2(A(D1T0[%2)DK)M><D,"D_\2*_*(*RAVQ0
M48QBFV#J-A'I0227,DE:'-'ED#R^Y8K97 @)B5$B01&EB%?2A"$S <V-$&MQ
M%X%?3&8CKH]8RB'^7$@6+1026Y$D<Y.)Y"VO,Y<M9:R4!K46.F=7H,-X!XX>
MN=PK(5D5.^Y&HQ/!Y#^#EA 15J5K#.&9UWI6T.>H#YW84UA$ %:FB+@MD1<!
M:4QPZ#:8C@2B:>E4810W4C.>_D82D?Q$B<*6B7*JQFL":>57+&@WEUQTB!55
M6'O:FA#\945Z ^/?WA:JD:W&R:L*H9(!B>*<H*)1-5[\DBK=>" O6L]?19-!
M-2L:%<!8_S6G^U!&  X @ ,$0'CLTMI"F$/2ZHAU6@-9HTRR\U@:RB"& 1M8
M.]WWRSH.S)$1X6=:],84S![  )SU;$@7HHQ 36=P0=$$. NGR9S LXTAJ^Q&
MHI'#MRV2JRAAD#[IU]$NY@2SOC5 9\6(' )*!UK,(R1J8V*H[;%4J2@!5W9K
MZ1 OTK2**\&K944%(A+2XUZG2Y[ZZI4OUCV0-A"QZ7P;2<EI0A4EE2N0VZ +
MGK2X-U.Y'&@YE^.<O(QN+K,]2<DV*I796<2Z&Z''2N/+..VYY';950]^>XJ6
M"@,S=S[AL'( ]37E*7! O:G4/+&B5XQ:JIDCF4%D+V?;&.<W3O_$ \X9BW(7
MY8D6*$957%T]XMJ8R"Z?D'.(/9<Z/]MB#CY8;?)&N'G9*)NH/SE[\Q(7=C8)
M,X0L=ETP1M B38>.Q:-HWJM(D9*Z;PZ.D*L;4!P?&9(MO]>!$=&6].R:X/.0
M98,]"@E._[R/81S@ #$ @$PR 0#3:/4ZP<.Q=%"=W/3NB[K9M0@C)>0^BOXE
M) T^R:32!#49T!DGF:X)IST-ZKX>;: C]9GIZI4:5.ZJMK"6ZV5G>+*5R+(J
MN9ZUD9B<$UQ6A1B=_C2Q1464\[XY*  ZK5)Z&K*S582Q+#692)#LE>L]CBR]
MSB9P(VJ -'M+'U&N5@)/MS/S7=DQ0 [_V:+ 8Z1U^NO#)U$)A+'L'N]!['<D
M'"X:T[B<5B4WS Z&GCSE:454&GA8*\WSKT2<J-AR$5Y>S#=\U)RQ0AY[+C(Z
M-+9(7!8O(X#&&A'8-.DG _IRJ\!%WJ>F0XL6^_";(5+.67_&23A6GX1?[*65
MSQ?2J(8ZD2OS9BJ\GX)-'NXM?&E8+N>D8\B "XJ@,-](0]CMU$94!<7.?3#*
M*7UUK&A;9D-6R-M_$\S+GI8@I42*$?M4^+_#Q;'8E@'C$8)/2H%L.Y&=Z)D2
M<&\]@E&)\=.1JCBD$>3U1SDDU3!JLJX00S70A111?4*Z/%T*>1S7S=V.I=7#
MA?CHEE')_=MU_T9E^C0FL=R!UXBB'_7$JDB7NMB>@8FQZ$AA-;'EDU&S3$[U
M'/&2SU[E'3Y*$4FPEEA(Y(P^"7R=O=+(IR31B<9MDWWIR[C13+AKJ4=]G'XX
M /D'*5._,D?16T4D'.4LV$58FD,D (L=6?1<2M\M25HLA3)P2K@IA%F5CR"9
MT6@XG$;P")ZY1*5 FS(H&9:I$@) VS[0E2,UFPP\H)=\#R_1 _O5A"0(AWT0
M&FJ05?*,UF&M&VM%A+OQF1M=WI<=6 <EW1") 6'X7*=Q5M.%EK*-U$DED')X
M$3'8ET1(&D3 'D( '55EX5AX$0YID9' 7U6<V4) E3(HX3YP84ZH&?\1'07S
M!%BK$!5!> YS%5V-'"%32,6=74_T:41C*98^^5EWB<%JN&%-R)Q8%5 9]1_.
M%8K.W=%$N.'6I1CEL03[[8YZO%I(F*%E><KQQ82: =;A4%G& =65/4[1'.#Y
MZ<2L>:+7,85*O=6E;%Y,_%KHI)FRC"*CY!(HW$LHT0N6D,K'*!*O($".D)Q\
M=>)(5-MYV%=,M> MU1XO>LJ3,(E"G-I<B)-="%SY",1A.5Z+:6+*N4[1@:+<
M_.#9F 42!LY-8./U><NSC%NT1-UR%)05OI+KB(D7J<$C4=53<*!&$$G^V!8+
MJ&/LH$6RR.-^70?&"%8:<8W7\!]!$.1"0 __RBP-+MI=R2T8"@XBFCB*A1AB
M341#/"[+0RJ$OQG?1(:3ZA1<=[1/2X$'RQ%,.PY=59#8K%A(9+PC<&B"AV#-
M=<R+\0$(@/")GU =V7RD'LJ &TI3Y4'/K6V$N53*I5&$"])@6OC)4/95)-W@
M<8$CEA3C*;&/W'%/WN&$1-T1;:"@"K9/Y6SE,K&?5[[+2@J0 :5&0B'70<T%
M^Z63F/CD8IVC8M5BF3$&#0&&BXT%+GI09OP1((46U^A%UY1E$A&24?&C"[U.
M(SD5:UFC(#H6"5:$+J)%[ZG%U0"?<*70S8T4./DE050E\M66.NT&M$E10ZW4
M,IXC/;T;2YCDCJPF_[,(1TLV(DSB8_@AVJQ0T%-8(IE9$^3-%&C6%ET"I<QX
MRPTBY]<("G,4W"LA&!"ZU \&2T709D8>5;-!A.91'';NP^"UH7^)%CBUW0:R
MSY>A(RZ&F$LT41921" N!,3%40!>A$+&1(#^4\5LHY09$L\<!3AM&/8AJ*M=
M'?M-7E.U#A%22%0\YN]\" H"%&A98%"@SV5&QT#49[HQYX%MT=&]XL_Q)(*$
MRT-@I$(,Z$'J4T+&!QK61,V$:*@%'\;PQT'511T2!-K5Q$I4D"*MY4F.A!8J
M4DCBG<0)YPMV(?<I1/$-'T*5J#DQI49DBROI(8QJ70DNZ5<0G:(9'-*]8_]F
MP,7P:&?.)%>1%N,Y$9C[&4FL%:"(W6:#H*="$ DZFESW9$A,_-*;(D2",D4
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M),$P@L59ET*%*WD[JS)@]35:=1F: :-J%<)<&\+^+ ]/05B;)\)V-<%.O96
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,SWWWWG\/_D<! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img43903234_9.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_9.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M$Y)J(*1^0XSYY<!$9$E+J! @!@.")53%:M6T,BB64.6 !>51Q@)QT @^"82
M;U);U7+T.H\<CR1@0Q'U' *6R"$D>]M[F$$T]0;P36Q<C2,(\1#20X?TCR$
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M<A\#RJSLOIA\')D0 P:*;S<0 S& !@AQ<FEPF9'<RKY,O6[L'&E@RS>@2)D
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M@AY&SO^(9BR_C>9GZ5D?:<%-]AD&4"!@*N(6:M*QD**B)"8(0Q8(1#:('N[
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MW "ZQ,!%:0MV[HXZA>1]#BB-ID:+NA]PC%7PN:?4&$C6R=-+6(YOIH0%!D7
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MNM5OV>K3,OAI_#(1K1S>#1.7U )B5E#_+WD1 RC8C[N W208 "#1P\8N@R0
MGS*8E0;O0QJ8%32(U4Q=,$[ KLS8KM$RJ1T=BP^G1 Y(K9N1D/3VD@CGASHN
MA"0PX4O0 \)^U9H@Q) .WQX'H#+,0/K=P ILBJ94RZ;04S2D</T(5J/M0QBG
M1UTN1>*:C>/BA ('A=+2,=@R"<:DSHL-\DON#AK<0#U$PQW"B8X&!7K@'A_"
MAWPN1=SRK$Y-*KJYGA6''1N:!#%H,7!\3'=I\N<.A+:%R1,'#*PVRR@_*QPW
M\3Z C=36L017CE"=&Q'7AUAM2F>QJ -!;$SLJMN1D(%$LYHELBL"<LL18$N(
ME5K8S*?5UC+$_W F=XD:Q\1)@3(V)U >.P3OEL1!D\0<PVWJ> Z; >_=O,']
M7:K:B,$D%#1#<'#;D=OE)$0XDW$2!Z!.8;25'D"J!$#(M&X];*HFLX8[6\DT
M7XH;"Q>3.G#;1O#8ODT0Q[17L7*CP)]2(*\ 2EA">R7J:O+0"F FA$$^=I8Q
M:0+P589F[8. _5=Z+&A2L'',A#),7)I/IZ =2^U"XQ#MD-!'[\Y+ZP=)8T1'
M#6&*E!MJ=C/J2J/;B<$06:>-U1#PL >[5%9$@!3-HC1PP?,^U'"Y5+,44H(F
M_ 04/C /PT11?T0O+\291,^FQ;79.$DA]6_N?C5LC1-HB/!C9ZQS"(3@#<AS
M3E6+==861BF)SP+'EHH5.H,FXJ+V8:OM:0QT^$ZNQ):O\N!.*7_5/X]+5FC*
M(P=  '0;9T!QY)&B49#HW\XT[CWS2%A&9Z)!-$J"('(2&J"!BW2R4A@VN0P&
M,(?'8#"MM<;$(;?L^<"IC(7T?8@5067P4 BR+NX*3!G%:&-L<.S_)]<AJV-@
M-5($-,T@MGGH-OA*K6_[A00>V5H+"8\EQ2WK8ELRKEQ'MWT&8%G9#UX/]XS
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M(A-H-SJ*9Y"KE427F8BK;H<_]GTL!&153C(U^4&;^)W->5#PBI8-=XM/M&6
M]5]^2<F0ZX/1BX.%]CM=I#C(T*+AE4H,^L.VZU_$_[*,)=E1]L'ZUK%OP5:Q
M6A<B)VDW8Y?GKA-=._I7^@L'_ZM+,4,3RD=[?B<&@LI<+(,I(C(YF0IY1RAW
M*5E]KSI)&Q.7(Y,R)7@$Q5/EINQ1#U,_S_E5\63GF,0(/P]J(1MJ-6&RGP*9
MK@^?S3BSIY>?UUB@U;AZW_B*9!$-[!DJ-*&.QTQ\T:Z%O%"%Q+!(7;AS5_=U
M+BA?\[HE_<:B<*NC<X6_5L!4;R":=6,GYG6!0[F<WQ0$)]J>X/>D$3A^??4
M&9D#P5E!&AJ1WP@YB2[+"&N1RZE(7C@VB<NK;S,@IQALQV 8=I>=F_<ZK5$>
M#5E%N *+>O(I3EIT794D:O_#;S080A.6<$"UHP<B)F+B*4 J,]+5K>&Z'FX
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M$<J+,G!0C$.A>^7@P8I2HA$#P&X-+ ,<]F:;JMXS7];$W\MJM$.3:C7O;:
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M;>GX5V(;_>Q'9TAX!\.6[\D!G@:383?K>*?(L>COQE*^0<G^/BX[ A]HT7^
M @V1?6][?=HVMLI-]N& '2$_!MMQK)\S#NO_$O^[T/X\;5BRRE!*'.DPU65Z
M:!6>N7OY+DK6L \0]:+16[9/F4&$!Q4FW+>,WL"!!975@U9OX46* @GJ<QCQ
MX4>/$3E^7#8R&C$Q$C,>W-?2Y4N8,67.I%G3YDV<.77NY#FS7D^@-.EE^GFP
MI,.C()4FC981XL.,3$F./,K1Y,:.!!$BY;AUJE2P5K,^#3N6Y%>Q4(U^52JR
M:E:)!C-6Q*API5RZ<I^Z%9NVZ<*W?0._94OVJMNE@@]CO3LX,5S%<.=:9#@1
M(N6+"3'?G5BQXMM]D]+HPZS9\^:\G5%37)9I#.F#6 \3&R/#]HQ,#:\&UI3F
M;,2@P6^R%%[<^'&;_XT.Q& >XX",&#=BX$ ^<])6CD[1$N;+?7M;K(\C%P[?
M??'@W>,-=]3>??5IC'0GGZ9?6G7JQN23.MXWAFAJN>Z;S[[)[()O0/A,*[ R
MO.QKT$ "ZY,PJJ[L@A! U2"TJSL&-=1+-LBDVDN\DHC)09G,B*MN119;=+&F
M:,20KKD#<GMQ)F4T\4L_L2KC;$&FVL/J0\=&1(^K$'<,";SNF 11/<K, D[
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M<4R8A=O.6CTT$_]-IG9TAKYLY<%1T5*)(6)!.8_@>]M-?<9S:S+99=_9<QM
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MGN#Z=7&REN3AMMFB)]B%9;;CWDQ$5G8V1O#19D61X+9[_\;\D(O:J)TC[#L
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M ^]-Q"3%LU.8PD1#4)'.(HUSFYQ6@[:X;<Y-4[,9H7:HL(_U+HD=2P,, %C
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MJT(D1FHV8?=<B[N**C2DELG-K:*1#QKPF2C^%<Z87+9ARVWEY"O2 QK(0!C
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MU+(KI8Y.H\XULCB:U)C'T ;$='8?$Z8/^64U"#ED-8%'I:YN&UA$;!/9!+"
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M,VO>S+DHW\Z@0XL>3;JT:<F(3ZM>S;JUZ]>PD::.3;NV[=NX<^LN^'FW[]_
B@PL?KI<R\>/(DRM?SKSH[.;0HTN?3KWZP][6LVM_&A  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img43903234_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (3!7<# 2(  A$! Q$!_\0
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MNZMXDOX[NY'F0K$W"#M_^H8KLKK7(/ WAFS&OWTEY<@>6K(N7G(]!],=:P_
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M-NB;N!^E6]<U&'4-8\-7=CXE^QVUP^4@",1=#<./Z<^M<YXQM+)?C%H"RV\
MBG">:&0;7))'S>O:KOCR*&#QMX*B@1(XEN,*J !0-Z],4 =MK?BC1O#H3^U+
MZ.!I/NIR6(]<#G%/T?Q%I&OP23:9?1W"Q_?"\,OU!YKSK2(H-4^-NLKJ\<<K
M0QD6\<P! QMQ@'V)-&D0PV7QLU*WTI42S:U?STB^XIV9Z#C[V*+A<[.3X@^%
MHK5;E]7BV,Y0  [B1UXQG'/6MVPU"TU2RCO+&=)[>095T/!KR7X8Z!I6HZ!K
MMS>V,-Q-O:,-*N[:NTGC/3ZUT'P:)_X0N=<DA;Z0#V&U:$P3/0Z***8PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BK7V"
M3^\M'V"3^\M3S(95HJU]@D_O+1]@D_O+1S("K15K[!)_>6C[!)_>6CF0%6BK
M7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R J
MT5:^P2?WEH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S("K15K[!)_>6C[!)_>6CF
M0%6BK7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[R
MT<R JT5:^P2?WEH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S("K2.BR(R. 58$$'
MN*M_8)/[RT?8)/[RT<R RM.TRRTFV^S:?;1V\.XMLC&!D]Z@M_#^D6FIR:E;
MZ?!%>R9W3*N&.>M;GV"3^\M'V"3^\M',A6,B#2-/MM2GU&&TC2\G&)9@/F?Z
MU1O/!_AW4+N2ZN](MIIY#EY&7ECZFNE^P2?WEH^P2?WEHYD%C*TW2['2+7[+
MI]K';0;BVR,8&3WJ/^Q=-_M?^UOL<7]H;=OVC'S8QCK]*V?L$G]Y:/L$G]Y:
M.9!8J$ @@C(/!K.M/#^D6-G<6=MIUO';7)S-$$RKGW%;GV"3^\M'V"3^\M',
M@L<K%X'\,0Q/&FBVH5R"V4STJUJOAG1=;:-M2TZ"X>)=J,PY"^F?2N@^P2?W
MEH^P2?WEHYD%C#&@:0ND'2ET^W6P;K $PIYSD^].ET/3)M)32I+*)K!  L!'
MRC'2MK[!)_>6C[!)_>6CF06,:ZT33;[38].NK**6SCQLA8?*N.E,U/P_I.LV
MT5OJ-A#<10_ZL./N?0]JW/L$G]Y:/L$G]Y:.9!8P;/PWHVGW$,]GIMO!+"A2
M-T3!53U%:E6OL$G]Y:/L$G]Y:.9!8Y:X\$>&+JY-Q-HEHTI.XD)C)]P*TKK2
M-.O=.&GW-E!)9J %A9!M7'3 [5K_ &"3^\M'V"3^\M',@L<_I7AC1-#E:73=
M-@MY6&"ZK\V/3-6(]'TZ+59-4CM(EOI%VO.!\S"MC[!)_>6C[!)_>6CF06,B
M'2-/M]3FU*&TC2]F&))@/F8>]4+KP;X<O;XWMSH]K)<,VYG*?>/J1T-=-]@D
M_O+1]@D_O+1S(+&-J6BZ9K%LEOJ-C#<1)]Q77[OT]*@TKPQHFARM+INFP6\K
M+M,BK\V/3)[5T'V"3^\M'V"3^\M',@L8^G:/IVD"8:?9Q6XF;?)Y8QN/J:-/
MT;3=*BFCL;.*!)V+2JB\.?>MC[!)_>6C[!)_>6CF06.=LO"F@Z=-/-9Z7;PR
M3H4D*K]Y3U'TJ[INEV.D6OV73[:.V@W%MD8P,GO6K]@D_O+1]@D_O+1S(+',
MOX.\./?M?-H]H;AB2S%."3U..F:T+72K"QTXZ?;6D4=F=P,(7Y3GKQ[UK?8)
M/[RT?8)/[RT<R"QSEEX3T'3DN4M-+MXEN4V3!5^^OI]*N0:1IUMIATR*SA6Q
M((,&W*D'KQ6O]@D_O+1]@D_O+1S(+'-:?X/\/:7>"[LM)MH;A3E9 N2OTSTJ
M[/HVG76IP:E/9Q27D Q%,P^9?I^=;'V"3^\M'V"3^\M',@L9$ND:?-JD6IR6
MD;7L(VQS$?,H]JNU:^P2?WEH^P2?WEHYD%BK15K[!)_>6C[!)_>6CF0RK15K
M[!)_>6C[!)_>6CF0%6BK7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:
M*M?8)/[RT?8)/[RT<R JT5:^P2?WEH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S(
M"K15K[!)_>6C[!)_>6CF0%6BK7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:
M.9 5:*M?8)/[RT?8)/[RT<R JT5:^P2?WEH^P2?WEHYD!5[5/J/^IT__ *^H
M_P"M/^P2?WEIFIC;'8*>UU&/YU$VGL"$NO\ CY>H:O36CR2LX90#ZU']@D_O
M+5J2L!5HJU]@D_O+1]@D_O+1S("K15K[!)_>6C[!)_>6CF0%6BK7V"3^\M'V
M"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R JT5:^P2?WE
MH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S("K15K[!)_>6C[!)_>6CF0%6BK7V"3
M^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R JT5:^
MP2?WEH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S("K6+X@\+Z?XE-F;\S?Z)+YL?
MEMC)]_:ND^P2?WEH^P2?WEHYD*Q@^(?#^G^)]-:QU*-FB+;U9#AE;U!JI'X/
MTR/PDWAM3,+%@03O^?DYSG%=3]@D_O+1]@D_O+1S(+'-GPOIS>%!X<(E-@(O
M*'S?/C.<Y]<USEK\(O#EI=PW$<M^7B<.H,HQD'/I7H_V"3^\M'V"3^\M%XA8
MJL P(8 @]0>]<+J/PD\,7]VUPBW5H6.YDMY %/X$''X5Z)]@D_O+1]@D_O+1
MS(+'#W?PU\-W>BP:7]GEBBMV9HY(Y#O#-C)R>N<#K3_#GP[T'PS>?;+5)I[H
M?=FN&#%/I@ 5VOV"3^\M'V"3^\M'-$+',6/A/3=.\2WFO0&;[9=C;(&;*CIT
M'X5NU:^P2?WEH^P2?WEHYD%CG?$'A?2?$]JD&J6WF;,F.13M=/H:P]#^%_A[
M0M2CU"+[5<3Q-OB\^0$1GL0 !^M=]]@D_O+1]@D_O+1S1"QP>M_#+P_K>HR7
M[FZM+B7F1K:0*'/N"#6K9>$=(T[P]<:):0-%:W*%)F#?.^1@DGUKI_L$G]Y:
M/L$G]Y:.:(6.9@\*:=;^%&\.(9C8LC(26^?!.3SBHW\&:-+X6@\.SQ/+8P ^
M66;YU.2<Y'?DUU7V"3^\M'V"3^\M',@L<3X;^'FB>%[]KZT:YFN-I16G<'8I
MZ@  55OOA;H-W?2W<$U_8M,<R):3;58GKP0:] ^P2?WEH^P2?WEHYHA8X^[\
M":-=^&8/#["=+*%_,7;)\V[W)^M6M:\*:=KVBVVE79F%M;%#'Y;8;Y1@9/TK
MIOL$G]Y:/L$G]Y:.9!8Y7Q'X-TKQ186]K?B5?LPQ%+$V'48QW!':JD_P]T6Y
MTG2]-D:Z,.FL7A/F#<Q)R=W'K7:_8)/[RT?8)/[RT<T0L8/B#P]I_B;338ZE
M&S1;MRLC89&]0:Y^U^&&@VT]I<--?3W%M*LB333;F.WHIXQM^E=]]@D_O+1]
M@D_O+1S1"QR7BGP3I'B[R6U 31S0\)- P5L>G((IK>!M(;^Q>;C_ (D__'M\
M_7G/S<<\BNO^P2?WEH^P2?WEHYHA8X[Q)X"T7Q/=+=W:SP7:@#S[=]K$#IG(
M(JQX<\':1X6@E33XW,LPQ)/*VYW'U_PKJ?L$G]Y:/L$G]Y:.:(6.9T#PIIWA
MNQNK.Q,QBN7+OYC9.2,<5+X<\.6/A?3GL=/,IB>4RDRMD[B /Z"NA^P2?WEH
M^P2?WEHYD%BK15K[!)_>6C[!)_>6CF0RK15K[!)_>6C[!)_>6CF0%6BK7V"3
M^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R JT5:^
MP2?WEH^P2?WEHYD!5HJU]@D_O+1]@D_O+1S("K15K[!)_>6C[!)_>6CF0%6B
MK7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R
MJT5:^P2?WEHHYD!H4445B,**** "BBB@ HHHH ***,C.,\T %%!('4XHH **
MSM3OY;.XT^.,*1<7 B?/88)X_*M&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  YQQUI/FXZ>]+10
M4444 %%%% !1110 4444 %%%% !44QN '\E8F.WY=[$9.>^!TQ4M% "#.T9Q
MG% SCG&:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM7Z6/_7W'_6M&L[5^EC_U
M]Q_UH T:*** "BBB@ HHHH **.^*0D#J: %HHJO/>Q6]S;V\F[?<$JF!Z#)H
M L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0B5!\H<XST[4Q:G3QR)-&LD3JZ,,JRG((^M.JCI.C6&AV9M--@$%OO+B,,2
M3UQD\?2KU(84444 %%%% &)KW_'YHW_7Z/\ T%JVZQ->_P"/S1O^OT?^@M6W
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!C^+/\ D4-8_P"O.7_T$U8T'_D7M-_Z]8__
M $$57\6?\BAK'_7G+_Z":L:#_P B]IO_ %ZQ_P#H(J_L?,74T****@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:OTL?\ K[C_ *UH
MUG:OTL?^ON/^M &C1110 4444 %%%% !1110 5BZK_R'=$_ZZ2?^@5M5BZK_
M ,AW1/\ KI)_Z!0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHH[T4 <'J7AR;38FNK_
M ,?ZI:0%N&EDC51GL,BLB"R\/ZCJFG"Y^(DVI-#=1RPVSSQD/(#\HX'K6E\2
M)-/L]3\.ZA?PK?)%<.G]G>7YC3!A@LJ]RO!P:GL-7\/RW]LL'@S48)&D4),V
MC[ ASPQ;' 'K3).ZHHHI%!1110 4444 8FO?\?FC?]?H_P#06K;K$U[_ (_-
M&_Z_1_Z"U;= !1110 4444 %%%% !1110 4444 %%%% '+:1XU&K>()M(&BZ
ME;RP_P"MDFC 1.,C//?M74UR>A_\E!\4?[MM_P"@5UE7-)/02"BBBH&%%%%
M!17)1>+=3D\8OH!\/2JJ?.US]H7 B)(#X]R.G6NMIN+6X!1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** .:\2^+_^$;N[6W;1[^\^T_+&]LH(+\X3
MD]>,UT4,AE@CD,;1EU#%&ZKGL:YCQE_Q^>&O^PM'_P"@-755<DN5""BBBH&%
M%%% !1110 4444 %%%% !1110 4444 %%%% &/XL_P"10UC_ *\Y?_035C0?
M^1>TW_KUC_\ 015?Q9_R*&L?]><O_H)JQH/_ "+VF_\ 7K'_ .@BK^Q\Q=30
MHHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=J_2Q
M_P"ON/\ K6C6=J_2Q_Z^X_ZT :-%%% '(76E^--6NI0^MVND688B-+.'S967
MMEFX!^@JI+X-U33X6NXO'>K0M&I9Y+HI)&/<J1@"M+5O%6I:=J4EK;^%=3O8
MTQB>';M;Z9-8'B'Q-KFL>'=0TZ+P5JZ27,#Q*S;, D8YYIBT.G\.+XCC,B:U
M=6%[;%0UO=6RE&?/]Y>G3N*Z"J6CPR6^B6$$JE9([:-&4]B% (J[2&%%%% !
M6+JO_(=T3_KI)_Z!6U6+JO\ R'=$_P"NDG_H% &U1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 444CNL:,[L%51DDG  H 6BJMIJ5C?EA9WD%P5^]Y4@;'UQ5J@ HHHH
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M% &/XL_Y%#6/^O.7_P!!-6-!_P"1>TW_ *]8_P#T$57\6?\ (H:Q_P!><O\
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M $):ZNKGLO02"BBBH&%%%% '*>(O^1V\)_[]S_Z *ZNN4\1?\CMX3_W[G_T
M5U=7+9?UU$@HHHJ!A1110!ROC+_C\\-?]A:/_P! :NJKE?&7_'YX:_["T?\
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M=M',/&GB.42(")(]1VJV1U  Q31+'>%Y+G5/%MQJ1T>[TVW@L$LV^U1^69)
MV>!W '&:[BF0Q^3!'%O=]BA=[G+-@=2>YI](I!1110 5BZK_ ,AW1/\ KI)_
MZ!6U6+JO_(=T3_KI)_Z!0 _Q1:0WGAG4$G0LJP/(N&(PRJ2#Q[U#X.M8;7PC
MI@A4CS+=)7RQ)+,H)/-7=>_Y%W4_^O67_P!!-0>%?^12TC_KSB_]!%7?W!=3
M7HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCGA</%(H9&'0@]*=:"3YH[,47T)****Q*"BBB@ HHHH **** "BBB@ HHHH
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW?RJE&3V07*_Q!_Y%V#_ *_[;_T8*ZNO*?&GQ(\+:EI4-I9ZB9I5NX9#MA?
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MJ_\ (=T3_KI)_P"@5M5BZK_R'=$_ZZ2?^@4 6M>_Y%W4_P#KUE_]!-0>%?\
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M8TM1_P"09=_]<7_]!-8W@3_D1M'_ .O<?S-;.H_\@R[_ .N+_P#H)K&\"?\
M(C:/_P!>X_F:R^Q\Q]3HJ***@84444 %<M\/?^143_KYG_\ 1C5U-<M\/?\
MD5$_Z^9__1C5:^!_+]1=3J:***@84444 (S!5+,0% R2>U06]]:73%;>ZAF8
M#)$<@8@?A4[HLB,CJ&5A@@C((KC_  #I]G:QZS)!:PQ.-3GC#(@!V C"_0>E
M4DK-@=C1114@%9VK]+'_ *^X_P"M:-9VK]+'_K[C_K0!HT444 <EX@C\675W
M);V6F:'=:;E63[9(^XD<Y( QP:Y74_'_ (OT[45TR*PT34-28X^R64LDCK_O
M<87\35OQHWC6_P!>DL+33[S^P JY:PE1)9SW!=CE1]!4FBWFH>';3R-+^'%W
M",?,XN8B\A]68G)/UIDGH=LTKVL+SH(YF13(@.0K8Y'YU+3(7>2"-Y(S&[*"
MR$Y*DCI3Z105YMK^L7,7B'5+?5==O='6)%.EQ6R#%SQUY4[FW8&WBO2:\_FT
M6_BU?7'U'P__ &XE\^;:;S(\11XP$(<@K@\_+FFA,Z_0I-0FT&QDU5%2_:%3
M.JC&&_I6?J-Y;R^)])M8Y5:>)Y"Z#JH*<5/X3TZ^TGPQ8V.I3>==1(0[;BV.
M3A<GK@8&?:DU4 :]HAP,F23G_@%(9;U[_D7=3_Z]9?\ T$U!X5_Y%+2/^O.+
M_P!!%3Z]_P B[J?_ %ZR_P#H)J#PK_R*6D?]><7_ *"*O[ NIKT445 PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#015_8%U->BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5#]&%/W+_>'YUY"?@1;C_5^(;I?^V0_QII^!TZ_ZKQ5<K]83_P#%5')3_F_
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M,**** .5\9?\?GAK_L+1_P#H#5U5<KXR_P"/SPU_V%H__0&KJJN7PH04445
MPHHHH Y3X@_\B[!_U_VW_HP5U=<I\0?^1=@_Z_[;_P!&"NKJW\"^8NH4445
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M'H6MV'_H1ICI\9;[K(EL#_=\I?\ $T>P?5K[PYCV>@D#J:\5_P"$+^*EZ?\
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M_A49UOXP7W^JTH0@]Q"BX_[Z->U44>VBMHH+>9XTFD?&#4!B;4H[4'UE0?\
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MZ_KG_P!&M765R?P[_P"18D_Z_KG_ -&M7645/C8+8****@9R7@__ )#?BO\
M["9_] 6NMKDO!_\ R&_%?_83/_H"UUM74^(2"BBBH&%%%% ')Z'_ ,E!\4?[
MMM_Z!765R.A.I^(7B?#*<K;8Y_V*ZZKGO\E^0D%%%%0,**** .3@_P"2JWG_
M &"8O_1CUUE<G%X:UM/&CZZ=;A,+J(6M_LO/D@DA=V>N3UKK*N=M+"04445
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKE_!'_'MK/\ V%KC^8JU\+%U.HHHHJ!A6=J_2Q_Z^X_ZUHUG:OTL?^ON/^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N<\(?ZC5O^PI<?^A5T=<YX0_U&K?\ 84N/_0JI?"Q'1T445(PHHHH
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M:3QZW=6*VI$D:0QJP$@SA^1UP<5T<*-'!&CR&1E4 N1RQ]:?13<FU8 HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=KKWB:
M-<_8++[9<LA18?,"9SQU/%9G@>#5++PU;V&JZ=]CEM5$:_OED\P?WN.GTKI*
M*KF]VP!1114@%%%% !1110 4444 %%%% #)?,\E_*V^9M.S=TSVS[5S?A/1]
M;T=[U=2FL9(;F=[D?9PP8.QY'/;BNGHIJ5E8 HHHI %9VK]+'_K[C_K6C6=J
M_2Q_Z^X_ZT :-%%% '/^-=+N=7\+W-I9Q-+=$H\*B0)\ZL",D\8R.E94&N^.
MTMD6?P=;23!?G=-3158^H&TX_.F_$6W\3W6G1Q:'#:26V^-I Q?SMP<$;0.-
MOK4=_:?$74K">QE_X1J&.X0QO(C3,R@C!(!'6F([B%I'@C:6/RY"H+(#G:<<
MC/>GU6T^V-EIMK:M(9##$D9<]6P ,_I5FD,**** "L75?^0[HG_723_T"MJL
M75?^0[HG_723_P! H M:]_R+NI_]>LO_ *":@\*_\BEI'_7G%_Z"*GU[_D7=
M3_Z]9?\ T$U!X5_Y%+2/^O.+_P!!%7]@74UZ***@84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!S?@S_CQU+_L)7'_ *%725S?@S_CQU+_ +"5Q_Z%7254_B8EL%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KG/"'^HU;_ +"EQ_Z%71USGA#_ %&K?]A2X_\ 0JI?"Q'1T445
M(PHHHH **** "BBB@ [T4=Z* .(\=F&;5-#L=4NI;;1+B2073I(8U=POR(SC
M& >>]<MI>IPIX4\,Z;IM[OU!=9;RX(I=S^2)GW;N<[=O<UWGB'45.M:/H$EG
M;7$.I-)YWVE=RA$7) '<FJ&I6^E^![C3+G2M&T^&.[O$M9RD6V7#\ J?8]13
M).SHHHI%!7.ZYX*T76]-GM&LK>W>8AC/% H<$,#UQWQ^M=%10!S^I>%+>Z^P
M2V%S+I=U8JR036JKPK?>4J1@@XSBK&@^'X="CN6%Q-=7=W)YMS<SD;Y&Q@=.
M  .@%;%% &)KW_'YHW_7Z/\ T%JVZQ->_P"/S1O^OT?^@M6W0 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOI=O;Z+?:?I%G=)=S75]'Y;2%.55%Z\GO7HC,J*69@H]2<5"MY:NP5;F$L>
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M !1KNF2I&(;!HA$5')W+DYIWA+79]?TNXNKB..-X[N: !.A"-@'ZT]1:&\
M  , =J***0PHHHH *Q=5_P"0[HG_ %TD_P#0*VJQ=5_Y#NB?]=)/_0* -JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCEM;< 0JQ.8\# PV<CCWJUIFE6.C6:VFG6L=O ISL0=3ZGU/N:N44 8FO?\
M'YHW_7Z/_06K;K$U[_C\T;_K]'_H+5MT %%%% !1110 4444 %%%% !1110
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M110 5BZK_P AW1/^NDG_ *!6U6+JO_(=T3_KI)_Z!0!M4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !WHH[T4 <KXUM-':"UO]3UF71YK=F6"[AD"O\ ,,,HR#G(]JYVUOO
MU]9Z+X?TW70(K:\298@K%[B0$D;F([L<DUTNOZ--?>*_#U_]E2ZM+5I5F5\'
MRRR_*^#UP1^M<G'HVMVU_8Z-;Z(4-IJK74>JJRA!;LY8CUR0Q7%,EGJ=%%%(
MH**** "BBB@#$U[_ (_-&_Z_1_Z"U;=8FO?\?FC?]?H_]!:MN@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]17,;S6TL44
MS0R.A59% )0D=1FI>](>AQUH \RNF^PZG_9UU\4IHKS.#$T460?0G& ?K70V
M7A?7H+R">3QG?7$2.&:)H(]LB^F0.AKB-+O='M_#=[INM>&-4GU&YDF:YF_L
MYG+NS'!W=>.,5TOA/QK&NDZ1I5WI6M"\$4<#R/9/L#8 R6/;WJB4=_1114E!
M1110 4444 8FO?\ 'YHW_7Z/_06K;K$U[_C\T;_K]'_H+5MT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5G:OTL?^ON/^M:-9VK]+'_K[C_K0!HT444 %%%% !1110 44
M44 %8NJ_\AW1/^NDG_H%;58NJ_\ (=T3_KI)_P"@4 ;5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 =Z*** "BBB@ HHHH **** "BBB@#$U[_C\T;_K]'_H+5MUB:]_Q^:-
M_P!?H_\ 06K;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U?I8_]?<?]:T:SM7Z6/\
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MW]?_ .)H TZ*S-^M_P#/"P_[^O\ _$T;];_YX6'_ ']?_P")H TZ*S-^M_\
M/"P_[^O_ /$T;];_ .>%A_W]?_XF@#3HK$OK_6;"RENGMK-UC&2J2-D\X]*G
M676V0,(+'D9_UK__ !- &I169OUO_GA8?]_7_P#B:-^M_P#/"P_[^O\ _$T
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M"5H UZ*R/M^L?] 8?^!*T?;]8_Z P_\  E: ->BLC[?K'_0&'_@2M'V_6/\
MH##_ ,"5H UZ*R/M^L?] 8?^!*T?;]8_Z P_\"5H UZ*R/M^L?\ 0&'_ ($K
M1]OUC_H##_P)6@#7HK(^WZQ_T!A_X$K1]OUC_H##_P "5H UZ*R/M^L?] 8?
M^!*T?;]8_P"@,/\ P)6@#7HK(^WZQ_T!A_X$K1]OUC_H##_P)6@#7HK(^WZQ
M_P! 8?\ @2M0V^LZG="0Q:/D1R&-LW"CYAUH W:*HV5U?S3%;K3Q;H!D-YH;
M)],"KU !1110 4444 %%%% !1110 54M]3L[J_N[&&;=<VFWSH]I!7<,KUZY
M'I5NN'UJX'ASQZNJL<6]_ITL;^\D(WKG_@.?RH!G56&L6&J37D-E<K-)9S&"
M=0#\CCMS3]/U.SU6*66RF$J12M"[ $ .IP1SUKR_19G\#^;J%Z<2:KI+7T@;
M^*Y4EBOU(<?E5MKZ^\.Z?X:\/VRWJ/>0275W)91+),6^\0H;@?,W)YIV%<]0
MIDL@AA>5LD(I8X]J\VF\4^(=+\/:F9;;4,BZA@L+F\MU$S"0X.4& Q7G'3.1
M5O2]1UPZN]L\6LS:9+:2&:74[9(S'(!QM*XX//!HL%SL]&U6#6](MM2MTD2&
MX3>JR !@/?%7C[5YA\.M5O=4BT[3%G-A;Z=;+(T) \R\W$X8'H(Q[<Y]*U]'
MU._C\1_9M<U"^M;R2XD6&VDA7[+.G.WRW SG&#R<]>*+ F=Q37D2,J'=5+'"
M@G&3[4ZN"\8Z/!%XE\/:JTUQ)</JD<:AY#LC3:V0J]!DC.>M(9WN,4444 12
MSPVR@S31Q ]"[!1^M2*P=0RL"IY!'0UB>(M/\/-;2:IKUK;316\1!:X7<%7V
M!XR3^-4/AU9W-EX.MDN8Y8@\DDD,,I):*)F)13GVQ0(ZND)P,DX I:K:C$\^
MF7<40S(\+JHSC)((% PBOK.63RX[NW=ST59 2?UJS7FOAO[!X;_L>WUGPBNF
M7C[;>/4=D3AI2,<LI)!;WKTJ@2"BBB@84451UE+N31+Y+$D7;0.(2#@[]IQ^
MM %A+F!YFB2:)I1U0,"P_"IJ\<=M,T[0?#TUGI=W::[;W=ND\C6KHQ+,%D#R
M$88')[GM7L=,284444AA39)$B0O(ZHHZLQP*=7!_%728;KPE=W\LUP6M0ABB
M60B,,9%&XJ.IP<<T SN7=(U,CNJH!RQ.!^=)#/%<)OAE21>F48$?I67JEK97
M7A]/M]B]]#$J2?9T7<7(''R]^O0URW@4V@\5ZZ;2S?28I$BV:7*GEN,9S+LZ
M '(''I3%<]!HHHI#"BBJ>J:<FJV#V<LT\44GWS ^QF'<9Z@'VH L++&Z&1)(
MV09RP.0,=>:A&I6+, +VV)/  E7_ !KDOAA;0KX.N+78# M]<Q[&^8%=Y&#G
MKQ5+7/#FBW7BS1]$T[1["!D<7]Y+#;JK+&A^5<@<;F_04Q7/1****0PIDDL<
M*%Y9%11U9C@4^J&JZ7IFI0+_ &I;PSP0$R8FY0<<D@\'\: +D<L<Z"2*1)$/
M1E.1^= E0R-&'4NHR5!Y'X5P_@&S0S^(+O3HVMM%N[G_ $%5X7 7#.@[ GI]
M*B\,:7!I'Q/UZW@>:0-8P2.\TA=G8L<DDT["N>@4444AA36=44L[!5'4DX I
MU5=0TVSU6U^S7T"SP;@QC;H2/7U'M0!+%/#<+N@ECD4'JC!AG\*C&H61D\L7
MEOOSC;Y@SGTQFN+\)6=I_P )SK=YH<"0:*L26Y\D8BEG4G<4 XX'!([UE:7%
M9>%X8'\1^#UB(NB/[5V0RX9G.QB02PZCGM3L*YZE10"" 1R#12&%(S*BEF8*
MHZD\ 4M5K_3[74[1K6]A6:!B"T;=#CUH DBGAN5+0RQRJ#@E&##]*/M,'G^1
MY\7G?\\]PW?E7!:!8P'Q[K%UX<ABM],BLQ;.80%ADN02> ./EZ$BN6O19:=X
M"FDN=-O(/%5K+YSW36S[_-$GWO.QC:1[].*=A7/:Z*AM9&FLX)'^\\:L?J14
MU(84C,%4LQ 4<DGM2U2U:WMKG2[B*[MFN8-N7A49+XYQCO\ 2@"Q%<07*DPS
M1R@'!*,&Q^5(+JW\[R//B\W^YO&[\J\\\,?83\1IGL;"30HC8[3831>4UR=V
M?,"#Y<#IGK53Q;:Z19WUI!:Z)-ITZ7\<C:T\6V-/FR<R<DYZ<\<T["N>J44@
M(8 @Y!Y!%+2&%'2BHKJ&.XM989D+Q.A5E!ZCTH 2*YM[AF6&>*0K]X(P./KB
MHVU"RC8H]Y;JZG!4R $?K7G%HFFK\1=&_L_29/#ZQQRHWGP>3]MXX10.&(ZY
M)S6MX\TO1;?2V$.B:?+JVJ3"V@D-LA?>_5\XSP,FG85SN4=)$#QNK(>0RG(-
M.JEH^F0Z-H]IIMOGRK:)8USWP.M7:0PHHJO?WUOIMA/>W4@C@@0N['L!0!*9
MHQ*(C(@D(R$)&2/I0TB1[0[JNXX7)QD^@KS&QMKA_B!H&MZAF.^U)+AC%OR(
M8@H\M/K@Y/N:U/&VD0+K>@ZLTMQ)<'4X8T5I#LC7!R%4<<^IIV%<[VBBBD,*
M**@O+N"PLYKNZD6."%"[NQX % $AFB658FD02,,A"PR1]*BDO;2W<QS74$;#
M^%G /\Z\W@AGN/&OAS7[\A+K499]D6[_ %, C^1<>ISD^YJQJ>F-9>*M<U34
MO"']L6,HB>.8"*1HU5,-A6.?RIV%<]'5@ZAE(*D9!'>EJEH][9:CH]I>:=C[
M'+$&A 7: OICMCI5VD,***:[K&C.[!4499B< "@!'FCC9%DD16<X4,<%C[4V
M6XAM@#--'$">"[!<_G7EVLLVMZII'B29ML']K0V^GIOX\G)W2$>K$?D*U-4M
MK7_A/KV;Q%ILUYITEI&EBWV9IXU/\8PH.&/'.*=A7/000P!!!!Y!%+7'?#2X
M>;PS/$?-\JVOIX(!+G<L:M\H.>>,UV-(85G:OTL?^ON/^M:-9VK]+'_K[C_K
M0!HT444 %%<!::[<:-9>+[.ZGFFFTV5IK=Y7+,4E&4&3V#<50T3Q#JND_#W6
MH=6N))M7TUS )'8EF:0 Q\]3RWZ4["N>G45R$6O7&CQV>@VME=ZSJD%JDET?
M.52F1U9W(R2<X%3GQO9R:5:7-K:SW%W=S-;Q62[1)YJ_?4DG V]SFE8+G3.Z
MQH7=@JCJ2< 4X'(R.E<#XA\1#5_!_B&QN+.6PU&U@4RVTCJQVL1M8,I((-;-
MAXHMY/.B@@DEM+"V#7-XO^K5PN2B_P!YL=<=*+!<Z6BL/P_K]SK:"631[FSM
MY8Q+!,\B.LBGI]TG!]C6Y0,0@,I! (/!!H50BA5 "@8 ':J.M:M;Z'I%SJ-S
MN,<"YVKU8] ![DX%8<'BK4+?5-,M-:T=;)-3)6WDBN/-VOC.QQM&"1Z9% '5
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445AZSJ>MV/GR6&CPW4$$?F,\MUY9?@DA0%//'?%
M &TJ*@(50N3DX&.:=7*2>,C/X;TC5=-L1,^J3)#%%/+Y84MD<D ]"#VK<TR;
M595D_M2SM;9@1L%O<&7<.^<JN/UH"Y?HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IJHJ9VJ%R
M<G ZFL7Q5XC'AO2_M$=JUY=2';!;(VTR$#).>P !)-47\9?\4_HE[%8&2]U@
MHMO:B3 #%=QW-CH!WQ^% 7.JHK TGQ!<7.MW.BZG9):7\,2SH(IO,26,G&0<
M \'@@BM^@ HHHH **** "BBB@ HHHH *Q?$OABQ\4V,5I?M,J12B53$P4Y&1
MC.#P02#6U10!A>(/">F>)18"^$@%C,)8Q&P&['\+<<J>XJQK/A^TUI8&DDGM
M[FW),%S;/LDBR,'!]".QXK5HH"QB)X8LVT>?3;VXO+^.<@R274Q9\CD$$8VX
M([8I--\-+8-(TFJZG>[D,:BZN-P13Z  #/N<UN44!8YV+P;IT$&D)#+<QR:4
M?W$RN [*>J,<<J?2G6_A&UAU6*^FOM0NQ YDMX+F??'"Q!&5&,YP3U)KH**
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M/+C485!SVK:!!Z&C(SCO0%@HHHH *P/%F@WOB+3HK*UU%;2+S TZM$7$ZC^
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MZ^X_ZUHUG:OTL?\ K[C_ *T :-%%% !1110!6U&^CTS3;F^F5FBMXVD8(.2
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M'@;2$AGCD:*U19 C E#CH?2NGI#04444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5G:OTL?^ON/^M:-9VK D66 3_I<?\ 6@#1
MHHHH **** "BBB@ HHHH **** ,N\\-:%J%RUS>Z-87$[?>DEMT9C^)%/GT#
M1[JT@M+C2K*6V@_U4+P*R1_[H(P*T:* *6GZ1INDK(NG6%M:+(07$$2H&(Z9
MP.:NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4C*KJ590RD8((R"*6B@"E8:1INE[_ .S["UM?
M,.7\B)4W'WP*NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9U_H&CZI,)M0TJRNY0-H>>!
M7('IDBIH=*T^WL#80V-M'9D$&W2)0ASU^7&*MT4 5K'3K+3+?R+"T@M8<Y\N
M&,(N?H*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img43903234_11.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_11.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
MS,R _\RJ ,RJ,\RJ9LRJF<RJS,RJ_\S5 ,S5,\S59LS5F<S5S,S5_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\K /\K,_\K9O\KF?\K
MS/\K__]5 /]5,_]59O]5F?]5S/]5__^  /^ ,_^ 9O^ F?^ S/^ __^J /^J
M,_^J9O^JF?^JS/^J___5 /_5,__59O_5F?_5S/_5____ /__,___9O__F?__
MS/___P               "'Y! $  /P +     !>!?<!  C_  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G/E2S+)ERF[FQ*FS)\^?.X/Z% ITJ-&B2(DJ/;HT*=.G3J,VG0J5JM2J
M6*]JM<HU:]>M7L."'?NUK%BS9,^J3<L6K=NU;]O"G2NW;MR[=/':S<MWKU^]
M@/L&_BNX,.'#@Q,;5HQXL>.BD] 4RSFYV#)BRRI?SJS,,F;-GSMO!LW9<^G1
MHD.;)LTZ]6G5J%>[;BV[=NS;L'._WDT;-^_9P&WK[CT\N&_BOX4G/VZ\N'+D
MT)LO=\[\N?3HUK-7WTZ]^_3OV+F#_[].7KOW\.?+BT<_WGS[]>K3NV=//_Y[
M^?#GVZ^OOW_^__@%>-^ _ %(X'X(^B=@@0LF:"!_J65B4V<Y5<B3A1A>J&&&
M'&[H88<@?BABB"2.:&*)*)ZH8HHLKNABBS"^*&.,-,YH8XTXWJACCCSNZ&./
M0/XH9)!$#FEDD4@>J6223"[I9)-0/BEEE%1.:6656%JI81IB6(B39:*%">:8
M7Y8IIIEDGJEFFFRBZ>::;[8)YYQRUAGGG73B:6>>?.[IIYZ ]AGHGX(62NBA
M@R9JJ**(+NIHHY R*NFCDT9*Z:669EKIIIARJFFGH'XJJJ>DAEKJJ*:FBNJJ
MI[:JJJNLOO\JZYB486+39,MHPE,H.1'#*TZAX/JKKQ4&F].PORIC[#+(%BML
MK\DNVRRPSUX6;;7$4GLLM,YN:VVWS'*K;;C?CCNMLMA>ZVVVZ*ZK+KGL2BMN
MN_"^>ZZ\Y=)[;[K@[NMNO_/B&R^_Y@9,L+X&_UMPO@+;FW"] #-\<,,1#ZPP
MPA)?3/'"%D/,L<,9>XQQQ_Z*O/'(()/\<,DLK^QRR"W#_++*,M=,\\TIYURQ
MSA_O['//0*/\L]!!GVSTQ$AKG+3)2\>,\]!'*RTUTU,[S3/16$=-]=960]WT
MS*'PQ.67056V4V@7XHI:VF=SQO9-:%>H=MQDP^VVW&WCBK?=>M?_O?;>?_M-
M-X5\8SCWW8(C3GC@BP]^>-^-*_ZXX7E37OC;C$^.N>.5;RYYYX!S?GGHGX^>
M..2:DXXZZ*=;GCGKD:]N>NRNB_[Z[*FW[KGLM_=N^^^E^QX\\+P37_OPR!>?
M_/'*-\_\\[M#K[KTND\?_?769U_]]K1CSWWNW6L?_O>P@V]^^>CCGK[PSGL_
M_OOGJR\_^]3#O[[Q[L=/MH0_85:4X9OYD&D$&$ .#=" !=S0 1680 #Z#X$/
M9& $'=@3"A)P@FEK8 8Q*#<-=I"#90*A:RY8P0V6\(,G#&$*1PC!%2[0@BTD
MH0QC2$,)NM"#*IRA#74(PQW6L(= -"$/8(7X0R+Z\(A!1.$0E5A$)B+1B$G,
M81.E^$0G1I&%5:3B%5\(Q2Y:T8M:!",6MXC#,8J1BU],8QC5:$8VHG&-<&QC
M'-\HQSK2\8YEQ*,(]7C#/>;QCWX,9!\'N40IJDT9D_^P2:XR2"'+))!LCHP@
M).T&%,T\LI&4+)MH+FE)26*2DYOT9">',LI*AI*4IS1E)%&Y2E5F4B>EU&0K
M9?G*28)REK!,)2UO6<M/BE*7N<2E+7\I3%^RLI>Q#"8R@3G,8_+RF<1<9C&3
MV4Q70M.9T;RF-;/)36QZ<YO?W&4WP4E.<893F=HT9SG1.4YUNI.=YZSF.^4)
MSW72\Y[&M&<^Y[G/>O*3FOW$)T 'RLR &I2@TRPH0J7)T'3Z\Z$"5:A$$TK1
MAK83H@=5$T\>6)DWV,1_[-H$3T !IDU :Z0E/6E.2(H3DUH+I2U5Z3)8J@R7
M^@JF-94I36T:MI6F]*4^C2G_4&?ZTYL&-:=#W:E.B]I3H@K5J$Y%*E25FE2F
MXI2G5UWJ4YM*U:E:]:A8!:M6I<K5KT8UK&<=*UJ[6M:M9K6J;A4K7,GZ5J_&
M-:US7:M9V5K7MM)5KG;]*UX#J]>[\A6P?BVL8 \[V,2J];%YA2QA)>O8R%IV
MLI>M+&8WJ]G.]O6SB 5M8T7+V-+N];2&1>UB5:O8UE*6M*Q];6AG.UK:FC:U
MN%UM;EV;6=CN5K:U#2Y?Q^72F290$A/24-]0IUP 6HBYSW4N3Z [7>E2QKJ2
M:RXCJ[O=ZW8WN]']+G6]V\'PEI>[YR6OF="[7O6&B;WO=2^8X#M?^6HWO>"E
M[WW;_YM?^YJ7O^/MKX #3&#L%EB\!DXP@A>,WP,W6,$/9C" (3QA"<=WP!2^
ML(,K'.$.<_C#&LYP?3%LX1%O.,0EWB^*/;QB$)M8Q"I^<8K_V^(:RYC%-W9Q
MC'=,XQS;F,?Z[3&0_1OD(A/YR"3&\9"3K.,>6\Y"F'E@*###/]6T[<%Z>W&6
MF[OEZ':YNE^^;IA+@^4R3WC,9CNSF4.,9L*Q><U:AC.7Y>QE.H/9SF+&,YG5
MS.<W]SG.?YYSH.L\Z#L7.L^'WK.?%PUH1@O:T82&M*$EC6A**[K1F'YTIB.]
MZ4EWNM*?OK2F1\UI4GO:U*!&M:A+S>I3MSK5KUZUJV<-:_]:R[K6N+ZUKM-L
M:5Z'VM>J!G:LA6UK8N?:V+MV\Z^5'6QF[V0S'%VOWY3!)2_EI+BB <5HM-TV
M7GGF5V72]F>X;3=OERO<V^Y?N+Y=-N..6]WFSA:ZW]WMU( [V^FN-[MAZ>[,
MD'LS\;ZW9<3M;WC;N]T$+\:_,1-PA.>[W ?G=\(7ONYSXYO>$-_WO NN;XL/
M_.$ C_C&%6YPC5^<XQGW>+])WG%YGYSE*7?YQS$><I//'.4U5_G$2ZYSD#-<
MY"^G>,,E[O.*RWSE0@?ZS6&>\Z/OO.4"1SK/G5[TH8\\Z3:7.M0=3O.?9_WI
M,8\ZV)LN]JHK7>MAYSK.O=[SKAO_O>QNMWK0IP[WM;]=[4QG.]7C?O:QZ[WN
M>;\[T?G^=;,7GO!MM[O<EX[UQ =^\6@G.]X;OW?%]]WPCL=Z9\B-*Y(6:S-B
MYA^N,",WS@.0W*3/95,G^/%>F7+U%6P]Z%6_T=@;U_6:A'T&4?_ZVN^^]KGW
M?0=Y'WS7_Q[WM#?^\(&?_ ;*/O5DT_WRD1]]X:.;^A22_O5G7WWE;Q_ZV=\H
M#@Y@ %V1OJ>KTSZ^L3\9]3\?#0<X0!H(-RS;$[_YK+\]]\/O_?7OO_W6YW_@
M!X#]]WR]5X#Z-X#*$H &6'S.EX '^(#WUWT2R'P4F'_D-@GDAP,7:'_,=P,!
M< ":(&03_\A_%<A^"XB )4B )_A_*=B""NA^$!@4FG  (4A *_B"&&B!)KB#
M*"B#.0B$/,B"/NB"0OB###B#^.>!2&A\;P  ,<"!'$4Y1VB$21B$5\B#-7B#
M"(2%*CB$.LB$^[>%!X"#8%B%,9B%30B#$;B#T\89OW(XY]<W:# A'\=] UA[
MAU1 :29\FJ%)=I-_KK>'4TB(R@2(T&9[@R@4A<B(AYA+@:B(:^.'BZ-\?PB)
MB;A=:$.)ACA)B!AEDKB)EEB)?/A>B2.(D^AZ:1 # ) &J"B*I8@K!Q # 9 )
MDY9)?3B*\W6*H>@VXQ<#BM1(CNB)F B*FN@VG#B,F/2)#[B(/?_1B,_XB+QX
MC)THC-%(C--X7K (C9QH2I%(C<J8B[&X#/"W AS8-J^(C#DQBP"@"70SCLR8
MCM4HCIH0 [,X@KL8.?(8CJ18B-Z8B=J(C*17#)H  _:XB/.UC<'$C_DHA[TX
MC_THC?KXD S)D/]HC $)D1IYD<V8BK%X-AH8A2NE(1]YC<M8C!V)-K\X?]^8
MD5=&D 9Y  BIAQ5IDI>8C>NUB0-9D <Y&O"(DOMHDQ&)C1,)CD*ID8YX94;1
M-U267)7XAY,A4@6(5*9((5+I?$CE@E?)>E39D#7%@%FI@%L9>UUI2F/)-L4E
MEF#I4E49E6NIE&1SEGC#EEXIEW$)EU;_*38A& -/9X\B&)=O:3>:9)=662$X
M$ !1")A329>59 #VZ(XDB1FZ(FUYZ7UB8(,&$(('  "S6'N,^5PWL +RIQ1N
MN9AX69I8^9FY1)A1>9I?:9J4B9I<F99F&9AM^9JIZ9JL69:#&9A:&8 V.)H!
ME ;Q%P.:D&7C-YIC8(]A,&**B966 84B&%UTZ8BZH@QC8 #Q%W\ @ -B<)VY
M&9L44H./.7J+A()RN869:8NWN9NTV9O]!RSCN9= $8=>@AFJ^9RSJ9O"=YD!
MD)GQEYEIH&Z3&9'@J9:PV9Z^B:#AJ:"P^9L)FH\\@0:(B0-FHW'$D 8XX)=1
M.*!O*)E@R)H&.2": \J@'.1MRJ )]!D4]HD3ZEF+XNF>_!F?RC*?G6DAW&:(
M!UJ;$<JCX0FA#5J7S.=Z[QF(4R:)U/_6)>JXB]J&.=<F%"-6H/PEI;.7$^#Y
MAMB6&1HBI1=&I:EGI?_XI#T1I4BZ2.IF(5=*BEE*IM_EI5L:ILNPIF_:IC[Q
MI>>92_7HF"R)IK,8 ,J BF!ZIJ!7#)EP #!@H4)!I9VQB@;@BG JIU!V$_:X
M K9H.E5JINDU&;\XB_88 P=IB.%UF3& !HD(J)@JF#R1IGL(J:E:IFZ*IH]*
M%!IH !S(I6RJE&"*B&(Z77.*7Z_:JKH:IU#:JU-:IV_*C)V! XZ) Q$4!NPX
M?TWEJ3$P"<N0!C!P .=(&L%*<CS1IY5Z=.TF%!MZ "L0D[38J-P:J#N1?JG:
MJ2-(2CZAJD+_L8J=:J'_9H_E5ZR"FJN8>";^LPR%"@-^.D#@QY;ZZJO&"JO!
MNJF>RJDLV3?[=Y5E\A/RVA.7*9P0"Y[*1X;[>J=8.JRP2J<=6[$\D:71^)68
ML8H!< -'(9DWT*F.Z:T%6TD)JQ,U&'_&]XN3<)]A2B;_6JBLN&<02Z^S:*\_
M@:_7>:NHRJ_3YK,W ;#L>!I5*;&;M!,DNZN40:Q=6K-,JZ8@VZI.&J?:]25-
M2DNO2:@3$C:807 #Z5U'FGH/U"X)V1,L%6W=,E]]\[;")[?65[?\=K?LI;?*
MQ[?>Y[?M92QX:R&"6T"$FT"&&U^(&[B@.+B16[@'5%^5BS@X4:^R_R&J''BX
MEPA]3>I4%'H 2FI^?^N<=7,LD\NXF:L,B%E^YX>KF1M!-'43H6FH\7>MG4E4
MSU:WR7*8,3"@.Y&C%U*[/\%2AU.\?1BWR M3=JLMB;LKK0M2Y$BN.)!>R,N\
M IF\S:L3C6N[EWN\EYBWU0N^SQM4T=NX>1M=:2":,1!"LSB+'W43FJ"=98B=
MS$FWX\*ZLY=Z,0N9TX:X.7I=.""=\]NI\7N27_J\=CJHQ=*ZYKL9G3J_H(@9
MW@J]?RN]DBN?AS09*FJ/&F*]4Z@31QIFVWL3R@N7GJ>I,1"STFD U+JVF.MK
M0>&WZJ6WX[<"Q&N_LV>(F="IB[/"J.J[A_^#$^%+M^,+N#E\OI,!556:G8G9
MMNV:P+'[F#&593>\;[A"J)X: ![RM%'6HOY;HQ^<HM+IC:!8P?9XP<N0P>J[
MP>RKN+-[QIJ0QN$EP5O\PW3\O^@;NDK,A^3[7A,,MW_\7A%TPMH;051,;GB3
M2*;A730K%!G)D5Q)E'-+79]AR62)R31)C9S\-B>9D_FUR?'8R:.,R*6LI:<L
MRC?I9HGXOO?H)2];B]GG&N&5B+RVBMCZM)0,7>:CAQK"4M<: $E;?:_LD+7G
MN>O*?*U;-AO:J&BS97:JS*1CIX;LE2VYNLG\R421>L29F-0\MAC)BY$ZB*&\
M-ZF<R=)ERD")RMW_C)"X";3M6"$UB,!D,PFTJ*1H0(O9"Y7>C(MO3(OLZ9 9
M<J0Y(:JDFJ)B8(\P&JDJ5+PH.:AEVY !78^FV]"-"A2(>0#?"L]M&=#G-WM
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M@O]$^?,7$?[L%\":Y ]'[WO2_];W)&6AA(#STY\#PY? _4'P@0V\7P%?!"X
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MA>*+W)$>4<*YXB,^C;"ZIC,GHQ..H/LEEU,ZIYN)4*J@UNJ?"J&PZ'JYPKA
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M"Z>7&!OQZ";=3,"EF ^9T[*T:[$$8RZ74 T5R(@UZB6M(BF8"<"E:C:.0B=
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MZF^_&::?)O8I/*UKD0Y"&OHX>;(+1FICUQK3EQYWM.?53E LHUY")M$8A_^
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M T4<4. $7R<&[?:4&4/J'G'W,??==>\]V3&6<;Q;(Q4'*Q, 4B1+&4F.=IS
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MA[W8+6U)K,7S/K!2AYT1D15(D8?E?OS3K&&Z7:J& &)0G65:5OGY*%#BG_\
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MDS )3D(E5'(#*R 04-*\DQ"] 200 4,Z.Z07G4,ZI ,7S<0O5C(01IMM RI
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MYWA^B*J9VMDV80C.%KGZ1?06N>Q80'U8/@HH2?YEV\<9FB<B3^A!'RIXV<H
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MZEFFC*F4@,ZHT8\;(.H"X8^(V)J6WH>LJ0EZ2 ,(M",CF:YK]5M3OB$7TMC
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M>(8G+H5_JFNNT9:ERV>@DCG&,V6"WDP2912A.=&QTMHW8.!4/JE?POQ"O9\
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M(WP@DY@/22U&@WD3=PP1;LD4?.@>JE6'PJT7YS15NIG_8$'\S0_J%"8J'DX
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M!_ICLZ"%/Y95%*:B_RL/$]]3S!$:\YAJB&DST7!%N.7Q,8,!481TB%*TY2J
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MA]W#8R(P HNC :%% QUP RE0&68.G5B .\;/!%/B>(8IH0QB>5*NH;8.[W#
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M1;/*VA'0INR2ZM ]HM(U_S.BQ:!N9;:S/X%)%:&&P1I,!KP2L'#J-(K/16(
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MT37Z6MA O:(S22! Y\[[TZ;#;6"7@YS"G-AE[/M*6&"Z&2('BF$,1J-2U*/
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M]J66)[;O9%5 82&\HT]7)14"H+"GN[S,^Q4"Z9PU%UNU@P K>"/+)8,!((.
M.H< 0+@O" "N P""9A.M@8.T9$VJ R#Q8A\,,1V?\HVA0G#M(V"88UK>)7;'
MQ*KEPQ ^"QC!J)OT4!:7N:W#A1TPP8'K.7=0>+HZ&6LTE:J\!%$<,T:=)7T!
M=SY<9E*B@[X>U6O;I":+Q')VN)"M!6=C*TD/B'F<!Q4Q\#O-^\(PW!5NBRS/
M8EQUAK!208H;$@,&.34?NP\XD+=H 8K;ZY\QJ)O@6Y&=RR'+4"#>!T'T=TM
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M(H@!:JD3"0( !@&(@2Q;I_\0 RR.32JX@0E'2,XV[DLY[U2*3["9EB@:)(H
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MXC5%XS5%XLF@9X0@*J*@6KB@6E"@!Q('Y)U@XM&'_JT HNPB4X"B,::%7*R
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MD@?]N(0\$H0[^@9CM _[:$L]UD\[[E8^GLI/,!>"%-?G) ^+\45FH!@!)0G
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M!AVVG'NNC(F3EIAP!,P,!2CX129X%L^%N"N5XZ!(D>R)B*TW2T^4^IY!B-C
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ME&0O85K*(\H)/[S+9\P0:( F#>YFIE8%!CY(#%*N,>)04&I#*B+B!HPO^=*
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M7CHII$ZD21'28<0JZL0(:;ZJ$TF^CGB')$N2Z@%'C!SI4=0,6.Z8TCJ+J)&
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M)7A4<AK6MH(DF#]JMU0[=US1%&^B-8*?9CRDT1.X=FU(126BAC [_]$QS":
M*W%L3L& ?P-*LH<ERM!*;H@AL90\5&-3?[%=\R-<P[%N8!58F8--X-:%TO=U
M@Z1V$X%JPL06@T=-FB4DSG>! (@TW,0TE=AAX)0;X=44R^43Q!![, ,;YG$V
M$2:*M((<Z)%$R.$IHX)$!\8>TT%$J#(9 P4WW!$=!W8>S1%0]O85\A$A,.<1
M.!=S731S#N(1JU=SSR*,QM@1Q'B,A2$A'/%A'#$&B@,H+2=SP (Y.S5%^2$
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M :ULY+*5$0AS+/);CO)4LYL=$$V<Y&<__2DM""822V!JTM0<:= $/N<  3B
M 1@: X::9X#.\=H_'<(6*]WG;,GS_]<I%_*\0V%E47;;1_,.U;3[^66DJ@2
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MJ0C&^M@P)XU429U42NV;2KU43(W4%MTB.>U43T4:UN3"[O"9&<#1BXBDED2
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MIA&N1%25&E-,+UF;XQ16HYAXDT59*LL3Y#@6W/'*UN;8GCU9D+KHN%):T)"
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M:&+JD5B]&*H91*J7-B3V+C*357>3C]'YQE?%?C4I VH$ /44UN< T(Q59QH
MT N4V^HX1G;%Y5B:"3KE; N85XL<.F3S8O3A/> /(PI'[:<Q-[))8($T</B3
MKWH)_R3L*ME74S0H.\5>L6V.IU@/L;^! WB)13$>FGLSD&C5Z,V;I<)M?RG.
M0QT<MVAX9E+ZLADZ":EY3B)<8J#Z02IYJQ_\0SWEMG)6B%!E5\-3Z</RL,D$
M]\D^,8@*FWV);G8A&#+\&Y*$:ZW@N*7E!!_Z<17>VEHJP+4;^%L)=N5KC)^6
M>25\V&=0S8\/31C%?EVX,*0(%J@XYGBC]1 #3<@;WX&/9: 5Z*V4I>I%X@T?
MN?_&P9BM.P1<NF"KH_*\-E8(Y_0GD9T>DN\NP,X2,9C]!U+?FRCDM>?VU[G=
MY<-H34SY_M#@AT. &9"U#13]@9AYGB,(]XD/.M%L@-@G</\@P8(&#R),J' A
MPX8.'T*,*/'@,H'*]BFC!RU3O8D>/X(,*7+A)&+*3BJK=Q*C0'K[H F,YA -
M@(L.0:&Q.7(GSX_+3/8,*G3D) %C8 Y-ZE 9 &(WF&82.0D 50 'F1+S&",&
M03$U!V+=!V#2PTP .C)D6M5J1+-9E>[SNA: &(,QZDZ<6]7D7((QZ!J4"W=P
MPAAD]5*-.E>G5ZX%!1..#!<-7LE"-<G(K%F& !D(-B-@X7GTY\VB1ZNQK##&
M@:TYNP90#5$9&DVR;^/./1"MOGWU>O^.YG*9OF7+ALG4K7SYODS*3*+4J))E
MQ8Z]?>^[?G#JVX;$2C(/3Y#>)V+_VL6C/Y@)P9B*Z7>:I=K]XU2;8PU.,O"1
M)D&JC&^\!$!4#DWED%GV.?90?:HM2!!3.FE567-?B94@ '\51,R%$K[GD5D%
MW0#@0!K:A*% %[(%UH4)=HA>)ARVJ- DG]$HPPR@X2C#::2-IMF S+W86@ W
MI'%1& ?$J,PDP\38I)/9#91<<AT1MPP]PG'TI)8>*9,)=,I8N<Q%-ET'$UK)
M)403A L-4^26JOVTYINZ41) &B[-^9!<%((DX$!W!2;B1&(DB,8*%$(U(40W
MP(C0)"L,%.*33)&5(9\3)3K0) DR*I"&!?9G5J5Y+N1G?Z,J*A"A%@EX:0R&
MHD$J;I,T_SHG):5E5F-I->8J0P(]XH@ )>G5D\D-!ZS0VK%)2F*;K,_*AI9
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M@QS@8 PXP($8?EQD(8L!R#E(<I")W.0QV 8X)YZRBJD\8O>(!+T7,8!>1(M
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MF9)TF5(PO=Q8K)<XY4UGK<#0X)MS 0#-= U5Q%]0G"&T"-'5[<@1<92O;88
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MII":+A5/0F0&<DA,"=U]$:+&'5NBL;]N[S[S,QB++1CW,QL#-$$;]!G-5+@
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M2M3)ES>?4%F:9.?9MW?_/N-BAB,A'J2W[_Z^92/I1:NG;[\ \8NF/WH"+#!
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M"%+F(3)YWD-C1&X4S95N_^2>2M*1+!^VSF%H@AC$R$1.=9I33;CNIL2XZ3!
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MHTJ=2K6JU:M8$Q)#0S2KUZ]@PXH=2[:LV;-HTZI=RQ;-QK291NXS^G9?IDD
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M05&7E,(4\RJS1%KV!4/QN4WWI-,7T#5P7?SRI'^$N,F6S"0N$\24JN3RQ;@
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2N][%[O2]^_WO@ _\T342$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img43903234_12.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_12.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M\]=>APWVV&*73?;99J>-]MIJM\VVJMI:^P[.=&.8'-U21ZUWWGSO[3?%F>
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MC\28M;)\H31_/%OW"Y, ;T!D :I8&:QC'<L!<(,M_*^NKWID-.\G)L"N#_
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M7N?TP#S9H>%[VLO]^I+X]>.;#HK8-]___Y>W[MN'TBN^:[N^_ILZ22C 4SO
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M(W3!F4/%,+1)HML\\(-&E/3+O_PU ;3&3/RTAQS )00UP[R^ZI/ Z\NWZ;O
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M,?#?1W0D^+$2W+>A"O6M_[M7S;X]?UG1TD]6M=?R=3]Q=&%EUUR6L3_^$;"
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MJ55TW,S@!CNE(6$F"QGJJ])5SF-L6\/8[.?Q;&RM4/'4)@O!4T=Q1_6E$F3
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MGE98&(WQEY0SUGCH%ZV22*BOJ5W(?6@,0B0A5L!&6J&!,A$.@.Q#*,E7$Z[
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M#D&C"( 8%%)-JDD D 0LB]2+X4&#]FE)#(B@2RH3BQ#2AY@1#4(QAM3T21"
M"TTRD:P1K]M'# !FC$FTBG[L[K;HLN)-L[C_Q!!#&6*(^622&#(A9DME,HG!
MRBO1Q$H3C2I3QJ_ #+O+KE! J:NN:%I+4\\KH]$D%*RBV>3//0DMU-!#$4U4
MT44-&^F^D3["2\S.H%)-O0\OO ZD^#+-[J;JAH,N1U%I@RK'#&'B]":0#F0.
M.LZ8X\RWI1!4KK;@7'LR/%Q#-2C/#V]\"3G[L(,O)LYN&LF\TK!3#;S4/ELN
MOX0(8I4^_Q#ZCC:!V%N.TJ=J7.C2I^B#=%.9 #!@DID >&N@G-@D#:*<=G*6
MHEW]LY<_ZYBE]KZE/B,M&DD 2&.C'8<<R"(<)!G# "0%$B,&,23Q"L?;AC'I
MH)Q40".-)5T*J:0A%PDBKKD;)^K*HAMDB"&&&\!4;1D A)(5_U>MQF+4*C1>
M[ED,F(%VV2R=,7-K,H_^@E,P.>U<IDZ[HF&,Z*GSHNO7J**A\VJJN>[:ZZ_!
M#ILRA1[:%B:+7EH/4KFT.PTO6*,A!F2+)AYF-Z N>HF>BV)H2B <)+(1[Z4J
ML@A9922^2$O7D*,R6/D$^C2Z89.E4L.HEKS!P L)MB@,3>;+"=;A]J6R)_66
M+9>AR=LF<,.2L]M(YN1&=;(UTAGL3R3;*H]]/X3BPXW8J"99@>ZT(:0I7XJ6
MS!G#ZMJ+UKT.+T\H4X.0U!<D%%6\T  5D$,<!KHG ?X@F"TR0$OL]BG)*(:^
MO,@LYO316+F[C4((Q<'?DFU$Z(#3./^LG(EJQ,C$) Z80 0B,($$%!MA#!B9
M.=UI:7R9BS+J HJH/9"#6J&+U*IBM0Z.D(0E-.$)T70YD>Q*'SE1ADK:$RNV
MF6Q*B!M<D4:&-ZK<*&\ RDD,5(8WH^Q-8QG#FYD -"IHY"0FLB%7CI)R*_64
M9A@YH5FYE)$3AH&,&+B921=+%4-M#6MVYF'<K3S#K\^ *DGTN]5UU@@=W['M
M/I&#X4K0XQH3P4I*)A.-$Z6"H1#1"$;^64T<.;20:&%J-2$A'(,JQ[9?0>4J
M'K+*IW*RO$N6:#:K,I%3N)*2:"PE.P8"H55RAD)5QH48[FK,7)YVRK/L92YS
M.44ME;9*$B[_0Q-;DPN==!E,80Z3F"/4CZ/:([7C$&@\Q#((9ZP()H&01 S@
MVX<1@2@5@R#LA\JI4#;WYTJW%6Y(<0.3_BZBD?F(BDFHX@TS[7B2R:%J'SQ<
M$HF$AZ*OM"]=ODF0&%1".O]4KEAP5 Y2 ,0Z=]XKD*5BRI1"U3;5<*8T$:64
MLCA3LF^-CB*?D1QJBH,UZT'$D&5;'8@.R:_KV0MZT+/>OD9T*0*5RHDP3!9J
M=N='G7*F*<U)4/=6!YXPH@0XL(O4"AL2T)14JS7_2Q*5M.+ 8D[U(&PBC)NT
M)DNMR F675T&-'Q)U;!E;5!6J:56Q9I6M:Z5K7'1U8=&4RT/S30T_^-A5S:A
M.LV1300A^^$ANS2QGIP(11G[JTER5'(1QD4%&O(SZ'E0])*66J>OUN.C=I0A
M@QLH(T$I@XY)U--" /0U&BHP0%1L-BRWA=8II)HF:ZP5F@U%"J>J<]0<8>='
MTMW*I?AY+1Y75<=O30M;>L1-3##T/'TQ2W?2J]ZN5OK2$HTH#2\9#W1Z<QS[
M=*2)')&C;E8B,;6IE(:I\>3ESB.;[2*6,<M01L5(69J,&@F5)*Q')KQBU;9.
M19QQ\0L%MY*L6F8P%'C:X'Y'& U0;$*K6>L+@B$<80FW=74PP4M.H/-%'@)@
M##)<[3Z,-UH_RD=2=*./:Q VB<S9!G#99/^7NV2%%\7B9:D*^<D-FE6Y"CU(
M(#=Z S&L.",I(6MR[AG+CH"8(R0'%UV3:$WSCOJVA*2G._+E2/!$.5QS'9=<
MS]S6<Z:C1_I8BZ"[H4A2:AP;:U&*MIERC4MO QM&ND>H+\V=2E$5U)CT"R9K
M)"<02\DJ/XJKKNH!S[EX@ASV66=T;N361K*,G61IYSERM9:.%)<?[U"R+6#[
MV9E@QH4;W&!Q)BR3T-8""OVN!:M]0:MSW'1!NBPFEQ,>H0BO@FM;[YK7O0Z;
M^<)7*B:F9"9%X2&;FA,24*R,7^E91C*8G1MH( P-0LI63B92#W9-(I*)-4EM
MY9).ZUG+)!I"LD3_)O%-VJ0!#>NJF"32((FR'61'*>L,M+\2Q9ET3QEI"%F.
MI54>*T?'D*U-J&P\Y)\HFKDYS3H77JIU&]F>BUAR?G1]3%0K5"&GN!L%C?02
MV:_)SKM?U$NI(.D[3O."1K=[!@ERDKU"1"-URJ9;6^.,%=S0(#-)TXED5);J
M&B)G)94%E&94RB2&,/%LU1P$,F_$@ .U&(TM_ZTUUNR"03L5^.J^[J#3PGI!
MKX^=[&4GE*6<HF, 0&=_O*D?  14&GMV!&$8$4C=,>*N%.^C0E_Y)E[V)P9!
MS\HB0-K(AK-5\P0!436?L(A5<Q)8<N)-0J99_+?\C0:G]*A@,,J8X&DH_QJ"
M:F?2GUQ;Q!&^97!G5#GGN;GI7#]3W^2)MFK>B$WX"%YC_48A\^6(IVKD*D7N
MJ\(BYS/9KF<:"_=+],P4S:MRI50G[6I5,2>/Z:;):-IX^8D/O3C"":ZMR[H-
MI(P!X'JM(E6=>260+[/2SU(>59ZY#'BE3M,-K/KTM!"CZ5'MZBFYZB^L)FI>
MS>P>B*P2HZP,< $9L 'SXC.&(_>&3=M")BF6H4*R13M 1B/B!F\& N_2B2 <
MKUWV 6$(HD*$@@+QADT4:_8.XB+Z1SM2HB0FHB%VY"L0(D*X"RORPR,R)MM"
M8B8X4#5N1"-$(F.D3I$F:OL\3I2>)*2 1.=^CU.&2N3F;",[2"RAL*O1-L3U
M/LE5UJ8+(Q"Q L0%R<4VX$F-9.=RJ@<\8,22S"=VCFK/L,8+7T]>BNS1&J?.
M<J7V*NJI*DVE1(^YQ*QQ? ZJ[ 4+"_^P!+\F2Z2B3/0KW=(&+7XF2X;&$=,D
MBR:1[_IO@/IKO*0"3P90+D1QP  CK!QPA)Q& 4-1:U+Q%6$Q%J6#?9 %.BHD
M<E!$$T ")+8  '21X.K)(C2/TQ2K!$T,E2S"8/B.)O:A%V6 \R@/(6:,?:))
M-B3G(RY/-7;D+7A#GZ(#ITI&]I(#R4X'18;Q9-HE/$:$,ZS$!<G(YP[$H*JE
M^@K-9**'H<ZC0,CPC(0G5"('GB(.V%IK%VM/.59KX?H0#"]%6Y+*S4"DX*2C
M^9(-HBKE-73+/FH'7-[0H7"/"7_##*/H][2%6+9L(1T2HU[C5O@H6LQP/CK-
M:]CO0D3M3,K_1/VNXDM>HBS&HDST1">E(@:ZYRPBJ"KF0E#\9,%&T2X&[*NZ
M3A9-*!08K)(^R"FILBI]C2"IA(^8* <M9#CH!;Q*A(<F0G(:Q"2VA-G,!R%X
M2$7J84=."]N"\/&LHBR'Y%SF)O&@\ >I94?B!1H(1B->#I0HJO1(@G 4XD:^
MHCL8@1E# F6<0Z:8$,T,+G6LHZ;PR#H&$54BD,9<XUGD\+<FLJ 0,<M"!3@R
MA0H#Q [)1;9\)28<$N0RA(62:88^L\YD9B4NI2!3)8\ CCNJI]'*4%G"13W@
MK%@<+>8 $0QYTR%!0J.([FN K-KDAM2JXDMLTBHP,8MXHRPV,3-\_Q)SE%$H
M/S$:CJ \CP (@@ (C@ .0@$.XB .0.&6%M$J=^G!KD+LZ#,_]5.M+'":HFP9
M52,7K:5"]";.R(D8XHJ<B,2I8@)AC,(@<F(86FQ[A)%:2N,B5B@8+X;U!HT<
MCT3S8,3?)"$I;BADB*S>=F[)9"A"2J/>++!2!"X]ZB/9 A&29 JC3/.=S$8A
M=LML)%.CCBDW!V^9' IN?*,XSB41\>.XR.@SE.OCE&]#!LUU((J[@I1&8931
M=,HXB+-9V/ /9W',M*7/2D/A. )+FZ/@+@VZP&S1!LC3@F:?HF)BU$(,]&YH
MM#,3CTX@@#(M5,TJ-N$\+V '+B (##4(CO\ 48_@/3>A3DX1K, +3SI#P"9U
M+RCU+D0B6335 B553@S,4T'U4T4U5$EU5$VU5%'U5%4U55EU55VU55EU4N\"
M+Z"RP"Q54D,A#K@*3W85:GRU5X&55X7U5X<U6(GU6'>5UCHU&FCM+IJ5687U
M69_5 DN&4_<"=?8S6XEI\$1R'YB((+X(L5PH4GD*9(R".Q1+&?;*7T10+D4"
M17! BSICVU2*+KDKA\9"T?#HJY#$!AD3-0C&8/1A$N*M8.%-WC0E&+/)*0S'
MPE1@M)".&6%#.U;R&\^42E>3^^#,=6"D5_8%;DCE,@]2!E,/M9PCCQ*OAGJ.
MK@:$CFKQXAC)?,C_M+DJDT/6+(UB2.<<A9'N0_A6T\Y<;L0\S!\;B5\$[5(P
M).90)UP.:EM$%BN*CFO610R:CF>Z<RN^Y$)BX!,$PCHS\08V<4^OXH#:;5V:
M#@X,U0* X (@P (NP *" &[1LP."H%#E-@CB( C<\SWCP#WO  XVX6]SU0[X
MEG#?TV\/EV_C0!/BX X6UW'CH#T#5Q/NH%'A<W)#@7(;U7*1TD_\9',[%RJ1
M,G1!URA%%W-!-W+]A#TY%W/9DW)7-W/O('9AMSUEEW9GUW9K]W5SEW=Q]W=O
M]W0S%RHKMU8W(7+?DW"'5U#8,W%'%SZ'UPX:5787K$[8LWIS=\'L8'A!_P%Z
M_41ZZX1RJ]=VL?<H-V%[C])[0T%Z:Q5P<U=0!'!ZZ4)^1?<OY-=/EO)IGL9J
M%".#E-)-*@<5M76 =:8U)$>C*B1 ?3%V*D07.>DDHBD30&+#%I3Q&E08=W9\
MNFE@A1%?R"DIA"1D C)A0<(B3&0;A8][\HHH/<48)X+(EL1@#.)&DA!<::)+
M]Z5'?<7#5(.&9(-HW7!*4"7W8,(%8X='+7(V;93\S.Q)MNO0R%0[Y*N)(ZJ\
M^$SYYFSXE,@T*J=V!C$P-01ZF".'DWAM3*/V(#,KA6?<5._FEE!M8H\Q1D70
MM,R@7#+]4(BSUN(38J!\?#(LY/1*J!8LD*A*./^+LS+A:LL3/2\ /2, ""+@
M G3@ AHY/0\U43&Y;A6U/..@//<6>>M$4.X@%"I7>AWW#@CWE!%W;R'W/5L9
M<D_9E1MWEF/YE'-UE'$Y< .7E.EBE 7PEX'9ZOAW*>OBE@"#Z^[DF.]"F>>B
M%'&I::"9F*5YZP;,F LL@\A*&8P93W:YF)MY&4XA5X=YG*&YG$WQG*DYG=]$
MG<D9G?^KEUUY<^V$5WT5,)PY:^;$<6&5F#]HU@"C+^HBU@P,NPBXH/>$B#DI
M);Z5 JD".;ZRN.HABTJT(W((*"3DV&)SPX1B&3HG7A1)L?1A#$J4M**C'C#0
M7XW0(&8B#0CRCPPR&C+_@1$^1D$\9AA.0TC"8 Q AJ<$8L>^3UR$[KCB^/FV
M);@P]AZ[I8L9:K[4C,LV[U:L3_M\L] L#-*J3. NCHS:J+7,I5:* Y&6KVU.
MI1;-N ?)M.8,SN)<DCTDZJ$D9R&+ZH&Y^FB?(R*7HYE:PPO7C*"AEH2F+?[0
MXDM(C=0D9FC2)-W&@CKW+SRCHI,SV9+3LU#7-FZ#@ ."P @0U0C,,PXTV[$U
MNSS_ECW_0A,@XC@N:3AF-6I2V\#P!*Q655E!E>L&#$]N":OF9)J54K;E,U5-
M5555F[4)<%)UP[098SXE VH I2DYZ+=EF[59K<#@0E23^9TQ".SZ%^RRSL#
M_\V@N;M1PD]W\.(6NW:!2V-)[&:VH"(3YF9$,@'W;N@EA*2][:A"VDE#Y3M:
M,%1#!P>,>F\D4"3_TA%&_AN),?.FE&1PC&(WYD9+'(4SS/*Q_C" @B\F-&I4
M5@Z-8\BJ5>C,'DVLIZS*XMK+-(J.E2.-BF,ZSH.CS.,Y'@[Z?L,+GROY9F]H
MMYI;KJ^NHP/XUF9S/L7XS$RC^*A)5ZL[!O&XN&,T**ZN'JTZ4 =DS<4@7[*#
MRN(ZN4*]>X;4J-PRR@1F.K%*@C)R.MFQR_,"SC-1,7NR(2 ((*"1(\"2T=/,
M\791Y9R3%]5OC1(. %@3,@%!VG$RM"N/@GN#H@8:"/GPJWY;3FS[NJ\9MZ.Y
MT?DYG?EWZP1PG?&Y:6[IF\'Y6(?U4UT;>D]UP00]U(=[N(^CU$E]U$/=U%,=
MU4M=U5M]U$%55IEU?FE] #TU.0A0M44W,'B=N'%]A9/[4_GYF>WB%&+-O0:Z
M.KI[V;<"H7^V=%YNG/R3?GJ#!Z&\*B;DT>X8D&;3.A@**X*.(VBP='8S-0_2
M6]#L*B9R+J/C!DUV2HS3RH!OD>9C<XX86C8"YVS<PY:VY;SE5%#.\/J3-"D-
M5S@4X]H(WCERO/1C-CJNX2WLLF@H:0TNXK(2J"\*E(@<[1)VPK$U/[AOG$HC
MZ )83-%:(:OL9W__[BJB]M=<A# BNN7%AA@8^Y?JI&\Y^P@*%9./X+,1E9$G
M><W3/,W7%CW54SU[7LS%?%'?LU8#NI<N!'3N3H(OQ*:YQ4HXK824"8 R=2\F
ME;5G->Q5FU2+_;:AV5$EO7^3ABX6]YBKFR[<4U#\HABL1NY#@>[KPNXW8>[K
MWD[P?AGTGN_SWN_[OB@%O[H!^NUKR5%!H90Q5YP!5U#V'FJ(%W[/V5']0O']
M-YJ5<M,]]2_07IP;MWA9ERX8_X*4TK5ISH !F]E3L:D)Y,=CZ$4MY2.XXUL8
MKA;'^*B2Z@V9"M?QD$=C17C*=#E\ZO;4>*;&-<?&^&6):\I$J1Z_6F 2_Q0D
M=+#"DWB,R\A# @J.PX4P&X=+>V+YA!PS2X-&][W-PM%*N4\<*T=?YWI)5ZOD
MU1!9ND6E(HZJF79VO&S$ "+:OF7Z]BG;%ZT>M($&]^VKIR]A-'T$ZTU<M@\:
M1(8:"SX4"'$C/8<8H]$#N? APGK[1NH3N8_BRH(C$Q94V'*B0((F8SK\";1A
MT*%$BQH]BC3I/F(WB"E]"C6JU*E#E4DRNG/9LE";X,0!$B3(D2!&CI@].Q:L
MA2 1+.RP$ '(A2!@@UPH>P0OG+-QS!KI&^?.)L&AED4S_/*G,HP.E1'SJ"G3
MS\B*'SL\236SYLV<J0I$&*JPP,.CHX4V;%&BX?^!T53O?)TZ-FG6JA&6Q+C:
ML&O6K&4?MOVZ]>N2P@UO#1W*3FA0IULO8VX8FO'IAXU'6TPZU'73W M[]PX=
ME.'ORL ?#QTG5.!-Z0</1KXI%//0\9EOFC^__'.MXOEKU;_8?UHM$R"!U4EG
MG'2LG80;0IA9Y!"$G4U(88467HCA91%&V)-*)H'DD44R_7128BVI=&)/-JET
M4X0:.;3B2".QV"&$."7T4$06L002B1FQM.$^F0 @F40G0DA01B>^"&1-B0$I
M(F,.O;0B1O48L,*&B>%XXD,+=90311%AUB6/+]'TV8H:[<1ACCT5M*:;,C%6
MTT8'H0@D8P5A=&=)#PK_Y%)(8^[D$9TQ05G0F1^*^5&7!VFTT*,\XI0G33'Q
M%"B(')J(T9DY-K;2H3_5B-")5#;TTD*$ BJJ4"4FR::1G6XDT9901F@BDD<Y
ME6&O5<7PR6;*9)+)),4>>Z>OO2J3QE3+: *'&F)Y%4<<>QW1%UICT347!!?$
M!0%;0$1 5UADY:6M6=G^56UZS:V65++**/,9,<, 24PF,Q)#S(ST* .DL@(/
M/-1I13WW&<$*2S7=5OH=IIZ4"P.59JDEE3J<<UJ9=AY]R*47!WOMJB?8'<B=
M?-XIR*F\C,K?;05S8>*=)G/,,0-8<RCZS;Q883T3*"#000N-G8%:(7A=@L89
M__0;;G,VQ%A)D\(8\,16<\83HQ^->=FJ,RI$J4 '82HVKBJMB=.+/^[)4*U6
M$IK3IP>]Z=.K.CJX*$8QQ!#H0K.R/?6@#;$4Z8\:CNT3CM 00Z22<8X4YYTS
M2ATD2W/C5*= 8D*$XYN<N\38CF9;67>H(Y+-Z)R%6NIEBA"R^2G8!5U^D8ZP
M0XD20V5NZ/FE>]J.HNZ9)\8H9D;>N=&:F^.M*(2<:O@U\)*'JE*)&WFJ:V(=
MY2U3X9X:E>S5$S+%*U63W+ W^NC'T)3XG1%SE6?10%NMR='"458<?Z%[EEC<
M<BN7<:W%+1?00;F,<*[\G>4.?,$6R)"SM,XH(R5+2?_6,"3CD&%H0C'A<Y\'
MB:*?HG E81\L(<:T@AQ0N"N")N3,:&B3'9O-)V;5V1AJ6O,ZA,S&.CRL3G5.
ML9A3;(5CWK'9RR!XLB2>3(BA8:(1GWBS(LZLB%3<F<,<EC,KZBR+/NNB?XBV
ML19RID6,D92',/.ULM%H1I6[B=\,YQ.6X"1JB3(52R+B*1R="G<,"=V&%A*P
M.TJ(2YR#D$O>1+HU_N2.1G(=F'BD$B"-:"-E=-"A!B4F31E25$#2(ZP,";>#
MB(DGR7L=Y)K4(Q99:74DP=L9+UE*N!$R1!KRE*30Y*8HX7%%;C.;G=;6$,\)
M1&V&8ELPFT22%NF.DC]:"&;_,!*GC4!(<K7CDD3F:*EH:@A%B8E:4LHGQJF
M4RJ9B($8C(5.8DTBG%)A%M;0HPD@O"$-:D@#'*C5%2#<\PC70DM8YA*6 =IE
M+7&YP Z"L!:P(! O^\.66?92+?><AH47@H:\,+B43'@D$\/@((DH2$)V:H9C
M18G&)CHH4@^.1CUQF-E^9I/2SHS&(CP\CBE@YM+^#$AJ(5563RG6)M>09JBZ
MZ:%12;,,Z2!5B$L=HFBH^$0J'O$[201%U6*J%#[Y!'F.$V39B$?*5DKJC5S:
MTDE$%*-#R>I'7*J(CIQ9NQ.!#I.$ ]L;;S([PS6O<XS,9*,DM:*YR:B5$_G<
M10[E_S=<YLEPJ8R;*'7UI5]6+R::\E @U2K(NR4$D)C4HT0F=\FST>I&.[(4
MJR U$,%)#9 KZ=&+3C59AICHE'";%*O:-I([)NF9B/W4,]V(*E(ZDW>"O.1F
M'44]5!ZRN+,\[*)JA2JA% 6E6,V0&&Y0W<P,XPT4BL8]JP4*36@B.VDH;SWA
M0)]JE04O8]E6N1 *P+D0M%QU66^ZU+6_]4!0-P,C8;*(D8S)8/2"/\E$^>:5
M7:,<IZ2A2; )(4C$X\#L-P[N+G",(\3P+$?"A3':4"L,8AB%."F \UTD33<I
MUH9I(\'K6S"C)UHV6:I.:*H)BP)W,5(UBHU5.N:F0I>H)/\E$B))0A0<(9E6
M/[;.CWK$W*AD=-A/I?4C4U,>CGZ[VV:VEFVK[%*1DRG;9!:RMIHTE9%RF\HB
M%Y9U.$%3BUX[1V!"DWIF7?..115EV1+YCYM<9BMSM9+AQDEJ-_E,9O.FF%P6
MMG LPM/=.'35H8S3P?7(!!K$<&DQ9(*Z2;GTB)5"C'56"(75@H,-X9"&>987
MH\52PQO4\-V^X$4L[3476"Z@%G)= "[CHN\1@,"_!OK%@=6",+P^*"4$.\1>
M/]&@1Y31T<N$SR,EA(X(Q?-IJQTG88>!QE1MF.T,U=0T27P.$G<ZFQ>&>]TF
M+"U;/V*W8WH$,UPM&VHO5MS4;A;_F51Z'8L9 RCG@@Y7S$3MJ=R:6K-9#U1H
M U5>U68WD-A;4$;*Y,*7],O.;:X@FKH<\##56VE>RFQ_W9!+$@XG)!6::PF7
MG8REN9!4<:14ND6(S!_+JK6REJLO^I">VY1;W\T91=#D'&Y=-.:NC8C>OEM4
MBE$U-3NNO"&#UM*>C?D@I6L5M77='K5!..),K$]]ZYL$!9\R"3&<G=T_ 47\
M+@2*[]Y!/(N!5AHTT6%0B$$,:9"$V76X#%2KP0AJR,NY:.V_M(0%@;@VZ%IP
MO0.P 'OR[<W6NOKB%:Y,E,(BG8ABI*2)9!FXP+RR:++6GB&#$47U;!>8M8FR
MG>/,K#_1Q$!]Z[M+':=*5:KC0:H.=5@:C!E)W?B>Z0MS+/S?MZ:US'^A\S$&
M_> O?_K2;^3M4Z(GHP=O5F_4D--;E%;:,0HGQ_2\S&7RV-WM47"UPAU,7NYS
M.L[RR(2,LI&_)N+WXZEL$O>13"")$9GC.I;R/%MS7)TB7'A6(M=48J8E<C52
M6#/1*#YG(R-'9'>S)98U<E*W-97T6@HW3)@3@D"16Y$%?B?'=&!&)EZU?59G
M9T_W*LR'/+>E*, C<;@4)DJV3,-%-<'_0Q235EV9( 8Q@ ;\XABA=EUB,!4Q
M(&JWMVS-DB'SLA76@EX-<ABGH DYH&IID D!,PF3@ :3<'<0PQY[ 0=B 6QF
MD7ATH7B-)U_PY6O AD#"-FS%YBX=QGDC1GX5U&R:L%$8I _$D"S_HAG[<3 Z
MXX3*(F%*@51*M#0_Y835 6'T$A6CP2"&@1U;9&Z;Z%+R@5/>H1];I(GYP44Q
M\VV\1S-0I8H<=D1&)(JN*#'L]EC1='-JI4K=LUCM!SR^U2:-(A)&PA*=DDQL
M\CA'9D=Q-6C80T&<TR)YY5IM!G):9SL65WZF$HTC,8O9TQ GEV4KHBO'M7"W
MLG1MDB0H0F.D_R1C?L)P/#)P'0$DCZ4C*<=G:X9(O<539<):_>9<NY-*!W$Y
M*J:.?10D'8* @L.,6797Q"A-J?0YB59G# $3X0@B7():LVA9/0$Y1\%I*:4,
MUP6$'1D#0&@4EF9.QY).&YE=R="$O@(M@X%>F@ OSQ(M\P23 D$,:!"&8?AU
MF9 &DP 'XL52>T%Y[:6&O_9>C2<7<"AY9(&&]^47[4(8FQ=IB:AL^Q!ZC9$)
M?O@0H]<8R2(E"P9[#9:(ON*)D*A@AU$>YT91X2:)$"0=:DDOL>@9%]8P->1#
MN7=4>8F6TQ&7&U,T2'67TZ%4F"B8?FD<?1F8@.F$@LB'Q  -]+!!CO]A$/ZH
M#(%X$(Y9#T[A&/HP+_6 8(SIF)!)$<1P'94IB)9IE1JA#/_R&)\),*X9B->A
MF92Y. >A"2?1FK/)AU=)FHYA49K9FY=Y$,,@'< YF144#:"I$:%IG @V#)=9
MG)RIFZ )G?^R&+.9G,*Y%(\9F:VIG8RI";_YF\?)F,^YG<LP#+)9FN1IFH_9
MF]/YG<O)F?0BF?.2G17DF?-2F032F-!9#]TYGZC)F[\IF_.YF\/IGN/9F;#)
MG 4Z+Y99FQ44F_0 GXT9G?6IFU=)G/J)8%+HFMM9#QWE&.L)GNV)H>QIH9LY
MHIVY*R!&##& 44-1#S> 75 QA-?%/NFS-R+_F6#N)##VN17WA%ZB<2B@L F:
M !UOP'=]!X4_,0F2P*3)(HEE" 1]P93:,H<!I:5OB&MA(7F_!J:TYE!/63_Q
M\2YCJ11[*)D.P5&3@:1\4CZ>>1I?AZ;=Q7I481$](Q\T VX.!C';)I>V\9:G
M 1T)4J>'.C$]N0QHD G+( E(^J@\J0Q@Z*AIL R*B@:AEZF6M@R9P C1$(:+
MVJB,J@F3$!EH,*EHL QB>*F;]JB:@ ;AI:IB."R6&H96(5Y%:&F3F@;,,@FM
MJ@R9>I/$ *NKJJJ88*F2,*H&IJMID"^3P*N+^JO"6H2P.JG0^@;3NFE<J G.
M*JF2JJA<&*R:,*S%_TJI/.FH;S"I6=FKN_JDEPJMXIJI;G>JQKH,;J"MCKJM
M^=*KYZJJ7"BJQ."MJ/J%OBJMCHJDNDJPO9JMHKJHFAH9WBH)\,HLFY:IUIH)
M8\"K&RNN\DJLLZJJZ*JLXQJL'[NJ$QNJMWIWL&JR8 BJTSJM"9LO(+L,#=N3
MX\JRDDJKV>JKXUJNS1JMROJP LNOU]JS-SNO%[NPRM"PC(JP].JNL]JK\JJI
M)LNI&@EB:! #2#&$43$O1BB(CC$OMN=@\#,QR@"47!%>VL%M6@$'/U!>W*H8
M:,"D,;H/RKII)'$8FM 5[0(6]P5L[_5X25D7A6N4"Y5X:,$N7A&5HG%LB/^J
M%(-*('>B#U<9&IH0;?20MS%1E70*N8<8"A9B&#D%,QLSE>XS()ZH'5+1B)UH
M-)\+NQ6"MLD)DP8V/P0R7L2:G*!@E>)ANS")ML^1N^*ANZ'7J7M+N]>Q0>+U
M+'6W&(TZN\3 NV\:>K?[+,DKO58Y7M4+O-V[N]K;O,^B%9DP/^.%MKW;J?1B
MO# 97K1KE<30O-'0J)V*NU:IOO#+O;A;OKL[/_C[O%JQO>:;NS!)KK<;O1LD
MO;0;OO-+OKKKP 1,+_,[P/PKO<]"FC!YO<2Z% /<J1<\OLE[O@6<OP>LO-K;
MO_,S+Q.<P,PKPL^[OR'\O'6GO\3JF</;P0:LPM/_Z[PX/,,VS+UU!\++N[W_
M2[_A91!#;,'AJ\++>\'X"\#Z&\($[,'!J[LM6F&>=A1BQZ.QVQA-JC"""#'W
MI'E:$11; 2T_N1II<$Y]%Z/U0+=@N)(4LPQ'VK=[47A.&;A).;ASP7B&2WF!
MZY34HGG-(2%<#!1#!+J+]%^B5SYM&A.,Z1"/B:A[FB'.06YI"1UQZ;F*^*>%
M6B'9056.6RJ&3,I'@1N6[$,T-1P-LC0W=,JI@1NWH<JJ?#&MS!JG;+I(E:>T
M@<M]=%2T/!R QR;6L2,^%)>]@<H#@<N Z<K,_!NUH1ND,<O0C$,XU,J6K,J
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M,[, R(2M";IEZ+F_7(^,L"T8*;,;V"])"  S"X-,L(@R(\#_T]$$,X.4)%G
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M[-,&+,6PV\0XUWPT)T?"9U5(9&\LI-:^$'B)U-9V)W/=WGY*;=4.B*D9U[K
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M;+LL*8V%TF ; #&V*O#N+D5*%("#&"L\C;(!0,.B@C*)&P <@$(HJ4DT20J
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MJ2@S+ 8!RU6-T5:MK"(L7_F*)IK1C.ZP0; >?3D\_TVRU$@NG5E'(X<5#I.
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MV4+_WK"+F[#/5R!C^Z+E+G#QGI8!NK8O+8Z)V];M,>B)O*B/W5I(K#@.X\0
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MAFO>TE:O]&J>O'LSV(<M5L=NDPV<7#39&EHWXV)MY<O=H&>;=M$@J%C_:/K
MS%$,Q)BRT=BF&UP":^P[^@6$V%B!5$BGI@[M2F,8(IFB/"ZKTT ,0P%JX "K
ML?I6G0;&]!A]MH,(50)?B[!>J_>NA<."?*RMA [']^'LZJX_HTXAZDY<I\R*
MN% GF1>,XM5"O5 +_UI%9+*02U345JXC9%DZ;NW+SE AKWP](7RMK0<S7^7=
MPEO]B.$<HL$=LN$<]B'-U[S-T5S-X?S,W0$;W%S-37L:[+P7V/S.VYS-L6'/
MW__<S^EA&LSAS^U\SOL\SND\T+/!T/U<T!4=T?D<T>6<S<&A4:Z+)/+FNO'O
M-]6BF'R8A+>I]Q!I,O@TAC4U-;OF,]FBB .%@#B"2?;4;JO;.*/63Y=-,[9K
MG/X&V=2M2=26NXCS:XT/WC:UA<51U[+I4FB%V,5Q;4/X*WR83N<$46D%;R=P
MA22L.[W<@83:VR6P)/FCVT4"%#Z.=1VJ/4M#PW$,0ISNG\@B2%S03/4X/!Y%
M#=0 #M*@1IA2CHB)D9'&(<%P(./ #@[YE;W,/8V5PCYHE0N4P8$\TW^WZC(D
M9Z[.0T/Y1"P40V-D:(8&9J37D-,P7X65WUZRRI_US!#_/MR%XTT&SQKCS3>9
M,:G P1RR(1ILX>:C 1QXX1N6P>:S81ET'N>)GN=Y >=[/NF1GN?!X1N40>F!
MGNEM_N>#_NB%WAQLX>=MP>F'?N?!0>N!_NN_?NI]7NR%GA>ZON>K'NFE7NB#
MWNNS 2:(:ZX(3=HY.MBGUNY=,U7*(GI$@B1XE&H3-=G5)#1]\4^*\?JN38AQ
M73!6YTY')2=0&(>/+5.5)YN@JT]7&->TN_)+Q;S:C6WKR5/IU*#W1/RB-O&K
M)\'&.LU<?Z@_M^7#/<$T)JK;BEM=CN1.4#2@087Z9:4LLC0 V4S+0E^4NLOJ
M;J, /NF ET'KAPWEY+4OV604__Z"5"R!<(JC#(9?UEU:%3**(-0+Q^@*N7#)
M@T9HFJS(P\Z+1'E#X*#LIGRME0S\BVWV,TC:R0E7[,J_J1T@HBV+!D[@/EL"
M"0XD&"U:/5[+ZC$<&$Z90'/+!H);"+%AP8L9H]E:6%!CPV7G!N[K^# D1H\)
M1PI,J9%DPI(*88+4N>REQ($9H>V;!$!30J#[EB5-ZE IT*-/,^Y3MM3I4HM1
MH\58(7"9OH@.L4[MZM A-+ 1SQH$BK6L18G*@-)KRA2IW7IG@9ZM^K7LW&5J
M@SJ-1C4JW+!5KR:56,^IX[58@3(6"&VR9:!6E2J3./=GU\"(0V+]>S3PWJ>=
M$T[&>O_6,N6@C0D;;.MYG^W;N(GAWLV[M^_?P(/?CG'C=Z88DX0K7\Z\N7/?
MRB0]GTZ]NO7KV'_7RT15>2;=O:-I@@-*9?;SMO'>5D8/=[10RT+!-[^;V##@
MRI01RX1;628TDTB2'&[_29(&&IKL<Q16H8 B7WD-P@=*0_(IQ=M \F4(WWQ/
MJ7?=>_!%\]Q^W<V%7G@991@2;Q7>MDQ[^^RGSWHGNG=2*)J$$D<<0!QQ1!P_
M!@FD$3X"$4001@9A1! ^QD&DCTPJB>014?K8Y!%PQ'%'''!P*&)U"\IG48UD
MEJE@AX"AI5IFBPG4UT"%E2796@-YYME@>#+5%6-UAO23@K'_H4E84E+9Q52@
M:S$5)UEYJN2G77;)N5=A"WGEU%]9L5:G7V7]A!EAGVK&IX)ROE8J8X%Y1EM7
M7U6U5J>E8H7JIFU96E5@H3)6F*)VQJEFJ%$%]F9ELKD&9Y^XFHJI;%'UV:IF
M=3U;EUFN'58/I83!A>:TRQ0VV:9_IE4H?F:2>1Q_O]T@1KGLGJ@)NNW&*^^\
MYW7G6WP-;O(EO<SIHXF][N$;'WV\<:><,F*D82"\MDV2QB0  IP?B@KN)IZ%
M]W9UBC*AG +AP&(*1EG%RH%(L'/^U6,;P-8!I6%#P2WC(,:W[:O,,%_JQZY
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M=UC;'*@JKP"  [MDNFB[NMVCN-1#6<(H!@,2<HI['$!)L:S;DTKT'-L!N/M
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M=WF 5J7*CDUA!,^@:[$H=4>^9%KDP@O(=T%"]\O=%8D;ISV?M!00BS>[H(V
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M+&3SBHVCWDVKEJ7:93G$E<QRMHXI,TM%H=+0J!(4*'NL65D5Q,:>X*4FXP-
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M/L!  +P!/<AR7&0R2JCR3+AR07*R)'XQ2/1*OA@ .1JC,FCR^;A)DEK*0P0
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MK<Z848IJ](H?+ @!V9D^489T=L,BZ4E1FE(E*D-W@5I& +F3'6BJCP7_@CK
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MT)1G0@;H\_K6Y^BJ6(^1(;8&^71&KM))R(DT,;![)]5B]WH!A1@B?OO? 2]
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M<\I7EW5AG]1*F15! C6"G.T@\!4S#];C;)"=4,=EX0E9:C8\W()K?:);*B,
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MYIMW_6@X:*'6/V2+:N:TU6]-]*6#FR<\""X<@A.;UG5]Z!GX^/V:Z9\?UX^
M;FUDA#^!LX?CQ-NB7LBB1S";7WQD-J!=2_^F79&KJMK!'XEN(+3M9B@KVS-@
MP"M6O'OQ/5N2@V!<%LS3?6\ X@"]??MNX"!(\( 8@ID.*-NG[( DA 25Q<B$
M$,V!>A /8*28, ;%& OWI1&)L*&FD2(M$@-9\< DBF)NP(19$^8!- EY[A-S
M@"(QCPDGQDQS,ZG2I4R;.GT*-:K4J52I$GM9-6M491RU>OT*]F8 &63+RD!0
M%JU9LFK9GC7;]JU;M @GR9V;5B[:N&[7WN7;]^U>O7[S^N4[&*[@PXO5(F[\
MMW#;N(X7XPV\MO+CO'QG&%8\F3/DM&%+FSZ-.C5!K*I;NWX-FYA/UT>.!(E3
MNS;N.$9XY]9MY$C_<-RY@\/Y3;QV;R.;H*XX8" &]  %#SP_@+TD&NG2]Q&3
M;N"Y])4-8P2 <8#ZOA@&D*Z76?'YRXCLQ0=XF,D\0APQ#A(T_\9/ 1Q@'H%!
M[<.?=088^!!(R@3@DT7_^32)0_^51! ,_A%C %8:8?7&3 'XE]]]^^@3@%$@
M<4?0)!<1A(8!*\;0H$8/T;<@>A_10Q1"$6$X"4^98*C0/FC,Y-V+ZY4T%)$H
M[5-D123!1F655EY)$#1=8=E4)@UR">93FIWE66B)88996YITI<P8"%%"%T%I
ME*7),@C5,T-;E-A)T#*4]%4G1<N,(=@8Q2 4S9]DL9 #:]Z5:1D"6,F0_T97
MT1"C%@M]RL"G)C(P2@R?^]3CJ5ECB$J1IY3(N>H^R["U)T)^O@6JJ,0LVJBM
M9 F T!B#I8%JFV_Q.BH":R)$!F1C;G:79&2I%V:TTL+VY;367@L6*$AB&^8-
MTHDG$C'>*C0)#!@"M4*$8G G1H.9!,#= 3"$])%T'RD378/*K$L@&EB]:Q-!
M0#F)D3Y Q7!#>0(;H,Q)"#M*T8/2"=13BQ07Y%]")37T)5#6E80B=YK $$U'
M'X$$X5#8?3G&DQE91R!%F<R6R0H81;2ME-C%,)M&TF%XPX ]0CG;/@M*5S3/
M/BK-;=-.OZ8,,= \'3'58([E;+.7#3;F6ZB"-/^G# C-B4"U%;'U-4&ERE#R
M33F0Y29,OE)Z4S2$9L:VVC#=&J>K"&'J'DS+Y, " JW>=*N^%)&5MG=OW:1)
MWZGV;1=99B.T-D'1;-EK85IS'1CHE(EM=>FF>W=ZZD[+IGKKKK\.%=-:*;,"
MJ@;!CGON5@_T-#$GZQZ6Z)];IG6S:AU^DUT(O"E#W""]*JE2<&J:E#)G76X2
M64K5 [H, G .$]F0DUY]WW,&OH^G*\$DP_HWS>F^4.TCKCU!:IP5O]QG+:6,
M\*(5EB<T)09:P"M@:K!GP 3.+F<*E$H[VD&0;T!P'Q*,X 0K2,$+:M""',Q@
M!S&8C0F&\(,;]* )05C_0@RJL(3F:-U.OI(& _".(!!JH UO:)IE>,ETRD @
M#I.R L\13S&729.HYC2&MF6/?.=#B ":U\/Z0<17&++>\I1!"1RP  =\>A6G
MU%:XE1#*?9- B_NTZ!<EWFI^JY%B^F0@!ARXCQ@X0(#S]M&\39$%*X0JVYW>
MYBL?^6H,4X.(#+#2/THM U.(1 NP/+6\%DFQ'F%S7ZF$@H,D$J0>>!NB_PCS
MF!^*,BH0&Z4I]U:T4RH%'.< 1SM8Z4I8OK*5[I"E+6EYRUBV<I;@J.4N<^E+
M7?82EL'DI3&!B4Q<*K.7K9N25X9Q@,!MQX>JK*8HJ7FM'5H3)@@0'E\20#PS
M_UT&<[1B7B2SYSQ]0!)N"$D+DKSX1,=@A1YH^=*^S*(OM0A 'P3Y$^CT-2Q$
M[:^-:&%!@[A7EHREP3W08$N#RGC(_93%>74D2ZNXY[YE5,Z,LJI<6>IB1Y"6
MI4'1&*AW]K*M<'82,,6S# &WJ4ILPK2!RF#@3!%BC@GFE" [W4=/?ZK3H/)4
MJ#XE*E"'BM2B)O6H2FTJ4YGJ2M>]\"L<*I#+;HI5'%[E=#+%81").$2P,HMR
M;AF;%"%J-CHBP*84:2A9-#%#6;%34.);2MC6PB=,C?1L3"2-VOI2E[X>#@=O
M[5/ASO([F%@O;ZDJ2R$QMQ>SGJPR\S1?6;85FO^!,@4R9Q),5O]/6<K/TC25
MHBVM:4^+VFL^EFI=O6'WAM<]<09&I"95'O.\-PE4<1)]BD6+$D'B5@3($21V
M:9Q9_\G7LV"%D^=4GN4J4IF4""!_:ML+5O31%K;*JJ")Y1L+\K=&Y@4.+ECQ
M8F =V4[.>B9T>&-I6UZ:V@*V-KZGTX1VZ8O?_.IWOV&*VGSY^Q6LL;>S1!Q=
M7LCY43E)D6QL&0-KTC!8PK" C793[B8SA=BNO*I!>HU4&E<S&!]9UFO)S2-!
MQN"?+34,GWI$+T'Z,CH!I.%+CF'!C!%BV</-C2QMLZ)9SW*XRH#F,YWU'UJN
M"N#6A3;)/"0MDY\,Y2A+^28]G')JA-S_TM$8V#)';)X2_0G2F6B"L(PMHZSN
M-@;R1&\?]"!LX*S'@FBLF(W89<V8+:H,+S9F2\4@[)<NV4^YL(88;T.?#%K5
MO\/.!9%WD578</"2.8&"'J5RG@RXDHFS6+JY)MU'&2&-X#>I9;RR_<SPA/@L
M*W-5U:7S':M?#>M8H[;*LJ;*6(3\26=A^2W4I4C8S(H\BKS-AW-:\CY*BH"X
M^LC$-Z$GWJA)V'/>-:1*B5ROE[&V+SWQ+3XLXY(%@$#+KCDI\?RQ#%*:)L[^
MSYN>K36WC.UN++$NWO2NM[UUIXQ>WYN;G=2U8 *8[E0K5I+G_!-ODZN41@A7
M*8MMW-N,E10O_R8& 9:"B28F3#[GXJ]Z":8R1X]M%@'@ 'QF#6VF>UVYVS(V
M?!UW+JF+:)GU9A;5,H#OOJWTWYN7IJ8Z[[G/?QXM>N0\UBLX4ZZ+)UNU@+HB
M:59P7]MG3S@)!JZ(JJE:<F#/N'E1#*):QF(3&BPZ%B^O;V:PM(7,]8@Q^-)*
M&>/9*$-U'Y$-TDIL$UKH+LC(RDE-7UJD%O6^1+H19-M#+KRZ_0=T*\$[\:69
M-^,?#_G(4R4:F5@\O;?,&''.?'1HB2=G#CMQ-.%%T9GJ/(P%H^AP@E[=^R1H
MZLOB^?8>EO 6-N19ML6W3Y5Z,+1/2^K;$OM=&>_T=R$]8?#RF-V7!4=2:[&Y
MY,,R].<[15O2K[[UKU\1G]]ZLT7VW.:%2."LC<;4PQ?]J<7OEAYK?LA;3HRY
M&1LYXI,?^6 ]?Q';?WSY&UZ ]V\,]O\;_W]@X7@!2( %:&_*D%CVQBSKI5+=
M TZG=W3L-G_=]WWTUW^O-7&\LT8LE64SMRAM4P^$,UPOYGW<UU+*US6FAGD%
MQGZ&%WKU5Q;.9X!/$7TS"!'W98,YJ(, IF+W5G2'UUXE&!G@UX%; UN%YX'\
M)X2&T2FB$7JQY81L=!-]-'Y%"(6:I6Y&N'[)QQ@PF'21LH-287EAZ"-.1H9G
MB(:G50_:='DP6(41&(4$AH$E*(=B%84-B(=[Y3@<R(<P5Q8WADE9!H1]*'I)
MN(*"2(&;!7-)&(-IV!0U.(/$@(..2(F5>$J0"&#;9X']YF^%>(=$5H46B']=
M&%87J&6>5(K_=X@ H/=ZG\2!;[B)7[A^RK)_H.B"JFB)23&&9Z@,9IB+OPB,
M-U1Y[A8#?M@8,D>+=LB(1DB$@*%\L1B$S()^?BB!\Z=9^'>%'B9^C.B,G?B)
MR])OCR&#E8B)!:@)"1B,Z:B.P%,/JP5KO9>*KRB*RAA6X,B%'OB"X8AT'C:'
MB8AJB=A]Z[:$V*B-0(B'7$B*GQ- 6&9TZX@ZZCB #BF1$^DZ_O5J!P"+3YB,
MF6>-_<>1[J6"+3A@^[B$G,ANG$=^S[B1^(A^W.B&]<B/6+B- J>.Y4B /$>1
M.:F3IJ,)_,1J B:3)"F2 OE:!AF-+%B+^2B31G:*\HB%7ZB/ VF*#U")BN 8
ME&^!C"V8C0B 9/^_N(MD&)$[*99C>2VT%F4I^)1&68LG:(U%R8Q%&7Z*R(P=
MV8W5J%(C^7U7N!EC57\!N7]PN99L67,.:9,!B)-DB9B)"2;$4)@S]8.?B(H?
M.7Q;"($PZ9<<"9DH.9+0&'[2:(N"B8BWZ)$%"8IUR()HV8_&XY!?&89AJ9BO
M"9NN898 AI:FN)%!V)&Y&8]QB)O76'X!=XBVV92E>7S5J)F_.82GV(E&YX5*
MB#?C2(F-B7W4%YO5:9VHH4,DEU] :8R P8"\293C9Y=,Z8W,1GO=.)J*Z(J<
MF))M27.5:8>C"9*WR9*^&7,8N)KKV(O7R9_]N7/\Q9F#F(HA:9+_*(C\X+D8
MXX67GKB;,SF+D;(M=G,F=@(]RHF$BTB<R\A>6OB22@B=CBB=UR>)_DFB)2H5
M(?I#W F:0H@6X+25>0B'=LF>@:.4AI&-7@9BC.,J$TH1L4<)U:)1;Q%L"#)A
M:,%'SMF9,VE^E,F0^FB/<BDYP<B:.[B?)FJE5VIEP^FB],><YN>EHWB5DFDF
MZ':47KHK.0 2>O40>E98BT,GNOA<]9!).2IXZV2? =JDR>B4Q!EP#-H7'YJ&
M*%I]KH:EA6JH_*6B1!B?"_JD?5J',EI_:H!C#4J+:E%*8_9V9Y$QDTIM25%'
M?T4Z>H6FAH2:03F?>_JD1O>=9I*5XJD8__D)D;YXJ+-*JS-UDGF8A2O:A5WJ
MJG3(CV3*I6;J4"=V<&O# GSR)6_:(A^W#W_R=G:R6 W2G)89K+S)JR"9@GRY
MJW(!J&@HJ-)'G;4JKN.Z35\EE8MJHU5IH<D9DFX)5MN"=ZYR-Z(&*WUR)B7C
M1?GC%A]!2>WT<8DD18%T4J2C/B?&G"P9G -:GZ&8E^&)K;":CJY)KA-+L0G4
M32MIGS>ZE-Z(@NVJ4I*Z23#Q-L@J%R2;%P_A;-_5)W?U12:!67/U1A"W#V[%
M)W.:/NZQ-@0*DY )C;CJD9>YCV?2K;RHGY-8L4>+M*=CKAMJ?Z0(F"BIF2MX
MG/5W<!$CA0G5*_\!66-SL3[6 [)XQ&UW<E!LD5ARVF(Q.9ERN8GYYX9 2X]7
MZ1@0*Z6RFK1U:[?<,H>5F:KN&9BOV+'?>'N^)@,CAV/4$[.'LZWLBA!O\[+*
M2A$5U::&U" XL"V#0G/S";<+BGRK"I[=]X ;.;1D^*W/=YAW:[JG>RU J:&Z
MV:@ ::WIQH!::Q9?:Q9DY$<DV"#K9)I"QF$N!K9W5TJ4)!>$MSY-!Q*5NK:/
M*I3N6:/MV:%NT96Y.*4Z6*6H:[W7BR5YZDT IZ>*.H&AR:$KQ1DI%6*2Y#P"
MNP]WTYN!,:K[H!:-2S[08+P$069NX1Z8,A E]1$YRYX8NFNIN;:,&IY;P:H6
MH1N&HWM:+L) ,<# ,:!=+M+ #AP5]H6]%6S!KJ&)F-MOW#L9"YF%;KF>](B>
M9*&@9*%04D2HR$:M>3&)&V98)DQ.;>$?YK6'.?JT:<NGOGF/\]>J3-N7Y/\3
ML?>&,$H"(Q^1"3? 5I,0,#18>9_@.RIRP5$LQ5I!9!ZLBNQJB,R[I'=ZBVLE
M46AQ.&23472:F7)1M11!3RG!%@:E1R0FIP.E5VW4%Y"BP7VZLWW;N<D)F(.I
MG_8F!@M!Q##A3""1'Q.<"8><"9. CE/,R(VL%*J+F3\LGWJ\LWF;H3#XM<)K
M:# ,$F*@L,;3PN2S#)6T;&I1O(]C>P0!"KG*E!IYA %LR4[;GE8<I< XO5&&
MQ$IQ Q@B,]'K%,1PQHXLS,*,D1H)M9^)S.R*%\QWFLE)Q\B'@WIEI(*2MKM+
M& IZNTEQ5W$#L-03#3/@'HIBQ_W;APD;EXU*R8S_:,!4>G.!+!0)DSS>XBV\
M[!35.\SW/,R]AY#BV[-WN<<8>J&'"+*74U)I$3]K<\Y8?%F3RFR*Q1;^H0Q%
M6GL4\:((8,7^^V\.*Z"GEEF\"H;K>,M0ELLWL2Z/N,ND9+3XK-+66XP'6Z:U
MJ;9J\;E.*AK//*UXP21LMQIDUA9?PM-#:<<(4,(B%RH1XT^?LCZ0Z[B+5<=_
M:84=BJKYMVNLS,<UV<[HF!]=I<3S!0I0O-)?;<&0C,>2&<FM>],8K:Z\5YPM
MR]1;[,JA%WR5$=?"MS6O-YP 7*WMRL&+L:6$"' >_1=R6V\23,@QL(O?,5_
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MX<A LLJ-=! CYA(-"KK 7;.H7+V.05W"OOX5;/]A_5.&5H<Z3:1ZTY6<4QS
M&B?$ F9"H)\)4(!8@( 8".  " @  @206QGH5@"\Y2T+#G#;  Q72 $PKE:2
M*P,A":"WNF6!<X/;'>-6E[@LB&YN?^M<Y$(7N;[%[G&%*UX$9+>WR\WN 020
M702L0+CNI6Y\O^M>XW9'NKXU;VYY*]S<PI>Y\4UO=.D+7.8>U[[0#6YOLVM=
M 92WN@J6+W2+2^#J^G>_WVVN>-WK7?=>E[\"^&Z#@XO>Z.HWM]W1KWN).US]
M(D#!4.PI5#Y98YY0%*,O"6,\"_<V=B8P<-R<:!A6\M/,XDR F0LG3!CJN!WS
M#P!&WL>S],''FLE KL__U*7!Y*H"7P:0R@,"6."B,5J7'."6N@QR 1O;M@&.
M<25KY"4VW\:_Q!WH;X'KIO2DW#CJ?<RPGNOQ%(.,-[EV.<@^W@[%8B+'S[4R
M9=$ 7P)K9E!=<@_)9&W@-#>]CQ4T%,>C)K6#>$KJ&HYRMF'LYK P[3(D(EJA
M9UL;X<;GV0.M[;!9]1EA28=FOK7$T0'$66 3V-!A5QK*;AVH.B&;L>5<$P<J
M6"U9WV?'C;%:ULKFZYW5!S$]*^S9+)&S_L*(Q@1"[H;I'J6!B,Q&0^\88*>&
M#JYS/-MC)W"'U'LRJ-7I[XG2VJR'#OA*@+A:?)=:X0N_SHUQ[#Q5.A'1LU1H
M_RHG3E%KK6VM2S3=4W5\R@0]=8ZD,]^A 1#F XQ9V4M>233WH?%?XLSE4&XF
M=@)0SJBJQ.5<U.4U/4OD9UT;T1(?7^*$+L2+GA,[?Y/X8H6\#S.J9)Z%C;2U
MWIS05Y],L:O,3K)'[M;&WAS*3C1MP>77N(Z3#MVS[M_9P,EPN,>=.O3&,6$Y
M'4  2%S;*BE9P=XM,[:UC^.L?%X?&Y3',]?L;YH( UBEJ1(8Z(M_;_SE #^M
MDL97'O"[IDYB<VY-:N^CJDT,ZVHK%49MN\]@ZB2XG#-*=^FP'&4 N';DUPWE
MQRB6W;>'I__^_N8W\UV4G>4\R $?.'8^T]?_C@$7S)$N>K6W]FQVSS'GY7Y]
M[%/&X346.:)[8KJ]%YS@(P_<*Y69:F+GB/?]4V:3B[S:*^?X>02%>L6Z;$V9
M3R[\U-&VO=&,=].Y)MUSN8]I.B$R-N$SP%T+/NVXOSG+NV[[/T&S-%5ZGZNS
MHFKK'ZW[/,.##OJ;*.M;"6H)G)EYCGY[I\8:OI<;OK6;J/-3P0?,/AF<_T')
M@+V>0C\*Q+_J>PPQ($'_68$E,A:%VJ%M0YOIFRSP2[CJ8+1N>HFRBT ^PA@
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0-.Z,+TYC-FYC-ZZ*@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img43903234_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $8 C<# 2(  A$! Q$!_\0
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M+>TM/.=+>!K?S/-5&*[G;((R0>!T'K38=5OKKQ1=64FIPV+03 164D )N(<
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MR)&8$@+C!) ]1C/>NQHIJO)6LEH)T8O=F?K-I)>::UO':6MVK$!X;EBJLOU
M.#TP<5AQ:!J]M;:5,DT$]U8W,L@AFF<JL;JRA!(06.T$<D<XKK**F-645RHJ
M5)2=V<CJOA_69AKMO8O8_9]6 8O,S!HF\L(1@#!!VC!R,9/!J6ZT35XKO4CI
M[V;1:G B2M.S PNJ;,@ ?,",<9'-=315+$2M;^NG^2)]A'?^NO\ FS@]:T.5
M5\-::DH%Q- -/N]@)#VZJK2<^Q3 _P!^N[    & .@%+14U*KFDGT*A34&VN
MH4445D:!1110 4444 %%%% !1110 4444 %%%% !1110 52-ZX=UV+\K$?E5
MVLEO];+_ -=&_G0!9^VO_<6C[:_]Q:K44 6?MK_W%H^VO_<6JU% %G[:_P#<
M6C[:_P#<6JW3FH;:\M;V,R6ES#<(#@M%(' /X4 7_MK_ -Q:/MK_ -Q:K4QY
M8XWC1W56E8J@)Y8@$X'X G\* +GVU_[BT?;7_N+5;%% %G[:_P#<6C[:_P#<
M6JU% %G[:_\ <6C[:_\ <6JU% %G[:_]Q:?#=-)(%*@<=JIU+;?Z\?0T 3M<
MNL$+[5)=03^5,^VO_<6F2?\ 'I;?[@_D*AH L_;7_N+1]M?^XM5J1V6-&=V"
MHH)9F.  .I- %K[:_P#<6C[:_P#<6J-O<V]Y%YMK/%/'G&^)PPSZ9%2T 6?M
MK_W%H^VO_<6J;2QI+'$SJ)) Q12>6 QG'TR/SI] %G[:_P#<6C[:_P#<6JU%
M %G[:_\ <6C[:_\ <6JU% &C!(98]Q !SCBI:KV?^H_X$:L4 %%%% &9+X@T
MN'Q!;Z$]VHU*>-I4@"DG:.I)Q@?B:AT;Q5H^OW=U:Z?<N]Q;!6ECE@>)@ISA
M@' RIP>1Q6=K.CZU>>.-"U6U2P^P:<LJR>;,ZR-YH"M@!". HQSSGM47A30]
M=L=6U74=>6PDO+\C-S;3NQ5%)"1*C( JJ">Y)))- &Z=>T\:XVD>=_I2VQNF
M_NJ@8*<MT!R>E7A<0,F]9HRN VX,,8/0_C7D^F_#+7M.@N1&NAB=M/%GYFTN
M;MA<+(990Z$;F4$9(;!P>1TBMOA[J>G:QH%DP5K:YN)GU3R5+1>1'/\ :(%+
M;5 .X[< #()P,"@#UY)HI2XCD1RAVL%8':?0^E/KDO!'AJ^\./JJ7 M8[6XG
M$EO%$WF.OWBQ:0HK,"3D!LD<C)KK: "BBB@",.?/9.,!01^)/^%5OMK_ -Q:
MG'_'W)_US7^;5GT 6?MK_P!Q:/MK_P!Q:K4C,%4LQ"JHR23@ >M %K[:_P#<
M6C[:_P#<6J-M=6]Y%YMK<13QYQOB<,,^F14M %G[:_\ <6C[:_\ <6J;2QI)
M'&SJ'DSL4GEL#)Q]*?0!9^VO_<6C[:_]Q:J2RQPQ-+*ZQQJ,L[G  ^M)#-%<
M0K-!(DD3C*NAR"* +GVU_P"XM'VU_P"XM5J* +<=T[R*I50":MUFP?Z]/K6E
M0 4444 4=7UBRT+3S?7\CI '2/*1M(Q9F"J J@DDD@<"J3^+-)C-DI>Z,UZI
M>&!;.4R[ 0"S(%W(H)'+ #FG>*-,?5]$>TCL;:]8R(XAN+AX%)5@00Z LI!
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M:PUS)#,LL<T;*1#*I?Y"K;SC"\8"KU.:W;"PMM+L(+&SC\JW@79&@.<"K-%
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MMW>3O&_'KMZXJ:G:P7N%%%%( HHHH A'_'W)_P!<U_FU9]: _P"/N3_KFO\
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M^1KL%^Z/I7-3_CS]%^IUU?\ =J?K+]!:***Z3D"BBB@#DF\%NWCX>)?[2DV
M?\>^WG[NW&<_=[XQ76URK>-H%\<#PS]AFWGCS\\;MN[IZ8[YKJJWK^U]WVG9
M6]#&C[/WO9]]?4****P-@HHHH JZA_QYM]1_.BC4/^/-OJ/YT4 6JXOPI/:2
MZM)+&[K<3"0&"%D2%5&Q@QC0\,=X&22001783^=Y#_9Q&9L?()"0N??%9-E8
MWZ:O]IG73X$*-YJVN=TK'&"V0,XP?SH VJS]:U/^R--DO2D+)'RWFSB( 8]2
M#SV ]ZT*JW]F][;^2EU);@_>*(C;AZ$,"* )(IS+:Q3B&0>8H;8<!ER,X.3U
MK.R2\A*E3YC<'MS6C:6T=E9P6L.?*AC6-,G)P!@<_A6>W^ME_P"NC?SH ***
M* "BBB@ KG3=:8GBIE,-U]J!(W"-BF['H!Z5T51[(?M&_;'Y^WK@;L?SQ652
M'/;R=R9*]C&N-4N%UR"-+5C 0/G-NV['<@XSQ4EYXCM[2_BM3;W#;\9;RF&,
MGL,<U6OTM'\3VX>:99<KD*O&>PSG^E7-0L]1GU6WGMY$6%,9S_#SS]:YN>I[
M_+_-Y,SO+6W<DNX["^9#<03N8S\O[B0?TK14AE!&0".,C%1SW5O;%1-,D>\X
M7<>M2UV)1YG;?J:JUPHHHJAA1110 5+;?Z\?0U%4MM_KQ]#0 LG_ !Z6W^X/
MY"H:FD_X]+;_ '!_(5#0 4444 %%%% !1110 4444 %%%% &;H/_ ",VJ?3^
MHKJ*Y?0?^1FU3Z?U%=17-A?@?J_S.O&_Q%Z1_)!11172<@4444 %%%% !111
M0 4444 0C_C[D_ZYK_-JSZT!_P ?<G_7-?YM6?0 4444 %%%% !1110 4444
M %%%% &)XG_Y!T/_ %V'\C78+]T?2N/\3_\ (.A_Z[#^1KL%^Z/I7-3_ (\_
M1?J==7_=J?K+]!:***Z3D"BBB@"/[/#]H^T>3'YVW;YFT;L>F>N*DHHH ***
M* "BBB@"KJ'_ !YM]1_.BC4/^/-OJ/YT4 332K!$9&!(&,XQW..]<SX8MA:W
M9B^SP[EC8?:!9+'(_(Y9Q(Q;/?CGK733017,313Q)+&W5'4,#^!KEM"6-/$+
M+;+L18I%E246@8'<N-OD_-ZYW<=.] '6T444 %9+?ZV7_KHW\ZUJR6_ULO\
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MR> ,_E[UI4441IQC)R6[!))W"BBBK&%%%% !4MM_KQ]#452VW^O'T- "R?\
M'I;?[@_D*AJ:3_CTMO\ <'\A4- !1110!7NXI9X'AC$>R1"C[V(.",<8%9>B
M:)<:)!+%$\$IE8,2[,.G08Q6Y10!AV>IP7&K7-M;+9?;%SYC ,-^.O..<4RY
M\/-=:U'JC^2)4*ML$C;6*]#TSV%:D&EV5M>RWD-NB7$OWW&><]?I5N@!D7G$
M'SA&&SQY9)'ZT^BB@"EJ,5_*L?V"X2$@G?N'7T[&J'V/Q!_T$8?R_P#L:W**
MPG04Y<S;^39T4\3*$>513]4F5/#^EWEI=W-W=S1R-,,$KUSGZ5T-5[/_ %'_
M  (U8JZ=.-./+$BK5E5ES2"BBBM#(**** "BBB@ HHHH **** (1_P ?<G_7
M-?YM6?6@/^/N3_KFO\VK/H **** "B@G )/056_M"T&,RD9Z?NWY_2@!;VVM
M+JV,=ZD;PY!/F' !^O:IHXTBB2.)56-0 JKT ]JYOQ9=:9-HX6YNIH@)05\N
M%B6.#Q@X[9[UHZ;?Z=!H]MY5R[0)",2/&PX'<\<4 :M%4[?5;&Z4-;W(E5C@
M,BL1GZXJY0 44C':C-C. 3CUK$_X2(_] VY_S^%95*T*=N=V-J6'J5;\BO;T
M%\3_ /(.A_Z[#^1KL%^Z/I7 :KJ4FIV\<*6-PA5PV2">Q]J[]?NCZ5A0G&=:
M<H[:?J=&)IRIT*<9[WE^@M%%%=APA1110!QSZWXD'Q%72QIW_$GV_P"N\LXQ
MMSNW],[N,5V-%%:5)J5K*UE]_F1"#C>[O=A1116984444 5=0_X\V^H_G11J
M'_'FWU'\Z* +5<;X?TOS=3AO);!6!C,LL\D, 0RD@JT)0;L<L<GMC/-=+J\]
MU;Z5/+91&2Y &Q0N[J0"=N1G R<9YQ6+X6@@@DE4Z5):W"E@)_LQA21,@YQD
M@$D]/8F@#IZ*** "LEO];+_UT;^=:U9+?ZV7_KHW\Z "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ J6V_P!>/H:BJ6V_UX^AH 63_CTMO]P?R%0U-)_Q
MZ6W^X/Y"H: "BBB@ HHHH **** "BBB@ HHHH O6?^H_X$:L57L_]1_P(U8H
M **** "BBB@ HHHH **** "BBB@"$?\ 'W)_US7^;5GUH#_C[D_ZYK_-JSZ
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MI5L$>HJ]10!4O--M;ZP^Q31GR,  *<%<=,5)9V<-A:1VMNNV*,8 )R?6IZ*
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MT-/_ +/D_P"?G_R&*5+.6-MPN!D>L8_QH 9)_P >EM_N#^0J&IX[6:6U@S<
M80=(_;ZTO]GR?\_/_D,4 5Z*L?V?)_S\_P#D,4?V?)_S\_\ D,4 5Z*L?V?)
M_P _/_D,4?V?)_S\_P#D,4 5Z*L?V?)_S\_^0Q1_9\G_ #\_^0Q0!7HJQ_9\
MG_/S_P"0Q1_9\G_/S_Y#% %>BK']GR?\_/\ Y#%']GR?\_/_ )#% $UG_J/^
M!&K%5H[>:)-JW QG/,?_ ->G^7<?\]U_[]__ %Z )J*A\NX_Y[K_ -^__KT>
M7<?\]U_[]_\ UZ )J*A\NX_Y[K_W[_\ KT>7<?\ /=?^_?\ ]>@":BH?+N/^
M>Z_]^_\ Z]'EW'_/=?\ OW_]>@":BH?+N/\ GNO_ '[_ /KT>7<?\]U_[]__
M %Z )J*A\NX_Y[K_ -^__KT>7<?\]U_[]_\ UZ  ?\?<G_7-?YM6?5H1W'VN
M3]^O^K7_ )9^[>],_L^3_GY_\AB@""BK']GR?\_/_D,4?V?)_P _/_D,4 5Z
M*L?V?)_S\_\ D,4?V?)_S\_^0Q0!7HJQ_9\G_/S_ .0Q1_9\G_/S_P"0Q0!7
MHJQ_9\G_ #\_^0Q1_9\G_/S_ .0Q0!7HJQ_9\G_/S_Y#%']GR?\ /S_Y#% $
M<'^O3ZUI522RE1PPN.1_TS%3^7<?\]U_[]__ %Z )J*A\NX_Y[K_ -^__KT>
M7<?\]U_[]_\ UZ )J*A\NX_Y[K_W[_\ KT>7<?\ /=?^_?\ ]>@":BH?+N/^
M>Z_]^_\ Z]'EW'_/=?\ OW_]>@":BH?+N/\ GNO_ '[_ /KT>7<?\]U_[]__
M %Z )J*A\NX_Y[K_ -^__KT>7<?\]U_[]_\ UZ (]0_X\V^H_G14-_'/]D;,
MZ]1_RS]_K10!H4444 %%%% !4-M]V3_KHW\ZFJ&V^[)_UT;^= $U%8GB..ZD
MDT?[(5647X.YXRZJ/+DY(!''X^E<U+=:SI_G1^>MNDVH7)FN@AC4,%38!E9,
M _-VYVXSSB@#OV8(I9B H&22> *0R(J!RZA3C!)X.>E<'J6J:E//)9%YG+VL
MD5Q&J?NW/V5GWHNS(4O@ EN3D8IAM[EHK^V^U7BRO+ISPQ,@98TW0Y= 5[$-
MW/0YH ]!HKBGU/6[>Y%CY\TAN;F2QMYI(5RK*0XD.  ?W9D[8S&/4UI>)7N=
M-N+;5[*%YIMK6;(B%L^9CRR0.PD"@GL&8T ='FD1U= Z,&5AD$'((KBK22]T
MR]ATJ*ZN-]O<101VOD@I-;E5WREL9SDN<[N",8]8]-U2]T[2K"Q/G1NUKIRV
M\?D$GYF"R]NPZYZ>U '=45P5[-K=QHMR'O+TO=6E\V(XE0Q&.0",)A<@E21S
MDGJ*M-J>IMK\%O;WZBTQ ;=YC_Q](Q_>$@1G<V.."N."1@T =G17 V6I^(;J
MTD+7PBN':!)8ECWR6SM.JMA3&  $+#DMT!SW.YH]W=#Q!>V$]W-=I&F4? "H
M 0-KC:"'.2<@D,,GC&* .@$B%V0.I=<94'D9Z4[(]:XN2.\FU1F@*)=+KN"[
MQEPJ"U.W(!'&"._4U7!O])BFU@PR3W$&H7,,B11,!(DN I"Y)QY@CYR<#<:
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M(+;3TQQ7H.JL6N/#XD):)KL%RR[26$,A7(['<!QZXH VV8*"6( '<TWSHO\
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MR  3Z @YK&TW7?$6G>#M(MVU76;?98W):;[#YTIOD*A+9@8R=N"3D\MTW<4
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MG@#TJ;5-'L[:U\62PZ9#'S$%:.W )0QIO P.1UR![T =X"& (((/<4%E! )
M)Z GK7+Z1\NJ7TV@6D?]F.D0V,6AB,N7WL@VG^'8#@8)[Y!K,+1S:L%N+.&Z
MU234F2:.ZMW9HX!)\C1-T51& V>A)]: .[# D@$$CJ,]*1W2-"[LJJ!DLQP
M*\WAMKZ)[G4Y+8)<7%G<W%LT$#+(S2R8"S'G=M#1[1QWXXJ:2VDTZ#4-(,,I
MM]+L)+6S9@2)?M! B4$]2-NSV_&@#T2BHX(S%;QQLVXHH4GUP*DH **** *N
MH?\ 'FWU'\Z*-0_X\V^H_G10!:HHHH **** "HXHS&&!.<L6_,U)10 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img43903234_14.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_14.gif
M1TE&.#EA0 7T ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MD?(8$N\SB79?;T?TQ.&Y*\9Z9VOGM=0XU$/0>DH75''8?Y7_/')%>E?U,$%
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MM)]KTSE1V0X!#;.)FL5-+[*M([2=U+EMQ-\=%+O=S[9<$\\MV=B]$GE]$9F
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M.EX84<[GW,B7H,Z6.-[A29X1> X5+XW$KWX_EHX0T>T2C%S)E(W/.5WE'Z'
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M4#_:0,,S:(!61XC_L9EI5:LBHI(?AU25AH&D2FM=,\UIVE$UI(Q,(N][2L9
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MZ_4%OL4:NK##)+A&!5)$\JT$=/U:3)C5H&7@2$C?MJ2)ZY"/^:$@0W"@=P2
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MQB$T2HC>!:5O1,,A4@0^>B12^B$T, ( 1,T&PIU@'<3ZN5V[/80_2@T[N$,
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MRT,  3' 3Y(57K5TI5%L*)6TB"8B(WF<Y3X0PSQ\4=6DQ5A0Z7T!IU4!0&_
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MEDP&_U('<\18*J (/R(I:F -J\1'P,"I,!5BWH:L#A(5^XSUQBN%Z$:6,$N
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M3[U/8EM/A!RV7X1P2Y;Y<67[18#$1Z3P:P:N!C%P"9Q^NZ2 UZIX4+ K(0!
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M;_VP1-TA2F@?#L \O 4Q"OO;ATK$B2B55STBDIW=LX+9_3?<(V)O:"P,M-0
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MB+LG3>R)MLIES7*Y:Q!_&L1"PIT40?9)7?(2N"#(,H@!F(N@_;)K3 RN_U^
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MEAM!&<(;;M(W_S\T_##/S)_5IP).[[]XPB@TE8B([$]N0>GK*852Q06JWA$
MY?$),QU_8C-K_&!2S1.$6R00):/IGA%B_ZS\Q,L> =Y7%H!"M04XT-]6,RD
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M^&"$$U:X44P71E2PQ;9M"10 AJF*70N)=0L K[:DJ=V1%NO68XDH'%",%6+
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MGVH2I5HQOGF>M;"89<BS*Y.S%FVV06V(R^ W QPKV>$XR%J(: "MM8&>FS(
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(WSK7J1X0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img43903234_15.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_15.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M]F/4I*%TGABQZ>0%N!)VZ+DWAGWQV3<?>P>F,9^!#!J87X,()N@@?/QI<IV
M'&84GC+G,5C?B/)=:*"!9$CXGH@'3HA?B?-5^!Z*\:FA(8 =YIC0,L2@1]^*
M,S;87HH)MFBAD1.J:!][$KIG8HQ!$CGB?OPI(_^>C@+6 R(E]UU(XI<R2NE>
MBE(.*>&#:-ZGX)=#JOGBE&-H&!V6R_7H99M>.FEFD/@1B:**7^;08AJ"=KG@
MBWHZV"21C [*YGX;TAF<EIJ(:-^312+9(GL(ZM!BH0Q&2.:;A]X)GY>>OI<#
ME'R>6M^)H\(GIZ2Z\:A?D6-V*>2+$8XAZ(E1WO<>$&ZRN"I^#%Z:IIXM+ENA
MC*;NIXDRM,ZVC"9*.LIGLF<BN>:$WU[('HLFQE?N?(7FZN:!/\PH(Y!X(J@N
MAII4RUJ/])4[8K+"^MEGNV\&R21\ #_JJ:E17I@#A*V^"A][.JAH:9L/-OLB
M?_:6I@PE$PN;)(ECIA'_<7V"RMNL@\>6:*2H"/] )*<>*_NJE&2D.R*Q[QVL
M:I^N:HIQQIV!>-_ X\)+<)O" @MNP">F>E^AOM)7H<TOOY@JH/AY66;6@YJL
MH),R4D(MT)9%0PS,AWH\M,51,PDEJ[A^&S69BJ8X;AKZI:%HT5N/<76)!\-]
M9JYAYMHNC>XBK<F<9#]&#)<]/RSDJ"CSJ:BN6:]*Z,Z^XBUM?Z#\MPP]X34T
M'33;A:+A>1Q?#G74%#/M+K"I0LEPOS,2$TWCBM53::95_RALQRL;Z?2FYTV[
MC)8,Z6/0E1#5HP]U/:)7=-3N>1JK?<>:C)_32WX\HMB\%[9QC8BN#3:A+(IO
M_V"J"[>7(7<7T2.0_0+I WU%W!538'SIBA_7D.8J]A2,/J(: R6(43[ G"U]
M#H,2\=#'HODX#6^S8AQ#\%>0W8EG=P,!X3[T-\(K.2]_*&P(>*Y5H#6Q2F8P
M.U*95&2@Q350+YJ0FK9V%4"* >I8\4O#>9:W$.D1Q'ESVIW]HH&_$^Y#>DH4
M" A%^,$K)7&$*5R(=W[7I%]!:W*<:Q2_F*2)_=T0+M>27/K@MB<H";!1*YK5
M$>=X/RD^42#B<2)"-&C&*XD'&@-QHO/$X\=]0"./*=0C07JD!G[A9V$(NE0;
M,7<?\IW1+4(#$Y!^-0:7)4UX)1-BO119$/R!IR!0M/]C'?<Q)R.B4(1//"$I
MGPA"1$Z1('-JI1:O1;A3Z8R-(3N9ILB0B6)<4BUI=)B+).1(<14O5U5:B!Y%
M.,AHZ-&4^]B=++-92!*>4!F;&-O]KC4V_,'2B&9,(2)=:1!;(6Y&G&Q3R1JV
MI]P=LRSG>Q3)D(2UAI'A#9J )1[Q.$A:^K&@YRS(":$'/7W ,CS1@ ,0U "$
M>K%2HA05)T$-XLTK:=.#V0PD0LR&K1&YT(OO U(%Q94&#=Z3*[[C&;*0U*NN
MC8%8E2,#'/YSD"4Z[Y98#"HU:9D_$/(QI --ZCZ(02P@_  (U-)$Q)P*A.B$
MQXG+0*(JK:G4@51QHT$5"'7_2AHD9A6P7_VTY$NSDDQ)5L@]'6M??,[S/*UZ
M=2 <%*M7"QK4*W'0H4'5'P@!>T(X/)6B-MJ'82>JAAQH5*!.+"1>L[E-@0!R
M(=71!+K>-J_\"(H]H721K%RZ5JD0HTEP8A34X J?S\91HP@![&0'$IV%AO"N
MLD5E5TEX1X$TDJ)IJ.@^$/L#BFXBK.B<[0FO2L6[)O64KE2DC^A)O+ZE+4ZD
M+2U3B#$E2;I)7: :%"5<:DJ[WE&PM]6C;&WYW"C:,;<(,2P<R/!4!BY6#88=
M&R*1>DIN9I$@AZ3L0"Z[W'0.!$3<0I_2*)>I25A4NTQ11M&R-:J!J1&T8W"P
M2S^H.<I5BM2YT/UP;^D(0@Y*SXI(=)Y4,2K<^1:7H@_F;U@)LC_PY!7$7;TJ
M*Q5)##CDS+.G8F/QWI0&!O]"&"DQ+9*%8>>KZ\Y5@Z0LKRK[&UT1DZZW/S7Q
M; FBS8.HX0<^=JHQ*<K8'QA3J3^-92R-.N-5<C6$LC2P03))HHJ);(! 8I5:
MCRR4DGYM;4FJ&+QLE-U]+/'&I1,IAUFIUQ%SN;<??31X>"M"#LY7HD!H<7#Q
M!@106#9_NNPP"FLL8T;SUH2F9K1T.G@V8*WV4TY.7)SX7![(S91=GXK9SM2@
MNT0VFLMY)>%@.0IG/P(2U0=U-(WO"$O#-K*X]:)H<>&0@^A(5M%8W)\2NZSF
M_PJ4CET5R /3Y%9F$M!+L*4U3G)H4K4QC&XSXO5(V6O&Y?9UKUB&'F03\F:^
M5M;_B"LNKJ89*UQ2"ML@ 5ZVI*4(O26Z\MIM9F4FWCK,UQ%P/N-5-TZX*VB&
M.?-=3=YS0=-YPH2'VJ-KMN/^O,GL*^D7I*J^;"U5^66I.I6!9$Z#1(U,V?YZ
M4*N"1+6._XM07$KQIW9EIT"$=L$].3/(3>*YQF/B.YK-ZWA]@JN@]HSP;A,R
MMD?_KRNUR;C^$CNPNN6P$^&@ V>W^+!JT(&GD\K7#CI:H(G6Y9L-#6YE@_"R
M2\=6]]3&+HIC/-U35\EIS?4J 6JM55P/<%8[N.A!+A3F?OQV0DYX:.?V%M7W
MOB,<\$L&,0_WR_C]P9P4R?D<)Y>WZE4(7QNJ9HB+E1*P_W)18]\40PA)/?$I
MR6'%V,@J9GE*#1H]]D%H+]1&"Q*IJZS'L4]]6;-O==%<+1TL"YL#B0:W7O>%
ML5<]2/Y/EQ"+>/<K'JV)XJ_>$KU(=6*B#ZR)0L6S>.'E9Z&!#Y+%YZMS'7<@
M*9,?OS=B"W59"?=Y'\9A>:1O!L%M<Y1L@75MWJ1!,/940(!S0!!<7R9UL^2
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MX4G\ C"<8B )R6?+ #GEZ29I(V_C]WD)I87Y$PRYBJ8#D0PK4*9/Q X"(+3
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MRK;;> I?C@F+_57-# J@%]F&PIB8%BG1O@4$U%9S7CE1;Q"6',50_SF%^W;
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MR/0TH,(\B=9(NQ+5(V;9NOW/J>;1=A  ['YL\3[I?9@'<$YF"Y@)%X\&78"
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MT3[L5Q$JW53\!RU*R+BYJ)4J&'!0C7\&JNHTX;!&4H=>1+OIR!AF$I& 2+^
M4-L$J;:2D. =C& %HY98$(+%D0*>).&T%3PJ*;01D_:T:Y\=QO 4U?C D(W
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M^P2K\34H.21#W1!W=18RYB"7+_3.,I5)QXG5*5'+2%MSINA*]+RA4\T4WJ-
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M6M8"8UXO),'JT]3Q*J0GT(HI Z\*0QH,K3*A*5%"VAP,6#[C*JYG/?;-!.'
M:*)"Z?2Q4';F(IXGO>"&UBBNR9",D CI&0,O/[KPHM3%)F\R_JS,OI81L,9
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ME).QQ@#J*I/)%RQ'-R98ZK2GP^5IP# G,<ULPC3 00[C]"%+U3")ME8R3)_
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MN-J:/5Q,-EPSU684QN14!>-MCN9&L6-S+5;Z R:</(VB"IE:MA<GV9R<1 R
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M#)R>)DA+#N1 &CR$BJHF@^:*<<"%)F1"<N#6),B KL+JC:I992C#KF[IL\8
M(PC8)$P+L*8!+7''S/WEX@375/*2G (8RZ%2G8 4.75,X4$=J_ 08WH3>>3
M 5EJ>,;,ZOH0'5(V L.DJ HAJ%F2*_7,WH@P3%QH K R;*!EUIJ^:JYN@1BL
MA''M1)-:*[9. G0Q;,>FP5A)6_WP5#/]*L.J 9&,P19$++9F G72'&!4ZZMF
M+!=HAC*4;,?:!XDQ2G2ZU/>XR<!6CVKR$L)^&9P9;4844>_PB%;\RN<@966N
M%F3F:Q5B*L_XV;/$11.Q*\CN5B"!8_6D'M?R".]X!;=V+,-JAK->:ZR*P68Y
M(.;<ZK5NZ<8*T-GB;+[15&%2C-JDCMT&*V?<*K1NZ;&8""#50YL*KABDA3*H
M@=].RVNUS8CTX'7R#8H9C8!PA)&D*KP29A^%5/TAY5(0_^74SF/,7"VQ4*'-
MQ22#VHH%H=:@Z0H &JHR .L/U&['NH;,(B[%AM97[H,8Y.H-[.JNTFT]V"ZP
M)D<F=*P^:E;3D:1(E*SMENPW_:[@/NL*A*+ %" T6"^4R@"U-JPR@$+)JN*3
M$ R<>%&B[8JB*AZAJA&B)>*J()N+KIQ4JB2PE61+C(=1Q.-J&<7]D6X5#A 4
MCH'0+0772$EN9J2K:58ON>0A^HHZU1Q(E.P80,,R*"^P9L)9J"VL/FG;^NST
MQ"VVZNH;&D3XJH$R'&\."&.B4:6<A=_RPL6O!MIEX">>7JN@9029 @^VCK!^
MG@5\-.PR. 3NYA2Z%2%7M%,@[?_$;W(,]R'>)#[5:QFKF!6$U9XNG@4P>!*=
MTT83&>0 )9#8509%=*SCUFT5.IHIMD0O,:1PQV*H]88!"_!NC @,5-QPKNZN
M?BZO)O0M\F98I.%4X1%#Q\)'$0,K#N0GQ@HORS(B5M$##I-P# AHQZ:P0^!
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M6YH-69FE.VYI%W?_5[H/.8&K-65A-JLGE5DJC*3')U6LT2"[,(26LP\E^%Z
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M QF3 C9$3$8<169@ND5):T@U,?4]1I(OX382%085\S W+\=J#*15YXB40*5
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MNSF^RXDL);Y'I[&O^CAV-:UBK)+%.\+\=S0V+**?R*0GLFGV"<FLO(+18(4
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;-=(C1=(D5=(E9=(F==(GA=(HE=(I7:N    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img43903234_16.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_16.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MPV.(Y9 &,3&MBEBKKP(UB0R3J#0)9JY^B:E%8B"0:TB@'):1,F,\5BM!8^"
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ME$C?AB.[$H$)Y)-_A))AN$4=:)7C-8-&=Q#%IQ#9Q#^EUCT?4Y&UET()D@9
M5VELEX%.-RSA D?59A#UH'))$8MJ_V1]3L& ?,<HW6B0YD,,X01Q/%DMDR!=
MOT.5>*21E0)KH@%0R018@QDA(;4/A7B34U<0.LET1RE%$E5I09F"+VD0%>9P
MF.@8G:(HY/)STD,,L?4&)+917/1:\Q9LG0F6:--H?H5= R<0=&E@>..20JE*
M@1EEP7D0TH9F]N=&/Z-O'R1V$OAM>S<E%REI.TAOJ\*/3D<XNB2(G6*36">
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M-W#M0=X ,YQ2\I?T(DU:]Y&&T 28)?A\""01XEPM1A$B., /( T26IC,_]+
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MU0J0Q:1TS20I1+1Q%W=&"'@^A7>BQ6;NQ=68XSHVEDGH9&DNR+TDI6&(H$9
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MMFZLMW2LM7YLM3ID0Y8L]&A4N6(LLEH5&H!KMJAK,BGKQ1[DR1K7:Z100P5
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M^'O[M1=QS/-&/O/$A[4(^-^1/U[=F'N%W&;HKQ?:Y]<+31E\\DIZ[KD #@!
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MI4']CA7I[?TLPDF2D4*'TD#7D;_H 0<"H"MR8JD \B>G;QF"PCADH@T+0AD
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M*%*"+&_E..!IL!9@S?[!:M7>V4(ZOE*$T+?\[QXJZ[L,(O]"O] DI*4AR8+
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M*&K*P-# !F1H.2>WT9>.[N 6;1Q((V740TFQ=VR(Z3;AC%OS*A"K50V4(Z\
MU':\ 8 E3303ZH;$;;[S5&W]:O^62%KE,5">C0V4=O4ZN6@ @*[]HP_\@GG7
M*CYVFEK5*FTB\;6H0;&C%\02&F/FQ@0Z\B:Y'19W/VP2!@S56IZ<7''+ZMRT
M+C<Z!:,^?</;0#@;TZP#;O P$_O@AU%8  W(;X5#/.)Y"0E"+)44YZAS/,!&
M'5H#]$$.*H88WM7-SU*2<(>DF2*9<#7$G2UQQAQ@7Z'-F!<QSA#_C7<<;"$?
M>; 5<V&7=Z4A)A_@SM']<L<TNCY1*W*P>5B0FP7&E(]Y@R3D/0FW*;W=_LKL
M!X]".*!O!  73@.6:".UDS.$2'8E"=&(IF6#@_WHA=$,4Y(6]Y*TJ"\F0X-V
M6/8DOW@=G-;!4$J*O)ZH%<< E27[VZ(6 +1K<+1<^KK</]PDHR.&/O:Q3#F=
M;._%P"TI):5'O$2&&K+1IHZAI <V'R,T#%G27 P'6I_MR:T81QSRE1^*/C2A
ME+N;1/.,U$3!K<6H!/]X259A_3*'-[.FW%'JF!$:66._E=F?'C""4?WR6[_[
M_06)1! ,2Q@X&"CO?"IW^"Z,%'5)$H*&F>;QQMH'IKS/&/HD9&:=JJK!,?_]
M)0:)0!2+,I2?;K3?>+R?_Q'8^0G7VWP>S&')=-0?H[B%+F$)_/W?8R1+7>C>
MS>')7FA*L81&&J1,O7U09I6*2]1*JN1<8\2-ML"*K.")D81@3[D;\&6@4&2;
M)I2@<WR@092()M@@8RQ+L["@;L@5#5F+7X26;AA MKP*0G!+"B9$K5A)"__F
MX&&(@0&AA-8Q1CE9B4<DC!>Z%)Z@'UUP&FJ$TE70 WSL P8^!D%-1^#8GQ#%
M@#^]QOAAW\$I8!8"30PP'23U85[@#'/ R!YBQAKN X^X(1RFE1DVX)*LGV'(
M(81X&W$HXAT2E"/ZH6$8 ,OM0S34H6-DPO# %U.,0<9<E6,4Q,P 0%08C/0U
MQE%@R&;0G3[$C*?\6)1Y1P TAP YE=?,!AI8TL.Y6P=V8DF08)S@H$:4HMB0
MQ8^!!M;4XEVL!RX&3IZ(G@' XD'(HF-HAM>DFB\&4^( !MS$ "A<8RXF(V)X
MWQ.>FNB4!D;LQ"06ACXTB<8=!3GJQGVQ"R@DQ7W_;$ZF3(;(#0DQ?F.'F)P*
M,=D-!.+!-6,[GD3Z*83Q'4?]?,2G8((4]>-D'$Y *E1$.@0]Y.- ["-+A8Y2
M9(=!P%E"SN+O"02[A*1$;MU*Y!!-XF3_B&1.9H1$U!Q"Z,/)\.10'APM9@6)
MN"11*J7:(.-2*D3=2,)VT,80.F55&IB9\86?+=,26MU.-@3S+"&U-.6!=)?5
MC65"7!AD4<MQ^![79997MM-95J4F,<<JBE98RAM<-L2(=.5DR"5"H%A?\AS&
M69W565YAFM5?6N5BC$&"%:9>)L3>..82VF7HK(=28(AI#5!]),EV/6 ]G>-C
MRAUD+J:!-":36!9IHN5E<$X"687*7SK(.7+=)& A9FC"<65"U5&=/1[&45S,
M8RIF:18&._X', [(%A9(4M8.(&;A( HG4XYB<2#GON&(4*H7%SZG68!(67[F
M8H@@@"C;@/0)@8#;GI%A[F5G6I659U7F09UGGCCG8KP3@40GH\3_9WIF1"F&
M@1@<%PX8 &\6AAOV6#9>TGLFHFHZ!"?*W7WBYTEDS.$A15HP:%$(Z( @XH<9
M%( 8XY8UZ%/@#)C4BSD. R@0PXB.S@"Q!S&0:#)HPG2%!D.*CXI.Z%#4 WO$
M*(G^9<8LTH><Z,LA*%%*S <I)V, T7:8:'!2TG:(#HG:D;[(*(NZ*&IHS)+V
M:'%XC9(2PR?,:'JV"AT:1U0P5$[%P'$9!VX(C0$H5/(5!T(: $0=@.(Y1Q@$
MP)@>  SDU)=NAIB^J8%BVI9V:$;(FP,ZV8]J1D/I%)D>A]2L )K:*9R6:4[5
M:9IVY_T1S9M&:GT>TP&HP)M.A1']Z4L$_\Z'%D<Y_>BY-("?/@4TB=<8O)UQ
MN-+_!2=/YB9U$(KUO"J J"KG'(UZV5F!Y.JG H5%DLB%\6E>R)2OHJ0!+I=_
MP.. E%X.EBI/=I[)B-R0(L:Q&@AA(2N.8&IL*"BPOD0TE"#U"(U<$N>>)>L"
M1:M"6.MCT .!?M^ZYN0PX,5]J*ESP.LDR6M"'%EUQNI"A">XYLSC.%=[$DR[
M@B-51DNZ0MR_"JQ\,BQJ%(S#)L0P%0C_?1C"/BR;C,<*!%5!1*QA&$E$H91J
MTD94\85<(AE**2QB1)''HM2D'AO%;FQ>0(,8P&Q%A>QAG"S+_N7(5I3>&4??
ML.QQ]&S0TFS 85/(WS&MJ #H6XQ(:5&&:@X#9G$7XVVEU&IF%4$6=X4*)C@'
M7TW"7"6/C]:L8]'59# M6R7#@G0E7_THN[35T!7', S77+T!JC[;94V"U_K7
M6VX7W?^>[4QP5$@5A$9EZ. J;H<L[DV0"%&%U IIU+XV;N5:[N4"3])B[N9R
M;N=Z[OSH[>>*[NB."XAXQT^2;NKJBNH^!(G@'NO";J_0!X;84^S:;D_>;A5:
M!FWL;.[Z+LMTX>\*;X#X+CO& .H.;_(>1[.&8KX>3V3V!D\XJV*."%DP!Z5]
MF,$ZQC"HQFUHI<11KA^B( U%:^= KV^8VD420ZN.VU)XKX%LAYJ]!LAB[^6"
M6[="3]S@P(G\#PY$J7?VA&88P'J<)9P%I+5(PC6*UD)(C9V2ID3( )-0"]&$
M;QKY[GS2&SII4TE5B/\N$\O!S9SV;EYD@L=.QM5*A5RB2 -8WZH:#H]8D: "
M;RXVX6]U!0H[7IRG](<8M8MHR4"K$H1N:!-M(,0\I0MVHN6NOISFYB!W5:0;
M7!E:KD "/2U7B $1*4CN%*MVRA]#;%&65*1,[ 5INA@0M__LPPXP53@4#,RI
M33FO$,V@" 'D KE%#U=AZ)Z$,6KL4S!O;B"$Q/QAZ\KLJS%Q!EY'0G'JG+:I
MX-EF =**0LRQ ;9M=RC'>2P32[TN:O0Q$7UG:.AQ(7.;[6Q58IDO:FB(/R5+
M)SM&H#H9E&1P:(QG0\0R9F@3-I7G+-H@,3@R^/XN8_GR61Y D8W?G=AG%?;$
M+&/&*PL+<=3R0DRALGP4,BMO7JA&D0E,=T QDM0QE%"=NC[$'A?%"RX$\VK@
M&U\H'T[S@*@0UB$0<TR(2R!7=XRE8<T$:8HS% H.$K,K*%MN"?T8B80/B90,
M:KA!<F"":F#G%<M*"R_)&>=%7"S_H0H<B$._A4FF73K*'3_GKM2LD4A8#7DP
MRM)6Q"=D"_LV!AA1Q/$2QW]R'0P4E#GN2@RE<^:IT$@QR4,^ALAUUBR=:TY+
M147QVA9S!640UW) 9C00X\=:1 6?$![/=% XS@HQ1R8@+]CTI3^58^*( 0"@
M5+D6!]\FM&I*A$IQU/ \]025<N*HU?KBB%,#EEYI= 0Q]5GKB%O;!(HUR?=Z
MVF%F%EO3]5^?K5T#]F 3-DS)XX<=]H#4\'#V!%G,Q>[%=6'[U[]FE?8*L9?U
MQ./&LV2[3\#:)EB4(M3@4KH1@R8D _HDP^-5Z6,4C$*D!;U&!BBV'&>3DC3G
M-$TD2M8P$;0&EO9IHX\!V(_@N 5]R XC_],V\+P&![496^ ,Q<4&55B$38DI
MFCZS3Z]F LVU7!]W(8UV.3-)4OBQ?C#S $,JFEI$FTX($:5AIVTWQ*3!(B_R
MF\[I0'HRX-VKZ5F,&#SD8D-M'$]T1K>W_MR IN84 $2W@<><:)4(]:#2ABY&
MU" O?^=%Z^"2;0<XKV2,**-/YZQWE*A@3VPV9K"%0DQQ<4QA)!/ST47VA2\@
M*6MXA<+59<PG12KW=[SQ8X0H!L(XB_>*,E>D/M?396SVCH.'&TJX6:@&HC!G
M=XPPF64WC[.?,EGX1 4*C<]GC+CA+?\AEHQO6!PYE&=K3%<Q40#R&[@$\RG/
MCVE(H@*&D4B"06DFKL(].9AK)Y&K"G&TBM7L\\ZH^9>;!=VQBXAP[V[3^:3H
M0U7+BV@)B"*6:9-UCVH<%607>OLL@XO*Y3"\$3T;K:,?!SZN!@Z\^:1_*C2,
MN>(*MJ@K):FC^JJS[IRS^JO#>JQ'T*G+>JU(V_JM_]**X_JN\WJO4XJK^WJP
M"_NP6RBQ&_NQ(SM:)_NR,WNS_XZN.WNT2_NTKP2U6_NU8_O%9ONV<WNWAXZW
M@WNXB[M0T/JX0YO[N1,[L*/[NK/[7Y=[N\-[O(LZM,M[O=L[Z:K[O>O[OF]N
MOO/[OP-\S=)[P!-\P:?GP!M\PBN\4OK[PCO\PTODNT,P_,13?,5;_,5C?,9K
M_,9S?,=[_,>#?,B+_,B3?,F;_,FC?,JK_,JS?,N[_,O#?,S++?S,TWS-V_S-
MXWS.Z_S.\WS/^_S/ WW0"_W0$WW1&_W1(WW2*_W2,WW3._W30RE]U$O]U%-]
MU5O]U6-]UFO]UG-]UWO]UX-]V(O]V)-]V9O]V:-]VJO]VB>S?=N[_=O#?=S+
G_=S3?=W;_=WC?=[K_=[S?=_[_=\#?N +_N 3?N$'&_[ALWQ    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img43903234_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_17.jpg
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M@% * 4 H"JJ4.%3&$TY\0LK)KR&<*+O@I1,X29,)IER2E![MAR/[,YINENK
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M:S@X>'CN["PO6B>6WLSKS".PS:*"HJ)-<6LB3""&?,A#GT+!X-X@M#()X?#
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M02"(":3#P*.2"$*Y8%4H(ZBHYP-/ Q#*8&DE,,8@V%(%<P@/9: 4 H!0"@%
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ML3)&L; ^-%QP+7SRPROF%G:V-[6[M <:,\2W1 E<MB<V:C@ID=-!D2=C)A6
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M5H\L@* QJ[X<\'8+[0E'\,4KSFPI[X=;>5XWH0SW)W.^\E@V\FI;[6.1)KX
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M8L:&CVHYJN8KV)C(CFJK;41R+G,.7]: XBW_ (;JU_IJ_P#_ )=K=/L:U?\
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M,I@XU?F5B'[437Y35ZK=NE/!RKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@%
M* L<X4O/28/1N0?R>JUN+ /ODT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP%
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M:GXX@7,,W;]D79+X-/.NVH#W]H7E:CN>03HJS^#58>0Z6YA,'R@:M$4K% *
M4 H#[$R-^QTKZM(_A0JJ2_W;OC.\ZE[8?>X?Q&^BAY*HDRF#C5^96(?M1-?E
M-7JMVZ4\'*N\MQ>81B]6X.\/*Z^2,+US)&;ZJ<'J,* 4 H"QSA2\])@]&Y!_
M)ZK6XL ^^31/S.E_5TP5>W8F\36+E6K?KJ4-8E7V/' 4 H!0"@*T-X/+AG=%
M!?>YVN5EVOH0XGWZNE206F_F>OTK6_N4ZHOOU=*DF7:^A"5M0)B@/5' R&PZ
M%IDN%<3A#BO':^><[/-8**H3Q2EM1;"\SCAP4J0.EB:KB*W7,MD+$UDNH$0<
MSF)\ L&I$R)PL!GHUW?O!_?49LER3F]8E9,]FQ#9>3F>4FV?VZ0;\B$%PZ16
MD=&3UN45+)32":F7R+I;@)'3J"ZBF(*^B9X)"F4+@B:XUN;&LX/$OBS:N"XT
MA4("@% 0FXE7[NW>SV0-COA$[JPMR^)?,92]/&GG)LUDP* QB_*R?*?1GZAV
M&]X0S6X,%O>J:^4D/1FS06&OO]7?DJ4].0,@-;8-&"@% * TV?)7N?-.?LGN
M;XOPU6N,)WO))<JPN:3IM[ SX14ER+%Y](F\RM'%DA0&-7?#G@[!?:$H_ABE
M><V%/?#K;RO&]"&>Y.YWWDL&WDU+?:QR)-? &YQ0"@% :K.$ES.D/IX^O>(%
M7MP ;W<KRK2GVK#Q\W9N_?2/D]5[FKSO;W7$XONE J *[=<B2FH0Q-APHSG4
MV1#>SRT7++$>^'4HF=EE,()%CDC>UKR*D9IPV:R;#0QPK&<4T4RB[K*IV9E6
MQ;TS\'#HOTV^<_'$"YAF[?LB[)?!IYUVU >_M"\K4=SR"=%6?P:K#R'2W,)@
M^4#5HBE8H!0"@% ?8F1OV.E?5I'\*%527^[=\9WG4O;#[W#^(WT4/)5$F4P<
M:OS*Q#]J)K\IJ]5NW2G@Y5WEN+S",7JW!WAY77R1A>N9(S?53@]1A0"@% 6.
M<*7GI,'HW(/Y/5:W%@'WR:)^9TOZNF"KV[$WB:Q<JU;]=2AK$J^QXX"@% *
M4!6AO!Y<,[HH+[W.URLNU]"'$^_5TJ2"TW\SU^E:W]RG5%]^KI4DR[7T(2MJ
M!,4 H"D\QO-(@>J"E$/TDE+'B?XIBLBD(TM #BR/YSK=XFC*0D!@XQMG&PNM
M^1JY1%O+GSEFA8P7WSS,ONSKQ&7\1*Q+4_5OSKP:N'1Q\!=A0B1IG;<;6+65
M21D6=IF9\=+*\DGG$GI"L.=-JN#73#(1)3=ZFG(Q)2.(3,33@P910>*X G-D
MD9OD 950A<,\<1E$5;D/X9<W9U,@@-DC2S/T;L\O(K?N\6<:-+F"B35V/CXA
MW\@W-HH:D638Z!^=$[P\@JPI%F%_'2WAEP/PV'=!$5;D_'XX#T+B0&RI_AQ[
MQGB)DN<)'-.-B#9,X4&#,%394Q#KL&+F2Q@'+,(<N.%G@*",%GD&*'ECGAEE
MCE:]\+<OB7S!+T\:><G#63 H#&+\K)\I]&?J'8;WA#-;@P6]ZIKY20]&;-!8
M:^_U=^2I3TY R UM@T8* 4 H#39\E>Y\TY^R>YOB_#5:XPG>\DERK"YI.FWL
M#/A%27(L7GTB;S*T<62% 8U=\.>#L%]H2C^&*5YS84]\.MO*\;T(9[D[G?>2
MP;>34M]K'(DU\ ;G% * 4!JLX27,Z0^GCZ]X@5>W !O=RO*M*?:L/'S=F[]]
M(^3U7N:O._O9Z%2&YT#L7.7(T1#C@AB;5DO#2M&YI5E-\@)"U'&!EV-"4L#X
M95H-IJYCE@G(UQ20@CI&/$#. 9SYGL90]UE4^!5L6],_!GMZN,_5Q N89NW[
M(NR7P:>==M0'O[0O*U'<\@G15G\&JP\ATMS"8/E U:(I6* 4 H!0'V)D;]CI
M7U:1_"A54E_NW?&=YU+VP^]P_B-]%#R51)E,'&K\RL0_:B:_*:O5;MTIX.5=
MY;B\PC%ZMP=X>5U\D87KF2,WU4X/484 H!0%CG"EYZ3!Z-R#^3U6MQ8!]\FB
M?F=+^KI@J]NQ-XFL7*M6_74H:Q*OL>. H!0"@% 5H;P>7#.Z*"^]SM<K+M?0
MAQ/OU=*D@M-_,]?I6M_<IU1??JZ5),NU]"$K:@3% * SVN)R;O2E$JPMFA-R
M&1-&J.M)G, JDM)Z1JW)EX@#MD 0JW4(LF)* G-[8V V[=MIR6,ID2[JAXG&
MTB9K2ZJW<Q!05&T)YLUUBKH5437<OG6ZS-;H2H0*7=N=DHGC;:>3(DB%=UMB
M_:B4X%C-'G78O:N7TYKQG%<-EEF4<(K1$&,W"Z29J6W[D=<DF.,M'3+!8S<&
M+J"4M2W()4L<9R6HB2(JMM6VRU;+$MM7-;GX."^W0EYP'7//5#2Z6MAX^E67
MV*KP:F<,?2MKP1)D@.QKG$>8-;H=0-@6M*8;,6['LT!QAB.I7)K3K;34,#@B
M?3EH9 $12)Q'O0RMJV+PJYUJ)?:MG!IX/%H/#+C8W@:G PLW5TQ"B8ST+A89
MISW0G^A25G-:80*:S&,'"BC&RB\5;A5SIB7;),(!J:5G8B?+!A+(1@0$S;/"
MW+XE,KBXZWJN-?FL7/?XN+SFCFLG&* QB_*R?*?1GZAV&]X0S6X,%O>J:^4D
M/1FS06&OO]7?DJ4].0,@-;8-&"@% * TV?)7N?-.?LGN;XOPU6N,)WO))<JP
MN:3IM[ SX14ER+%Y](F\RM'%DA0&-7?#G@[!?:$H_ABE><V%/?#K;RO&]"&>
MY.YWWDL&WDU+?:QR)-? &YQ0"@% :K.$ES.D/IX^O>(%7MP ;W<KRK2GVK#Q
M\W9N_?2/D]5[FKR1+S?&:=N)!K M-X[>P<D.S2NY0#C#)E? DKY@68Z!^GHD
MZ8$1"\>91]=0P(_0<0^6N^[N<,Y<$;-N@7MNLJGP*MG%GMNU7K;L/X.(%S#-
MV_9%V2^#3SKMJ ]_:%Y6H[GD$Z*L_@U6'D.EN83!\H&K1%*Q0"@% * ^Q,C?
ML=*^K2/X4*JDO]V[XSO.I>V'WN'\1OHH>2J),I@XU?F5B'[437Y35ZK=NE/!
MRKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@% * L<X4O/28/1N0?R>JUN+ /O
MDT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP% * 4 H"M#>#RX9W107WN=KE9=
MKZ$.)]^KI4D%IOYGK]*UO[E.J+[]72I)EVOH0E;4"8H"*>U4LM6%R$0O)62Y
MD>[V.2N$TH=AB$U?$FXYMDAR,%^ X,I72%5S-!C+C:1F:5>$C*H\DN))930P
M8^#\/*!50;*:)0RB6VW79U7@2U,_'?8F;/GLX2J99(K4;&2[XV1AOBTP3$PK
MB1RKEE?'B-%9/94<?2%<*)A)9?S2BW:!P/)(8A104"X2XMMYIN=*;*?EFH+>
M!! *G%(J,^)6K=FLSK]+;,VE<YH%H1/07!%,7.U2S675&S!<RN*$$ (JN!G-
MY94A 0,>\ !S/*2<9-9A X?V @\A;X!X_P!G"UK?JH9M5+E4_P +<2Q4Y2C6
M3W'&<?+Y!BF@#[))+;,;BJ49QXK8+$J<:Q8\FC@MXT6Q!!Q ,).!08&P05@\
M\;!X]P8(S\2K]W;O9[(&QWPB=U86Y?$OF,I>GC3SDV:R8% 8Q?E9/E/HS]0[
M#>\(9K<&"WO5-?*2'HS9H+#7W^KOR5*>G(&0&ML&C!0"@% :;/DKW/FG/V3W
M-\7X:K7&$[WDDN587-)TV]@9\(J2Y%B\^D3>96CBR0H#&KOASP=@OM"4?PQ2
MO.;"GOAUMY7C>A#/<G<[[R6#;R:EOM8Y$FO@#<XH!0"@-5G"2YG2'T\?7O$"
MKVX -[N5Y5I3[5AX^;LW?OI'R>J]S5Y(UY.D^3V_A!HAR=*20G+<0S(KFHG1
MXFP6HE>1A'5X_"+.IY3%=M&A&2YVIB?%+-MKX.5.P<H2N;S% QR !+K&ZRJ?
M!P7\>?Z+;M1XSB!<PS=OV1=DO@T\Z[:@/?VA>5J.YY!.BK/X-5AY#I;F$P?*
M!JT12L4 H!0"@/L3(W['2OJTC^%"JI+_ ';OC.\ZE[8?>X?Q&^BAY*HDRF#C
M5^96(?M1-?E-7JMVZ4\'*N\MQ>81B]6X.\/*Z^2,+US)&;ZJ<'J,* 4 H"QS
MA2\])@]&Y!_)ZK6XL ^^31/S.E_5TP5>W8F\36+E6K?KJ4-8E7V/' 4 H!0"
M@*T-X/+AG=%!?>YVN5EVOH0XGWZNE206F_F>OTK6_N4ZHOOU=*DF7:^A"5M0
M)B@(>;80=,LK+&NC\@9\QBR)%U[EQPR4FYRZR74_&4O$W1",L0LJ))U'9KWC
MY="-!)\I&%<@= <0001M,"#,%C((N860RBHEZ6HO$MFGB7S$99UUYXEVPL-R
M;!CVG31=+:$LLI?83E4FMKA/I1R$41RD!DQ1-(1I6V@6$LNJ@EAQ,R(Q]*42
M@9BP>8Y,P';(/(216HJ*C76HJ+[I.!?BEKM" H!0$)N)5^[MWL]D#8[X1.ZL
M+<OB7S&4O3QIYR;-9,"@,8ORLGRGT9^H=AO>$,UN#!;WJFOE)#T9LT%AK[_5
MWY*E/3D#(#6V#1@H!0"@--GR5[GS3G[)[F^+\-5KC"=[R27*L+FDZ;>P,^$5
M)<BQ>?2)O,K1Q9(4!C5WPYX.P7VA*/X8I7G-A3WPZV\KQO0AGN3N=]Y+!MY-
M2WVL<B37P!N<4 H!0&JSA)<SI#Z>/KWB!5[< &]W*\JTI]JP\?-V;OWTCY/5
M>YJ\D:\E(^%M_""4&X=BRJ<<B"9#1IM-9EE#^L:J8**[ P+*$LOG-!,G&_)!
M#$<7&-T@)=)!JQ(5QY7#PL&*75MUE4^!<R7IGMS\/!T\&L\9Q N89NW[(NR7
MP:>==M0'O[0O*U'<\@G15G\&JP\ATMS"8/E U:(I6* 4 H!0'V)D;]CI7U:1
M_"A54E_NW?&=YU+VP^]P_B-]%#R51)E,'&K\RL0_:B:_*:O5;MTIX.5=Y;B\
MPC%ZMP=X>5U\D87KF2,WU4X/484 H!0%CG"EYZ3!Z-R#^3U6MQ8!]\FB?F=+
M^KI@J]NQ-XFL7*M6_74H:Q*OL>. H!0"@% 5H;P>7#.Z*"^]SM<K+M?0AQ/O
MU=*D@M-_,]?I6M_<IU1??JZ5),NU]"$K:@3% * 4 H!0"@(3<2K]W;O9[(&Q
MWPB=U86Y?$OF,I>GC3SDV:R8% 8Q?E9/E/HS]0[#>\(9K<&"WO5-?*2'HS9H
M+#7W^KOR5*>G(&0&ML&C!0"@% :;/DKW/FG/V3W-\7X:K7&$[WDDN587-)TV
M]@9\(J2Y%B\^D3>96CBR0H#&KOASP=@OM"4?PQ2O.;"GOAUMY7C>A#/<G<[[
MR6#;R:EOM8Y$FO@#<XH!0"@-5G"2YG2'T\?7O$"KVX -[N5Y5I3[5AX^;LW?
MOI'R>J]S5Y(UY8&K[?P@)@%M)<GC$,R8CBLXVFX:BX"Y*\?W!QFPF,-BJ#RW
M>V.?]#XQ0', %*N^[#7O;/+(+=95/@6[@X[=7!XSQG$"YAF[?LB[)?!IYUVU
M >_M"\K4=SR"=%6?P:K#R'2W,)@^4#5HBE8H!0"@% ?8F1OV.E?5I'\*%527
M^[=\9WG4O;#[W#^(WT4/)5$F4P<:OS*Q#]J)K\IJ]5NW2G@Y5WEN+S",7JW!
MWAY77R1A>N9(S?53@]1A0"@% 6.<*7GI,'HW(/Y/5:W%@'WR:)^9TOZNF"KV
M[$WB:Q<JU;]=2AK$J^QXX"@% * 4!6AO!Y<,[HH+[W.URLNU]"'$^_5TJ2"T
MW\SU^E:W]RG5%]^KI4DR[7T(2MJ!,4 H!0"@% * A-Q*OW=N]GL@;'?")W5A
M;E\2^8REZ>-/.39K)@4!C%^5D^4^C/U#L-[PAFMP8+>]4U\I(>C-F@L-??ZN
M_)4IZ<@9 :VP:,% * 4!IL^2O<^:<_9/<WQ?AJM<83O>22Y5A<TG3;V!GPBI
M+D6+SZ1-YE:.+)"@,:N^'/!V"^T)1_#%*\YL*>^'6WE>-Z$,]R=SOO)8-O)J
M6^UCD2:^ -SB@% * U6<)+F=(?3Q]>\0*O;@ WNY7E6E/M6'CYNS=^^D?)ZK
MW-7DC7DC'Q]OX070FA/AY.3HAF0B:>C:D$LF:ZH1@^KQ_F61Y.CC-QE33G?R
MQB6%$82Z$W3^",5*+-LA1.^R,HFZRJ?!>E]UF?Z;-EIXSB!<PS=OV1=DO@T\
MZ[:@/?VA>5J.YY!.BK/X-5AY#I;F$P?*!JT12L4 H!0"@/L3(W['2OJTC^%"
MJI+_ ';OC.\ZE[8?>X?Q&^BAY*HDRF#C5^96(?M1-?E-7JMVZ4\'*N\MQ>81
MB]6X.\/*Z^2,+US)&;ZJ<'J,* 4 H"QSA2\])@]&Y!_)ZK6XL ^^31/S.E_5
MTP5>W8F\36+E6K?KJ4-8E7V/' 4 H!0"@*T-X/+AG=%!?>YVN5EVOH0XGWZN
ME206F_F>OTK6_N4ZHOOU=*DF7:^A"5M0)B@% * 4 H"#^P>\S6@J0%6,4.%9
MXV">++B\&;I:38*0F$K7B")#JFO)"0[7?F_9%CVRLHN,XU'=DUF PK/*1G$3
M:B^=36F,7*ELS@DC;>%$X$MX5XKEXTSK8B<9ZQO6^VE*7"RVXDQ@K95RL:0]
M%9M?#-<1'PMB:ZU77!;C76^L%;#!A#8EU)*/E#@6(P00V. V.(H88ELL+86Y
M?$OF,)[I/&GG+!ZR8% 8Q?E9/E/HS]0[#>\(9K<&"WO5-?*2'HS9H+#7W^KO
MR5*>G(&0&ML&C!0"@% :;/DKW/FG/V3W-\7X:K7&$[WDDN587-)TV]@9\(J2
MY%B\^D3>96CBR0H#&KOASP=@OM"4?PQ2O.;"GOAUMY7C>A#/<G<[[R6#;R:E
MOM8Y$FO@#<XH!0"@-5G"2YG2'T\?7O$"KVX -[N5Y5I3[5AX^;LW?OI'R>J]
MS5Y(UY,\\>V_A![!Q*_5M/0(@F1%,S.FS!9#CMB&%Q78 Q9G.:%?I$5R?:Z\
M\4X8VB.[%NJ.#4P01PAA[9G2PR;NLJGP+=>G!GX>'@\7:>,X@7,,W;]D79+X
M-/.NVH#W]H7E:CN>03HJS^#58>0Z6YA,'R@:M$4K% * 4 H#[$R-^QTKZM(_
MA0JJ2_W;OC.\ZE[8?>X?Q&^BAY*HDRF#C5^96(?M1-?E-7JMVZ4\'*N\MQ>8
M1B]6X.\/*Z^2,+US)&;ZJ<'J,* 4 H"QSA2\])@]&Y!_)ZK6XL ^^31/S.E_
M5TP5>W8F\36+E6K?KJ4-8E7V/' 4 H!0"@*T-X/+AG=%!?>YVN5EVOH0XGWZ
MNE206F_F>OTK6_N4ZHOOU=*DF7:^A"5M0)B@% * 4 H"H"27NXM0-T=MI:<D
M+3E+#.VCU\U^ B$]"L.2%,=E&68,PF=N+$)NK&/F\X[Q\;<Y5]-)PM-TOVS<
MCPT HNSQYU$!T0Z'<2O1,^=%6VU>"Q,Z?1=?Q7G\D*<-20#VAT*ZNS#M;LG'
MZ1R3&)!<Q0]%PNM0C%"R,QF4:DC-Y)<+QUW?[^\":$-JZ;FJDW]EW+6L;0,D
MD#Q4$N7/F&,EJKBHN=515MMOT*B;"6/),E[^\5W9ZHT=_DKH,9/U&_2_^8<D
MR7O[Q7=GJC1W^2N@QD_4;]+_ .8AWM3P3XCW:,L@YM!MKN?*9F.0' 69@IE8
MU>:WS( Z1$<5>PPQ8VJ[9P._. B D999*6)S(OXG:Q3("PQBPO;T73M+4,D9
M*,FUEDF%AK&1(,O%QUA8Z,[_  HN+BY1_N;+;<]MB6=#356J"K"LNZF*.ASB
MRB14EU68G(.32,L-8B?^FF8.-C+"9[O&LQ?:V6K;$G^JR\/CTN;B_P"HL-_\
M UVOY<UI^%7?5)#[J=)[&]2/@"%]>I;[^?I,_):>'T$7'%#EO<3(0,$43#&\
MB0Y>U\\,,LL;7M: ;7O:][6MW+7M>_\ VM>GY<5I^%7?5)#[J/8WJ1\ POKU
M*_?SAFJ_R:G2R7=8=<98DB1=NT"1)/@:()#?J"1>46(I%$>CUCYO.1TI!-&5
MX+/*R2535Q3/$RZ8IG3BB0!!P*G31@R$*+F_+FM/PJ[ZI(?=3*X-ZD(JHE P
ME1%5$7N^E<Z<>:?L^@[S_59>'QZ7-Q?]18;_ . :?ES6GX5=]4D/NICV-ZD?
M $+Z]2WW\DGJ_P ". ],7NMR-K1M)N;&+T<;5,LE:6R[AUJ<^9UL&U='73"7
M<D]=7W(F@8B*J D&[FBQ,$]C<G8+ SB7&,!"]=2=8Z9IB"R7I&=69@PXJ1F,
M6!+0K(J,>Q'6P8,-RV,B/2Q55OMK;+;%3MJ'JI5V@)B)-411<.3F(L%9>)$2
M9GHV-!<^'$5F+,345B6OA,=C(U'>UL1;%5%G/R3)>_O%=V>J-'?Y*ZZ0^CQD
M_4;]+_YAR3)>_O%=V>J-'?Y*Z#&3]1OTO_F(?OG@JQ/)+N7WV]MMMSEQUNA0
M$5%U6S5]72.9\^+CA@(8R*)FJQ(@!?+'#"W@RI4 *W<[M@[7O?NZ[I3!1@_I
MJD)NE:3J^V:GYZ,Z/-3"TE3$)8L5R(BOR<"D(4%EJ(GM8<-C4X$-VU?W1N&6
MJU"T=5Z@:Y1*/H>B99LI1\DVA:NS"2\NQ7*V&D:;HF/,Q+%<JXT:-$>MN=RG
MJGZ!W7_^*'<S_,.M?\L%?@]A3!C^R[/WM3O]4.X_.MP^?M]%_A^JO]#. S]P
M9(UCD"'1&3L5N"KYO>?HOCEU6-G=?%2R:R7:H'2SB5R]D[6HK<@;(  !9@*A
MVYA.)7ROD;*CXY8VL]A3!C^R[/WM3O\ 5!^=9A\S_P#7\7^'ZJ\:?_H^([]^
M@=U__BAW,_S#K7_+!3V%,&/[+L_>U._U0?G6X?/V^B_P_57^AC] [K__ !0[
MF?YAUK_E@I["F#']EV?O:G?ZH/SK</G[?1?X?JK_ $,E%%/#N680: ##BW?'
M=5JM,L>/*0*0$#IJJX8'5(3$4Z/XVNZ=JA_*XXF..5\,C5PL.YW L,+=VU?<
MT!5ZAZL4>VBJ"DTD)!D6+&;+I'F9A$BQE1T5V4FXT>,N,J(MBQ%:G^%$0U'7
M&NU9J_TU$K%6ZD?[8IF++R\K$G7RLI)JZ!*M5D"'D:/@2DLF3:JIC)!1[KWN
M<N<XV]-%9;4-QH,?U]I=Q7"(W(<FI#PGX:1])D-7C8-<68Z%&89&%,-+?%G\
M2?\ F3+G3SS%PSR9(C;*%/"@9+X(9KNCY?&2Q4Q6Y[,WML^O'S>+A) OW1-Z
M2>Q7I&KZW_W77F3(;3<;&>*'F2TL(8++5=J.<0'"DYGDO34BIDL5%(4#9/(V
MG'29\O8:XQ,T7,8!BX<L"/%EH\&9@/R<:7BPX\%]C78D6$](D-^*Y'-=BO:B
MV.:K5LL5%3,?GF8$"<EIB4F8+8LO-0(LM'AJZ*W*08\-T**S&9$:]N.QSFXS
M'-<EMK51;%*L?ZK+P^/2YN+_ *BPW_P#7T_Y<UI^%7?5)#[J?&^QO4CX A?7
MJ6^_C^JR\/CTN;B_ZBPW_P  T_+FM/PJ[ZI(?=1[&]2/@"%]>I;[^<!1ODU>
MEQ[:21HC-R)MT%'+8@&%I&05_%XQ8&>.O9]R)/C9=J0,M9P7DDFRB6A1TRCI
M9+*D05%.&6#9L\:,EE1.!*ORXK3\*N^J2'W4S[&U2+$7^P86=52SN^E>#%L7
M_P#/MX5X;#OW]5EX?'I<W%_U%AO_ (!I^7-:?A5WU20^ZF/8WJ1\ 0OKU+??
MQ_59>'QZ7-Q?]18;_P" :?ES6GX5=]4D/NH]C>I'P!"^O4M]_+=@=1I:+@A
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M]J=_J@_.MP^?M]%_A^JO]#.AQ;P=(^A9Y$) C+<+=!KN],+GRA%8"4=553,
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MX@#WE-SH4B:I<2>$V^QE05"=R =<;I<XRULA+C@R;&$*-^[,+#LHTN.2)',
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M 7PS2N;)JK*)* !H)JFDG)>6"R#FA6(6;Z8>%2$3%/2K!DL!$ZG0"@% * Y
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MVO!TKIT95<[V>KC/99J#C=[J63)M77UD[GX0T=,Y8 !%20)4F7$56TZ;0P*
M4!Q)PL>05&?8VD!,/Q:'&S98$B-UTIZQ'XRG+IAPN50:)IO"LJ1\5@ )L-/
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)67D7+C+;<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img43903234_18.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43903234_18.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M?TB1T@H2RS![8?YR1LSYWY(Y$*3JN6R=$^,=#,:MW@E>#NP@#.8@# Q>#N8
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M6,Q0@2.?QHAD+V>5HTGLX%*#*/(-0HU8C$*!*X>BH"65Q/_L:W^QZ5]#ZG/
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M5!DZA-3L* 6^#5(@SW:X([.0".XEEA$!5@@21/N$RHZ&6ZAHQ8GP7SNFADF
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MBQXO;>P1*82:&C/+YV@TZ,9]N@3IHZ20O"$GN);<,ZH[%;I3H(\FK(C-HM*
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/P<\W?IS?-WE^?2$*"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>alec-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-27T16:11:44.8573+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alector.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:alec="http://alector.com/20231231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" id="DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1" id="DisclosureTheCompany1">
        <link:definition>995457 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995467 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995477 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" id="Role_DisclosureCommitmentAndContingencies">
        <link:definition>995487 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements" id="DisclosureCollaborationAgreements">
        <link:definition>995497 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>995507 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>995517 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995527 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995537 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>995547 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995557 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>995567 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995577 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995587 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995597 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995607 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>995617 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>995627 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995637 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995647 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995657 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" id="Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
        <link:definition>995667 - Disclosure - The Company and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995677 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>995687 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995697 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995707 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>995717 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>995727 - Disclosure - Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>995737 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>995747 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>995757 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
        <link:definition>995767 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" id="Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
        <link:definition>995777 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
        <link:definition>995787 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" id="DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>995797 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995807 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
        <link:definition>995817 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
        <link:definition>995827 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails">
        <link:definition>995837 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>995847 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995857 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>995867 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>995877 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995887 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995897 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" id="DisclosureRestructuringAdditionalInformationDetails">
        <link:definition>995907 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995917 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alec-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="alec-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="alec-20231231.xsd#DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="alec-20231231.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20231231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="alec-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="alec-20231231.xsd#DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:href="alec-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:href="alec-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="alec-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alec-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="alec-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:href="alec-20231231.xsd#DisclosureRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="alec-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="alec-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" xlink:href="alec-20231231.xsd#DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="alec-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="alec-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="alec-20231231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="alec-20231231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:href="alec-20231231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:href="alec-20231231.xsd#DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alec-20231231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alec-20231231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="alec-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="alec-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1" xlink:href="alec-20231231.xsd#DisclosureTheCompany1" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="alec-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="alec-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" xlink:href="alec-20231231.xsd#Role_DisclosureCommitmentAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements" xlink:href="alec-20231231.xsd#DisclosureCollaborationAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="alec-20231231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="alec-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="alec-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="alec-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="alec-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="alec-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureRestructuring" xlink:href="alec-20231231.xsd#DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="alec-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alec-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="alec-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="alec-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="alec-20231231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="alec-20231231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="alec-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="alec-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="alec-20231231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="alec-20231231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReductionInTransactionPrice" xlink:label="alec_ReductionInTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationPayable" xlink:label="alec_CollaborationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_WorkforceMember" xlink:label="alec_WorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockClosingDate" xlink:label="alec_SaleOfStockClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInPayableToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfReductionInWorkforce" xlink:label="alec_PercentageOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IndemnificationAgreementLiability" xlink:label="alec_IndemnificationAgreementLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ChangeInEstimateMember" xlink:label="alec_ChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CompanyMaximumFunding" xlink:label="alec_CompanyMaximumFunding"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_UnderwritingMember" xlink:label="alec_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockOptionTerm" xlink:label="alec_SaleOfStockOptionTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsRefundLiability" xlink:label="alec_DeferredTaxAssetsRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TransactionsPrice" xlink:label="alec_TransactionsPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NumberOfReductionInWorkforce" xlink:label="alec_NumberOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_Al101AlzheimersDiseaseProgramMember" xlink:label="alec_Al101AlzheimersDiseaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DecreaseOnUncertainTaxProvisions" xlink:label="alec_DecreaseOnUncertainTaxProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CertificateOfDepositMember" xlink:label="alec_CertificateOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of reserves on uncertain tax provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Reserves On Uncertain Tax Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal Reserves On Uncertain Tax Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant, and equipment useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Un-recognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance deferred tax asset change in amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReductionInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReductionInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction in Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReductionInTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in transaction price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, long-term portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon follow-on public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Method Accounted For As Change in Estimate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Method Accounted for as Change in Estimate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Sublease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in sublease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Automatic conversion provision of common stock reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds before deducting underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering Before Deducting Underwriting Discounts and Commissions and Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering before deducting underwriting discounts and commissions and offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase on uncertain tax provisions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to tax positions taken during the prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Federal and State Income Tax Provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of instruments in loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional area of property in lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Area Of Property In Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional area of property in lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivable from collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease In collaboration receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Collaboration Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and related cost expected cost remaining 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Expected Cost Remaining</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount form letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Fair Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax Assets tax deferred expense capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Capitalized Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 R&amp;D capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extend for an additional lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Refund liability to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refund liability to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Refund Liability to Collaboration Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in refund liability to collaboration partner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards And Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock from employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss from disposal of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offices and Laboratory Facilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offices And Laboratory Facilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offices and laboratory facilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of options to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional area sublease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Area Sublease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional area sublease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined matching contribution plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, existence of option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restructuring Reserve, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restructuring Reserve, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Beginning Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Beginning Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit beginning expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_WorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workforce [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_WorkforceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Workforce [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease on uncertain tax provisions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decreases related to tax positions taken during the prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decreases related to tax positions taken during the prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and accrued clinical supply costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in accrued liabilities and accrued clinical supply costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering closing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Closing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering closing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to tax positions taken during the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of common stock issued or sold, Price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Payments Owed Under Company's Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Payable to Collaboration Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in payable to collaboration partner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative adjustment to revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property And Equipment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 4)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Of Development Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Development Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included In measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award requisite service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation uncertain tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture/Cancellation of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Present value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfReductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reduction In Workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfReductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Reduction In Workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on-offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refund liability to collaboration partner, long-term portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Refund Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected weighted average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical supply costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Supply Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical supply cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits, net of uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with customer, refund liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Refund Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Refund Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities, one year through two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of underwriting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Transaction Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount on underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount on Underwriting Discounts and Commissions and Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount on underwriting discounts and commissions and offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IndemnificationAgreementLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification agreement liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IndemnificationAgreementLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IndemnificationAgreementLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification agreement liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two inducement Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under 2019 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments owed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments Owed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestone payments owed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Recognized Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities Right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ChangeInEstimateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Estimate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ChangeInEstimateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Estimate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ChangeInEstimateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in estimate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax, Penalties and Interest accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from disposal of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock subject to future vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards And Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Related party transaction expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, cliff vesting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdimabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdimabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adimab</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdimabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adimab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CompanyMaximumFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CompanyMaximumFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Company Maximum Funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CompanyMaximumFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Company maximum funding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from (payments for) issuance of common stock as part of an initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock upon public offerings, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Awards and Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents and marketable securities, Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refund liability to collaboration partner, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Refund Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option period (in days)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Option Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SaleOfStockOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Stock, Option, Term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of option exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Refund liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Refund Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsRefundLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets refund liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Fourteen Adimab Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Adimab Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value per Share, Unvested, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued or sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Agreement Effective Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration and License Agreement Effective Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities due to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable to collaboration partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TransactionsPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TransactionsPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transactions Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TransactionsPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transactions Price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for enrollment of additional patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments For Enrollment of Additional Patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement milestone payments for enrollment of additional patients.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Newark California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Newark, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NumberOfReductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reduction In Workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NumberOfReductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Reduction In Workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Estimate by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">accrued bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward beginning expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Beginning Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards beginning expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, long-term portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie Biotechnology Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie Biotechnology Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie biotechnology, limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive option rights exercised for each program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments On Option Rights Exercised Per Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, milestone payments on option rights exercised per program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee 401 (K) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefit Plans, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments related to initiation of certain clinical studies and regulatory approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, additional milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Estimate, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GlaxoSmithKline plc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GSK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Upfront Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, upfront payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of stock owned by Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Stock Owned By Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of stock owned by Individual.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alector</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alector.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alector [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income and reimbursement of variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income and reimbursement of variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income And Reimbursement Of Variable Lease Cost1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State Tax Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic And State Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Domestic and state tax authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_Al101AlzheimersDiseaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Al101 Alzheimer's Disease Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_Al101AlzheimersDiseaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AL101 Alzheimer's Disease Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_Al101AlzheimersDiseaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AL101 Alzheimer's disease program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds from the offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents and marketable securities, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price per share from fair market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DecreaseOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease on uncertain tax provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DecreaseOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease on Uncertain Tax Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DecreaseOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease on uncertain tax provisions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CertificateOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CertificateOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificate of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CertificateOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Certificate of deposit .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon follow-on public offering, net of issuance costs of $1,148 (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseExpirationMonthAndYear" xlink:to="alec_SubleaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ReversalReservesOnUncertainTaxProvisions" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationRevenueMember" xlink:to="alec_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationReceivable" xlink:to="alec_CollaborationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ReductionInTransactionPrice" xlink:to="alec_ReductionInTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInSubleaseAgreement" xlink:to="alec_AreaOfPropertyInSubleaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:to="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdditionalAreaOfPropertyInLease" xlink:to="alec_AdditionalAreaOfPropertyInLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationPayable" xlink:to="alec_CollaborationPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInCollaborationReceivable" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" xlink:to="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OfficesAndLaboratoryFacilitiesMember" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInLease" xlink:to="alec_AreaOfPropertyInLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TaxCreditBeginningExpirationYear" xlink:to="alec_TaxCreditBeginningExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_WorkforceMember" xlink:to="alec_WorkforceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SaleOfStockClosingDate" xlink:to="alec_SaleOfStockClosingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInPayableToCollaborationPartner" xlink:to="alec_IncreaseDecreaseInPayableToCollaborationPartner_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LeaseExpirationYear" xlink:to="alec_LeaseExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AmortizationRightOfUseAsset" xlink:to="alec_AmortizationRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedPropertyAndEquipmentCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfDevelopmentCost" xlink:to="alec_PercentageOfDevelopmentCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncomeTaxReconciliationUncertainTaxPositions" xlink:to="alec_IncomeTaxReconciliationUncertainTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfReductionInWorkforce" xlink:to="alec_PercentageOfReductionInWorkforce_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FollowOnPublicOfferingMember" xlink:to="alec_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedClinicalSupplyCost" xlink:to="alec_AccruedClinicalSupplyCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInLeaseLiabilities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockTransactionDate" xlink:to="us-gaap_SaleOfStockTransactionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:to="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IndemnificationAgreementLiability" xlink:to="alec_IndemnificationAgreementLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandTwentyTwoInducementPlanMember" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FutureMilestonePaymentsOwed" xlink:to="alec_FutureMilestonePaymentsOwed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ChangeInEstimateMember" xlink:to="alec_ChangeInEstimateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LabEquipmentMember" xlink:to="alec_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdimabMember" xlink:to="alec_AdimabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CompanyMaximumFunding" xlink:to="alec_CompanyMaximumFunding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedResearchAndDevelopmentCosts" xlink:to="alec_AccruedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsLeaseLiabilities" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_UnderwritingMember" xlink:to="alec_UnderwritingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SaleOfStockOptionTerm" xlink:to="alec_SaleOfStockOptionTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsRefundLiability" xlink:to="alec_DeferredTaxAssetsRefundLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandFourteenAdimabAgreementMember" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TransactionsPrice" xlink:to="alec_TransactionsPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" xlink:to="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_NewarkCaliforniaMember" xlink:to="alec_NewarkCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_NumberOfReductionInWorkforce" xlink:to="alec_NumberOfReductionInWorkforce_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AbbVieBiotechnologyLimitedMember" xlink:to="alec_AbbVieBiotechnologyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubsequentOfferingPeriod" xlink:to="alec_SubsequentOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_GskMember" xlink:to="alec_GskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementUpfrontPayments" xlink:to="alec_CollaborativeArrangementUpfrontPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfStockOwnedByIndividual" xlink:to="alec_PercentageOfStockOwnedByIndividual_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AlectorMember" xlink:to="alec_AlectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DomesticAndStateTaxAuthorityMember" xlink:to="alec_DomesticAndStateTaxAuthorityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_Al101AlzheimersDiseaseProgramMember" xlink:to="alec_Al101AlzheimersDiseaseProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DecreaseOnUncertainTaxProvisions" xlink:to="alec_DecreaseOnUncertainTaxProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SouthSanFranciscoMember" xlink:to="alec_SouthSanFranciscoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CertificateOfDepositMember" xlink:to="alec_CertificateOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationPayable" xlink:label="alec_CollaborationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="alec_AccruedClinicalSupplyCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="alec_CollaborationReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="alec_CollaborationPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_20"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_23"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInPayableToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alec_AmortizationRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInPayableToCollaborationPartner" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CertificateOfDepositMember" xlink:label="alec_CertificateOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CertificateOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IndemnificationAgreementLiability" xlink:label="alec_IndemnificationAgreementLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="alec_IndemnificationAgreementLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_Al101AlzheimersDiseaseProgramMember" xlink:label="alec_Al101AlzheimersDiseaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ChangeInEstimateMember" xlink:label="alec_ChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReductionInTransactionPrice" xlink:label="alec_ReductionInTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TransactionsPrice" xlink:label="alec_TransactionsPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CompanyMaximumFunding" xlink:label="alec_CompanyMaximumFunding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_Al101AlzheimersDiseaseProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_GskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="alec_ChangeInEstimateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AlectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_PercentageOfDevelopmentCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_ReductionInTransactionPrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_TransactionsPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerRefundLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CompanyMaximumFunding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaOfPropertyInLease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alec_IncomeTaxReconciliationUncertainTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsRefundLiability" xlink:label="alec_DeferredTaxAssetsRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsRefundLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DecreaseOnUncertainTaxProvisions" xlink:label="alec_DecreaseOnUncertainTaxProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_DecreaseOnUncertainTaxProvisions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="alec_AdimabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfReductionInWorkforce" xlink:label="alec_PercentageOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_WorkforceMember" xlink:label="alec_WorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NumberOfReductionInWorkforce" xlink:label="alec_NumberOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="alec_PercentageOfReductionInWorkforce" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="alec_WorkforceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="alec_NumberOfReductionInWorkforce" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_UnderwritingMember" xlink:label="alec_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockOptionTerm" xlink:label="alec_SaleOfStockOptionTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockClosingDate" xlink:label="alec_SaleOfStockClosingDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_UnderwritingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_SaleOfStockOptionTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_SaleOfStockClosingDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CertificateOfDepositMember" xlink:label="alec_CertificateOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CertificateOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IndemnificationAgreementLiability" xlink:label="alec_IndemnificationAgreementLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="alec_IndemnificationAgreementLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_Al101AlzheimersDiseaseProgramMember" xlink:label="alec_Al101AlzheimersDiseaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ChangeInEstimateMember" xlink:label="alec_ChangeInEstimateMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReductionInTransactionPrice" xlink:label="alec_ReductionInTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TransactionsPrice" xlink:label="alec_TransactionsPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CompanyMaximumFunding" xlink:label="alec_CompanyMaximumFunding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" xlink:label="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_Al101AlzheimersDiseaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_GskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="alec_ChangeInEstimateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AlectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_PercentageOfDevelopmentCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_ReductionInTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_TransactionsPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerRefundLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CompanyMaximumFunding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaOfPropertyInLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DecreaseOnUncertainTaxProvisions" xlink:label="alec_DecreaseOnUncertainTaxProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_DecreaseOnUncertainTaxProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="alec_AdimabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_PercentageOfReductionInWorkforce" xlink:label="alec_PercentageOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_WorkforceMember" xlink:label="alec_WorkforceMember"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_NumberOfReductionInWorkforce" xlink:label="alec_NumberOfReductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="alec_PercentageOfReductionInWorkforce" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="alec_WorkforceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="alec_NumberOfReductionInWorkforce" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_UnderwritingMember" xlink:label="alec_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockOptionTerm" xlink:label="alec_SaleOfStockOptionTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" xlink:label="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SaleOfStockClosingDate" xlink:label="alec_SaleOfStockClosingDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_UnderwritingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_SaleOfStockOptionTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_SaleOfStockClosingDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="alec_AccruedClinicalSupplyCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="alec_CollaborationReceivable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="alec_CollaborationPayable" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerRefundLiabilityCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_CollaborationPayable" xlink:label="alec_CollaborationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_AmortizationRightOfUseAsset" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInPayableToCollaborationPartner" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" order="18" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="20" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInPayableToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInPayableToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" xlink:label="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alec_IncomeTaxReconciliationUncertainTaxPositions" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="alec_IncomeTaxReconciliationUncertainTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsRefundLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsRefundLiability" xlink:label="alec_DeferredTaxAssetsRefundLiability"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="alec-20231231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_IncreaseDecreaseInPayableToCollaborationPartner" name="IncreaseDecreaseInPayableToCollaborationPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_ChangeInEstimateMember" name="ChangeInEstimateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner" name="IncreaseDecreaseInRefundLiabilityToCollaborationPartner" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_UnderwritingMember" name="UnderwritingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_NewarkCaliforniaMember" name="NewarkCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_IncreaseDecreaseInCollaborationReceivable" name="IncreaseDecreaseInCollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AccruedClinicalSupplyCost" name="AccruedClinicalSupplyCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" name="CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_CompanyMaximumFunding" name="CompanyMaximumFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" name="IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_PercentageOfStockOwnedByIndividual" name="PercentageOfStockOwnedByIndividual" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_DecreaseOnUncertainTaxProvisions" name="DecreaseOnUncertainTaxProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_AreaOfPropertyInLease" name="AreaOfPropertyInLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_PercentageOfReductionInWorkforce" name="PercentageOfReductionInWorkforce" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alec_ReductionInTransactionPrice" name="ReductionInTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_OperatingLossCarryforwardsBeginningExpirationYear" name="OperatingLossCarryforwardsBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_WorkforceMember" name="WorkforceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_SubleaseExpirationMonthAndYear" name="SubleaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_IndemnificationAgreementLiability" name="IndemnificationAgreementLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" name="CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" name="RestrictedStockAwardsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TaxCreditBeginningExpirationYear" name="TaxCreditBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_TwoThousandFourteenAdimabAgreementMember" name="TwoThousandFourteenAdimabAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_IncomeTaxReconciliationUncertainTaxPositions" name="IncomeTaxReconciliationUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable" name="CollaborativeArrangementAdditionalMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_SaleOfStockClosingDate" name="SaleOfStockClosingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AdditionalAreaOfPropertyInLease" name="AdditionalAreaOfPropertyInLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alec_AreaOfPropertyInSubleaseAgreement" name="AreaOfPropertyInSubleaseAgreement" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_CertificateOfDepositMember" name="CertificateOfDepositMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborationPayable" name="CollaborationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_NumberOfReductionInWorkforce" name="NumberOfReductionInWorkforce" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_ReversalReservesOnUncertainTaxProvisions" name="ReversalReservesOnUncertainTaxProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AccruedPropertyAndEquipmentCurrent" name="AccruedPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" name="TemporaryStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_CollaborativeArrangementUpfrontPayments" name="CollaborativeArrangementUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" name="ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_SaleOfStockOptionTerm" name="SaleOfStockOptionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_Al101AlzheimersDiseaseProgramMember" name="Al101AlzheimersDiseaseProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_GskMember" name="GskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AdimabMember" name="AdimabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_FutureMilestonePaymentsOwed" name="FutureMilestonePaymentsOwed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_TransactionsPrice" name="TransactionsPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_CashEquivalentsAndMarketableSecuritiesMember" name="CashEquivalentsAndMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AlectorMember" name="AlectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" name="ProceedsFromPaymentsForIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_DeferredTaxAssetsRefundLiability" name="DeferredTaxAssetsRefundLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_PercentageOfDevelopmentCost" name="PercentageOfDevelopmentCost" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" name="SubleaseIncomeAndReimbursementOfVariableLeaseCost1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" name="AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_TwoThousandTwentyTwoInducementPlanMember" name="TwoThousandTwentyTwoInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborationAndLicenseAgreementEffectiveDate" name="CollaborationAndLicenseAgreementEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" name="AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_SubsequentOfferingPeriod" name="SubsequentOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_DomesticAndStateTaxAuthorityMember" name="DomesticAndStateTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AdditionalAreaSubleaseExpirationMonthAndYear" name="AdditionalAreaSubleaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_SouthSanFranciscoMember" name="SouthSanFranciscoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AmortizationRightOfUseAsset" name="AmortizationRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_OfficesAndLaboratoryFacilitiesMember" name="OfficesAndLaboratoryFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AbbVieBiotechnologyLimitedMember" name="AbbVieBiotechnologyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507690896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALEC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2933343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Oyster Point Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-5660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alector, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001653087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,749,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s 2023 fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508268528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,555<span></span>
</td>
<td class="nump">$ 154,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">474,306<span></span>
</td>
<td class="nump">558,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborationReceivable', window );">Receivable from collaboration partner</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,946<span></span>
</td>
<td class="nump">10,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">565,807<span></span>
</td>
<td class="nump">726,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,861<span></span>
</td>
<td class="nump">25,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">25,195<span></span>
</td>
<td class="nump">27,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,418<span></span>
</td>
<td class="nump">6,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">621,827<span></span>
</td>
<td class="nump">787,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AccruedClinicalSupplyCost', window );">Accrued clinical supply costs</a></td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">30,378<span></span>
</td>
<td class="nump">27,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">82,975<span></span>
</td>
<td class="nump">48,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborationPayable', window );">Payable to collaboration partner</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Refund liability to collaboration partner, current portion</a></td>
<td class="nump">39,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">8,462<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">177,948<span></span>
</td>
<td class="nump">93,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term portion</a></td>
<td class="nump">210,845<span></span>
</td>
<td class="nump">443,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityNoncurrent', window );">Refund liability to collaboration partner, long-term portion</a></td>
<td class="nump">67,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term portion</a></td>
<td class="nump">30,456<span></span>
</td>
<td class="nump">35,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">487,669<span></span>
</td>
<td class="nump">573,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">844,044<span></span>
</td>
<td class="nump">798,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">184<span></span>
</td>
<td class="num">(4,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(710,078)<span></span>
</td>
<td class="num">(579,687)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">134,158<span></span>
</td>
<td class="nump">214,442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 621,827<span></span>
</td>
<td class="nump">$ 787,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedClinicalSupplyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical supply cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedClinicalSupplyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506898896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">84,879,693<span></span>
</td>
<td class="nump">82,895,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">84,879,693<span></span>
</td>
<td class="nump">82,895,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508219040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 97,062<span></span>
</td>
<td class="nump">$ 133,617<span></span>
</td>
<td class="nump">$ 207,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">192,115<span></span>
</td>
<td class="nump">210,418<span></span>
</td>
<td class="nump">189,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">56,687<span></span>
</td>
<td class="nump">61,033<span></span>
</td>
<td class="nump">55,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">248,802<span></span>
</td>
<td class="nump">271,451<span></span>
</td>
<td class="nump">244,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(151,740)<span></span>
</td>
<td class="num">(137,834)<span></span>
</td>
<td class="num">(37,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">26,561<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Loss before income taxes</a></td>
<td class="num">(125,179)<span></span>
</td>
<td class="num">(130,056)<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">5,212<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(130,391)<span></span>
</td>
<td class="num">(133,310)<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="num">(1,557)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (125,632)<span></span>
</td>
<td class="num">$ (136,942)<span></span>
</td>
<td class="num">$ (37,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic</a></td>
<td class="nump">83,733,730<span></span>
</td>
<td class="nump">82,467,587<span></span>
</td>
<td class="nump">80,416,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share, diluted</a></td>
<td class="nump">83,733,730<span></span>
</td>
<td class="nump">82,467,587<span></span>
</td>
<td class="nump">80,416,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507312496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,316,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 267,530<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 676,956<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="num">$ (410,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">40,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(1,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(36,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,986,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">300,724<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">748,036<span></span>
</td>
<td class="num">(943)<span></span>
</td>
<td class="num">(446,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">46,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (133,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">82,895,718<span></span>
</td>
<td class="nump">82,895,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 214,442<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">798,696<span></span>
</td>
<td class="num">(4,575)<span></span>
</td>
<td class="num">(579,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">42,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (130,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,391)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">84,879,693<span></span>
</td>
<td class="nump">84,879,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 134,158<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 844,044<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="num">$ (710,078)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817505012208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (130,391)<span></span>
</td>
<td class="num">$ (133,310)<span></span>
</td>
<td class="num">$ (36,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">5,714<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">42,798<span></span>
</td>
<td class="nump">46,146<span></span>
</td>
<td class="nump">40,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and accretion of discounts on marketable securities</a></td>
<td class="num">(15,318)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AmortizationRightOfUseAsset', window );">Amortization of right-of-use assets</a></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss from disposal of fixed assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInCollaborationReceivable', window );">Receivable from collaboration partner</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">4,804<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,949)<span></span>
</td>
<td class="num">(3,926)<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
<td class="num">(2,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts', window );">Accrued liabilities and accrued clinical supply costs</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="num">(2,655)<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInPayableToCollaborationPartner', window );">Payable to collaboration partner</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(66,782)<span></span>
</td>
<td class="nump">66,383<span></span>
</td>
<td class="nump">292,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner', window );">Refund liability to collaboration partner</a></td>
<td class="num">(24,512)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(4,968)<span></span>
</td>
<td class="num">(4,274)<span></span>
</td>
<td class="num">(4,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(184,162)<span></span>
</td>
<td class="num">(20,329)<span></span>
</td>
<td class="nump">298,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,381)<span></span>
</td>
<td class="num">(4,117)<span></span>
</td>
<td class="num">(3,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(551,729)<span></span>
</td>
<td class="num">(556,898)<span></span>
</td>
<td class="num">(343,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">652,523<span></span>
</td>
<td class="nump">402,001<span></span>
</td>
<td class="nump">286,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">3,505<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">101,918<span></span>
</td>
<td class="num">(159,014)<span></span>
</td>
<td class="num">(49,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options to purchase common stock</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock from employee stock purchase plan</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
<td class="nump">30,295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(79,694)<span></span>
</td>
<td class="num">(174,829)<span></span>
</td>
<td class="nump">279,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">155,795<span></span>
</td>
<td class="nump">330,624<span></span>
</td>
<td class="nump">51,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">76,101<span></span>
</td>
<td class="nump">155,795<span></span>
</td>
<td class="nump">330,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AmortizationRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AmortizationRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in accrued liabilities and accrued clinical supply costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInCollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInCollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInPayableToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payable to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInPayableToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in refund liability to collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817505010288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (130,391)<span></span>
</td>
<td class="num">$ (133,310)<span></span>
</td>
<td class="num">$ (36,329)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507893232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508962064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company  </span><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507889152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,555</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,472</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,101</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,795</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, certificates of deposit, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#8217;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_94e46f7d-4030-4cdd-937b-79e7aa9936e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize an impairment loss on its long-lived assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each performance obligation is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the performance obligation.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits within the provision for taxes in the consolidated statements of operations. The Company accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and penalties for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the Code) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021, the Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the Company&#8217;s consolidated financial statements and disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511997040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.5%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">543,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">501,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">655,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the remaining contractual maturities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">503.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of investments were less than one year and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">were after one year through two years. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. For the year ended December 31, 2023 and 2021, the Company sold marketable securities for the total proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for an immaterial realized loss and gain based on the specific identification method. The Company did not sell any marketable securities for the years ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511997040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.     Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2023, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into customary indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for certain losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded a liability related to such indemnification agreements as of December 31, 2023. As permitted under Delaware law, the Company has entered into indemnification agreements with its directors and officers that requires it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by law. The Company also has directors&#8217; and officers&#8217; insurance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817509257392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.     Collaboration Agreements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab, and AL101 (GSK Agreement). The GSK Agreement became effective on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 17, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the GSK Agreement, the Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was received in August 2021 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#8217;s disease, Parkinson&#8217;s disease and other non-orphan indications. GSK will also conduct the initial Phase 2 trial for AL101 in Alzheimer&#8217;s disease. Development costs will be shared </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by GSK and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% by the Company, except that subject to the GSK Amendment (defined below), the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company and GSK amended the GSK Agreement (GSK Amendment). Under the terms of the GSK Amendment, the Company is responsible for funding and sharing in GSK&#8217;s and the Company&#8217;s development costs up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the conduct of the initial Phase 2 trial for AL101 in Alzheimer&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disease. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the GSK Amendment in accordance with ASC 606 and concluded that the GSK Amendment was a contract modification to the GSK Agreement. Accordingly, the transaction price as of May 2023, was updated from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">571.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the difference of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">128.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as refund liability to collaboration partner for the expected cost reimbursement to GSK. The refund liability is an estimate of variable consideration calculated as the difference between the Company&#8217;s maximum funding of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the Company&#8217;s cost budget estimated using the expected value method. The Company determined that the modified performance obligation for the AL101 Alzheimer&#8217;s disease program is performing development activities to support the initial Phase 2 trial, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the modification date relating to the performance obligation which was satisfied in prior periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023, as a result of the planned closure of the latozinemab Phase 2 trial and concurrent agreement by the Company to cost-share additional R&amp;D, the Company determined there was a modification of the GSK Agreement, resulting in a decrease of the scope of the performance obligation associated with the latozinemab FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Phase 2 trial and an increase in the amount of R&amp;D cost-shared by the Company in future periods. The impact of this additional cost share was accounted for as a refund liability, which reduced the transaction price for the GSK Agreement by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The refund liability is an estimate of variable consideration. The Company determined that the modified performance obligation for the latozinemab FTD-C9orf72 indication is performing the first Phase 2 development activities, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the modification date relating to the performance obligation that was satisfied in prior periods.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of latozinemab and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to latozinemab FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The transaction price at inception included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was decreased to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">569.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million due to the estimated refund liabilities created from the contract modifications. The Company reassessed the estimated refund liabilities to collaboration partner as of December 31, 2023 to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">106.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of latozinemab and AL101 and estimated research and development costs to be incurred by the Company in each of the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management&#8217;s assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GRN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue under the GSK Agreement during the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">66.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, the entire amount of which was included in deferred revenue at the beginning of the period. The deferred revenue related to the GSK Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">247.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">444.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company recognized a reduction of research and development expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the GSK Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AbbVie</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">205.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector concluded that further development of AL003, the asset being developed under that program, was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. Accordingly, the Company is no longer developing that program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. If AbbVie exercises its option for the AL002 program, AbbVie would take over development of the product candidate, and the program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. Alternatively, following AbbVie&#8217;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company and AbbVie amended the AbbVie Agreement (AbbVie Amendment), which resulted in the Company receiving a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment in March 2023 for the dosing of the first patient in a long-term extension (LTE) trial. In addition, under the terms of the AbbVie Amendment, the Company was eligible to earn up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to support the enrollment of additional patients to replace discontinuations. The performance obligations to conduct the LTE trial and enroll additional patients are not considered distinct from the AL002 program performance obligation. The Company received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the enrollment of additional patients from AbbVie in the third quarter of 2023 and received the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the fourth quarter of 2023. The transaction price as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">205.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million LTE milestone payment, and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment for enrollment of additional patients.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was included in deferred revenue at the beginning of the period. Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The deferred revenue related to the AbbVie Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively. The deferred revenue is expected to be recognized over the research and development period of the AL002 program through the completion of the ongoing Phase 2 and the Phase 2 LTE clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817509257392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.       Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.333%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,228</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511822304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.      Leases</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, the Company signed a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in office and laboratory space in South San Francisco which serves as the Company&#8217;s headquarters (the Headquarters). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to renew for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The landlord paid for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company signed a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in Newark, California. The lease term ends on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 6, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The landlord is obligated to pay for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of tenant improvements.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">measurement of the lease liabilities for the leases excludes the options to extend the term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#8217;s leases consist of operating expenses for the spaces.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2019, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters, which was amended to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in December 2020. This Sublease expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters, which was amended in May 2022 to include an additional space of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. The 7,100 square feet of space subleased expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the additional space of 13,150 expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In October 2023, the Company entered into a second amendment to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters. This sublease will expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">November 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company entered into an agreement to sublease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,300</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of the Headquarters. This sublease will expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The sublessee pays its proportionate share of operating expenses for the space.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.91%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,141</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the weighted-average remaining lease term for operating leases was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Cash paid for amounts included in the measurement of lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following are the lease payments owed under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510113888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.       Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.022%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan and 2022 Inducement Plan</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#8217;s employees, directors, and consultants. The Company&#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value and the term of the award shall not exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The stock options generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period with one forty-eighth of the shares vesting each month or over a four-year period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting at the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2023, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,144,785</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23,018,705</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock under the 2019 Plan, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,579,341</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were available for issuance of future awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,630,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407,389</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were available for issuance of future awards under the Inducement Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option activity is shown below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,644,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,996,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,628,925</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713,272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,057,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,467,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31,<br/>&#160;&#160;&#160;2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021, respectively. The weighted-average grant-date fair value per share of options granted was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Activity</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity for the RSUs is shown below.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the Company&#8217;s stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">model </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be amortized over an estimated weighted average service period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,539,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">414,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,044,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,142,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,584,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510,513</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of<br/>December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,092,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">591,397</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unrecognized compensation expense related to the 2019 ESPP expected to be recognized over five months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510389904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.       Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal and state income tax provision for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.509%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,627</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits, net of uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.569%;"></td>
        <td style="width:2.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.256%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.256%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">931</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,311</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,608</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175,925</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal and state net operating loss (NOL) carryforwards of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">202.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of taxable income. State NOL carryforwards will begin to expire as early as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if not utilized, or have an indefinite life. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had federal and California tax credit carryforward of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal tax credits will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2041 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">while the California tax credits have no expiration date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,588</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and penalties for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company recorded an uncertain tax position of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The income tax provision for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, included changes to reserves related to prior year uncertain tax provisions of an increase of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and decrease of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The income tax provision for the years ended December 31, 2022, included changes to reserves of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511172944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.    Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#8217;s development of antibodies optimized by Adimab in its AL003 program, which was terminated in June 2022. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies, the term of which was extended effective August 2022 (2019 Adimab Agreement). In December 2021, the Company signed another</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab Agreement expired and the Company did not exercise any option to carry forward any of the results. Tillman Gerngross, Ph.D, the Executive Chairman of the board of directors of Adimab is a co-founder and former director of Alector. Dr. Gerngross resigned as a member of the Company&#8217;s board of directors, effective June 15, 2023. For the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any expenses related to Adimab. For the years ended December 31, 2022, and 2021, the Company incurred expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued liabilities due to Adimab as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of any covered product candidates.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511172944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11.     Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.22%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>&#160;December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,092,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,044,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713,272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,644,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,348,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,925,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,088,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511822304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12.     Restructuring</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2023, the Company committed to a plan to reduce its workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to better align the Company&#8217;s resources with its previously announced strategic prioritization of its late-stage progranulin and TREM2 immuno-neurology programs. The Company initiated a reduction in force impacting approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees across the organization effective March 29, 2023. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company incurred restructuring costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, primarily consisting of one-time charges related to the reduction in force, including personnel expenses such as salaries, one-time severance payments, and other benefits, which were included in operating expenses. Accrued liabilities associated with restructuring costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511063600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13.     Subsequent Events</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 17, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp; Co. (Cantor), relating to the issuance and sale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,869,566</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock at a price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.57</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> paid by Cantor. The Company also granted Cantor an option exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of the underwriting agreement to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,630,434</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Aggregate gross proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 19, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The option to purchase additional shares was not exercised by Cantor</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508187632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,555</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,472</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,101</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,795</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, certificates of deposit, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#8217;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_94e46f7d-4030-4cdd-937b-79e7aa9936e8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize an impairment loss on its long-lived assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each performance obligation is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the performance obligation.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing price of the Company&#8217;s common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits within the provision for taxes in the consolidated statements of operations. The Company accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and penalties for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Employee 401 (K) Plan</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the Code) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022, and 2021, the Company made matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the Company&#8217;s consolidated financial statements and disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511046048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.72%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:1%;"></td>
          <td style="width:12.92%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,555</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,323</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,472</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,101</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155,795</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817511069760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.5%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:9.94%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.9399999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">178,206</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">543,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">501,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,346</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">655,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510157904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.333%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.503%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,616</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,228</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,911</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,050</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510988624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.91%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.74%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.957%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,638</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,141</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,293</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,551</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Payments Owed Under Company's Operating Leases</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following are the lease payments owed under the Company&#8217;s operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,557</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506899840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.44%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended <br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,391</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,798</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.022%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:16.793%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options to Purchase Common Stock</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option activity is shown below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.34%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,644,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,996,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">298,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,628,925</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713,272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,057,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,467,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31,<br/>&#160;&#160;&#160;2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Awards and Restricted Stock Units</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity for the RSUs is shown below.</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value per<br/>Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.35</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,539,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">414,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,693</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,044,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,142,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,584,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.41</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510,513</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.03</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units as of<br/>December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,092,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507687840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Federal and State Income Tax Provision</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal and state income tax provision for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.509%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.183%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,178</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,209</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,627</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits, net of uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,661</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,421</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,212</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.569%;"></td>
        <td style="width:2.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.256%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.256%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,448</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">931</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">806</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,311</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Refund liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,608</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175,925</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,550</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,544</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022, and 2021 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,138</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,588</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510919264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.22%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.645%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>&#160;December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,092,101</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,044,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,096,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,713,272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,644,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">160,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,406</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,348,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,925,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,088,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507921152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Credit losses on marketable securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss on long-lived assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax, Penalties and Interest accrued</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined matching contribution plan</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506579616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,555<span></span>
</td>
<td class="nump">$ 154,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 76,101<span></span>
</td>
<td class="nump">$ 155,795<span></span>
</td>
<td class="nump">$ 330,624<span></span>
</td>
<td class="nump">$ 51,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817503563104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">$ 67,101<span></span>
</td>
<td class="nump">$ 74,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">67,101<span></span>
</td>
<td class="nump">74,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">178,232<span></span>
</td>
<td class="nump">506,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">178,206<span></span>
</td>
<td class="nump">501,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">29,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">29,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">140,082<span></span>
</td>
<td class="nump">44,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">140,133<span></span>
</td>
<td class="nump">44,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">129,474<span></span>
</td>
<td class="nump">29,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">129,569<span></span>
</td>
<td class="nump">29,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">543,975<span></span>
</td>
<td class="nump">655,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(4,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">$ 544,158<span></span>
</td>
<td class="nump">$ 650,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alec_CertificateOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alec_CertificateOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506900272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Remaining contractual maturities of investments were less than one year</a></td>
<td class="nump">$ 503,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue', window );">Remaining contractual maturities, one year through two years</a></td>
<td class="nump">41,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">$ 3,505<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817510996560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IndemnificationAgreementLiability', window );">Indemnification agreement liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IndemnificationAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification agreement liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IndemnificationAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817503818944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,115<span></span>
</td>
<td class="nump">$ 210,418<span></span>
</td>
<td class="nump">$ 189,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborationAndLicenseAgreementEffectiveDate', window );">Effective date of agreement</a></td>
<td class="text">Aug. 17,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementUpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Milestone payment received</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfDevelopmentCost', window );">Percentage Of Development Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,600<span></span>
</td>
<td class="nump">62,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,400<span></span>
</td>
<td class="nump">444,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ReductionInTransactionPrice', window );">Reduction in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_TransactionsPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Contract with customer, refund liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CompanyMaximumFunding', window );">Maximum funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Cumulative adjustment to revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable', window );">Additional milestone payments related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_TransactionsPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_TransactionsPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc | Change in Estimate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Contract with customer, refund liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AlectorMember', window );">Alector</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfDevelopmentCost', window );">Percentage Of Development Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementUpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram', window );">Exclusive option rights exercised for each program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable', window );">Additional milestone payments related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500<span></span>
</td>
<td class="nump">70,700<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
<td class="nump">$ 46,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients', window );">Payment for enrollment of additional patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable', window );">Additional milestone payments related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborationAndLicenseAgreementEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreement Effective Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborationAndLicenseAgreementEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, additional milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments for enrollment of additional patients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, milestone payments on option rights exercised per program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CompanyMaximumFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company maximum funding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CompanyMaximumFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ReductionInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ReductionInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_TransactionsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transactions Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_TransactionsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_GskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_GskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=alec_ChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=alec_ChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AlectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AlectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817509221616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 49,911<span></span>
</td>
<td class="nump">$ 48,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(28,050)<span></span>
</td>
<td class="num">(22,612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">21,861<span></span>
</td>
<td class="nump">25,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,372<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,493<span></span>
</td>
<td class="nump">17,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 26,616<span></span>
</td>
<td class="nump">$ 26,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817509248144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">$ 13,539<span></span>
</td>
<td class="nump">$ 12,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation</a></td>
<td class="nump">15,297<span></span>
</td>
<td class="nump">12,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 30,378<span></span>
</td>
<td class="nump">$ 27,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817504775152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Amount form letter of credit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease expires in 2029 with an option to renew for a period of ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included In measurement of lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AreaOfPropertyInLease', window );">Area under lease | ft&#178;</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AreaOfPropertyInSubleaseAgreement', window );">Area under sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubleaseExpirationMonthAndYear', window );">Sublease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-11<span></span>
</td>
<td class="text">2025-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-12<span></span>
</td>
<td class="text">2021-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AdditionalAreaSubleaseExpirationMonthAndYear', window );">Additional area sublease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend', window );">Operating sublease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AdditionalAreaOfPropertyInLease', window );">Additional area of property in lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  06,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Extend for an additional lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AdditionalAreaOfPropertyInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area of property in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AdditionalAreaOfPropertyInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AdditionalAreaSubleaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area sublease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AdditionalAreaSubleaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of property in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInSubleaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of property in sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInSubleaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether sublessee has option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507268016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 6,626<span></span>
</td>
<td class="nump">$ 6,638<span></span>
</td>
<td class="nump">$ 6,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3,149<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1', window );">Sublease income and reimbursement of variable lease cost</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(2,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 7,293<span></span>
</td>
<td class="nump">$ 7,551<span></span>
</td>
<td class="nump">$ 7,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508206672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 8,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">9,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">9,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">8,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">48,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(9,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 38,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506580800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 42,798<span></span>
</td>
<td class="nump">$ 46,146<span></span>
</td>
<td class="nump">$ 40,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">22,407<span></span>
</td>
<td class="nump">24,895<span></span>
</td>
<td class="nump">21,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 20,391<span></span>
</td>
<td class="nump">$ 21,251<span></span>
</td>
<td class="nump">$ 19,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817503335520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507183536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards And Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue', window );">Grant date fair value of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based payment award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Un-recognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Automatic conversion provision of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,018,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,144,785<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfStockOwnedByIndividual', window );">Percentage of stock owned by Individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price per share from fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage', window );">Cliff vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,579,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Automatic conversion provision of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubsequentOfferingPeriod', window );">Subsequent offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Un-recognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfStockOwnedByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock owned by Individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfStockOwnedByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubsequentOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsequent offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubsequentOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817503515904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details) - 2019 Equity Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, beginning balance</a></td>
<td class="nump">13,713,272<span></span>
</td>
<td class="nump">11,644,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">572,538<span></span>
</td>
<td class="nump">4,996,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(132,192)<span></span>
</td>
<td class="num">(298,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(2,057,381)<span></span>
</td>
<td class="num">(2,628,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, ending balance</a></td>
<td class="nump">12,096,237<span></span>
</td>
<td class="nump">13,713,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">8,467,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">12,096,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, beginning balance</a></td>
<td class="nump">$ 14.62<span></span>
</td>
<td class="nump">$ 16.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">6.98<span></span>
</td>
<td class="nump">12.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">8.16<span></span>
</td>
<td class="nump">10.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">14.21<span></span>
</td>
<td class="nump">18.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, ending balance</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">$ 14.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable (In years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817505314048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details) - Restricted Stock Awards And Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, beginning balance</a></td>
<td class="nump">3,044,618<span></span>
</td>
<td class="nump">1,373,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">5,142,444<span></span>
</td>
<td class="nump">2,539,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(1,584,448)<span></span>
</td>
<td class="num">(414,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(510,513)<span></span>
</td>
<td class="num">(453,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, ending balance</a></td>
<td class="nump">6,092,101<span></span>
</td>
<td class="nump">3,044,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</a></td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 18.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Granted</a></td>
<td class="nump">6.62<span></span>
</td>
<td class="nump">10.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Vested</a></td>
<td class="nump">10.41<span></span>
</td>
<td class="nump">18.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Forfeited</a></td>
<td class="nump">10.03<span></span>
</td>
<td class="nump">16.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, ending balance</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817512251120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Federal and State Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 4,178<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 5,212<span></span>
</td>
<td class="nump">$ 3,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817504526048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at federal statutory rate</a></td>
<td class="num">$ (26,188)<span></span>
</td>
<td class="num">$ (27,205)<span></span>
</td>
<td class="num">$ (7,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits, net of uncertain tax positions</a></td>
<td class="num">(14,460)<span></span>
</td>
<td class="num">(15,138)<span></span>
</td>
<td class="num">(7,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncomeTaxReconciliationUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,842<span></span>
</td>
<td class="nump">4,919<span></span>
</td>
<td class="num">(2,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">40,661<span></span>
</td>
<td class="nump">38,421<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">176<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 5,212<span></span>
</td>
<td class="nump">$ 3,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817504704464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 12,448<span></span>
</td>
<td class="nump">$ 20,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued bonus</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">26,682<span></span>
</td>
<td class="nump">26,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">15,311<span></span>
</td>
<td class="nump">13,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">63,004<span></span>
</td>
<td class="nump">67,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">9,030<span></span>
</td>
<td class="nump">10,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Section 174 R&amp;D capitalization</a></td>
<td class="nump">62,305<span></span>
</td>
<td class="nump">35,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxAssetsRefundLiability', window );">Refund liability</a></td>
<td class="nump">24,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">214,939<span></span>
</td>
<td class="nump">175,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(204,550)<span></span>
</td>
<td class="num">(164,316)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">10,389<span></span>
</td>
<td class="nump">11,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(4,544)<span></span>
</td>
<td class="num">(5,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(5,845)<span></span>
</td>
<td class="num">(6,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(10,389)<span></span>
</td>
<td class="num">(11,609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Assets tax deferred expense capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities Right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817504669376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax asset change in amount</a></td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax, Penalties and Interest accrued</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain tax position</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase on uncertain tax provisions related to prior year</a></td>
<td class="nump">2,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease on uncertain tax provisions related to prior year</a></td>
<td class="nump">594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ReversalReservesOnUncertainTaxProvisions', window );">Reversal of reserves on uncertain tax provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 27,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_TaxCreditBeginningExpirationYear', window );">Tax Credit Beginning Expiration Year</a></td>
<td class="text">2041 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Operating loss carry forward, deductions</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">$ 202,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_OperatingLossCarryforwardsBeginningExpirationYear', window );">Operating loss carry forward beginning expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OperatingLossCarryforwardsBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OperatingLossCarryforwardsBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ReversalReservesOnUncertainTaxProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal Reserves On Uncertain Tax Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ReversalReservesOnUncertainTaxProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_TaxCreditBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_TaxCreditBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817508186720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">$ 15,138<span></span>
</td>
<td class="nump">$ 6,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to tax positions taken during the prior year</a></td>
<td class="num">(594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to tax positions taken during the prior year</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken during the current year</a></td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">8,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">$ 20,203<span></span>
</td>
<td class="nump">$ 15,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817507277728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Related Party [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Adimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued liabilities due to related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Two Thousand Fourteen Adimab Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Related party transaction expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=alec_AdimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=alec_AdimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=alec_TwoThousandFourteenAdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=alec_TwoThousandFourteenAdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817506820960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">18,348,694<span></span>
</td>
<td class="nump">16,925,023<span></span>
</td>
<td class="nump">13,088,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember', window );">Restricted stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">6,092,101<span></span>
</td>
<td class="nump">3,044,618<span></span>
</td>
<td class="nump">1,373,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">12,096,237<span></span>
</td>
<td class="nump">13,713,272<span></span>
</td>
<td class="nump">11,644,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares Committed Under 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">160,356<span></span>
</td>
<td class="nump">167,133<span></span>
</td>
<td class="nump">70,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817512079616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2023 </div>
<div>Employees</div>
</th>
<th class="th"><div>Mar. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfReductionInWorkforce', window );">Percentage Of Reduction In Workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_NumberOfReductionInWorkforce', window );">Number Of Reduction In Workforce | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_NumberOfReductionInWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Reduction In Workforce</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_NumberOfReductionInWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfReductionInWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reduction In Workforce</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfReductionInWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139817504686208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Event [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 17, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Underwriting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Date of underwriting</a></td>
<td class="text">Jan. 17,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued or sold | shares</a></td>
<td class="nump">10,869,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share of common stock issued or sold, Price per share | $ / shares</a></td>
<td class="nump">$ 6.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SaleOfStockOptionTerm', window );">Option period (in days)</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate gross proceeds from the offering | $</a></td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses', window );">Amount on underwriting discounts and commissions and offering expenses | $</a></td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SaleOfStockClosingDate', window );">Offering closing date</a></td>
<td class="text">Jan. 19,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued or sold | shares</a></td>
<td class="nump">1,630,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount on underwriting discounts and commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SaleOfStockClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering closing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SaleOfStockClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SaleOfStockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Option, Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SaleOfStockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alec_UnderwritingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alec_UnderwritingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MLEDS&&JQ674 MM2JV$H/X)H3]_?8ICR5D-[^EZY1P",]-+/B==<9Z)]8JV;
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M&E -H)($HS#3?,\TCS+]T_*T$=H\@DI8S0/*B=N97)ZU]F1\=O, %Y0/EX,
MBF5HA#&"O3#!5S)-&U463I?<TA44'>C'7N(%: A%&1[A=R"<*#ZG71:-3]YN
M^%'0490-R?FHE,)\A%PO<"BJ*;O\B9##_F-M-.)AX@1P+&,I'5E%4:]*B)PD
MP57)'\JJ6^N#.HRBZO:]0ORCK!T[W2L<BDO<AZ*0K95>JQ//3D*"#ONZ11@;
MYEP 96-K+&QZ<4-Q=;,$5>L2SMXH"QM!NEVOJV>K<GHDCGS1LHN5QS: 2I(Q
MMKVVH;BXO; ]B*$@1U^A""3,RT0?AAEC8^M8KV0H+F4W8BELK"_LIF<CFE9,
M][*VELI5#4'.OF)E./?#P(?1#),QSKVPH5>4;1N?P,C3"QSD*Q=CD P9^R@X
MPK87-Q17MSNQ;)L^#)Y':9\V];Z>D9S28;46@(TX@GO)PW')&\KT06"?1!W[
M2I?1% ^8AU!P+!MQKX<XKH?')=LK.8E]V4.,Y728E %<3K(Q?<0'&\"X/OI)
M6<GF\<P(54<GV)=#C&!&AWD9P%%*"!N+D%XV<7PW]QVA?II#Q*\#&*3#,B
M&W.E%T,<%\-HL)]&/B"5D";#^B\$2W Z4L+@7BQQ7"RW!6#/]+60]T40$39<
M'P,H-IJ;O5+BN%)N<_,U@KX 4EOKI?F0HH]+&,$'&_!CEKU2XKA27LNZ+HW;
M0VWWJ85L7'R(IK",P=L_I!& O@M2CQH.UW4@V*GY_X:.G>\E%V?1@OC>R.+K
M2E8+H?0OW6[2/(<[4U'I_N[6U ^R=NQU+]TX+MWNE=M%2SOGI^ -/(<0(K>&
M@0VO6O$>8 BG</L'](HKU\)HS4JJ\E^Q> \R.LU8/DUSTD5,AJ=9GDP9RE[
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MPBOH+CM4\AM[_I4.A$)M+V>5Z/YZSP/67WCY04A6#X/5#.JRZ?]G/P9'G Q
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M63@!E%5C7) IH5$+(;<8VM(=52FA4.>")]H<X" $I$H4Q0DV*=BX*"*)*6D
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MUK:7LC9U[2@=R1L-,_ L<RP(^N%&7AV*_J%S9G1$)WW$-]H$PSSB2=8WC\X
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M^/B\1[^(N7,N&^'PS.H?*O?E+/F00(Y;T6A_;7>?L<OG..!)JUW\AUUG.TI
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M9O',<.):U45+54JK3PG7DQI=PA(!P-]Y&JZG:!CN.4OH>10Y#@I< 8U/$O/
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M(@9E6C:X69/G _A>.S3B\,(.QKOZZCM02P,$%     @ 7();6#:J)R/S$
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M>+_8+%"Q.'_$RQ#=66*'<D%N(Y VB@U7+4MQ"]^2Y'49N1\\U^V(V,M:EV?
MX4"FA6JV2E5[O0^M1K%I-]&!G?P]QQMS7!9FT>8KM):!Q5RTELCTI+Z598O@
M5LU:YWV7RQ7%'(-2]!SG''A2*\--*9ME@;3C1 U*=>X]ZMN^7MN0#CVE(:AP
MQU@P",$*MJUK;1[ ]5Y5Y\M90TVAB^U/E=X>KO6V+V%P2!>YMCET%4Y1U2WB
M (RV1L7J$N$7Q7M,#;1EYY5H)3=D?ZIF$%<H.P B,O\#55GP,@/)J]9[^/Q\
M^G4TL"^W>E%)7 LN7=B<+D9'6'$5(H6)Q0/+7!<<I9 %[Q0Z1Q:]=JC.L;Q&
MG%/I3-VD ^H;Y#"U62!H3F83'] ,&E *&O" =I1"R%M0<@?-T>.T?N@#88"G
MUA@V>5==]]*HBV&8QR6BI [\^)7<U-]>]S- SV\191[@>AK<7X@[<7QZD""4
M&?96O]IFNHX?QBQOK49U1U[%2#Q4P+M?KP_%U=?:+"_F>[3!U8W?M7"6EQO=
M5JQC+VVBBWRH*;RS;!M2?C0M.7R!;T-6(MCJ-,@XX?3*:@*R8S<":;B'MW$?
M]R;>I;![F_G@V<7_$"F#KND>[GTZG0?O_@^1]<OAU=!$P4)=J3F *GII61@H
M+QAQ/WC]+^'2Z1>$);;08ZB4ZF2LC(F^55B..!\U,5:I%'HY>SE)QQZ0]]+
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M-&W [PNE;#,A ^W_0"[^ U!+ P04    " !<@EM8SLMYXC\.  #+)P  &0
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MJK6NV"K^X[4V0'GZYD4/"Q1E^I;B\?VG#MAL2W0?$;%MO9#90M93[% B^.L
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M\D#=7CQ.,?M4%>WNX?B^KO3+35L.-,/UW1KV^.=??GR"@J#U 6+ON2X].G=
MSR<7PU#ZL]#*D:%"EQZECF .L_.]8'48L[:3!<TSDAON$ X3P#"REI8<L?*@
M#S%(30_*/OE$?"HH^.8Q^YO#W@ENQ\QW:7>9!$^MJ<HK$-DA @D6L">4P$5*
M=1&!M'*>;Z$7$=XO"/BE]N:547>,_@90@7"UY X%O@4XD?FNJ6'AV3CI8.&-
MGBS&V26;]\<>VVLT!HV!&U3:A/(C[.D4&)(Q^*L.^SR^2P@X9C^XG(Q(B(+]
M3G+[79^0 BW1+:>PQ!2UI+Q$8G'2L&X@>B6W:$D\HZ:;/-0>W,Q&[ECAN]GC
M,N,[T=)'4]OE9'-,%#[[A]=^&NGOP[(+<H9&?-G(RC[%14BN?JRAD#F7Q_CQ
MY<@]&^1._I(G2CHI6GX$=X1B-U$(6XRC8\M;"L_%8'>%U.!CN>O##3!:%$I3
M92"W#/7);2L'LP;4#Y@@N,<)Z2=<WVP85'.2QC30"QXCJFG\_-P68_<\\=W_
M*>5"-57Y!:Z/ C<R->S"<1M2 Y.A);C8;"[%BM)[V^RTR70@/R-/-9IJ'<QZ
M7N+N6B1$3B"_%$08(8OB4I(:3D+15EADFAH+C _+-CF$\L/W=(9 $8]G 3^D
MU]&0KA;MG;&"V?&:$H,^1P\Z="2C'NJ9JV+@A,8KE*8C;*U+G]WIA7>L.S@D
M4&B!7L)K,X2=IJ8S TQEGX/!P[#]_QKS7_/*54T^F&@3I+\I31$T@[KJ:4X$
M/IF9+?\H3DKI/$H6BP<XI&$JIVGPJQE@(ECD?D!V>[]B:QI-YO._I!6&OUGR
M@%:9'TI1\=@[#^W[_7CI^.(2]8A0?23HT@[0W39+*!T2,/*A3MP'SHQ"@NF)
M$K#?]DGWM65MGH44A3](0_$,7>)>VLT]_>1)<'8PWZE*%BY6(;%OM:E>(O:$
M\=T[YA->N:&NYZJ+5G5M!AA$3IR0OLZ.(-T!4WA%B0LBE(ZP2_';]N0CM&PN
MU??S"@^G#8]8OY.\(/.7G'F>DB^5\(DK]$:',V@0Q> $Z]' C:J1:@ZTR-!0
M=>RNK1OE,7DWM2LF/I%?QJ0#4N\PJ&I39FO.!!K[,_HA?)YJTC&YBSB7CB^@
M'S4:;.'&A^;EXQQ']C?(M(:(N:SKIEGQB6/(\CA<'EHA7"EID LUTG#$_#%0
MF'VM*#8U-*_8%MG?PO-O3R>$BPFWS;3I:8=*-M"TX1YU5W2F=Z?[G%]N^,G(
M#YZP7Y:TG6GI]"O40U=2W0G_29CM,-IKC]TSX;LV*+BR2QY.FW0\/=&F%/VW
M\?'M_ZA+^H J8.>&J.'<TV.K!1H)*+-N^VP\H8^0_=;I#$W]D6.K$/B^072Y
M,J +">!.2W),FX3CD\[LT)>(-ZYY[S%2^LBBC^&.BS][=T;N-RTAYYV<CZW"
M\9(WKM?54,:#1X:^.UWWO@DB,M;NRZ?K,&OK/P]V3[N/JZ_\-\7C<O]E]B>N
MU\2L$BMLC<>SR173_FNGO[%JY[XP+I6U:NLN-X+#!K0 [U=*V?:&&'2?G&_^
M"U!+ P04    " !<@EM8J1Z']Z4$  #J"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6R=5FUOVS80_BL'MRA2P+$E.6W3-#'@).W6(06"OFP?AGV@
MI;-$E"(UDHKC_OK=D9+B)$Z0[$-BD;Q[[KE7\GAM[$]7(7JXKI5V)Z/*^^9H
M.G5YA;5P$].@II.5L;7PM+3EU#4611&4:C7-DN3MM!92C^;'8>_2SH]-ZY74
M>&G!M74M[.84E5F?C-)1O_%5EI7GC>G\N!$E?D/_H[FTM)H.*(6L43MI-%A<
MG8P6Z='I <L'@3\EKMW6-[ G2V-^\N)S<3)*F! JS#TC"/JYPC-4BH&(QK\=
MYF@PR8K;WSWZI^ [^;(4#L^,^DL6OCH9'8Z@P)5HE?]JUK]CY\\;QLN-<N$_
MK*/LC(3SUGE3=\K$H)8Z_HKK+@Y;"H?) PI9IY %WM%08'DNO)@?6[,&R]*$
MQA_!U:!-Y*3FI'SSEDXEZ?GY5U3"8P&7POH-?+=".Q'BY8ZGGO!9:IIW6*<1
M*WL *\W@B]&^<O!1%UC<!I@2L8%=UK,[S1Y%/,=\ K-T#%F2S1[!FPW>S@+>
M[-G>PM^+I?.65O_L<CS"'NR&Y<8Y<HW(\61$G>'07N%H_NI%^C;Y\ CI@X'T
MP6/HSTS1XUAI,H%'@O!94Z33@S'X"N',U(W0&T#MT9*\U-Z  *HX)9;&BMA5
MI46D)O54M[Z"!76L6([AXN(,]N+B-;14#1;6E<RK6\#24?]<T5QHI"Y!:"^7
MII!(N]+EYBH876XZ3#(/TCL@[N87><5;0A>PN$B3%!IK2BMJ%[8>Q#6-E[7\
MM0MV<9$D60\#>QR%7F+1N_AZ M^)_LXS$,H9UK^25/I TW+;U5<O#K/TW8>!
M5] PJV=PF_7<QET@U\(!Y85&0D@FB?[1:B:791/.XZ(M:7HPV?>WT^EDJ4GA
M28D,?G!%"TLF.;9W'2@*R>I";?D2[3$Y%KFAB]<>>3  KE88IO$-RRP+07^_
M*^CD#0T"K)=41229[O9'&]JU3_:JH\OE75(YH>5:&5P=ZFF/#3Y<"3O.R,U&
MVL"HN$6TD 4023I'FTN'P)N<=N))G94+:S=,;2UL$<]609](T17CR*14JA8:
M?D.K2VL<!?JRFIS'<'R\QKP-,3VKA+0LU^DO#0/2HB!:N3?6\:(O,1<J87]E
M8I<R:;[JZ;,7#](J?$[@G/X&^TRMBS[#U#%%G=F[I7^?QGBK$$+QIF_BI)_
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M1K?@B*WDLNPE']I.UR.4[(IB2Q^[H]@##<4U X).A*[(XL4J[USU"$Y[HS#
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MYXV!@+>/L/(HHZM<Q/O:B9JZ2XN&R0(A#42:..D6()4%F(+1(WKZ#8W**O(
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ME-UUI8[2:U@0FTCABPV8RM8E98O*)1F;E#:C-:SQC50LJP5R5":4+K>-*^S
M%_=7-N7A6N?"G/\E@;::ONTB%IR9Y;7=(AD48)@XK9OJES1]\$M,U)FF/9 !
M<XW)Q:\(BZ4N(44X3GL=B_;>8;B*.U(MA)%DT,A/$RPR)908N4VFR;]0\?+1
M"H >[M[!4)?Q"9T/WHBLUIVT,UJVUN22* 5':<PBO&@0<A -5+U#.A$1'MP9
MX(3/PR6+J-6J,FRIX7O*4(]M-R\HX"[LZ^0+?B8S3E%FE(E\=C)@X)B\09_X
MM$/R#0"5'J(CAF6++YZ#*Z)2^8RH'M6'(Y)P7/ZSPV$^A$-[SDF$SZ/0L23
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M5XYL<3"F!$<B([09/B\/VW@=L&Z["'JG&GV$$.W>DUYMO TE#JJ"[G$B1'N
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MC8::>A"Z'.+&(Z=!A"(7ODJHR\9WX=TQ]V[X@V.!JMO-\KK7E;5-1>D8:#H
M6+J=O9J_VZ?;PL9L2%62(=B';K:;POBNDM^:?-5>6VGO+.B!A,E)O"]GZ6.N
MT)<+0OT5*5$+&IV,N_B##@T'Q#V8*UO[1HYM]6+B8Y/ -[F<$=_("'L1?25D
MZ;)^:+RE<V4AFHN+K]ZX*:"^,@SINK]2,Y[ZMU>^9N-WOFXC1W8=.;+!&.''
M0"6W1YQEIR#E=(!B,=?\[NK&0.<4@:\SJMUO*S\14;73^QA+(E#LMSO[MOW
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M0OLT/",TC;)TZ@>8/8P.CE W4K\ H&&-S<SVXM L8M.)MYUD^6"+LJQ19#1
MC7Q0HL 0:$3I%)_3/ W^PB ,&2'923+=B<F/A'U&T@23.?<B3J+)Y+B(\<'5
M78/9= W*GUFK7'^+#ZM##[SNK_Y7\[Z!?N1F(Y0E$M;HFEQ.4#_3-Z5^XG33
M-8*5=MA6NF&%?1R,-\#O:ZW=?N(W&/X,%C\ 4$L#!!0    ( %R"6U@6Q,O[
M;P,  ,4'   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;'U5VV[;.!!]
MUU<0:M%- ".Z7^S:!I*T10NTJ-&DW8=%'VAI;'$KD2I)Q<G?[Y"2M4[AZ$4<
M7N;,&9WA<'D0\I>J #1Y;&JN5FZE=;OP/%54T%!U)5K@N+,3LJ$:IW+OJ58"
M+:U34WNA[Z=>0QEWUTN[MI'KI>ATS3AL)%%=TU#Y= .U.*S<P#TN?&/[2IL%
M;[ULZ1[N0']O-Q)GWHA2L@:X8H(3";N5>QTL;A)SWA[XP>"@3FQB,MD*\<M,
M/I4KUS>$H(9"&P2*PP/<0ET;(*3Q>\!TQY#&\=0^HG^PN6,N6ZK@5M1_LU)7
M*S=W20D[VM7ZFSA\A"$?2[ 0M;)?<NC/IHE+BDYIT0S.R*!AO!_IX_ ?3AQR
M_P6'<' (+>\^D&7YCFJZ7DIQ(-*<1C1CV%2M-Y)CW(ARIR7N,O33Z\^ *2ER
M<4^W-:C+I:<1U&QYQ0!PTP.$+P $(?DBN*X4><]+*)\#>,AFI!0>*=V$DXCO
MH+@B43 CH1]&$WC1F&)D\:+I%/^YWBHML0I^GDNRAXC/0YB;L5 M+6#E8NDK
MD _@KM^\"E+_[03!>"083Z&O;T73"@Y<*R)VQ-(E[Q_QVBDX1W42[#S5^PI(
M\2Q*;:- 'X4<0 *ABNQ$C;=4+1S4 )HM2*.#8W0P8H3F$S@7GSC1E>@4Y:6Z
M=+ZV(*EF?#]@%D)I\IJDLS1,^S'*[1CZL?.#2F8J[?1L- OB.0EG69Z@[<>I
M<]=M^WW&D34RXR4V -9L.ZD .X(V&3R<@;I F#@/R25:P2S/>BO$  &Y=.Z%
MIC52R6;A/+)CD@1V#/PYF1 R&85,)H6\PY99=DAIE'%#GQK[R[\>H"3?\89(
M8N2F_.DO7!Q_75^CY]2>C/BRVKV2!IJBM+HZ_J;V2$@80ITE9'8'4F]>Y6&0
MO<7MYZHJ4QV8U6E=V/NY^+,<<#'&?YK/\B0QDX3,9T$:&#-%,\XR8V9HYE@/
M:.9X=I[.'62-K\I.(WB(M3(?Y$**3!6BXQKY_I%#G"->XGP&I19D8_+'TGB@
M=8<E4_Z+S=/6R@7&2I)L+( >I,;B83733T@V0@9!?K8"O)/6VH#<VP=$$4NH
M[[+CZOA&7?>M^?_C_0/WA<H]XPKC[]#5O\I06MD_&OU$B]8VZJW0V/:M6>$[
M"](<P/V=$/HX,0'&EWO]'U!+ P04    " !<@EM8ZP0-;(<%  #E#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R=5]MN&S<0?==7$,H%-L"LEMR[
M+P(D)TWSD,:PXP1%T0=JEY(([RX5DI+B?GV'I+22'5DU^F!K>)F9,YPSL^3%
M6JI[/>?<H)]-W>K+_MR8Q=E@H,LY;Y@.Y(*WL#*5JF$&AFHVT O%6>64FGI
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MC9&%>]P S4'9 ?C[2DKSV+ 3-!=DBW\!4$L#!!0    ( %R"6UC,X^Q@ZP(
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M( Q S\\Y5R\=<S1O[GK)/U!+ P04    " !<@EM8948<C\H%   !)0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6S-6FUOVS80_BN$5PPMD,0B*5ER
MEAC(R](62+8@:;H/PSXP-AT+E427I)UVV(\?):NB)%*R4S!!OMB2=7?D<[P[
M/C[JZ)'Q+V)!J03?TB03QX.%E,O#X5!,%S0EXH M:::>S!E/B52W_&$HEIR2
M6:&4)D/D>:-A2N)L,#DJ?KOFDR.VDDF<T6L.Q"I-"?]^2A/V>#R @Q\_W,0/
M"YG_,)P<+<D#O:7R;GG-U=VPLC*+4YJ)F&6 T_GQX 0>GN$P5R@D/L?T4=2N
M00[EGK$O^<W'V?' RV=$$SJ5N0FBOM;TC"9);DG-XVMI=%"-F2O6KW]8ORC
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MD(>P1?UL=W745!\J+U>N1I6K46'/[[!WQ3+Z'5P1_D5EY\5*00+_@4NZI@F
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M<;F@9$9Y+J">SQF3/V[RMV"JMYXF_P-02P,$%     @ 7();6,IA2W8= P
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M'6;X* )I#/#[1 B]G)@-FF=6_ =02P,$%     @ 7();6.^&].,2 @  .P0
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MH:N/;VB(RV%,)!X3B0-O<H'W7AGS1O[?>^>#UA:$^7=.:$]X?9[03\/<M+2
M#+MV-Z /@/-/'Z:SZ/L[<I-1;O(>>[Z6)0C)*E;T%:6U!@C/P!G=,<[LRSG)
M/>EM(/7S=LBCE!Q.=9"37O!C]8OJFDF#.%0.$TUN;S#2?:OVAE5M:(^=LJ[9
MPK9QTPW:.[C[2BE[-'S'C?^+_!502P,$%     @ 7();6,&E/6.$#0  G,,
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M^A!?#R0KJG/P Y/J5%U=[H DP'6 >KYA3#X-]-&Z_2LE^A=02P,$%     @
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M[\NI7Y39JOH"DJ>L++.D^G7):,AR,0'_^R++RLT+T<'V6XON_@)02P,$%
M  @ 7();6+-'W1OU @  \@@  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULK59=;YLP%/TK%JNF5EK+9R#M$J0F=-JD5:N:MGN8]N# 36(5;&:;I/OW
MLPUA":59'O82;'/.N?=<.[Z,-HP_BQ6 1"]%3L786DE97MFV2%=08''!2J#J
MS8+Q DLUY4M;E!QP9DA%;GN.$]H%)M2*1V;MCL<C5LF<4+CC2%1%@?GO">1L
M,[9<:[MP3Y8KJ1?L>%3B)<Q /I9W7,WL5B4C!5!!&$4<%F/KVKU*(HTW@"<"
M&[$S1MK)G+%G/?F2C2U')P0YI%(K8/58PQ3R7 NI-'XUFE8;4A-WQUOU3\:[
M\C+' J8L_TXRN1I;0PMEL,!5+N_9YC,T?@9:+V6Y,+]H4V,C%3&MA&1%0U;S
M@M#ZB5^:.NP0W/ -@M<0O"XA>(/@-P3_6$+0$ )3F=J*J4.")8Y'G&T0UVBE
MI@>FF(:M[!.JMWTFN7I+%$_&7T$53:!S-&5%R2A0*1!;(+.,;E[4Z5+/TP0D
M)OF9@CW.$G1Z<H9.$*'H8<4J@6DF1K94N6A%.VWB3NJXWAMQ70_=,BI7 MW0
M#+)] 5N9:)UX6R<3[Z!B ND%\MT/R',\OR>AZ?%TKX>>'$]W#[CQVWWQC9Y_
M>%]^7,^%Y.K/\;.OQ+5$T"^A+XPK4>(4QI:Z$03P-5CQ^W=NZ'SL*\__%$O^
MD]A>Z8*V=,$A]?A;"1Q+0I<H-Z<X94+V5:]6B8R*OAW7<1AZX<A>[U:E#^0/
M]T%)#\AS@A:TYV+0NA@<=/&$.<'S'/YAHA8)=T+[;G#9,?$:Y$7#0<=$CY(3
MA/TFPM9$>-#$K)K7Z1.:L@*0NBM4KR#%O.("5/.0^JY9'^<T?)7?N1<,O8[5
M'I0[C#JHI$_+#=Q^LU%K-CIH]H%)G/=E'KTZ'I%WZ7<2[P$-!FXG[QZ0ZUQV
MTK9WND$!?&FZJE!UK:BLK]-VM6W<UZ9?==8GJJ'7_?>O3/TU<(OYDE"A=FRA
M))V+2!T>7G?8>B)9:7K.G$G5P<QPI3Y*@&N >K]@3&XG.D#[F1/_ 5!+ P04
M    " !<@EM8J,VS<M@"  #K!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6R-E6MOTS 4AO^*%29@$ELNS;6TD781 FF(:MW@ ^*#FYPV9HX=;*==
M_SUVDH5"TY8OB6_O>=[CQ,>3#1=/L@!0Z+FD3$ZM0JEJ;-LR*Z#$\I)7P/3,
MDHL2*]T5*UM6 G#>B$IJ>XX3VB4FS$HGS=A,I!->*TH8S 22=5EBL;T&RC=3
MR[5>!N[)JE!FP$XG%5[!'-1C-1.Z9_=1<E("DX0S)& YM:[<\;7;")H57PEL
MY$X;F506G#^9SJ=\:CG&$5#(E F!]6L--T"IB:1]_.J"6CW3"'?;+]$_-,GK
M9!98P@VGWTBNBJD56RB'):ZINN>;C] E%)AX&:>R>:)-M]:Q4%9+Q<M.K!V4
MA+5O_-QMQ([ \PX(O$[@-;Y;4./R%BN<3@3?(&%6ZVBFT:3:J+4YPLQ7F2NA
M9XG6J?0.=$H27:"Y_MYY30'Q)6H&T0QO]?8KB;YL($>/+ >!;GA98;9]HP<K
M$%@1MD)=B+>WH#"AY^@,$88>"EY+S'(YL96V:6!VUEFZ;BUY!RS=0G:)1NX[
MY#G>"#W.;]';L_._P]@ZRSY5KT_5:^*.CJ?Z_6HAE=!_PX\A:VT(?SB$.2)C
M6>$,II8^ Q+$&JST]2LW=-X?,3CJ#8Z.14]UOOZ0IU85-2ISRM9I' ?!Q%X/
ML/R>Y9]B!4.L5A7NL!(W=(=90<\*3K'"(5:PS_*C:)@5]JSP%"L:8H7[K-CQ
MAUE1SXI.L>(A5K3'BI,P&6;%/2L^RGHH0!?=I0(Q1(SWB)[G'" F/3$Y3N0*
M4U2SG,B,UTSI&D";NE!U=6'(2+)GQ(_]Z,"_ZCI_BI1SU,L=2#E&,W/DF$)K
M3&M ./^IRZ-Q,EABG#TG%TD0'/B[W)URZ?['KK0;00E>$$K4=M" NW=J1W'B
MQO\8L'=*M[D&/V.Q(DQJPE+KG,M('Q+1WBQM1_&JJ>8+KO3=T#0+?1N#, OT
M_))S]=(Q%T1_OZ>_ 5!+ P04    " !<@EM8X0J-*E@#   ;#@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6S%5UUOVC 4_2M65DV=M#:?!.@@$I!]
M5%HE!.WV,.W!32XD:F(SVT"[7S_;"6E@ ;52I+Y [-QS?,^Q;VP/MI0]\ 1
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M(4_Z^C&1MS=@*D"^7U J=@TU0'4?#/X!4$L#!!0    ( %R"6U@5__YEU@,
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MW;'(KAWV8S^)@\;NA'_8\ \OY/^>$RK;V5AQ#3L<0AQX01"TN';MO- ?N7B
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M)[GF<@.';2:- 3Q?"Z%?;\QQKCN^+_X#4$L#!!0    ( %R"6U@(A7GIP00
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M@3 3]/,%YVK3,0'J$C+Z"U!+ P04    " !<@EM8!0R.(G@#  #<"@  &0
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MQXUB:$Z%KS#3*H#C09[[8RU%Y>]>D3^89*KD) 371H 9 )B]&R#Y,&,19 Y
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M][*1\MR7_5#7FE6[UUAVK^!\^P]02P,$%     @ 7();6 ^45$C: 0  62
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MCGH[@=Z.>CN!WC[:[";0VU%O)]#;46\GT-M1;R?0VU%O)]#;46\GT#NBWI%
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 7();6)E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !<@EM8VP>]<YH(   )-@  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 7();6%#6!)Z/!@  K1L  !@
M             ("!WA   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( %R"6UC<A$L>C0(  "\'   8              " @:,7  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !<@EM8X157F<D$  !+
M$@  &               @(%F&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ 7();6.0<%CAO!P  ZCH  !@              ("!91\
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %R"6UB0BMP;
M% @  !<F   8              " @0HG  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !<@EM8=9.K$&0"  "*!@  &
M@(%4+P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 7();
M6&0ZHFM# @  B@8  !@              ("![C$  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( %R"6UBM-YR)JP(  ,8%   8
M      " @6<T  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M" !<@EM8@4*-?I(8  #620  &0              @(%(-P  >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %R"6UA29^T:<04  -8,   9
M              " @1%0  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M A0#%     @ 7();6/P@9AC;!   MPL  !D              ("!N54  'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !<@EM8-JHG(_,0
M  !;.   &0              @('+6@  >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;%!+ 0(4 Q0    ( %R"6UCWUJ$!=0,  +('   9              "
M@?5K  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 7();
M6"';70V%!@  #Q$  !D              ("!H6\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !<@EM8SLMYXC\.  #+)P  &0
M        @(%==@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( %R"6UBG&UI P0H  'X>   9              " @=.$  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 7();6*D>A_>E!   Z@L
M !D              ("!RX\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !<@EM8\2-*PAP#  !Z!@  &0              @(&GE
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %R"6UBUJ0;H
MHP,  . '   9              " @?J7  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ 7();6!L-&OIN P  C@<  !D
M ("!U)L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !<
M@EM8Z@NTA,P9   (4P  &0              @(%YGP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %R"6UBO#*[%\P(  )L&   9
M          " @7RY  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ 7();6#)=-H#3 P  V0@  !D              ("!IKP  'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !<@EM8)KD[X(T#   E
M"   &0              @(&PP   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( %R"6U@6Q,O[;P,  ,4'   9              " @73$
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 7();6.L$
M#6R'!0  Y0T  !D              ("!&L@  'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " !<@EM8-CR=9.0%  #6#P  &0
M    @('8S0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M %R"6UB-KAW\,@,  *T&   9              " @?/3  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ 7();6"A^0842!   +!,  !D
M             ("!7-<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " !<@EM8S./L8.L"  #W"0  &0              @(&EVP  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %R"6UAE1AR/R@4
M  $E   9              " @<?>  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ 7();6,IA2W8= P  <@D  !D              ("!
MR.0  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !<@EM8
M[X;TXQ("   [!   &0              @($<Z   >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( %R"6UC!I3UCA T  )S#   9
M      " @67J  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ 7();6%N_"7FQ P  5A$  !D              ("!(/@  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !<@EM8,A$ 2- "  #0!P
M&0              @($(_   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( %R"6UB-[B98] D  ,%H   9              " @0__  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 7();6+-'W1OU
M @  \@@  !D              ("!.@D! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " !<@EM8J,VS<M@"  #K!P  &0
M@(%F# $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %R"
M6UCA"HTJ6 ,  !L.   9              " @74/ 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ 7();6!7__F76 P  (A(  !D
M         ("!!!,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    " !<@EM8\URDJS$)  #+5P  &0              @($1%P$ >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %R"6UAHT5,5(04  *,6
M   9              " @7D@ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
M4$L! A0#%     @ 7();6"TC/^&Y P  $ X  !D              ("!T24!
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !<@EM8^)C:
MG;0"   %"   &0              @('!*0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+ 0(4 Q0    ( %R"6UBR[S8MQ ,  %@,   9
M  " @:PL 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M7();6(.3_*U !   R@\  !D              ("!IS ! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " !<@EM8"(5YZ<$$  "0&   &0
M            @($>-0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( %R"6UCVF=HD$0,  $H)   9              " @18Z 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 7();6.$"4V4+ P
MGPL  !D              ("!7CT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " !<@EM8R/C@N>$#  #P$0  &0              @(&@
M0 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %R"6UCA
M-:H@]@(  $X*   9              " @;A$ 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ 7();6 4,CB)X P  W H  !D
M     ("!Y4<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M" !<@EM8H1^%VTL#  #,%   #0              @ &42P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( %R"6UB7BKL<P    !,"   +              "
M 0I/ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %R"6U@1>WV4<00   8D   /
M              "  ?-/ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !<
M@EM8#Y142-H!  !9(   &@              @ &15 $ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !<@EM8(5VG)LT!   D(   $P
M            @ &C5@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /@ ^
+ .D0  "A6 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995457 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="alec-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="alec-20231231.htm">alec-20231231.htm</File>
    <File>alec-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img43903234_0.gif</File>
    <File>img43903234_1.gif</File>
    <File>img43903234_10.jpg</File>
    <File>img43903234_11.gif</File>
    <File>img43903234_12.gif</File>
    <File>img43903234_13.jpg</File>
    <File>img43903234_14.gif</File>
    <File>img43903234_15.gif</File>
    <File>img43903234_16.gif</File>
    <File>img43903234_17.jpg</File>
    <File>img43903234_18.gif</File>
    <File>img43903234_2.gif</File>
    <File>img43903234_3.gif</File>
    <File>img43903234_4.gif</File>
    <File>img43903234_5.gif</File>
    <File>img43903234_6.gif</File>
    <File>img43903234_7.gif</File>
    <File>img43903234_8.gif</File>
    <File>img43903234_9.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="620">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "alec-20231231.htm": {
   "nsprefix": "alec",
   "nsuri": "http://alector.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "alec-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "alec-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 290,
   "keyCustom": 47,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 17,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 164,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 620,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 620,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6938cb01-3217-495c-940e-68f940751ad7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6938cb01-3217-495c-940e-68f940751ad7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_a87639f8-76eb-442c-be84-1c45bb446983",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a87639f8-76eb-442c-be84-1c45bb446983",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1",
     "longName": "995457 - Disclosure - The Company",
     "shortName": "The Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995467 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995477 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies",
     "longName": "995487 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements",
     "longName": "995497 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "longName": "995507 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "995517 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995527 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995537 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "995547 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995557 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureRestructuring",
     "longName": "995567 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995577 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995587 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995597 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995607 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "longName": "995617 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "995627 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995637 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995647 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995657 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995677 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:MarketableSecuritiesGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:MarketableSecuritiesGainLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "995687 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995697 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_e182d36e-185b-4b5e-ae5b-376f53a27ec8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e182d36e-185b-4b5e-ae5b-376f53a27ec8",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995707 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
     "longName": "995717 - Disclosure - Commitment and Contingencies - Additional Information (Details)",
     "shortName": "Commitment and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "alec:IndemnificationAgreementLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "alec:IndemnificationAgreementLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
     "longName": "995727 - Disclosure - Collaboration Agreements - Additional Information (Details)",
     "shortName": "Collaboration Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d58b91a6-8565-488e-b02e-ec025dddbb45",
      "name": "alec:CollaborationAndLicenseAgreementEffectiveDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "995737 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
     "longName": "995747 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "alec:AccruedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "alec:AccruedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "longName": "995757 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_acc458ea-fb09-43a4-ace2-5afee4642294",
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_acc458ea-fb09-43a4-ace2-5afee4642294",
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail",
     "longName": "995767 - Disclosure - Leases - Components of Lease Expense (Detail)",
     "shortName": "Leases - Components of Lease Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail",
     "longName": "995777 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)",
     "shortName": "Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails",
     "longName": "995787 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)",
     "shortName": "Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "longName": "995797 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "shortName": "Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995807 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_781e8b1b-18da-4c56-a6df-8621e45c8fde",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_781e8b1b-18da-4c56-a6df-8621e45c8fde",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
     "longName": "995817 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)",
     "shortName": "Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_8e75b2f4-4239-442d-88e3-f9885bf64bfd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
     "longName": "995827 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "shortName": "Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_6ad7b64a-0330-47d7-be46-238226e3cd18",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17dd9f30-445c-4242-aa65-4afa4e70a2e0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails",
     "longName": "995837 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)",
     "shortName": "Income Taxes - Schedule of Federal and State Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "995847 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995857 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_331414b3-e237-427f-b014-b2fbd7be148d",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "995867 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "longName": "995877 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_cd9b5156-4a31-481b-b713-37aa7a33df0b",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_618c715a-60ae-467c-8c7b-117bc9bc8695",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995887 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995897 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
     "longName": "995907 - Disclosure - Restructuring - Additional Information (Details)",
     "shortName": "Restructuring - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_c0a79701-f609-4f39-8ea8-fa90332bbbba",
      "name": "alec:PercentageOfReductionInWorkforce",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c0a79701-f609-4f39-8ea8-fa90332bbbba",
      "name": "alec:PercentageOfReductionInWorkforce",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "995917 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2",
      "name": "us-gaap:SaleOfStockTransactionDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2",
      "name": "us-gaap:SaleOfStockTransactionDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "alec-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "alec_AbbVieBiotechnologyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AbbVieBiotechnologyLimitedMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AbbVie Biotechnology Limited",
        "label": "Abb Vie Biotechnology Limited [Member]",
        "documentation": "AbbVie biotechnology, limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r632"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premiums and accretion of discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "terseLabel": "Amortization of premiums and accretion of discounts on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "alec_AccruedClinicalSupplyCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AccruedClinicalSupplyCost",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical supply costs",
        "label": "Accrued Clinical Supply Cost",
        "documentation": "Accrued clinical supply cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued liabilities",
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional services",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "alec_AccruedPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued property and equipment",
        "label": "Accrued Property And Equipment Current",
        "documentation": "Accrued property and equipment current."
       }
      }
     },
     "auth_ref": []
    },
    "alec_AccruedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development costs",
        "label": "Accrued Research And Development Costs",
        "documentation": "Accrued research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r139",
      "r465"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r83",
      "r145",
      "r461",
      "r483",
      "r484"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r32",
      "r381",
      "r384",
      "r420",
      "r479",
      "r480",
      "r736",
      "r737",
      "r738",
      "r745",
      "r746",
      "r747"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "alec_AdditionalAreaOfPropertyInLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AdditionalAreaOfPropertyInLease",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of property in lease.",
        "label": "Additional Area Of Property In Lease",
        "terseLabel": "Additional area of property in lease"
       }
      }
     },
     "auth_ref": []
    },
    "alec_AdditionalAreaSubleaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AdditionalAreaSubleaseExpirationMonthAndYear",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area sublease expiration month and year.",
        "label": "Additional Area Sublease Expiration Month And Year",
        "terseLabel": "Additional area sublease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r632",
      "r821"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r500",
      "r745",
      "r746",
      "r747",
      "r799",
      "r822"
     ]
    },
    "alec_AdimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AdimabMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adimab Member",
        "terseLabel": "Adimab",
        "label": "Adimab [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r303"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r668",
      "r678",
      "r704"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r671",
      "r681",
      "r707"
     ]
    },
    "alec_Al101AlzheimersDiseaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "Al101AlzheimersDiseaseProgramMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Al101 Alzheimer's Disease Program",
        "label": "AL101 Alzheimer's Disease Program [Member]",
        "documentation": "AL101 Alzheimer's disease program."
       }
      }
     },
     "auth_ref": []
    },
    "alec_AlectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AlectorMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alector",
        "documentation": "Alector.",
        "label": "Alector [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r672",
      "r682",
      "r699",
      "r708",
      "r712",
      "r720"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r341"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "alec_AmortizationRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AmortizationRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Amortization Right Of Use Asset",
        "documentation": "Amortization right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "alec_AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount on underwriting discounts and commissions and offering expenses",
        "label": "Amount on Underwriting Discounts and Commissions and Offering Expenses",
        "documentation": "Amount on underwriting discounts and commissions and offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive shares",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "alec_AreaOfPropertyInLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AreaOfPropertyInLease",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area under lease",
        "label": "Area Of Property In Lease",
        "documentation": "Area of property in lease."
       }
      }
     },
     "auth_ref": []
    },
    "alec_AreaOfPropertyInSubleaseAgreement": {
     "xbrltype": "areaItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AreaOfPropertyInSubleaseAgreement",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area under sublease",
        "label": "Area Of Property In Sublease Agreement",
        "documentation": "Area of property in sublease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of property",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r141",
      "r165",
      "r201",
      "r213",
      "r217",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r374",
      "r378",
      "r396",
      "r457",
      "r537",
      "r632",
      "r645",
      "r759",
      "r760",
      "r807"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r146",
      "r165",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r374",
      "r378",
      "r396",
      "r632",
      "r759",
      "r760",
      "r807"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and marketable securities, Fair Market Value",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and marketable securities, Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash equivalents and marketable securities, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash equivalents and marketable securities, Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r456"
     ]
    },
    "alec_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual maturities, one year through two years",
        "label": "Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue",
        "documentation": "Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue"
       }
      }
     },
     "auth_ref": []
    },
    "alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual maturities of investments were less than one year through two years",
        "label": "Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value",
        "documentation": "Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual maturities of investments were less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r454"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California Tax Authority",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r137",
      "r605"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r112"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r90",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r90"
     ]
    },
    "alec_CashEquivalentsAndMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash Equivalents And Marketable Securities [Member]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alec_CertificateOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CertificateOfDepositMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificate of Deposit [Member]",
        "documentation": "Certificate of deposit ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r180"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r180"
     ]
    },
    "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Method Accounted For As Change in Estimate",
        "label": "Change in Accounting Method Accounted for as Change in Estimate [Member]",
        "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations."
       }
      }
     },
     "auth_ref": []
    },
    "alec_ChangeInEstimateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ChangeInEstimateMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Estimate [Member]",
        "label": "Change in Estimate [Member]",
        "documentation": "Change in estimate."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r142",
      "r143",
      "r144",
      "r165",
      "r188",
      "r189",
      "r191",
      "r193",
      "r199",
      "r200",
      "r229",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r268",
      "r269",
      "r271",
      "r272",
      "r274",
      "r396",
      "r490",
      "r491",
      "r492",
      "r493",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r525",
      "r546",
      "r568",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r728",
      "r742",
      "r748"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "alec_CollaborationAndLicenseAgreementEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborationAndLicenseAgreementEffectiveDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective date of agreement",
        "documentation": "Collaboration and License Agreement Effective Date",
        "label": "Collaboration and License Agreement Effective Date"
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborationPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborationPayable",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to collaboration partner",
        "label": "Collaboration Payable",
        "documentation": "Collaboration payable."
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborationReceivable",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from collaboration partner",
        "documentation": "Collaboration receivable.",
        "label": "Collaboration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborativeArrangementAdditionalMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments related to initiation of certain clinical studies and regulatory approval",
        "label": "Collaborative Arrangement Additional Milestone Payments Receivable",
        "documentation": "Collaborative arrangement, additional milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r131"
     ]
    },
    "alec_CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for enrollment of additional patients",
        "label": "Collaborative Arrangement Milestone Payments For Enrollment of Additional Patients",
        "documentation": "Collaborative arrangement milestone payments for enrollment of additional patients."
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive option rights exercised for each program",
        "label": "Collaborative Arrangement Milestone Payments On Option Rights Exercised Per Program",
        "documentation": "Collaborative arrangement, milestone payments on option rights exercised per program."
       }
      }
     },
     "auth_ref": []
    },
    "alec_CollaborativeArrangementUpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CollaborativeArrangementUpfrontPayments",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments",
        "label": "Collaborative Arrangement Upfront Payments",
        "documentation": "Collaborative arrangement, upfront payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r639",
      "r640",
      "r641",
      "r642"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 4)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r68",
      "r458",
      "r524"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r248",
      "r249",
      "r590",
      "r754"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Automatic conversion provision of common stock reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r639",
      "r640",
      "r641",
      "r642",
      "r745",
      "r746",
      "r799",
      "r819",
      "r822"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r525"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r77",
      "r525",
      "r543",
      "r822",
      "r823"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r459",
      "r632"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "alec_CompanyMaximumFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "CompanyMaximumFunding",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding",
        "label": "Company Maximum Funding",
        "documentation": "Company maximum funding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r151",
      "r153",
      "r158",
      "r451",
      "r469"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r64",
      "r65",
      "r222",
      "r589"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r64",
      "r65",
      "r222",
      "r485",
      "r589"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r124"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r288"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative adjustment to revenue",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current portion",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r288"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, long-term portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r288"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, refund liability",
        "label": "Contract with Customer, Refund Liability",
        "totalLabel": "Contract with Customer, Refund Liability, Total",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liability to collaboration partner, current portion",
        "label": "Contract with Customer, Refund Liability, Current",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ContractWithCustomerRefundLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liability to collaboration partner, long-term portion",
        "label": "Contract with Customer, Refund Liability, Noncurrent",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r271",
      "r639",
      "r640",
      "r641",
      "r642"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock to common stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r52",
      "r76",
      "r100",
      "r273"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r265",
      "r270",
      "r427",
      "r606",
      "r608"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r744",
      "r797"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r744",
      "r797"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value of instruments in loss position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r233",
      "r615"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Unrealized loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r233"
     ]
    },
    "alec_DecreaseOnUncertainTaxProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DecreaseOnUncertainTaxProvisions",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease on uncertain tax provisions",
        "label": "Decrease on Uncertain Tax Provisions",
        "documentation": "Decrease on uncertain tax provisions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r114",
      "r358"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "alec_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "alec_DeferredTaxAssetsRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DeferredTaxAssetsRefundLiability",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liability",
        "label": "Deferred Tax Assets Refund Liability",
        "documentation": "Deferred tax assets refund liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r796"
     ]
    },
    "alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Assets tax deferred expense capitalized research and development costs.",
        "label": "Deferred Tax Assets Tax Deferred Expense Capitalized Research and Development Costs",
        "terseLabel": "Section 174 R&amp;D capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "accrued bonus",
        "terseLabel": "Accrued bonus",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r796"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "alec_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities Depreciation And Amortization",
        "documentation": "Deferred tax liabilities depreciation and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "alec_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "documentation": "Deferred tax liabilities Right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined matching contribution plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, percent",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r50"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r820"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r305",
      "r333",
      "r334",
      "r336",
      "r626"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664",
      "r700"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "alec_DomesticAndStateTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "DomesticAndStateTaxAuthorityMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and State Tax Authorities",
        "label": "Domestic And State Tax Authority [Member]",
        "documentation": "Domestic and state tax authority"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net income (loss) per share",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r186",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r387",
      "r388",
      "r452",
      "r470",
      "r610"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted net income (loss) per share",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r387",
      "r388",
      "r452",
      "r470",
      "r610"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carry forward, deductions",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r798"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Un-recognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Committed Under 2019 ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r133",
      "r155",
      "r156",
      "r157",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r230",
      "r231",
      "r275",
      "r337",
      "r338",
      "r339",
      "r364",
      "r365",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r420",
      "r479",
      "r480",
      "r481",
      "r500",
      "r568"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r668",
      "r678",
      "r704"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r665",
      "r675",
      "r701"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r394"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r394"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r111"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r391",
      "r432",
      "r433",
      "r434",
      "r616",
      "r617",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r393",
      "r395"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r297",
      "r391",
      "r432",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r297",
      "r391",
      "r433",
      "r616",
      "r617",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r432",
      "r433",
      "r434",
      "r616",
      "r617",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r395"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20"
     ]
    },
    "alec_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on-offering",
        "label": "Follow On Public Offering [Member]",
        "documentation": "Follow On Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r708"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r708"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r708"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r708"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r708"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "alec_FutureMilestonePaymentsOwed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "FutureMilestonePaymentsOwed",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future milestone payments owed",
        "label": "Future Milestone Payments Owed",
        "documentation": "Future milestone payments owed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r548"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and Administrative",
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "alec_GskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "GskMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GlaxoSmithKline plc",
        "documentation": "GSK [Member]",
        "label": "GSK [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r664"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss on long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r96"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r368"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r239",
      "r553"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r553"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r107",
      "r108"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r344",
      "r350",
      "r355",
      "r362",
      "r366",
      "r369",
      "r370",
      "r371",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r129",
      "r183",
      "r184",
      "r204",
      "r348",
      "r367",
      "r471"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r346",
      "r347",
      "r355",
      "r356",
      "r361",
      "r363",
      "r489"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits, net of uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "alec_IncomeTaxReconciliationUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncomeTaxReconciliationUncertainTaxPositions",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Income Tax Reconciliation Uncertain Tax Positions",
        "documentation": "Income tax reconciliation uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to collaboration partner",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and accrued clinical supply costs",
        "label": "Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs",
        "documentation": "Increase Decrease in accrued liabilities and accrued clinical supply costs."
       }
      }
     },
     "auth_ref": []
    },
    "alec_IncreaseDecreaseInCollaborationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncreaseDecreaseInCollaborationReceivable",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivable from collaboration partner",
        "terseLabel": "Receivable from collaboration partner",
        "documentation": "Increase decrease In collaboration receivable.",
        "label": "Increase Decrease In Collaboration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r739"
     ]
    },
    "alec_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Increase Decrease In Lease Liabilities",
        "documentation": "Increase (decrease) in lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "alec_IncreaseDecreaseInPayableToCollaborationPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncreaseDecreaseInPayableToCollaborationPartner",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to collaboration partner",
        "label": "Increase Decrease In Payable to Collaboration Partner",
        "documentation": "Increase decrease in payable to collaboration partner."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "alec_IncreaseDecreaseInRefundLiabilityToCollaborationPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IncreaseDecreaseInRefundLiabilityToCollaborationPartner",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Refund liability to collaboration partner",
        "terseLabel": "Refund liability to collaboration partner",
        "label": "Increase (Decrease) In Refund Liability to Collaboration Partner",
        "documentation": "Increase decrease in refund liability to collaboration partner."
       }
      }
     },
     "auth_ref": []
    },
    "alec_IndemnificationAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "IndemnificationAgreementLiability",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification agreement liability",
        "label": "Indemnification Agreement Liability",
        "documentation": "Indemnification agreement liability."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r672",
      "r682",
      "r699",
      "r708",
      "r712",
      "r720"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r724"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r724"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r724"
     ]
    },
    "alec_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r631"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "alec_LeaseExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "LeaseExpirationYear",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration year",
        "label": "Lease Expiration Year",
        "documentation": "Lease expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, description",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Payments Owed Under Company's Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease term",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal period",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating sublease, existence of option to extend",
        "label": "Lessee, Operating Sublease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether sublessee has option to extend operating sublease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseRenewalTerm",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extend for an additional lease term",
        "label": "Lessor, Operating Lease, Renewal Term",
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r165",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r375",
      "r378",
      "r379",
      "r396",
      "r523",
      "r611",
      "r645",
      "r759",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r115",
      "r463",
      "r632",
      "r743",
      "r751",
      "r800"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r136",
      "r165",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r375",
      "r378",
      "r379",
      "r396",
      "r632",
      "r759",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r255",
      "r755",
      "r756"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r255",
      "r755",
      "r756"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "totalLabel": "Marketable Securities, Current, Total",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses on marketable securities",
        "label": "Marketable Securities, Gain (Loss)",
        "totalLabel": "Marketable Securities, Gain (Loss), Total",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r300",
      "r436",
      "r478",
      "r515",
      "r516",
      "r574",
      "r576",
      "r578",
      "r579",
      "r581",
      "r600",
      "r601",
      "r614",
      "r618",
      "r625",
      "r634",
      "r761",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r300",
      "r436",
      "r478",
      "r515",
      "r516",
      "r574",
      "r576",
      "r578",
      "r579",
      "r581",
      "r600",
      "r601",
      "r614",
      "r618",
      "r625",
      "r634",
      "r761",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r92",
      "r116",
      "r134",
      "r149",
      "r152",
      "r157",
      "r165",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r190",
      "r201",
      "r212",
      "r216",
      "r218",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r388",
      "r396",
      "r468",
      "r545",
      "r566",
      "r567",
      "r612",
      "r643",
      "r759"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "alec_NewarkCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "NewarkCaliforniaMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco",
        "label": "Newark California [Member]",
        "documentation": "Newark, California."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r682",
      "r699",
      "r708"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "alec_NumberOfReductionInWorkforce": {
     "xbrltype": "integerItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "NumberOfReductionInWorkforce",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Reduction In Workforce",
        "documentation": "Number Of Reduction In Workforce"
       }
      }
     },
     "auth_ref": []
    },
    "alec_OfficesAndLaboratoryFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "OfficesAndLaboratoryFacilitiesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offices and Laboratory Facilities",
        "label": "Offices And Laboratory Facilities [Member]",
        "documentation": "Offices and laboratory facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related party transaction expenses",
        "terseLabel": "milestone payments",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r212",
      "r216",
      "r218",
      "r612"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r631"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, long-term portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included In measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r416"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r631"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r631"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carry forward, net",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "alec_OperatingLossCarryforwardsBeginningExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "OperatingLossCarryforwardsBeginningExpirationYear",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carry forward beginning expiration year",
        "label": "Operating Loss Carryforwards Beginning Expiration Year",
        "documentation": "Operating loss carryforwards beginning expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure line items."
       }
      }
     },
     "auth_ref": []
    },
    "alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureTheCompany1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r109",
      "r486",
      "r487"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r11",
      "r110",
      "r150",
      "r153"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities due to related parties",
        "terseLabel": "Payable to collaboration partner",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r632"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r670",
      "r680",
      "r706"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r673",
      "r683",
      "r709"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r673",
      "r683",
      "r709"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r88"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "alec_PercentageOfDevelopmentCost": {
     "xbrltype": "pureItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "PercentageOfDevelopmentCost",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Development Cost",
        "documentation": "Percentage of development cost.",
        "label": "Percentage of Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "alec_PercentageOfReductionInWorkforce": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "PercentageOfReductionInWorkforce",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Reduction In Workforce",
        "documentation": "Percentage Of Reduction In Workforce"
       }
      }
     },
     "auth_ref": []
    },
    "alec_PercentageOfStockOwnedByIndividual": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "PercentageOfStockOwnedByIndividual",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of stock owned by Individual",
        "label": "Percentage Of Stock Owned By Individual",
        "documentation": "Percentage of stock owned by Individual."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PostemploymentBenefitPlansPolicy",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee 401 (K) Plan",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds from the offering",
        "verboseLabel": "Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "alec_ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ProceedsFromIssuanceInitialPublicOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds before deducting underwriting discounts and commissions and offering expenses",
        "label": "Proceeds from Issuance Initial Public Offering Before Deducting Underwriting Discounts and Commissions and Offering Expenses",
        "documentation": "Proceeds from issuance initial public offering before deducting underwriting discounts and commissions and offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ProceedsFromPaymentsForIssuanceInitialPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Payments For Issuance Initial Public Offering",
        "documentation": "Proceeds from (payments for) issuance of common stock as part of an initial public offering.",
        "terseLabel": "Amortization of premiums and accretion of discounts on marketable securities",
        "negatedLabel": "Proceeds from issuance of common stock upon public offerings, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of marketable securities",
        "terseLabel": "Sale of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r160",
      "r223",
      "r228"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of options to purchase common stock",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of stock from employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r438",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r603",
      "r620",
      "r633",
      "r730",
      "r757",
      "r758",
      "r762",
      "r818"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r438",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r603",
      "r620",
      "r633",
      "r730",
      "r757",
      "r758",
      "r762",
      "r818"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r149",
      "r152",
      "r161",
      "r165",
      "r175",
      "r183",
      "r184",
      "r201",
      "r212",
      "r216",
      "r218",
      "r229",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r373",
      "r376",
      "r377",
      "r388",
      "r396",
      "r453",
      "r467",
      "r499",
      "r545",
      "r566",
      "r567",
      "r612",
      "r629",
      "r630",
      "r644",
      "r738",
      "r759"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r138",
      "r466"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r455",
      "r466",
      "r632"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r125",
      "r128",
      "r464"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r291",
      "r300",
      "r328",
      "r329",
      "r330",
      "r435",
      "r436",
      "r478",
      "r515",
      "r516",
      "r574",
      "r576",
      "r578",
      "r579",
      "r581",
      "r600",
      "r601",
      "r614",
      "r618",
      "r625",
      "r634",
      "r637",
      "r752",
      "r761",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r291",
      "r300",
      "r328",
      "r329",
      "r330",
      "r435",
      "r436",
      "r478",
      "r515",
      "r516",
      "r574",
      "r576",
      "r578",
      "r579",
      "r581",
      "r600",
      "r601",
      "r614",
      "r618",
      "r625",
      "r634",
      "r637",
      "r752",
      "r761",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r665",
      "r675",
      "r701"
     ]
    },
    "alec_ReductionInTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ReductionInTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in transaction price",
        "label": "Reduction in Transaction Price",
        "documentation": "Reduction in transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r424",
      "r425",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r544",
      "r573"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration partner [Member]",
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r424",
      "r425",
      "r426",
      "r427",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r544",
      "r573"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r806"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r553"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r424",
      "r425",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r542",
      "r544",
      "r573",
      "r806"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r425",
      "r428",
      "r496",
      "r497",
      "r498",
      "r551",
      "r552",
      "r553",
      "r571",
      "r572"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r265",
      "r270",
      "r427",
      "r607",
      "r608"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expense",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r343",
      "r815"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r666",
      "r676",
      "r702"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r667",
      "r677",
      "r703"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r674",
      "r684",
      "r710"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount form letter of credit",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r733",
      "r741"
     ]
    },
    "alec_RestrictedStockAwardsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock subject to future vesting",
        "terseLabel": "Restricted Stock Awards And Restricted Stock Units",
        "documentation": "Restricted Stock Awards And Restricted Stock Units [Member]",
        "label": "Restricted Stock Awards And Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards And Restricted Stock Units",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r238",
      "r241",
      "r247"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost expected cost remaining 1",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r242",
      "r244",
      "r753"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r244",
      "r245"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "totalLabel": "Restructuring Costs, Total",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring Reserve, Ending Balance",
        "periodStartLabel": "Restructuring Reserve, Beginning Balance",
        "totalLabel": "Restructuring Reserve, Total",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r243"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r101",
      "r462",
      "r482",
      "r484",
      "r494",
      "r526",
      "r632"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r230",
      "r231",
      "r337",
      "r338",
      "r339",
      "r364",
      "r365",
      "r380",
      "r382",
      "r383",
      "r385",
      "r386",
      "r479",
      "r481",
      "r500",
      "r822"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r211",
      "r214",
      "r215",
      "r219",
      "r220",
      "r222",
      "r286",
      "r287",
      "r438"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r729"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r602"
     ]
    },
    "alec_ReversalReservesOnUncertainTaxProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ReversalReservesOnUncertainTaxProvisions",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of reserves on uncertain tax provisions",
        "label": "Reversal Reserves On Uncertain Tax Provisions",
        "documentation": "Reversal Reserves On Uncertain Tax Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "alec_SaleOfStockClosingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SaleOfStockClosingDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering closing date",
        "label": "Sale of Stock, Closing Date",
        "documentation": "Offering closing date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued or sold",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "alec_SaleOfStockOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SaleOfStockOptionTerm",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option period (in days)",
        "label": "Sale Of Stock Option Term",
        "documentation": "Sale Of Stock, Option, Term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of common stock issued or sold, Price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockTransactionDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of underwriting",
        "label": "Sale of Stock, Transaction Date",
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Federal and State Income Tax Provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Recognized Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r549",
      "r550",
      "r553"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r112",
      "r817"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options to Purchase Common Stock",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Awards and Restricted Stock Units",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r793"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r512",
      "r513",
      "r514",
      "r575",
      "r577",
      "r580",
      "r582",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r604",
      "r621",
      "r637",
      "r762",
      "r818"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r220",
      "r613"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cliff vesting percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Percentage",
        "documentation": "Share-based compensation arrangement by share-based payment award, cliff vesting percentage."
       }
      }
     },
     "auth_ref": []
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cliff vesting period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period",
        "documentation": "Share based compensation arrangement by share based payment award, cliff vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of units granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Unvested, beginning balance",
        "periodEndLabel": "Number of Shares, Unvested, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value per Share, Unvested, ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value per share of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding, beginning balance",
        "periodEndLabel": "Number of Options, Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding, beginning balance",
        "periodEndLabel": "Weighted average exercise price, Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of option exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable (In years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price per share from fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r631"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r164"
     ]
    },
    "alec_SouthSanFranciscoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SouthSanFranciscoMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South San Francisco",
        "label": "South San Francisco [Member]",
        "documentation": "South San Francisco."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Tax Authority",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r142",
      "r143",
      "r144",
      "r165",
      "r188",
      "r189",
      "r191",
      "r193",
      "r199",
      "r200",
      "r229",
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r268",
      "r269",
      "r271",
      "r272",
      "r274",
      "r396",
      "r490",
      "r491",
      "r492",
      "r493",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r525",
      "r546",
      "r568",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r728",
      "r742",
      "r748"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r133",
      "r155",
      "r156",
      "r157",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r230",
      "r231",
      "r275",
      "r337",
      "r338",
      "r339",
      "r364",
      "r365",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r420",
      "r479",
      "r480",
      "r481",
      "r500",
      "r568"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r512",
      "r513",
      "r514",
      "r575",
      "r577",
      "r580",
      "r582",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r604",
      "r621",
      "r637",
      "r762",
      "r818"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r438",
      "r488",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r547",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r638"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r438",
      "r488",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r547",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r638"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r669",
      "r679",
      "r705"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of convertible preferred stock into common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r29",
      "r52",
      "r101",
      "r267"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offerings",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on public offering, net of issuance costs of $1,148 (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101",
      "r490",
      "r568",
      "r584"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted common stock",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101",
      "r314"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of convertible preferred stock into common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on public offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101",
      "r500",
      "r568",
      "r584",
      "r644"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeiture/Cancellation of restricted common stock",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r101"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r94",
      "r527",
      "r543",
      "r569",
      "r570",
      "r632",
      "r645",
      "r743",
      "r751",
      "r800",
      "r822"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alec_SubleaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SubleaseExpirationMonthAndYear",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease expiration month and year",
        "label": "Sublease Expiration Month And Year",
        "documentation": "Sublease expiration month and year."
       }
      }
     },
     "auth_ref": []
    },
    "alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SubleaseIncomeAndReimbursementOfVariableLeaseCost1",
     "crdr": "credit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income and reimbursement of variable lease cost",
        "terseLabel": "Sublease income and reimbursement of variable lease cost",
        "label": "Sublease Income And Reimbursement Of Variable Lease Cost1",
        "documentation": "SubleaseIncomeAndReimbursementOfVariableLeaseCost1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r430"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r430"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r430"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r430"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r430"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r431"
     ]
    },
    "alec_SubsequentOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SubsequentOfferingPeriod",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent offering period",
        "label": "Subsequent Offering Period",
        "documentation": "Subsequent offering period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "alec_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "alec_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "alec_TaxCreditBeginningExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TaxCreditBeginningExpirationYear",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Beginning Expiration Year",
        "label": "Tax Credit Beginning Expiration Year",
        "documentation": "Tax credit beginning expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Convertible preferred stock, beginning balance",
        "periodEndLabel": "Convertible preferred stock, ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r340",
      "r460"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "periodStartLabel": "Convertible preferred stock, beginning balance (in shares)",
        "periodEndLabel": "Convertible preferred stock, ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series E convertible preferred stock, net of issuance costs",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "alec_TemporaryStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TemporaryStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series E convertible preferred stock, net of costs (in shares)",
        "label": "Temporary Stock Issued During Period Shares New Issues",
        "documentation": "Temporary stock issued during period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r805"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "alec_TransactionsPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TransactionsPrice",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Transactions Price",
        "documentation": "Transactions Price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "alec_TwoThousandFourteenAdimabAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TwoThousandFourteenAdimabAgreementMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Fourteen Adimab Agreement",
        "label": "Two Thousand Fourteen Adimab Agreement [Member]",
        "documentation": "Adimab Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "alec_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand nineteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "alec_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand nineteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "alec_TwoThousandTwentyTwoInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "TwoThousandTwentyTwoInducementPlanMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two inducement Plan.",
        "label": "Two Thousand Twenty Two Inducement Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r244",
      "r245"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Government Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r622",
      "r624",
      "r816"
     ]
    },
    "alec_UnderwritingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "UnderwritingMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting [Member]",
        "label": "Underwriting [Member]",
        "documentation": "Underwriting."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unrecognized tax benefits, beginning balance",
        "periodEndLabel": "Unrecognized tax benefits, ending balance",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax position",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r352"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Decrease on uncertain tax provisions related to prior year",
        "negatedLabel": "Decreases related to tax positions taken during the prior year",
        "terseLabel": "Decreases related to tax positions taken during the prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax, Penalties and Interest accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to tax positions taken during the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "verboseLabel": "Uncertain tax provision",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase on uncertain tax provisions related to prior year",
        "terseLabel": "Increase related to tax positions taken during the prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax position",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r121",
      "r123",
      "r126",
      "r127"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance deferred tax asset change in amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r631"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Shares used in computing net loss per share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r193"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Shares used in computing net loss per share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r193"
     ]
    },
    "alec_WorkforceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alector.com/20231231",
     "localname": "WorkforceMember",
     "presentation": [
      "http://alector.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workforce [Member]",
        "documentation": "Workforce [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0000950170-24-021183-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-021183-xbrl.zip
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MCV8K ^@^';[*\FHJ<F7:YT=9_O6:Q_%K*:K%X^>7GE^9'W[;/IJ=7]4NQ6'
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MD($*>2)%;RV&S[0.^R-=SF$2R2D(-3Z%-IG/\%X])8E-8AJ'7,3Q_4<N?Q_
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M$Q(P3/>4$NM1V)306(@T2JF)^EN*=XC3>Y+55#;H&S:1\%-#02.(D7J=;QC
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M%RM[D\CKCP:X^]=ER:(?*_ :X>>F-<K\U=2RNQ"3;T0J:"A1JO )XWY T Y
M3"""V/@LX?V[6:3?"4T70.%.;(3+-&&I(IS9F##?YT08%I,D$'$:6BO#_I78
M[6OX"XCOR8W%=UCHS52<UU%JC8P$47$88ZAU3$0BL-""I F(!%;2WH:5];7(
MP5!D]-XU#*YURK0O21AC@ GC%#0,JHGV59QP$4O:W])#PRWOCTP\QI=,ISK
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MBQ'VUP0K^MLQ?/"O637-[+SMVKU*X(# LISC'+#2SV*%SA\C+>;!EOCG5[#
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MRZ.B!,FVOMD.,/ A0/23NVU[?]GI )\#?-X*/H<B>4\)/I]?32>NCDJ#<;=
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MH[0P$.M K,L ,:5F92?.:^F$7B:!H*:=NY#N1>C^J0&980N8]R2;NN2 OV9
M[4X6K3E_A^Z;]!!H"$_&$!LV4-^"<W<RA[I)($M>O(SC.2U0#W)PV80?5'B]
M#3#R3-TDY'4#>:WTOK):[Y+9=K<DQ;MM(1UR7!\BQW5 QA\+&9$O9^,)BH/
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MX25M;2COY8?#O9_:),3]C__X]/L>":Z2A"_RUJ7@T[C*N[)/^]&J^--\NI2
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MGZX^K2[?<!ER?R%)I16Z%]6+<0'7P(T#.G?+>QT8T)6^QWB/T0)UNI5\ZS(
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ME AS-ZTRU:]QG89594R2HJDVOO.)EDJ'#S5(O<ZSN%*,6A3$HC04;>/PU>W
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M+8E<(&]%384X;?37*P#%UN#N?L5%R:6ZP3X1(7OB]^I)1]P>1G\)Q:EJ-M?
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MO-3J12WW,8YGLRRMK?B>>?BW&,D+/1N[$6&6?BRLT$C3_:O)U$TWNM T[.3
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M\ 8LS382N,]^T*WVB9HCOPQC.4Q><?ITEC/-%8_%YCHLGB5C8ZZX%FI3*%8
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MQ%=+\@G%E9.Q!Y:>!9.%@GU:=45G&?CCO3&73FL7+[%,97"@1C&]IV+Z'2P
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MJ.DFBHQW4,S])#MW7K+1H%6'K.QY6:/)I54=FEN0PJF-=Y[[&EPY<S%/V[!
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MES+:7A8"\(_1ECJ^X-OV<:@V'J@;5]3E\VMT'#TG\/:P)G#2Y(8\3@85]M5
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MF>I3?-D,#W65<A@Y(@VN<?$4\RC.H!1?#I\8$YL0A.#G8U]0KW5.*R$!U^:
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M0;/-I/OF/=)3(W#GZP)W[H_ G3\5N//]FUMO,[H\K1)O?B@(4N#5W'Z 19>
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M63C9"*$Q!&2ZZW!(L:#P^V*[6M.7\L;8*3 ,K-A['*H*O;2*273J33.73$6
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M*?50V;0H&K;5X]PI8OT5+M1"+O4A=5#7YUTU1M]*\0O$C8Y(V8A]WQ32>AU
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M5WN")LFA4$A E79%4C.2*YJ2B#_]=\*I6QKT-%9^W@]%K]=\SKYKKC!ED:O
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M0A\O,#!DK[N08^DP@XS1^3=F^YH17::U\W@[BQ2RYYC;B+^-2YJOFD;>FDD
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MV%1]-W[L&[^:<H481+Q(J'%SM(Z$=5<[/?:*_+VVZ(,JI3E@2KB.E),K85-
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MJ#!.9TY/3K)-@P\AKBS7Z[YVR@.O"1P9\X\K)0@\M+8 #_F5PL5U,<L9;/1
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MY*B-=/E"/!X2%$=L-F&7RQR7GJ\Z8LI  G$9X+K!T\=SZ086@B(''O#EXAU
M\(R5CMX1O0]#MT<S(;5Q#X<+%G%W=@OT]E?A\NA+A@ ;38/@HQ8O18,E"MWK
M:] 8/V ,_(_.9G5TE*\[A]UMPJ!7/8'?&P%X(T\PS.9J=U,=0TZ71K:A^&"Y
MWF VDW:+O*9WN"07Q6]SY4H^"NS 8.*&U@A,O:QK<VHH4_F"R>9PW$PHUCT/
M-OG!HNTW'WU080_!Y:571P^05O)O+Q=703Q 9AT'[\-G)".,:JQ%,;4C\[6>
M'D+5Z>4M/5''F()R':4RR:%7VP;(S@:#<@S3Q\ODY["CJ.U:QNO'K_+DLGJ
MF/C7$[NRV,:U0\/=JR(.& E5:+GT1*_BXY+DTO;F-=Y*.HK6]4LF_,);=3Q8
MK+R'@F/"D!M:;;S*\]7Q]'"%0:]NL,'I7I9%TRD!C]6MR-6>FM[0]>TGN.&1
M9R3^/=T?OI$9_E@/;_1* S NO%<,'=D@U3F;(D=$&5-BLH=MV_2;+3GY>G/8
MDG%)1O$A\TUAT1B-19J-4F&L':HEP%,T 3S82TL*:\%6@FJF1LP@4/K32F,
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M% ?4D4!\PFR1\9)F,!Y(@?4)[$JU-5EN"'^$>RJX&_;RG5H+63$K01W:'A%
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MM87_PNJQ.(8=[]U#E\P;VPM'#JV<M#7Y$[F5[Q@GOU[3S2_^FM-36)$=R-:
MG]7Q7%5E7N231Y(_/<Y"Q*3/!)&2KU*X.#3*Z\XCG\Q*\U7;=)W4XZNF*2Z6
M+<KG%!:7/.3[>E2+X'/YF.PD,8(TI_U8@SQG[0G(Z"6>7(L.MQ^4$*Z9\P6K
M7W^54M%97(>A.(V[C]K-R5?_[,NN]'L7.OVW6:B.H%KE1PJ1Z#DR]LN@X!I
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MRMFX[K[G^CI73$4?9KPB6H]H!JSL0D%X>;R-@D2E&V>SF\T.9A<F$)?\6C9
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M%P$3"BFKM:L+14$EH[BMV_=2\>2L/&^+2M5:4/,0G/(#AJ#_>&I^>ORNI"J
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MEVW3<Y4C[%5^5D17+!>;<[$\.X955SUH4:&(-G<RI6AZJC$R S/N[YZZEDX
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MCT'PP#R  :(\(--OG+3A=[0LV,1V[G"Y> 6EJ[%!"A)$B>Y+\A%Y-$D>7]H
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MQZHIBU ""#.F5NL:8A^'@SI7U4^TU9'Y^M*IHMHO]6X8%J0@F+*S.TF!45]
M%;>I:V>E.YL8F&+N1S.+[IM!#E&]TMI7AYL&+;Z0&#RW1_;"&:J(S_+H^^<O
M'F<AWT&2AL=[XO%)?"[JEO;D'C$VJ<K_V;O'TX"+D\]'#F<U&7)1?KPTK/ 8
M'R".Q+]^D>WB@C>[D@@@P([4"A80TYQ\<'@#?76,4L/D57&IW B@EVV3%Q#
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MHY,N; GLHUY\A O)D@6M Y_7^>K(;?)5WZ(XY>>3M >=:L#=?A*O1H;HE4X
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MU(0 1)4$&;\B$D.&MLF2F6#@^63#D-(]0UR4^\_N>CA1-*5$/U7G^G7.?@*
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MV^=X>REEWE^XO;+2GJ&)71JO&IS/L$9Z;5-F9"Y*\HF$J.12KI&;PDQ.$*/
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M=F+) G!(.\,%_6O<B,&6IQ7#.U9=/CL85B%R)AU,#\RK(VTQ*E0KY9/@"DJ
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M,$)@T1B48-@+?90F,AZ%*E/2X@AW(! 31H3E<_1\ YQX\N,? :5=+O[J782
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MXO0YE6+EX:.%/])QJZF?+DPPR2IFVO*-G#HHQ_M&BNRM+P=4D^@\^D4GN^]
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M008UQYR"'7E,CCCN#<YQ]_GXEW.J[(+XB&#A*/&)&L]8'"O=P92B@S6'UAH
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M]_;KL+L-=G[W^>7BOXR0@[E;LH(&,+].;Y?44G'#*9,*"GFEIFC^ G7; EV
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MV:,'#Q\7@+HL>7/J0X>6XGCN1,9C@H)$E# -[_>&F3.@CE)M&%.S9MQ1G(<
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M!#:.B" %*^+T+^LN!,$\P0[9H6?.&59H$Y#7ZFMOIX3C0%!%FR!;S=OD%E
ML,6:ICUNFEW5!-CA2#O)O(038R?B5_E!G6,"\@DV'Y^G^(50\7^[8?K00MA@
M@DA="LK<87%2G)_4 WCLL#VR&"5:!5K($\8W<62C]7BJ,R[;IISI&\XU\F)Y
M%9V%6\OPJ:T !IF[M+T59]B&K:BWZ6@4DCYK>4G\I9GP8_]HYG*HXS=EOH#&
M#:KDH]99I&>U$X7>^J_,Q&/%K$?F1.Q=A1MJW]00P+E<_ V%J4ZZ2^&[83V9
M/E[-9R'$M\^P:5=2M0<9*U)HJ4^SCSVX].W&9DOE.RK J[([9 "6UP1IY?+3
MR(Z)Z:6X8V;778_<*.8N$_2ZWH HJ> 5-7O7U&BTU4P8Q-"GM#YG2BKT9\1-
MAG&*E%K*.+EJ-ET,^*ZQ/5;=SK$"/3T=88G2!D8\';J6F6A!6X(DBU^TOA@M
M)=JW/0Q8['#LK_"%!=>;+8D$UN,OJ-[8ULXKLOF]H^"AZC!PSDT>O_XI0!)E
MB>*/U"OY@#&]/IKQ/@G'>+3"O!&XM"\U/:3]F;N\NO2F>0BS=^9KG\L;3/LI
MZ50W)['73="%+LACKGQD%G]!EN--?*U2X-8. _4<NHHB'>5H.'FQ\Q$MFN#7
MPM1Z[R8S8(?>/E>$WO:!I;04>6\(OJ 3ZD0;Y0\\1]6E$>_EXJ=3F<*_>I*D
MQ2Q.D@5,-MZ!IF(BD-C58#<@7<XBUN]O@"2/T/5DHD!#?/%-O,!H?-:Q]M@-
M$/<C/N;Y)ML;&0G0A ETR)QE#R][=B.["^[Z)HHR^IOU3J\[XB32*7#MMCQ@
MORHRUVI*N-.T2Q-O_Q4;5(9+-T>\.9FK$+#M4\%^?XK9"")&8141H@$Q$:(;
M-(AF-*7+8VG%A23$N!TSQU2@L4BU367LV,QO4S/E5TX=SYG%^ULSL?#2'YI:
M05]@^J!!J2B;IH6L3K'0WW_WU%"Y& 6I>QM.#4>_IPA-XC:#V@VVY/P3 C/K
M1D7!(O559LH1X?-?Y7&UO?BI_,7?.PN@OQ[Y+;GF/;6YRXD#^LOJ#PP2\U[T
MUI4M5+P3><)-G"G"MW>$;#-C8O2<C-06QS=Q4NSIQ*EE)\4OI&'G]C);BX\F
M\!UWVQ#\QU_JD=_!PR_D<D-\SNB#J+FJ;XQ>!*;ZPJZD#QZG%H@3/L.<01J5
M:QXI$UW^8*)63D )UJ(4=B D:4<.D>Q?4I7+:G#F,,,0G\O;/?_)YRY@0Y[1
M&VN>#LD'650NT* 5$M$AN/MK3Y4YL;^2&AT*F_!G_C%NR011XVJP,XKR*0F>
M:D#0T%BPABD<)6EGWGFIH2!-86H2L5%2*S7G(%!($YJ1K=T8\M%).7,+-;=V
M^NDF!X:D.Y)(PJ3$R;^USPU%(G'P:0X+64FW:D-G/B2@L2AM];?-891\WDX:
M)@7G2!*<#20"8JJ(T_;.QCN1!=$:"1DW<,L^Z*UY7A:A\K@^[LE=64X=5GHM
M:%]C$MVBVS8M#PK2Z03A*N=,B4>4<U IAXRW'F'@BLF$@>G$5_%;,)7D86-\
M@+]M[#!'E+\Q?3#HTH.:S42%)B'RSVHR=S#6S9'BF4:*I]X_CU$T?K7ZS<5O
M+<TMQB0'@^YC&J6<H+*RDG<8J+<8>QDP'M[!\$DXR#H8((]P7^B/&3Q!-EY<
M06*R@36>R?J%^Y,'%N$6K7KP)KWEFGQ>F>Q.Q)G*7 #^+,WNFCLVA@CR[3+_
MO\>*N;R1!+HKDY?:$6":@+CJ1I9LNES;5';CW=\%B^MNW?GX[QE@]GX!9H]F
M@-D,,'OW6\ZFK1'PBKNBV![MM #[%7(9\E][G[PBU1)NT.#9=ZP8O^LEO9MF
M^XWIG);!7.(&X>M:ECD'UK\XQ<59=<(G;A@![XT!N%S\-<X#@A(EB(#PMJ'L
MQ>KAS7,J;#OU?MRTU"7D28%(,^-?4GF5JVN&7>XWD-^>Z\T?678PEN JIDE9
M.'2LTS1J\WC"UI(%H#\DS@RC/G-M^:S=^?/467?.O;&8NTTSV? <=XQPZRC9
M*0]98CYB,*F=&;&OC+2AK_E"7)22*Q(&I7@1EN'98A]09\O%GT8L%GQ@E!E4
MJ$\/+CI(V8D25QT*XOZT>PSQ^1]HBF-*PNYR\7KZJ,+>%3G;XY/ E9$&BSR4
MT]?&!'-4(,/ANLXI'Z*4]SCW7_N8F%(1EH&A7P0&-#. (V,[4#(-%;Z?_440
ML!;C-CL@;PD/L]3" A>/S0O"+_UU!9Y\O]D0L&7'25NY\O>SKU8\A"<7U@%Q
M2W78."YTCMO(Q^\A?G+P"MEF0:#G@1T.5Z)=JZBC4L-]><OD::+NT( QSIOJ
MRH>" !6?]A'" B5\SSYIYW &\9? (/8Q5 3*U^;^[8&*'7R68'HY);4@BHP5
M9I]X]O(%_?]W/[S("PH^F*HZ?,9XR)3]6YD'\13X$0SNMS;D&)82KR,B>J%4
M3!])<J?Z$.-U'5MU?_%#U,X@?]8J30.KNHPZTA%]Q[2:Q-2(O?"TT&NH6J+6
M?U,(N-M;V'I0@2+RD)J1-CM'+Y*_QW]7C\&_&\0GL<+#WIO;<5=]B?:,6R2B
M@4X$2/"X<Y%)9OLJ5UO+.1+J3OZ&\%\B_HAV-O3%S93QZS0JM[4(2M\=*ADT
M%BV#0M&*O+@LT(Z2\96P,L9+9LT*+!JG>_38B[/XQI%PCF<.QQ2>M ^A:@A!
MPV$#%1Y_17QA SY[IJKD@?4*&ZHT(R:TGA"2HB=#U*N!,41_L(['7COCA>KQ
M.#5 AY:8+V!QQJ#*! L-.UZ4;=3QD=B2&:N(6D"1*#[%M',H2,2]5<9818O
M)<35);RA04&IO__MJ1$P!<JOO;-)*OR;D>8/\UDH??W<"CJCG"95DDS+$XTR
M@A<A "Q7_^JK,)9M.K:%*5P;4>#?BVEGSOW>LP1*.DD?Q_&+3&O*_"&)G*BZ
M51U[826%OKRP.W/#6KQ9&(>J"*5.$'O7>_MQ3.8GR'?_K\-MW'9M-Q*_$!(P
M.CTD0MZ0UQ&2J3&B"LMX,B7^@;T+Q6E &ZZ;:KTP GL2ZI*'O.#0(/199-?<
M5.#A,,L$84"_5HPQ;Z-6#,8JHXC(86 )D[.,%RZ)<X64S56=21)M9M0.9QC1
MWJ8M.Z!][2S31J(^9HOEH;[APLXV^%,B*P0P;BY(TU"HI,UEA&=V W['Z6?#
M1_!W^G_^WZ\?/7SR;6P\9D]OB-!)I9D=T6'S-\))$CP*_%[+Y&+1O9'Y:M99
M2$*+Q!Y%Y1#(W=GHE"..O)"@G85X=H.>:+0@+;N<>"&OM\Y@KPFU%3TXAY%W
M&9/28W<F+* =WZ^M4MA_"?;GG[I_G/Z%N;4AZZ!'?>C;KG<+S&RX*Q$64V4>
MO:+6W?]2]*&PGJ248LHC5[TY#@_/2.=IIR]/JMS)K06U+I1)^LZ0_%?$)?]O
M1U,#!]HS("*/BHX6M6E6EWJS?NLD5WDW48D_$D/0AYI/\5)YTME_T=$5!@K
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M+ZVQ==)@ V602AESTS537L_*9<JJNT[\*9JEW!BTZY6>/WP29>@^3\1%WB/
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M5[/1R>,9_8Z^-O 6^C"07FO\9%C0KE3<X)@TN.Q&?L>_MGJ[?*[X1 JYPC9
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M&>XPFPY,Y[HAJ4PD\-@+" !) 0+W#!(9/T4VF+8"[S%M6XK^2)=N.V2#F#R
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MOA>J!L'W\FS\J,<I%YSR.%+AU#TF,5*Q#359%@RM:BP/+*">G7_Z7/:4>*6
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M:S!%L#%/&D>$UZ! N0)NE4213FH=Q;UT5%LET^&)@'E0"S7XG!EN.1<4V/Q
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M3!;S6[WL4LVKUU(6]4"[AK20F52;7LS 6V"03D2Z5)[]LS11D>DFU1'UX$G
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M6PY$(N1MJE!-Y</#/;N(Y-Q[;]27CYQK9F6:+:@W."D]2@:3>F@:')RVC&F
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M4 E2^SQ*5+R4QHJQAT&VKA7JQV'5WYLD-INL%G1O'7 0[HAF1-S-SY!Z&MB
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M4\?'6[%8I64!P_^0X6O^U*33[ORBGZ<0Y#*7KW347&]!1F=.0S_#S\/W3;
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MXJ"B(CS@8AA^B3:5<L+^+8GPF2\%X8B_^/7-FT\OT74LU5>$;O_)X.5-$]2
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M#_YAQ>+-O7!U =<R/I.E,8I"T+$7$4J%\Q21\3$D*;/+"$4-2-8B$TFN@JK
MTB! 8'T@)KA+J&[(2'(GD_.8NOYP&X\D!\U=W<GT>Q@-[XI ^6IGLHJR,CQ_
M"F)D8Q(46PTEMB:-$GUA40L^4!!0T%0](?4*S> J"X&O2A!?\1RLA(T.I"R3
M[6:0%,)58HYO8--H("_D,G_EO8A>>A%23C1?Z?7"5@7%B_PE*S?"[)4/3Z\_
M;LG0]6ZH]FCT*KRKU\\M4NA,1,#=Y4 \2WSL\J4'JE0:D.QM>DA+Y+T_C<+W
M!0R[A81>P"$)6"V95["R NXJ&"J?\T6Z]4-PH',O(G(PRPJ90A9PAZ+&MW6.
M\@?<2/Z6]<& >@="K4:!MB.7EEKHB?-,<J]NV YX7!]+),.M7S6:#ZLBV,[J
M$ML4P :)&%N0YJ"'*9457GWQY8O62\W#\",B<BGP-H?;^E)RRUUD"G7!A:"3
MXB@@.62&[618R8 ;$&U@G%2D-TY<BBC&]VDS=[R0DR9C'B?"+M$,!AZ8P8?-
MQ_7^Z(EREQTSSQ-VB-:$:+V!K.8'5!I! 8J JI"+8& \*DO&$CO8<M:2<& L
MY6PKK<E:XD8E0TC+NVX:Z25JT/CUV<I;@)I5:?CP\7/LO0;C7HF,,TUBX#[%
MLHJ/]$P;^4!1)V7<+$&QY@](DL_DK<,Y;\H*GA3K\%)D0/XH5^P&3FQS$&FJ
M,='#P\TTN2V8LEA@?#*+</+"VB3\!+)RD1;*'J$[AM^&9WB-NP1OVU-:3:[,
M$OOJ,/LG%KH[52;-K-3)M"3:%EKXVEQUF_FPG%@WRVCGR&(5(7JI64=&;B5#
MP5*RN:<5B-HSD$NLWZ.MP#-G4Q"E$G>J L+#,1<X"/KD:(Z:0'QCR.H>81&>
MR 69+V <E3#QK! 1;.$9?Y3R&='5 )I_(/)JY?CM./HNX2WX0!H$> ]7)$M"
MMES"XH-JH* V?SP&D&_80-##:"U\ FY:[A97I B.Z]LO5V87!663$NF<>8)F
M1)W,YU*&6&W+]III\YMK>1]*W%CJA*8=(]J94I]<3I1 G@_,_M+S6*/1VU!#
MSG-31(!N2_J;LX>.PKYX$P19"0?ZV99O;RWY]DZY7IR5=-07?$;>1SI*XRPC
ME<VH9YAZJ5D^+\IPQ0*T+J+TN^W*65YWGR&?&PM+,3P.7F88KRY8^+(.7G5;
M9,J*$ABR*$DF^-[9YX\L(],DX9@G/UZ;8X0N-)55<ZX4UZB0>[X(=V*89HT/
MVYMAW^95<(:O#KV6-0&<9N<B47FKC>.K6Q=;.BJ1JSU>?"P;PE<U>R0]@@^R
M.D<K16CMO?JYQ+@0,HIA8K@:F8 &%_/"T"''BULI5S9I5VEE%J"^H.T+N@T6
M:1+!9=(T''TJ5\YW]:X>78V)>CWE(BLGZ0ITS#R/T&PPFL 67QDG0Z\9S8JZ
M9R*F"R;:HF:037&E/+*5)L.7M?EW;;L:Z%G9$'S-&9^\?I#;<2HUSQP3MP:U
M_:>I[88&FXHU0)5B?<E^VLH!'38I05H?J6D#ZZRL/?9KS$Q;AM1U/%>M2WBX
MXX2'L4MXN->$AQ-4&;]8-1]G5LV'TQ"/4T/\LJU&!VQAY;((UP.WYQG<07Y=
MO:A4R;F(LBH:2;<S^658';"]#^IRK/PH4N4MFG 9A;11J3,>)64IOBA!H\3P
M.KZF\ZKY=R])/:E=YC1AGKXUNSD9OKL39BH? 8=!V4_>O&6^<B/ATW^-P>YN
M?0DN4DJ<IJ^TT(=*<<$TE/$1W;LG1.Y?]SJ;*I4"S[+DW*J\G/T3U1%T+EFA
M;0[:UZ,8=1:PZ858(2</>EX?)TJ"N SE,79I5B>)I_;(R6+_*^&==F9]A7-]
MN#,A2=A[_?5"6@%&F!%:-F@[)X4)2)$##4--F_1F?*-6@#(M"YT0P0&=^OA4
ML J#7G*&8B79\@B$- >5%K*X@(\R!Y2Y8I=%%'*\8":+*_+]XQ6 /L+S2E33
M-[1HU7:T,I@BY8I4:U*7R,:JCE& GC2G_#W%B"#",#PXOVAO=1PM**\N2LCW
MS.X6ILA+,UOM\U8U%KF77XA,FKS"6@7&E5095.30(']_)D)6@S#(L"QGL%>J
M3(K2=5,*'KV7,["VLY4W]JE$8XWEK,G8C&=R?*UL)9Z'>4%E"G/<B,*N2PG:
ME)H'_3BARO2HN%#> KC@P2S.5OH6JAZBM"F5W6 $A34TQC8PNHK2 "-NI+@)
MS:AX9\*EIP+0Q89(V<;(G ?1Z_0Z/B?1G0/5G$>40L6JO_YP>I786V'M6J0C
M&GP-FUA&PPX[N7$<<N-SE']OO<^DA-,OR/OF?08-_<%E!R4WX-SF.+=(SPWS
M36M9PY2VV_X"7)21G;3R5I&,P20HLTOV0')RK3*>E#%%#E*V1$ R_%MF*<R
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M,3P8!LZDY)F76>3PZ"&-_3.4UF3;DO-VC[;MC;@FZ8M! XOTQ1=C$5A(,K(
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M]Z:%W]\K^'[&U=OR6_C859,51U8M$==IB_+HB>O'_>0_59-6^1S!U7] <2/
MH]4@M7$IN%)8-PT+>R/"9;WW];=OU;N/M1W6'*TO=\)]0K_3JB/G[Z.MZ8QE
MDB8K4CTG7OQ,[0">5GT5%-H5%2%)EJOZ$AF<31*R+1Q]5E&DK92T7>SX7W 5
M)C/,K\-B-IF]7][@@I\V5-"UQK*<C9GM,4YYD A\A%:C5BV#WAG$S<?&S3*J
MF /G$),LH'PS\L=X"8)IZ6TNR:1.6K_LGYMUD^_M>IQ0=I (W.N)@_SW+ZXZ
M-"[OK4.GX\>@ $8JKF^W/X\8G>$>6,R^42\*O#;U]*!R=+$>' INS9[;Y;AP
MLW7$ZQ:J77GVI1IS?6JG@D, !AT&:$.<$E,FH[PI!F103=U)4>!40="Z*8QC
M+J/M9$IG;TPIN!HK)8@I*1.\/]/\1O/TMG*13/6^%9!X)AJ@Y?DZ3O'P3\-_
MZ$T7W7TC!JJ-A)"2I1R!6=7T#A89?-$(%D.L=&2RDYTDG-_H(OQREGO334;P
ML1-[\Q\=#&:>R&R[M7ZRY ]J4Q"1[C/O44OA>$A-V68 Q5%4/F0>4!HI,15O
M8B>=J?9$I+898Z'VY@XY&,SL;N;7?T.]^/;7@R"_&]\MZG=_]>L>NNJ^%_>9
M$;X3K+>NY6M?OWEI\\G/FW*22;K_*'*&HY":S/XP^]1T7)G-5\UY9%$?KKBO
M+WN_: M6%ZO1O(Q69[C$!N+M8;7-9BJ369BE21MKJ ^T3>"?[1@C[&6)HUO"
MS9,/U^*=XD?(DP6VR']>KW!]/GN1)\N+:?CTO'GVQ47(32>:&T?UR68S79US
MZY__NUZN)N73U7>V;P2<Y<H 'YOEU/<_OR:#CP_$_+=W]-/NL?MN-^?B"PZI
MM[N][6?7'H*+\!XWAW\(I5[G\S#]/7Q:OOCAS[?E<W7S6\#==><?<X/W2D^[
MWLT[2/GJAAXN2?V^$5"L2KN+>_#R,6QR][78QN.VT\7\_?6KW][^TOT5[7QW
MQJ,WAW1_?GYU0/?F47JHXVNYK88> %_S> W0FNXW]?4_/VOI?\XO<!$:S;?\
M9UO;=QAP?W73NOCU^FH;\^-MO> #$NGFWK7.VR]*$D9--<(!7><.6^^X-,?#
MC<$?W\RJ$3M?+ZO0EN,1?DS8A%[.-@9O'M4-=OE7W7_A3T\@Q-T-VT.S>3H]
MDK4GS^LC[.9"FXMZ'M:K^=51N[F6QA:LE]Z\'*H5/U]7>WSR$?.+S5=QQIZQ
M/UZ](34MK2^6^'R)]8A3J>;J'K0>E<UG_W [PO5ALIRT#HI/SZ_>?U?HJOTZ
M;9\)SO]X:=O>\0+^3+FO/?VUY]@SZ\2N;Q[T]WXE,.GV-59NNY;P"D1W -7U
M2K]//-^CJ\7M;;P'9]^8[_%=J1U/)O9=--5]M^Y_,"Q&KV<9OVRQN]LV>4BJ
MU"'<P/XGBA ;$1M]BXV^-6SH],BHZ?9-S$,8(8Q\%2.",$(8(8Q\%2.<,/(X
M"Y82?;\V$V\Z#76KM([BT0(_X&R-E,T[N$XY72:8#31Y+$5I,2D-CAD'RDD&
M/C,&E8)+3)EKH=GMY#%N$7/)&@P*"XK[ *Z$^IN1*>LDBG5INZ"[!=E?%_/S
M5_7#FHOX[\GJ[-5Z61>.B]<?TW3=Y!2\7"ZQ_C]WUSC/VS$S/=:,'$6J&!'9
M@8J2B*PC(N/*9!ESA!!0@LJL0+ A 'JCA-0Y:^MN$YF-3#N/&8H,V S4S!"2
M=Y"$X-D5;@USAT-D7,JQX3U6&!"3$9,1DSTYDS%KA ^:U0LTS?1L+9KQE0A,
M^VQT=EGSK?:=3%G)F0P@4I//'[0#)Y&#D"Y:6Q)S11T.DPE6;3(WK-Z=^VR
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M%THEQXI1#SS*Q-BG_^+_A=7E-B8/!FFJ4])4]TS!=D$X[3T$7D+5+(E#+"$
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M8TM1  JC$JD^]888-JFBX<[HDH )+T&5Z,''["&&IJ=1J):_V$KCJV])ENL
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M<.O@JC +?;9UF?G!/I0X/8Q2/AM,1[<W *, U$4!"J^?U,X>^)O57J,A67?
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MD9&5.I.&,JYWK02_]?8<5-ZOFQW?&@_:@WJSU-\W)_C&;]J1-2"200T(K/]
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MP'%2[-=[B<5?_S![F<N6GS31R5V^ C"J?O4 5*JJ=LL;C4I>->7C>N%XO>^
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MCH738*OR2BR<M^=)NV^?I #_ZR'*^5=9N)#EAG8/0:8W*3A5?ZDWRBGH/U\
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M]Z N ""6((@A&."BFIG-6M^CWJM]<D5W5/LAJQZ2D9=::B2QTKX.7A5?=K)
M7PA >IRR1O2W7_[^F U=O%Y1U,/JW*/0]=VDHE<%;+=O!E,;46'C'/CTLZ2U
MLP'G BD,I?=Z.YL([S>\:U$85Z?EO>\TTWOG?*4?Y4KOB4_ N F,$_890 T#
MM<4GYVX:^(C\'6Z\/$A0NQFQDY22L\@(&;.,A!Q385D&FFR>"Q+E21Z&<2I%
M-#(@WSJ]8,Z1;I710Q$PCS>_"37E<D)\:SO4DXP*26*3IR&7A"FC";,L)WD>
M22*E3BC\3G$1CNHM&7B8IH)0Q0SZ:#B1<9X005D2YGF(+3 ?)BHDS<^G>#4"
MO3&MCK?UA^Z8?5!70,KH(L.::.!Q--I.K5ZDIEY0W+4O.!AK<*"<7*,B3(Y,
M\U  K ,D2Z. 5G6DB.#XSS24<1@FUD:C'G$ZXBJA+"2I >)DN94$_D^)RI,L
MH7FH,SGJ9O" \2MA.DDG_WGP9K'HE>9L[.==IN^P!.I5KUM<*SXTD@3LH],A
M1.M(;Z6.?1X7KS5/C7.<@>:^5&9/$5(L*MK:'[#T(0+]L#RV&&K]6&*TANT<
M>3%:BR.:*>%Y;!3QL7M%J4#V?\FV'LSV:0I=^1:A"TPV]V$DUBD=H-]<ZX>K
MO2-GL2A5KU;K6&[Q&+L%TW?O?L:!W0L.>; ==^^491_O IIR:U[95OW> GPO
MMNM8JX[[J8_R!]2ZKFZM*R$_+/[;<XCUM^R&]+WAGN"7<%>Z?3^P+<"&@.FO
M,5AL*;Q<O$W%JNO-I8.!02.G1A'!H0WLFE^FNQ?P6'^-6&D8"[WAQ\U&!Y5/
M[,?M\%>P97ZX2*,N_(J\Q:TM;-#:V+8]HUKU%U<W&R)&G64/&8=\8KVOR[PT
M\,TMJ7<F'\\ ?-N#WN=X?;!XGHM"7#8N>J2 MI>M#U"\YO)M[>,.<%=8$, A
M++QJ>[*-O0(;#^@"[?"WLEP<NWS?CV#_%G@[=+E9-S)>Y9,8]6X86M<?>=1+
M#0O3*M>AI<&P9E>\I(F7M+^&G27TNCJT$SH/OO79PMZ0Z^(MW+B.L7\L:K,G
M*[A]YQ&&I:#K4(=S<P5TCP.<UOZ\;1[7L45L#M>4&J^/-7 Y^W<S;^-##B=B
MB9JSY1XJ6R[J;_N<+3=GRYUP/P;XV$8J=&$*7?&OIA&[E] ZV0Q;#*!<I7"0
M:BN;(M!ALWO?<'*0#>#CDQW;N[I.Z'WA.L.-; $YXMB/<<"KXK3;/N=W(O8U
MKN7SX.N^[[CE9=?XCP<"QZ#ZQ6X)KIZVT!=N;NUU[GJ_CMS/O7)?.Y[H=L=V
M*N<WE1^Z=:V-CU? 4EY=):^N.,-6?6C"\MW[7#W]=9/&Z7^-'N5!B@%IA^AJ
M0+22OMZTG^\]^?/V8+:MH^#E'[!(6"-?=-%"S1UVY_Y^4[C<4M=C ?LS7"\+
MXCLR#(O]I3^-;_HGZU31%;P;5$Y<K2O2!SKM>R!Z1U;]:H%+L>[%S@XVP,V^
M/MQA92@V#L(DMIU52I1]!]E%C9Z*ASEJ;=+)IEMJWHV-[ 5KMH,W87[>T''@
M6KKN8#6J<%MMOU?;Y84AV+!*>FL=VM;1&9K-]#9:^[JFQX\H\S;MEB-/_),S
M+$MA6*RRG#!J<C0L,\*%,(1GH9'21ES'HRKGMW$7'A54UR@]OW2ZSHELS&DZ
MW:39R5%"G%,9,Z9)0B-.F)$)X2;G)$\DSRB5)HM'>? JR>!W.26A,9'O/))S
M$Y)4RC@T2:;DN&;NXU!"-,E0R2'DGS76@G51]2WDVT2A+EX!Q MLSN6DZ!8B
M&XN)-(#IRU[4@H^8]'QQ]*4AF]L!UTD"EDXH+"*5).5 =TP*P)U,&I(FJ;(Z
MB5@6C^+S;^.P/8I,3Y7:QK)IYG!/$J!":N+<)CDQ$BMOY#2' PPC$F?,6&$!
M;$(Z\H&J,&8Q38BR(7PGX91(%F?$L(SK,.1IG-PN_OM4D=MLHK';D_-!=@+4
M 00KZJV%P"NF(Y/I=3JQ1\>>@H<JV=!\B^:)A6G%^)LLN!,QK[XHC:%V_0&'
MZ8:J) =L'YTYO*=5;!,NT230Y[,WJFVM"0-]_N6B\)D\V*S/=$&"VV;(33EF
M'\;2KVL!3WG[5E/'MG$B^@(58JA)NE:)[>NW?I[)*T!]XT'ODHK;Z<F3C+J,
MM(KB++%$A&$*O,G5W$@88:'5P(/"2,A1&-E=U*C6M/)FJ7N&E6_]SIQ**J'G
M?)*L:8I""?9VU<H:HBVEV,0A(SE5(&E:KDUJ0RW8J*K47;2FASAXRLZS"1[\
MKI)TP!;TM#GO,VF8^4;*?Q3FA0HB?<NS&?1^[/451G'A)[4ND3M'@/--X4:W
M;\'71>DB=F"Z[X'2?UB#WO[*_^Y+'\O:"C6]QHI.>?]8=OZ$->R-\:X56-U>
MCTXSYJ#7XH%JU+M/GK6?7 H]P4!9FT5Y(C4E*A.:,)%E1%(5$B9C&0L6:T5'
M_7.UM#+F<4(B#D#.:(PQX/ '3[1A(D]TJO)[3'^XD1^'R32CO)]:D[C$9EE&
M(V)3E-&D#4'4XB&P:IO$,LQL%(_RQV]#&J=J"G9CU/\TJ6&2XEEH:!:*."4"
M1&O"$I"V>:)RHGF<B\3&.M(C]P8@1 CHD1&#U,&R-"%<.KDN"N.$Q4QP^]!G
M'H7A-$_=Q09TO>#&T;8#5H<DLNT51_F.QW/@ND7C<R_.[Z!6V/EEVYH8/5:X
M-PSO@.&F#<=U"W(.^%X\OS<LU68EG)/^4-!)RQKQV'1C57<N<M]=N?-EXQ1W
MTE*:"3=*\C=QO/^!L\#%9[4O<C'2:"> M>_XN>VF<CD*_;W""(T?PK#I7(%9
M-!BSV8O"[-E$Q'K[3CP+#!KX*"H?K]JMM DCT,''"D,SE_B82W+OK_SZ):&[
M_[\VL#E-1:UH3YWI7O^+91DL2N"WW<J\_W<[7;<ISDGO0U*'W<UPE'%*Q\ -
MTAO*A0/XI0ZI$V]"@>'9+HBI$<E\+490]KOO;U6573&JV\&+)IC318_5&!_C
M$I!Q7/,)PU!<TGA0^MR1PP-NBVRU<\3E3@^04Q4QH25)40%F,:B],HDHB6TJ
M:"J!0ZO/8L+7RF<_[K8Z_&GYD]O77US.][?-?NN?3?6S/\%3P7<R3?@^#[ZW
M+26UU :* UHM5SLE1GMDW:D /E%G+7[W,7N[6+,W^+S7]ZB+?QIT;5LMBO6@
M!F\31K;#'MRK72\Y7ZZLB[@:-$_<K%PF]Y[@,1QD&\_U9@%PM12MB<$" 94?
M$5G\2KLPK.Y*HB?@QFWJWT9,\X"G XR"1QONME7/.(>E2>5PB\%>J$TCR+(:
M UVQK-=&Z*[SZ:AA8[#M]#DTGMR@Y8VBWW=:K0(W7CZ-/JMYFH<F3SBA<0PJ
MH5&4B$S'1(0\5C;,M12C]FLVS54DHQ0DOQS[K.82:W]G))7",JGR+%3I _19
MO27*1!-5#8#(+T>=4G=C#WK)22Y$\$/3]\?3F*_%.>@H.8C!;#."\<H,Q0PQ
MY) -I6^=-GCJ[3700.$ 9%?MOV^4.I^VT?%)6MF^7P;?&5FU#:?WM&%KA>->
M)[:1M-19P+I^;-M"EECZU#O_=CQ6<%U=J[7I85R86FH$X)4V/LX!\"K2*0DS
M2M.(41-3-=)S+0\%LPDQ!I"-\10#8E(#DEFDM(A!KE(C_]-]Z[DTFZ;O:01?
M2!T_.FAP00JM *#+NA=ZY0M&K@"'FF\(I[L09+T@2L!+7 SSJQ]^_?9+KX;N
M=$^_@5OO;Q*(VMK3Y-111(T)=4BXQ3JJV*=%9"PFN<3^YDQS0T><.C%&ICHQ
M0.H6J%AG@N3")"1DH8CC/%.<'U>[YB$Y-8TF6?M@M_B_65:P6:TXWZ.<AJ1K
M7S)TM8 )^7QDIQ7W&?2AI/3UL <TW(!>V6/_WKTO1%&_*3[0&F>ZVFQ=VNE0
M"=\_A=V:(HT%:W)W0H29 +68$JZQBD<F&!%IJ @77&0)-ZF)XE&\8RYYQK@B
M.;,I86&8$V%82K)(I#RVH$V'#X[LR21]R[M"Z,T4WS,)M1+"^J*H=/!OD$C0
M- ??Z^+6.K+RPN2E*%QD[N2(+(HE958G1&9Y3IBD!H"7HG]$)BS7N3'1*/8[
MHPE5.D])1%,*1)9'1%CXCM0<NR/1-#=T<L";3E.\: C)EFBTW:6DIU!H;")J
MT)Q4_E!)Y7%_V^>D\CFI_(3[\<@!J\^R*BAC41*#% EL&1B\X: E&8V6S5"G
M-H?_1Z,P119G*:49UD($>8!Q(T H4!J$RC03ED>2"C&'Q>P)5T2JF!P%A#8.
MM83#YRS"EK44?N)&DBB"D\RX%I)'GT,!+]U"A!KLR$JT=79-CAZ$29@1C!$J
M<J"'5('X+G1&XA 0(5>IM&RD5YY,Y!\)^M^5U;>=ZO63W:H$/S=ZUS,WO+16
M15<<XB8=="X-L+\TP,C(OU,=H)Y@=LPD<VS#3(:IX9:$OM,.YK4D(B(A9313
M8622<1/*N_"*1TD%CZ?97/9L>F20T,3P3!@2IIC;HJ.42&LPU5HDN>$J2NTH
M>#)/5,(XG'L8"?B.HA')8R4)LIH\SH1@@D^"#&@XS03<TR7\WQ=<1FU*'YTF
M>EDCK [3C% 3 0EFZ OEEI-0B8B;) 5Y9]3_FB<VC'5F2<(M(R A8[P'M<28
M4#$!<)>;V[70O2^RS<)IVM$G&?T-"J^6H<R)B5RM"(VU(N"0K<Y5%*<Y?C+J
M&)='J3!Q3 2H1(0QE9*<TYCH/&1I:C)-=3H)2J#3K""P+Z;[IK(CXUC6*>**
M2"60@&#$)IA:E"I&1*AR$EO.$U"@11J/ZD_<1F-ZT/H3Z5QXY/@ 0I/2/ 5)
M.&18(PO327) %&)T#&)0%"8R&ZO*N3(@/#&B!$=S2V@(MUA-*=:12F/0KNEC
M'?PT^<>$G%F/K1-N*R8< :4GK7\R#)PX7 3%56E=OB]17&SS:5I+5_MO-(A-
MM#A*0_]_W\ %*]36?W6,1^G4B=H/YE3"]?5]HL>_HL/%9L,:6%0R4D9BK^L\
MMJ#JI8SD&<C,L6")E#+D83+R*=#,&(V!!JE!*S26/N!6H/TQ5CI1D<WX*#+E
MW6:U\NT\Q>)KL< XGG<7QJR_*6JU*+%::?TKO.'K1:E^_R(P (LK^/:ZVICC
M?(3/)/4^/0_\?\T>!6Z37(13N42SX>=<OA//]>G&+M]Q(_RCQ_2Z^+G":D%K
M'\G\[;\W15,Z]^]F_0@'>/R\!T>Z'V=NNF<'<"96-K6IT82"_D58KBD1D9$D
MS2,6BX1%43B*"KT+SK0[_S-<G_6;I>XV_PAT>0JD^WE7=D"79DN72[-NG>)=
M?'*7/O5Z(@S_""[PJ(=R(P<Z8I$^_B;XR]KUX-I#EV*S+K]J(FAP*G@^L Y\
MG"S$5;E9OW81#U_Y-V7A>?BG]GF74K.JS>LV![K=#Y>LZH?^HIT"S*$+ L(R
MW5Z!>=V.T7L0GM2=(.3>FJ;G,=Z>+_Y\S4/T/(YN>N2FW\?G27CC>QYF'M'M
MYO&7/Z^K?5O=A$QQH"4IU._O07A?:M(0HG7_[2?$CW#&/E#KM0_7P@\.G!(H
M%&N4Z!O2]]=AWV78<^7XO4:^W4K1WQ-RM=:W6/#]+O!H/>$SE@=T@;]U]H-K
ME]K%W+6!D:MUX H=!BVZ3>'T[R('W2:P]?8D<LV^^<L8QI/8N1,2UHQ,,S*=
M$)FB&9FNB8R=$6F^+_-]N?&^1/-]F3GXA';X12'23;K%%,[VE'CSZGM,Y"LW
MM5CJ^LN[D\ 4]N7A4,69XL:PH@!@K;H5@NR=\\X6PU8]1O+89T0EH MG@PFA
MG=GU&,HZ9B^N19R'SZ7[?$3M#[LLI[7D(04<6NM_G/AL]][S^URZLPB?D/H/
MQ":KC.?8]XE&1A-&$TMR&3*B-(T3'24TI^.,]82+W%!%XA1;,T@,X&(R(R:S
MG*:6Y2$?Q28?= K]K2KKPUDI\2 H)[XIE>TLSJ*#43E/E=Y/>YMG")O DF<(
M.V5886*C),H-L8F5A&'736G@)\Z5RD+X [3770B3D:5<1I3D2KM.=AF1+..$
MYDKE><)B:O9E9#X(A-'#V;A/E=X?4MQMM>@7+^Y^MZF (K%",X8:6" W#/&:
M^<6+N3\SF^BSB32+.,]B0S)+4\*8SHA(3$S"E$O-DUS%=M3PU"8RB5.=PZ)H
M3%C&#$BZ5),X2:74,E&"A8_$)E@\LXD9N>8C?0'()0&$6)H*DF*#/)8HCF)K
M3I+,J(P:9K49!8A;0+54 ]H)FT6$Q3F@71XKHB.:9ZGE,C%R1JXG*>#.]MQF
M<W\0<C;EOL!K,W.'83LV:D44<J(UY=C511"A9$R2U!C) >RY&)D_7#/=1$4D
MCE1.F *Y5E*)Q7 M3PR+0!S>UYKK_KD#Y6<LCV?V,$/7?*3/'[JD >E444E4
M# C$6*Y)GB8922P5,C8L$SS9A2X0:F.9<D,BS35A4@K"L3J.4@E:?1/%0O,X
MT)6=T?1P1:271>>SZ?;S)%LC:G-1+G107&(+'Y>U.YMN/_O^W!RY^61NV!T/
M_5:QJ\^)UR0V LXA<I*:!*O.B)A(B_7Y@>,PRB.3I*-J5E&2I2)-*-;XI2!:
M<_B.*STC07K6P*ZR.'L<(TIZEM+T?GG-,5&[S_VVS! Y0^3+@4@>ASI-C"*9
MX1&(XU0 .EI.<IU(P7D2)9$=61+"-.(2.SH*;)%CT?J09AQ$^"P"49Q&4C]2
M+%AZ%D6'*US/$#D;HT\JLOO-'?]YJ-[#>Z3UAV%7]%%Z>33C_Y^W\&59%?_G
MK!;+FM2F*NQL&II-0S?P(I$Q!O IB=5*8YN%E/ PY02%>$8C&F=TY/.,8\HH
MDS$Q49QA\5D+XCIE1$96ZDP:ROBH^.R#\"*6G^64SJ:A&=MF;)NQ[9]QSA,A
M:4)TCMZW%(MJ96&*#KPH3*(HUUD^:C*L<YG0),6RJ90P3B61&8T)EH+/1!QK
M&SY./ ?C9S2>/7:SV?O$,O0/IJX#H=3F<N-K7&L#WU=%TXP>A&EQ6<)Z_W ?
MS':?V>XSVWUNI)M7=ZPC>$O^%EN>F3 DJ0$1G&F>D#S/$J)HI#(NDX3'([?N
M763W-UMT^*8'#O"SK[ ,+.]-#R,.LL-369SX69C<<VCC1"U.Q^6S'97(/Z/T
MC-(S2C\ 2LM,149&&9$B8]B<#+N6@SZ24\!<F\599D<H?1<M9&HH'9VE])Z3
MQ)\G2L\.@A,["'XMU]B-\G!!Z/^?O7?M;20YTD:_GU]1F-U9C $FG?=+M]\%
MVG/QZ<5Z9C#3]HO]=)#7%FV*E%ED=VM__8FL(B52E%H7%LDBE0;<(XG%JJS,
MB"<N&?E$L9?=:B(=TJR*8;K(U,Y'M)C'.?__E,DX>>/YP'8"EDIR99#P$>?C
M4!"26$J13)0PZZG'?JN#6:?;"3_'S@P8&6BYY\V$KTK*Z6UM%[PL>%GP\EF<
M*MIIG1)#G'.'N(H9+[D&;Y]%B!>H"GBK6K+3+8H.\5(,!"UX^=)M#/@Y=[;X
MS_N;?;VP<\N)M8IJ+\V/>JQ[#P2[LT4,U:K=X"@>HUW4T\>[OVY#SIO@$_.(
M,ITA 3PN2Z5#..5NL<8HO'VVYT5=S?Q%#(MQ_"4MYWYMZC]DR2U=A];D<GP[
M.:MN0Z794&DV=">C\X)F0^K1!CY/N.2QS^G0['R/8PRCL($7-O#2::@#GZUT
M&NI8L HR%60JG5/VB$RETU#1EZ(OI=-0L> G.\.O"I%*IZ'2:>AQ5"FU/E^?
MW%6Z=1;K:&?^HJGM"?%3'$^;W2W0M[KP^9SDP:#2NJ/#;>8@O8%;2<1\)MC1
M/B)C=$""1L%,X%&[+>[*YY3EV''T;Y;*^-M2%]]-P@^WFOA]5L2N&.#8 $9=
MCL(5$.O[DA80ZQ#$HI7.)]$TELB%])(AS1U%"N H,"&9%%N-)9Y3*W-@$*,#
MMN]RF9,!L7*>MQ,W.%Y>C:?7,8(27%[%25V.[+XN-2KV8MU>$'!VD[8461T!
M^XTCR%CX27DLM3(>P+\3:IL?EUKW6VP.7ZW517V_F,VZ.U%%Q( :52Q&0:^R
MI.>/7BE@0ZASB#H/[BN.'FF2$B(X,N45!40*752&'PR]Z$")/?-$GHRHE[1O
M)_[NU6R:8EV#'-EQ5<?9IY$OC3=?D1H5B[%N,;P1FL<@$%88?-?()=+>6L1\
M4L9R)9/;:C'_0CJ8K'V_KBG?3[%S<S$@I*1X"W*5)7T%R$4-#<'[B *A,B.7
M1<['A,"+54Y1*C7IBB+E$,AE=.%I+'G=#K3EE_E%G!6K4,B\"IG72RD2.;<!
MLP@&0H%_:ZD'HP+_,/"4C6(I\NT]PY?XQ(VF;A^,[=:R<+IGN])3/JWB-1=\
M+/BX%WQ4*D:'-48 > "2F!IDO*<H88\]H9H'VTF6^2#XJ/">,P9GA8\E![V7
M/D0MV:#=YH$H=JJ09A72K"Z,EA1>$:<UHB3WPI.<(TN=1I@1*B.QF*2MOAX[
M)+KW9J\8'C!UT-9Y)\^85<"R@&4!RV?1CT>B<A<D $L-P&>81D8+GDNG?33!
MX4APA[GUO8$E50.E"KW@GN@%[_TK?+4?L-D!&=C63/7QY5Y*Y_;Z7JY3"D4E
M#696<V2<38CS8."G8)%U@D45J&1TBX3U)12*N=56C+]<Q9F=CR8?_SO:.M9/
MH$U\> %/C-_SH256PQ:DVAFYEYMP^2)G3!WY?E+]UV(2*XJ)'C1,D=]/+V$4
MUU4- XNALM4XST]E/\YB;$XWSZ>K/UU=S:9?P%#.X_CZAO=P_1V>,<#.71!!
M$TT0DR%#&$<\2(N<LQ8I'*)Q*D@?U%W]XM8:[<'[8$0+Q+&/2(= D?)1&:M]
MD)%O'MR:1?M+6O$<OY\TLK3A>]3_2O-UEP,_MI&/Q0!FX$&7X_ B4M7_6MA9
MK%*,\VHTJ:8IC7QL#KV/+3@O=CZ=@;CDY^:/?Y\NYA?5[S!*&/O$CVH_K6!H
M_J*IE80GVGI=SO[CWS0EZFU=740;\H/ !ZZK[_(5_^_:7_XPW%7 'H!AP0*#
M&)WF)IT4(!7\3XOA5T>E8=%!N"ZW>@=T!<._7.6E_3#]\0M,=3B*_G^ >6ZU
M.7ZY&LW@.["$^YEI\.&%II(B'/))2BH4,LDQY!T80FX)<3;N,M.-0C;S^F-^
ME>88VO]$.SO*O%),S8U)N>OF'DV3/X_FF:VBFC:"EY$<8B7X&B 2 #W(YF@:
M,F/P?@3 B\0=8P(E)74^2AL@'J0119\@*F2"TL"ZR*#=IVJ_Y?>TXP]Q=KD!
MP*@&H0F+6=Y)J./D*+("_ZFN05#KW@G,L'<CJAK  ML##PO5E1V%1GC_O6_>
M1R I:FP%"EK9]B"-4SR@A EE*1)C^%8"Q'K/A8X6)8<-Z(?E"$9 D;!@>KGD
ME!J^U6+!7F>GK/YI.@,OQ -:UC_-II<?XB2W7,B<WV"#XX/9$+F1#1&/G@4<
M/GP2\ BR %>/\Y1GCO/FA:O1);BDGQH_M1Y6X-S"U9/8+DP#?O.5O=MT=IO4
M&WB[HPE@8G9YY_![OJ^'OX[FE9V!+_.Q]7]'D^:K]G*ZF#3\ZKT3/BL,]0FD
M33AP7KE)#+GLV(!#(ZG760))%T#[6ZSG  ?S&+ZW]<7/TXE_)/GV3'$;BCY*
MF\WD^N-\;FUFQPWZK E5Z^F.X)*QK>M1&N40JLY44<N9JCQ,535M92B3].>=
M_*8%MK/CK*M5?0&.=KTO?S> <^M%2(C$?%[# -(8RB'.X0P@*^BD=;HK&T*"
MB^XY1P9GPZVM02X(@;S-+>V5=I*RIQCA'V+M9Z/&]SA6L/N+GT\SE33X9_B\
MXET2'+4Q8H2C=;!(1B,K 0-\Q.!"&^OX=E$-CS%A$35X9 2$04#DZQ*.*&!M
M*<0^F*8MB].&O+]%._ZQGL-4K(+?W:)>/5#]#7H!XQ\)>N&&=O;/0?6]'8_@
M12<C.ZQN0RM BDLP,:'.>K\?M>8X&(:30I9ER,\GL)SR 07NG,1,@5NQM?K!
MX&2X4XB:1!"W@B!K(,(BEHA$M5<!IVVUWHBO?@ !()MKF\$,7<*#+O(W4;#7
M*#NWZ$C.]4_1S6 EKRLYR$JO^^?1;@=EL<D'M%$9V)L 'DA[VG1/@;EG#&8F
M(&F\ .1PX*MZYI'$(%4<)PO@T05R9),PG9U.7)9&GV)? [/-. C\C:D;CSXV
M?@0(T)6];J1G<95_ZYU_ZE(R*7&+O"(>\1 PTH30[)*(Y%QTV&]E@EX"5@<-
MCO"0]\E^/1(;]4ZB&X$^WN,O 8P6L];A6[;,:FWW>D^M#5^_!ICVXT6(;3J[
M1>]Z#;[S7[/E[TG#+5CHY8 W>\&-XQ<41K,V2,X=H1:7D[=A5%^-[?6;_.G;
MJVR!)A_7*I!'[3-71;OPZS\6]7R4KE</;[X()C^\==,O^2UR9ZN;0H<O^ZYF
MV(U9>K=))Y1OE$8L:QIR-<3%3;GSE?T8VTIF9!,,]8T=?[;7=6XKM;XXJYEO
M)N.^:3_*[!YU'WZM=.1&G%_1?NT#R?D#):IO4-'65;WP%RW4U0WPY6AI,IU7
M(-0U.*L.0F0/<:$=-2[MU/O%;%C]W<Y&33.\]C8-47;KYX['*]R]NS&X1-NU
MAH;3E0N9-ZW@^6O0W+STK7D[,N:^(L%\/ZG^"EXGQ<1\+;4ZV4RLU+G*K?^Y
M%:6#)<$(1)U,X+!2@@PW#(7$O<A\ 9YM1]<L1J>H@5B*YB0LQ%=:@[M+@F,Q
M:.V8^7HMP>_+N7FWFK"=,BRTUV4%2]5?W_%?Y5(_ ]; )$U"&]KT7% 8\3*S
M/R:;][@=,<CR$"'082PJG(AG6Z%TQ(X''> [VCG$X3=D(#Y"CFFCF+*8:;;G
MHA/*!K*_P@$6Y*8%8,[;YN 7(MZ5?BPK%\+^*A<L+$^(D2%AB44\P?H:J10*
MUFEK@A6,;]6(,(XC<9BCY&E 7.:ME&@94L)02E(*3,>-55V]SFUR[:\YB?9N
M$IHBAJ_EV(Z97_LYAY3+E2&]BRJ+(W ,1V!#)L[/&Z!<8>$2 WNN/>(B6*2)
MQ2A0&;R6C$>\M;VJ)(U:8+ $/N0CSQ+"/V<XTCB8%#2WAML#>@-J0/J+]T]T
M!D8KCY/2+#RC21,-WLF8MSLTNY<T=<^;YU/B)$8DG(_YR O-=8<2,>.5"SX*
MH[::HP@FO60BH6 HN*'2@W,IC$82>T<B6'"MU:80W4S$'@I5V8"(OLI0FQ]O
MI/RN:+42L8*:L'_O08&*4X@$4.*Y<I'B@)SQ&GE"(A?".A>V?$(?&,8^8PJ$
M%HB3A"&,@.!!$ 8>822>2'P.WL.Z7T=[YSTTV[U-K<\]@-+*__[%)YA(DLGV
M0H#) 8$QR& :(12-5&MCA0I;!1L@(,Y+X0%-&H*-("!>!:\5:^$H]H)&\S6@
M.%%A6G<[6.^$J2E'6RL_85^M0*LC?#.TMN[$W*/ P*1YDB#R36"EA(H0SR:P
M;"1Q%[#51&[Q*B9O\ZD,CPR)$ -'!LZ5S&<WH@Q!2JN888>T;+2WENT^[V@9
M$-_(Q^?1>+P$ICV:-4&B8F#1O,O.B$\1G%D-#BXWT48OP3G>(CDC.A)JI$$:
M?)Q\+#@@':A 6AAOO$O)&G,.9FT=B7C_D.CU1J8WU4"/ ?!I1J;2,^UE] C'
M!)%II S9 #"JG)'.. T!Q%9AA9(*0[AA4<!&93T6X)XZ@L#'-%9R9X/X>OJQ
MV\C4#-A)1:9'P5ZFP(%+!"-J8(G!S,*:!0N>GF(B"$&#9?=D()ZYSB>*O>LJ
M+OJ'O4U@VDA+KH_.E5IU-9K7N:O$U736N#3S7 .>9>X)6YU]27!V>C0>.VEI
MWFX#7P)<"RP@8O;:(8(M\]X9B(&WCNZ^[$PFB'=NK_@A[TD_X4S\^=O(#Q=M
M'[_I))>)90F\V6/)TE=]!AN9=__3-)?/U6]Z(GY'8"TX)&=(2RW3%$[<(XEV
M,9^N6&3R>'(U$ P_7X[&]GJZF,,COL3PMGV<(D/\[>KZYB3+51W?U/'* M+$
MU30T/$'MK;^YC[#QTZ@>-85QUV]6]WB(B;%Y*C=#0[[-!4X/7T.&BC]VR6.?
MTZ$1:M>;O.IQ/$+1J;_*GG^?4CR'MO/1#A0K5;Q'X_5>JP?W1*WV'.JXKE[P
M$,QQ(!?YT__S#?WFZZ_Z4A[H4YJ,ET[ (^Q?KV$*SD8&.E2(IY(&=C4]+^4,
M;!ZWSMKTZ#80(X/]*E(OIJ[H5G]UZ_0GXW4;F^*]%N^U5X#2A]7OTE9O;*[O
MVT87?2GZ<OKZ0HN^%'TI^O)D?2%%7_KG\6[/6E\4]NP1Z3 O>(-)N35#[]ZV
M2XCY[GVF7YLN:CL)]1]>[:J77FR[]4F^*<VX/<Q>.@B=8)?QXW0'.M/./TR8
M1*50*)E\[M5)AHQ@%&$L9"2<^ZBWJK]?4KNS22.6BW@Z:ODC!Y+*_7;\.9E>
M/@6V>KRD!;8Z9?@@2A(6D=&)(\X\1X8IB6)PF?XP$K?=C4<Y++2) 266:V^3
M#<AZHY&GE 2=X(98'Q*VV)Z[.A;8*K!58*M?L"4#B9PY1(,WX&U%ARQV#D7P
M88CS5/&T=3@4<\4(9A;1W.F(6Z&19I$@RK13*GFLMZE;]PA;%#_,FWFJ,G[(
M>'R5R7OU\?@]W'+%0+P:Y2EV88.B1DC#&+BSB6,)[JQ6R&GA$<$Z=]MRD=M.
MFDNN=*YKL\ &A)MB%@I8E24]?[#*+6<2U;D=H*"(\V0 K%Q$@D#HS46R+)HN
M8N]]@14=*/UPIZ(BV06L>O+*!:PZ:+.4(L350D*(G1.%B6'DJ L( F<E=-!4
ML"W:DY=$W/OSK# OVQN[!-QE WPYN3<$O*.)GUZVS;%F<73I%K/ZII/&IQ*5
M=V\[7GJ,I8<Z^,)%[^Z07&_MSW<OY%9XGCV+P5$%)@DQ(AG$^MR (^WA'RV#
ME%19(W?*%&Q0R;QO@.+=)/RV#A._I"UC1SISS;FF^[5V+S]1U8-MEB<5OQ4L
M+EA<L/@ 6 SA 3;$6I0X2Q GT(!,D@9Y9:3$5"5-MF*+YR1"CHO%9*!5P>*"
MQ06+"Q;W'XN9S)RTS".=VY-RZ3$R2EA$I?7"$*/!7]XESW-LOYAP4K#X^5A<
M:C1VTK46\];__3"=VW&Q?-UJ&QW2K&YAFO'EF+;O.,5^3YF,DS>#]YLM&[#S
MC"F$E?1@MJQ#FBN-L%98A$BT,5L,T#M1IW9DD-2 &G9(@W1'*HYIDLI.:\'&
M@HW[QT8<I,&":!2QYN">.X9LS'TW,>=*&DXLW6;'?T&=2??8*,1!G?6"C04;
M"S:^*FRTW"MEM4,>$XHXHQ@YI1@*1&C++&B_WRG=L3]L)'C/A<)GAHWK&0SX
M.:>7_G.[/T88?7IIWX/]X^/:LSMCV7]-31[>-8T=UDEW-UKF'7Y ;2>FEKH%
M?"T+BF@_QFH6+^UH<LNP 6A[V;0_F6Y2;]1-7]C]M-KQDGC!740X=]GA@E)D
M#-6(1^ZMU($0%[9Z?S/""0?W,E*6.WZJA!S.#<!I<D&Y2+@.7S]A]W^74_&N
MG8G?5A/1?/@!IH%LX"*JHW\3%K/<=^<H$B6&/>S>F6>CONGAN25=853[Z6(R
MKW+;BRXDJ'.CK).,P0N+B FY-D<99+SD*+@8N%.>)[\5L'0N>S\LI^DWF*5?
MX\S?;?!UM9C%&^.-Z+KU?LQXZ^'#9?.'EY=OA]7WMKZHKNPH-"AC+_-[UZO.
MTDV/URQ)ES!+\-*K"L<6F\8CV[1#&:UU:,H"6+7-JH_W6KV"^4R&.6A4,M/\
M-4KW[WW3.@'>;PPJ(JIS$A2\8J1E@%^YPI'IY)/KI/O4IM;]:J^S0-4/^L5R
MPR\6CZK6PZ>JCP#%</48AC#HWVI'1127(B&J?%ZY1)'&%L.Z)YT$%AQOV_?=
MB3\Z7^V'"VN.N=I9T7NWXEAI)9/3R+@ H:X/"1DJ7+:J3GH>2&);#%6[<R9T
MO.)J^'#4>\P5G\7Z*L)P/L7Q]:#!]W7K.8GSRF<;NZC;/]PZ\OD=/K7F,_]]
M,<LKT-0+@-^1@W;X3S.!V>0V]TBY =U&+]M.FQ 2*2UU"M8X$H #X\&'\@K\
MJL1IT! 64KK=W_A%.VFY$>2FL/SWTIFX_JN=+V;PW]*@<"5JN4%AVWRPD9I9
M;#RMU@>[6NI8-?T,(K, QVNVWN+W/_Y-4Z+>UMOAHVVDJD<^6N_Z*KZ"#%#7
M?18E/D:?1:6'<N>F@8]]KH=,]K&GX*EQ5'=):EP])>G=GU?O,:/^J4M"5_36
MQ^\552BP^UW.":X*+WOP+]Y@O!R%,(['7_.][Z\O7_1,]\ZIXT0D19$SSB >
M(%RTR7ODHY&4<!NILUVDZ;\:*:[R"S\LXL_PF ^?X_A3_"L\\^+AE,/SMMKU
M0(M]T=P<3Q,*5>-Q[(8H=N/5\*P4!J&-4BOM!5.6H\0$0#^X4$@;Z5"22@9N
M?8AN*_^\3W/Q/]'./GR>=F0ES(#(/1>KGHS<E^AB5RLABY5X-=I2K,2&E4@\
M89X [#6!?P)C2+L@D:6)$X.Y-&&K"F'O5N)B%F-G=H(K5>Q$B28ZL1.JV(E7
MHRW%3JS;"2F]U"H*Q)TQN3XY((TI1I$E+J./POBM#B#[MA,_31>SSLR$+OU!
M2CC1D9G0Q4R\&FTI9F*#MCIJJ:P62 :L\MGGB(SQ#@GN,8XJ2K-=U+QW,S'Z
MU%4TH0=&EGXA)9KH0'\^7$1X\02:7XQ%X>,K?'PO-#B!)X,YHT@2J1%74B"M
M0SY<@3EGQF&'#[HI_BYK=,=6AP[H80^?]X9%K^<!3#/ZT23 H-J[OL14K9?^
M-C=9ORL^5/GS+I8L4^OE,OCE"<X8[M3)%P/W:IS"$@UM),T\SY59!H60*[8T
MXSEIYA%8&(B'3-Y?\8<T3AW9(ZX'7)5.9"4,ZD!QLNB^J7Z=Q3H?<_]DQXM8
MV?"/13W/0ELL1PF-2FC4$ZKRD!P.CF 4LGGB(6%D@_>(2.>$T#X22O=NS?ZV
MYF;^^,7#I>\:^HS.]H&$V'.Y0$]#K:,0EI>8:Z>8:Y,2YKI8RUT/!A2:RF=.
MQLF;SH<H?*EPBAA$79(0N 6-X%>-N%>:,Z4\D9T$;@\8N:YZL.J!(7J_1VE>
M+VOEO7^%K_8#-#M@:+B/N6"#^V0<OZ PFL5&K#)MP.)R\A;<LZNQO7Z3/WU[
M94, Z5YS=D;M\U9N ?R:8[U1NEX]N/DBBI, HO4EOT&F/[B1LB_[%J7=CDWO
M-N'DSFFEE4!=W'A35_9C;!TEU&P=OK'CS_:Z7E(@K"_.:N:;R;AOVH\RNT<5
MW]L)[93 1]F@O;8"D:1RI^Z4D%:9W%@(AUTPGN&=.INN;$4F2!Q/,R/@+RDS
MS<1);;/B_1;'F;HHDQW7OU_86?PSF)*PROH]@<SGX75^G/1D/]0]Z^P#'4B"
M'B[1_?<Y3 1R>7ZJ]2G<A06GX[%NT&MT*J<L<*RXY4AIE\"G$1AIRBR$[R10
M;I+QNA.BJ=_]10R+,4CICY=7X^EUC+_'V:>1C[?"N3[W[\8@G<U/OZ3?HI]^
MG,!+AE]AX--6I@L=55LMLJ*7JF8WLP1CN!5HOS:IF6FJ9:^JJ^]&ZS0=O6-\
MZHF5Z2V]DSX*O9-00_XHO=.0ZUT9GO!0[\PBU9=AX,,/XT!\5\_AM[I'#T^9
MN>?8K%:'R)+=<%H1_ BI51\6MTL*JURH5?W8,F>[V1\W"!)?+A%]F*7#D5<5
MD"D@<UCBO#ZL?I<HM,Z6OQ_ZO#[,6-&7HB^=Z0LM^M*IOISC"Q<-^IH&D:)!
M?3Q2<)Y5GK_%&B(M?]%TZ@CQ4QQ/KTI]YXG621^G:>J95IH$PQ3)37T",Q1Q
M0Q1R/E@D6!)$R4!<VMJ5L=(8%:A$Q <"WV$1&:\E<E%;9Q(S+"=R-G=EEMLL
M,=R_"_/CE_QC9P?6Z(#CPKI4L*SW2UJPK$LNN=PUDAF.$LGD#SPDY+A)2/.
MJ37:6[/%$42)U<P'C[#+57/&)F2LU$CB9%)RDANMCHME?*!-.>QT!O)>X*W
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M7(;KC4^0&PDTDP\(^WDT'C=A\FBRB$O__&/VNM?R63=/'%:_MS?.T#IKX@D
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M:!1.0DIOD),ZMW/Q%)E\Y$SS)+UGBMFT%>^^1&A>[#3^W.P5_9):&7NWJB\
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MR$<YK7+K=@#@KUL/L!I7J]NT":-\Q8;S8N=@2<*H]M/%9#ZL?K1@@*8I <Z
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M5!:H[-497<><$LI[1#WAB%NB -JD0<(1Y;@W0G"_Q\S%[M#V=40SY[=S5BI
MCE0!XF<QC.;UH)K$>3X&MYAX>"V;3X)E*K-I/<KR51(4KT>I7JLI.8S7[1./
MFH*%$3KS\QB%D64R(BJBLTPE&9C:8X("_O!]J_%=\2'S 9?X[.Q1\; ++!98
M/!PL8DLEYTFAQ)P&6+0>.:\)_(J)DUYSMTUFW&$RHGM8% /"SL]-+[!88+'
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M$\#] 2\[$_.UP[')@:3"<SS A=1!C!<B:J ^)]()&6,@KT-A+Z&&V(X2Y7F
M"SD@#4<Q$L:Q3SPW9K[C4,"&P4(1P'K(\#.*L P^>8<B3,OZ?X(,V\LA8K9C
MSS;]IG-V?S9*FFBW2N/7Z:$7:PW :!Q4'3)VNV+= 1[(ETR\,SA9P(E9RK57
M211*IN,%3;MLV'4.]RN9V+;R*(G\P &<9C/"(Y40'GB1" +*@V2I;?UC+#L
M9F>:0.T#O%&/$@OZZ^=L[]&CU$ES3\2N[U&)Y5H*HZ<@?\/8"8C#74?XBHM
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M.RN?CA(P77A)O8KF>>B[*LN&3#U+C46_UY#T+)>J>DH)WQ[PHO:IZP>4>"L
MK$* #0D+Q&UI 3:=4Q.\@;?3J3I3)&L-@5>0H-X>O4@=PZ_S"<K)8(RK*2?P
M7K!C>%=FO[E)B[[^.WVC9?SBG44^&<A[;'VO?AJ2&NC"X=?:986_ZJC_NFGD
M</<$ ZE-/D,3O5H1">U;[R<%>L" K#>CV,L4J751??M8X8T!S Y2?'Q>K5 U
M0700ZRCHRTK1-;"Y#O1RN*G26!C^5O,/OM><D#KJ>ZV)59,=/D;(7-SDG@G8
M+$6;ZRT=+X8GC>$@+P3'VBZC^?EGC].<H1UR*D1"8B\&JU5*0+^12PE3DE(O
M$7$<TDV$8\_%)1!VH#XGOV>%$OE%AF8;J-2?0?Z 1"J_PIE\7^W3-W3V?8/G
M_3S(Q9\O+ 4 :H05"\5$K2L^N%,XWTF@3DIG#:]FTDHGA,&9&\):X;;5>49H
M>(6RH% #/JZ8>)7(F+3HKL]97%->2[0F,%QV+S*L_V65R(2?J/52RXY\4L)?
MRE>ONX89.N+GNY/?[^OG:_(1:^Y;/GM\,LZ;3$Q<#_I 8?EX.1GP:3ZI$T/?
M5(^+_+[]4W,];-2 CTKUNE0C#DA0-630V;;5K5^LJH="75DIP=?-/=84.E5/
M#>V^[?Z$;MWUU["^'=YQ";WK<Z\?/NP>.^M$\9CZKNX7</W,!SH;BJ_,HZ"F
M,.%H>[N8KJ?WBU@G?D2C1! W5)*XCL-(+!U*%),@01P5NC1>BEC34 34X\2W
MN0)<%P@"?X@)I4$LHEB$?N3=1'AK<-W&FAA%SI;KB0^R2L"4"&]=PWRH\VG+
M!80- +I*YD;K;<S_5.T<R[_$Q4F]B>U_Q02,W#IKVR@FTWG#=-YXI$ZC4GI<
MJ8A$'+.P_-@E7 A%N'0<3FTWY,M9?4%L>V$$*C#!<CHWX1*^$X5$,$9QMD'@
MV^$]==I,(GQMO%OOBWQX5IWN+[HP!:[^THB'#:G L$>CY]E2H^.#>IZC8<6,
M_GHV>-/84VW=X\K CA/*";<9Z![I^B1VA$UH1%G,/!Y[L=I$@?9V[2GJ]:@3
M&H/*&%3[Z+FT*8-J!%"K,.;4\SJMSU4=[6BH4>0X2G@!L3TIL5C%)G'H"Q+&
M+E7,%;'D&ZG/7:/>9K)AP;3Z@N=\:X:5%YGVZ%UHC_Y\-6+C4# *T2A$HQ"?
MIL#B)))18&/N?NA@_W+0739/B)T$D4@D*+/0WZ("6^T;W*X"8STO-+:<L>5,
M<*PSS+MOY66"8\\V.&;;OF0!IT31P">N%S'"8U2%B1LQUV&.+Y=JH+:N +<=
M''-Z=K"^3,X$QTQP;(?!,<?H+],.V;1#WH@UQQ,F1*RS-CSBR@BL.8]*(AT:
M4!H(%:ID$]WCMQMM8W:/V>O+>4TKY'NV0KZC._"Q55X\ISK4#U6]WNU52I.L
M*;%<-#'O4,.[?YL>U@C.WT07<19JUN0URZUT" \=-\5:JFGWI5\,ZV":<LT6
M#>I*PJ:_ZVWM9)NJ55A%;5</IDUWV^MT?'E+']R%4L=9]=@(@*[0E8^PXJHW
M,=;S@YY19=7N>*0R/L#N\6U/P-KMU!U<X $]O9RZ&'16 EN5I/$?53VEKN.$
M;4:LK6^L"V:QS[+>]KH1I2Z<;5=I<B&*B>I@DPH.%AB+HY!$7()^ OL*C"W)
M2>RJ0,5VPH)H*2-_@SIMUE'N2[-CIYG\4&_E:46T#36QZ&@SW#5\VZZ#[%X9
MY")SRUQ51<AUTZ/I#8F([U*+@'$EBWB99Z!%IWA1B3W0YSVIQ_D8>__H]B5X
MHJJB[/6B6(NQ$O1%F@ .T;*E+N>O#S-EUA#>Y'*U6#9='O921]RPSFQ7EQ6,
MKF5?HV6M/(-]!JE]USR!>9][/&JE54Y*O)FN'M7=_M4/6'Q6J9UXVBQ"U^%/
MQI=YD8Y!+<2Z@WD]&V"LQ&6&D-="X#<&0?]VL9]U4[;<(0C0U"NSQ99;2/T"
MEWH+H9/NZ:S0M[GC^9($&%!S<30P3^R(V#( W>4E4>0O]=/:H%.Q\ALVKL4F
M261#6LHS#;;NWS';]FSL@4N8EX3$=5T.*,9EA/G2C^-8,G_9'M]@Y<56^2#L
M)%I9U7&K'H>BI<8B9NYN&X>]&F.5P2)G75ITHY=2%5>+YLH\?>:F;)XUYZEU
MY,P(ZZ*P3N(P#",FB!,&$@Z<< D/&"5!#*<S$;$-1[7S*1 /[)+8]SMX=NO>
MYAUF%=<7TJ<@Q;D3>L3E-B.Q$[LD\KB3N$HE*EBJI.M<NN=#C=(NLLH#!?M2
M/=8=0FY-_]M]LIY( #/0V">^0#8*A$.X]"+B*)^SD"4V76X]]1 HH9LV?E57
MJBCYX&M-B,_9[XU@1]::B?5'.?J[/I)CM2NOQ6.%&D\*T&D731- ^,L0=5ZK
MK]L-:ZW=*7B8E^/*&5>Y'FOK+57+_=+F7DBT$Q?:QDW;*^(3W5FP]:"\F#^B
M;2/.GH*?3L9:O+8[JM4N1/C;;*YE->!M,*A/4O6N)3H0LZ[X)%9&./Z79:WI
M^O;(?JFQB*6DD21*]RH/ "J$0<R(YSH\LFUF^^'2D-''2/VO%;3ZPHOQ]%O!
ML[(Z$N7;M!2#O)P4]VGSMMX5LZ^>;M=5DD2<#^0F&(#:?8QRU<2R-+6L-KF>
MPIL;7NMS=:!]R$#+4G?1EZ/C[ HC,BC(+-V'+,[K?K;\HE#52$X=<#F5H$/B
MGO7QXYGULOKE5=WUL9E?N2 P)2BN03[2$B\;IW$N48!).#CYE7XHB,CJ-A@B
M09D)W)/_)\T4_@FE\^E':E.$$1<%'U8-4=?>-Q^-073^9]5M3S^"0&AN8[U$
M*C17G#:O^*J2Q"L_JYK,SWJ[-F#FIE:JUZ6_H4VL^Z[-:=;6Q+RN,7*FYUSJ
MXP27_F.2*0V2^A;LX^GD8@)Z"Q8;+6XG>K3UB,A[;*1^#T17O-!-5.72"TBI
M4:M6E<V[]&IO9C'$2^;+!0ZO8-T\#CA;)6.:Z-$JHL/;S( @=CM;_3Z@<2]5
MT1$%9X;?[&CX36MLAQE^\WR&W^R&N^XK(6O1AZH27D)5;9QG8G.FFU[JOJYK
MM<J*S^HVSE*+WK;0DZFTJOEQJA!I6<5&487D>A*![@=M-7-,]&=)JRTVFA1@
MC\.K6[^H(M.!T)[UY;+_MA*M[WXH,='R^>R2IP5>5W\_SNO!*)40RPMM<S?J
MJM1:A21YI?%QT6A'PH_-Y?KJ@?ZQ;[V%_V;/QZ75DAQO,ZS$_:R;^*(:75Y&
MKZ54M"*D7A-0?G\/QT)G9M7@QG;-A<$8!X,I\(AGX^@0&8,T58*2)(AYD@@>
MJ7BIUDSZ#J/"#XCC>BY83SPAD0PIB=T@\B(7_;9T[73),["X,5WCW0^P64NU
M(;=%UB6G!?9(%Y-"GTU5OV;;1U\=J?LQ;ZMK]"(SZ4>@^)@]H8O.V=")F"O=
MB(C !3,]M(&]9.B0!'YW8AHP:K,E,UTE ?.D0VCH>?"=A&%7-$9"/TQDP#T_
MN64\[;W9ZQC2@'K=C+!R):,D9(I(7W&0#QXCD0H4<:@/F,X3OA<L^694[ @W
M839<!%OM>NC%#VP'ZWYHX'#JTF2IO]"V-YWVNS1']+9H:GO6==>X(?"E<L+0
M)7[@Q\2E7D2B,&0@ FR?,T9IZ"Y--E(NSJ]. J(\&PO ')MPG&_E1C(23'D)
METOQ=CU!]N/<55K7:VU&OZR)4H8.Y<SVB$HB3"7 D5NN] D7G,4AIW80>#=?
MS7-%'$@X%S2AJ#SCD/#0$Z!Z%=S*EX+[SDY?;:7J[ [7-SFP;2=X/8ZGAJ;<
MS$9<RMCJ6[]KF#Y>Y]-:!!.7'"?+2(4R1I7C'##VB$^K_&2\I4Z7S*^5-<BO
M"9)^F$IBE3C>!Z1\>I&.K2*?\L%X.O\>&D\B'P[1B.$#JP3.+!O,#V833M'!
M2=E29T3?6.^RJVAQO;/U-!D.:]8-RWWD*O5 G-I/N;3:LK_[@(<=<">*?(^(
M$/2IZP8A":D*2)R@/*2VXZJEIGV/"7B\J^<%?5'%^24WX0WMB:(ZO %7CBT<
M=6M]P4E'2)V[IQH]<KM##]0B=V.2N("> 3C')!*11R+$4#(4H60;V>[Y5*/3
M;)S*=*!] ^<*C LM:]]5KB&I*Z#A]$VJX.3GY!%\<OQ.I<5A1_ED7(Y19L#/
MHQPO276$NJ&R52+AZE&"L5)Z[%J5 )$ N>OI7P,Q&<PFVNFOPN=8-(.CX"R
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M@R^3>)"*SS75-N1#"KQ^I^(6C1,I5K!L$$V52Q28I',<X:+'SW'!OHLQ_!3
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M?HO=/3N,T7V6Z820SK,N;RI&*CD,E"44/87:N<6+ CT&3:0>JT2PJ*_Y"KP
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M;LA,O7YH(//!0>8-:PP#F2O(S!SJ!V%$3Z1'/<J"_4/FGZ<#?ET:<+Q_-6;
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MOPW\-O![$^*+V09^;Q-^TR ,W'W [W6^\RV4F];5IG-G^GL5%WK /'4, #<
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MD!F@_PUG3!YMDA< ?-8!@/\^S3C\"#\=%< _)(%]J$K3T-C0V-#8T/C8:&P
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M,C <!RT:((U T%],T*[$[86S6(FR<B(N:TK<9&HS\F*;(R\",_)B%R,O=L%
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M& XG+CQ/^D\1^5V0\(>9R]21]^U&PLXC,G/FJ3>8EJ.3BNOLFTK=U5DW23Z
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M D+<W$OCF#".B:[""%,>L__C8\IC-C$GU@S!V^80O- ,P=O%$+QGW8%G?Y;
M[@=(WV8+O.57J;3^4)>9L0,.V0Y8MX_'A5X,^#=1R0XB8.-2/!A7O'$R[D#6
M J[XM4C!H,F4]4^>),\R2-G];5K<HTVE2F\0.W0'*N\</3SAU?>+'XR;9%=N
MDN@I;I*_G,2YG/[M?_WEY'(\'/SM_P=02P,$%     @ 7();6"]IQGN,,P$
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M@0<4F7RO]&M"@Q5=:7F0JN/0S35E?SMLK,L&Q5BFF<74_>$Q?'Z_HA[.!GS
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MF+F.Q'[2'B#1]M04SK6FM*I2LZG$V&07$B].*&XJAT2LMY,9&&JV'BA@8O
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M_>@44DT80S7!L+F?9P"TU.)</X#0%*H7ZAG+93RF#@^8A[ME"W<9W <K&KW
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M?;M))*WDH)>YY_ RT.Q '=)76DD8CY52UBO,6+_R7-C&E=+&"Q!YS[0"S_X
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M2UR!QMCMF?'-T-VK(#4^8MH,':;)TZT37$2@.L=N6&\WK&MJ.FP! B/6'GN
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MR09)#_MVFA-)+,^\*(+BX&>>/+M+Z"V8Z87+YDHZ: Y^[S32!&CC!BJHD]^
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M\@(9GQJ.!CL6?/2@BEZM C"8?-5YL-7@;[D1_N41G8^BLO!N P;7*>:315
M8O?%V1QTS\H'Z&;T"!"<.O-^#=^6+HB7FRU[&^'M6Z[AS;[RGNF*+X7_H#Z$
MG-S'O>),L@[XJQT&'(?*AXYLE9L<0DB_*-\"-_(C)"YA=8$\G@WWPV-\#S.5
M>OW(SJ(.''+-\TS4E:*8<8+6V+Y9)MF%Q:E(.$%K]K U7@S+5[Z(5>4*70V?
M^616K)HK<^V<#0^P(6JQ+]=EV*">)[2BC4AB.5@D@4DV_)E=+C]T[>SZ%H<2
M),  -G)=J .%48>XSKR@-7GF&RM:;3G-P0.O^N:?_\+K+@28>0 I)G<A?*4A
M613<NN=?:>1Z,>V-:%[R9U-!F0-F+PAGC1<Z$LS!2@=PP+=1'3C)7QO[<VWL
MX>L"S$G)%R]%&1;,O04JU4!J4",DK&7L<[-2^D4!RYD,EE*"/CO1[Q2C&S,+
M"T?I[C-S&57-Z#0?4?P&*<:LT%<;56 D@WNKATO0+%PB&#%<XA#!*FKVS5PD
M/R]-376^,<-:#A"J#"#7+M^"G"@0N1,[*&GF1<[PX+H(?,XQX2Q)>^H[<2PN
M@/VK(B U=>6;/N]^%=N#ESS ZY",#Y UK"Z#OI5R?^(R!9C?)5?<^,6,S0M:
M&7C]:L4LW'E57,E*= 2V,'>4TLZ#B2SMU5+4,TU4VQ6@N>TBC_[ 3H4JW=,
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MA'5949R% 'XU[W:JLN5+OM^F#WAZL)7A\83:SV&0 ";=WZG3UT)5+ $?B\X
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M9L#N &>'@\/(<%A.#_4<N%60LP'!<4R*D3OU1Y"EV<D[QUJ.9B2I,&;45?+
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M:6-$I -$]D+J$3]EM"_KB_\^+"#TP((7/21J #B^JP@!7?$!X&Y+&1X:L '
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MI!.SF)',@0$!5?(.Z YN]S<Z99JFT2Z9)9=UWK@B[8R],:T *P^-E0Z"? )
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MSF'YCLLX3NGJ#%GA9@!4JV+\,:_8[>&LJJPH7:_=6JCA.)RL%2^HJB@#6 %
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M;JSO**.E0-3&ZGKW <#  EMT=?[594V/,=&EWRT)NORKQ/ ESQA3D-6"F;?
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MQ:XO3Q?5=G[="Z]0$]>(,Q,G-EWL4QNZ7+BJ-GX/!XZ?I9-59<+SHD['F?Z
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MRZ H4_'M$ 6>CZM685=#!KM;DE5L;+F\!=E5H]S64Q@&&H"F))5 #@25 X$
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M S*'32*28":R93R2@V5H0B,97A"YU.Z#2 4WL94FEEBLEMXU#1P?,4J#U67
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MHAH@X]TU:-^Y>?IZNR60ST'@%=]+=&0#+39@#P#LR4D\&*,26,.V%L/362T
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M.]7N8[H[C.YMV@X% 0*:KUA[0G$69$U1D%%41&%!,^X:S"1.! %;\#_714T
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M*H3H?1#_G<1%R5O^++T)PO2?H)TTXG/:&:!@NE*Z7AR>Z8=5,LN@&PKR1BH
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MR:<6#GE*&9-[=>XW=D%Q0GK7]Y-@X4Q>8[#E'.SO)]$GFD544B+ Z^#0GK>
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M4M52&V)@%"QB"4=,.F0V1E/+I%E/^V)%!$A36#KJ35"L36.%<>/<Z_;CH&
M$^?:V*%R"^NJ$G\FW+B>HD!T]7<47%85]8DXV/I:\;.8Q7^GRV,=<GPD#&LL
M>:&YW\U[VY>=0EP3?[!!T:^ZU5_6"L5*U11$I==&WA+!"@SD48%*H<[K@#%9
M\O%1K'I?HX2B/)Z0>+9\?0W)*[U$Q[>0=)X,BJ7H58]"*CW[#(B")1>.!^;U
MIS<"E3XYF&NN?VF5';.>*(@LY@6)#J*IG$V;^:]J,3I:XON-:%^0URX836TM
MHP[V21*2X6^")(1D>.XSSJ&9F[/HM1U1;.4*DKT>"DG2$@41XT63YF6-D46Y
MFL\+Q0+53GL!SNAYP0?(?2.UM=X-!7EYD)=1)!B*"##FW4@V;AR$=RE 1<WY
M4?X9!:<[!\>*X$09&FBN<PY>B;KQ:];7GMMJEIL-U:VB]'_ #O%%;M21-$1"
MPM/.\;R+)*)3BFJI:9(F6*;]1CQ/ZXX76UB=-%24?G9CL(+<^AOWW=TDCE>M
M#:QLA$-L"!ELI8H#W"5]ZPOF.*D@:-'?ON8JF"09:LB=NX8+)U<_>7E#]YU4
M"\VT[XUB=8V F'*-B2>9L$@,\7=X8MT'\=])7, T%2/Q3E4M3+95K$T&Q5)@
MT'@?BTJ^6)5R88HHEHUCH9)0D['?T!0%&:WJW>$N6P?@1V #A7K+>QW&MK0A
M$B6GKC5^ENLZDH8H5J$GBO#%03Y 57F:X',HV,D$IA# I+$V*9K:5ZY$QVTM
M9E_> @7OGY+]WF/WF^.)IG;!QJZ/M6O1'PG!)8#I9_HQ#<2%JC$.4KJJ+#([
MQ*,;?;^ANGR&3P(%S[^Z/F04#:HNM?PV"D;S+-P"*S\U?:GDM:8Y"G)^<4(7
M;/5:"/E:(_LR5A534\-9ISKTM4^'].!OJRW5']R8%6EXH%VK3M:!AT:QPN.?
M3IYK:$<R\&_;WX_WA$[[^Z7CN=N JER.PO$G;X9@^JG)ZI%L$J:6W/J_!N%W
M.DF)]J)KC&++9]A\16ANAM)W<8![6R6L3?JA(+#F]:)_R/XM]1U!WFSXSF#&
M6.:#XT7U# @CCUK'L5$P:E !E+EGKL!V3?S-HZH(]]@?1<%:*'CDQG=J$(CT
M5Q23K6WJ[!^X?F9T#LI=[,OLHK 6Y;*8O!5=D%?7][D?.<7[ <S%FB!O/0**
MM6Q35NR&JG"RQ6T[!@K"<_' :N)$=P"'\$5M]M,T1T%.D9HW0("\0:W4H;YB
MW=-*92LH7JLP=2#)'*VR-BA671;]GY\\6(9VB0.2KM8MVQD6W^<O+\S?735H
M5W]'L2XY\&:YUE8)P$> ,%?;.HR'L'^#+E]>?G')A1O$9/WF!U[P>KAS=R[5
MME2(0 T=4*SD,]E!O9WPP+V160TJGM)M"C_7>A#[JVELMUFEWEA6G:" XW@@
M(96:KZ%33_ 9;F@4.R0_A,LD?@M % %<J-Z$*6N-@AC#FH):ST7;,>QO]L(;
MD2$3J1#I% U1K-T]B2%#A9X->-QN+@[?(GA?\6I.(&[R#%U=9D3[45 07[H7
M_XMJ!-'&96JF6J5OZ(*"K(<@B@F+<&*F#H[T!UB0FJ(_37U0$/9$7F%VCV0/
ML*LM@ *,.J(@40G=J7>-&G1#05[5A:M\,TK:V1?Y*B6D\#O5U!%Z?1'WO4IF
M_]%0K*:\Z&HM&;+RNUH(]1D/!T-T[^/6#VH<)"D],GJ)9-(/!X&&-0]-VJ,@
MR#A-5?1^Z+7SGD.B8,MX(<4"=BNR#,0V,T.Q2"6<H!HJL;J5?=W@YTA2;+W\
M"PH.=]YL6=%?B'#E '$L;C(K-UY-4YGB>R@8JH@O4]^,V@XH2.J-9JVM[S,^
MF+;YYZU[*K*Z?* 45;T4XF\X]H4<7YFK09<#5BHU'-&^U%>]X;[M:2,_SC0A
MX[=?I1^*53<W[O4S#=I?S0)$*L,2^_!ARD6R;&TAF[O8)VM)_Q,'DO2D^J_6
M/>N/9)]>\'DN*RLV1<*]$W*_1_UF;=41Q9D:7>6',]90OFR:SZ-@MT((I>7M
M.XHP26\4Q'9>W"RJN#! \GLX]3K^KBBZ,-[GK&MGUSE8:GA)U?77(%3@0)2:
MH-@%L&-OO. #HG+H'XO[UM](-FYAX-&6R>XY)@K&R)WI3<\U>7O[=_M30C5B
M>K+X+!GRH+M[2<*(\)286N+0YYH"T'X(^V1GA2CI;-E#6EP>A9[3W 7%]JR'
M\:=9M;J#V=C)_HHMO<]_^KST?G^CFXL^ZJAP@.V4QN0H5=/&/BC6+#=X!\LU
M59!"(BN@('7;FG1$06)N)KXXL B=2\^)E"GRRL8H2)&EU]3KKQAGYDBZHB#S
MTMF[L>.QA*%-5EF.!>AN+I(4N.;!<:4ZG6E?%(0V9%.A2XC*P^'501O-H?3Z
MOC@(!7/(6^!MJ.CF[T:E!;#4RKK6G]E=8<\'(03AQO#J>X3#3VA/J:NT54<4
MZT.?M45!:\6[MVB 8LIBO4CC2I.M.Z,@-?</K;;IVXI.,XC82UFG"IKT0T'@
M,B0.9##3:R:".6<23:K?*MJB(*3B7\K,&E< \9,BPC7%E+0< @79Q5V4@PT6
MZ2=TC<HI*&WJQ+4?#P=#!+!)[JI.(9^45C-98Q2DF*S 588]P&W ,B([#(."
M_(;::CL((OZ=ASVQK 2IR&HY!@K"R^FX%:GT2,#DE?VHQ&-N.P8*PNG#SO5A
M-7R>5T7W(VC6*;C)TO<3P/XL?@0XMPQ$-'4!*MZ+?8=%P9[.&-M9M X3<2QV
M,(N=U'!MO*^A8.:W".ZX-!A6*CO*+>S;[J[(.H3SNO*_T89A3(\PE>7,'Q95
M(7:-.J!8A_Q2,JQAJ&MO?XV>@B1^>W+\FQ!T_F@=*&RJBG;V";B$\)ZMNZ9;
MGFJ^9 ]O%@4-ZJ8H-E;?>EN"IC]XZ-PPGT;!9J9"@.7H=K>GDH5'!JHS]S3-
M49!341 KZB-H":Z?!$FEE&_VM/_\Y2MM\1:MPKN +G4H% !6F7=&_2 *EM9=
MM^89UFC<%3WQAN]T=5&'&AL%HW*ODV$M.UU[7 1='/(__M6ETIAJN0<&)F3@
M@-/TQ$5DFO(/8ODF9+F?ZX,Z*L.@&PKR:AY>I>/&R#^L[(V"6 A4!S.MD)VC
M7D%E8Q2DC!<AR:NIVHG.+'\;!Z-U&0#WY(/]U#YW(.^)@LC,II/F2YJAZS=V
M0D&:Z%4#O9$*I:].S-"U5EOC.)BV@Z @76(0T.D;FN8HR%%C4>K-O-7656+^
M_W\I:*$:XW?A%_;#GAY72*$ "06_IQ\K$>;P)(4_4@Y2NK[\ZV?Z?_\2.S\"
M/]@=_H51^$C_DWO@L_^%*Y(%Z-[Z='J[<@E%0'[[WW^H?OX/)6:3'S'QJ2[\
M!\GB!.5U\2"1+\C?GF\AV?+Y1Y0 MBH16?_Q-7C_EPUQ&17PAY_@#W_\$6W^
M'X@@N*0/T["ZB1CG>(1!^7?9CAEA4K(<-6%.I9\GFM*2?G##=#[/>97,J?S[
MQ'SB]]"UOQ%S8B4,*[>;>)(W5 @Y'D-7I?\2::99;6EEHIQ79E,5VTXTV>?0
M 9O9TV'W$GB2"99_GVA216H"#RB0S*O69-*IT;OP=D.7C=MRH>2>?IZJ]I-.
MFL<*W7B!(Q/0]3:33DY3S*LV25E;RY/]TF*R7ZQ,]A)4TO Y^/";IBJTM#%1
M%@>V"IG/S5_+KB%M<QM3!@PZQ_L_[OXRV#1.N-QXHNG"FD(LFF*"I9\GFA(#
M(GQX"WRUD*\UF5IO!/QNE^,% 0"?3H>L-IUXJCPDHW&:I6:3'I5'\NJ"]N_'
MD(6F/"259I-.\9( IIEW2Y]-/_Y&#LHY5MM-=8:Y\:30:M6*NK+IY I<+?U4
MJL,5K2:=H+2Z>VV"Y5:33O!Z1\)7JG[_' 8?\5NEH'MMHO+6TT[X1R$(RW;B
M^FSK32>:ZNUZ&RZ3C4O'6<8QB;@)1?$@US2>_#WI/\6[^#H,@_ RH =\K9FV
M0:=IC]H;\;RF#5QJ-*WHYP(SQ]D%K5+Z8-<VGW3*OP1>XL=.R 6H>J[5=M/R
MU0"CLLY=7:>)II\5VKC^L69XH JE1=ILXBE6:X5(II<WF73Q6;5%A\714^7#
MJ7B,:LNN:#[IE'^E NAO/GWZ/A$GHN^.#?/%J0T[JO83\SE+VLM*IC  H?"@
M?8[J>TU\MQEG+$JNN.:^4]GVN9J@$!7BK]-.* -J5$\J;S'MQ&[<<'<KTQ#+
MOTLF)?J^!G$S[EDEFI_6;ZZ73ZA(K)5ZMV1HAW]8!.&&A/_[#W_^RQ__](?%
MGJJU('__]Q^^_&&11'0BP9XC!L%O:4[^':=;.44V/RH:(\):8F='Q<.5\N/?
M_C17?BB<:QE?/L^=+S5_7L:9+V?.U!R(&6_^=:Z\J?@K,W[\>:[\J+M*,Y;\
MV[Q9HG319OSY]WGSI^0-SGCR'_/FB=0)G?'F/\^\J?F\,][,5ME5NMA3SOS[
M;-5>O4\_8\]LM5]=_$#&G-DJP.5HA8P=L]5YZY$2&4MFJ_:J(S0RULQ6_95'
MA&1LF;G66XU"R=@R<\6W%OF2\66V2J\ZV"9CS<QUWDIP3\J5_YBYOEN)*,JX
M,G,U5Q'&E'%GMGJN.F8J8\UL=5Y=C%;&G-EKO[J(L(Q)L]6#97%G&5-FK@6K
MHMTR]LQ<&ZY%UF5\F:TV;!+,ES%IMGJQ/&0P9<M_SE8QKH<I9BR9N5:L"H_,
MV#-SM5@9BIGQ9[:ZL5'49\:EV2O)!J&E&:]FJRN7(E<S;@RL)'M'Q(@B8C9C
MQL J\3$Q(XO2S5@QL!9<8T4*NU.%MQD3?2>O/7(9^%'@N1LF*QP/*JW0%R01
M"F%/CKVS=:(7QK(4P(B'5!,OCK)_*6*K):6C%$7XTF!K@PZ#A(1W(6*Y7L.%
M%CTX!\#0DJ>/-#2V-WE69<V,^?*VUJ8.Q5*7_@;^!W#YWNDAHHQ=\DIQ]*G'
MT"L5I)CUM;PJ1LMA?QWJ!<8:)J[I8&\S%38#[;ZI-K,V84$2LH*K+=? N+O%
M;65>GZNVP0RZ=B4,[NJ?LDN:S9B74N458B]I2W?M>$_)?N\=H/A,98X-C:VQ
M6P8"J;_*=#VLD:'$[[TG*CJT7>Q= 7G1=J@#>NNG%4-5=X&BM45YZK-C]JL;
MOUTF41SL2)C)G .4-]=N+=/>-G4^>3UHM=JG:#^P&+H,//KIU-KR2-:$ZC8O
MM9QK;5-K3"T7MGJ$ZABK[;>(,$5'P5A]'YO[(RO6P""BP;,7DC?B1WFQ-H!U
MI1)FM7UV?JAW3:M14)WV1[)-_$V_,Z\> Q6I^03U0L"HJ\6;D^SIW<%*4D<
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MG)>F40>-W; 5/=:>!WT?^QM*E/8FYZ+6'LOVR@K7+'=0_6<9QZ'[DC!,_^>
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M[XPV"#7-_?#(V*].^)TP8U(C2)997T3GC)V 0HML=ZZDG6WB(X:$/6.$-PP
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M7]U,.8/B_IT&(]N:AF8!^M>6A08&IPFQ_8Z&<<8FK8QYYX=%!XM7SKWS,\/
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M0W,Q-W0!:]K/ME5_+(*EF"95#PE545;;+L*_>9A1%\O,<M+0Q9Z+N20G?B4
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M(P2BX\N;.B,&(%@%J;=PF*P9G<\D"Q;YXUD>89)'56_,H"@.YT4:QZ-S!G9
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M'B2YL04"&MLM6<NQL;'F\@V,2[?T>N%7*FVPC"(21V -XAJ&YP4?CJ^L1CW
MP-B8PLQGR\W_)%',S&GM**_UMD_>";P_6[Z5!KZR9_%\&H;%ZJM^%B^E89@H
M*A SJ3MER+@.VLR@T82GO>_::DICU'LZ4=:VTK1F4;5I&+[6E;591&9U99["
MY#8LIB]^DUOM%(+&XCHO=%?%+CE.+$L0SX'/_/\B?0)934Y=\P$&-D_(OW9%
M*,?7_)C3]5GN@C!V?V=_E=DHV@]BS^DIYW2Z%3NM4J6O/03$ZI12GX#_>A=$
MT:43AH<MCZ%5O:O;C&#_;6W5M-WJ.#U"[,]J^RTBG*WF9ZC6$\_N GZF_Y9>
M;8]42(?O!"3Z<KT.$\>+V/\24<";;KVNPUMG4+[;S(F6=K%.B+@4_$W<288H
M>N,A3V#Z/5$BP3;TPD-._>"4@AK]3:J!1JT-\:-\"@_CRJ?1E >57N/=)^FV
M(Y2+:LEBV&GL64HVAK-WZ=O$_9U 5AVASZTWNC^NR#OQ@CT\'QFBA1$UG0<?
MF^I'LDV*Q\S!B)AJ'SS'@3WOC15%UAC/Y'\.J<)J.GG>&,_DC3V J%U\M<FU
MN%P5-ZJ-^*O63_O<5M[A:3VHMPNOQZ'5(UPTIK5ZXIY=AW4&&G)^%JP;_&C7
MG_F#.E[G<)X[&Q7.+F[CPR[=X+/@7[<3;V;@&3%8X%GJU<''QV[G76I:F@58
MU##;46G'&B7ZXJ2W8G^[V2PB7H;C>=7D-HNHEM;L,[4$SB)V92#N=;=0SB+(
M92 NURRBHP2]'#WSFFRPLP#9&8YKJ?%W%%";T]5_--&0 X'*S,& (6K>P\*X
M8(CM>Z3_^4T:X+?<;%Q.UZU/GW$[(74602Q?%,:"RX+^K7!7T+_\]@@!PM)B
M<]5?A_6F-$SKJ_/#W24[Y<3*OT\Z-<8325'@\F_V8\262?S&SI^VP*JR^= >
M8_J5*';7&<:1^$5UK4.#7O89S9$(7HF_/MPU%&C7][%&2OW^JPKW+)%@N0L2
M7^7+;#T,JK73U3-7M[=/0GX@-(7*%8T131X@JEL1D'= 1D1+:8NA+/4E??I3
MQ<5WG9N0GMHW-X(I7@1.N)&*9O-^]M<&(0A(D^KC^GK5I_2[O1B7]&J^!$D>
MRN]P?5MK4V^='( Q%Z"4\OQ?2>A&&W<-EZ]V)9IZ62/'#(Z(98D&OC9 K\M(
M RN[ZOUR05Y=WZ>_7/_8NQRUZN_$D>J^[0>QMGA25Z965=3U&'@Q\D^UX'UC
M'VNL_N:'=">_^F"KA\LV=<P5D+'$=SSF/_4WMWY,0BIXTZ 1Q5+T&1$;&SCJ
M-YUZ"!ZB*\+_MQWABC&PD9I-,'HD4>*!G+@)@]T#V-PX!<]J=*5!AQX\M)Q_
M?%5&5LB0D!5Q\@U]L"U>-N$1%J_=T ,OWB-Y)V'D>%GD6IM%-.YKUVZN,)J"
M95QBN#SI:%*I-31C1(E')\T&4\MKX2LVL(7.BV,Z$ZKH<VIOJ)PM'Y4U756&
MPWEQ2FEXU+-*4GQUC@RK"[86ML29\LU\D\US@[7$%*J+NI-F5Y/:638:SR*E
MP43?:K!6SXM/IEJ606;A_#C60I\J5(IY<<O@'#9Z+6:1_=+Z1';RCLR6E;6C
M6C%4S)8QTCW6U6,UBWR?;C>!G.6S99A6M&E]A[-(BFIW4IO=F;/(A6J]SWHY
M3F>1^#042U5.V%DD0 VX+]MX",=(DWHGX4MPI-PU="7/HOCW4%NRI=-ZE*K<
M1[\GS3WDXV1223<G*I1TY>X[0G1TS&'(_:-8V@6FH)O^T0?AG$/+4# FK5,[
M#FO4@V-C3CMJ?_LSMNO;S/^H)'X,[^.>K?I3[(0Q2HVG%\LZJI,GGHX_#&^[
MO1YG8A ?@;.:*V!>5M]>O*5WPB@67RY&K_WZ0;<*(?%(/) ^#U2Z'YY#QX\<
M[K[3X$E@>/XTI"\^P\Q6VUM_X[Z[F\3Q?G7C-T8JT/;F[I^#:_I.5L 2=!EA
MTNS,*S=DZZQ,SZPTL*:E*7>7_OW9V,U>PF-N(5#-\>)0^D63S]]M+&QK6;,R
MF:WEG7W B=S=S(#EEGX&1->8@%MKCV)-M#G_DH8H)JW-$Y8T1#%I]1'5@$>T
M&&!Z)*$S]M+I8"\I-IJQ>*CW&3@_;[EQ=\Z+&F^I]+N]FSYYB=R-ZX2')P?N
MZ*<X6'_7G&]U>WLD%!.!:-#5UG0[&'3$MKW;2]Y>:Z/8VC<!I(2M_(?DQ7/7
MJRU]'U)]0;W5M>TG%6JU]XY"P,G;V=/A(,I4 &%.;2 J#4[1^@2A=50X%!_!
M\UN01(Z_N0F2,";$Y^)V^1H2 BC+ZLUJW'?H0Y7$24B^NAZ)XL G#\Z!E3M?
M?=30)!J;VT^?Z6B9R *(JR__DTXW:FM%*,7X=WNHSYF?M9>\-!VG_E@>@V<(
M0VS4;VV13[+'[9PWE>:!K&+;+#)/SP@>=5:<$3R,W^]Y*%_Y,3T+!C6^S$MZ
M@,$;>!9<,W@WJP3R1"SS$'&KEY_'@(_2:W$6^]#<*)7+.+U5Y:2YUFB:R>[)
MUN_*DV9;KY>.RJ0T1AX]HG?.&=RCIRIF;EN;!?/&OD+' [? I(BTD6#-UM)9
MQ%@.MO$T#XTS(TT8J=%>9A&1.@@#ZY@AIXU$,/:]<5<#PY@ I,!JC.\]B0%1
MY8&$K'1RP> KUTL T(?]<W3]8^TE&[)AL>2.MT[XXR%M1C:58? $ W>*WUS2
MU] FHY^LDY I^R4>!+M]$J<\N'9"@+G(J3<+[!SD(]:<ZSUG?W&0#Z )U1CS
MB_:JBE1FV1#\K&R.;!\TUIEJ[#8X[CMEE+NFDHHK:@PY:NEO*O_^S7?C2!WE
MT&$49 MC?%QJCXAA3^.=_1#OGA1HJ\<,,[8]J;3;>\&!$+:;5TS9T09CJ]OC
M(,%\\NII6]5VAU1(1#5XU%M\%E;DI@M<'G<TS'K.@L&F"H8 8-/^JI])F-($
M2GNS=)E=A8*A-;$!!?BLBI"@OT[KUJ?3]@*U$>T&JNF)^V 'X]KT2.:VX-O8
ME9^LXP1B0I"C%K1*<Q+(@IAKKMT 7%_3L]VHZ\"V%RK>UL#-5V:V3S'@;_U?
M@_ [78=UU5)JUL=BCIF2@]H\,WTO>Y5QZ=C 8F%Z6L.=NCT*W 7QO .'F9>'
MI268HBTTC8!CXQ536T+9!:Z&-P%GF/:W1B)'Z6$E." P 6IP-.1OZGI@(T-[
MKO1][.-@I"D]6DN:HO' UTE^!ZCM]-4F \_@/H%1S2\S;7M[]F^.'2]$,VH7
M5]D<AT"\I ^H5R4\B[0IDHG#U6*J-6"9=*JZF$P[:XICXN4K'>34.OWS(P%)
M2YM\;G=_:L;!\5YL\UK(C:C-.ONI9WD8ZOFE2C%J7?K4N=5!!R^'8S4P^]3Y
MUUJY5^6S-S+_U#EI\(:HE\12ZNHSY9;:DJAZ$,S"@]!H+,GOS]HCY=0W4B<M
M0_^0.O7TC9YWIE;0G3KO6LLM]6MW%JZVML=3_\8>PW.$:7>-I\W>U5R\)\O$
M8;8<MXZ,DA$4Q(YW<F<TM\R,D0]T<MO+S!QTJJE A:,<LAG)/Q(ZYO4[9(2>
MCJ^\0AEH\ U K;+65I%F*Q/2H[,JVV,AH<E-J6R.A0"M(UG6] Q3?(8IUFVH
MVG6EWU1W]E-G!.:*;*7W:/-J5#L,[)O]1F^;\ -BXG38RI)66':#U@DK;XMA
M'V2F')XN?!M%]+%]ZPN+;7!.&X>P%P;Q3L*EYP4Q&!L,$J+4[3&LU4/HKDD6
M=-R\+N7F Y]7X3N<3\\DW,F.K+RA-78^A,&:D$T$0=VP51U_36Y]*E <KPQ%
MIN"O>?^A*RRPD'^HZER(0'@(P+]"FLQEL-NY$2OQ3/^6S4)1_F:($8>.-C5E
M[ 6A+QMRQ4W/_NMP_)AX!N,=R$OZ.(2YU.]U74L<YH&&=U\5RD?QQCIUKTW3
MVTS'IGFXDX\"4!8;PW2/&P6_:N^(63B4.P">RAXX\^!5DRE,(ZQFS2@=A)WT
MBCR+J([OTWGXDML)+8,G]$P2-]N<2SVTY,F&=70\F16#QCP .+M)^;OY!""8
M;":=#6H>,*0M3EP+F]<\T$A--UA?F]MT 0C'P,VI+7PI]__]S'V=?3#ETG^@
M"9+9D*WKNY40F4I42L? F3SN])+NF<!S-PY#E4K_,5IMTRAYOJ, \R4D;W0W
MN>_D_[;WK3V.XTB"?V4QW_NFJV=N'HW; _)9FX>JLI&958WYU%#:=%I3LN2A
M)&>Y?_V1E*PGGS(E!I4&%K-=:9)B!(/!> >MDNLN&*:*EU6YG/L#W3FN3GN1
M!EZT!X')EU9%NXC'N\R71(1O; GEWJ(#BI(]Q6NY/P$8\CF3MM EKP/E]_3B
M/2%\((I!R@T4D8^U[%2Y22+RV:3@"8\$0W$N25^7C':!R@4ND2-H^\P=YI!\
M&;Z*8ELQNTNTW=%-GF;)#N&B&!<-_4S);4O1^CGX(21J\Y7\(_7?R3L9Y)%#
MAO,1Q80)1F1G5^L=>;(I Z3%K>0L1S4+SA.@R_H!;+E(JV$RBF+3C9%N&[Q_
M(7)9>U-RNE%,<EPTAB+TQ'#"."?;JT7)0ITIQA%>PRXP2K-P)8#TG!4=HX%L
MICR0:W+--Z%(?!*-=K;]+RA3WJ'V&+>WIZ6;U+NZ.@1A1"7I^P13A:]1ZW7]
M;_+^4>FN()Y'M(H"HCQOPC+]L/H])7 N-N+G=;KO.T,Q!SH%4F0SP#2IN Y2
M(=/ACP6S];)=C>;F3Z.=;?\W%+YN:1V( V'9KZCM@5SD69H%,15!92=BM@8T
M4,LCZ.W6#%CA*AQP:[L1U_16N^ HJ.OL5YI"A=;__:<,YZC^(WEMT8_L+F)&
M"2*"HU?Z'R++767["N/LS^MP5QGN@B@2V.N$IIR6\Z=C.Y&8Y@9CXN<>)C9!
M5(M?VJ"NF3KRTZZE%K>!5EI7.HE^,CN&IZC0TOLJ8ZW,[@ 9 5NR,E[E+^@G
M\E?Z&-;Y X)KP&V/QS=@0 9<XQ+HW?Q!9A#0F#D1PD_K%JWWK@777-6A"-[5
M\03XTEIC%_K*"#0*%OIO)8P70FEX\AP9>IQ"@K(QX/\%*#%PS':>@V]X_$V[
MQ1B0_P4<Y KSX1A(^"LT))QE=AP#0_\;)H8X%LDQH/\;-.@[!LTQ8/X[-)@G
MM(R.@<]_0,.GU PZ!@;^"0T# @OJ*/(E.%54:(,=!7QP\K6A#7<4I("3.HVM
MO7IH*4,#VZ%_D (#6=SD-HG(L:1W_\D)0)=@P-D& ][0][\\<VFQ(LY AS[+
MF-S)+"286YZ"==5-E%6SW!-,$\>R&EC"\3Z2D?O@KH+)40DPB0E6I?OGCW7I
MO=\EL0[M=\>YI_8.*E,=BN?.\9=PW-/^,R(;P@$^%OO3]6$KI[EK&565!5T&
MX?HAO@GV819$\KY1TCE0SN8FP/A(W6$L4^LJRW#XDF=4?'A.EBQY1N^P--9Q
MV? KW^6LVJW(PJ'J *8Y'P++UKUMTBD.H]@SPL+0^J0[2P]&,-CA*]13<D1/
M3V^@VTT711UN66WH)2(J9ZF*%N(M=< N-@U1MS;^R0 <OB@T9'P+HAQ9QH7F
MFM!041SA%_3&?AIT_O5D:,"Q,QD(6V<N-- *U#=R_=.['PBOPE08%#I@(6A
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MVU\291&1S[_B@'^PVM,<EHR):;WS0@1Y#-/OUT0.V^X"_%T:G**<Y@R@1W1
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M9\3<)SGVR1PU&5[" QIJKYHK7JXV&<(]Y!@6Y@+0=WOVC<6E;^99 />6 X^
MZE$\"^[3*GZ 6SQVYP/,UO$"Y.(9.QMBMHP? #,6?#[ =!GP '<>GK.@;J\%
M2CFL]<)&[\Y:.;Q'Z[)C&VL=5HUA=7]2%A@!*3) T<>ME:53V-X96 2\3X38
M(G'_8 ^T/7/8R\/5ZIH,1\RRWJMOXM09/;KC J,WUS5H8K*2 26<Y1.[+ KT
M54U;R:^T;%\[1]);CEG#U()'L,+5Z40IM>8$K<<63F;*604X:MW8!N7X9#;3
MP,(IR9N'@J_Q"F%"^3&5'LH".7ZU"#J?#,@?;C!:AXVPP[^^"\"_))3IYH0U
MOD2GT %^";R6C]>#LN+GX^:&E7=]B$]U?,B (@F$)H 4P$11\D8#=KUJYW ^
M9HJHF;IU.;=YPT4PM;U].\^['&@KWX"&*O$K;X(,X2KV2[@8O--]M[C1?&A'
MU7R)30ZG,0\:2*9OK G8AFM#0XW1$VN"%Y.%H2&E_[J:0-Z;[9.:WCNNJQAN
MME-OLX*L3!/YT8>"%#UX&B>D0$%UZ+R.(E["WLK4E)XZNY@^65<&TW<[S]H#
MC4A.GATS2@/<QK!.B6<OP1]PH=NTX3'(O7O</>MB6*>FHX\@GT'DTEX7_H33
M#3U\\A^=FLXWP3[,BK(F.JG,,\:-L'V:!V&$9SSJ[4LU- S.,Z Y]Z"A:)(+
M4)J)TGE8DL_#5&&58#44-PE^"_"ZOAL>]*"T2B:41^)#7=(ZB-)^[F6%G7_,
M&CMU<!*9P2</P\:34_6[$FL%O497G*%P-JYM8P)M1-(4WE4@=68Y!T<FI0I@
MX4YQ#@B?-:B.PW$M)Y'Q0F_SQ6#+7A%=M;OO#]&<.=Y^!:JC=*?\.9/@5+^C
MX<!%QL;T<#U-XT@&+SXVU#I]'M23X+"<KFJEQWLZL^" 8T5ITL.!C4^!0AQ7
MA]+&!6\V*/"&:4E#:4%O>3@(DBE*FO*(> 5MYVCY*_V?%W)ABC__GS^3G?\:
M[/=AO$GHG\H_Q'&2L178W^B?4,1J$OQ7N"XY\0*_!G'Y(-XD<9I$X?IT/9>8
M'%%<K-"H^L_B3XK,E<J+^ERTR(J#'3D0NVL6ATS/,?R5ME*(7Q_(T&?RUS_]
M5YJ_I%F8Y70U(JKF^V+@.OMU2W['J_P%/11*,YN^9YW4G]F"ZQR7HD0<1JQ^
M]'__*<,T^3(@:]+.3^6__RQ&GG&#M (_QM.:*-@E,<H"?%0B(?PU/ /T#;F.
MZ#3YI2@'2F:BEU,$&A\CIWB'.[*C'3G2SVCW4@,N^K6 ;YWAG^A_I;^NDUT0
MQB-#:'ZXFCVY1(>L.1W,8:_8>R5#$2L$\D8+K<>O[9/F_0+RE(4-14N*%?UL
M^93".,T"6AW.^HW\@L@+\_V&Z 7DL8G#H'U.HE]!GI5!.UC1'9SJ/,>\=<(N
MC">P)0.@D*T:RON$VC07\3)_B<+58D-DJ1Z7D8\!2<,- CR@*XSI@TA'? XC
ME&;D1*I"2W'12)S9A^INXDN$ESAYQ<&.PZ+.7M&C6U#6G_H<_ AW^>Z>O*SD
MZ&N<<'\$ YZ2:UOH\BIB@<8+^8.U;BN8N@T,;0KS.<C*?]&>KF&\B-'SENSX
M=?O\EK#D^U-3E8J16EL/"M]5HI!P@Q75SU[18O.4):OOB[<8K:^/#^0*'<(U
MT=)/R-$9V67!^V+.)-0C 5*OAVE+IS6: EAE/?&!13L/XU2MH>(;ZG$>L04"
M2=UCJ.PI7-UQ_H]=R@W(,-=DV[QQCT6V!4V-^BW!WXGTOD*\F\D?9_]>:G,D
M"7R-O3X3,28-V#^6.*Q!DP[QALGR[=T-V>WZ6 \IQ;<K:BBD5<XID9+OYX5,
M1UV<S]N@%.W2CV2)+'V(EPR.WH/FX,/^L FQ>?8:O89Q3'ZY^[$/B^_3][VR
M=YI/;&+EE?[)-6\YU6SG@,?]"1P %7=KJXB]/X/4"D\5A&LLLTIV1#!O'H1J
M5.],V,^N#X8(P\_;)$^#>/TE)/<?H?C4,H.)C<L<K[:TPC"YI^VS&S(3Y/$2
MD1CM"JF1\=M7C-B(1A#&25M3#O3FD=.V2Q#EZB[&9'11+?MJO0Z+X,(EF5HD
M'AI:.C16] :-=?]P1O/L-4Y;3=_9W[_&(>W$W;P^0V:"O#Z5[USQ#JO'@7NU
M&BR.EGFD+.YJ'>Z"E^KJ"UFB8CS(DQP0Z'521XTG0KGA:E.F6:&%RJYG, >,
M$*YCU^4S^9J)]]B]U&TW9!$HI*-6)(/H9'V[B<AQQZ^WK+9**2\*?FV"MZ9%
M.QTSP?I4Y)8:U3#+-AL;)HWN3D\B?,6N168HSD"()JD;LMM"7&55$_:4Y71B
M/B0C0+Y1G:B,HS <H/H-"KM0,]<O.46\W'HH'].$-8PS](K.D:%L7#%+T6:?
MB(9)(:E>6/OK#G +C$OJGX*7JF]B^];R?@%Y6_7\,KW#-9X&[NPZD2P'%.?=
M:#O)")!G2?>(TR Z10:K?%3ZXSV2?P>;Z&^B<+/Y1H1:2L!LLV=;_7E+MH3'
M$@^NI1"=)K*MT"CI2'^><YZ!M'344'<>T7WTC*KB.2#YQ#/:[0E;PT>FVCRD
M*3G1VQQ71,J(.?V"WMA/%;LPGM;B^>Q'UX0NTFN_[C<XB;.3+JM2@WO#P?!'
M=7P*3E8(K=-[G.SH.=%I#S'1"X.H'05XC8C$BFX+(39^;08D4^&,OO34&$HX
MXBYD;:[IOTZ3RQ25"I%3?]6?\[#UMI0!"[:?K&I9H)%(&MF3/0.H:""4=\O$
M:E5$#] >KQRC5?-'D&)'].'G#U?1'UL4[H@@2BXXZY1:!-.V7UVMH2 ?VX_I
M]S8HC3^ W'#A#^F@O_4WD-N^S[,<HW[0]ANJY'CI$"BW7T-JK0.WTE9P%^<'
M?Z"Z"=(M%:0/Y%_%(_\YP-_)AE^:<<,=#=UH#DBR+14J:36#ENHE'>G/<5\5
M-8:[7+[U1Y 'UD\($(D<.B/]$50M5N<02&3#%X1"]D;:5R/81JH2\70H_;E@
M"$S-$M25=@2$TQOG#STT(LT[9,T+1N\-:0*ZI\78G2>&%%[7(KJ"Q4J%NY<<
MIZB()/L6X) NS1@A!>%#-S;39*9'M'VUHZ8+:F _QXQR[BI@$*:\& TKZ_,;
M^>5(_O 0K_,5&R>URBK&@Q0J6JXFUBMA18^L"EZHVAXVPU,,)X&+6M%,#EP<
M$%[$I][5C?3 E&9)'(;D&VHMZ<TC0EAGBOZ3,S99W/B.^TKX.T2CT"UA_^2S
MJU-'9/K*Y]DV(2=W;-]YG9$@;WL[$$LO=\%L3O-@X60RZ)9^E(6L]D=#N:<:
MKNF$D.=3$-]C&NY"GNTV/0M_ADG$C6#ASJ$TQ!7Q$']D$<(UR<O*6A@5SVV"
MC_?!JB3(]AGJC85YH"\OWT)T'2896FWC)$I>CY_"'?GBNF.D48YS"EY1NBU=
M;=$N^+__'U!+ P04    " !<@EM8M&$OBF(4  "+L0  $    &%L96,M97@Q
M,%\Q,2YH=&WM75MSVSBR?I[]%3@SLUMRE>1(OL:R-U7>Q+OE4Y/+B9.MLX\0
M"4G8H0@N -K6_/KM;@ D15%V;HXX(TY5QK8$XM+H_M#=Z&Y>S.TB>?$G=C$7
M/(:?[,)*FX@75_\_& WW1Z.+9^YO:/',-[F8J'C)C%TFXJ\_+KB>R73,>&[5
M_\A%IK3EJ3W/>!S+=#9FS[/[\Q^IWUC>AH?\MP.KLO%P_UBFYPN9#N9"SN9V
M/((_)^I^8.1OV,-$Z5CH 7P"_5QDH8NI2BTV$>/1,+/G;AJNPW/Z;LH7,EF.
M/\B%,.R-N&/OU8*GH>%$6:L6T-:*>SO@B9REXT1,+8Z!CX=A[N;2BH')>"3&
MF1:#.\VS\\K8!S#V@\/!6'<RMO/Q5-I!!"U%BH/\Y:?1R?#\XAD^^^+B60;_
M@#Y$IZ=<HD8*U]<8J43I\4]#^N]\\XKOW/Y,5!)_"Q)<W<_E1%KFV:R@Q%/3
M((+AA=[:1F]G>5O:X\M?KEY^>/N^SZ[?O-S_?"(\/N[OA YO/WZXN7YUQ5Y=
MOR>"L)=O7[^[>G-S^>'Z[1OV[NTOUR__M</DZ5T:QA<BC47,5,I>B4@L)D*S
MXSX[&!X<[FTB#:U'PF.I'9_LGYR<_OG\::CU[]Q8.5U^*;F^4H@2$5FE08C2
M:)_U[%RPO_QT?S <106NM& /7ZI%QM/EU\SH:Y$6:1*?[[&)2*2XA8?LG%N6
M:74K4=U@$3=SQM.8B?_DTBY9!%,6J>%6 M-9Q1;$=8:I*9/6L+\IKF/\XY74
MM .FM<2GJ6Z/]/U >Z)NA8Q(+II;G[64<L7>MH%QM8!^#7P*<)@R,9W"U.2M
M -Y4"3(HMU;SR/:AH>4R)6IK<8=L6O+HW1P::L%299E89(E:"E%LAI?2UC+R
MV]P:&0O6IFW99^S#7!I6GQL1L\"/=RJ147L)ZZ;7 FJRJ=(+.%5_(WPN.-)]
M?W9N6.8(J<4,^+J [16L1KZ?:8YR GSMT9RC'!@4$P3O-4:"7?R8)L+ (S"L
MOI-&L%A,90HZ!_PM9-J'D3)I:6XQ ^UH85ANX%>0-(L,X+?X3B8)FW.42YC_
M0O 49SD#04V9R:,Y/>H>:E@>_F!7;LIPH -U4,+?)1S&YZ4:--5JP2P0%Q=$
M/UO+63#U%O!5GX%$2H=R."4&&Y8JEJAT!IHD[ 9L)0 H?4_T!,Y!D*TP3__!
M#87N$3F-A/EQO;+)OI,,AX6_4_P<_H@$RV$S-4"RA%ZHJ^IX.$5B8Q$#=UYQ
M^'H-8XC9)H(9E8@$I<)D*C5RD@@4))J1Y?=,34!/)>$P,'B4:PT\-%FZ,=<Z
M13[#KO+$AH,AS LDB^0MX\L%'43-/< /(5'%<@NLB,=&,V\WE/6;?/)O(!%*
M[0V>WH!69_UU^( =+8]W7AS/Y6<QMR)\"E H#9S\U)NQ\ UN#3(9C)OZ4>ZD
MG5-KF4HK><*R''@B@CZF0B,_KVH )2 9 >P"CXCVJK?OJP2X"01H >BP'HD'
M;E9K-=RK@J=>P31;0+3][<V!U<"IXI/V@().X/'A_N'AX9_/8VD Q9?C:2+N
MU\#)HTSHG!H-0#BU/2<8&L *%F8\X0:LT52L 58Y13_:XPA&*[[E6L*1,3:@
M1"4#T%C,^7=CK,/]HZ/3L]'9Z.AX-#PY/#LM:2137.6 2/4 :7Y\,2JVOT)\
MU_UH.*QW^)0D((+'(E(.6,9TE-&@W\(=@H=HU4 H. _]_)_E[6_]6>B:8L]C
M4I^CS:ZL-,WA:"+BO"<;5NC=UA<>UOHR+F/44KFC&VEFVM,-#_2?CX[[,#NR
M4,&&\78_RX1V:#LZ7PAA\?3G%@:,.1@<;(K^ %0>G8/+MS#;A.4Z+N^65 !,
M+"3LCV"=?*PA1J$;K^HQ?2::)6>N0*/5:)IPYV"(YEQJ&*+!'YD('J]U089D
M\2"9?=ZE228C>B+\;E4[+-5ZH!F99V !"*Y!=N-8X@$ ^^K%F 20HPPFB;HS
MX_;H0ZUAKN]Z'6LY[E>#'HA!#><^  'G@O$(,'ML/@ =1>6@V\A[$9^[H4Z?
M[X,"X]O#!B:@F8BQ$1D'#:/0 .D.WG5-@1$PO@Z#WTHP[64"EO@X/.\;0:MX
M55LZ/=L_>@[[ I1[9N,-C0Z&^\>CPY5&\(NNCQM"+Y"L=S#_P40+_NN8_C_
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M<0632T=V53S+F N+;_9*V'ODB1QI'I,..#I[?N(FLR#=RV7BNHL*;.]B]UU
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MF4(R'#WEHB3O?;$IBJ>I7V-PPK.R^N(:.&=^N)I4CC0^D. N',QN^*$YU%Q
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M7L$EHWS 6)X7U_H*W2RNE)ZM<4:,&'1Y46XGR(X!J2O>BMN]#@DN%HZT'97
M+:%CV_#@W4YLPC5Q'["I^/E+Q6.PI:#2BM13KES!4L$^JV9\<;OWI"LFHS:K
M2L;NR+/N(^+H%TG1ZF?4_NZQW>C#4J4)6DR4<%85B+URZLQH4UI%^BM,GNKG
M[5:#OS<9W0WJOYE2W]4[6YLP\+=%C>MD#;B0[PI^&0<A L*HT(A497>O'[MY
M\BR,UMPJ1K,4>]&O]NUO?R2[2HQ7C"G9:! [#_(^8AY(PJ"2.N103VQ+C.5K
M95EQ[2FXFYJG]<+ ^\';<3NDU+_'AIR!'L1!Q=$Q',M3,-1N%=H>004;S^L_
M'T$%(ZA@=!][W<<')_]Y>-"HB4%MU7V\\ TK8<HCVP;,W5;TF Y%14<9E0A5
M)O5 !P76_GLG3G]H155>PW=LF99J/GA\LTKZ;"^H=/_N2-0Q_;]&?I[M=?K?
MHR3TF!NVG4T=XX/;3/_OU@Y]7Q93<)VV61GPA>KR^*'VX_'6]^/3QS]:C7V?
MBNZ]WI&_@T>?+K. SQ4=WY^+)-7;#6&_3F<S35VP,'^;UK6FP$X8KDSL19=E
MT2PE-1;6L7&^6,D$_1C$* L;EH7]%H9=8-/I!/2PPJ,DX]EKTTU<U4JB,JY>
M'PQI_5DOEB:RZ1/K6(IK<QN]<['D@*1[AK7$Z[*9UD2'M<X2QQ@2O],%F=UK
M1PG;N(3MMXB]HXAS:*EO5=C>N1"X'U96D^)*V-0#;(0[13A#<7!RZ+  !"'X
M^3!2[L0RR;VI^85]$HP"/G3=U*& G2R763HE>7^CKJL1/SSBE7P'HKA&>T9<
MVX"#?W>A2@Z<A!$A:7P_5<*LZLM*%3X&K;QTEDZCI"$>C41GFM,</@*'I ?C
M2MZ#NLU:2.PH)RMP8$0.UBM")F'VT;',O1C/K#WSD#:PA]&5L*U\>BE(7X[;
M8M^<A<WLBPJT#B-R>CQ+A.C,BX4!1DARV8"UK54];I[]LX,?0JL,(.6G8&R*
M04GP6D9PC+OHP7?1U7YL(B[<(,#&@DPJWB GEZ7VW/"FZN#DQ@VSV0VS)_LE
M5#KX;R:+A(N2E*(_,=>$Y>B%HCM+."]![_/U8:^$F0=0[.@ETZVL[T7XCJQ)
M-%?HF-*O+%T(AB_N =A)L IY)Q%>1_,F*NCPE'40Y8.@\:)MD.;WEC2M' \9
M%V4Z/*KI%(YWDS$$-T&E5ZR@73.VH N;(^GT?HMWTI3X.8@**Q,&L:T\G* K
M8"(<H"35$><;RZ"1^EHQ $_C#,BOF2GD.ZOZFU"27V._]RCPFQ;X/3$S4A-,
MDHY&-\F_8%C;H/UQ_VQ\_^S)!J)P9-EHB=' GH$7U/WG 5US$M:EMGOH,,A\
M!(C>^5O>':/YPP@0_68!HJ-&OH5&WA.5C(V*P&R=(#$\,D:3VL7?I?C_3:8K
M^8TK!7!V9>%9[VR"XZ]OOJMJ)H]@\O!;,&_5)$NKN?0PI\!^4R(Q/1$+<,**
MK%R7L\J+_-''Q^>/HTQ=4YT/WBE9:[R4REK452$9;?4YJD$7<%F'Y+ ''C::
M)IL.?GS>#S%8% E"'K#^BZ3 BY => DC6P7TDV^J'/J[WU"A..^3J3)LZ@?I
MRFQJ"/],& PNO8%]7S\RY7[X(EM!FV9X]=(V/A?+J&]PSUOT,IZK.%!T=#CN
M^PWO^SW9]E0:%KV'0:?3=*DPR.?C<-84&:82-X 7Y P*LB=)6"_WO;\5QWVV
MZ7VV)V:&9='AUC.ZK+ D$G6?GF)  7Z:Z+G*9JU>B'1Y2EXC'=\""R.U*OW;
M\&JI7O5*9F'\5VG15-G*>H^2SP]"6^.&W/B&W)<=2:I/^<J/L+YZ)KD-Y&])
ME[79D*92&7ZDRF4Q5A.=83!WU:X OBZ:+/'XNB;:L$*0VO3?:FKS>>>^1,MY
MW)4;WY5[LBT7ZI.F,C=F 3%!5CEU$TS%)5&NL:\E&I)HL"970K$RHY\,=M"4
MTXV=%$8"H6"7G?*YB4Z$?Q0Z$L;7>DK NJU7APZ,+Y'Q57%;/H*XLO((%29:
M>MSA%9.4N2"071+^%IB_)O'&XL><ABX;7HV%H)LK!/U^KPM!3V'94W;+MRHG
M;S&GHNH&)&05>O7Q.IZE>U'KH)!TN75:N#2*2+2@;$@:-L![TKJ;>*#@$:8G
MURAY&Y2\YWLM><&^V9LBU]&F^IJ+KM]88,YVZUE/,6XMS-G&\/':-TE=1 O9
M1R5]*1D\X(7V*VCR-(8/&WCU;X;A+6]1;I'#:P;![::"XD/RET.NJQD"XQ<,
MC+]"8+SQPBM#O196Z#(T*[4C#\FZ$1#F4U&:1!-3SA($3&)#OELNC"1H#$Y5
MIO-$E=$*.5P/Q&&'U>4D5B=DQ28D/$PSIYKKHG(( YEJC?1VN8[F\"0*9LV+
MIB),39%E"NS-@W^%/1_#7CD4LK1B&1JSE-#B?ERY_TV"B<-'^07>+OFTRG*J
MN$2!XM1%[ZK95X%'FJ-575#;/N36E6U$Z7#\@9<??K5B@DDYQ,6*O_ECFGUJ
MR6\=+STWAL:7F4T=?GE:G<IP"=HWC[IYK&<S:O%"^(184VW=J37T1KI'53M:
MOQXU3<9S6-<VI*UC1Z1DQ1B$^.#)T2'IL$JZKGL<_HX DB6J*(G% !^A*J^%
MNV5$[!_A[T6I"SH&VC5X@R>+YS"$X=CK>1%'<C98/3#P$"?[<51<@_IB959J
M3$OA#:#*%T6IN0H7%\-2?3\Y<ES?=5&K# MI)Z2'K@JZ<8D5D30)Y([-5"7:
M5!1FJ/Z+<E#[>Y]%;AJ8C8M9P%\.OG_8CS;BY^ZL"NX.8?MQQ,]]L_BYT=SX
MFL/KHL)/3;7)>Z)S1NO^%=;!)'KKA!1C=G'/:L\?-I =;-2MF\=+9+>>>RZ[
M(42?A=5-7-3:0Q_ODVS;%@I]3F8?'J1##S$K$"> I]<72LU#!:"/MQZ!_O[Q
MT2:DYLD>).1OZV\-[(UEW\YXVM&G;;/GYN$.6SY_\EX(E^O@Y/ OOC>7V_3-
M-GRY!W'>4#V=]ZDGHV#R(I(.'C"V(,@7C-,?:(<&Q'N+= X('+['GK'Y36ZS
MGUO;;.7VF=<\Q]]^B8]-7:I2P?W+.3%K^4V[/$:NNW]H;S-N\"./Y\P=SYGC
M/3QGAA,MN[8Y1V-H(YOTZ1YLTK6M=.(A( <E;-3PCH4M]9 [M=46S",G#<X$
M2QNG3$5#B[0B]MKF/#M0A\YP2/3H4.\=:]>#>M1_J)1[)G.U%NXLZV2_ALVY
M78C B6>$.__8M[D'"$!FZ6=S^."T4"K\W*]Y4H<XQ;:2<XP1E%1W/!'<,PNV
M!.7 J/HH10==S]C*'WSV*'G[1WGVH*+W2\&YM5T)M?;@F-NR0,B7Z50O:P-.
MH1E,_1D8!FS<]0Q*L>:@JSREMG2ZGG.!J-2K?''2^/YC];U\:S *>U-X)8JS
MG+,1#JA$'ZR8O8 S_Y"J;%Y&8+Y'T[F>?H)_/CVD-G1I5:%5G!>U;D.)ECC.
M6HJ]6BS'<73P[%#\0].(T*9&20/YS1VYLV:/N=$R,FRSVK#AM(,R=<T=+XBI
M*H=>HK>WHI6A$@U'R]_! JS\II1A(T7")"57NJRT0?#@7;CP,&8->Z'J]+GL
MI8&R^Z RA+95D?FES2\I5QU^8RJCNNJVVA00530IBT^Z?*0JLK82:H9+'XEW
M -F&WAH2@Q!R<6EQ],NBN9S;YT3F;BRZ0M]^F5&2N_M^[$]9@*4W=; B1RES
M\/P0K\<NL^;=\,L?I&TW[Z'6IH?OTQ$^&[.V#1 #4L9;;MR71/G]XZ&<F@A-
M")H/N7:6/(#*%_\1"#6V?NMD>G8!##5:;F,2TN.<-TVK2&6>6ITK3;7A.)*6
MWER1M5T'"M1P"[K6[6SBXXWQT&7^#5'Z_61GQ@)A+DK\#3^2?CF"M.[\J>^.
MD_II!&E]4R"M/_ETV=U0KQ>;4=5-F E2594F:[>>#T.#3W(_C(,^2N#A4/5Z
M-"LE.DMI$+*5ATR%WK1G-]7PU:0]3WK +$0'X-:0"(Q]+T>\KPI<ZA1[!L&J
MBQ=J?:H#0^5#WGROXX??B_NDK 2#3!G\@O[_T,&2A=<%7?DZ$Y(6\QH7Q>-8
M.P9YHUF#130M9^E\78V/%PQ,*Y^=N2XNV27DA(-SH7P&HUI]UA4VE?_%?[$?
MAA 2ZMLX=Y;39HU8!'Y=;^F5,'\12T-DYBZPIF;I*, &\$QRI0A=KA8VQ. C
MZ1'8E,Z(/4=7WFB\:^*;GH$CQ>HAF!DN<[4LFDK#D#_"U\Z"H$9IAW6 E648
MLP#?U[Z4B.:794K1D;Q&%@M^\Z0H/G6JJ0K&;D1)DZW\):=,#G*UP#&8UZV[
M#K$*+2KQA,.M<U74Q/(MTA"!!L$Q)97!>[!'7WK&9N6,35YK_1FW1WM3>M/V
M@&->>*Y=#%?[1.0R:%M"=^'-FUY*RT@AD:E"YGT?]'88Q'TP,+:L<8EFIOMD
MCYA0O7BD$M1C"TYM\39:J$3X0^SBV%"*K"/^U<E@B8Y PF&P%%^?HO06+C;6
MNR%B*G];UD$;-)\M[%E_U^TU.)?CHZ]2V9_V!'M-,$\RE!*;G8()6 UU_D#'
MA'>$[8\>@YS5I.U;E8&>*X)_K%3FMWHP&UJ$N*^_^DU*^K:0EM'7_[KSHQ<>
MP25LH ]:.&+GZ5(\_19OQ%;=_;-9JRQMBO)F ,C=P<8^!HU.\-9)ZHAL?*9/
M,;PD;-\]?WWZ&U43_]AK2PP:=TYKM&GL.>,=V]9\H.0MG2".5)1SPE1(*VWQ
MAFO&!VJXG=A?L:71RI?X4SY KE1X/!S5^@J?@FUB9>'XV<NT#$+=IG3.SY7
M>&]R/@Y=%DQ-*BV!>.5-DF;>?W/LSXMT;JD7*LU[2LKA#LI2+6#_S"N'';_5
M#B!3BM(=CC7.GI']6'4PZ=8L;WM+I!4Y7?)=6%][.X,3<$$N4%2[USD*?]OD
M\H@E++GW<<(E@EL"GGZ1I)DI4!P:95)H'N?-N]=F&=UW[%^G]NC,^W5L[>_N
M5#OYN)XYC4'L$7[@'Q=.(Z-0>-MZKTXP/H1O<1+MU 'T;9\]USK#4O$GQ^/I
ML[W3![VM--_J>3-F@3:>B'ER-*:!OJDTT&BS[59_TX<UV=B;WF%K+<&V]/#"
MK#_:L YZ?0L;@*,)6XL'\.L[UAC.!"\3UJ]@4@]FJ<4]:1%_H2R-WD3G>@87
M4%6HM9+H==Z?HCF\=*)U[M]J ^5K/@:5H7 VSF%M97T#&XQW2U[<[M5].9\:
M$X;^.G6VD-S%J3V5N2I<10#B=>Z!)CHKM)Z"AQQ4A[:E>;A%3$ZG[.OUU_<&
MLI,*XJ!CD V!+"V8D_M#S:C2QR3;$ER\%/8;&[U;-LV'=\'=#/(6]IKWT[;,
M<+^R=L@D#S< #JTJ_(3V]FSMZ!:8J]%2V*G&U@^;M0"A19$]M>?-=E&(_;JC
M?2RC/E=951C=02?SR&7R#7*9I+,UX(.6I5B'&;K>G4;UZ55_PBXZN'4.K">;
M=2C=<UP)2Y::L"HGI"U> 'O=B14S>! 8DU,KT 6<LT;>A_6VH_>TF^S&F.HS
M?CZ4^W.T9^\<,\!C*)VJ3,2A:L!F\K[^CX^/GAUY_WERUTXS\^TIKT,P_GV<
M2J:J6OR!W*^%LCOUBW8#5LN,ZNW;H]"XAWH;U$T/K^*8GG6>3JA7*%;UY2NQ
M=(L,[>:)%N37O+>*C)]RE1:9P5R5^I(] BZ^HW9YJ*4J#\L# M.4:8UQA9-I
M_=#ZT]..X?7*#S7,TQ($^N#I$:F'RM,/&_E:PN;N\$D#&X475,#)H&MX:>75
MI)8&%_CQ%SH,8XN2-3KGA[UN4=+NI;,W=79C >C7W*7D5],F=8?V)Q(#!(R;
M7!QGZ]VIT9L/4.VA*8B#DY, K.TJA9@\8:8$DK.S9QUZFU;97L=J@;7S56^-
M1#Q0$A^W*!1&>1P[4PP>$\ZGW'X3(79R^V3$EKCZA1VV\;*7$:(^N'BQJ1TB
M$;8FGWFPC31W,.66D8@JS!SU@E,18:':W:72!ML[C_!9+VPDGL=K&_Y@JF-:
M8COA2UM4@;4CZS1-8\MF2K<.V!:H2T.2J>7MN(Y&\,?FP1]/1O#'-PO^&$_?
MK[E1PX5DF]4.='$][2V+"[JU_6!:SG?"SVM.&:_2&HY Y/9S*?8X6F8ZN:3S
MM4*4 /%M>_Q)$>Q,S=@!3 ^OEOB7*?WL3B^J%&3KW"NZ[3WE1]MW)".RF_X=
M67+>[M@N*^;%[4U'E*ET@863ODW:MN+6""4BJC@SBP7\R,TF<!&LOW7%T:.X
M;%1<]%Z+RP>]**Y4UM*H6VXV:P^M'HA2Y_A:>TYYV!SJB]BY@",W5*;N\AA4
MKVS<T5)G6-8BL1_CD*'\,OQO2<PB?#QUDH\K&V'J.[A(,.O  Q5D9-==9+%V
M?N6P8FGK% 3[94@YH1W>"3UH2EDPF8>G8FC:Y!D2P [G#SN$2OQ'O;%)O3';
M:[WQ-VZ"PCQJ6]46KSD#MR8&U(V\&MZ6-9JC2\$65)X1PXQT@A%^CRZ'!Q[E
MAA*V^9(XT'A$;U34+O=:U%Y;5AF,3+)]^]I#&W^5XF>#P1[GDZ'9P89+2; H
M?'CZ$&PXEU6:]+?UOE$DQ=CP!9+K)W*!^ 9$/^%KD92&7IWF]D4>6-AV9 Z3
M4Q62([5-_3H,)!@&E9E.:_NKRG]X_T(.T%U)3W4<ZZAN-JINYGNM;C[HNBGS
MH2RFY":VJG+>>:4^-X,H\9>=F3C2J4#H*"V"<2U.C?1A^&UR!IE5+[$P0T1Z
M6J!=;=B0Z WL7(1^Q1?*V@CF62-I/WY58)[H8YYNU98>3X$1TA- >K:JY?O%
MH]T&[$: SBV(9K'JQ09N!ITS@AVDDH5GS3XPQ%#AQ_8F"LCJ+H-%WH=R\'"O
M8$$Z/ *#%H)3JT2B,S:1\18:6[N!B\- ] ]Z%/X1/^2".[!%<..\*N'-9:H\
MQQ,Y]G8LHR)8(,W5I]2"QHR[)R)*5E\,@KW4S)QJ4.A28.YS3=KGH%.WT'4;
MWG,KR?+P2A-Q#8NFK_RX=VY$D=PWM0G%I&V!@)K.4[!3C>H0*Q774,?DKB+>
M465Q-&DJ5&>HI5(N,8)MCNXL=AFZ+%16(7.SJ Z\O&:#.%VDK&-(&<%8D(=7
M4Q]<?FD)XR1'_S#V,[8SC73'5$W-9=N5*Q+@.FJ?*A=FE=Y,#-[YK*/V&O$7
M5D><JC*GV/2NV==1]!'%=:%U;8YE3U#:$MZE/EL;$T/Z<-0KMS)W;FBY&AA5
MUC*Z'$)Y\\+VXJ?7Y;I+G313RC)=*YH"O+*CYH(6CJ""^^8\(ACOOIGO@6 \
M'A&,(X)Q/$%[3]#]QE!1MU.T^>$&,I&Q5'^U]?H!&0-U&8$S'HZ? 8L[Z#YP
M(U0#X\C(';2A=C1?B/@J\HPL?#C0;Y@5=I94U3RV:25JJ]!JW(@<_*,U/ *\
MK-R\PLKN+-L^L<R796TPQ]ODMQ-SR8FZ")AXOV.J97.IEI_V.M4B57!+>-LT
M95VY \BE44V/^99."?5N;M7!6FJO4#*HI5:#$VEG<'I+HV^5UG'MZM8:;D/V
MURB!8]+#V^5O6U7"NYCD('P*6/S+#+:\MY51*H:R$H,*Q9= %+:V%(YNQ!A4
M=T%U WQ^7^(>V;6$X!([1Z+8.H3VD@;::O[I-SH,J("#;IC#9]<MCQQ:'W-M
M7D2",U7@HH-\SN'+$!4QO!+C&0?X_0_-^?F+2LOH=U5^ A_I;RIK>'(T_C;)
M-0DPNE8A?T#K]&M!38?83[Y0P0R9 #>KFWOAX48M\S4''@?E;H<(3 ;'R/FQ
M^[&8A-HK[E#?#;V<KPPET3SK3Z Y&65X##@Z2\'G8MQ-=_;D!BGNG%*F5_,2
M6>SA.7AF'T8KK<!7M6W*@V.9 "\H<]6\*$U[*)0R<7_#@M:^".B-B?PUCNT-
M"7ZB!VHR+ADQE;3/X?!@+"'=X=E$1/3-$,;E,EN1RS[T74==,%:)6E'S,G;#
M1SNQWVT?EG,[#R!N-=%9A\E9RNRM@C"U(XSX9=J_EI OFJQ.0<80;##VB=AP
M1ZD]H)M&9S9)9S-=4M^8B:ZOM9 H=QU#WJE]GJ';S%=RBH66Y4L*HE;C#MNW
M!NH;VF(=2L3!,M%AQ9U6KJ'.T*F_[-M'G41K&S1U\]2&<5-_\L8)E_:$VR1Y
M<1/QVWH:1YO3@2#<@XMLQ5;,1@L"27TJ(&0+OU(9/NX*-8/@NL$P7.@ (8+^
MGRYFCSVLUXB4O-V>N =2\NF(E/QFD9(CJF3-@?GD:*]A)>]UB>T4J7<&0Y(P
MJ.;_=ONIQ-$='T$F'9!)9^-^M_V-VAW4@#1M!D 2;P9!\J6)^C2W+^N6YMYZ
M!;RI$ZV=7T4X"OR(:;&%O"9,L),"3^FT]L@\^5$H+FF=JHR]&BG!YP; DRRM
MYD/I=Z96G&@,>?=FS#NOYBC*FG>#BP7_EASZEX1B^)6C5(Y8FCZS\1UA,](K
M7>T<IF:@R'[IC;YPHS<$W[:$T\.9^ 7E&&C".E4J*%><378%Y>MZK1UVZ[Z_
MI)I_=:LJ_E+$?8W.7%_0WS%%9#7)]I"^=)VF<7=84[\FUHQEJC)*0< 3N7W=
M]*4_">;G>\Q_2EZV&[(,SO?>C5E:(_A3^JX,4RD,+/9&"!6VSZ<0CX0*NW=>
M[3<JRQ J[*H=Z<B;PDX1+;4#AEV%;26P'05>C"RD WY71_.M8UR0$/\:-\X\
M3LK91 3]-+)-T_5I2P:M>C),Q^.LR:=^BJ&7P*8H,:=3\-EXAU.&;.$)9B!%
M'R;!>EM*"-69-,]Y(Z00=QCWS*!O^H<UJK<1L&8UR'"U^\YJO&XE_(TJ[':U
M\-W&RVM5ZI>7NR^11/V&(0LB#O^(HVCG.P]8OQDW75V" 7J)EE#7*P^<=FO8
MTT1O&(/B3.XT*UPKY[5+<2@I5[4^WSKJFV\>%.=7Y.^LAKE'M3[(09/CF7P;
MM314NQ]W"99'<N4_-S?[9*]SL^^:N@)?/7I-4!;8+V]LP&F[DO6VB#IC,YAP
ME8*Y+]5I9HNCNT* T57T"QRF<)[]'00MIF.14DPZKUB7H,0@$@C[ J"$^I$'
MNO^$?RLO,**35B0[AXP!"TY4/C+A)\4& OSQ7W_X_BB&)2*"V9([(X'H_NL3
M^B7\UR@);["HY? UV.U/ES:P+O$-<F?R[J(<T'B"DYN27?X4)6I3L,7!*H%T
MU@QM@9$7[LX;_!YHIV<CVNF;0CO]N<?G[N)J64L=>'$:5-M3.-X2LG](G7U\
M?/XXNM0YQG S[LVV)!YSN Z;GU(8 S1KNLQT=7B(T190W%U=SVF'TJCTH)3?
MCT"CI>2I7E&YE>C<4XHW:\:+KKL4S+*\:K(:]>N!!.WQ-.A7W8<2C\= -TV+
MGKUL2FQN:<N.70;(/XI,-9)G?HS&W/V-N>.]-N;>:'7%&^=D4F$*ZCO39#GZ
M62HDWA33'3#N/MZ^I51LXY8XK5",7=,YUR^J6E+LVB0/T9YK<E(#&:X.16%Y
M<:C L5.D1,*(]IK$DSWQ-R;;5'&PXR ]I.>W'\Q=9*]<"-L4-*&UEL)-IF-5
M90M7,O-9C-1[M_C%+=;M0SL.QDYNI62RSIL)J)=4E2N8V2\M37*6H[F#H6+&
MT+];2IN$7+I]\22X>=]44WH4_-;HX.EAM(!/-W>-P-"=M?FWAFO"_'"8]SA0
M5)>-HJ_%JT&)ZYH"U[@A,+C&/<-N>JBZ_2K#2_$C5H7W;@JPYU&5?HX.GIL9
M@;K-LN+:%GZF984L$U5]:%J2>E/!)_<O(FS#K#=;0?O)WTLU>0B)' <#3_,Y
M,<P-1,^A/KLO2H?-6_B M)Y%N0J>,1X)&SP2GN[UD7#1:HYGE>@NZ'_/!G0M
MC/N1I19'@1H*Q1N5?9&!8(,%F%RBA*NJ@CV&_YJOEOB\J:*H@-&V)?[ C0A1
MB C,(1$#&&ZN39Z,+#88!0DAZE\>$'=AF,&@JZD@#_R6AB2W$J"P]5ZQ.8;8
MD)MI@K<8/AFG*F+FM^WJ$%:.W7-RH3X1%$H6Q;5 S'3,6HO_P"H(EAX#A/1[
M]-=JPF3<'D]"C=*K>S1''S7,.@WS;*\US$F"L\-SNWJ)#5=!*AO3M?M-^L\F
M3>BE+Z/?=7G)V+%7(&&79$Z]0B.@R,9N;E])RFF_"S^\K;S5X_%,T)E7%BZ(
MAU0BW70=HB,X?PZNY[KFN'%/7MB2H=<<M#!@N-@]#96[+NO588S@';5,:]B'
M_R78TXK,2_AXV V)6GW"4=WZ95%>JMS>L2!Q)]@>J 31 C%?_:A9XK]@!8K9
M+/93P?@<L'*G<U5QN 6\$=86K@C;CMC#](5NDS>KJ=4U@O19XM;!L9?-M&Y*
MW?:XU&R&L14YM,TKI_"FP=XM%-5$&W]9\C=+$")AM:#.,Y#[H%_=1.=ZACX<
MNFD%?GF,]-O?IK@9$@Y465""3>NU&^=)USS<NS[$B@[V#*PB;^FX3PQ;*8G.
MP/DHNR0^<.-WP@?(CXKY.9QL9,) ]\AIP0^9K#CO4#2UY=,A(X1ODZ=IN!MF
MRB4 %-HB((,)9SWUR?9&YMFQ2L=3C,.VQ>XH:]F]J$K)Q4C",6=NS!V-U;6Z
M33P*(>+M^K4AC!)(9U$:D(!F57;EJFS(!;"C([=!34V-7N$#)-.:@*#L:NF<
M5%M:-%6V\MT;ZX'06-F;PU>EBX5.T%& RX,AX6G0+!9AL,@.2,8R2OU8!61A
M0#OD*W2%78F9TS8B*(E%2#=*-8DI(L:'* /^)6&F5]RDIC/7>.!([00(![QV
MVY6W16[K]<5UYJ*)A2Y5J2YAR>9><]S^@B2R)K2KCL%P>07BS; ,T T>X4JQ
M-/,NB;$%1@2;%H/!-G8*NF"J05]V5DI)J!O_[:+<9LU[;QLNSI+@48EC*P50
MA:M(Z"Q),,"UGJZ%Y8-)@PV7K<QJ^9ISA$_<61+O 9_X?H1/?/WPB5Y>K.YY
M_]408W4=_V&]F!2:S3-6N4RD:G2J)707#ZPW-35K$%N!Z56.@R<,%J<#@G1T
M2&Z:M?!I_JDDZ41ZR"#GJ=]LW>#'*U>)X\+6571=-%E"L_,2 ]S\E0\7&1<'
MO'%L0:MW?&6[&18.;5V'K$PMA00Z[M"\F5'AK[TRFT<,JY,$M4V0<EDG^KED
M_0J!K9N(<[<]J'P7+&R-B64!%ZW\B[M=L;V(QW69ULB]JVS%J9]!#GP(\<L=
MF!C6P2\CXL+,3@61;3OKB$'T@LQW+G["LH ;&/PQ( +&!%R=\:ZA_35<YKK0
M-9M?)G\!FVE&H!IK5ZQCX'-RDH2"8HF%/9.NQPQ;[YRUUQ7!V!B70M ";-4,
M=E%9Y+(AK%C?8N2VL,[M=I)L94JD<2DQI73+RM5.K8G9 ;<=B_/P; 5P3_*?
M!]=FS_O6E/DOHH)#0%=*QG@E\2YPSMI.](2=9"R*)\.>-VTZBUMPA:%=2D^"
M)Q"^)-#E)JY*1CB79\:TG<B$YY!<RU'@IPUZ\P-C,.-786":PL6Q!*1[@[A>
M$-J,T IHYUVXT[DXM9+2\X6EB&S-BA :9K]V@B(M@SXZ0*D [6(>?JTI2CSC
M#Q)-YX5$0(-Y2A>"U;+[)[RETKD136_0X#^J?Q2E9.;QC_ZIRH?DX4M[B,1P
M[S4&W\7W2D7@PK?=O'(6(I/A)YWRRG$T?YU311ZM!SSJRTNOY/0T^\"+BO4^
M,S:3LR9+.!F.@-LI>6K'XZ&^U3& !3?F;E>3K/J-@KC+N(-.89L*9YW\.'O&
MU";?;[VE3 \^(Z'V%US!)Y0_A2'(D/X^ SMBC<@,;99O78VW>P2 H01:'/Y!
M"^9#<9^!-O?BG" 2Y<K3[B2Q:$*A(6RKW%'GJ31YA-O1;D]$+U<S90O7T9A"
MZ4*>IJY]YH<U>H^.-J*03 &[X19% M8JP4E6_A'>>0L'@%K&#M.D_/2R,M+>
MJZV4O&5JA7K@+82#(?J 649R-"0;[KUPN-:/NCJN+]7GKY38K/"N- <A2NDT
MP-93UDZGW\K'H\4,P75__E;T\F$=0N(Q(OZM\(QT*L!V -#W1[_#'-9;M <>
MW\[WVD#PP@M/?+?&1##Q"(EU>/E__H#8;B(XUET\HT8+S[+$4SQCC&&,,8Q.
M#&-,%FPC6?!\3!9\_<F"$7M\!^SQ]WN-/;Y0GT?H\%=BE.\W=!@-8(RLH&GQ
M@:$%V\<1O_=CM0+W7'' ;.6!::ELVN_R;$,6!\Y*U8:DZ="V;-0*E@^-'6*/
MY_@!5JE=>VM13&!#2FDCQJ621LCN'%+&<$E3 *NX%N1J8,@G2'='$3CS[)B#
MV+30K5YS%#U8I#:&[5'EF&9R53,#VS;5?#5'6U9<="[$H3'3AM)KL#@SPYEI
MJI?,']&%\K,U+.EGGTID,%#RR]FK$V]A#@,LRH0KX"EBW3;AO<*>WB\S F9'
MP.R 3CHI2W2LMZ^3.JBL(2(\!IM[6LE 1:>@# 0[D#*8W? H]W2O(#(]3%K6
M72UAY)X>/*RX:(#7<QP=9U*7\!B,I!]T,7&'5!2^5!0IX$0757Q3#ECZQ5IE
MYX,%\;6>>RW*FAQE4L]%:10VW$YAZ)XL ,8:TIP*N"M;$K%0G]-%LXA<J; H
MP0&M$TN9.HQ:1B'C#HHD,O!7DM6CXAICV'_2R&3W=)\>QFI:2I2 D*;2H:>3
MB;+CH0BP3<^S/L<S:V@XHZX=8<H6IHQ-;%(*.%$LU"2%GAW]=+)=UF<3]C,;
MGXND2;MBJET)!H:+@TTEM)$"[@:@4X8J?]:+I=>G5X)YDJ2*F=1A@9VO442D
M?;9G"_M=M'%=1/$:@:-@<6P:/L;(IUAGVK"\)QI+N,$.\W,X+;2"7]L,ZISQ
MUQJCJG[@D4.7_D!B4DQ+*JKP=;#/4$2)J-8)U=>U4I24*:3RX=&N!4"KX"H-
M*[X66M<W+Y[/$X&IM[ILY+/2I&$;U?W<2K3J]+YZTQ,/*DBD<-%T3BC=EY5$
M_\ '%FN6DJ3>!PXF[[ I9@DL"2"S _*S$_=@68M@@].]MUKM>&?V*J/@\D*2
M)HS*\D[F V&#68>8=QY1Y;T,_9!T,6FPLC.TE6;R3#X2TX70)]@2RZ*B*KYI
M4Y:&=ATFTF1U>QE'VH -ANZ>[W7H[FT1G1(2"Q-=IT%##^D-LUWZ43GSK([.
M109"7@VDUB+4AFHEI582O&B[\-+$9&U\H-3,>ES-TV5_CY^8AF-D?\6J _%I
MAM#D6JT<#*O_)083Y0(MK1JF+] D#'NQV%#2E>$L7)_!V!9'&?=IJAK,6M;!
MZ<%.FU0'G3B-^$9=5Z,:V: :^6&OU<AKP7!2S\ZM!S:"9G:"3 S,%,8+4HI:
M4,&Q<SU-HZY>7.4G74D8U\@9'JKTHC8JP<1G^73.B)28T4U(:GP35IRXEVM!
MN';?:!MZ&4Q 3W--DFRRMI#Y&&P<RO=3E-BV4 @JDN_2_&^4ZG52_>->2S5V
M]B/.?SAYMRK4YUW_X_A>;>JO.5L_*;)D(XC [:V.1]01.S-)U,.T6/A(>PML
M964$JTF$*H9$DUKX)E(A+#KIYT*\1F;,1,X4TT$.R1D'2Q)&@,V==\(] #8_
MC ";;PI@\^>>NKM+9OY!7[+=A)H+;5$,S]36/:1^E93X8%>7:_=J.=T0X'CP
MY.@P6FE55BZNRK8:ZD-GHI$ZM.A,ZVHE-@D?1HJ>_#0>4JU#:C0O-VA>_K37
MYN7) LYIBC91/SO/N_'VRP@L^TH2B_L-+!O<JUL/=G3;1GM1ODCAN!&-7V.X
M4GCY*=YHPX16,X^PI1&VY+875;5(U^$3XOA7VR7]NFC#%8L)\VE[ U4R4(.N
MY/ROE=TPMIUKA,%@&!UE&E/RI2F)\1+HG:CW*"4CX,3N2Y,\FT7NA #MNBL'
MQ-O"[7XY!0P!,!T%E92WU_W&EZ3F%95H80E:"N*7>LFJR@J:7S\F[M&BJ1ON
M&X6(BZ"YP U59"UD(H?C71': BEV)]HG>,$[!5+3TP*D59V&RF3=A(FFAC]L
M9S0N=6=Z.?@5CA8\'11=(HFGUR-G;8UF"Y,2!-6"8+WWR4:?:G,^U?'17OM4
MKUR=XT>,]IY5"-SUF:)'A^HK.3CWVZ%ZHR_!3'-XS>WFE[PVSX(3D[:SO?4X
MC>N;YO/?>'4AYL!)C?BQA>E*?^A:_[5K+,X 8SAK2N9K:N'8/,,7FQA6.K-,
M/@$;;KN.96J_P"B>H_=GA>*,>J*3M?5!PRN14F8'.A:>( S+UO([?RX@H?+(
M-LW6Q["(*5,3AJ:*FMO1C2%R@RO79,XL>ZHD)(DI29#N4?A@KL!SYI]<8G@U
M2[1UB<U92-\2IM:9$=#4+C$+.,.PB*9!7L[P8$/5H[D1EFTWH@,M@M1T@A,N
MEF"OLF$[H MB S0O@X^+N!139C$:E1LT*O>[._U9[ODZ[SCJ<M+ =D7&O*W'
MA-+<ZZKG"SWB&WBPR@R6LWN$"]673::HW&E2)"M3-?6/IDRK1#C9V?.B$U*;
M;IGNE.X#J\N373+2HK.1-,XQ;_70VM"]?NTK <BP^A5[WL7T9UOU2K\QJ-$F
MTVPCR)Q2KX'IN:-UQ"M.31L?Y)P#X\02)C(+GNOR8S!PICQ9Z/$4:#YN9J-8
MD^91EE:UM/0CYC*:[25VH\EQ67@>K=6V+KWY+G&P:G%[M4J:I&>K,(".F&+"
MMJ,^#QIK/JX6<[$^'&=RY;&X=NRT2F56OYN:.N.^2YN?$DPYW:H?E#M@@+(=
MT]Q:6[)^,Y5F2("&,0&T+^D3HUKW%7F'C)DV695B-OK.ZV5-6RI[I%8B+!NC
MHM^HHM_OSM6O0*],U/335G7Z0%;+5!<3M+Y3RF4MKV&4?64+A;B%%E*0V59?
M;=^H0P;L^5LET2"0W$U1N+),I!"TR4RG2'%H7U#"EVJ6KITRF6=3*M&1J,Q4
MEYS&8*HOQ))<\1A31[/-0PJ(NRQ5F,^RY14#N5:B=#+XE&;.2F:4<9M8DU'%
M%5W<(M*T\4E0P(PYM"LU$,&LYJJS@OT*6S:?(2D[(&;QU2$J1-/1%48Y@0-G
MSB5VN, 4WL;>S'BPCZC#.POL/5"'/XZHPQ%U^ VB#GV*"_%%&"[M1QLZ=!=R
M2+!5#&>%Z'8Y+4SE9\CRD''[I651!G6_)M3XG:.ED+"ET\&V]Z.A=:BH-+?O
MBH1UOYR10@,_U3J16_@77&Y"AQFW\$Y[/)JA8?CA5 JE$$&CB8>V6"IQSE7+
M<G>]KV]*TX]6[>:LVJ=[;=7N))+%+]/P32,;R#?=V-S@V^UU37U7?:TS<.H.
MGAP?1@MXS[QJ%WCY% =]B&8JL4%WLP]*8P9I_$439902?DIU&&XSM,<=40N+
M_VWQ,[V,]AVYW"2A_5V.UKM^]L[1NCM3_K)]?U?;XJ^3\M_O+W4;LVR"Y?_:
MS+;1Z7EPI^=>E1VCT[/+TM-S).W<_MUP;=#)F]-7%^\^Q-'9VU>#G6:^]D7
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M0!3=*CPZ:HDA+4$VAH&1AJEJ2RR\1*/65A29"(ZJ++D]G9#=ON0B1EPF$DO
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M8$$XKL9%-GY-.;^T(H(1CUP/Q5L+_U82#I5.2@)>V,)J'LC!#245=';K%BM
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MSRYS4RXA+[SK%;!YX=;K+/],$>W:4"O"L*!Q$Z?9=17N@"BY9]"I_V'#CED
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M#*IHMZHH'E31G<9&)NV#4D!BC<^"-Z"&IN K-$.W@PCM5H34($)W&MMK/H_
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M(7:,$JK/RT08:[HZ"YX>CZ)QV XRACUH&P+7.B%V2TWG3RR(TC(W@[)A&@J
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MC$ !;MU]@\H[.JX*-=I-%V*;T!-#W5C\Z=M.*.DF\M@60RF9X-8 44'A)R=
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M/*A(P4>/\@(IU1:2H6/^-B1Y5M.:X*\M-#R)"W-K-@,%7\2VU")?,<PKH90
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M:U./2O,=]N0H(M3R^=S2W5Y?#Y3WI:4:NMU@);0:=EG^8#WJ *G8_GPBM!V
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MF# :54<DK(64Z>$ ;+4*G,+SZ#,28BUX$> <=6G#F%8$FX=J)K:CRZ/0-EH
M_5476'\%0\JGV'>HY%9%*QMEQ1&A[L6:=#(%P*&]BB0LF1 -C:9AB0H,A%*[
M!C;3)#0J#Y?-(4O&+R[Q^=Z=-[Z#EXE>LDNEXKPI/0K]DCB6"-J332E4SF#L
MR5SI[J%9!:8^ZXUS3GV<E#)X,V.N-G9-:RPPE852E1MF[G\#9B?@G=S+)*-
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MRBWD8::7+DE]#.JA,_K&I2X]XJ(KO VQ@\%*-!HY=6D<FK>EF.F4_"%@L\N
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MF.@=%@J#&Q(\"3(0.1J2FPLTE@2IC%ET#;892;R.-9K!: :"_J%0K G-=W=
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MY7FFP8)YD5QAR3\\N\3^=G6*\TYF&PE86^O ?=^\M1#8<KOK#]9/+A&UT]T
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M5:UQ/VJ44Z.<%HGG+R\&Q%$"2$8^6(&BSP A*Z@SQ!1WX,L/X%>IOLGK";
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MKCB\Q$9R&LDI832(S!]9ST=E/NZE67,VD%_ZDF^^O#!;S.W^9?@ IG)]-\P
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MKJK.3VI$[4T=:+F'J5MHA*U9M0YX<66ZL::ZV)]D>5!.H7]Y1R"OD:2>/5H
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M/#8E'IWHG#=(I]7IKAQ/W0"C%[>B.YB([&X,>+(WEM@1VSNA87ZB.ZC:/"M
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M+FAT;>U;;7/;N!'^W/L5:&YRM6=$6:]Q(JF>T3ERZVDOOG%\,]>/( %*J$&
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MHA<.RN&9BJ20%(,@;,LKL<C 8$3(YY;34/@KYB@(#PS&<[9%7#H2;@?"Q0=
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MEDH&2URKH.U1!W.>?"8M7-T[YQZX.4EZF%TOVA-A?J$0>X6A>_9TN!(,'YO
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MV/U,F^"N(]P)? -FF.FQ$48NU+^"^=0*\KQPULAX?95ZAJ-P5N:!P$.Y,:^
M7Q.9@BU(XK("V] @-Z(N=&3HPCZA-&BV'42O^]$?[/O7[H 3*3G0<26[P@@>
MS,0'2?HVD2B%%'NB8.O*6%I+-BZ(#*,+HS#P"@)#)"ME26UCC(ADR@Y.H??T
M"/4^UZGK*QU'5_##)%$X+*CZ>3U)]L_P^<8>;VWK))Q")C8H<IN=;&PTY-5"
M$L."9L.<A6T?#RZXMK8E#)7(J"KPF9M^BK:)<THQ41>Q<IK#VV$3;*!MW-!>
M,R02=H3.AI[V#]YFIJC44!_4\YV0ZJW#?,?1\^V3;ESDSD3F"B,2>'ZAW>:_
M78#RXR/(Q+7*J@RC<KRXJ,#QR3N!;4[%<(ANE,+QKHVX%='W6R)VW,7G0Y[G
M?FN5JW:H1EDO'X@7X$T%FO*"18D+(YLFC!PEE?2\DL%G(*]2,']R,J<4"9Y.
M,(ACX/ 7)/0\QN?A)=JXD6O9Q-9<-[($9&V[09AZP@-3I*"LP:03KD,: SQ+
M<298W4KIRJ:X;EO!",V<@I^[,%2]/+?<6_UZ0@("1UCK*D6CUV(LP86YW( 9
M_+Y^G>+MXFFN@;7]Y!OIZ^UK8'BE202A6PX;=M.31X$_,"(SH3]#,0*;@?19
MWA'4&;!KHQ)!U\#AACD84IE EQ-^<B9]_D8F(XH3!="R>2JOIPEE96'ZYS"?
M*LLO0,47J=B<X[<>FU:+KR$ FA-E_KWTXRFHS\]"IMUUO.J&+7YR_$/G?7]_
M 8/-C/K[Q((7/K7 3/-/0:@M38/F6\CI#!S7#U,Q!THZ%^E:;.RW!/O[A)VE
M=W\:0]Z,^KMO=7T_:,"/6O4GG_6]^[USG:9ZC0H"?2XT,*;R>BEP6BM.VZ"9
M(:\%6!V<?V)_A@S^'K5L0YW\Y84R/XHCGU/*/1Y<+"8[[D])E$8M,%[; AP$
MJNW\*X)2Q\!F@2!V,T6IYQFMI2%;2^Y5@T!\IKR@Q4UA#9D]GX&#FH(-L;4-
MS23=J^Z/%Y\<GW[_Z.S1TR=/GYS]^/W3I\VR58YSG]+J=RS8F5-G9_7F!KO*
M[S@].>D.>S^BYJTLC:9\"(J53JY2.)GBXRK.8BW NXP5B)V:=E U-0KJ0$/[
M3$/H(UHD( HL4:D'QO"L7+"SEQ-HC$C,>=(AF9$+UT6<49 18T3:+$2N_JA!
M+*6IXK(R!T(\$&(?(<:IL%;-O42KR2TA& /(,@QAZ$)R//E 1 <B^AB-V,3P
MX(>JW!SHYT _V_23X+)\4): 6I:5E\C0GD+EAFFSW*'Y.%:,)I8VT:RRL Q+
MI08SET>)CJY^?OL./+R4$C-YNGEP(+P#X0V;89@\M:6./T0P157:"7X%M",[
MG_*_"&@C\\12&%\34- '%I!2&4%_H^6U5XFW#D3AV\/F?85PED_2.U0J)JA<
M6<>(LC)7.=8V O=,_R&P,"0\V'O,8_ATW(AVZJV,)>S3/9:,(<X,,1.82XA>
MQZ6F,E"N ATM.NAR/G?B^:4HQP 1FH!31%@!W+ 1;927HF\HBWN/5 8#I[*5
MS:<*Q8A<2_0(PDP]%7P@88J=A3;'T3L$S^R2-G412$+;,$)2?N'K,B]!P2B,
M\(Q3>M;H7X<RN&G7O61#!2X016#Q/$G*$.3)?3*3L<AD?PT%(=Z6TC]JI5G5
MV.2>ITN"=)2PGI 96]65C&7P,+A=2V# WLY%DCK92M2/5V9>(T!P9-1$I>,$
M220O#@7!QS$$GP)6]<CD+D8B2WVMP*KG#!^!LF=2Y@U!+P6392I*I&;Z,L Y
MSFADA]YV8**D]E*/'!I]ZRQ@'$4E\UE1E:[>H5UO1-0MKB56#JO$8>G[1B(D
MUEP:XZ&E886:#4K4@)4\H2)H*)>,21)K^):00'ZW>$UA/N_8G^">F^0ZP/.T
MJ:_O9%#R[*3!FGC8BRR,BB4#1<E;7 HCER /*-&*-1 3K$(S,E*EKW>SU>PW
M5Y63"9@1I@AB0LK!_\=5ZD*XA-F!LYX;G3FX:I-/P#354/7W)%RFEW[UM$53
M@RXC^)'*"(3L@&EDM?E_]0_O&>>6ZX^JHE5)NG-SL=+%<_&DUB[>'J&U9.!)
MD3>5Z+C"^;10GRT@+G\HRMX5#P"HMWH 8.EJ3J-Q6P:>EJM#9$79GHE#$![J
M0@,U,BHU.W+KC:O!D-[C+=T'$F1A!/P$N$,*D^.?P'LK2>8X\_@:V"^E.B0@
M<6KC0AQ(,J%$SLE\^XCHYQH\\[:.\/\*O%(9L-Q_]J4(*^U*G^$WB:YF(&!R
MW3^Y0A.S")Q (.9JR$D#^^V4B?-B2/H6E2FT]87F,*A[%"51.L"C2!_!B[;?
M@ZY,*@K[Z3!-&);$M&,J6X&IV@(6/GKRN>C->W#ZVO@K+NQLP:]"V!5%P[NP
M(3Y[_F6Y6[IW3^4\LB(5!AS&BVBF\\HZPRFR.I5HY90#]2@#E5) /%RWT9H2
MC4A*5/!;@$IU6I-L:!<"T<*8=KZAS=C%'OT3)D8+A@![#2>5:2,].^">!N9=
MGCSDTG/8XR;SAJ%M-5=8]D[%M5D#\[[@ _J]PEJFVOR+BA11_&L:U/'2;>:$
M]45RH6**@/OL,(+6>95P+E17S&]SPR./-NJ<Q)&W;#C5O"" /[Y6Q$LE5Q[*
MOV,[6S[@0HN4M2S*-8<+#(8.%_81.Q<=R>/%\83<3V<N^_%;"WS@3Z4M+<-]
MPR/8L1I[T/ECT_D[3FL$*I]PKX[G^@036YS2RMRW4>FQ7/M@:Z[M$QH"5.SC
M0RY;&K0/1NNZ:Z#AO34U0W[VMJE!<I:,XLS;$>\"/X$K) <<!:I%2JW>)2CL
M<?1\IR#))<P+9=%,!EN&F^2<[%[ ,*T RXY\EYJY2G'4>G.#SDZXAKJDDI2/
MQ>SCH?SCJU8H?(G6G!]5"C*]^_/^J/>?W?/[IP'1':I@]J(*YBL5K=Z0MABA
M=7'_.>+:E-CR?%4^I/$M!AV=;>S2,8U=OTO'-D:V&WSGD9%5328.V=,4NL Z
M=Y>E*L2&@Y;.&)]$5I9EZD*-QCD8^A8I+1V#CK:@^.=HH]<9<XIKYDD=#.05
M[XYO!/N7:,G.#0(ZJ'W$SDFTO:-=NQCLB /!^<AA*W5^\"7&QNUCR=AW(H;4
M]6AII/1.,16M$Y-OI,!V>UDF$VPY0LUG060EWAT8"/2_; 73B1C;[4/:.Q'%
M(O=F=(UYHO[ZBN/G])1U9?+4$9>C,NV:B"%)A8MH=:=JGM S(-0Z^NZ#@ .)
M-VHY6/?]T"2(B&EE)R'8ZRF@DX*(U.3 EV/CRUM3\:A8%J@:<8(4OB8-!FKH
M/#H2#SCVB:FJH/]-V#BGW1D'(WA!B,I]J7W?OF[7UE9KHQ([%KFV9\PF<Q=)
M]?]FMO'-."88CB,^9_!LT-7:+INDO'^(6@>Y8.[-O4CZCY$CD4>S8%MP+RI3
M(LIW@5E3O Z@1O)BXR>,300+I6MZV!>VK;G<YOU[W6\'C!>VT@:RYOLM"L.&
MB92BWJ6 MAK IRZCW--K$PDR9!*DT4WOJ.T^BXBZJW-O[8[TK?L;J(N7G^PP
MZL4WX?'60F_G1YX;RQ!&'G1Z/\X\[WF+O_N =G-@_F4!R;F169#/=]G1FH&=
M+*R#I02XGLE6AS7$>UG9;=*5:))I%##DWV Y $,Q! U#_2ZW5LNP'AB/IX)[
MZ(R>;@7]IY6E$!\<*E/"RA30AN,O2FF8Q$B5S< 5E5YDQL+> ((-^DUA0O&B
M">G>1:73@:2V26KV#9"4E?(#$U33L@-%Y4)04::[W\.!.^KXB;R6)E96AI&4
M":;:X1.^[DR&EA(N5#L7S8W/^5"7).6LZ($BOSA%QM\ 18(_@43E38%&U;<
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MIEM7H@E+?'%\4_!ME K_CNVCUQ3WNLJH<76.M;NM_A('0ZG1&LU]NZH=$F+
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MI]6OG[&>H\]*_>#CYZJ$F<6#;\ +=$!EB.Q3>P4/#?S@0.MW0QLT0B)CS7F
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M5@'(\8?TD(N (_I('$FI'P*A 5=,I $;Q7$^*TG$G^OH!I*F\<G& C6++?X
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M$A8.?TT:\D5?Y4<1[&$61 BP).U9);0H>'Q3_3"\Q/&I65RJ6A*GI3"\+K
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MXOSN[JF7">\$*'@M?OZY$^\@)<+Q)C\\Q*M2)TF.C[X_P,,&L<!I*<? T6Q
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M7Y85S2_&29Y:@.35/8=];G^Q-Z>^GHQ\5'*PHP[]V=/9;[# &UZ]\VAPPEL
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M,1T9LIU)PGQ!@9",.[C.E*-E-%9G]7#^Z4-A_,>%DX.ANEVQL@ (3/X_  E
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M]XF4#M(FS9SS6"YSGMO@R97)@MD4KU,\.V0-84>[>A#C4X:TCSJE.-2GUK;
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M!<87<(XRND](^B!G$3&SR:9B36H(Q?^D7#^IY>.5]MZ+;[Y)[6B0OOXF11D
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M8\7YN6(K U#_9"ACI3$QC 3U%$I<.^&%\8QC36)[[?OHI'N6726F9B:1B06
M8M&$J0DT"KTQUAL<21*#)K/B@!,Q&^O45<JNO4;0SUR]%LIL>95I&T4FC;OM
MAQM)/2F2- US W34N5;"*F;]AU4)3% #_38LM3U00A-\H'6LLREVY T_B@!
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M-GH-680-R@M#+KS%ZL*Y+Z0;,\R(,_$YC[M%+$M EC )#FLK$:0D8QH#;JO
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MSCNJ52Q;3XJ@DS-9I^[DO"!-3V"-6?];6;_L/ &Z4H7@B(C\2Z%3S\!Y"92
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M_TL(I8(+KZ3D"Y6E-, +2PRU>O$2D1W4H!.=!M+-R%,4^H%85E;E>TWEPSL
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M@RVZ2^%I#_-)9*=:RNCA2S@*B9"*JBI!"Y*RYP%NIC8JZ1E:*9-":1WA9T0
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M)J 8U/7#W#\J=O8T(75R5E_F:X)3\8:B-[8BL_:)H "Q3^"^>ONB"8164)_
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MY3@22-HHTFZ1'[DLCC]ZF%!<S7E>75Y&"_\PVU(=&:ZT2*H04K@$B%(,T-7
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M'U1G@H0-'VYHN>#4CVI).DFOF?#""BT!W0*)JO^DBJF_IP)T:A]E=I(AK*[
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MR3J<IB!B$,(=A%45:LBK:+*2#:%$8WRRV3[0-3,-G<0@[PH-332ALL^-@7W
M(V(12S<0321/*ZP;B)AH![O8605A<,'=8Y#T&+V8@B"O@Q)!C#@C/ WO2_H
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M<;!;;[EF%CO9_V2=TWU!M!!8WE)13?.;0J(=-VQK0JGXF]1)A1,<L],2S8U
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MCUMQC^>P:TTDI@#*E??97E(R#@.GC7FD!Y[A[TIB%F;!E-?0,T3Z%L01FO@
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M7@1I_.%/5VP2M0"A$]TN?K'N=Q_VYCM_1/1L"#$"G1XRY("'12YR#  P%6(
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M@PE$1[05MR]E95X:,W!$BP'Z_@ Q;((J3P5"@RL>MLPE-ZT1SQFV,575(F+
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M9OO\("7+W7GX=HJ4X6/55C6161K>"#5E[3!F@A9G]SX\<>J:=X#>H3)DM S
MGS)@MROG32#*G8D3$"5$\1H+K7WNP^+>-;9 -F'O7S)F<[B.VG?RK7<<HGD2
M%D-]YVK%R")"3_XZ0H1+^-@<K#-YU?98C]CQT4?(3Z-9KT8D"W<9RQT53987
M&O)NC=F.5SN2 0D^CY7.I\X*F'R3F9L]Q!)+\&&,'P)/;D7/M9Y5<13?[UT8
M!J!_8,QNBWP.<P[\0*9DPD27,5(Y_Q@:U^]Z*X1A ,9\;N&8D8>=>V1KQ4@
M1EC/":)]:F8E]3=O.0^ 9SE2D$@.!U1&]-%V"=3[)$0HO/ +PT37D,C8V@J;
MQUBN$"^8C]39":QD:^-DN]K-,01B4JJD[-37(<08Q'(,R+41US6B<\%>RMUN
M#I;)<>A:P).1;KKE7O9"/'<,.+".T$I0.3H!FKI;44L ^O6 @ND',TAH@\5[
M&SML<A)'; *Y_]9*[#8D=OH\E0^PP*F)G<1V^8Q0-(BM#WS%OP]TZ9'8-<3
MMB-92)YX; ]L^?@V33%+Y@TK68>,M&S]<H&B*%E^3#?E<O$2HZ_=D%Q+N04Y
MTH/&"$:"3/\"D*<NJH\RC:!N+4^A=N!\ &E".4=4S^7<YNH73TZQ587TDF^+
MC8ALS4S"0)"@P&)\/T\E;_^6(;4/K2 [@GB'K[_/#(ZY/+J1S^"PK&<\T,P/
M(O51@6M86IX'_,DG^A 7-X4ZIBNE8[NW$QLVNZ=Z>=CU&@$W(<C>8_'NO'%@
MVXRY;AL#!;/^)BU"# /CDK?0.MA("+KD[J5:[W*XC1QK-0JU;F&^XJN4USC/
M=G-WT0TX#9 ZW_U#: @<S >63X]+(%HG>@?RTC;G6!VLO':R,/+/6/Q2YSY
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MEVV$(XRB1I#L@Z?6O,54C5;?PTE'D'+"CM?@]/^1'C[FMO)$DCCS8M"]C R
MW=/NB-UCG_UD-V&1:JM/)-655?+/*II('X-\*182^W5]*[X)0S]"+Y>4%29[
M\J -B7-) I;OR#?2AV4G05FE:DTNV[Q%9YN<VR1-Q&S6D<YGLR,>F28XFMOB
M\&B0*F#9\A8G>,GJ?AE;IH%>:T+0 ^Z1I%F>R9GGQGEN3]U8>10^RQ@I%/TN
M*$ZA7/X0!<7LN6Y3"*?G7/I2QS=98DT 4Y"^Y. \J (;FFH3UG^2:\X?Q%R
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M7,DZQ/"5$-F57MB!8EF6IU0,Q/ .Q)"$9JD0*M66<,D9 0$ .U!+ P04
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MQ@^#\2-A_&@8/P8&!<"@$!@4!H,B85 T#(J!P0$P. 0&A\'@2!@<#8-C8"@
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M#D9?])!AA=01>X$)=>M _.95J%+NT)H.ST:\:Q0_'._[8E,$;U/R:6.U3!U
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M[D_TA_0 SV3:M- L>9&<^#LB4I,N4UG$# IJ6GZ.\@E"5,/)ED:'Y7GR$?^
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MMS\CSD;STMC/GN>('JMZ#XW\9-]PD?[Y1CZ4.G'E1FGSC#K#'5BJY>ZY@7K
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M]Y4TV28=FQTLXEG5R'^F! 42Z@1W))Q0,:CN,EW>.)4\1=6<O4GLS'FF NK
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M& ,>:NO*5[N9MHW2^9MPGZ@9'KRT7W5C#%LP:X\1:[LXS.4U\75FZHN<L%Q
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M:N45O1E$'T*AA^1Z<2^:38HN1TL?F+*$-T;!KB]6@@KN!'*H,,'D:4"P '?
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MCW%"'R)&O=3*C,]&:S!#J_1+]:HR5V\BK;%$13!)B]+H& M,<M0AVJDR=\]
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M!7&V!]<6:%F XPTT@)&2:+H\EXF$U2PB)8H" U00@Q0_T;;XXL06;C)\:L3
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MY\<97E5")A65Y$8Z% <D@1<(+Q@ZGEB*!3HY/)WZAO&:Q=\0YUOY)A<WZ7N
M1GK(0-KBV&JN=R?(_S"?)*J8=1UGD;$^&_1]*34^ 6*?P($#8P!01G!?)@
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M]UEG35>3G=149J>#P(Y(W2F2PX#W0 A&4((3I& %U2(\961"8VN;44;PHZ;
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M-4O+O QV@*$0.2$2H4V88J9$;&2$C/ &4)P/%!0B4$'-51U.?JZI3V64)L2
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M XZ-R)Q?_"V8]2SE^V4(KLG([K"X;;5$1X8A#]'59A4<(/@!(ZA>.)@63;"
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MJ/(>KK[DD6HYGD'J%DU6V76.W +L^OZIM_PH1(9GJA936 3,\38R>G3RY?^
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MXY#7,3,$E!)NH1'^BS*(H1$:H8?MA1AN +9B  T^!+8\0QG&V30 X 8N9!(
M(!/JN#36N9W)B!@ ( 4[!)X7XXX?0U:EUN6T P/5B^VRL7UQMI$B2V#MXONV
MZFR=UV__02%D)]E" U=9G3=PEW7\,'.&JD0^-*I^1'"7B6ZJ;#0FG Y;12(9
MVJ&)%6(>@N&4GS@E@L%1DR$EZ<;(3/1Q0PF>@&]!8M)DR*-'WW4D0,9$<+!)
MZB$XRS$LVR2$O>\1]^HS6Q S^),>&L$7&J$7BJ$RL/D6**$70D09)F&;'R,3
MOMF; 2 &,"03ZED@S)DSRIG;T,":.4,,V/E"T(">*06ND=*NU7HQTAIVH(&M
M-V2O\?E"8"Y4;75SRH=N&^[!5.G1;&2%'K<U&[85A]61+UNBV10S0_:1=R62
MA?,A)?I--3I-L!K.S.N')\HN'7?A2F@ *P*5S5<AUI<>D*$=_YR80N9!&"IJ
M'^1!030.I?)R>-3-L8YDS@3B0S=I#"8!JH'7E9 ST)0A93_VC*[5E[IK,KT2
M\L[OC1F#&'J!$MR!JRFA$6XAK-^"&*C9$7H!%XAA$GSAO.$+MM)9,[R9OA=C
MK@&@SV"+0MPZGC61OQ4BL#5CGA5MG?,Y51$<D^8[)\8ZG"7EP$O#K7&K490A
MO]$YODW#P1T#MA[\,@[\ML1@K6<K!L2 @B8\MFZ@A\<:G8-Z$F(@MDQ\).SZ
MOS5DPQ5#P;U;J0G)*]\IV*1);=+O)1)":09E8>E!6!EY>BTT+:MWHHM563G;
MD4F[2C0F)]$.9ZE5M*Z\7)^/00!DN_]DQ(GG01Z"ZGP%(A^.6*:181Z081^&
M0<RU\R4?;&?,A==4;LX5\V;(0^%^2"/\C!A24G4=F5]]XK?3"6Z5['5;XY5J
MU[NS>:O3NZHG 1<R/,VRV1>&P1$F@9H; 1<BX\(M?23N.2+FVL,38\)%_"4&
M6R%,'>?&S:T3G)S9>JS/VC-N'#1"_276F:\?I=8S@\9C)@9N0 QB ,;1^0:X
M@-@9A<6'_=A%731XW3%@/*XI(Q-N(-EO8 7FN]AOH)[)FMA3/,VX/0:V'0!4
M?<%A"]U7),6/?=SF^;XU1-IQO+##VM[L$,/V2'GBZ"7RT3Z)><28UV\S 62/
MI61;>!$7+Y+_R=BAPZ*BGQ>T%T^3..DHRD;'!J^\>(IO;F4$"Q-5DOB)@R&*
M69H>HG@?5GE%V)<>5GH?R)P=BGCEW]7UEJU_A-2NA(R#1;(EQXZTSXZ;(&*K
MO(B%J=OS?"F0CVQ)FY2EIC8E(R,3IQH7.)VJW]L1J!DRZ&&:N;JJJWJ]&R$R
M#.#<[SHRYETR''S !6*N:WRLUUT2@?#L,:/ 2V.NJYTSP'ZN>WT?R/YU]/XM
M8OU1_%LANIGN+83O+V3M<P*VK)G%5Z F_%X@[%J_7\*;U]G6$R0&_DL9['XD
M GQ#"A_Q+V12@0)41^\*6]3M\*M0U8* "&5=M"XB8[%9&%G)'9XL_S^[. U^
M]A<O9-&2LWD1#9_BK'R&CH1OY@],9T:IRX#:1]E<&/1!E3^"'6"Z^05BI5GB
MS/5!&-A!&8)!'HH8&5[(HS 6;_)2K?S\GTSP*N*Z/L^OZ2GTX)7TM'E9+[+)
MOJ*A7TP[FALC&JJ:JJT:(!SU(M:HD:]]"!,J7+AO6:-;DWQ-PC7I5B-BMX@Q
MW+@P$P TQ  8X$@R(1H DTJJW+<"0+T8 #(QA*E,(4R-*W.N! !@9T^=0!$J
MXQFT*$.B1HMZ!"F2X4F92:-*G1IT$DJ=(7]2W:H40 RN8#D^#;OUY(V-/&LJ
M''H58=:%,,5T!"!FZ-F28@#<39@7*EFI8_]W_BVJ=E^]?= .+]2WL%ZTA(H1
M/E;XF#'"R(X9ZZNW;%_-SI\W+U.VC-[H9<1.*U-&C)@F8LI>@R(V.Y-KU\,T
M:<JMV_7K3+&#WZ9].[BFV+=?*Q]#9@SS,6F::R+)N)YEA/0N)^R\;_)D[HPG
M=]=>.6%VZPBK[],G3)B\9/3D!=,G3QB[><D2KA.V?IX^9?3@QPY[[.S#SC#[
M)&-9=NM-!HUAZRG&('J+C5?/@XI=EYUX"'&'D";.,9?&&&HXIXQXC]6S&FDJ
M*4?<BJ.9YAEDZTFFT(6.J3AC:0VIN!J'6VF54SW$]-*((Q!1A%$CO>BT3"^X
M&-2+0$?VX@LE2>7_I5%:"UFUVDD\^6453V3^9)5?)0WUE4=[)70# #CMXU$,
M#ZJDS"0&\!1#2@KI)2=,=!56)IE0(8404<0 6A=#F;S)DQAH"@5F3&\)Y>=:
M>?%T0YP(30+H#84QQ!9#T'A*YJ)]?@5FI MIN0^7"EF%QCZ9QC KIGK>"I0R
MF>H5*32]EJD6KV3>@*9="0TU*YX\Z<I7GG0]..:@=AJ:4": &B!7GP"$.FI1
MM>IJ[49S<O1FI-]:10RP/*UP[+AL+D2,HW3A)&M'V:**T)N%O>E9IIM&9=57
M1\')*$]U?IN056V^VA.R)3'<)5TD*;L/F ;PB>VCC/8*:JS=$@-MIQ\E QOF
M4?^#!<5=G0EY9]AC]' 8WDK19%9S8HDM4UHT,5O'XS+ZC$;:BK"-UIIRLRD7
M6VZT[=:;B[LE[:)MLA%C6]),RS;,;%QG\EQTSDF7[&7ZI-BRC>-MEAZ$:C=F
MWMJ0 3G>0O0$PXXPZR23=SO($ A?,O,$DYU]^LRCC#S(&'A,W?G0PTY^]"0.
MX4(N,W08AG!OY*%Z->[#X#XE-O<<<Y0H=MAJIZGDFG%%HSZC0AB:G5!B.P:-
M8V*K%1,J5T+FM(PO1E)RB_!7%L0I1_KX8KSPPALD45+?YK6M270]"JC&-\ 4
MPPTW;'L2GRKUY1E/D>W;K3(WM$2P2AX!L$+VS:;ZYO;_9+KYJ1@QJ&7MHR+U
M&FJMZ>.8R:SG%4.%9'IRTA/\8D(]O0"*)!);2$OTTBLT.= K>ZH84J2WD),
M3%$#I!\#=0*F[0$J3FS9W@2W=Y@2+C!.!TS( ?7T*9L04"Z-TA[W$+B12EE*
M4[7BEK?&5:UN_0N'%"M)5GA(LA7,Q7O5HPNTP.=#DK4)@)HB&?AH!40R%88F
M"8$)F.BU.YU8A8D.*Z/#<%+%BUW*?!J)84G>Q,-R<62&&.3))/(BPO7MXWYD
MBLSW^*?%'SHK(;U+V9 D@Y[#?,YR)7&,86@G(V7<SCHUNUF.<%<:H:DF.<0Y
MSG&HAARDN>83KT&E:VP#'%&R_RYIQF&=TUQ#B;"%;4184DF*JF,9Q<A-(=69
MS"/?EI[#1.,ZE\,.,O+&CF#8;1^"T\=^Z@--_K C<?69Q]WF89]@M -PP4C0
M/! "'^VHIVUJ.>;D)H.9LAT&F36JV49"-R(2.2<-:Q&:2J!!'*JE9D4Z\M#D
M9D>CT#@F9CT;FAJGDLB5*,,7RK-(+RAAI8(<I"3*8Y+RC"00BD;%(]M2&$+:
MES^$@ ED6]S'O7RB%IA$2DML\2+[/C926#FL+0ZS8"+W=S*$:&]A-FU?G.AX
MK?I9:GTA*6E-?Z(P9?BQ@S@UGU+=:,1#];0D(/WAQ+Q2U!%^;V$IQ8L86):7
MD2"$@_\F32*MQLJ7IAQU@%7-BEKB-=+I626L'!&I4_W"%K_PA%-M5(E+%0(I
M\85/3ZRRZ1]'2-(ZG52K(%M?^PI#C%LMI:A^-(N;#'96 >[C30TSXQNY=3R?
MEFQ\O8-)(V1X*37AA7P+$6EL94K5)/8U(1FSH5WU-)>4L 6-KU)D46!V-AM]
MSI@W<F?0E@LTT-3L,PWQC(XLR3.>"0U&L#F:++=V&ZQI@I562XYRQ@O*67KW
M-J1TI28F(2+GE(A$"4$GV3(W7^QTB#'<D2?<OM.AC9RG1IQ+1H&<&9]@!,YP
MW Q<X>8C#/P(@S'!D =[@+$. [N''@T6\#B[<QW*T B8OMS_S"]=%IE="B5$
MHGL.,1ZCT)4D)S@KTEU#VE9=^ZYS1SVC77,!^I>&.A2BDT#21 @"D=(F)*-7
M&MY#)MJDJ(#1JF@:V$)L^E64NOB-[8-+5?]%Q)4\.:<*.8D?B<C3=U7UKZUJ
MK6*S[)8WONEX;Q[?4TGRIBW*EB4C=!A>9[+EJZJ4JX1-XF#!8J@O.ZPD!GQC
M&V'"IS-RY*Y8Z7*@P:?8.Y.$S3;T,4.FE<'-ZDIA4A9BFWOGP;:R*JV4WJE6
M^!5&M>XCL#G1;,'46.=1!QH +/.*6D(26C$L4%_<(DD;X]?6/2=P+X\-,TJ@
MT1(C'TJX0!GF0%6"GIH%+;H[F^XD_W%4$TU*=VBJT1URDN::9(BRW%"336\R
M\1O<."TXK83WZM3+NN2,+L5D")7<9/>RXFY$;3.;MF5F=FW$L -SR1B&9>8Q
MCV5Z$QH5;O!ZW,/-NC4S< .J6S<K++CZ[&<_FEN/ASX7S/@"DVS$]=S),;D6
M,HS(Y<TID49\5#Z.N+(X0ZMNS!A2N0C-^*"@:0@]2 .;'D>%&!'AJ)$D$B4U
M$H1)&*F(080GT*"(U-% 36F<279(CVC,A-GS2ZT1N>7/<K;5?,J>VN>\V3B-
MB]?!GK*0B#C8.W^+KJS5"L0<MCVU9XI/CUIHH)T5:H7@7=*S%1+6:]IUM[;O
MU$DI=-D1?_]H2^UE[UPWY$96ZE#*)U!<9W^UYP/=:T"/%.PQ.!:G6>O$FNY6
MZYR5;037^.BVI%#M7' 43EQEOMV-?O.F)^U&QOY;$>:YRG(N6)G0B.:-8)[V
M10VMR?;B]4U_9- <T32T*>=OGB,D8=WIY+65L1G:?09'/#OHCE"W(O:SIKOH
M?O'4OEM>J<5&E%";M_ZG5DKNQN:>S0$V:E 8G\,@CR1/R*0V//-AD&$9QV0Z
M#.AS&'8=W/0?=4,/[+$.]  XZX , 8)QR, .\M%,%29@$98,[]%,];&" 6(A
M_\9]-6),$.@V#%%P$4@,HX-B:O ?*^9B4.-^]= SR06!QU5=Z%?_29XA-#T8
M%MJG.L.3)!0548XP3$B'"\6C/ (A$347%*4V0(41&*U6&&<"57PR*7I$=BS#
M10C$:B!S%O4P*$*2";Z6>S8U+D.!0&0V=XE4:TDE*DBQ>) E>M,#AV6"$S%E
M+"7!:,H65HOW>UWX0U\85:C55LTB>!#D:R+45M.#5@N#B8["6M,#=R#C%^T3
M*,H&>0P16$BG=BWA5V5G:>;B:IV%)F8HB21C>K#2$I&84D_61K.'>&,H>H0H
M>?T2>I57%(!(=FJDB,)()GO",JX%BB3!3[PE=PLEBLK8AFLQ"=F#/VH%:1,#
M*);8A-NW$@7G,YX3=#VC29W17#@R?C.F_QJD,73AQAKJ!1M*,TKN5C6:  JY
M 5Y.PTI:PS7:U5W^]QK$,1NK,0FA8TMCP"EF4SD,@DQI^#;J-#?:<38%MR"%
MP1[Z@&'<U($7IP^/LQ_Z8#?!D Q\HX+.% P<-P\5-D[+A#>"$PR)@Q_ U!EM
MHQ@Z>1@9 DSBL3NTHU\?UF$@XE[V- :4,!HKP4^B9&ZPP1HL4A.%\1CEL6\X
M C0']5S@!B!,.!5(!U%,X@@1(1&W(![TT#P$45%,YFPZH2FYIW97Q7F=%2?@
M"%2'=#  D'NY%P,CTU;'4WC.-T&#XG:]TX=D5S!QIQ!O,BO1J!"5(IC":#+K
MHU@<L3'!MQ!CE_]YX9B8/G$#<2E"8B*)5:0,:#!!J*B7<#A !L %T%(8I4@M
M;S6;6;>-(%1(.2%;]%(FJ098O]=9<V9H0#%9:247(G59@6:(\(*+FK92L-AV
M;>5[Y A\TM=\UAB(3N$5:K= V3.-9RA\SI>9UOEGZU.+U?AG>>EUR886Y;@2
M$C))T74Z.,:.,X*$H;$,%U(:"B4T/J)0_Z1=^2=*O.$;O]%NO0$*IJ0TH;0Z
MK;2@_(@<[*<)*?9>8S =)@<W)=8R-7>1'-)('$9,C3$9&X8=#[8@=H,,^!%A
M+DF3ZZ />H.2%39-SA0XV=%,*"D/[# X).$R'38WF,& [G2AV'&5OM3_$ V)
M8A6:$_O7.J,14 KQ7QG9'=E!73D&=/LY-%L8>5-!)!?!) 41$54B%(X =05A
M41)1#& YC.U2FXRY9<A',JFY6&KJ%\+YB!L1%\4H*+V#>7FXF G1;),X%S\A
M:P/$6GLQGFGRG0RQF7\66H\X>EDQC*WW9Y%B1VDVG:@U"7JZ6:;R$87!%IKJ
MF:*W%W)$/7A%G']F;/)B+7QDESC%AMAY6 W#%I:(:%4U*F]ZE[TGJL69C1M1
M9;!F0U]DC+\)5=59=DN5=R01+(0H>,S(JZO*0XK5A4(U+&\$AJ:Z6-+W;.V9
M5Z01-$;(7(FA2>':7,L%=*;A?I[D?KIC-$93_S6W\0FT\8^^$5[^>&[KAEX%
M6DKPEX]6\TI,XY^B,[ DXB$^22,+4I09>;#D$5\06!X_:1[Y\7W-M$W.5!_9
ML8$%UDTHR;$<MZ(D"3AXLTPH* S0<$V?HQ;O9!B]U!T1ZR 0PC)9NG,<02'U
M\'))62)9>B/DYDI#LX[2YK(8:4P(1:Z5])_75:LY@:E*=!$481"3L"0'X0L6
MX0L"<;53$K1!052)-U>2N'6?-S&JRA85J8;0.7BVFF:&N:IMTJ=D9V;ZDV>]
M&JA=-7V:"!1TB;9UJV6NN!)<NQ:PXA$KD(9_*W<Z\9A6A4C;FGR+N7>(&[;#
MQUG(V7E"<BZ&=UIFM_]%F+82@IMFD')65F=3+F5HNFIVAOD_;R1&EXE3?L80
MO&=VTID4DFE5I:6HSQF>BTMVSA*LC$MVG!)!=(F-I8N>5I67W-JMJ?BM[6@[
M.'-)\YDC.Z90\[B?42EN2OA^QQ%*I41>!5JO]*<)\KIN+D)N\CH;X8L<5Y,<
M4-E^0_->)0(V::"3<Z-./><Y5TE? T<C*-*RE<$=%#).AW%P=\,8(6DWC6-A
MZP ,(X@,\N!QSA2C=M,>]4%APF!@&!=APC!,F).1 R>#G',C$!ND" L>XL$8
M1YF#9&"A%3.0K4,:YAHW.Y>_WU</!Y65(C:E/K*N5:>E6Z$\8@D\E+!1RF#*
M/),P)15!46X)%)9I6E#$BVZ:F6^:G6@D5U(%FYYW56"RJ8"+A\2JAR/T$F^4
M*5:\92TQ/9,BC4N%)G)85\4(><GX4]_'1WZ:?<C*Q&FE:TO54G[A0]BWJK>:
M*9>QQ*,V+(#<9J$X6JEZ5I\&*V(6:4*BNDL%/HW@5G]F+2=AO*;UJ8'R,(O;
M/9\*$VTBN% LMXLUK)N817DL0[=REUEL>. #J\)I+7U<>\Q7=B0%F<4JB(2E
M+_50R)@E;(BL6,!K>D[UC;88C%EA9/],FS)8REP[DB- 5SOZR7[KZI\Q<EW9
MU5WG1C7<O$KHIFY6P[T-2I#^ZB*E-&X+2LWV>&\AHL)LL["7 22FDR)UPAWR
MJW(1R!$P,[& LP^! S@)UI(R:A\OBI(6[)+ P!\2!L$0#++S( _D-VTHTK#4
M\;(<4;8SN \@XKXA(GC1X*!1J0S%0 \Z5A(&BQ@[$H_HAR/2U<)*BVA@H3Q@
M2@Q4X@O%X,.W$%%(O!6SFZS$FYR0H4 _,;EH0<IOVUE"W;K9J9UZ<G9O%WP
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M152>* .P9F.^Z/&OY9N*IN"W&J(DH4"3N$BR: "9*O0+7"P,9>B%AKH%AH)
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M&"A=K35DPPWD1K9=E,3=0EED']7;YE)F .""1HZ9.SYF32245&QD@<!F2MG
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M0(<U;-N-@3"#%8B)(2T-(AD:3.,7[@!@!>8JH8CT@S![H<<MN8F!QL35P>4
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M8J5U$V&)Z^21#-KY;E#2%!ZD&%5<135*(/387552XA  L@ZVZ/P2]?@$OXN
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MQQ8BB&=HC :I"!]&(.>1HOW=":FMCR2!0M^P(BM^ F7)#THP#OKXTOOQ$I]
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M<(?^H<XL_EJ?+.9Z680\0%NC*->F+ I>LN4^X.5B_2)^ZD-#O!.58,HV182
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M$DLF=QFX@1WX/(Z-CNBT580.5@ 3""<&1^]6,$G_!S']=-4*(O-(9<] ^#8
MV$41=6FF2$1(@YDR5D=MR7AC;9Z.IQ7=M2[L(E1+Q)4TZD2J%"]P&"_2*D36
MKE;ZU"6/*"KD0N$$6!.AY,["IHNV(RCW 4/+A P>.(NU>(M%HJCBB(*,U2"T
MM9C*L%D\2.BPRP9?AFOHB9@X)G*P8AEP-?/>CW(^9"OF:4-NXR?H >JF!>F
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M7Y9!0=P(ASA?<RK[$")8A @22)5M;C)KI&E%^Q))9)(S0BJ=8RSW4JI+UEL
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M$L([2+@6('$7Q:86ET*"/!0LXV%>SG(ZT+(,@(*&Q-$1N[<>9^A[8]-=Q$>
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MCR+6"Y=1<A(D>DC%9[EC6E=D@SH8#48QA9F@7F@EP1J)A5/_3=K8KFH'%K9
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M\\KTY8%,CSRJ'+*5LI??K5EONMB17IZX[.M? SO8]6W7>C&$G?VNECB.*DZ
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M./4-$(-3 $ 8 (?H.C4.# -M ( D6#  ]$8:J,!4\\9NB(%36^X%DT=:,RX
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M)(,^X*M^M'1*Q_0MHZU);\(=;((=2,XD(( ,@+T,?/T!L  "K  "E#T+R(
MK+W8A_W;P_W7?[W;RT ,S+W<TSW>N[W>'P#8W[W?^WT,_^R]WY<]V M #+"]
M %RN9(^6F5M'0JQ #"@$>6<";>  @4>#XZ_//MP #.07 !1 Z[]YYT^1I#4"
MS;O7P#6SK3/GJP!"\#EIL+G#[4\\3JN!>V.;%&B!?7SNZ[XG@EA@6++&I$$P
M*=4\C,U"6\1^/.\P'81,>Z^WE(=F \C<KGKU"@,FJ';#<W0PL ,1!S&E9FUQ
M"#'UYH-J"X.+)P/0^WHT?"R/WO(;P,$; (%)]_(]'DM&G-[LJ-MA0^FW:_ON
M @0Q4,2(*2,X4%/!A,H6-C284*&R?1,I5J08S>*^:/J6Q8A13Z(R &CV210#
M@%A) &)*Q@!0<M\RCOI6QN2(!B7':/0 _\2(-@DEM'K13F:*B5-9O7TUE9VT
MV1' ,HT9+0X=2F^GS:0SI4J4*16KLF7*R!:D>A9M6K5KV;9U^Q9N7+ESZ=:U
M>Q=O7KU[^?;U^Q=P8,&#"1<V?!AQ1H;$$FJ:1&9,&LB0QY!)25'I/GH3Z26;
MND\?1:D7)V;>3-$S:(PQ06V" T<3'%!C=RZ+!@H4Q5!OELV#HR_8.DV9,F$:
M)BP9O7G"Y@73UWQ>LGG(EFL&ECQX\&%PAB5KAZPSJ%#0-(%Z ^<-D")P0H6*
M(S9:4M29XVHB(WF,FLICQB0<N)@A@Q *L+&!!/)/((42U&0QA!@CD)C1]H$F
MK<PDG @ '/392?\3 #2A1RH< -B0F)&DN@$ L4J:9)\2)_EJ'Z R 2L- (R2
M<9EZ,@$@19, &*I$-(8ZB:Q]3E(A*XM6JX@CK+"J1ZB=HK$J2GJNJHT>98IA
MZ,+$O/P2S##%')/,,LT\$\TTU5R333/)8C 3ROB+##)-*#KMLXGFV4RI*4,K
M#32E-F12,SSIJRB:^& #11B)Q*,'$ZS@@&:[>=9Y@S=A@F$GF F;4TX8X#B=
MAU-]]$EF'7:062>88(0!)1,XA!&&4TU"42:46,_[X0<@0@$E#CMBD@@FS>8!
M],]D)U*6(DIRV(_.RA ,\,$$JS7P/VL3!+"A!!W4)!E-_MPGLXVFPDK_M4 I
M$DF2'*.1)$68  @CQQV)X0@H%= XB209GQ(IADPT.8DE@WB4Y"27R(T&@!M*
MVE'<9>"-(0V78,"AHGHXTBRFC-P%4;,IA7K2JXV_(LN@R]I<F>6677X9YIAE
MGIGFFFUV"QK&^)L,6CL15;<BS\9E<LEE^Q34,PF)I0HW6>F!0YGXIH-:$TSF
M&8ZY9)(1)I-V]IFG.614Y7335MD99AUAY$GF[#<R<?N3-^IXXQ/90+DMO5XK
M  *4.^+P>2+Q?$XFM-4R&VKAQ!&?B!+^]),S#0:KE7Q ;@5D+*+&'EKLDX.&
MV38A"<T]O*J)EBS1J)U$?'(I,21"*L=]T @ _P 8TD@*)R=%)L:EGC*)<I\=
M&^8]!GD9F1)>%8WDT74 )/G9HHTIXJJDJ[J"R2LGQQ(KP)N]_Q[\\,4?G_SR
MS3_?K?W2R&]GP#EF4D)ZT.W3T(FZ7%?9^*3B"!1--L%M+'< UZ\8,X],V $.
MF0@&L)"#B7:$*QAB8QNM@M$<5F5''L )QF:X-JM,Z&,8PX!&*&03A_:$0A,_
ML$ %X+ )$MZ!/;:R5?PD\J<E#8U)F8&&G-@'&4IX2T$*DMP0@?@?!@UQ<PA:
M4)$ 93K0:.10Y!I4QDHC)73%A'Y2:B(5.2:3CM4#2B"QGTK2<*6G2'$9%++*
ME"J"IZ)5!"PBNU(8V1,8DH6!J"QF0=\>^=A'/_X1D($4_V3X[+,^RD"FC$_,
MDX3TD9GD+$LTD 3:TN9!'POEQB+# !9N0!&U:)#0#G' !-?@X(EA9&(8Y]&4
M.I#Q-;65C57K0)6F. 6:["B0';-ZS3#VT1KQG.)7+A0/#%]C!-$1:T]-;"1F
M_H2G.^E'/Y597W\*<A @EL6(!J'6Y)*XN0<I<6D+^Q-]U$BA+1**C5(1HY,P
M\Q:90.EZ.1+*CGYW%3%^I38PT1V@,*(QI8PFG#:YBD!KPY$KX3%" WGC(!G:
M4(<^%*(1E2@@B3$G1$)&#5P\S=!6\YQV*O)"2QK*L3)2C];HCS.AT42BH*0,
M\9!P.W;X!&[.@[9@R",XPH@E,O^RDU-6@4T8KG35K) A,#58  Z!<Z&MV@,L
M.,0!%,74!#3$,D/0$"LTH\'(H!9G+HI4%%H].Z(VCW@M:U(N(@\:QEBY^<VE
MF;-/'R6-$_&R4+0\20QAR 0Q:G0#,&[,BG&\I_0FHL;H*:9Z^4R*E,*XL:1P
M3YL3E>QD*5M9RUX6LWR)!L_PPY_+;%6DIB-=2:YH5Z--KX;[&\ML8H-"<\YC
M&;F)C_Y>BL!@\%(?[(#5*&?EJNGDDAW N. %?\NVX.#T:4  PAO4 (&DQH0]
M=MA$*$D852 8X3Q&D,VOHC:6*Y:.BXO;QR9VAA_)3 *MDB-K-Y>(1&LUB)L0
MX2*@S G_174M4R+B?<OH$B<5TTYH$@?@$0R$5+)E@"R>C60L%P>UFM%<:(Y5
M\I-4XDF6L3 HLQG6\(8YW&$/EZ\1[%,?&0#GS,]H3)*@.1:*Z3>1<#;3Q%U:
MAB;^%I^5AJ5_=A"< .4AC! &(QY;FY5.=5K!G.)4':W:DY&S0^3T6. ':C "
M$%8:U:9NPE%P4*X:E$ME."I#'Z=A\;B8E>)]:.)9.VM?M0C4YFJJUZUE'5#F
MNKDD<WDU,^.R:VB&LDPEB?-Z?1I4LOY9H73"1"83-FB5O!C)J0B*/AQ]DE!@
MM%@0+1J/*?OOASG=:4]_&M2AGHLFHAE6][5SHQ[C3&K,W$2 _PYMM;>R2# [
M>1N7UNT-38T#>H1QC%&Q2CJH:A6KJ+./86_P.?00[K'7<:DNI\$(VH5-:+K;
MRV)VV0BA&$IL1_/(SSAXC!,ZG%<;%\U2(RA;DJ.S6ZV95@@Q:*W;;*=2Q-O/
M?E9QKN5"]#+]#%X+23)*A\*([G0G1DL_Q62$BN)%1BO&,"9VTF'<WH47+FJ+
M7QSC&=>X9)5Q2$/F)\\=R]/B1C.T>6QHM!2IKYZ@.$76A *'LX%&)\V#GA^P
M)UBTS*4LE;WSX*QJ4\PI<G"VEIUE%UT86H:#$=1PGD\L![8E"<5UWS!E(-AM
M+!>BQ[A8K,AS-A&LAY1F-:]9ULM1"_];UC*0>M6]K3^?=GJ%/:T.2X/#U=Q;
M(R:V\Z$*M_"O*"6_5IR25QX.F@NA_%PJ7Q?V]AU&H<0D2\NH9D W7GG+7Q[S
MF9=9XT1,F1J2BU"*S/-HRN6UBRBXWZ=)!HKEN@PXE'P?OXIM;'9U=?'$H3C*
M@(8PD$%!G%ZP;-GAU'"%"PQ.Y;(XL$K#TH%0AV("5"-;1L_5R16*N%.D'4+!
M(;+@:,.)D%?$TZ3$0+)%_LRE%:V7,S^$^K<8!DFHZWFW+[[E#OJ]S_?QGVFT
M,]D(^O=1,7L8J]**I71NB.%4;;'JX2L,:O!*8GNZ1_,B4 (GD (K$# T 5KN
M@S\V8:[\;''_MF]"[N3SJ((^Y*>=_J1_7L,.X(,8[.!6HHJY] ;G[*#(:*6W
M@D&XC(M5R&:XAFY4Q(8YUH$>,B$9E$$-ENX(E2MJ6@0(>D7IC(!89@,S5@,:
M3J.?S,FK!B[T0".:>*9.%$2;M@6(0 >^T"]ELBE!["Y/#C#?XB[/_$0C0)#K
MVFBNL#"*Y(BQJD2@NF^K_LW_MLB.%I#"J >R)$]E+! 1$U$1%]$"Z\'<U"RC
MSJ)HXDK,MBB9_I#NXG!I'.SU[$ J8/" ;$5P?J "2)%O7"B!,"&7,.$-1JG9
MAJ''UN$ZY&'9LJ,=@.&F-&4><&K)1FDBKBW*KDLIIDP->N6ZHFHT6#II>ARI
MI)HHBNBM(A!)FAP'[=1.#*O1W=P+K28G0E8.]#8##I\H_OJ.KNAJW/BL_^Z.
MKOIM]'!(8W)D8T!FL4Q'[S+"JU9.#_.+TA0,1#(-PQ@1( -2( ?_LM,F(:RB
M:1E#1HHXPQZ'QIRJ<"HV9FB4XN08,G FPDZB01.N2S;N0#R6X11>X^I<*)28
M;S@PH<FH8SEB*1@>2!:S@R591:=6!3G6H9<R 0VT[.J42Q,V\NHL@"<5!9.X
M;0DY8\7(S(D*)UWBD"(P4.R^D%JBDMW2+HGHS.SF;"#B2A*UDJ[Z#VA(9Q)#
MKQ(YQG 6Z@X9#T9($%D01\S"\L"FI"L&JM+(8DLTX7X($B_S4B_WLH\ZSG%Z
M!GHR1AW',O\<R<0>#37*L2DU$C:Z[!/_)Q26X80\,@Z(";M^@,A6Z=APL8)^
M;]@X,VTN2%6:@QV608%.:<JTZ^JT3,IT_\ (5HH8HL'UH*9/2&\B4L/._(]T
M6.\/G7*:\ .MLHGMUHL,K[&:'.1RTE!0TD+!(.W/E%)9&NW.$H<I38NK,,*K
M$"LC^ 0[E3(P__"=!,_QK >R"((OSQ,]TU,]9Z8+YV0,* 'N+++5-DU/ZN=/
M*,0$3>-GN RIN P(IJ1O1!&%8.@..+*8$B@5-<55U&$72*55@B')AH]L8#+H
M@$U3-&$=)('IIDPD1;+:2B(:7"@[Q\4$I2CD6BT32T+-*$,-?B@,I5(XSVX;
M^^>:BLB:TG(MV*B<[$_?U/(/=;.*4"_2 .4NJ<( P5+,!NV&KL? K*<D(.L?
MUU-*IY1*J]0P*O]* WMH$QF2"G63S^"NST /&N:A2TE''T:0*3-#&;I,RWHE
M<((E#H+E?SI4N61EE)1!&';!5<A&55BE''"0.8(!599M^&9I;=BA)/2A492!
M-5G3SX@E/GI)/OR/6 A',;5*8^YN#L=K3CJK/\PO%(X3#">OK6"4(*A%W=)N
M+,ZHWXST1X%&G>RKHV95\>PQDKCN2]7RBHH4O"HB*2A-,P2Q>BSL5*W46(\5
M69/5+:(A ^<$<)93KIAR>ACIG)3C[?:!U8#T(C9R;W12-MAC'S3)3EX##HSQ
M#=(@5)KCMA0H.$0E&=2!@I8L-,VF50[5;/XD.EQO-:E/--)I&203DHK_)DL2
M4ASE:D@G C\NZCU)M1K?Q,T:EJW6+SC?ZU3#4U;1(BO$BUG&R7"VZ&@^BCZZ
M5.1(+THV%2[H"/ 0+60V [(@4%E?%F9CEDJ)00-K-@U&8^5@3UN[1+^69!XF
ME?6L54Q/KR) H4Z7[C4VX4^*4!.0JNJ4*Q.4X0W@9)2"*VTX13E\*OC4=;B"
M3Y94;C-TLE?4H)_*C  M24]RU0 SANN69!DBHUDUH1C6#\LBQ"%$54;#$,XF
M5E3;#W/( DK>YS!-1\]"-G%R-2(_<%FVJOZ@\?J^2S$KXO$,:Q+5*+ 0SET4
MD%BC5&8[UW,_EQ&5P:+43&52KF,X:FBF:*/T_ZTB.Q;,2F>9LFXLF$^[JFXH
MPV7+SF.YF$-6F.SXKF,Y*B@9A.N56'+X8,EL,H++TH-?/XJCQ'&*E %/_ QG
MZR\<68_SHB4-U(!4T; :O=<A)A9 QI J(6(AQ@)QXB]CZHM7#6ODYF]QR,G1
M_"UZO%*=U&AC+#?BM.]C=L+"\H@^05> !YB 0XUF'S$_J,*<["Y7/1!Z^LW;
M***22L,;-6(L2&@3-O(\1-(NSVS+BF UE2&7E&$8+*BG?HY5]D$>)I13:M S
M764=GF-65N\7@2 )X4!0[$I]+1(WS<QT%\HOQ:X_V"H,.ZD@ML1NB=-4\58,
MT9!R+F=:YA$M]@?TJ,EW"Y>R5W-S"OUOY93R'7]5XAP+C/)0 3O&CK)'+!*D
M@->8C=N8T]Y6S79F:>I'Y!QWBR4)+ &E,Q9WCT^,J_3,*T0R&(% &9+ANGA%
MN3 E%.8!&+C&N(Z-4XA7'B1"%F-)4]9A;<H&ISI%3U0E^]IT;+E/G;P*4C,B
MF?P0A\+L3M80 T6L,B;!(&;,I;9E;FLT5*,R8JO1O="P?,^0S?+K++H*C^]M
MM*3G(1>2W@HG6<QR2IXD*P9P +<"'K^"=;JB//7(C;-9F[?_.:*(X7'61S+2
M8*X:+>[PK+Z\. 2]CD19C:2\[E5C*W"N[;JN+CW4P#]?0QCJYI(S(1IN<1UH
ML@=SZ]B" QCFP:8JR)*G1SJ>1@<ZM+Y.=%F.Y33 ,3/(U.X$!2S<%^Z,T*(,
MJ3Q>%(FSY4431/(&0O*V22HA-JV,Z/P@A"Q8AX)]N*.<B$+P+EHCUW051\+H
MR$H8R\#.*!";I#:TY$VXV:B/&JGW2'1'%S)*+HJ6IN*TM9WP;DF4HS>@VB(,
M:UPD<W:93NDV,@V4ZW9FC)1P21A&214!FEY?B7A36!^6[9(WA=7JX>24#@X:
M>JZFNAWV+.^2]%7[&#'SQ"GCF'O1_PZ7VVPX:[3\FOA49]2:<%E!*F?^QBA,
M^8G!P$VT[(L<U9&95K8!?SI[@!HM4W8NRX)SDQJU4UNU7X9FS0LR6$0M!"VF
ME[,/LQ./F:0B#]<F+$)"[$2V=HTGE0X3TD Z?D<9BNHU]E0ZAJW(7M)XE6P?
MV@&&?2H9>LP*YX'+.M0Y^:R^VCG<_,_;;F@U2C35Y%-A@5,A3CHB3IJHSXYA
M[3*])T^]P#=OS2I5_Q8$^6F<_B^*-M9YH=7^0/2@X'+1(NP=)0YS"YQ[+FRU
M&]S!']Q,F+4]*X-8<KCKYK!H;)J^Z*/1""O%T#:=[8="_A4T7(-#KTX?4L6
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M39U'GQ@9&D'25T-#E4@BK92ZOFJ/4"V.HN0HRIS/\29A#QN=!Z$VNT9V)\W
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M!*D9-WK(A'G0B,1P#T4:CM[B,L*:"=>)GV<QB61H!V1HA]X:AE4#EOD*%8+
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M!L2R^JN'AM'7Y\]Z>;(@VN2FMXU<0>'7TNBU G:]*VH(.T6H?8CVJ83:B6)
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M(:)IE%9I643*J2< HJ<&7;1JPE^P9D_00YZQ*(U(Z9 JP[)Z:RC$)OLF*QS
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M2@WEMV-7-,FFSRZM>A%_111)A3"Q,7!9IB=2%7V\E( +R( -V$7_TS<8GV-
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MK"Y&K%#7$SGKBWYF8F^(<GMF>T<!"J#ZOLZI'M':M2S)G)Y[ESU4@U-W1\M
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M[_5N[_>.[_FN[_O.[_W.%P$! #M02P,$%     @ 7();6+3<##3G@P  /KX
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MU-:UM7=T=G7W]/8-CXR.C4],?IU:7%I>65U;W]C<@N]_/S@\.D:<G)[KA0/
MP_GKYV_J18G5"Q<?'P^?Z%PO'%RO\P<H\0FNB!)>5M0B>N!"Q2$61$Q]*SZK
MHO4"YW5M&,U#UR$26B[Q16[XN6H_-/O[% O^IS3[0[$_]9H"D.'A8!</CQ(
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M=PYT8@M:F+ PMRWC+^@6(G\%&"#ZK!+ V"C\7!P;RZZ1\&8'_KWMXIA"#KH
MA &4%V( 98I3!:/@T4T,X/"0[;!TB_P"UIC91#1')RS@^X?DQI.*2M0Z@.PH
MWG^HE2L@2I;(+6Y5C!#&NSJLU+PN$2OD6G"6IMF06 /2*QR'@[>_GT;=!UF!
MVLU%:R;D" IG5=G5S=MXC-X#9 -O/ 6G)R6D2]5"$?=20W=/T.-UEU6<KIBK
MX4T$Q1(\\OXR!<)%U!T=37&(E]E=X(PWR*YE1JMD?"FHJ@ZS" 1QO<QI,/G\
MM._"[?K"@UR.II"B3[8+Z@8F'^'<NU]*A;HSR$J-+!\B*>N;B+;-DQ;2;FWK
MP1S?^OKR)2\9]GJQD[V+GZI)J:P*7Q!)HVG0^B14_(9%D]"MX5!^NP#AX>'8
MA#?,>;V#:[]GRM3Z&^OHX-#PEM3@9NKC?E1KAR2\,NX MZ'^7B/\6VS'5'Y&
M87ONYM;J%?7,/4X8UUFBV4#L[J,&F&0Y&7O*F;0E75'WC5+@\].R5^@+U5"3
MB&1?+X\$L1;*+XK=!>)$.L". 'ZX2I@<DSUMULK5CRZN@Z1)@/)D(HK-Q .D
M@%5[G4&T(%16[>W\)<6BS8]7KE^Y29(@1A(_D3H\X2 GN[0K9UN=\O(NX^U5
M^C6FI G(O$MZ '0]U6;,#P=.V*X8HG<6D.'=)Y?@!E4]&.A3J38&5$OF+>WZ
M+ETMS]XT7O@8-2T8-12<I7QC,_UP(X"Q8EP<)9HU?DC05/>=](*>2^@RWLE$
M8GZD+P1I/+'[U"/RH-9 ^$FX](-]>"O-M@+3L/"!.I?1W%:BG1N1T%%DT&S(
M=,(S?YN;L5;= ==&#W:U!]K3V6),]!H )]$X^ZTWZ(FB#U=.M7)MP9?$&XV_
MJ.WJ3VM_2+Y9K65%*"%OZ"P#CC=4X$@6HEL.2P/[+0H]B7$1@)6\-"BOZ%XW
MSQ/.>TSWBG$/\)WE?='+ 'C<37D;/!%#>$%X)5.6?:&=5K>"F)6F8?D$"_]J
M=81X23^KNO'<D?33A]K#]QIV\2 J6N8NL*[A;KUQ/S67DE;\XV:;]@LM#TL2
MWUG/1_7")O9*T5=,IM@0R64-3>;S=1?OTB.O*[6MY_;#B=JJMG$2#<*I("LM
M/'BC"RZ(\=DO10]L\].4E_;H=X["O[_PRV5]+;_=*SY L:FRD#1[9M@V$<?4
M8_WX4W!94,BDR_!':.\J.$R!-/@)T"KAR??7&2J6.,CK)UK.M=O/I*+%V2Z9
MR5>]*>0:*9S]:*NM4CA@'(8!= <PC(A,]6WK15K?#B<A)5!X'A2DYE*P4>=?
M43LB]#2[64U5H>\A"4.*TU./<GZ8?%A],<)*,ZJM7:DN:DG?:*61YTLO'@8P
M+O\=J\8'"T3(O1'W#0_2DI[QX2>DS"7?!:A&Z(N!L'?>]F>ZMLU3@_ZY59_=
MJKWR]]Z42\ U8GPS_=@K1[ZM1JE:-?6(*JR2N'6!95*ZZPA3\OWD!AV?EF:%
M+<C=Z7L1YM";F#AZ/H;.TK>(081;AZ?,(^4+U%4B+\(^<T9;L7AS32AA !<<
MPX_L21,#@IF.^)ZNWKVHV+K;K0!=G[\DM M>Y(&9?FBG^ 9?_\B+6N<[;@0S
M>G61FG@OP%"EE+F:/CM9'#@W\:.7J4V%O?31$K#=_J39G6>YP"=0YX2>KP"J
M=SC;[UA?]0MT*S"/E^M_Z=96J0'71.>I^8M)E\;18@!ML@O-Y!UT-ZMJC*[>
MB0($W:Z+9?@BW2UO'P4'C"W!O4(+1BMGKX/B(9<ZDE76NE;/9@MK3+<EYB/'
MIU2BRPZ2;!@[-:9[)R4WWM:PY9E,2-![D%NU&W@J<)^Q0-M7V8D[S,C;XS8'
MRMS212L_6$0;XWYR D0YI]L\8C)-4.G?GH(@]GDMX=7!V4&7;R0ODQ0"-*7*
M[VL2.90A<I1A&Z!=M8T%6X4M5\,XTXLNH"&D4JX]3%7RC3]+6_=Q&^S3(5'J
M]S(.7@E03%W?%KQ;X#8#+?PS#AZ32Z!_I+CMI?;'\(_:U<-)E_O++ ;N-BVE
MO=FX<3:9O>CV,7&)(C0;:I(RMC3Y11-P<4G%7/2=VWCU4PE2=>T^V4\,P[X^
MA'J#,/O> /H-1OV<3/MJJ:IK,^J-.>3\>U/UJLOR"M!!/T8>]*7:":[0II<4
M#Z V]ZGD+T;QYE_[AX)%F7\PZ)L0FV7BV2>=SV%Z/_^O(H9;1F._<QGL8W.&
MGS%G+/V2QJ;$XL>=22[T_M#GP!(EXQ]W%%IYCI-C'Q$8\T_\N'-T =A0Z<;.
M/Z3?='XG[KTJ:C7G#8Y^%/3'G1]#,/>05.J5_[CS8XBUF_^'!Q^6$8SH6:"Q
M5"2J*0'__&+?2.4GH:O3.U/^E9ZP/:$/HD&)<YG5,'2\;5%OD<DF3,GWJM?]
MDC#I;9.,GUX+M>(@YP15C1:,/JB,$>&A3[94L#X=8QH@0GAIUB=L?;M;E>IS
MT5S9W/ T=3/@)ZT)HLNDU"J&A0(^%4QU.Q N37/2,\AO 7?,I,XLSDQV7, V
M#M-'T7Z373(H >N?]34LO,D>+$9!^+%,#IAK^'7&:-IV'#YM^J[_TOV2#)=?
M9 ON%J +0HJ2@1AMJK),@[_>/R@Q+@]S-W/(<5#3"%Y<,BO\+$VZF7%O0^$7
MP40S;4ES6?C<SSS>.[[';TMW2_RFD7)[Y.JPSKV$OJOO;^*VJ/2)#E<U_?*2
M?1F5>M.(U0BD-#OYB]S3T/"^FLW[HTA@[K;DD,F6Y*49)8K3]\M[_A1V,S\O
M#^VUITBI'-OC2P/6^=.M@KS:4G=:]>25['XQ 46KY!J82I@P1+UCBCOGGL;2
M+2N>&9+ANF'Q[=D;ML>2FJI/,@E"7SJ8NK?L&F, O\P ,,_;ZL[@JJW[K"2I
MCZ%E77E_W/VQB -_&2%]=6W9N\FG2E/?@[Y?*XO[93P.%DY0]>C::!9V39_0
M)U@J/&$]O+7=VL3<V"15+2-?FD(V_:;/?WE+Y;:9U,_651%39%/WI.)I\FE,
MM!0ESXR!1?W!0:%X.9E-*G.9\-O\5B<!X1&.<QG2QP9_MFI2^E//N );W <%
M7SL=KSKL^U@QQ17E@(8J9_GY<BH^1N&GO;A7V"!]_)N<:1]@^2$%ZG+CS\P:
MQ#1"N?B;?4!:!R5UCBE6N<:H%%!5[!1Y9Y7R-3'?\?)?Y/S<'-)PXWC7;TH^
MJ^:AFJC&!7D-F2>50NXEI"PW-H_&XU6>>.$16[Q:+V<]+/O9.07=DLVI!MU7
M:M74A>>X:]43"2R:FC+NU1+&%YC8AM^/^D)3P1Y".%-$5$Y3_NM[QN 0I'S>
M'&F]T-4IIE!I(]R5\A%Y_IU3R32/HM8BD#5URDLRI>L4;P(RTI[^,C,,ES<9
M_:9RC=\EQT-W.)^Z47[G/2J!_H(!AK\YO=C_)H R_X7W \]?M4U]/<T2G#ZA
M%;>N)9G>\OPO->"#\3BNTL57>-M:J//QC!/>_X]6[!\<'/IBB8)T$\TM^039
MCXX4><N6/-E[? 1)_'G(4DM$>/LI./)@O&(TYTE$U>&C&X^=-.UR RA&.&&)
MW@[WVSJ#\+^=G$A_<3$#_6+P_1FDF_V+BHMMW)*X(KQ^\PK7WZU/2'PQ1G+
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MW;7-4G.J-?+/JKVSW66>S7\N</^EBI E"@I;]-41]=@\)G&3:@'.!_&-BI"
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M' <2?U(B,G5?-%#<Z13%=DJJ/_NKYV[\6V0;+W$0 UC)1.2@IIU0N'5]*P?
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MKDD-57YIV934[9)7S5CD3,O! "85SFW&>&MK_</!Y;_Z/Q'?DL@)2P,/&C6
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M5'Z*L&,DQVG&$3A"*.#KD?6^7ZV"P^0RZV'X$@5-#+L=:8FWMWH1]X)A@2\
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MOFM'.L&R4:/-X%PL^$05LBT7A'7/?!A]B_Y:B %\+:FR($(X*.R%%E"<>5G
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M_@J4",@W]"U686<*S3)LFB?&WP'&=3!=^]Y!Y_9L-YIB39WU2^J<1:#9D<P
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MAQ+60=KI3;B'G]7E)?KS6,#S^L[(!B%N;6Q;$DYG).=G-3[4)86@IJ>M#I+
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MG;3 /Y7$I\ ,PA#8KJW+8D42XI\W'>/41_';F7WF'R(@R1B!<'!_Q+' % 3
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MA6\-43<S8.YDMZ4+AIPM(VROJM-HS0J^)T*K3ZT7SKB W/NP9M@,&V6R5(Q
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MA*B NO?W?]\/[_EVKG-=)^[[/M?SG)?J+V1D[:SO_B+Z!?A_!@$ 8   !@#
M P $ !@  $, 8!@ C & \0 P 6 , !A# ,8P@#$&8(P'&!, <   #@' 80 X
M!@#' ^ $  X P$$ .!@ AP'@\  < 3 + ,Q" +,PP"P&,(L'S!+^RPT@0  $
M&("  1#P ,)_SG^U(1  # + 0 #X_V(0,  "AD# , @8 P'C(6 "Q!@ ,89
MC&$08PS$& \Q)D#@  @< H'#(' ,!(Z'P D0' ""@T!P, @. \'A(3@"9!8
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MF%D89A:#F<5C9@D8 @!#@& (, P!@R'@,83_T/^/; @> ,,#,'@ _C\R\&
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M$"T+(]8+P*VF!/X=PN(<+- <*B04*DL6IC 4\G0_1.5W**5,Z.^]8#7GCYX
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M#,OW[D\@E5E/TY?)\13"V YA266YL,0C.>S;[B,YP!\@QI]1#(=FT9L'67]
MV2.2V9DNW"LPQ#WS=+J1_ U@+I5Y&GXOX#L(82@0-4.8XS]LCEZ*D)T78.1]
ME?.'O[ NC6'].F(A%<3*4\C\HK#T=2'A=\$3ND*U5K5#&+>)!M),HVAMI]""
MM6BTNLASJ>CI>>$>1O-J'RT:553' AB!(VT#BG),*#%> '';7!7EPLP:).DZ
MTDND6.\]P\_F.XW.<L9OB@ZD0%TRT3]9B.^Y(#9\,1)PTBBR$K0(6B&Q*)"L
MM-2\R -9%*_!R.H,8!\J=,,EVR(1]G)6;Y$V54NX5M9BO:4R0_-BSY&8S&#B
MN"AB.D;28YG/VCNE$N+ T012<2_ GAIKCX:/PF1Q2L"[$P%&M@  F!95OU"R
MPEHBGQA4NE3*JZ;Q-!>G0JA!9K[))<#B=TS*0[!E:#^!?W64X>3$07)*ZU]2
M;P[+!LG+>EI+LT9*11>AMQ]2G"X8+I88TH0S:"FR1EY&W 84F\J55VL4<UC4
M*"063OY.0=<@B;R(7W)CH!.E<0<5=RW4@64,4BR?!W]%H[RR[30$".8EY<VO
M:36KZIRK%(.KYOW+2D:JIG?KH$35QWZLQL(UZ?4,?&UER<KE5N9U6F5%7,LX
M'=;BI2M^;0W-*O42!GIIM+(7\8'52VP S<Q#X"*#*)/[JJ3-I\O&7L&F.9.F
M/^^;C@N;1KXT?=MK.G$2]7/E#K%0"DM7BF"S0; UY\@T)UHTWS.R28F6D=&O
MJB5PX]C]FM/(/FD?&C$& #3>!'T^RO!]*XH:;<:442+,@O8BRS!LRH]]&7)=
M2LX_5&2J&WU]U33L@Y80SY%/S&<V:%/L,8@T;/_$TC1$8?B^3"RJ#5Q!8;"M
M5BF38#TTVGX'TSY6QA#KVI86V)Z&;IJEZ/S*9C2YW.S/9N7"A96@5:F3B7[@
MRX#-R71"9.+5F[9Z6^O2 B0H,-,1S;(!5C)<F9?+I>>!238W[>_E2@:F6G?;
M0)ER73D(T#?RCL_@CB1P=N1CD,B;>%;[#L,2AI>LL.5 AA&*M*SB4@G:NBD7
MP$QK(_K(57FCZ;"P::OI3K]K5]UK!&:B-+JNM^2P+9(0RK"AV;1%T2S[L1-%
M9&R,S8Q:;#S!=M?<HB52G*#MGLTJ)5FL ,Z+>OVYO'\6^0\R\J8.8G-,>W[Z
M]8PF]!RV]1R7-=<%#F(3!C?X>RS^]+W[T[7/UJJ!C]R^M6:@;/K\QYKN7>\2
MF[*1EH<?2JUHP^HQF!$TG&BIGOQ6TRK;;M@Q:OBQ>FS&'VE!#.JZ8?A\83@_
M9JBPO+!8= 1Z (OZW?EKG_^11?3B'NM&"J*]$;EP4Y],:;6;'\G::S#/"E"W
M^%1UG-"PUW(T\K'"0IIMJ<2YSND]#E_@4!QQG"+6TCK\9_AY8D _!CVCT,@R
M')THA\AMAY9F#$\YC2A%C:P28A*:@?4GIMQ2B&Y'"+"^I,!9*7J1(N5;3+2G
M5O3Q00+(IT"6&U> S;.WC1=G+14Q:A>2+7%:3B"RBB]:GH@E9T3X ];(O[J#
M)O:@@4I@E(J408E(W%;&Z$ZY6X$?9G>?@38PJ54MD9E^S*$[R';7?1L($' 9
M'\>/?#\>X3Z)^<T4Y<XPOG@DO2N J_M=488&$LRG\X[S:D8]C13\$)>B <^R
M2 &-WT(F[7,FG\0P</R=?.X^^6)LQN-%EL!)C7#)0-QV4L[*R"'[5PPOOOCC
M. "D]#Y=8'1=/SV_D5-+YI-#=37E?!DVV7;,!I%94Q-0&_O)+OZ$WP1<GE11
M&4?XZ_B4O=SLS7^7.G>*=DWB6*A1.EA"LR(]$?CC(,_!BWA;D-BY.[7?!8_U
MJH$F3+?X#&0  0_NAN /B;G5*M):)N>2@%NL )GNK.&6X@&]C'G9+@P<S/HF
M7@1>\1T)^CE4/FPVT?2A6W\H&:J<P>.W/("9M@TAOK/<-T05<OZ!F!,)ZFJF
M9!Y-8AW!K( ^S[< F>6C7;PRA=^$5NX3]T21MDH"3V.)YQ<-L1-?";+MZ^K?
ML+;?$,-)(JRH>7> M+)W 4>C4>N"<<6"ROFBN;Q]OGM#8>Q'+%6A[$;:# [\
M5Z%+') %QH#.F,/[$S+ZRCX.<63HE]34!!:RMF;:$\17 :6E3-0"OY8',>>D
MW"7 <&2%L/FJWN\MX_;N44"(="(I\%]E\X%5'A;8WW)'M*RT3B8/[;\N3;9S
M_B$.(!^4X4],'L0M.3%J&8>&PENY@8/V@!"9SN6X4G<^D[7H?!S_TTU< >5Z
MQ\RGNG "U?*@/P@+)SZ-K;A;02F[C@[.S( J50R([[[Z0]KLLTR5@QD=8WA$
MV=73HO^!\_,:!G='AY*$,X0T3HU+K8PBJ*Y2[=NKN*(M7":Y!S=S8 >1^.>F
MS(Q["<O;<Q/W)C+<M_* Y2W5,UL#LGLC$Z#NBOV^L4&:.(9["IDS%>5YUYFO
MS%?3_8FKJ'LY/D%=Z'<="-:[R*#=O.OL-QYX_=/=)YQ[<W$,DDIELX=[Q4]!
MR>OHC]1G!2\K.:V\="HWZDP:TSDVT[0WN:-M!+\MLJT85-:+T<M!Z7F&#_%S
MEPVB3FYB#%J@IC+1TF*OR'<%-CP7^#M-#^,G_D6T"'_W%\#K2]!<\BM>?K&X
M!,=?RG\'RU==/%&TDJ8155K[,B'YH^FHS:OO0A<)O@K@'G5I?<5*/(\[''0!
M<?O7/'*+E]:?(L?7$HOM96K@NM"6W.I!-N5@<6U<[1#RNUQI2L 6T"T^T+P^
M(0B0E!N)5W!OQQ\S95CFR7VV7ID,[6+8DJN,U%C[\+7T*F:22C/:WP-TY5>2
M26!%?<-T_VH&L8Q=I]A4D J33AU,)!'5!YK5>T"@DO$7U>\N)*LN-'0OZG1_
MT+G]4*31E.W2;_.\>!Q_"U]HC7N4!#V/EE'*^S==>CP\2J[0U1K+X%*=9O-]
M+5VB*UF).T_N+Y$2CK#U6]QV0WRL5I9NRQZ.5F[+Y<CLWC5)D%8#_?Q=2WZ,
M_A*5_VFZ^G2A^/OA3*9&Z3;93P#=EE(,8"0U2I:6*Z*;B7B:$>*G=)=:X@Z(
M4\U!#S7 1OSD&]Q98JL6<4=0C!>3Y"AD+Y3"Y'#@ RJQ%XZ>?.SL93:*$:(;
M[)Z<LM6TQU)WE^Q+3-="[]\S[T^DCU22( >2XV6&X00E%F*J& GTH'!,^+W^
M>H5UB<$YXF?R.([?1;"B<,-L\@(R:$11VCL'Q('I^YRBS-%^N=A)\3>:;>K!
M'C_(GFUT.]$.D"*P/ON2%0)2\WRME&/&_3[ZU.W!6RZL\6YW\_B;9W+0%3K>
M+!GD@'.BSH''[F(E%T[C3DY2=&PL\._*'>#4.&E7"1F5LGNL@WXLWG=5HTE9
MB[B!LB]LXY732DDU%$K1*7S*7]X](+<?03_;8:BRP13M_H'N56T?%-[N,[PI
M)J(:B6?Y32NJA]&3'@7F:?M@O4#J"P[5XND(5Z^GH5PWCY1^D=\F-*<]9M<I
MFEB!T-53*?+6U-[7_^-9!WA"8*]18M>=\1YD\ZV=+.2P$J4;Y(QEI!_J#7I>
M.T3FP"ZIRFC&.%[-\HZ7DC]:\OQ$K%*!WJ$Q/TOCM"%6@&&H/).>9R@?Y?';
MHWBM4A,24;C>CY!9]7,%PH.;C4@C(UKIG<$@/9%!P-$(R2/54 \](8-XA,:S
MNU4DM49<O8@>;@ +*P>OY&,:6O)(+12#0WXXF69^60\"=#2UG)S[7+\XZ:WO
MW49;@&OQ*EG(AO3NC$_L5TW]6%K&L; ";S-:0Q'Q+\S9"DE+?,8%DU]<"GT-
MS$5RW75E:%\:EHAK>J(=<TJ2Z:JJ)<B8&LJ^F3*4MW6HF8_J))O6O9M\W.+H
MC<HT(K1YZ.:8AP@9^0GS)E<<32@)HX8-[CRL:!!PJ*K&4F(3I*12@)14B..;
MI";[B;.AUHKR, KKWF1]3>YY^P7US<I*S>N";.J3(^%?7G<D5-RYM2Z*Z&S(
MW5:Q!B,%W/&L<M3:W^,,]@N4O",^<*=6^3B#M#U^"@$*D;=3>2-DXQ_P+.9)
MZ 7)Z=[K*L0 3&V2J77D&&K+RS9TJ#-=_]@8]\$"V6*K^Q%46#KR9/)YWSXI
MM9M]LK[ U"/!Q''A)('I@J)L+D%G[6*O"/2JLE.&KAEB1HVB+^%EW*QC\O1,
M"JS&_.?^#IHNOZ7D2=4R4_LX-6!22#O-,E7#M6W'>WFWBT!EX._A]/QB/\\7
M2_,ROTQ+F"J1PVJW)W; 1%W9*SA,B-'+SJAQN9>3O>9/EK3#@T)A7;?L@$SS
M$,+SZTMFNG_'S-W8;9J7WP.G"'._^)QRP^"7T]G$?6G=?Y7/@JG:;8AL2!X"
M),&/-XET]0<9:XXRPB!9F[&2^U>"?<UOZ$F5%Y\C"U)C& M9% ^85$S5*&MF
M2)ZPX(#/R*&-]@5$5H_2P_ &FXSJ?MJ@2?N8#CX?^*G_<U)-]31USO"45#<2
M*K.I_JRX/G:<E@[#@9S2 5(BA86%)%9"?.-$;4>JP792V&Z*)"OLZD79L+=/
M)+";B@SU<'@H0@K<3!0CPO+XKB1!-W2*(8?D:._I/WV]$([R;#Y0<S>=5+4W
M&\72SX64-OU_ T))_L-L=])0RV(DT1Y3]+FIO7U',7RR#J*C9EF(T$IXX0NA
M%N7%F8N(9,=S %1\R]\K(<J CB^1QW+TXT0RJ3TM+_J+96JR"#T YJ$M.)IC
MOFDT1.L84"$SU](C.E#+]";$D(_/WT0EE2>+.*/_$4RXD*@VC-1J8SWM(G0M
MF9:LXRO^!:Q["W5NVIR</0.QW['#HPT**26:D8(RML4!*XZTK7Z"$/K 6,V$
M/E4Y^\)DT?Z,YXM...)R3>/@%2/;(N)1>\<\A4?*:B;] +I.M(^0JUG/K_T4
MT*9202Y!Q>)%.)(.'2C,&TT*B)>/OY,EL?1#8W0I25FF5EB"K*QLM:#D)=AA
MMA$!YF?:@6F:7X]YO=E]CSC>E*4K'?_8<&D0BT,0-9M-=9XWF'QW9,YM_H)*
MM?5!88^W&TD/N\A9I6OFEK64V/CR_RH(J^8"E_@D7_&P<Y>KS47314NG*@M1
MB;W(V-GV4OBA^54CX=F-O*UK(2/?C=BCD#%>UC>N8/."$/#ST21W-[NR@HGC
M^TUWJ#PNZG$/)89C#8E[:-4GGK%\49MXJ&^E&_/. <"P2Y(O 4?+UZ#&G"SK
M]/GT-=3H:S,\:\5D3^VB9X^+*8/]?QGI@#3*2 UXU&(_Q+K*$JJT4LM"TC:4
MH!CN*--7XO1.Z!,%([M$RFW5F"(JV%.]&IO[+C_7XV=)=&>T-64MZ-'O#YD1
M>T=1]B@+(V&Z"?WRPF\N4A$SJC]3&PNL*NK8[W9=J\WQ6\JJ*P3*L4B&"-H]
M!6M]AM@K[#CO"OXKSU#:=0%S%5(D"O6HVY&$MRV8OH!*F)HCE63ETTZ'^:TE
MN%_?YY_(U2+GQ^XS\V<UQV@1'?.[3,1R85+;" H8O@;4F+9"4J(YQW=^9STU
M&,O%DVC1X@8I>[[?62_7&$[VVX1#ER3=!MGHO0OUI20$U'%W&)\'VTO6K=0.
MK3@DGC7VHY\PD$5/5:<\;Q44%N0N&$:<%3Y,<S;5:11)D$B[8YILBD&:W++D
M.?)8H3B?<W')5JH";!6=[NXG"Z\LH"SH;1A=-N5*+$B]R)[-]5L=*>:RZOKA
M*?/^^%=,>L9=9AQ1:BC$"WIOGT*J4KPSE4+M)W2N1D9U4IWU\Z<%R8--?UK+
M.X3<3ZN?Q7YSS'9:B5I+3;QC9=-&[*SXF)##W8204KO=G4XBQT#@5U)[<7J=
MI4Z"'BKY_.KA0D_,XP["=K")+=TZ'I?+>7]V!,S]OQKZO,V:9]]-CO/?,C#P
MR1-\LOO+H74BEOI'KN:3';'#-?C,X;KKPTA'(%%;Y;:"$0V(I3V5&U']+BE#
M:6M7_O!N-PLPD%:W@4$LR8PZ9S4?V-T]!A8&J:UXQHC_X$L:B-"?=RZ^8 H-
ML^/J=#0Q\0WM)7YW*4CY#5AM1NJTM*(A=TG9KM&Y7)97'H[,$$EU):FRS7O*
M HC5>/9,Z8[8U8;T/FJ,_I-3QMO"^3]C>L6T9Y^K+@HU;WZ.CK3$,%%;>O'?
M%8UV5;?.UMVN7J\@*,5._C@P>*=F%ZL^_L(;N[ _-]679L*U9D'*/S(U.,;@
M3O]>?Q02^QK>N^(CH_4B^TUZ;RHQBY9V<105?0L'26B1"S']*1CH<4-3":#(
M7ZBZ;N9P=N7_$*AT@6M,?0O,M&ATKBDGF#/6RB"W:..=[>1IKEF/NJD O-31
M"74\O'$2H/PSOZJ/K!6B!F2*WDA21[)-+A:$'5LP&76"W)-[]'GV.:R+OZ6"
MNV,KN]L%-8C;O%A;E-M/U++V+\EF<5S<_70D),41SLJ_JD5NB),,P4^B<I)L
M^XC4%I$5II1_(&![9_*&LZX8[^(.>B01.]>6A%+:>B_]###:EB:<ATZ%($D3
MOAF]DLBIW]NRR?LTMKJU""*8SQ"7<\N?9BA7G!ZEA\N9.\PFSZW>#VCI;5:*
M>)NQ:/!TDZLB)"E[_LTCHGS9*94'=2.*UXE1Q#?\&R%TQN5<K]BY3!R?JMJG
MFF8,D.-4C=I5C3YRW2][8K#"LBW$IUU-?F^SL)XKFH4K.7 8;'>>"TN7RF%I
M\9I.9FLI$C GE>!Y1(^*,GP&]*[KU6\A!VVPTV&27)=*/3>X->E2A490ETK-
M]KP,_4+5K8'WJ8^Z7D#(0&=(97V*3K)\4U[R-K)'[S&438%L<D0UMN?E8H&Y
M/%-0-] @U3M51Q)UVP(9,\I!5^X7 W*#U_25IH3'HLPUG &Y&-IE9M]@II&A
M1T=ZK)=]9-J7")91,.4&='P=F4>"(K.G#&>)2O4+C=K(C6-'8Q91 8R]R0L,
M?'@I?<M&L3J$*8;=2XO['K;A)(>=OG?8FPXA7D+92"OCR)#U ?](FB\J$:?P
M3OX188(V5Z95Z+PF[8R/9DLJ1:_)U(+>((G.N8!2AP[QPID=L\AH30ZG76(7
M9DO4!DLW_V#O(./4?JMAVXM,S@FCNQAN2(ARE7\NS%:!^_BP13BK6_[^L4Q]
M@RU-UE"'A&UTKW>&>#(7YU2IU '2S ?H?(QD"58>Y]-R^!C=# 0T/![G;N_'
M#;%V7FLTKF379##5$0I LZQ4Q.BQ3?8XL5%R6[JD7)_X?RJA$PH9G*$\0\@<
MEGP^FQG5>96:7QFJC*%\HK>%^]S48X<=S,-?L7HBF[U?)S02_Z)%L\3US-II
M6$:?F\8 F5WUJ+4RU=Y6W&-*2^!-BAF=R#?3(XK5LWF7P*2,(\E4S:$;IN77
MNV(LZ6]I7MT4EVCF^''+W5,NF9D,_()B<W(FF4%(-*+XVGZ#(W_3QKK$)%(4
MI[&PG>\+K&IU%Z)I,-.U]:XU) X/T_2HF(804H?\%3S":&!WX1OI.!5!I6.J
MK..4B1"!&WGPT5 <=A.)[9[<5QGPYE$LA8M32,C,MNK1Y&6A3=49!E)I",9\
M%,:J]!WWE595*9P&J(T3ET+5NTA*_DITB/;2;CN3I9.+''(_YRR7=S:@CI5C
M*;WI5'=134RNK-23DN@0F4P@N_1J*#:-&Q57&(('7Y_I9[7V4FV4UDL\R3G$
MRKTS@&[JTP+[?-@:3J.I>I=*7)>?9LY$#9()R)?34QL9<6](2#S+_JF, %/$
M/B3O8,K L3I&OW1!($B^Z#ZAV3< 1C@7D]2106[D7TFR'?=P=@B#,^3(;5C'
MIN5113Z&45R4[QNB&N3BOW-1[\M0# 17>_?&Q-?AE&X&-UT03.)S(E=D&K]C
M(BMRZ.M+>R8,F52*TWJ>T1TBES9+[:^3S.]T=Q"P\:(:?/94,BDR<P+&<PTR
M0.5M8'*+)/1._Y>MK%'6B=3R5R(2,SSGAOSZ^KGN^E021F&@@:&DEV&+45!$
MI: 4W3E=CM7'U&*FBBS:RA\MSY\89]ZGXP**+2?,<-7-<FW@"CH8<ZI\$ZI7
MS:/EE_]H6M2? !NNS!/=EBDZED-N*FZ>3W96(__YU"^\1:0.!"\+\4C/:)[Q
M ;FUBM)GF#?%=0]P'!%NY)W.)85#)&'/M1^M@LM:F3O3>YP2"J_HZ!3L=!S=
M4@ +I0P]J!<U%&7J%'>6HQXKY4J89X2E4XUD5"6SA'X<#A.=%+4KK?Z66%F!
M4.O'ZX27*F3Y*0Y^6ETD*,Q^<N/OM:W2^]/<'&YQX2]6'9O4Q81M:UCN2,GN
MC%6]$F.]5=#WVHCZU\L ERV^(DY>X6^&'0ZG4Z:.3X9YO!.JSBB\6$@FK%+0
M7>5&^.76) 6_'K5J]RI[?A1=D,@ N4Q1=%F4DN=B2EH7UYS_ 3"4 O$J$M/[
M7*PM>I<(';%JHP<[2DJCZ#0S1];E2J7R6EYMBXBEG=50*=/8F:7JL<DF#8?)
MRX_0>)CP6D;3!4FOK5-P!]GZ,F4"FLW6-GCB6*WC#K6:1 52,.F5M'QK)0RP
M920*_BRB.\$E(^R8NZ:Z.>G<I]$QO<:^FHKA9HUMB*SRM[WVQ"(C9[+D+.(#
M(2GV:*AM:>+;I#-WW6]ESK&G(Z8Y1,E)%_:5M-3/P7P-]-1F:TIV91B!*F[,
M5C7^3QXR5E\H]#GGY?70+LC"S<[FF\$#9LT'((I8HV_]P%K5@E6Q#KY'%#76
M+1T/MHGH7U[I)<KK<SH\O9?(672W@C$XVY$$%N^V^_P)C"1V-X5E2C5S]]I[
M&>@S$>%*<\:=^#J5+_'M?;(WZBA761/O:NFW2$!UNF]NVNL[11\_ 0/>F'KU
MRG^]4#*&"!0//W9X@Y+(74@J4:AJJ>K)[4H%J"B2TOY2BB?68SP'@U]:&Q[;
M4EJY%-=Z,:DLEBD-FV ^L7Y7HRK39XK.51CT_>]:ZO0GD,8IZL35=RM_>.68
MW!@7ED]115; ,OK@8CBII!!V[Z]HOIBZ@[1J+F#/LW.75&["X[2\>#I1=#IF
M0QMSYZ!]PA"X7[+!EO3ZE;O#.MK$JS;Y?CDTQ1O9Z]U:?4<ELC/9ND:RCUBJ
MV30Y<_99=UM2?Y1K@3FNTI^^PADQO*$1N4M!\C&U( '4+T-G[1N;/BY(=&Q;
ML82,0*R>T$TFA=*^_#M ;38=)8-MZ6;L852IJ6&)OVLXR!M%6D?]3(42D4L2
M^\_MV3.K^#.&%1:R85L&U424IW%&\)FR-B1=<H5M/L<EXUS>7]DE&$#Q.UBG
M^=R]'@*XU.M'T9,IVD5+V,ZJ$I3-6MX+E5?8K,O$5HKG%JAA3%T+Z]&4(J+/
MB$DLQ+@1=V%T#ENN&9.""?RCW:0JUA5*#;+W02*E(7"E87&%;#\L&YG%?)*;
MXZFN2X23*$KW1OD-QS0L=V>W.:5&RRB)XD^+UD*YDX[^[^Z6?Y;T(]8V-+\J
M2.TM:)OH**%);-9\='O+>0+D#&O/Z>=9F'1M6#S/DXP2?JUDT67OLBD.L//&
M91L^8&DK.1V:LE]*D9=[_&4NYL@\SRJXMH:(_G'6_M("<J=[OWB"6S EAEAG
M7HSP,DTI]S8S*;$%%/-^*,""\J"6T>?Q([\ [.=M*Q26AGLE5J:6NM^4B+)4
M([.;X9JP]%;J2$/++AZE3TDE4:7X(\UW>-1Z3E.-XW!$R1L8<@R-^<'R,IEI
MS9ORM03:*]LD2XPE.@I*Z]I89$BF0[?\X\5W)"IX0S*5-T]).:84Q'O_-GVI
M.0[@W. 1@[S.,?X0)ND<TY!FJYG'!79\^&S%G99VDS*RM!V5..9DM[%O%%R4
M)*)P,')G/!GWWC9-":HJ#"4[\?*P%KMG=OC/WI(?V+!Y U093B[)$RJ<H97H
MG34<SM7L26;\]J*!+%YN&'LV])XV:BX1\([8;2B5E</90;HF@A\?_M^;55;)
M..7T7T)F2)):J58+F9&ACK\PY2&[&,TV^62/M)YMJ;2.5B AGG([W&[<ISLP
M*I6!O6JCQ>CUGHZSYT9Q[OLXKR]W[HO^XH+0$PF_EVSJ>VON;7-&(\@Z.?6.
M!OF.L_1'7O9C/;FU6$B,N)W,3<+C;;NGU&[T.^9+\YLW%SM9E9G3!][L=%:-
M6SB57S\L^(EN1>@"^5W6:A4KZUY#GJ;<<KLG.!D%JLO+9>.3,SGEOO^C>#.%
MR!^*V3=<O^4%,2!?]9A$;,3B&?T52\CFH!%C?:9QSF+LG"/\.%^U+!)>G3="
M'>LEX6-:"^PRR#AT;?66;P!HV5+\!Y 2QDQF_8!*I<9!O!8QUER9"Z<$[%TA
MO9@D_$)W2ES*LF,']DJS]3[=_+D5(93*?,G5F_:YI6RX)9C>?D8&$K$E>GY)
M[3J^7SQ$?6O6=?<I72M\E<Y,0;+13Z@_^/WFVR/GT<?["GBTD/I\5(0&B@U
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MK+"[ -XLJ7CXC"ALW"I"$BX ]9^?,;0N]&96W3<S6?>T]^9/-?E;\]C ].3
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M7A93_'\ #$#SOWBGE3EVBP$ K'D,H+F;OSF<Q[F<SWEMNSB=._<- ,!L1P,
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M<OV#4$23  0EP&'L!5"3$2_D5R5]1\1WF'DS*7!?>D<:L6"$#R[XWW]+NC#
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M&(F#]IB:YX*!7!;12D=9% TF275?E?&6@CHB(C*0>&.'U\DJEKD>;/+6H+&
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M"06.94MU,U.!304^UM0U*E2V1^..'6A4JNMD0!EKPL&B94P9,PSC_FMXI=[
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MR0V*8S*7"I^+ZYY\2\,A+,(P),(C#$(][,,\Y,,_'$1!+,0A7+WYBX;78I@
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M++I^_Q&^_"0&'$C'BU0VM_RZ&;51P9*)+_71?0LHQIH$>E(F)?4:91"# P@
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M&G8D]M/9A/9ZM%K.BD/#>M5)Q&49K\T3>6E-5$\O^\0TEI5&U7V-9M>,%7V
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M)HA=_<DOQ6A4MVD3RXT0WC70(9J:O,SG"0/:2:S+0)C;/CH(" TJ)L'%:@2
MC='$C:S.ZMQ(0E],CB$/O#*T*J$<>(+GQ2A:&S&608?61$<)4=PH^<[C!IM&
M;3E(IWD&@PG: ^&FZ:Y:7[H*-3(N/)\>G=770B8*,,*()EIS!6OQC#I7#J.A
MV> GO8Q4-?(E>J$:&L  T^8C.^'120SS]J ;ZFK:AX;HAR9#-DM%ZEAT4>28
MTW@U\M"'E'AU5R./TX3_=8[=E%FC]5I_-7VT-0*,]5G+]<4LS--I<]2)\1B5
MF(T>AWDR2OBE<<2(71HHK?NJQ!IG%/06U/TI6:@=ZJ?Y*-(01B_I9WNM,#.+
MU%N"CIXRJFJ,P:8X:FC+!'/)@&B7MDR8MFG+3FJC=FN?=FD#R%/.@*,Z@&L[
M:II5,K$ED/U"##2@$R,-JIXI$91-[6: 4 RB\L^AXNC5EC."7I;ELN>VB-NV
M8RQ+I8.^:#0[&@*XU0)#731\3WUJ'%)NU4#@@ H80%-C7"8$ /*VXD3('RO>
M1288():==/N J'!#4"IKXQCD  [D@!C\]Q@ N( +. X0^'\'^( 7.(,O.(#C
M_\"!"WA-0/B!XP""7WB"'_B#._B!)SB&,SB!XT :>/==OYCYSE FX"I 971L
MJ"F3B ':'4 8!-SQJK-[_FM)_=ZI2@A'V+=5!R#.!5?I$.!YU*:$:>0M@8\'
M?4*);RT1:T*42SDE1#F5:P*59X*5:WF5<_F5=[F5?_8,I,&7D[F7F_DD5#D1
M;[F96[DF9'EN$UO(+A NB_1SD_!@4?52AK!_CI[,!%KU&BQNN1/[=!P^-9IU
MZNHF[BZ9Q6CX;JDGTH.@R6)/"FPZ#:4D"3$1/UE"("E()"N:_Q7@O=/_^EZ'
MS&X'*H-<Q:>JUTNKJSH]Q&>LUPNLM_HRT#JMRWH]9/^" .3 0\0ZKJ=ZK0?[
MJM<ZL-OZK\OZJILXY*DM(5U*3=!'C1Z/M"]+W")))OQ.)FBG_,$YTVR4-OEV
M4>JEX%'.8 F1$NZH8SO&3,D/=GA4GX$RS1!23%#;LA])Y_*.;POY5(4ZZNI9
M> %*S (1"0_N#0%:*7K&X2)E?&PA);)RI#[DQ=+>AT$DEW*@S63.$@K+0#+B
MV1BK>W^:,@3 #9B&TJ)!4?L?$$G9?(5(MQ-)BTBRO<O\2Z#X 7GS V<=3[PX
MVGZT-M6#S$C&,NL0)O\A$_,HGIV;Z>*C?#%EQEEOAA$2,= $;\\\8&BP=_5D
M ;J[YW6>OWO'Q&$<DK,T=.]*)R&O"B[1(&K<H/ZPZTY[H\F9'_>.7']T- >^
MG2@SX0WA'R:C$Q+C<T<TJQB41-T*$D2L0 R,D"PRW]>O3ZF!1E..,0((6]53
MODO_Y+48>>7@A!_CJ9*UDZM:<A36IB+@*66?HG3I+7S##0VLPO.6Z68I.L3F
M]@XQX, ,N'SE[T.;\0[E]?FZG[WE@*H_!B[?&!:7L32(<*9H^MWK=DM8-7RL
MV==K(F;MJ@738;<;]BX:(MF^=]G?1W:J9DXO@QUZ#^E!3()$)2T '   &( 8
MY''55E"?98X 2X8F.#G87$J]XS[NU_Q! 80,&0@&"C1HD&!"%@D%,CR8:5]$
MB1,I5K1X$6/$-,HR8E26IF-(D1V532(V$F5*E1>7$4NFR24Q3<F(*=-DDR8H
M8L- #;O),Z;.3\2(Z11:\V8F9<-PPEQ:<Z=-99F*[NR)_Q2H,F)#7[Z<JK4I
MM)5CR6;4) /'R;)KV;9U^[8C,33+X-:5&&W8UIH\F2J%ZM7O5*A,96JE*36K
M7IQ[=8)5ZK=K4<*+A\ZL:OBG5(YN,R%LZ-DSP= %21\4+=HT:8>I#X(N71HU
M I!V:=>FV#*SU:H]#4L&:[EQUIM@:_;6>1@J6*V\HP8.S)3O\KR8#2L3:QO[
MOLXY-F?W_AU\>/%KT8@93_LLZL^K7W].C8#2^8HQ#HB!*++DC1@ Y%/\>+\_
MM^@Y[K*DED*L,9=N@HHYKJ*J2:G)+--JJ*-TFLROHWH;2JJ8EKH*K #94D8@
M4$0\$464-)&DNQ0MTF=!KPK32_\I3293#"C>J.H). 5SFFY'Z&9:4+&?CF(J
M,YAHJO%'P:YCZZSV8H.MO=8*.FVT!%R[4C4NIUS//=+&:-'%_I0!##'!/M0+
MP@-_,A(ZO8:JT<VN)J2*PQP9V\O JC+T22N@-*&G3)6($6#,0A5=E%'L,C&O
MT9$FP9(@%MQ3SR%+"1( (0 #S.2&%0X(X 8T)NFPL330H.^ &&(P\<22R(S4
M(^D^G.XG!==\:JBA?)/L**RNTK OZB*DT,,:^:3IIB&156966B<Z*P>UI+TV
M.V70B+;099",R4&PD'PI*\@NN]%7G8+*2L];@T,JJ+W2C)$HWF!Z$LJ%P R3
M7X;\K7+_!O5<$YA?UDJ;X=*&6)@-V^ST(>JP'M=<MS$;UY2QPN3T @JYQ;32
MB\ *D7330UUUG9#;:\_"@:Z&77XYTDD@A7DB2EYS:$I,;Q8HOA2UI4]4 _8[
M (8# &BU53$T<5$923RE>1]H+79*,I!U*W9!CWL\[+'?:#JY3J06\Q,S&2-K
M4S&H]R$&+6O5?ALE91I)V<6'[8W8SJ^2H^HKR[P:LLEQ_R*2)E\=6\PKK'7%
M.B</ZW$KRIWWQ=)*@?_U$K1_<Z823)UE.& ,N.M2QJB\KL+XUZ]&5HR8YWJR
M=\VD=.T:8GHM*[<I=Y,E)AJU-1% #+I%'YYXLMR86>U,.*V2_Z" +=UW<ADF
M470J,7"@#_L;Q#")^C3<AKH>PKB:,$GJP'TP75Q9CZQO(6U"TOUC4S=9;P6+
M\UT@X8N'.Y.-I/466573"OG8QZ8.14Q>S6*6WO+6I@CY9D%T@LYQJ)8XW[RE
M,U]B7L(2@C N5:XUG@-AY@H&O8$P;']C@1:N(K:4K $+5T^A(-<T1J -0:5D
MK[,?@4(FK]811V1:P=?+MJ._%!X1B1*1F>@BA[D1&HPT EA:$L/SD6&(#AI]
M:LRQ,O.G!6EH0M'94^X($QQ;S<]><B)*K]J4&2,RBD0YF"(5B4<,%DD+&D7Z
M$7-N)Q7GN/ E>@GD4,HHOAF1RX9&6N;C7^HE-C4B98%O24_"!A(P*5FI7Q_\
MX&HT9\+-$4PTB:)CW'ZEH[)9AD&""^1R?&0Q0-DH06PDEAEQ1S4=-B4F"B(4
MU XERE'^,HF/$MVD"O*\SG4)9U9Z&C#M4A)8O:T>R!F?=!S).@<)4HN"6M+'
MCO(WO"V(C1QS)(?0UK@ANBQ*;V1FH[2ESO[40RO/\=H78P(4<C(';ZG<XN"(
M$TC8%0MDT<F+C%27)DD^CW(@U-GEV+/!+840BJ#<Y,+6V1%X^L5PB@S443B4
MH?/):&N+(^"#_*(G@!:.* ?Z8[.@A3^6512FHO\K#Q/?4\P1&O.8:HAI,]%P
M1;CE\3&# 5&$=(A2M.4J@#0AJ-^JHM0^&?6,5R'GG) %(K6Q+2T[A9DF3B4M
MO 2G=/CL$3Y_>+)O?LUL;\H;_'9E2'[FBD,QNHDD2WBYZ$$1>NR)C24Y6<E-
M:O)2:7B<5B<"#:F-*XS.8AUA;E>Q-M7R6;*3#EAC(B.K-5",JALLS7X7/,)^
M%EO"A!LQ)6K7#A),(,L$[4I*\CV:+0.(ERF2AP!E,@=IZ++8M$E,"%<8I_!E
MBUXKJV,2J _\56NUUQJ&_VAU0P/V29!586FYT#;9\^DMMA/KFV*4Y53$6,9P
M&$3F)2V75\ N]*'I%:'_)RF:7'B.C+$$95?I6'FK75UWOA@2EU' QB[9TJDP
M?..).PM5Q.0>6%%+A)O-:HK)+B%$7PGI&8)9.PG5ONQA;%0ILO;81I2R<H'/
MH6=EP1G0#=/K?<PYI9M"!#42R>"9%*;>'6EEV*;*%:VL8ZJ,(%-B<Y48DK#4
MS5?X5C+5\5>IX[Q?6\ZB+TPVM*'J':_!3*O)S8U&(+X$[6Y=B%V^Y(HW]C29
MC(";4B4-MT\9HPE0)ABOM18T7IN%62\)+&,[PT6T;WM#A&NZ*=9 67IW3LE'
MZDR]E *K=F?T<M:(6EF9I'5D<.HG2V-2H\PZZ[>[[4K+.-LV01=*$\R-5#VH
M_](X@@)8PT\M<9<1.[%P">= 4)%E8L*\FS@=I] 6F23FT.M!)P)V2WTEX1/1
M&QH4@M9'"90O?5%L&4DSILW(@L[[-GJN!#%I+PS:4Q#/V;"5<?K3X<;.3.&F
MB6+O#+4.D:*X0]*T"[LLCZ^;#NY,5U9(?U<J])KJ^8(,E/.9,974=A_K<HTB
MMB&7W2>R8\'!0P_2%09(:C)@LB$$R48V:9&QMM"TQ7Q/B/VPWF&>[F[%6T(3
M IN\5/)<,H]IY3\+) 9CD#-AH\%BR>9%S5@1S+  ZD>Q2;I9E\'VAYU%F+^I
M3I'V8[B(#N79A#\=S\B#VB3"A% L:PKE,GCWTULK.O]2$Z>HC=0XH(3SM3#'
MCL-5>>P!)YZWH.I-0QAU";A?EDZH!ZB=_QNHB=>N6$0?2,PRPFT0ZQ7I;*<]
M8VE:'4IYLW2):,+)OVZY$^U:L"A#%//#SIP CDU8NS5'UE7IRZ_>),-%-CI.
MZ5.I_18X-<( Q=*LOA %8]+MT") RW?7_4H4_+9=GS;8I3&FOR;,J)I(ZS]8
MK'B>'JO#?7M,C#KQ&_G*!B_&.U!LTS$@%P/8&+61" =SW'UXN.I:11D6R5#I
MT9T8B.F258UK\:P^_#'=N"ZN22>-MB%5Z"KE=#]1(!"FKTKKUP:0@]IC#&PO
MII2C.*!%.1X0 AU0 ANP 8?=PV,B, *+HP&A10,=< ,I4!EF#IU8@#O&SP13
MXGB&*:$,8GE2KJ&V#N]PP !:18EPP+@*15:\SESX*ZX"Y5FLHM6B:ZGX0H]Z
MY+KZKOT6"+_F[KC,[P1K8[D<+SO")UY2+<E A'[:3-Y8"7:4COL&AUFN<$^0
MXT*ZS"FD4#O^JKP,\,HTZ#.T!+6PK#VTQ,&XI/,^2Q]Z)P_W@1[T<!^BX0:7
MP;@ <1\$L1"-:S-ND!#WX08YD", L7<()1HD41_J80_W02P L66N8Q'W4!(9
ML7<6$6HT(09*\ E/$2/_>@]_AL_EL@Y,=(IZ@(8^)"(3#F!Z<-!IE.]OILTW
MQ$R- BC6$@]PM*U^3&E!AG&W\J1B=*=-O,_%\@<5O:-IT- V# O;0J]Q8NG&
MVB6_)L;4Z FETB7T9B\J8$D+Y44IZ$J#*L_D.&>\UA!S?.W*> TV9"X:QP(O
MJ)&9Z.P>^S$B\DQM2.O)2$,>,6?X;K%0Q.  )&$?KF<BZJ-[G-!EZB$W>,3T
MQNXW"DGZ?+#4"D_D[*NIHHN^X(= &H?B#D0?Q6-E)-(?UT(3YN)_^,DO1(]7
M<.1<%,20U&7V..;^'@T;UP>"; [P=(@I#BI,")!26K$]"O+_S NO1HCS6G+0
M_X[O[CKCI:02%<G-]_H,HC@E#AF"!<3/1?0C(L3  "9"(;O'I]YFA9[*-W:$
M=?1O,LJ,"PG#XH1KE2RNC))#4#;,UIR19@Y.++%R1&@L4APN]I(M8\AI<?I&
MN!1S;\:H2,HNR,:,7@#,9'J'R20'Y5!+  =&\@HP\]CPKV1 U @3([Y.]WXG
M]U!3]P 2:M* 2UCQ_RJ/(&!0/@( 4AQ2(LR2>B8AQEQ,7/*-Q>Q2&-<,M^RK
MS:S08B!.WL2&J+H1QUA/,SM-!E)2*N4".^MB&=!*LD(26=0,QWK$X]AG2)*-
M@<H*E?2&NLQ(@D !#3M#*46SRMH1T*;LDNK0/:+2-?\SHL6@;F6VLS^!216A
MAL$:3 :\$K!PZC2*ST5B  ?*,@ F8A9QL*=$!T;0!&OJY/[V\FNH"M$ #LXH
M2..BB\M&#S%T+-8$5!H];4!=LJN:RS&#S.P28U>4A63RJ87^*,#,IT%8QY3.
M1ZZ>0AVIK"!\S3Y!TS;S4TF/J?)B3@1?%!/3\>Z:CNZDE-U@DV:4!]B^DL_8
M S?/@RP;$@8D@A@@$@>Y!VY:XBFXK'9^)2^WL$\D3D@ 0Y_TBZGR3RC/,3H,
MA$6SXRQFX$^C,1E.LU&:;RZ9X\N\D\2H8VK@;XS$J.C6A)S,,PO34Q,44"4@
M[R@52N7<,0[/"]T\:3370S;_L+0B_O/I# Q5GTXK?8< )V^#X&-1,B$ ;# M
MM8,^PE0\2H)7(R6/Q//-?J@G=6X,,:TWFD)"R&RWF.-(MLLO;8@J Q,M!G-
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MX%N1G<LARU @W@=!]'=+0+B_ ,@Z7D=!'W%?8">8(5E&))2;F4F,_V8U#,.
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M3W4LF32\)#*:W7PBJD,(OP*J)["T@I4KIJRZ4"L,I3O*4 K'A H[LG@E99!
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M3=3&;-1\ZC./I-C"-5PAP50.!9=, %6Z<"R'#0UY8U;">IQ0DL\:%2&!R;J
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M0"7ZY"02CAA,@OU59TLBX'$Z(P(:0+AN8G*VA)KZZWAX(B7NZ^$\9R7*!;@
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M6F7[%CZ<>''C>6FB87N<>7.:%4]F9!%M7PZ1+#@B<#KFXTE*SL'//+!<HI@
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M1D]KEHC8!R,6):MJV4/6@5XT-AII"UO!8E;35#1'%RE$1VCSWH'4MC&\T2V
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M&&B9,CB?(!!-_&J33D"<:4UO6L(X6>G$%-70!%OTP56&CSYN$( #L.XADSB
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MZLC<%*^/8-'>%!,\*F).?;%,/T)#-$$F)@$C'@0E+P(F+W-!J^1*\V<,S#5
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ME#Q48U-_L5WS(US#L6Y@%5B9@TW@UH72]W6#I'83@6K"Q!:#1TV:)23.=X$
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MI<H$MJOJ:4N?9;SB:A^Q"(Z)&$GRA:Z>QF"SE9C!=%U+PQ('&VQ1 U0X41,
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M$./IMB2:V%M]Z+$C_W75CAZB;H@N%S(, >EET86NYG(%O_G$3(S"Q?'+Z(O
MW6 Q270=;Y&-?.20_R!R=AWI#@(N6+2(/'EJDD0R$S5YY'5E1\@['4B\<(M"
MEX2T7GY1$4(Z*Q #<VFUK.1::GF(R8+\TJ9JMAXN!;*"7O*0R"C9%WQ/&#!
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MDBD)<8UH("J=P$H_W% *NYTM*G)5%5WC7(NWA?I*_!!%48J<R++XS:]^]UO
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MSIB'=.*8S\0%7O?JUULDW>L;_/J9@1:=DB6EK5L'4T,GF1Q8G )ZJ%E*! 8
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M *P0!"L$PPIAL$(XK! !*P1@2! ,"88A83 D'(9$P)  # #! # ,@,$ . Q
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M!"+)J2C3G;G)$)2/#?GZ SW"=O,H,(M31KF"N-61ZHM 0RK45T[FOHCJ(]:
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MY,>,O:M?&(;2"F*Z<&BX>E<Y,Z82";\0QR/EI.E19OO$&89"@47TU^ZOH^U
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M]Q#CO/[LW/ZM:"E[GLZ"5N2C/:ZNCA6)L=>;6$S^ZSRW@J%IVKU:9^N#'<4
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MY8<(6M'ZI;!0H++-DT4F7]9H^)" 6'%28W?(EMY,Y=,(Q]HJ0EXXOV=ER2E
M[Y5-&J/XV0_ZYXJS097-!&-)H:(5EA<APAG/S\GL/JNEX3KDY:B.#=;N-\BX
MMTT4>"@<S-_G5R8[$OS .A8%'S0: HZ_G_PTLN"F%JD2XV-LU'(N4'N"!.R]
MUO8F'B);]>T9MF>*_='*SK_R5;'!\B6%=CF4J$&\CCX0.T#5$?74A:!Y%=U$
M(8[-@Q+43A&D;TMFTDVEY+EY]QD?4.NA3<H+S0QL:56 T-#X!#I54)/6>2B:
MQ%>4EE%O25?0Q;B+$IS'N-/%@<3]W&0'"",6S.TKYH*2NVVG6,<>+1HU[+KL
M53_L8,KQMVO(8A<=DL^][]-:*:B$40=\\*<SXO+OP2W=$&7VZCW,Y M[%<KR
M5.6Y)MV/\!H=%_KP>;U%R6R'=>R2-.[/=0U+CYSFNC-=[+CH'&F.5LQ*1XA1
M6YW/K^&;2 @0L<^8%).&=AZY(FE/4'8W[,#'7#HBFX1+82^10[G;'..*?, &
MS8OSB,I\KE[F;DW54U1"*C'267>&I6&_DD8G^GDI:<I/(X$I,DEB7GATTXQW
M@9Z0,O5.W_HSZ^PN-I]^T1=9Y_ST)]NHG4C_0LJE&]RT),Z80))]6<ZX0U[[
MT-!?8]<F?N9(N<>1#',D^LU5Y=??Y7X8^F*6!(V4<P)OY6K9$LN3E7K[T2=X
MXDM6WR RQ7>P0F;J(WZ$1[3$O'9 _HDX%$_)17-RZL& 9&)&KF*:SWC<OF*U
M];E0B+-SQ0_;FA.HIP@V(MOR'V','?CA.. M\SY\M\O32B*)=7'7U&?P&SGQ
MUJ&PTA&%^2J9SB\L5W]%O%(I[#$R4+!_,L5'%2U=-3;"UVP]#?ZZ/&D4:]Y+
ML3+OB/C2^OJ3<W=3%*07[H*QK;6UT=7EB0:T'U#Z+RS?7LICQU/(%=RN04XQ
M?ILI2!('6:&*N@<O.)N]\BN/G!D@G$Z;A%S%H]E]Z(J>/%@$<*NB,Z,8=.8R
MYVJTENM7%[347F-<:\Z:"F'4DM#6_J7'7W3"_&C5_P;;H&>0TC^Y62J=,2#Y
M.ZIKLTX^-"Z-:F0T9$!)0G1=O%.$DW2E73HNQ\>7 M4R6*R/Q9]%IX^1)45D
M=>+,,^''?W\-JA*\6$2I1?#EO=JE>O\>!8ZUF?PO$*Z>#$(!-7.U1=\^^5-L
MUH<T3AE? 33NXW>?);'\':<4%_U'+I-]NJ7&FK4]E!4L>#5-WBN;>$H&62K=
M%(1;LDYW@U2VR,9G2'"L)(9W;I%DUXL)3A1>S9_#3(5\K7"DWN+7^\M^1@;7
M2.L88&JUA_R5/*:2"YU**28NSYGOPP1$E!H4>>LI C;5(?695LJIOG,XHJPC
M.-^["4'>*IESC:N+Y[^PN*YDE 2U5N+?BY*M";XQ%-;2%QSK:M3K%$@E"Q18
M4WDF4E%^#\H'16VN6JM)PY01["2:_JYKJV;$B9O14VR$+K\0RS*?R'EE.+/^
MD!W%7?V2:WY\PUQ!6,5");^+_3@\6/V$NHSS63A<PK*>,DIFI3NYVYDD4PRZ
M<C4\W"_^/C-8G]*Y[V!VD/$NZ8XB8LT*C?!Z4]^5!#W]G20^ED."^M=.9=;,
MSP;A.-\T,FWX:!T)%1.1B7X]LG:L R*7GXU9)6R#L00?/X-.(6W!'8W%82='
M75HA'53M[6!V@!0DWFFW2'BTU,Z:\.:(;#[O;H;J$&I>_I[T5)*50E<8\Y/E
M?P_25 )Q.)F[KR\SS918S[]&NZ6$\10=9_+MZ'!.T7"\!H)K)"JMG39-;-P5
MYJ;=F+0@),I">H!*FL =+IT(0J0IY C5HI,TK!7ZR]-T8[@&1 ^ (OFD7^"R
MAKS*Z5"2GDP.%LR)A[#Z#R2/Q0)T5&XC$Z[YBW(H(-RII%\Y[PO>8Y.Y!32)
MTNIU+]0KKSJ8O0;!#3:U]:*\.VDR_V[YT*7V%LRSDKP:]\O?D^E6-[Z@&]@$
MO>?]3NVD3"8H[DO;T;X!$B#&7&:[(XJ+7V3,15'&E!7&?HE+1O W#T"Q1:X*
MLD9#Q FR[;<\8\1\K+XH*:RYK+UOSX$P2ORU:%;B*US+MEWS@TT=V?:],!^;
MRHDS*/&O4%^JDY$.HQP__9ZH4YO(=P:G)?'N+Y%2SNF&789!>X,ZL+>KG7M#
M,OT'HK<DU-XS9=&8%+_&#EYDL(*P(B;:'H<^"9H2+*=2H1*8YZW@\,9AR4"7
M6$-^&$NULX;2>(G:#!;H@O[5>1LDO\>BF\:4+C"+1HU6M0UK8R_NXAL*69SL
M)^[1/9]0V5UR?<031QM<=+*T#1 G#Z4*=T(3*,1P,"494 R<;,?SU ^@"; T
M_JNY'/('RC,=A#7^V7H3Z_I3?TI,N3KVZ#Z0NU@>94^U5(JB3IJH^T9=SDM+
M])=]0-@QAAAQ^ROB+T4,1A]Q,7\&0F6C-203=U0H%4YE.O'FZ)V#YX&O%$?E
M_U2,1%P3Q(PI!EZB80M^%<;&[H*ZXKNC];6;HI/#AKL""YIYAZ0^,T3VYT2,
M44GBT,9\G>C<-UJ%E&XR]5KJJ+S55_N5.;(BTG_U7JS[:V@GJNCV.ZL[!M%C
M5R:875)G=!9DBO&C56F0?^!!"A7S?@'4<1&QBLZ=2ZE/\YIDOV@".F)HJ=DU
M>[AS9FE9(G\V1?.Z0TG,3NPJ%]^HG:E#6>96?W$TXHV<-S3)=1_:JG(=3U@6
M_M8$=F Z+?;REZJL-!!\+(*I\4HZI3\&M\=JY9YBZS!;C,3;0T'VKW^_Z&58
MRB4)+@QC]NQ@<SN %O_?9\'CM<IX.DC26J\1YC->U\=R--UR/=;=[LU74IO?
MR)TQK6!429 QG;_279N](LX?R*_*KA4" [U5\(9)#2<L?%L3YE[,E-QJE^/\
M*58GUM7X,W^]\096_.9?G^/I85SOVPFRD=N.:>(?A!$UN">W(X=N2=!4\IET
MJ&7Q$&TTI#IW,&2W3^K-<(0LM9>>XM<LGXI-B*V'Z07OB$@P:3%+19G>3G_^
M20*)G9+QB].:E![6R/ZI$ZZ:#^A- 3383-'%06C?_H4RO$QAM-T<^+(P]5+;
MHX)!M-V(TJ229B;*Z!3KEZO:HB1\PFY!)/YK^N6[6AURI+;N<2IN"!.YHX=N
MG/;Z^;R&27260#PRN1A$FM-O!36 ^"9SVHF%>!S+&5G23^83G<^^W9+XSE$E
M-A 4C\9"4#(=&; Y"EDQ+Y:JHK R\XU-5U$CCCA+B@=/N^X2E<2*YY<5:/=[
MFF(+45&JM$,TLGQ^O,7U/A3^.J!*4-J>TOWV]KM$RNHQ5X],$O8I'/L[WA$
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MG A%&?NK27)4<A'&104:\C/H>5#TDI9:IZ_6XZ-VE"&#&R@C02F#CDG4TT(
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M\6S5' 0R;\2  [48C2W_K376[()!.Q7XZK[NH-/">D&OCYWL92>4I9RB8P!
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M:]9%#)J.9[IS*[[D0F+@$P3".C/Q!C9Q3Z_B@-IM79H.#@S5 H#@ B#  B[
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M!&8ZL4J",G(ZV;'+\P+.,U$Q>[(A( @@H)$CP)+1T\SQ=E'EG),7U6^-$@X
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M*J$4!:58S9 8;E#=S SC#12*QCVK!0I-:"([:2AO/>% GVJ5!2]CV5:Y$ K
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M-X!=4#&$U\4^Z;,W(O^98.XD,/:Y%?>$7J)Q**"P"9H '6_ =WT'A3\Q"9+
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M7A<[Y-=..=9J3G_BT,F4[$5[:B$RR3=UY.^93N)(_NLFP%OE>;62&,^3LD[
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M31=\^2/G,47_MT1%LDBW="&-(T.6)8O)NQ2:M-LG!EP&P5R4H NZ-! # P"
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MR#'3)A_T*#M+NXHZM;G!QCN1'[TL+^ET.?^K*Z(+A,)BRJ(%J2.0W,)]R$(
M/9Y3O-8Y-(OL4%AY;9Q/LD_*H@_&Z!"X^!RRR)P]NA1-J$/*X119LH@,RZSH
M<PMH@,L-98T1!8X2S==#;*OA"-A^)8Z[4E%I><I$BHS7<#\$65"'996#60Q0
MP(_!FH__:#C0LPN0W!SF01S0.RSPV#+V@TWNI:F",J&A4+GPW5H **0J31(
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M5$4S:7";7764ILODUZE"DUR%AEIJX5!7J6(<<%4:%RDUB71\JG76I "HH!4
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MU3,]M=B@KV/#;_Z@Q9ZT=BR@-N6B_PF_)+"+!Y"@E,4V^-$T,J$1!"RG"4K
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M3.:<;MUF& E:&78&QAL,ZB@.F\C2#WD()2H=*4I,BT,0G+2&*T5TASZ*FI6
MQ-$=P6%J[#Q9,ND51=),<969"5OOCJ7*5"K1<<6+!NJR$BA$W:E.8GE@ZJ)8
METU!\EK/"PD](B685&+E+8_A7;6B2%-+D;)-CY'D6S3'+#-6U7:I1 U92"-)
M9F62,H&ZU10QV3RP08I.>4F*WOR2Q-FY194YG<JWJ,J9EL:RII]IJEI!R:V[
M(!*OD!OE[QZH+;@U!GK_P!'A2-$0@^!DX@:*'6F9B $^R5I6?-"(K&_V\QM0
MY"@4[4NF/HAA(6>2"I\KXHU_EC,,<**!?\38)@!O XV'<6><N&D@O40$%8Z!
M#&AQ4!&'D"+-@TV/&.7!9T+0$\'B+L>9]EF/,'_30,!LR+<+V5=#WGE0("F-
M2C>\DM.&IE$LF7>\1&M2U!#ZT?GH\[(U^AP9,;-7H-XMJ85THN \Q4K.$?5-
MEBO,%J^X5F0-9JV1.\KA&+?7--WNC8R3J=P&R:RQ5.["3Y$OM&Q5*Y0&M72,
M$M6:!CG67\EI4XH;VQ7#NJKA9=6PAEU53EN7806K!5,T%B):5+JVP:I2,VZ\
M_^\2S>K6R%0FE)-\$X %,YBA2CC!(D.5JJSR/O@.)0::M8T8KN<<B(E!#&CX
M,IBGFTQEI,'*:,[:9I@SW12Q#[Z<W<TC5232V\3Y??ZAF?X,) G8 NA  ;V0
M?-S'VZ2 0DOE.46%,LA L3GW3,H Q2;8B;X:\>S1S=F7/6TSC.DF1#[!A<\I
MZDQ PB@:N$!*$GA_%(0<WI"'Z 42TYXVZR!=R:-=.J8FJD;--#L'5FG<HE-Z
M'+EA.T]L;8D3VL!H+2'*%\:5"U2?BA74UAR[5G\Y\K-.14=0U4W'<K3B7=@X
M&<A!D5&NG)6W?278NB[XJ@X6EX/G^)>IU+%9L\.I:O\@#+L#0Y53)O;B84T<
MUN+YJG?E!AZG?A*N?/<4I<L:>%T*.4>?AO%0M>*6M'P7R&DEULK$4)?T1,YF
M6Q*'"S<@3LJS+-GH^/KE]-JT=W2YOGRB6>8UBY![$TOFAJ$!G #;L\+XIY_N
MJ!/3U,,@S1 XL%$+EX%>PJ=\K&:O3'SP/.*!CYG\:9OOG(1C&5S&*28]PA0E
M=$<RO%)%9PBDBCK)2>(-KWE]5.OT;A2A=_AH?.+R%MX X.^ CP&8)\'R\?DG
M$YEXU[L0KWC$.][QBT_\XQD_><I;7O*7CWSD(7_YR6^^\I_G/.47K_G,5_[T
MG4>]YQ\?>M6GWO6L%SWI5Q__^]1_?O.-G[WI,0_[T^.>]K_W/>^%WWO4A[[Q
MKQ>]\8O/^=8W?_3,A_[RAU_ZR,\2OK:$+&^LIWWF:*\11:>G^&&^#TWXDOSH
M)Y/.EH/-8GI6ZY=ESVU,2ZA%UWEB GU?)AQV_J'P.0U"83\ PDWM44[ U$ZD
M%C"!X2!Y=P?P!#231CGH)A%?H@^5!B8$929= 5H; @=& 1C$% T.PBX9L0D]
MPU$:-21VMP9$ @0<=00N2'<X-'<\Q%"VYD-34QX  W@\V(/; TQ;)@,Q$ -;
M,(1%2(1#R 5#* ,IIX0Q((0I)X1/& 9)^(1'2(12:(5#N&58.(1/Z(5"Z(1(
M6(1*_RB$,E"$45B$9RB%1RB$6R"%9VB$-U"$;XB$Q'&%60B'2VB%<<B$,>"$
M4HAR?/B%=,B$1PB(-["&7ZB'>VB&?_B(@O>%DDB(1NB%6AB'DTB)F(B%:*B&
M5#B&EA@#. "&,4"%A\B)C^B$@$B%;IB)?1B*K2B)8FB)2EB&29AR7SB*D"B$
MH\B(1-B$E3B$4>B%@NB(I)B(E+B$81"&?PB,D)AR1:B+>GB$5RB,S.B&4*B'
MT+B(NPB+U*B+P:A+A;=+7*@N8;9E*5=9S&%+Z=<;RJ".[1B/\<5F U0SNR8F
M2$=$\%-$8>=<FC".U]0?/V<@_><P!H(&%B(F/9<U^+)FRO_A,O&Q7%KD,@J$
M@(W6%=QA(0NY'BV2'10),D]1'_64(S2C@7$Q:5RR4"<H-#T$:S.X4402-3$)
M=V]G=X-R&SV8DX WCO+8DS[YDT 9E"WG:YF CBK'!6+ D[L19D!Y9T+YE,*Q
M?LLQCADQ'O($9U>76R8C0=!Q@=2U?S^7E>^X3>>W#'"0!HBWD?,B,-1E4%QY
M0.@$,ARX:.N37,GU7KUA<_UD4 ["@0O1+W$A)IG0:^4B(A@200J$:C3Y-#*X
M48YI)3KT@G& '_D39@8 >.L"E9JYF9S9F9Y9'4H93+W$'6J9&S=0C^A'69^Y
MFOW1'%[I'CDR,Z7I/3<Y%;AE&]#>T(^\04U2^3XX1PP$B0;WDP9PH 8*,YOM
M8E#VLH%]69)8%SP;,AX0(FD?<T:&!G\7!)(5@A3804* L3+H$Y :^&G=\A3<
MM5"V]H)44D,R*9D9]2/.64M_!X^L69_V>9_XF6;(.5*H^1O6\QWZ\0GC!W.@
MT'_Y^93EPV;"(1!=<I7Q%V@%!9)X:6<!B'_"H3]H8"  0UG$F09J@!OTP$W[
M62,:,IT.$3YR\G[M]%D"<U!1MX$9XENR42;LY(Z: ",66G;RXR4!$T$K&5$]
M1"4MR'8_$@I=-I\'FJ1*NJ1,_SHOH2E9E+5E_=D;14D<5IIRIPESP-FD3;I:
MU 5V 8AFSI2@%B,0?;E<O4$/$ H<,F5^:8!;0O<&<( QR_ _W$2;@ &!P659
M^L%;RO"!& 0'=^"7^/@V\I*!OY%9W2%_9"(;[!0*$VH;7?$S02,T[NDC1MH<
M:/!W!@J5F@ #G+HR-_!WM\2E1"0&?V>JJFIE(^H^O82E@M<<(2=X888&C0!F
MF?ER!;JJ0NFERW&;TC.EDD5,,4)_]<= F&9U![,;!&D@)-EU$*,P#).CC8HA
M$:(2!A6?P&2AP[!.?]D])'0*"IJ<*=*<,%-$2:$A6B(T3).IWH>DOA8#/:@"
M.)"5^_\PJBI@9SQX2SV(?IKP=\(J'#SX2Z,* +QZL,GTI/HX">4H!H/I'(S5
MJK_TC@@+E(3)')VV-<#J:_ZB2R?1G'6&,:_I&_L7K7,Q:)GP?W[&31F+=2!S
ME^G3D6BF1 RZIEKS'IN03-F:3_EX$L:4CTL)KVFFDW_76#CY=^"QJ0# 'U1!
M#'^W+A(;/IE0M-8QM8!GK^-3L!6[M4,4M?SB'T;IL%SV'&#6E)W*M>FWC^9C
MK"2KL-LZLF=B?\[E(3$2E>N'L]^T36&Z#T*7!@##ML$QJ<BZH/@"M-L:@7SK
MMN<Q@BV7$3,3(H9;/:'J:X!G9P5;JO)JM/>:JK>AM%X;/L/_\'=8VQRH*J\
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MV?B28PE-D') BD(&16<0=@\OS]D-[1[:B 8U..8HK_:)N-MZ<&1->/9H=WF
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MW-8Q(0NRYO[Q(0\R(L-MZLHJ!$><!/N/&!S  <3  <# )H=K)EO*)Z\&)\=
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M_S\O9E3R#5:O%^O(CE0X: N&)/1,AM,$A7=X?PST3A@U61[$3QL 3]/V/L!
M +P!/<AR7&0R2JCR3+AR07*R)'XQ2/1*OA@ .1JC,FCR^;A)DEK*0P0 Q01
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M,2@&0.QCSSWK-S2@-0Q<,V=B.\@>CS6 VIO0:+8Q)4=KTC$ 5BR-1WCW,3B
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MNB3W.S=6@B!4<$7V;__76>7T<J<#"(Z @1VX@2'X@24X@BEX@BWX"&(7+@[
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M2_4;6&T,">?HCFJG-7D74=WZAR%7!G*V/G%Y'2VSB;?YP?'Z".! PBG\F^/
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M@4'MPY]U!ACX$$C*!."31?_Y-(E#_Y5$$ S^$6, 5AIA]<9, ?B7WWW[Z!.
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MZ4M=]A*6P>2E,8&)3%PJLY>MFY)7AG& P&W'AZJLIBBI>:T=6A,F"! >7Q)
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M,C9\'7<NJ8MHF?5F%M4R@.^^K?3?FY>FICKON<]_'BUZY#S6*SA3KHLG6[6
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MP:4IC2^K6]>=0,@B#H*P5B-,#PF']"@98,UX*)DA5;K829L=:X@ 0)/A#I=
MFD4N8#8$G$K6N#-3CDUA:210#& 02C%0;R7E0QL.6**Q4Z)O9H0#9NC"P+"
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M83D=0 !(7-LJ*5G!WBTSMK6/XZQ\7A\;E,<SU^QOF@@#6*6I$ACHBW]O_.4
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M'%UZM[13IIGIP.L )]!:B2IB)<\Y.9: @8!1)Z\CJ(OZPI@C*XW"CE*$"1B
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MT>.I"EJ%6MN469SB#I^=Z]0BZ.$;9BRN/%I*,GH63Z>3TYHN\PVBQ1*P_/T
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M4KJ)I]0Q/,XT2H.S&N=& R7\3Q#R\O%HL<^?*_"\LLR&5 ;]R_SP;VR*5_(
M3/IUA&N7.;:HF+UBBJ^2$!"T%6/((1U.H@W;#U.D#-X0GJB),T3?TC_I'GMO
MU;<; 8]!E?Q^<J>@3$OFV*/1-? 0[A0=M*:_M2ORJ:FHB6M55W#45*MK,HM%
M%](I(<$9(YG9B_AA*PH?Q=<U:$T$Q^\35^[[O59^-\DHR:*(EDJ8Z^,.KA9R
M^GY)@>ID517]\=GM@C([!3W5&4&&&2_JG"ZA+P*E2UIB-?<^7A."=*]E;+*9
MO,Z;%=Q;HI:L,;'"H,0VMD2"&=($).K.%:=W90L]J>+##>_0TB'!B&91&>R+
MV;WR%7RW1=9?1G^BV-L_RT5+]!\WL?>-Y:?6(W\;D AVKOB<G427A!>X\R=A
MJ2L3(JNL$T*T#T ;_(]I>XC(!C'ZG1MIWXPV68CEW:3?95^9C&Q)T< 3*VJ[
MA.5-MQ[.5Y(<J7IV=^#ZOF];QQ\=E\OC$&,F"X97:P/ZAT5DMVON))=5ZT]+
M!W&&$<PZX3(SGE<TMN$YBQ/'B;\5<0\[C;BSD=!0$2] RO$'.G#47QFRVWV,
M?3ES/JD=NIH+4RB1OW?G^X:F ;+X7(%,@A9(_C3> LZTX='"O7#/^NA_.__!
MOXMWX!JR;<.A<'0?E[.PH*^M(P53#\_.'CM2T;_BC;0?2<NXV7I-A+FUJ=_L
MRG?Q(\BVC8>$](;2D\KD0*_]O=WWYHBTZF1!C6.X^2YW-U8I:[ON3NJO>H2B
MO.L12D+"Z;4SGIH/@#7FE:-/CAW/BOW\^1Y$QRC87#*>;H.M;H,I\T X9W0:
MXM(8ZS ^M]=\:+ZJ%I?+;)^7PM)EU!RX)2Q?M.'D.)>7#>E8^&F;X@*_WA0?
MJ=/L\-_1 40],^<[O&QZTO*(?Z?.-7>.0\967G99)@X!S*_JZPWQB25M NKY
M/N4 \#.U=OKS4NYVH_+X/8OBC6I[DT]LXH[:Y_QJ\&5,.$WA3ZD<Z419@S3D
MV+2V/!;X@^##5OQ='Y,P@!.SO&?V )2%W^[I5NG=V;:?C[6G/5:5$K^)1:JI
MQ3BD%S*,?RM%]0#8H3)"O8ZXC0B9GZM.70";-6.Y8>XBPQVC8,HX#3J?1#\A
MPN1WGM]1>[G+P]T4U(*AFT092Y@"/X-/*EONRA7S(P)AH\:\X4KT PGHH/>U
MU]3[&Q]9!?'% UI$J'6OPUY?)X%C_7JW#)K;19ZKA9'6YF3,3NQ93,D8,)_!
M !JJ<,7M<R(EYD+O[]6O(N 0;SU*AQ>=OQNPIFW1S=O@ILV+26!KYO[K%>/?
M( )!TQ/XSW-Y4O:[C+DQU/&TX2$H2*G>,UR9#T#?4)&/2$%9=J-#\8)O^:D
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M6.$] N@?C-WFCVSRM\4<U/_-5MN_ZC?=TS6X4]_!++#KG\AV,RW:G(10P8_
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MM@N%/^D_3 D3]<O,FK:D>Q-[NNI_RQ'_MN'-12G=B9%=IJ@X%I;L^MO<_YR
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M2"2 1@(X)$#X5T,B "0"B42@D0@<$D% (HA(*P!IA41:H9%6.*05 6E%1&(
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M0>,P.!R&@,,0<54 K@J)JT+CJG"X*@*NBHA; ' +2-P"&K> PRT0< M$'!'
M$9$X(AI'Q.&(!!SQ'_O_Q$82 #0!P!$ PC\Q" B @$ 2$&@" D= $ @((L$*
M(%@A"59H@A6.8$4@6!$)&(" 01(P: (&1\ 0"!@BH0H@5"$)56A"%8Y012!4
M$0D+ &$!25A $Q9PA 4"88%(( ($(I) 1!.(. *10" 2_V>$?VK\H^0?KG_%
M?U9  $0$DHA $Q$X(H) 1!")5@#1"DFT0A.M<$0K M&*2,0 1 R2B$$3,3@B
MAD#$$(E5 +$*2:Q"$ZMPQ"H"L8I(7 "("TCB IJX@",N$(@+_VOVSVC_U/Y'
M^;][_]_F_S^X?X)( . W(/J_Y'\S 5"4 C\H.?3J\7UA% PB]B/UA?U14%Z#
M7+V&HL%8.-)C?:2A>#B12S.&0[^Q9#15R*+*?K2Q=#Q3\L%8KGY3V42.O.^7
M]=&F\JD"5!@5IT%SQ4RQ7JJ(PUASY5RY:;%!GD%+U4*U39/'QEA+]=);I_X8
M3L/6FI4FM[DJA_'6VK4VG]VQ/,.VNHVN@.]?-L;;WGY\CR&COFG47K_=CV5
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M/VKVE;I]I" *5'DH,[I4R=3;IE5U)%0+:XPM"-@X0/.TLT9.JLMW_+VU5*=
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M.0FV)S,ZXOB?N;GTA:L)_!3CI#6IRU"%:>#E>T8N(=>D&I[VY(Z'T2X=_\!
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MMNWEJ7VE@0H$-F#4 U7+J@X[[R14D8\$64^]3V);3X0<ME^$<$N6^7%E^T6
MQ$>D\&L&K@8Q< F<?KND@->J>%"P*R$ 0 NZ[D-Y*\RHTY]K;%WF?5U/X9]&
M;1>$2+M?'+&1DGM/U3K]C>I=1&U@+$L8R   @++"(TH+@9;QC5:C^R& I &
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MAGK$$]4\@5B3MJ'^!BV4F$/K;9B[>7)RAV&'T_I3*WTX#3@F(($%X%M3&SI
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M(I99'4(L>1("$:07,D\2R)*SQ-"DD@<4FO0T-Q#$M@Y$2Q#="$1@/:PIZN$
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MN/#A#5DKI6P<:XS+Q)L[?PY=*8"M<?>A 9#<:^GHW+M[S\NX<<])F6Y<Y6I
M[O?U[-O_NU<8XT#N@;M[CQW\/K_^_2_M*[W>4R;$ # :5BLPQU^""BYHFB0
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M4 +U,PP'7>AU%*4H--PFH,YJUPT$.IV++BJC&,4!0]$PT'XFE* ,5:A'<6
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M?80A #C)S3Z_U#*;^<O3Z2[-052*[X9$(SEP(8:';K "TJMT&:47RNP],B0
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M'5QR@</@&'JDP5 &L>[E]/AE)X;!8YDHE P^-6./U0G&18VOE+G\ETS(=3-
MCHPR_GR##EI$R\M1QJ.=J&5,"R0:DF"S(D_=KUFRZ 9C<#7%,BN&BLVYQ5E!
M0WS)->NNJ9J(+][Q?5J=9CYK>A^-.%0,X'SIR/R9<I- LZ>[[>UO@SO<WN[:
M%>,L[G.C.UB*Q)&_;K S@DZSZ,J!3#<:0TWO>^,[W_K>-[_['=E'.LS? A^X
M1/3R507;NS@ 2**1-D?PAT,\XA*?:#C%*V[Q7Z6,8F* 21BZ>_&/>WLWH3IG
MG2NCUI_\^9RQ!3G+6^[RE\,\YC(GW43-&X,T)'SF.D_CQ,)RX\[4@]@^+_G.
MBV[THR,]Z4J7.)Z7[O2G0SWJ4I\ZU:MN]:MC/>M:WSK7J1X0 #M02P,$%
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M )C_DO]Z0R  . 2 @ !0_]4@8  $#(& X1 P @)&0< 8" P @4$@,#@$AH#
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M,'&LF!(W>%:46=0;2*64_.3<_+O.N^#\/M 9V62PWU;IWZJHMQ1?54.T*8%
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M<UWC68\<6.=/$_P6W[X4BO4E/JP8*4P4*&>4) A%5C6.H4IDM43G,[P+Q2B
M(F=9(#EJ6J24&T>ABZOJJ-)XI0#$-612A%?QC^A[+@'YBBZA$K$2,*'D^;UX
M&X&RO=Q@94HAU5ET]R6Y3%Q3*_KGK(@YXVR'_'/#P;W+*3A9-K51_5[):! T
M>?NLHF23Y[W4O)RA]K5EK]2%_N:I4@*R:#2* <I9?L"+F#_M"7%-S>;+5TIA
M$_21ZM@GT0[JGH;T^WF,\/I-]S_PO?JAO",RC$^^V)<[VU0A%%T-OB0<U+[4
MI-=II"FF0(>)8.D05UP*]I5DF72J(+64-.:DY[\#/]AB6*C51@.-WCEP)'VP
M4(]:H0S&UG8_2OD+9,W#%A2Y94) $J_=)_C\)#M+#&B/2A\;,G[8<=E84&_Q
MR6URX/U-6?M[\4P[YXE33''"S92$(-?AEOS8V=3;"X8UQPXH5-9=Z]TV/[UH
MMS'<;[F%7D$\,B?:@JO4! 1%]F$?2QPA":.K)IX\D<7-9J65,W(=5D9#^E8O
MQLZKDZ\0R;R.L\P$DO$/:=3:,=P>2RNR.D.#'70UI$?[73\(>GE?Y&#+55?.
M5NWZ)YU,)B5W2T6#R+3)WXDE3EE:]2X>I48+TF28YR;]&*WF)TU.I=D76VLR
M9_P"R.X*59$,4,:_74.NKK048UI[<LK,7ICVH;*BLFD""!5OL&7^N1ML7SXS
MK\:YS67N.1#W(JS)]TG%,AJ:A#+2!7>(>S*J!-<[O!OZ1FF.W$J,0#<2W*.>
MQ.K[RRB'7.6ME##CK92_Q5Z>?LQ0H1![6B4Z6SQ7#NX7&N$T_HNVFTOU.V"5
MS]EHKH4V7;SU)9&"_9E]@0T:VV >PRYA[""+\QQ8M8 AJ$RN"1B$GB3_[$#-
M(T"'LEN-[!L$#@H9_2Q?R43TJ#@S=T>PY9432=:Q2D8WQS_FY<H%QAC$YG1K
M+((#=(<%'\=/AFE*,[D24>(2RLE:F> ?.B-\V%#@KLZY6Y(AX:9WI[[K#^6I
MYB+!%4SYCLYDCAP*3%X1TSZ5MII?0C [7<O_MJ@+&*6MVKSSQ'#/27Y@W8Z?
MO'L4)=SQ10W42%41A$ON#QXY%-C]>\27R57]D][:G8.%]:\,\;&A/6+Z,5F=
MWV_SZL>L#M;>O[\MH6I[K=*9C'P5<3?L7E7,1X:ZN8:C9/=/&F+9+TI;B,I
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M/\V6\X 9J'%#?5^YI)F4<+;\4R%H>D3U>1.L/TRPUSN*2%JOMAP9K9VA2Y:
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MY-S_$ RD.DZN*#%J76IUN>(S]\%O!SF].W*OE9[>O*V$#Q(5<A'L.*4I0:E
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MYHA*"-F4VW#T48"*YBX5!%-%P?0E69V<\:MIS<H9]Z6,0CE)S=Y*OL E4OQ
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M!;%BIX<V)S%C''54$%(5!)02LL<X$7$A+G4B-Y=S-DB+/;$WV2(W<9,&%4%
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MG).>)!F1$4EK(XW):0[#H#)N"R!L\CRX.!+LP+A%(D=DC D)3)5B2 J;H!_
M@Q%;,96HZ*9-.[S?64P$F<*/X*YRP2_CC+S"R@2*($^X<)7#4A^D^)!G)(N[
M621NH2QN\A&],15DC$Q3>XOZK(B!%!^U3,ZSU(B#* L+],1ZBHZH*,L8@JW0
M#)D9^TV5VBVIZS5AXDT.6H[0::':?!,UB$T1+0T6<J$=/)C1U+)BPK9@2\&;
M<P[BN/\3?[D2 ZFGN2B7]E,:7%&0>BI*!1E(M5BB\R@*^B@P0.- 96A*13.(
M;[JB,HP*P32/(TE/A#H7Q.S1\LRTOYJ+K)0)K;A"0B,*G\B)@>!2OL*J[\2B
MG=&BM6#+]"S(^B21R#,9LT3(H?R6&=&P=SQ+= +,^N12@ZA+=\D6IE,.R>$D
M#)I1%<S0TQ@.?3@ZXQJ=')P$Z!M1V/RIXZH-VJ!!X-R@D?Q%)HG0$+*2,AG"
MEYB(*P30/[51%KE"**U/$G-.%A&*K<P0]F%0NC"/J,#*-V"W)NT%*345K8C5
M[6"OZXB.\4Q($M,+ ;K(%NE1P\JC;M*B@WC5/AJT@D1 BAO_"$*CJP ),<M<
M4N(3#^1D2"A%S+J!B\'$U6HELY$@2GAT3BBM"!CUL6&3.F$<3>4(1AE=JL&(
MN;\H!AWD.2'+@5BT5!%M):,3JLT0KAV*':02R=CJ28XLG([0-LHQ"Q[%+^P(
MR'6ML+9<UCAE+V7 RF*1SG0$- E!5FM!BU[)%.TL2(W 2G3U4C#<6!X]QC=%
M"$J)58Z]PD-AJV")GIBXTJEJ6:G9SI.-BT:!1W%%5W=AQY']5E-A6D%=TGH2
M66VZTKG(67$,E]XXP<D1SL=@'2U[LN*3+F*ZF- $,L[PC-_2C)9$6-@<(6A[
M)5::KIG*,N-+)AFUV T=C>5(-!+[_](N-4[+?#0'+=##18E G4X$'(B,\%&!
MQ-7SH"(KBKN</=?++%:4(-8&5=;(+*"V7-*F#$N#,*<YZJ^ZU(AV@E6SZI"M
M =!4TT^H;<LB4H-R\5D@B<AG==":A0O)_"H[!5"@==6T: T5U2'B($6:ZS%@
M@][063(WX;F'F5NZ=4F',1A>"A-7<LV,B3D<^\G*R!,LDYU@(R6,K8P9:5=
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MI6'42SD@E48.Q+[(9G,?Y>>7JQ^:N!M7<35'8%4#,AIC5"9C69=2DHBM:)=
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M+]N#4%\XU;_*OE<[!?8><Q )R!#"]]89!N!SSMNV['BL35RTRF\Q DWQ]+F
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M>-+C&]%?>90)NSU.5^$BMCP=Q4C,$CY.]R@C-#[=,N!G#,C %LA #/]PP23
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MQ&*2)N0F8L+%C-(+G4SJ5*)!*^2@P WNU .<&$1DMN<C4PMAF# \0_0_@NA
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M[%G2(7O"F"GMHV/&\Y*;'I>TYGTO0.:#R B?\B5BL$\_]& /\H@10V48R'F
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M . 8 !H#P/PG!H8?@.&'8OCA&'XTAA^#X<=B8  ,#(J!P3$P- :&P<"P&"0
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MSF ]<<E5)'X QXK3'":A">\J0>TTK,Y@#G_<N>@A7P/=9(]8Z[<).9-P+KF
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MFU&>KXBT/67R+7P?60O!3!:;3\K9P17IV;AN93@&X_CF40RLK.U4,<&9QF9
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M)/M8"2[A=5[ (M<K(COIU#G> WK5:#6_/7,@NK,8>2"+GC7XL?WV+=O;?Q;
M $@I;L1;L@B4/Z'C&YHH!E-><I1Q:RPDO,O\Y6KI6^?7-RJ<C?2OE:\34^A
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MH]$SOOPP*;,!VG88:2QT/; L,E>WV1M/)->80)["'\$"SY1:!S[!/G)CO$O
MJBER])ARN;6G\KE!6EI8"X TD'@2ME9?/G,2D$#X6@LC 9_LGA.^2(?/HD(*
MC_)R3JCN9/0_/QN;AW?Q_G)#304AZD*=1AUD<SZR1''7WBK-)%54AL@V!)*(
MGZ;MJMJ0WPU-F".\)U $-LGDX:W,-"?)J:&(?M;"KNQB\'*(Y:E!(IZ @] 0
MNH>X*I*G3,@EVFH=5RR\IA?#_[3<)3MGMY&@M(-D4G0ST?_"ES\TR$  *%.'
MZ /9!POLB!9%=M$0Y?C@Y3VYKE_RR]:7D0\E1BB14M2#8;>9 A,&(G-L?L@Z
MEE*P--P%F"$#YZRN>> 2-BD0Q#X:H,*ZI3_I*-,=2,]&:([C^CT84/7#A"Z,
M9*KLO8[<>N&\S[C_B$VD$7(/?IS5SE]85UB:C#KDE5"HJH^=ZQ-HZA4Y]MZ4
M8MUU0]XQ-*@?NZ0'"U42$JG+QDM7Y#K%*T0KZX$^OVL.*A#*SO@]E*UF\K)>
M*TD?+\]HL8H\(BYS3+022JAO'/^]14"<1D#5>(#*1]647I!W,# W.RHW^QD:
MS^[?FEYNJ_9%Y#,[,@VIZS%>E,G M= _M*A49OQJI9E)CE4"JPUQ2:N_#%PK
M=[P+')!G;0T236QY"/.ITGL\YE'[1@:$^WPF0(0P(%R(!_ 4PGIO:_5\67("
M\A02;).P(5"*%7CVJ,MI=;S8K*:KN/OE)$><P9[^J8FKC;:M;TU-$UG52RC*
M!_^->6 XR<XP6YX"L;]? YZ@P#"X'@)N' -O@9_V"3A?*0#C]IX5._'9\(Q_
MNX34Z3C$NH_+*C\;O'KZ9FC</K#"C$Y 9AV9%5OWVL\Q-L((V^"8WYN)B--W
MA;,%F$M\BNH7>I@IEM*YO_%7<XM&:*8(=X\ES9=6&\\8KK]I#0$F/2I3)"K;
MSX=<%^*Q05^.,743)3Z[EK4&?!63.X!.TK32HR2XXJ%#F *'L?0(Y6;5 5.T
MG>2UN.CLT+2BI(WSF(JK\H>'V'C+QV$N_:::!)G^Y#"TN,Z+/D$(EDYH],%F
M#BD>5D$>8R'J&F-3OO*^VD]EZT)P)F1085#_,Q3XJ4%H($L@+]XD:7OU&Y1D
MB^/9.ASBK1*F3R#QK4R(HL*HX@'I28XB5R1YKJ:C46UK]EN8RKI4BE'TL(J5
M"I)!G! ?#U((03<JDA>=_H1DD+D(*"['[-+DE$-8_*+J*)[6F\5+#YO+C*R\
M@7WL"%TF:E[9CQQM'];=OU@N;,R1UNW=\E_!M5)>[EOF0W29=O;@_63\JFDH
M68CG\L.$\5)X:IT/C5PAU'!\'Q.(.>%S$/NBU[/ F]NS*R,[_GAY:"_1=UGG
MKU:7>S;>0PMYS-W'4!/%F@#I\!.NCA/(.X+?@C3!#96+1+9"1DW51MO.B^!(
M 7#@.(NM^S:GIP7'_+:0_,[WAK()5W:,U X7Y0[[=K3,OQW+C :^YFVB^;@:
MLMV #$Z5Z2<QB;O0C[LT(N0(*W:.7[OAGW=,BW_0@&=(T[?/&G[8?F0U9]YS
M_/?$^N-+-NL]UQ<L6A_W/'\],9 '?18$.__;"_Q'ZQ"V'Q)&'_!.R^7C/K*8
M/HSQ(%J/WD<(]((2'/KB(&F3!MNY?I V39=8S&/,?)A33/<J[##_%VT;W4;X
MQ\,22KHHYJ.*C[1QS*#X7]*5'X^LSP\:_AWQVGV9^>S)+'+(?GG85/R3AU6?
M7ODG8_HA4_JDEZ+PTCWUA# ?K]T< PXO[SL27(.>,# 2\05430GR^_>#=4!P
M5HBNYV):WN=X3@ZL7PO"".6LA FD;X.]XOTWB\'?BT_&WH%P[R#KTUK13&#S
MUD^17?'/E[[+11@&'Z>AF)X-BQ$*I!V1Y_8(;HWRE!K1\NX_<0<"OP GD&.1
MMQ"4>_%3'%VZESO>ADELRGI%>ON"K#_X12Z>X'R!M+E\G [Y\H@&H"]%R3"A
M$34(D %A3R//V R=N9N=&+' *Q[WYUY(@;? R6B/4"LPAP2:)OV28>#R\=SN
MHZVDYU\7(5M'+(HK>'-QES1A%H(T4-@SV"3<:4&,FNL=->O[A>+C?_*5-$=
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ME2+.<X+C?BC+BMA>_/$CX4O8FWW"KV5%>_"5LG^Z"/<(_C'7>0,)D5GN ,B
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M:IZ8Y)X;"F[N[!IFZY7JB'G/"59%<X2HVZZ9=""R."H4E5S)= 4K.*ZL;%1
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M1SB*2-!=Q4NBU!IG."]V+U^BTF&SSJB=3+BG/*I+_^,;KQ6_$L; AW"<R"0
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M=0+ E$7B<:@P'YN'&T%VZ Y14O%1&6\8AP^"O$+6<5XX=4NS?&)@RE8 !@*
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ME'3 B'XVV%68@8RQL@STYUM#EI"S%X-W!GG@(8D+<75OR"RW1C  -0FD0BH
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M&)W<,Y[,&*-LR@BP J2<RG4Y2NLT5K_CLMO'BF7C62>W(31HZSS0D!5F<B.
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M A!@5,I1A6)YF!A\3Q(!^!UET!"#\65J!=<DIV1&(@9TII-=QU.G.L-I&!S
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MLN'KEDF2I%->YVA 254VY7;_=B55\I.M0I=WZZ)0-@":"1'EL*KEN8I_O@I
M81Z"QHKF.>A_1FB#3FBL .B%?FB'CFB%EFB&ANB)1FB IFB+KFB-[NB+YNCF
MR>B/WFB2]FB0/NF&+NF1-FF51NF(9FF87FF9/NFO:&F;AFD CMAZ) 85R"6^
M48RN (")=0\#$&H5< \8.  5N%BD]@KW:*  @ $ ,( 5*.JB5NJK!H"HGFH
MZ&H#4 &K!FL P.H $&NPKFKGF5@#F-BEAH^E/K>CA@$5Z&H F.NYINN[MFNZ
M[NJ[WFN]WFN^-FJUCH$5F%BA'NJEENNZQFO&_NO%=NR_AFRZ3NO"-N/")NRU
MOFRE_SX Q>YKO>[KP,[KQ6[LT09MH3[LD+WL&&AKKT#MT7[MSW[LTIYMT@;L
M]X"!PH:/U=;MM]YL,WYMV99MT19NX';LQ8Z!PZ9JK\#MM29L,VYJ_JV9SA.#
M,!"#P4B#XE5<&)Z@3#D>@B &O;GC.L:@2@9DZYMD]&[D/,'C\DYO/]XR]V[O
M0C:  Y+O^/;C;PH[^][O.[8^_D;D2[XL'-:WKBBK;_J04M)O!<\LO>$ZD3RE
M!$^294R292"&,* 3"C<EEGQP.A9O.N;P>9[P><Z\LCFE#8<D$/]P!U=Q$#]Q
M%T^2,2CQ%.>L!F]P!F]Q#<]P4^(;%)?P'I_Q-U9Q&Q?)$_\W\0SG\1<W\A2W
M\1I?\1G_\0T9\A^?\A5O<B%W\%%:ABF2 2JBI!BPI!C0(CI,GE!DI0%7"P.
M7\FXQNOHX1>Q->HY\S&3<UY;-WK1AS2  >6%BE:*$3;GE'_;M^C^K$%OB[<(
M<)D[D>]^VGUHD>\9%.PH(QA9 40O#S2(N_'X<M'B@@^Z.B+<\SH!H!9?Z;^O
M?=#R&.#B]"A &/GSZJB'&)(1VB1T&0D1-;^Q27B;A8B!(]F'Q!V(Q<UT.C<+
M$X(1TX,1D1%VNSH/5-=#4.<UJ]"39*@;\H@B3R^/5H\1$G/U0F<+(,T.35<[
MR,#U).$;I7GA$@^9';Z./G^1-"<C3,>.;L!_LQ@9<SW\]5SKBJP@!K[!=?*
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MQS<K+$C4^*),Q!!$HP6)# [X4KN-KG ]*\RB0 U#SY::;QB$_!>Q#I#0A1Y
M: TU@$3K&1F4=M1Y',2!2"U:T9<2I:1%Y9M)HY46E Y-J#!E'[K^4LW&0"-U
MT2-&_S)L!XJ GD\I8G5#J-X@5G$]IDG42LE:)X$HS*PU#9BP5JA2$D_HR56L
M31+K&Y Z59M\]*_ZTY="[HB:K'8N=5Q5+%B#8E>SJG6OC?T),<0JJKUF(@V3
M_4E=K377SII5-W;%+&25LEG!ZNBI!1$:7[)V5]3"-K9N.JUL>Z?:,!R@I,1;
M8VU[Z]MU=I9=>A55:(AA@$@!B"7Z] \+"70QVA)%*^?\[6$"2UVU55:M2I$$
M6[-"+ #DA$#)@6Y10N+7PTBG0,V]+GL?PCRIK(R6+#E ?(]#CUL"AKSG&UP'
MCT.BX67BK>TURWD'C-KW J; 7 $1?/7K6+(I>,'AH9B#?X^BC)#DU\ :#A#5
M-.N?"RNMPC?YG^%$#)-HD*@^$28*-#(A@Q7$<L-%L:Z,VPNBK'GX/XXK,8 8
M'(,<^R<: E$Q</ZC"0NEM\8/VXM%$*).64E":"/Y<(@R_&&IB43  Q0>38^#
MX/ J^28F#O-_HD&;S8WH/\J(<@RFK&,T!( ]8S8*DM$P9YC\M\O^.;+0^O]+
M9ES=AXU@X@^ _I=;-RN/:H@VI-3T7)P60UC-2P/RGSFRXDH;*&K*P-# !F1H
M.2>WT9>.[N 6;1Q((V740TFQ=VR(Z3;AC%OS*A"K50V4(Z\ U':\ 8 E3303
MZH;$;;[S5&W]:O^62%KE,5">C0V4=O4ZN6@ @*[]HP_\@GG7*CYVFEK5*FTB
M\;6H0;&C%\02&F/FQ@0Z\B:Y'19W/VP2!@S56IZ<7''+ZMRT+C<Z!:,^?</;
M0#@;TZP#;O P$_O@AU%8  W(;X5#/.)Y"0E"+)44YZAS/,!&'5H#]$$.*H88
MWM7-SU*2<(>DF2*9<#7$G2UQQAQ@7Z'-F!<QSA#_C7<<;"$?>; 5<V&7=Z4A
M)A_@SM']<L<TNCY1*W*P>5B0FP7&E(]Y@R3D/0FW*;W=_LKL!X]".*!O!  7
M3@.6:".UDS.$2'8E"=&(IF6#@_WHA=$,4Y(6]Y*TJ"\F0X-V6/8DOW@=G-;!
M4$J*O)ZH%<< E27[VZ(6 +1K<+1<^KK</]PDHR.&/O:Q3#F=;._%P"TI):5'
MO$2&&K+1IHZAI <V'R,T#%G27 P'6I_MR:T81QSRE1^*/C2AE+N;1/.,U$3!
MK<6H!/]X259A_3*'-[.FW%'JF!$:66._E=F?'C""4?WR6[_[_06)1! ,2Q@X
M&"CO?"IW^"Z,%'5)$H*&F>;QQMH'IKS/&/HD9&:=JJK!,?_])0:)0!2+,I2?
M;K3?>+R?_Q'8^0G7VWP>S&')=-0?H[B%+F$)_/W?8R1+7>C>S>')7FA*L81&
M&J1,O7U09I6*2]1*JN1<8\2-ML"*K.")D81@3[D;\&6@4&2;)I2@<WR@092(
M)M@@8RQ+L["@;L@5#5F+7X26;AA MKP*0G!+"B9$K5A)"__FX&&(@0&AA-8Q
M1CE9B4<DC!>Z%)Z@'UUP&FJ$TE70 WSL P8^!D%-1^#8GQ#%@#^]QOAAW\$I
M8!8"30PP'23U85[@#'/ R!YBQAKN X^X(1RFE1DVX)*LGV'((81X&W$HXAT2
ME"/ZH6$8 ,OM0S34H6-DPO# %U.,0<9<E6,4Q,P 0%08C/0UQE%@R&;0G3[$
MC*?\6)1Y1P TAP YE=?,!AI8TL.Y6P=V8DF08)S@H$:4HMB0Q8^!!M;4XEVL
M!RX&3IZ(G@' XD'(HF-HAM>DFB\&4^( !MS$ "A<8RXF(V)XWQ.>FNB4!D;L
MQ"06ACXTB<8=!3GJQGVQ"R@DQ7W_;$ZF3(;(#0DQ?F.'F)P*,=D-!.+!-6,[
MGD3Z*83Q'4?]?,2G8((4]>-D'$Y *E1$.@0]Y.- ["-+A8Y29(=!P%E"SN+O
M"02[A*1$;MU*Y!!-XF3_B&1.9H1$U!Q"Z,/)\.10'APM9@6)N"11*J7:(.-2
M*D3=2,)VT,80.F55&IB9\86?+=,26MU.-@3S+"&U-.6!=)?5C65"7!AD4<MQ
M^![79997MM-95J4F,<<JBE98RAM<-L2(=.5DR"5"H%A?\AS&69W565YAFM5?
M6N5BC$&"%:9>)L3>..82VF7HK(=28(AI#5!]),EV/6 ]G>-CRAUD+J:!-":3
M6!9IHN5E<$X"687*7SK(.7+=)& A9FC"<65"U5&=/1[&45S,8RIF:18&._X'
M, [(%A9(4M8.(&;A( HG4XYB<2#GON&(4*H7%SZG68!(67[F8H@@@"C;@/0)
M@8#;GI%A[F5G6I659U7F09UGGCCG8KP3@40GH\3_9WIF1"F&@1@<%PX8 &\6
MAAOV6#9>TGLFHFHZ!"?*W7WBYTEDS.$A15HP:%$(Z( @XH<9%( 8XY8UZ%/@
M#)C4BSD. R@0PXB.S@"Q!S&0:#)HPG2%!D.*CXI.Z%#4 WO$*(G^9<8LTH><
MZ,LA*%%*S <I)V, T7:8:'!2TG:(#HG:D;[(*(NZ*&IHS)+V:'%XC9(2PR?,
M:'JV"AT:1U0P5$[%P'$9!VX(C0$H5/(5!T(: $0=@.(Y1Q@$P)@>  SDU)=N
MAIB^J8%BVI9V:$;(FP,ZV8]J1D/I%)D>A]2L )K:*9R6:4[5:9IVY_T1S9M&
M:GT>TP&HP)M.A1']Z4L$_\Z'%D<Y_>BY-("?/@4TB=<8O)UQN-+_!2=/YB9U
M$(KUO"J J"KG'(UZV5F!Y.JG H5%DLB%\6E>R)2OHJ0!+I=_P.. E%X.EBI/
M=I[)B-R0(L:Q&@AA(2N.8&IL*"BPOD0TE"#U"(U<$N>>)>L"1:M"6.MCT .!
M?M^ZYN0PX,5]J*ESP.LDR6M"'%EUQNI"A">XYLSC.%=[$DR[@B-51DNZ0MR_
M"JQ\,BQJ%(S#)L0P%0C_?1C"/BR;C,<*!%5!1*QA&$E$H91JTD94\85<(AE*
M*2QB1)''HM2D'AO%;FQ>0(,8P&Q%A>QAG"S+_N7(5I3>&4??L.QQ]&S0TFS
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M)-H.2$F 7:!ISNZ4VN$G@&1A6$_OPP&85M11>*@<@TEK0'V:0FE\B>MF'%>
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M^C%5F7X:?:KAR;P+T9W;XNHL$(G(O#ZR;?PJOX"F3 4M+AW(BN3((#T3BR9
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M80/DI'&<MWQUY?E^>N9,FG7#@#J/K_PFX6P>F"SA#_1I+7.CE5;MT8BQDY%
M,QVX:OFQ7!7V:E +"%2ET[X,P;(6*X^_. 308JPGD9?P;'%M=_#3B>A6P=3
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M#!^ZJS<NM][!'JK1#NK'<V0K?M)::K=-V:7=V=*MEJ JG5>AT8;$&F5J1UP
ME@\Y?:K72P0(*KM:L3,DF35WKI#I:Y-8NMTH+)\K^LY8_@!6_31&U\\,0?R$
MS]2@I;VO0D\<2I.GG[7D,7T]J&XXHU-MMVM*$$TU[@6<_YT,,N_/8D,-CF$=
M"'3-^$2*JA\*ST)EM-P;CFFL?JP:E$E#:<IKBI8^3Y/#@(9(N%:*77+3\4(T
M#CMT"W""C!V51,:Z++WSE(N W+:VZ\RHPP^#'(]G&GJ*;H%4_8T;@>G@I$LF
MW*>2DX6M(BFRR&89"7SMQ&GR9+MMU''L(V (L^'H0ZU\K&<YQ-'8,U7?W&&)
MJU3$P$AA"$3Z/A"P8:B$S:#TPPJP]NA$DF1NK9C\#A6?+/*T_H2*6P_-U2(!
M'W!0_(C#,$BZ6#*"D4/1$01H5M?I=U#\[RZV@:GUXX^[\9X,U7%:S;5VAH%A
M?G\/.N2*SUX_$5W"<&$$E9$/LI.I5(BB:<#AX5EG:&K%#S&L^0&T7%-PC\[=
M3 $J:S7&Z[*DK:)R@H$AAPD%&1)_%+'^J8]EHW#<.I\2[B!\AN7%"]EY>E]9
MKL<"3&\3,[W*QBW<K.9GZ$IDTKF-?N,GD<5"6NV_>)/8U-QIY=1(,_&51D/5
MZ'+S)O=8]7[@ROF-W!]#(!60^7]0: F6SW9!OVY$3O/$KKZN-S20#Q/D!35?
MRFY:]&S",.4G>3PV&J&9-=_)V[$IZWO46P]KQ$_/U)$9UQP.+3JQI.2,_9EZ
M)2A)"C"W?JYW(8>V8$BQ,]4WD*G%#7%&%8JPYK*U^F&9@[\)K]![_#Y69]+!
MR%V6&3-ER2]L(_N@)/SYV^P'FL K44<",04S;G7TOL12C3#,XD)9,RABJ3PV
M;SA3>1* (G&'[?4^&=6$ULED9N/QKGCK(?'W=)3<EG63XV+S"B;Z*(X7[?!E
M/V+8,Z#(L/4\-@TED,S%E+Q#AA)4?U 4AT5&QH*F O@9$>W<Y)&EP*DA !\+
M#&S6!5K:?W?,9ICLLBE2#(!,X[L/,27.09[.\;<CN"/_DO!HD*/A<RZCY=B&
M:9G%=;HT8,H@G$-S!7?3RIIS38H[-GC2H:]?6%K,$B%A1U7[Z$J:]2?UA$4E
M>)*W+KOZ14S;NJ=!Y'^.$"A+)ND/WQ6=.2>5L *WW!!DSX\5".) "(PG@.UI
M)$) 1SG'C"HGE;8T>@?C-O?JW*9(SJA_B]'.'P;'_)1Z\Y>WO.I4];P1P7/E
M"4=BLTRMWTNL,H<H\5V4(W^V-M0L:C] +ZQZ0]0D$B]I#^V[#:H$J-;_I32%
M!D>WZ^=ZJLD?E4'%O9N=^_S3)1<16[NODL\TWG1 M@R>Q:?4R( %A0 U+=!F
MAUK?>.>$BW>HZ9TCTO5MQQ,Y_#*;I!,HAZCHCZR$)]B5FY$)F6V'N?6I=F2
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M3(:4.;B*]-$.O<#$^7*FPHS@'F >W$<+^&"JMJ6CX<:0P1Z&M38FCC"QWRM
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M(Z4=H<.,0U>CR@[]5?=]02</&)%];HK?%0,EO8-Y7,5<\:6W$/M&W."?%!R
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MD./4=D_BK4^MFU82YV%0Y<4K"16X ^78/LID1AP]SYHC7G1@._W( PQN7<:
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M#:& ;8DW8E#OMVE(86?S6+,$TEE<?LPVNJ?NXY,>7G?MU4T_]08[RK7\3XU
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MEKP&3:.MP48Q.6]3C[D"S$VS U=)0^O2(A90%-Z-^A;A,:%B)('%V-C64LE
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M#L3<H5CR1O^^]3VP!H&T,=1O)GD@/"0X7L=LNPY,;I7%+W$3+U2F*,));JH
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M;N*>2<(%-AJN*<C!3"F8N$.!62;GG^3MKP#A4[26U+5[L;6I'MN^":2CM[M
M,6LEWT/RK+<FVRCVK11"84]SO#0A/LA'8 @X=#;3M&,JZL)Z!1\=<KE/UP\_
M85(33LMGCIB?GOJLAF2*#NL:QB>*/'$2_A(P'6ZT_>6AD1BQ8!5<\SQ$=9@,
M5&ZHG9"@45QXV\"C,?&QZ=YN&'_P< %,0.@#'U^&.-IR"$RO?IA(ON2;_J=K
M?PIBU083<(1C*WF=0%ZH08U1*EX)&K'A8@Y^!A9N:>UJ34E:LJ)\EE)IED?@
M:$!*/MDR'>UE86=G[M0FI19D\KG<?=[P][GT_XN]B2;UCEDZ!VL2ES\FC=W)
M++EF"@)QZ&3KX6;G42G7]KJL*@TOU74DG]91@'U.G+M)WJ;!J)-A+K3APX(D
M(N>SCVA0^;!@VX2W9H_N>?29PK VRZ;BM-[#5A,^X/[$<\_2HDR=:S4"!YE9
M#^:(C^=1\30J\UQ=ET<3@<44'J%K!JJ-"Y6!96E":XH'1M+<O Q3T^E1/(G6
M*-J.UEU?-\FZ!?E;3R0NX_BQ__Y#X>_-%1/EG7AFXU]\]]Z??.M'4()=N O.
M(1*EA^:/N$-7Y>K3;N"<RND.E4PLB[CF(XL&RJ !275Q\>  F,O6 T9ZT-?S
M;S%N>2)@B_4T_>>'KC<;WJVT.N$<O]]='XG,1_:=3!'9=]AP2>>$S$O>%F>^
MN!MH.?C+W"'VH:(B?\RRKBD/7_=  ;O<:#^%&5[W_4L/3QN3_0IDD:2+PIB?
M"VV5NU9?(>-=_->!ISP>KY "Z"6T1'PJK)[OW9'%^6[0A"Z5Z<XG8J8(_%&V
MM[34;V?MO"VC__G_%_[3BUWY@9@::P2OM5F!4YX_VJ3XG>[7]MV@?K*EM-::
M6T$K03!QLS.V.[[+,E> ^B1_YXV2A5\^'FZX><=)R](N-7BMT4R]!^=+&8.]
M<?]WVGT[A#DUOFP7BXW!H.T?)A]5SOP1+[V\(O(BF]\F(9BR-YR;>0DG_]P+
MD2)^1FW::QZ=V'#RSG:"-]_6KM]N?E;RKUCJ&>GIV?^W4)8_#YMN[(6^GHG2
M*[WK;7/+:M$QLK-5V 4K;XE]H7E8WJH>2/UCS6&>]8"-J7^FY=9WYOM24@]U
M'RYUG+EORI_XE<SD7,C@__*L;0!/-79<:Q[_Y2?ZY,L^LP;8ETP(?4>I?_'E
MH\J=^(G**FM1IR^L]3'-[ *>.S(C>8\TA\<2QFK+_K&@'ACZMBY2?2K3[H_Q
MHE'O K65T'9\HE?[K@B2.;VW>(1?/MU*OZBW?C7CN_378+%7_O_GPC\8%*I^
MTX)7^",7/%X1$1RH^M >_QJ]HN0.AD=%.;2O)<L2.0I78VMN;WQMOJC[[ML\
M\%T0FL=OY,,DA)AWNR+\$U!+ P04    " !<@EM85D)7BDY&  !?1@  $@
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M-!09;+_X@H.<2/1L6=1:R'ZQGO2[H^=(@Y;R0Q3O;K[[%L<MH8@"\:7>2=L
M46@?,97WYG4XZ67CV? T48G-"4WA9@)O#R]_3?KSL/3F<A)\S4>F'V791U+[
MC;FDM$Z*H_L=[4&*#5D1TPD=ZQE^Y/%%[]G/@3U6A;T+PAT<D>TBW3TJ;Z*?
MPN6#1##/Q"\\WR8-\SH7DSK"-CL#+H5?Y7ZNS@[:C#)VL>X-'AQEKEJGLM\;
M_W[6/4"$ R>^TCM3GR$"O[K\171U5(Q/]X&D2/=:)U7SS??&8OKZ(.#0AYH^
M__9K1U*$0%?62#&N3S$630-6;B/N5"/QD'#O[D5U@S;9I?#)Y?3N1.]Q*2'I
MC0[Q<2/1R.?M+I8K3?OK69N3":\]D;KIVK^G\)HAGO!O:?:GT&I<]V)T>0"&
MC,^=)C&&6S%Z;@JN?O^0_,O97TP___W[=G5%B"KT(BKY<'TU=WQM?5*8=&8X
M3T1"M./X^EK6%L'M<(.Q>1["_[WE5<X4 %N+&,,]!=T]Y2Y\]DX^A9F9^?ZE
M)?E/.Z+B^MVRS]M3NB=7X3]&IXF^IU#^3'F@>74-*XSO]68U69KFTZ\!(RLX
M"[-D(N[*&^YD&@G"^^\JB+'S;@XP]@YRB]&'A'$A._B/[O?2W]??SFR',FT<
M3!\3UE]J_'N$H2@?"X\+"DZ@I&,Q1V;OSNZT4.A.NW?R\EBOYW[YV-$9O'[<
M:L %V5\GSQ+%7:^+$%\2-NUYSAS+?#CIEJ=*:KA/_?BG!F\)QSU[^>/?#\EW
MF@VX /VW._*?,'')IC+<4&ME]KB+-! :_?WAR.>-93Y3;]/1H.<'K\T<?4?I
M>+)U9X+.5&N-+ 'KOOP0/^K.5%:U%0<UXF/=0KGP?QAT1JZSUC*1*X8Q 47-
MG[1C7T73&9\;Q<G[534A5,>(Q7-M5#VJ>-/--&$!>@+JR8RCJ<?'^IA0/PZ+
M+G+##^E:;W*L+"XWEC$9S&[L<KA1+XRQ=$H,!Y,87V=5H=<XL<C/])5)\MIS
MQ>!. . U066C^2DZDBM?3+_7#U5:]\<0DAX()K].%_Q<8/EKUOEU1,HMH=6T
MEK,#5&>![RR/@U&>YE>9VH)=M]V.0=:V0,?3RE7Q67M+YY3EV.71M%JF>7W@
M&V?4;%YA;'(6S:#V\'N^11GS&N?L>PF70<VD5*Y4"&G0VM[10- &?*PJ;<#2
MC3ETP)*P^W%NXUQR:FF<M?%T?W#B*S[\N:*=],+=I=5"^_"L/6Y35D0UYY_2
M>%^!F)L@D*4CK9;3F2PWN3A=E5Y , 5YZ\%$BKL0+>9OL*^NVBJ&P98T*?A3
MN#<)XJ939%&V"65<&4A$%+3%&\U*C-APM.C$9U3?OJ;A7<"(^Q-JH0J'X)3,
MJ7?.U6JP^Z]HW$SXW1CX%MQO$KC3.O/1.RI-B*$YDSN7H&FWWLAHBBBJ7BVX
M%K[;U$\;B9LT3]/6,:Z=,-K'</AI:/[KJ>$5BRWB)T@*5:RE3DY_THE?+K*0
M4_;U'961@.#%I/W4K(!U 267\^[:=<O.^_2 U^*[+%B&K4OQ">N=)9RNBIU9
M6W%U]N- =:0*_-M1$VZT.=5<ZG9@M=SF."<YKP[=#T[6:5$8.9O>J\6OP,)3
MTAIXY*F*?^G?+&A<H>,ZKFJ9C]J/#-L<Q6K#6(;7O[]NS"Z,SVM"/D8IV2,,
M[M*SC29:QV?EX1227S$5<FDK=''1OZBKO)TYU7K@XEL[^)&",.:W)%W@/POW
MJ44ZYY2L(_M. 810:ME81PWF4'X\"O;RG]%*V) F.D=+#_9,;6P]L7D,(%_U
M$L0!H?P[74MRVI-*#S3R!Z37B7)GY;:RF52XD;?_\\-#@3/2.8@G-"B2D@T4
M7&W*CE6](+G2,AOUL]_^W]5E_\>WT54TLN3?JPL;8Z 5L_[P5CR<7DNZBAL1
MM617F(SXTM?)^IZM.5%@+SL/7==RHZBWK/AMNW:*:U?]R0\N@E4N7W'1\?W>
MXN%.FQ^WN81E = E\PFD];.TP& FY;% EQ5$W7U7!\@X_AS'.V-&95"ZZ'PE
M/;GV>=GF1=(T@2.M\%3<@U\;,#L1PYJ6-7O\0V,!@_ ;<C?V;>+=1JAJ>(JH
M;VGA.'^+(O]79>:+11R;Q&'!GZV.[_U(5><&HQLBS9!ZD>Q%HW%.0BZ9I1J7
MNP91/#\(%9/,$A4C@;$EQ9R9PZA+CX]-9[9*Y_X#C<)8NG?5L_)9^IR,>C[<
M!+);' \*'7XW#O'HT)BVH&"5K$?5UYFL6#B<BU_K]9J\94H()I?TFIGO.%04
M^6.%D:QI-,\ZDC5\N24XGT I_/-A]+SJ<G?P"2S:*8>A#AH,21,.VA4,#2OW
ML2:D4]_KJT&AC3R\?P0E_?.1J5D*3_/@1*54OYQSM3O?XO;03VW32U%)@ZZX
MGQ>*Y7G=4J*0WS0V0Y3+9^TXWP;"3/QW@\HG4R)YZ+ZN&ZR%D/?K'?J]A4Q(
MBP<KI32B%]S0:Z2K_YQ6BG0R FN: !/*^K[!(3$07.M_ISBIZ^MX/':M\PID
MHK)_:;E0;#B^N;?'.0V+XF5,M#_SM4;'F27725,PS&-*%14(4N:]R ,6AS7.
MVMG/5(B=!=B1HCSZ,(7"6NF=21?VUY(%8KB<*G6X&YCOUL@-8B#<9ZDN;W!+
M)C";4OV5E:%I5NQ3OP@R6-"TU<UQCLDM*>=>_57"X8SQG5I7AS"%NJLK0MD;
MM3T)V962XK9R:-G/W!(L:&7LG>\0JU>'+FHXB\H\CZL,Z5<XPGD)9GQ)"QRE
M:"-:A>2+F+386JL8OM2W#M F*LC:NMV-N#'%5AS).;F=X)WM)6["F3OF ')F
MZ)..8EJ<A AN4YRS;N?FN7%O:&?J6K)4&AH]K!XB*AN8(LJ% JZWO6)GF%37
M5&J8IV*V5*=.:"S5R#K*>4.7D:BRX4GMW70NSV-4]EDA!F&:E(HR,TTK:ZW\
MF)N#03-64OEQ&EOW>Z"006/NBHU<4I;,4J7F*2G>JX53:3PW,QIXY-P[L81F
MLO59@2G#'F_O%*^@3^B<%D$+FN5+9;EZHU]#ABEK>HX;MFHM'(_WE@!?1/PN
M-)WY5J.5@VCP7#X^5QH?G57.4FD/%JFX*O:$V%H2UIK@;VD+#2\D/#'!5-O<
MXTRFTE:R %(.-7LC'':21=,\2MQH5G&+AUJ)3_!)[D"@8UZ^QQ?O6Z?HX2@N
M)[& S%IU< F3HF?O&MF;$NNG,+50%U1(8'HK<S>7AQI3SB+=6N-'6C50DD1=
MX4!'UP&#3&UH28/63 :IB02I0@WOI+P?+_C9(91?TV0TQ0HWPW6X+I1[4-\O
M_1O[+B$Q,/IS_)[J>F^)R$*F>"J\V)%BKGP)G4[3'I>N0G0#RO#-)%]:O'0>
MSVUFP)1PW)RK%1,+PPR7@_<9<S?\!/3]TT86)\F=E:ZD'XVS\*?4]"UL@YQ:
M+78@[=>[1_MW826X.\CEE\4#FO:<+5^!9*4SP43($(^T]#>(-,:AN/R1TSWG
M6V^GL43RA[B4D@ST9E,"YOYS0IHH+!&>,!8.R4YELKH1JG9NW3G5."K26IB&
M'ANAV_B;8!/4(ZS9M80Z_9'0=*0$9E_5YJ";-*?C@-,7WJA#QM)$%&1C(U^9
MM-S&&GFAE44J:?;V!'N5XD&T<4&A%!OK?(\545^>[OL885),01HERL7ZJ_S]
M)F_^>BS8M5RUMU\]XF\XCIEI39?VW7[:=1^_$ ?\,<^2%YL-2L'SW9#]+W0!
MR;^>_-T]IE>93H46D[^GC)"2KRJ"9/4S5'7@"N)34_'A=9I+V.7T[SZ$KC)!
M&)_ZYIM_QN(ED;_(GI)-\OYX6MY_HL;%75,,'>MD"WT[*Y\!,:E2HZX$,WZ.
M6IKT'_U-:)USX$_"B*]DX/!9?@AC&LR?S%5['[A.K7SO_/;C'X63 U0:2>DA
MUOS?5\/R*7^O/[)( EZ%'0AQI7?:[V+R[&$*R Q(A#*H6,2J-+/8@!A\W"'.
MN7@X>*39>E'02)QP]>1<LUA[%GE[==R+"^BJ?>\J36$:*^L3/4XWVHN/_E]I
ME0DVE(0>NM!0]'%_%A4 2PJ,8G&(Q7;. TS_JFCK%(BJ/)&.'21)GF+!A\(Y
M3I$WH,'>+-L^A$&3K,3Z--IIH$$(8TCXCV(9^=!WX7K"C52?WX,\3B)R2KA!
M)$-2&4K"P_'.N4.RPT,O X2B$NC%YX9>8PS+4PR_-D+W0&M24!Y6-AI6<1I6
M#5 6T5;8-TO_ H1JR*.+;RA4 @88-V-U+H=1(^IURR(]!U.0%-&X91K"4(NB
MF\<8OQ=X4XM,=<),A//QZOS9=(N*X0EX?SIXM]9D9*$*=&(X4G,I5!2CCCW$
M]!1M63G=3)#,SF_8#GH2KAFCT&)I@?/H-MG:UU,X'"\H3/EQO98H>L:[@//Q
MNX]HEHDXD[BX+=4)$89C7ZO(B=!>/)9^Q4]7<%H:&RE^':\G(5DUJLT0Y[Y)
M_JEU+-RLYX5%_@X:07WJ9_N0+AKW2@;R-&/_V,!')GN<5G6X&M$AE(*W/+$D
M(46A?[$#*/NN+;Q5W'%S+$LY-[L,YS=Z)R-2H9)%6GL3.^.@O+P&ND;2K1&'
M$>[ @$5+CZN@DB+\53/<#.Z_A%>4(H\L2=B'U8^1R'I-CCEN#M3Q8&4?3E*?
MC:6I=][@28F9C>._(&4S__*#'B<OM$ Q+76O4],3P<5B-U&_B>VN(=+=BIKZ
M::&::35)J92>HJR9 XAFD&:M34FS)1 <6X-,=L0O^BLL1\GU!FA\R>/,5@;5
MSN4E?*4QTIZ,C(AR+VFI89'BU<AC7IL<K<*64A<4CU/K_Y/4589T/)PJW]6,
M^$;TJRHV2!DW6SWO>&U@%9+\LR;A^RG10*X.#GU9J+9N.$?[AL>$\X#T5".=
M<3J^-7^<%=IH1QEPN@R?D+3L$&_T.+'F;XK.#\_^#0@R4:MW-1*]%YHP3)L=
M]UAZ/""]QY#:VB1/ ./R,I\-U\Y3D'ESYR0[!=&M+\L]OL&C<F"% CK* W3*
MJR>E$O#^-LY6<\Q=&C$='%81$ K=YT^K57.9EZ%4+-!Y&>")A/G:Y;@I403Q
M=0-XMW=ST$9Q&?(RVK]S#4M3SG8ZNPRT.^.1KB1,<@O$WYTHTI3Q\<,9&3)Q
M[D%C#/8+D6QB/_AC%.@Z!OEJCVZ5:N+I_RS)L\11"+<1?$DTB-(K)+1&BLK1
M.VC%._Y^\P22XJ.54H?SDI"+?:"?75C,8E#0%A? D?&H)[I=G%^7JCB5>L%H
M2,2[T*.O*N/>5@&)_ZL>A<9H5,X@=5:])%XP/,4QYTY'B^<LBQ QR,H9>SEM
M%,7#3Q958)A$1:)BA$]NJ#?=L7TZ4KR6+%*\I(W)42%F;!*8?M*C8#O=4<NP
MS!5>0$EI C73H5R(E-1Q6UGT67;YJY?[ @\Q@2;DO/Q\:>S62X).:.+-6#7!
MLW)9ENA+:?(GI, +<_5'W$I@+QO&^2)])YE_N DBM2\C8%5A<?X])I-OYNIL
ML:G;T8@WGMF'7N8<,;/=LZ19$MTK?C-O%5#NX JD /4:6++64DU>[X-[Q3^1
MH)+;'5H-O5^#NZZF<F;7?4MFV&5Y7DKY+&[N6-!R%K;^]6:E+]_<[UT&13DH
M3GTN5F<MA=0T<HV%45@PLW>]DF>]]"\%'@@Y0@ [T[?(]F$:1-#M:C.9)UGL
MKZW6&H.8DPHC'UGZ?ZRG"GS>E-;&)S>J=TY6C48V&EFN\M2O?NW["Q!T*3!G
M^DL@WT9/X(6;>414,K+QOL[\6T96\N)7;9(H^@'E@O>6 RSU2$M:#W>K0I]"
MO&XJ\48*2:W5B5,H7,"BCW.V3 #:D2>KC81\&NCNR[-"L/#OX!A>TENV.6],
MV/'NNM-V^69L)L6$5C%5<Z!*^<YP:[SJ>3!-\@)QQ0:Z(^6M&)71*ZJPOUAO
MJ9?S,E.NGS+B4) ;]HO62U[4$!FL7_6R?]L:(,08)>*K]6I:N-/Y1ENP0-O9
M[ZQLI9MA>U%N^]BQQ$8X1U8P0A'.F-VUD5G=TOYR;*?80IIS&UU4P@EHQ5*6
MN7CU]3EZ5P*NF+$A[TZ[<ZQIG-94/1%BQ5S M:\IV%WP59'3ZB <5VMXPC7
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MC#0L\=QDXO.^-O+B9:RO>P*V/TEKQ_7SOD]+(83KO="S^=5XX7#>.-+!2/A
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M,3B([<;FV-S5?7#$8U=V0F&(8I_%4WUV*9_S)VN"#NC #U3ZI5MZA9,!$/P
MIUMW=5_W=>L '.2)LGG_1G!<"O!&[$&I#T,L Q(9"'EE#/#BL4AZPRZ4 RV4
M0RV0PRY\PR[@.K#G^J_K J_[^C<8>RVP PAIQ%S#S7E-#T89,KT81/9%3TGE
MR+,_UDP4%W6P+:X!:X^$5<?4AN] $;>[DBM15D(P1\N,N[JS8$P\!CW@P%WD
M-(JM+5&".U'V.[B#N^"(Q$,$"\@>!'VL-W??:\%/:XYL^(W_B9VS8  W@C&1
MN(*A14/8>VK#]FWA.'ANO \&,.+,=57DKQ)N]2=;.H5?N Y<.*>S_(4#P<O+
M/!#0O,LK1);KYN'UN5DG(RLE47XC"J%8^X>,>4200SGD>M*7P](W?3GX>M,K
M_SVQ)WU"H/DCP6U>IYILFOA\$T-917D:V)QG)82/8Q<.80I>F$59H4$CL UP
M7<K(7](EV;?<8\K8I#T-FYU(# /"VG<G=4QLBL'#G)#Q,J&^]WM@VLHP4 (T
M9<*;('Y:TJF'P$I)R0=T.=.X+M5A X^:(*&)!P9$D<X7LDY"55K'G+6U*->0
M/R=+BGZ9A$Q<<Y*M-[$^I[(F4'?-CX&%6S<0Y,"%^[[*6SIUIT'-6W>IWX1D
M!#VPK!BD( 2L-_\^:,(K?_Z)3P9@CTNV!E [2#W3<__2*WW4.SVS!^E4@$_9
M3BSH3Q-MQX8FM*^ A8<@3E/"Q1?>EP[5W98Z GY_-/_$DW,X0.S;-XG8/C0W
MQ"@3F&E2)H$/#18<EF:?LC &%483@Q%B)C0;(884.1(BL4R93*8D>')80Y8-
M-67RA7)EP9(V,XF9]-"AP(0#'_X\R?/GOI[[?HHY"JVHSZ,8T0ADBK2@FX(,
MJ>[3J SDU(IB"C:,6'&G2&)1LS8D5M;JV9!BT#PE.9=N7;L5ZY%4>)=O7[\0
M@>A0 P0(&2!^,4%$LQ<-,:X""8)T^)A8&(4HO8X4^QBI,F*2_X8.R6Y7N=*[
MVODMNX_IWM7[;A@M*Q9IT-B0(5Y$VC,GM+=!T<;.Z5/V0I -RY[<^1@K<Y#/
MC1-'*5(I]<L4'T^*.FQCID;_D)7MU"XZ=+U,FH;%U.0WTUZC:*<O=&CYZ\*R
MGWG;-.HPY][J'8M"(Z_J3.IL(/YVBFN_K$Y2)JJAABKJALO<P\K N+A2J#JA
MSJHG0_) O$L9]T(B,<03^0)"C1P*^^$POL3 (3DQE)J$QO 0XB]'GW!0)J<P
M'*(Q*F)NT$^2'&G43@SA<E0&AV%0O*L<T\KYQK2^E@3)*&+JV7&@)'-"Z"N$
M$$*+'B]M[!$IA)H:,\OG:#3HQGVZ!.FCI)"\(2>XEMPSJCL5NE.@CR:LB,VB
MTH 2(C)_]!,I/A/,44PAH[3+QTR&B>^N/8]Z,,ZOQ$A#R>ILI+%/R. 2B*M4
M][SAV36B:+3ILS@SD50G&O?\E"M7Z;QS&>YJU-,H2HW+<T_/RDR(2+AR.FE)
M_2I%49F\1C(QVFNQS?8A'[7MUMMKN4+K6VSU\VRA<=&M:)ETH_S(VA,78U=>
M;Y7QK=IY\9V7LWSYG7?/?D4KJKUS 2ZXX%,K!<O@A?N:5B^&(8Y8XHDI'FE/
M(!]]M^*-&9Y$3(XE'O%AD$DNV>2344Y9Y94+UK@BEF&.6>:9::[99GQ%WK8>
M:#R\V>>?@0Y:Z*%)]K!G$ETF6NFEF6[:Z:<KLE>DI*&NVNJKL<ZZ96K&I];:
MZZ_!#EML\G+N>NRST4Y;;:@=OG?MM^&.6^Z4ZQUY[KOQSEMO=MLV>^^_ 0]<
M<!$UIGKPPQ%//&V7#5?<\<<A=[KL$CT<T?++,<]<\\TY[]SSST$/7?3122_=
M]--13UWUU5EOW?7788]=]MEIK[USKM'%O6B4=0>Y=XY_WSCXBH>GN/B)CY=8
M:G0;A[AYAI]?.'J#ER=Y^I91OAY@[?M-/EKN^:4G^\>]S[O\R*67]_R%H^%]
M_)/!SS=^G-\W>7Y](0H( #M02P,$%     @ 7();6/YW59?1BP$ V(L! !$
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M HA%@ $(, @!AB# " 08C0!C$5   @I"0"$(* (!12.@6 02@$""$$@( HE
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M6OW./J$9W%S>&5@#6]C7UL_NCV^>]L#K//F,N-^B#T50E;? @\HQ[, L.ZW
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MZ8PAD4XL;$8F]UC["4L5+B7>624V.3TYB1XZQWG^Y'14*;S0,$(>,B9K_A,
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MW#Y+>TCZ"V+&:_G9*BV'#R3O;/"@3+!+=LU=^@"5UGU8KCLV5?SQH6PSN4C
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M3L7PXD'+'8?2:\ H_O1&QW$) 7:N)?=OG1^4QJQREFK7>X,R$G HE#S7V@$
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M5/E>J;Z=,BO$F97?$OP"TH@[I(^<1KNTSNG"PP]RRW2<3>-$Z7_*FAA"@AI
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M'<X6+-7)XX"74<U>QG_7?3]X<(7H/.P* E_U)YGLJ]^V1@FW[:2O'GZ5(3K
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M]9000BR)#%IB&YGLN:8Y'P1@A1E:3.#,G(7_))EIG>:L.LND([[R8S*MY@F
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M:]BQ9<^F7=OV;=RY=>_FW=OW;^#!A=>>! " IM;*C&<J+09 #-/#EIO_+@Y
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M4O.7?2O/?2&V@75 A2E511?R?LM3?YU.@0D1A2D44.<W/PE8A ]81/N1*M4
M*KGO\"X8""WN![T/U0+&%S-%&;G$3XZ44)8DBU?5-Q3C>M.B-[185KL89V23
M9C:#-J47+;*81Z.E*(4R-D_6C=V$&!Q@#+@7 7B6.C3! 7Z6?-MBWKRQD.7-
M,UM/'VUOD?]7KY$5>7TA.9$?=I(][Y$IN5(_[Y(M.9(QV9 UN9,YN9)!>921
M-I1).9--N901.959^9-5N94A-I8O[Y5=>?@V&95K699UF99ON?1@F>*&UH-_
MU=U035S(F':A;S5Q]%&6I%EJ)6:SI'G98EV6V9K?HDL,HT7?&#9/)OK*N(N9
MV36KUTC/99K9!!028'OO @<< !E=Y)T'62W:SQM_H#B7CRPWSG*S$G-;V&BQ
M=GV9$N0Z5_T85UA)-S ?S_O"\Y]3US.=EN)8]QM/&#H/^FW7LG[!T"POSD,'
M,UI/F"T'487_%@ #5RYC43T3TUY!^BM)3H4/UI]_4&D#&HCO=J+_^9:(46Z?
M$SH08SKRI)BF ]&FF:^@'=/R$+J W8^AS3):>WCQ))JHXZVBA_4K&Y(KJ]'C
MX& ?EB$L+R[5I- LZN%&G/=BHYEV-[93#(..=9)EU26L#^9V8R TH+=(<4-Y
MX<5EO<07(X5?,!4890.OA70RHF]B,<./H4,3-&$2X,!G?583OG<U$&"=@S:Q
M*SNQ7^8L<B !S"(:*-NR-8$8OK<>WD"0Z2)HS6(90F,MEL&S/SNT$T^HYS3>
MSJ(>[K3YUD(3./IA29*W-=GD[AESO?57Z3!<Y185Z[$XTQ AT]>W=1NK8[M@
MAQNZ8]?D</H;D]N4>9NYD?:WB1E2HQNK_XF['C?TN/41NPMY4G%.JIU;7HD[
M=@^VN,F[ILT;Z2 VO1<V6T>48-T[DHDUOI_.NIGOO!'YOBVYNU^9#ME46;^[
MXLS"D&47U5*67QAC4SLE9R E4WBF1J89C&%3"[D0F4GV9(I$C5NV2I?P=S%G
M>@4%-[00LX<C&M) !AP@ 1   60  1P  7! LB%;$]1Y&7+  6;<QGE<QQ\
M!TK[+'! !I8A$VQ\QW.<R!T !])@%M,  7)@:.5"$[+\+&0<LI4A#7C\ 6;<
MS'6<RM4 1E*\2!2C"L4F#"#EKP% !8#F4SF#9,1 .2*F2J;D86ZF:W8C"G=E
M-R8AS_<\+V!7&_^7& A^=FCA@'*!X/!RN]T$XTUAF*7K\:6/6H?E#82=FI\]
M,]/U<=.%N)X]/:CA#=/EC: _#W1].MX^_9]#?:)97=-=?6T[/=93?6Q%W=9)
M'=<Y_=1W_:%MW=?CK=4E[]5U'=YD':+[,V_Y&=B5/=>'W1WMEBTGDXGQ&5J'
MECG_E_M6C0A]0PP^%E>PSW?)W7@! &X(W557X&%P%BW2'3" DDN>YL7?>%UF
M5"T0Q=ZYN6IP4E "9Q+6Q0!L1IEC(VJPI#KHH7MS0!-DEK6781D2^^&A4 :$
M' <@/K2) 12*@1FS5X^_]^&S' Z(X;%1?AE07@UV7)#'  'V."ZZ' ?_9E$-
M GG>'QZT01L4+MOB$4#)KR-6[QQ2]-K$+V55UYF;T7ID29QBBB14)&&+Y[Q(
M5D/.S\9)2MPN5-TK)7T??G89X,TL-@'E!)F!)2^EK]TSTQXL49J)65W ?1!I
MG7)2%5W:IU'1]W)R\]X'K9OOU6"8N?ZZ[3XPK9'O_WF@8S<(#;I75WAL&Y^Y
M"W_1@7O6(UKQI?KOR1*H(;\.KQIV80ZBMUV_GWUO8S%JSY;S'T^B%WWM0S_O
M&1CNG?OT 5+TXU8=:[\N]U[Q_3Z1H9I$HYN5O3H:AID>Y3DZ$CY5A)P2X ++
M<P M !D!9B#?T0++E5[(94#I;2,!:OY=NI<U_V\FRTM;Q@4Y&G@\Z%55CV7D
M-M2B=[=DR44V8V?R1LHD#-* 'G@DC"7F)V?29$,<()3MRP0 @*1]^VX4%$@0
M !J$8=+0&U@0 #&$&#-JW(A1AQH@0#Z2 ?FQ))!ZT'0@#,ERV3Y-'T$"<:E)
M)DF6)3W:W'G39$R>,GVR!!H4YU"B1DTB37J4J-"?3IDN?;J4*52@5*=*19J5
MZ]:H0K6&]3H6K%&Q9\FF-:M4;5NV3;%^E5N6[MJ=,>L6_0DU+\^P:63">2DS
ML$R.B!,K7LRXL>/'D"-+GDRYLN7+F#-S5'A#LV?*RA#D:)P&@2:$RF8@ $4:
M@<!].7",9DP,P0^$Q/\>F%:<8S?&- ].[YN4( WC90YF?UY,K. DC07#8$13
M$*-" !R; V@X#&-#Z@!>:XRQ<+GY\QNIBQE6\.+O\ACK.<=8, ;"^?<!V-](
M/OSEHDB=%@H0 M4D4X$W$;C/,G?]995,.N!E581VB12733GI)=-(74'8TU84
M[I54B!*:Q"%9.KVUTXEZ44C53R0^J$:,(EIX%88AI7CAA@_NY&*/0,3X(HT?
MVHBBAB"QV."/70DY(5PG@J7CC3QV"!*3<7T48H<C)1C4#RQU&:2'1KD46%X1
MHJ?FFFRVZ>:;<'I&GAAQJIE& L(MIHEL"&GBP!B.:5(<0KVYQ%@TL1F:20+_
M.!BZ46_&992&#*S!YL!%T=03S3Z9<HI::7F^J4Q!#V54D P8B5$=1*MJ-&IX
MY.&0*@!B3-(>1_VY5^>NBZVPW3X%T8F1K19E]&HFUE6G';((J8H=?[=:QA*8
M2>7PD4MPD!'*@D%>2QB&^T"#(Q!G&D5MB#I0:U1@Z *A[DUIZ#2FNT"-$:9,
M[UX)YHPFY1LAF!&:9-B5(/U XD?EAI@#4&?*FRY08)XX4KX%NZC3P#8M3##"
M33T\+TCE:DEOC/OF^)'!/*E[HKTI$YQCN38![&'(^+9+KU :?ZQN3H:1F.](
M@8E9L$T4QMN6N@HS=2Z$.[/$KH?Y(NSPT#S9:R'5743OJZ._(Z]+-,CR%D8F
M$!KS1>V)(:I[Y@\JJK%ISN0"P>O<=-=M]]UOJMH9WI?EX(!XBBTS@P.H#=J8
M,G\2ZIIC8RR.4!I\;N2G<M[AB1 ."3@PN P.<.XY J*)!O^XF\M"!\#>#>V]
M3W\5^;>/=L0T1-]V#8V^SZO[\3VW[/LXFQ%X@!,K7G\4N;YZJQCACAF/6).T
M$D@(J2O0)D8-MDQ,*$-U-DYLG[5T2=W[)/.73_T@=,%/6=L4M2:&/]2[_+H/
M_M=JR!]2]SJ7?S75XO/[/H[U4U+]_J*^_OG(?O53RK^*Y+XNP>]^&;K?7[K'
M(OS%S'_@>TOVN!<6N&70*&2@6 )QXA$+XLM$$%P?25)D/WJ-Z8/B^U@*Q7<^
M=Z5/@Q\*85C@5\*KC%!+'#M:3.15,B0YS46W:XKNELC$)CKQB5!,# X0X"C%
M((Z*+W% I&AC.-E4D3<.<-0R>L/_+(S4)@>VNY- EC'%V.3@C7",XQC>4(]=
MO>HYIFI=?3*" ST6ZW8+N6/QAA.MC/2GC%%DDZKV<ZQA%9*0?^Q==8BEJ^M
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MC\;E:<DRT WH%@_X,6Q*(\MH7&\0T'>_+SX'Z-9(-#"'@\S;,S@9(49O,I<
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M?OES<9EV.4F)@KF7A(F8LJ:8NI9U-^F8U71]A'E]''D4E)DE#CB3<PF4EZE
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M4U0<\L8E7Y&=?>H)E$X,@^:\<\\_!QTE8HCVFJ/1J=X'#:>=1F.ZN3\Z?74
M8O H#=D!N(&C96"0?>S8T?ZH;0!,LGKLCF*XO?1]ME[=>- J%UC+0+ELU4DQ
MN05/RNE/K-[!ZU?,_L;MN>L^QN]_#)]?(<FWTGP?ETH?RO7C*Y_']_W5?F,J
MZ6_??D,)WH?!SA,Z A;0@ ?_9!C26M<1!2Z-:,HP'?)0!QVBJ0V"#"0=V6Y
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MO/D6G8/F:';A79I M@]J *S54TRQ1=9;01HYE$9$!GBT@HIR2;5:/1JQ5*)
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MUG5N7:XS+* ?G%C\'OJN6CQT8]%:847C&-*&]JNV]F-68--U7+NV\!@;WF<
M[SE;W6PWQC.N<<7HPQWM:,=OVN$.INSC'<1(=:KWM?&5L[SEAX+OG1=7[6\%
MR%GBY&N^_VWAG /6/T+FCK_C961,0WK(_]UVNM@3X-+Q%5Y<S%P2"RS7(S]Q
M<>0D(H-<KO6M<UT@]6C'/#X^#W< ,2O$>(<O3)[NKK.][6['CI<-;F_#=MFM
MA!8RA 7-9WH2?.@[/_#>^0E/,E)XGS?OUL!M+L: 2IC*B*^TM,[8<'T"'3S2
M?#OF,[_B:,1(9@+1A\C''O9V_\"-'JL^.:LUK_K5KSO)\&JGP2F?WZL__,_T
M)=VSX57Q8L/3R=N"-\X)B\6?[Q.^1"XVMJ)]K6.C2^G[R7VBH]]LK$N(]=:_
M_EC=@?H<\G#THA](,<P=_G>L'?OF/W^*A8]6':L.X(>VMZ.=[I[I!W_]CR9X
M?ZLU=V)%65I6][_ '=S]/9F6I57BR5, ^EI: =;Q.5:!B!SZ1: $!E,]I!HQ
M>!X/A9['M0/)G1K*I=X$AJ (CB )EJ )GB!9$4,QN,,OH,]OA!T,<E^Y>2 (
MHJ -WB .YJ .[B /_D4%JEDQ>!/(#2&NF%RJJ5T/)J$2+B$3-J$3KMPR:$(H
M$$,HL&5,0Z@@.GA>R($=%UK)V5D@QFP"*&R"RCVA&9XA&J:AE.B(7*A2J[CA
MR]217^R)7XA;H<1$+!T*=\'9'K9:%&H"'&B")GC>"J::-(7=;WC<R'F=!:X:
MW(RA('K08BR#,A"#,F"@&O]FHB9N8LO-CT94%%[8H4: U&  4QU^&UX$38?$
MAFGU!"=-T,@41E#4X%_08:+T(5]HD'05C6_QHGA%D#+$@1AN AP,B2^,GT#\
MQ@MVH=F9G/8-Q"9H0AP,8J%,@@ @@ !((B=N(S=V(YQYXE\@$H9$U5\@4&$P
M%%)5!"U*32P21LH<!C@B2COBQ3N^Q!XF!*W$Q$C<3DXY4#0((AQ$H\K5 ^IA
MX.B1G<<-A!&J&C' S3+  2A0(Z%D@@S(  *L(V(H@R9D@B9HHS=^)$B&9*/8
MXE^(XF*88E\DQ# 0QA[JH[^4VM2\U&'4SV&0I!Y.SR?UQ"PF55>0CT#TT9,
MP.7_U<Y#1J,FD&$S^H(+#B$,XHHRK" 0#@0DQD$97D@:"( ,L(!'(H8F"  +
M"( 5BJ18CB59 H8IFN)G3 7)D$IG:<IJ[00Q^$D-[E:(^(F/:) !F90?^:(8
MW(Z(R-"H$96(Q&,?!DUIW!90%4UIX&6J> @N/E<F!$U7I4EX64:K6.8;=DR5
MZ*))&*9=N(8IV@ABCI=CMJ-H=%5G>9!*0>9-O P<5LT?Q@$HP,&)62 &BAU"
M%N')%0,Z-*1 %&5'%HHF5"0"A*5F$(, X(  O&99-J=SCN6>8$K1! _47(23
M^,Y'D 7%/(;"=$9'N11"48G!O(A8&,E')!=6Q(18B(85_P(3 $ 43Y8)CI28
M8C()OZ2$SRB#Q6Q('Z9C9Y *=]HC:%B$>5V$5)!B0ZF,?QZHH.3(F8R&*XE!
M D'&*S*,4%3H1Q!H@[Z$77*,=[XA3-7%[NS6U<@,"CUD%0ID,J+:J0W$QY&=
MV'EA^*G90 BB-)9A/7 >9DP" ECD5AX&,?2H#!CG<Q:ID8:DF*&!1&PF\C 4
M[QQ/E=#G3I %B7842@$3]CSF3[I$*4G4VV0414"&(+'F7:P&K11HOLQ198S$
MF#($D? ((K$$FGD=2]1C0\FA=(9I3_11F<VI+;$$@I*HS;3I7BQ/B2&5G:Z&
M'/H+I!B,:W66B'!73774HG(*,?_8J.=!PS0&8C$RH@JB3STT9<@I)#'T9CKX
MYCXL@QU$HU1$X:42Z5UH9!J,01H$)_WTJ #4H"9,PJS:JEWLZJQ&IILJ0R;@
MZB14HFIJPJQ.@J\R1#2HV25F!4<>D"5BY)%>*[:ZW9RVE &,5FA<1CW6HP'(
MX?6T(UU:DO5\J&>X! P4#VG92ZNLY,U\)UXHTGA)!:9$#4D%Q5$X!'SBR[Y^
M:5IT)T.L!&JVIL& X/)@9T.AV+C"Y6OQ!!WR:U\4!-S,3SW.C\'JA6N\1$&P
M*8Y<24.)B,A>333^@B8XY%%*H2:HG)JAG>>!'HR"W2(VQ.G1J$ 8)5721"5H
M0B58:T/_4 (.L  "L(!%$BV/\&A%1@U%XJH,!( ,C,%++$,:R, U6B16XD"5
M="56$J< )*=&$,,86*U%DNT85.4^:$( 8.-!C $VCD0:$$,:]&.VUJW=MEU4
M&02I_219V(R8U:.Y;@@D6:E]PJN=MD:>/)2+_&EI> EHHL;!:M3P6$:WJFL?
MND9I=(QKUB?O:(E8T*&6MM;7@(G'4@5-F@W-)":=SI*.8&Y@2L7\B)DG^4]>
M;% *"<6DUF?NWDBE;DHQ4((F4(+*/20@$F-MJAGWT2P1@M^YG2K<!*,@>EX]
MV&@0XH4R'"T"Q$#1'D!%"H#4#D7W&N=5=F_96JT8H*T8="W9]I8M6*:MD II
M1<X 0PPG L#O^\J IA!#1>)O&@AI#M!$-%3BW0XP 6M=P<240QBHFUP&=NXD
M'7%H4>$DF59IG0JLC+B$(7EIC.!B0K ,9N%%/'XB&])N;WFGJ$#LZJIE3Y C
MXPIH4939GZ1F_-@%P$Y//%J&)&K)(#$P5IAG"A])H_;$3>T.FHWH156-($:C
MRE;A4;IL^/U"Z8D=S9;=/FB?!5;O/J0H' PO)?PNT XM HR!)ESJ))1M<3*$
M&F E J@,)< O1V9"#O0H N!$-.QOC^( K8*Q#( *#N  <>(Q#N14D.ZO#."Q
M&,#O'M=HV5:MU2) [_\6,"1'\K@YA#),@E@8Q&HP!,8B#^"66KG*84KA9.X<
M+E6YR4^5E"_5"POG!1Y*2:D1"6HND$=LST@9#<,^S&4 4O*DS85>TO*4V2V'
M:&P(D,VX*68YQ'+!S: V:2[/8X?>Q4ZN)L1*<V2  M84@R;X@D1&0R!NZI"4
MJB6ZJ#)^G&ZJFCOXPD 0[R9(Q?0FL5[(K=-<KPS$P/<B!'%J"G'*  ;6@Q]7
M)-P,@QP/Z>_( ,GV* L0J7):I!A@H#(D=!A;B?W* +,"K217M$6_F4RT5(U8
M<FG083UBIT^.HN &;FZ)C%B$+C M3V.4S?Q\AFJHJUU(*5*H*>?*B$'1B*#_
MRND1\W*8%,3!YNF6=A8*[0G#BF.KL DDV22\ODQ/8X5'8X6=^O1+U)9>^/![
MAE95B$\(S\O*4D(82F% ELVY0?'GD;/H.>4O:)\*/N)1;O%O4L(F=/%@N&V/
MI@U6:B6E=*UQ=J5%5LGZPJI&\#4"^ A?%[("X0"NXNO]8N)%-[9CRYD8/$J5
M6/)\7H:8B9DL_R1E\(PNVR<U7Y(#6U>*M(IM20;<N.232$1LL"4E]\1*Y&%G
MS0WV:%5B6C)XV6N .BCUK+9%K$8,@+)DM$CNXJ/8%,W7J.-NJVY9\(2=TG8J
MA02@5F=0RE9O==9O3_7<M+9N[X1-[&Z![J[57"K*_WI>%$ZC(#JD+V@?.X]S
MV-6LR:E@JI'<,IBWYSVE(%+T_USJ&XQ!/\O 4,BQ%59MCZ9!)E!"@6<"([>O
M/#OR.QNT<8YM7W.HT<YQ5I3OCSXVAF=X>SW&<UGP=,OG\81)8^QBGTHP7*1$
MG);&:5 %:'5,)7?&B!\K ,AKCEA&^364RW0(9VD$+)?P'(E08W8$3G:-CUB&
M3IAX:TV"GZA,QZ!!)CMJGA YB'I/C8_$H\[T!B6$GH(X:1YYY-[%BA=/W$C&
MCFO04%:-47KU;P9B* 2DRM$#JIU=62OO;WCAJ9X:6Q,C%\<U8]M%-$S"V%XC
MT1*M13)$&R_M0 PM^0IZT?_*\4(4MAKHA29P[T5JA!_7]=0*Z?<.IT76LX:/
M95J%NJB/.JF7NJF?.JJGNJJO.JNWNJN_.JS'^JNSP\=]>AQ1LY$&+R50 GG#
M@:_[NLJAFB^DVIR3\\>1'-H-^[!#XZ^WZJX#[SMW[QW3JMM6) 9.0@Q8+9M<
M>B$3<K=7I%?3+T%+NM$NIT80<D_0 W'^;T,<+=W:.DAJFCW-^WS1N[W7.[[?
MN[[G.[_ON[_W.\#_N\ '/,$/O,$7/,*3RVW >P09]7,Z AE$O.=I A#H !"0
M 1!X'C'@ L=7B=X\R&D[ BZ(/"X,!!Q8O YH?,23@9IGB!R+@29(D]+ZM\FK
M<9C_5/L>+P,T*$, 4^+.'Q#44GA>:(*0&J<>HRU-X.I(</I@,[Q8WIBL1[W4
M3SW55[W57SW6C[JZM,>9.[W5R*21JL'*2P7%JP$0G#V^COPM8+&BD1PQ- (N
MW (N- +<E#T0L,PRK'S+VP7.>T0:$'J8E'&$"\3XMN]=+ .ZLS*NBJ^#<ZA>
M9T6/!L#>>WTW4AF473Z7;3W,9?[F:S[F>S[G?W[GC[[HEW[HGS[HIS[IH_[J
MJ[[INS[KOW[KSS[F7]H.43[65*F14L+*>UXH6#P0F+W&<[PC>#RX#(0O<#PE
MX (Z"P0<G'W&9X4.1/SDOP1Q$BDCTSQ"8&4V6LG^XH ]\3*$0U?_,HB()F2[
M# P*<B*V]F.,&2MV10(V[F?B\BF@[>/9G>6__>/__NL_0)@SQT[@P(($!2(T
MF/!@0X8/%T94.-&AQ(H4(6*TF/%B1XX?-X9$J)'=.8/T]J54N9)E2Y<O8<:4
M.9-F39LW<>;4N9-G3Y\_@085.I1H49]JR"15EE(3$#5 H"Y+2<S1+5S$4NIC
M>(X@RGU4<>&J*G5?4R Z0*54EI2,FIDR$*P8PW(27!D"TBPMBT"&C!Q84^+@
MRP('X'W*T@B@I)(8W[YY4];3A$. X65V$8PAIG<?#A9]96A2J<FNC+E,^R*8
M9)1U:]?_KV''ECV;=NV< DV6-,AU8&YSO'43!.Y[^&Z"P7\?)Z[<>._FR(L+
M9R[=.77HTY-7SWY=>_3MR[MC]SY>?/GPY[FG!\_=7+N%"-O9EC^??GW[]_'G
MU^_3$5NRH*!R"@BOB G+$7=2H@>WA1C#Y19*</%%)3AT>(JL8MA:3*8Q'!LC
M$TW2N,LQNZ12A@7'!!#M,,P(FZ$O 63 P:M].(3K,QQ2NW&E&N'BBZS+1HSQ
MKA=Q6*FQNS+93\DEF6S2R2>)>FBD@J2D<DJ'%'K/2HBTQ'++B+JLTLLQQ2PS
MS#.O-#---+E<T\TVX03S33GCS)),W!""4L\]^>S3SS^71(J,_S'(TJ3" ,ER
MQY&P *O'H)$(7#2L1NI)"8X 55QFC*0TC$F9U.""40 <2"O-JS$P,XR8TOAR
MC#"R4DH,U!$14#&E:,2 \45]5%*&,KMTA4L,6+]*K5- D4U6V669U9*W]G9[
M;KUII:W6.FJOM?8[;<E##]MMLPT7W'&[58];\\P5M]QGGW6/(F;AC5?>>>FU
MCQ+_4@H%JA\LG J71JY*D$KWS%')%P<7]:72?2B$2B]B=$C*5D]?O N'U0[+
MP:YH4H(&51D.,&R?:!JQ$8$3274I$XU%Y6L,SE9* T<?Z?H5 <<F3@D4T)*L
MU^>?@0[Z-MZ>M0@YCGQ#6J3?ED[:(O^G*8*Z(:FW:MIJDIC&FNIHM;ZZHZV%
M\UII,MV%J.R"A4Y;[;791I:,')("#)1#HYI*TF(2/(ZAA0MTY.!&1G-*AU!2
M6H8MMVI2YD.1$UP&YGV@<=RE:)0A1I/-9%)&F<L9=ZD>S5^J_/+'5Z*'\K91
M3UWU/>4TR;DMV<4H=H=F?ZCVA6Y'*'<\>;===]E_ISUXWWO'?7CCBQ^^:.6!
M3[[WY9]O/KM'H16(X"R?58BWU;GOWOOO?UI&<J8"?.KA20'3*FEV>/T*X0@7
MOM3A7AU?&/S[\<]?_Z$:NE*Y-$>2/8; 9X!2$B#UJJ>W]QQ0@=?K4DG\MQ '
M^H^!$BS@ B/_2$ $!C"#UKL@!ZND006"4$LB?*#K,-*5?;1CA+[)T_Y@&$,9
MJJTI3ZG;/MX!L(#MPU'4,<?"?.$WL=R"8V4)T"9FF$0E+G%_KVL7EE#HM.Y4
M*8JMBY:S$B)%Z% QBU8,&Q:U<Q#B<#&,7?SBE*J8I2V"\6AF9!H;M3A&.':)
M/"FIHD68F$<][E%)H= !$/@%A/,M"C *DA+?WJ<P2U7H!\3BXR.718P; ("2
M (@!QA@CADK&H&?PFB0E6_+)38H!9LJH)"5C0,J59"(&E9P$9T19232L! VM
M!, *.AF32522<:8\)0!4N1)H3,*6P"0=3J9$P8T0L(,"O-+9DCF]_Q%ZL)G1
MM& U/TC-$$JS2] LH#,?XDWJ@?.:VR0G,\UI31.FL"#[H(<UJP>^5JH$E)!\
MB2754L^@^)(^\TR)/O7C3WNNI(:(LIM5"JE @;0/+'];F%F D+.!3A1*RHCE
M*0VSRU\"H'. \B4E<[F/8OZRD\38J#XSL=$;J&2DE,2D)G\Y2YF<4J:,.2D
M5J*,%:C4)U6+)TL,Z1Z7.&]Z7$&)(;-C/Y441*@M8>I3B3<]Y$F5><(CZNZ*
M*CWH9=6J5(U>5[>*5;%"E9OQ<8?V1@@^?/X3I_D!P$J!8E),SN:M^8Q!3S3)
M&5/>=3YKW0= @Y+2D-[$KRS)JQ[G!I5^115F'[ R)&^:NH^#W2)A$_HC$!Q)
M4<W_,NF3P:Q')@R@EY12\F&<A%=*8]!*,1BVGI_E93X!@#$T4'*U?UTK3 &C
MR;G:%)B'L:526^)+F++$EWJ!:2=M6=MA\I4GND$@VA#BE1=2*2MBA!."%*1
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M_$TG@0><X  W^)WF5'"$_QN]#_\<TW?;;1U\?YBCO@ZIKVE<8@!DHL6,@RD
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MO:@K4V0H>Q_#H@:?ON9;>Z/!VKP% KC!$.J^T[6[)M^H^&GMW*TG)XRX,;=
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M:)Z*$A2BN9EJ5!EG!(\@H9Y\__AZ\@&>SD2>7:&3,]DH9Y1%!F(I Y*2_-E
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M_$0^'./[;,\=U4,S9N,U+N,W5F,REN,T1N,S;L0[;F,XGF,[=F,^QF,_KF-
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MNRXFL6D"+%K?K&9-I?5.?%)L71R)R;AZNLV?;BNG-'5I43OBTY4F%5\Z92I
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MARMR+'S%%6.!)CR^I)2%SF1<PQ$5PW29??20<E-NJ405*4:76<Z'J-$\L^^
M?.W\Q$/;7(54C^XCL#Q H]-\,I3_"I9&J6Y""0FEI=S"?I26]27$'+JZVH[0
M-I6#*L2C.QJ]^%*$2DU7/**YB\;AH*7D*'N*NJDZ)^)DRFTI'>ZOO.3IU*=1
M.*AO,*A&YYGB $E@+I+)R'E(LFC0\<C=LC!53N98DJ5D,#V.UY#RG (_\5-&
MH&N2>R1+/9<+,7UJ'NA-R/GB$*+UY.07\Z=':NN*]N% 'TA'%LEQ[,2>UE"@
M3#W!RE/N8GH4HTMK*6C,D?SM_TB%O+0H2TU&47BVT"$Q:O?Y1QT'9>@S'C4"
MS_ZIU)?FD*6]5EIN%+DJ%V$M:OA/4H(R8]*IC,A]:XRCT13%-*&]@G:$P$S8
M22B%X'C9T?.+0-#N,_US:0SG)1/[MMQKV#=>H+QCW@7)*NR]PM@=2K-\W]TV
M0:EQ@=V1?Z H;NTNOT)KH@H'JU8JNN,QTAF%22WZDV[.Y3H*Z[2-'HF%%2TH
M,RX%YR'E;N.&Y[^.Y@[S@(3IT@G.Y B/J ]L8P_/2"^);&GHE?BG1IBN2,P&
MU*?+A%QS:9K;X=14*\S12L#P.ZE6335"&LFD1#5"[?'/'C.K5>3*Q.FZ<8ZP
M[A^E\O]^G>6YRY#*\90 ?^Y1#5$Y#M+S"(8,,9_=)UCB*C[\7G0]F/;L+IP3
MI>B*9I/,?/]:93NK<SQ<\-58>! -,8HP-O ]#/-SW7%O!RA?"5DQ_T^2))B[
M!+RV43%XZZ.)U&K7_N<)[HU0;6%$31-G&4_V37>4<;FV"<M?TM74 ]9QU";M
M$[ZJN9S=CJWTZ/L]N_&&".2XW0.1CBPI5\H $$X26NE=/+<.0N^N" Q37U&9
M=O;B3CV9'""615NF;* ^@0BC*=NG;-DR: @%*JL7C5[$@P4=[G,(K1Y$BO0J
M)EQF\6/%@0+K96S8<>$RB@(M>G1XLB!(D2%5*E1(D:)-AQG_ZRT[N/$G2YTO
M(09U"3,:TI T'TI%R'(90Z=4)6J<*!*E0H0,9P[TN7.F3900-PZUVI"AU:D;
MTW*-N3.J2Z4&$4*$2/0AS(YO!\J$R!'L6K$-!^9%K%&B4*)M7W;-V%>B8(D;
MA5Y5N1$J0L@#,ZIU>5!GS[53^PXD?)#G6[<>0484>54J5H6=V6*]25#P;=M0
M 6?^"/C@Q:2%WQ+<6-HD[XP6U=:UR!.KV["HT;)UV)H[R;(0478N*W!@[HR$
MZRJ&ZM6EPY#1%T9N:%SQ<H=:<]J?&+@A>ZK22559:)FM-I1]JPE%4T'Z+5B@
M5)XM")-6 _K5WUI>6:@8?9(!V"%?__BA->%7%;JT$8F].5A08DSI]5I&;ZV(
MTD'I311>2G7-YI=3(OTE(%#[,:0,"VFHE5-'6$'DF8EKJ25<8:?E)1U7CT4U
M%F!491B>>_?Y-1>,7Z5%$V??&18>10%B)55B42$46XL,?E:>9"%Q:!R3MI&5
MDG(W;G25?SS*E"2:99X(5$\\"C4C29:QZ51&//8FVX1_(LIA7<_%M96A%B(4
M'$>:;;>8A*$]2J"H;"$:57=D09>@5D@BE1!%VO6GF$]%:65?2]$D.9)3'2G%
MFZ>/-G4::&"Y9-Y:/]5*+*1"I<=>J)SNI6BR;A+TJU2J!B656MU]*RY,,[TE
MUIIB/54L5O]]J962F..5*YZ-/8$I5)W*C1M94;<Y:AIY7U77V$%+^JFM=2\M
MB!]@*-IW4Y4-11063O:QI>E<*-FTHIN/6A9=0A9)1=B$K)4Y)F#6HF292E-9
MQ^)W(WZ:V(2N4C<F5RLVI=5,A)E+F))J^B9R8[I:U)UY..\88EM5X<A8:2"7
M*IJ+(D&--%UM4BJ?PP).Q"9L)\EF7*I8'FBE79%>-Y=CD8;WL8'D$C<BE44'
MQNU83"N88+\Q*??5B3,Q5&V4B>64%>!Y)T3W=+^9A%QL[1D,7*1W=P@Y?DW:
MUF)Z/I%[TIX,OX61N<#&IO!.#9V&(WQV]ZKXTF/MG=R*)]*.G+7_L#8%IDR0
M6OQB9GS"Y%Y>@28*E%L!OT<>OBVY]21SOO^WE]WU<6:OB"I/33>-DFX'HZ$1
MH[Z?BT +GUJ7N"4<%IN G>6H?#AJ5;O+XL$54?,@9ZO:P63^:.Q/M5M=5(#F
M&>Z9RS!AH]RRFO,2ET E,J.K'Z+ZYZO8621"P H1F2"5.KSP#SE0^EYA]".;
MV$5+4=>RB(PZ2#B>..=;@#%:P@C#%/!@"%1!4Y2,&G.C&FZ%8[V#$5[@!ZN1
MD,U*,UO+C>(6*@[^C6WU.AR4?H.O^]$L4&MZE>"BTA09WB@]HLM.FZJ&N<#,
MI$&WJDD:K^6?^!5(1JI:S^>RA9P*%0]:_Y%"4<)>D\4XTN4_MV'9VSA6IS5N
MJ"LHE$Q5HN0I,9J100JDTU?V9"B@)<QXB_Q-@J:6,-#82(/?.<NL^L0F-F'-
M/JQJ"9GZ8B_T7,Y;2"F?>D 8+!TZ;24]2IZI'K+%%-6K5/HQ)?+H91G)Q!)F
MDT3:)N=G3/3 S#;O A66SK0="/G*=L?S6^I$(C*(;6A"C%I62R36FXA9D70^
M^IPIOR(;&4*O)X1QTFD"Y,.1_49U^"O-JS"B'?;EZ53IHXD*2V4V/FXQ=N0D
MIX' Y"A& >Z)??.*Z1QW$OW8+'E\5(K!^(DHPXTG)SXTD.2HB:3"V"=>RXH,
MOJ[&J^ZU3%::BO_/<=CSG]X$$WLNDMY]?+*J2^)G1#S%'8S6M):2*,Q02 M0
MO?X4)F+M=&.HU(W%[)51=(KO866Q'?CRM+$:S21==J/AHQZ$.D[E:%FUL:1=
M>DF[HQA3*>B<W%;J1\(:7FMBFO&:IK"(0JH&"YKQ/$R,(@7'! *P*M.BC2(E
M9TCJP.@@W+N6N4STR=G IZ(CT4=-4N0D1D6PD]H"T3XVM)R- 0^N!(O(6FB$
M*8\Q2W^A=:A><-.0LT1+6ZE566JG%XT 7I9-$(.0W7(V/8--[[+YXR<G053%
M,&Y,GX49IYB"^AV;\6N'&I)DGJ9X+GDQZ7+5/=G9:I02^-WJJ$HT3&?_DX(4
MA-YMH$XK9EANI"9);1:MR9FO0KD5RFP%L'1@)%G"5DHZ7Q+1O28QZK*$9T+M
MS(]*"&+DE6RI6;J$[RV%A ED,^?!.(W&8)"3EVKW<R5)505)'^O;A40RO= -
M4&?OHA9_,I.S\_Z(G 4LHD"%:YQ:ABE4LH$>>_AC$@X1*V0_4=)L3-F<YR T
MF=NYD:[.9B&K':6"WKF)@H$TLR5V+)#&@Q>;\)7.887&?)7A[TA5HC6A"-A/
M[A%M6]V249ALT6#+.HS41,RKWL75L67VF5"6HEK!K7!/0VNBPNZJ,"8A#\BA
MZ]-49NRW%"V./_H\DOU(%F3\M(92K^-C4[N"_YRQON]^KFV/XL;2LJW]2%D.
MF50&7^>6R Q:99>1=%;)EYSR-6U9-?51C[-R'/!F:*R8,YXO,P1GB?Z&(*K"
MSWKQ[*:29LM'/J5D[\BZ4RLI*"B:]-VLE#,SE?DL*M2NCF3Y5N";Z6PW!+T6
M6J\G;SPMZU7/QLK4ECJF'.4&8'N"BNJ:BIFH;?-(0-XE%J&BS_#)QI52Q?#G
M;KHG?EJHNV2,!BL-4T7A !>SBH5&_0P8*QB)+<OJ>?BI:A-&X_2%<Z'<6[GH
M9:JWU?9-(XQXFL<&/6C);\3[$J,HL2L:KES6G?9E=)9LNAZE"3R/]/J(8Y 4
MOH;"W#<V*6G8I%R?C__5)MS(\TYGP>@O#O)4.H#LCZ'P:NHE-Z9<?1F;RTPW
ML?AH)WU7S*ONT,U>A!FG-NX+33EC=V50.\?A3TK?_"S55*026+1<+KB#0O1#
M7/-'\'\K][CF%26]!RPQ:=QIB_D.[#GNZ9?U[#=USKAR8D=SEE!SGF1:4Q5]
M.OE#.DI=WP*K)U&&TBP32R_=T.ZF;5.Z+Q1D7;Q*;68W9^B3NSH9F4)_)@ ;
M"S733!4?2U@8./.T6+@COL$.JI7[@#3L*/98\0X#U])-Q<>20K'B7Q8;KWY.
ME@S7S<QP1J"YR.4FE 4WX[1/A=$7^<=4J3))JB12#J1N6U(Z9H<A'H8A@S$4
M%1,U=;:T14:6/NDG)HYE14M!:K3_81,*=EL^!D\*HE::,A59\C4'4TR5$W:Y
M]'$,Y2)QTU-ZHDBA5A9XXQ7!9"9+DR4H!$:&(T+T)42/%#7?IT@JTT.!)&6&
MXR&D53$,,S?&Y6F653\P)WMY]R0LR':VECDZE"$1X7L@XB7CUTCV 4BI@S$?
M(F!8=4'L\B,]N#"W%FL,@S$'9V*/)G3&<V<-A#2@1CQLUF<3XET8=2(?PST!
M%3Z_-1(_DQS/)&"J\3X=E1Q20X8IYAL3!$+N C3-\C5(^!/EQX7:]AZ$1#GB
M\B#BYGZI=#F*YXD;$V7>4408E4!L5F/= V_X4DC'07L!HS,_P8CO9C(>5E&G
M(ALN<F[]_R9@8#0>WD(P//(Y\X(I/'(I?"<G*K-71O97P-8H3:@X 2)E)"5M
M_%=::Z=7[-50\.-Q+9--/\-HNB-X]&4X/1-8)Z4PD98B*$(H4[ACB-$XO=88
MZL2)"S)K4A8PU%%3#&1?NH)+'?(IBK4S#SA M5@?='%,GUA,G#1L>K8R+],>
ME\%-30=XVO20>0:,LB4_$"E/KO&,+)(H6A<X+U:&KJ,G(_*"&>E4?R@?XU=;
MWC>'&;1ZL.:!3^11EW<IIK,RZ94;*$@A,2:$(G$6==59 J=UP]@]2#D:B,0E
M"?9$R!=G90)>D*=NZ^(95#=23H,2!!99+/9V+L1@:])L2[=7!__Y$Z8#&K=E
M.,13&(73=!,BC0+A-G[Y83I(4+42---B;4+),>BC>9SS/713%;@$;BK2*;,T
M7+5A.O#T<[CF?#L2=@)D4+_3*$O9>JR3<ND'/&\R6IBQ-I%X)FYS3W=3+E5R
MA9FV)SOA&< B-%018E %?:#"0186$:PS-**25TY#F 5R?E^B&/>D'9_2(;O!
MF UD,,2%;5RICDEE%X6&B70'35,%18+6.U5"A9<D0Z<7B6BW2QA97725CS_D
M<UJ&%8+2;0>%%'K2>DXU$L97);II:XH%4)TS/36$E/*65W#F)3475LYW+R<I
M'QT5;J?Q0@7R?0I";=,E08JE,S Q2/C_!4#&-%C* 3PB93?',J+U,Y'7QH,/
M&B.Z&4=AB%_(-RN+$6'7N'T(HWDRBC"4Q%F4-X?-^(X/])J6 F*W-2CX=T,1
MU3?8%8XKEE]65X8T=E*F]$74>6$E9Z6K-D4PJ&YE9Y-,25"@4FKEI6JE<BU'
M2)<_M#!"N'3\>3>U92!:Z*8_$3*6A$759J-71BP)ER().% G]"2]YS  YYOA
M27P&\A^<67 N64P(\S!2)7<A$Y=+U&=3@F<'>BMK&E\@UG_2H::@)1:#Q(:7
MP2\EH1,Y,V(;%$V4V6JZ^2U) R;K.4:]05^'\GS+IXQ8PH$XXBI^1HJ9Z3BE
MQ6K+]#H3=DNA_QIT%;<MH9)GDF9RT1>DZ.8U>5&6Y:8Q.1)U-ADJCJ$<[?*;
M[$E9/3>'Y)4;X9*'651L-P(5?-E0LK<9.Z:06V%LCW=KY0)BTX,VWV0@/=.'
M3V*/-@4@$IHH,=EO9N@B[I$K$L4G%JD7+(.E)7JE?>,CX8$].7FE7^5!U(6<
MU[5G@\4T[PA'4 65J@HZEA:,!!=^L646JD8<([MU]K-#._2QY52AL@JH0U-K
MJE8:37,Q4O.K[P=MUW1=;]0DPFEH]O- B?)\^"$CK$9@G:5;-W2?P".-4+&9
MR 94+4)^MX(Q9#)/%^=^L\%FR0(\;W0:L)@L_P-B;_$\PU-\Z?BIN/^B/I>G
M0;"V#[%29Y/EC):BH]8C:+:2%^4U2M<2N)0#:^MJ..^94@(Y-30VLV_IFTTU
M/#5EJFQ$.8!1)4.TC&=GN3HB*PCU)&Y%I'(K(5OR?B+V*117?&G:2%8C>??V
MK%'':2I++7VG+M3Y.]8JF?6GMOCC&VCTI6J'A?II&/4W6*%R66<'1 -:I@);
M1)11K2;&>3ZY,1E&B]"C9' V7S@W*TF$FH1'/^Z"; :27?OZ%:+DH[3Z3]YR
M4 WUKA.T+@<I*\/F?3Y7C38CHTL6JMKGJW]B/UO$;P8)M#PS9;597@&B%;8%
M@:P&(E6"LU0Y&3>ZB#Y%8V,(%S7T,A=*3#__%BNDIH/#L98RH1O *ZI\9%M[
M>T)\)9)YU6!U94QD>[OC L*=(TG@-%V!M:O3Q5Y+A[/#(;9, EU,26<3^DLR
MMG>4@Y$4!:BBZ3*;)BS(.,!R5'TIV!BIF4T+-4N+XAU'B(S1%2)R:#/F541Y
M>%8RU!TMU2A*LT.7D<4ME8E)B5$;UAV518]=PEM_1&I_Y:8:Y9>N4TL=$AF1
M*$+09)">41OK(R+T=5O*HD(;9417\8B&8AR=616])<+:ICN?ZAVLUAVI118"
M^ZZ&JG=O:S=8$R^S^8@GVR\&6\FYHQT$3"<%9SY!#+E,U[^P>4*:TSHXU!C\
M,K09\FE#8U3>1LL5_Y.8VBBNSZ2T[4.-T?17)L=9)2NE;RF,,.-$OG.AC)PL
MG$IE3\8HU$1GSP9&G^G HK(V%)N!W=<[YR=0O)C"V+<C56(XMDFG1#O+CB-6
M4!D@O/E:G*JJ+"='Z"*3PB-[H=<A,FP^F3BO]6M&;W>"-L1YSO%Y:^4M9[5L
MY1(_:*DP+L*( A1MMQNTT<>*YT.,=3$Z8"07@P?/UO-$"EA.6X4Z(08<R,F2
MJ(.#TDQ86WQY=9&=OB)\J^:RNP-@E>-,NCAI<7F-U\J"F4=4@KA9G]8C,O(Q
M7T5&T(2=XVNK D-X_J-+?2-/W]45%^49REB^>L8;R9S(R*0W%A+$%7-*$?^L
M0';EAOV)4O4V3W$+S\U*;6]]G92G8F%DHCC$;PI;.RCH*]/E:N"[U4**-UJ[
MA RK/+SIUCR58](6&,8<S&1W6FP3,;XH8A!5.?X#?;WSQW&BKB*B6@@41HY#
MG&SMDDF:J\!E4G+YM?;3-\1LD,ESGH#2/]+<K*>1Q=ME+!/GKWW#.G$';27C
MH5N\N^XBF/G2;([[5GH=/Y^+5.7%2$.[.($(6EEW+^Y)G2P3C*L\AYZ4/*&J
M3J,EJ3RXBYBF(Z:'JU.3K,2;U37V+YB<ST^4E_D"?V&C>LFV1Z:60A<"(VPM
M&QI%7(4I<7U%UMQDDBQM>8W!-#(H+YT6+HK,7K'_TC,9I(N1_$YJ4J[ZV-;/
MQ4<@U7ODQS'':T*M")>F0X8'/:*#8U6GHS>0)F\T;M<(-7R[2ZCE'#\&=;?
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MB-SJ)*B5^9$N)=.+"O FB)2%&>0&"9P,WC03/LE44%TOH]$'00,_C400+)+
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M8*@VBSH"K!8V$1XI9 WPX8F'D*U"X0DH00.;^A!"BYJZL9+HL, IE N*$17
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M"Z%472'5R+C@V[6,KPH+)04+@I$0RRAAG:K@PEP^@GBCI.T($_+/PH()IP2
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M   " , ! !0 @ $  0 @" "$ (!P ! % &( 8   # * (0 P' !& < 8 !0
M@(( 4 @ "@= 40 H!H $ ) @ !("0,(!2!0 B0&@ 0 T"("& -!P !H%0&/^
M.QN  0$P$  &#L"@ )C_G/]R@T  " @ !P%0_\5 0  (" (!(2 @' 1$@8 8
M$!@  H- 8 @(# >!42 P!@0%@* @$!0"@L)!4!0(B@$A 2 D"(2$@)!P$!(%
M0F) :  (#0*A(2 T'(1&@= 8$ 8 PH! & @( P=A4"#,?W7\US8( H!  ' (
M /5?61 @  ($08 0"! . :(@0 P$#(" 01 P! *&0\ H"!@#@0(@4! $"H%
MX1 H"@+%0)  "!($04(@2#@$B8(@,1 T ((&0= 0"!H.0:,@: P$ X!@0! ,
M!(*!0S H".8_!/\1!\$!$#@ #@>@_B,"!P+@0! <"($#X7 @"@[$P,$ .!@$
M!T/@8#@<C(*#,7 H  X%P:$0.!0.AZ+@4 P<"8 C07 D!(Z$PY$H.!(#1P/@
M:! <#8&CX7 T"H[&P#$ . 8$QT#@&#@<@X)C_J/_G]@@% "" L!1 -1_8J"
M !00A )"4$ X"HA" 3$H,  %!J' $!08C@*C4& ,"@I 04$H* 0%A:.@*!04
M@T("4$@0"@E!(>$H) J%Q*#0 !0:A$)#4&@X"HU"H3$H# "% :$P$!0&CL*@
M4!C,_P;A/S7^0_)?7?\%_QL%(  #!&& $ P0C@&B,$ ,!@S @$$8, 0#AF/
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M6H;+\&?1@B#Q.:0/-@$+Z$=$$1\VB4\AGU\]UL2<UK=J4H3A<F<"TS,<UJ"
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MSHH"@&(R3N\ 7TA.A33@&A$&<VJV$X>2ENBEZ8P! '*EU2JBM7'N*&Y2<3F
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M8QTV:LP++?&ESWPYX4A.73C4R^PCSH^Q=XTQ< -8IB/F[UAC(RX3%KT<7>D
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MSO JGES@>6>JJ6Z4R20]92([A,MD0HE%%2J  ,R$)O[',4,MC';_#&S@H,:
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M<CUK6T_8YPBR*E0;/*&K6C5F^U40K;*BU:WFJB91N6HC9O9K4\P2P[14^LX
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M\S$)NQ3F5W[XZ&PAT[ @<Z (.[$5F[$3R[$8>Q4-NUL5BX\'NGZY53(FB[*
M=+(HR[(EN[(N"[,(FK(S^[(QJ[(LVWXM:[,G>[,WJ[,T*[,RV[,[*[0_VWX^
M&[,_&[1(:[2%A"!4Z7(<5S@%XDHVJ(/7H:W+L@QN.B(%=72WPZ9R&J<\0CX:
M\CV7*@9;USW:4STTXJ=#TCY$,B,P0I<PE9CMDY<T<H:(28B/JIAN)R9.(K>^
M< M?DF@]%3^:FG<OD2P$Q%2?B5294%6O2@E+%2C+<%0'E FJE[67H@D0Y)NT
MDE87]"JI:(JQ,BNY*:PY\ ,Y /\$K@L$L:L#L@L$LRN[/_"ZK#NL<;**T(I!
M934K&:1!O EH=((#:4"PPR)NTM*PG7M7U^>MOQ< 15 (X"@ANP!:H(8#U<@0
MA!  G642^D (_?JM!=.>\RDMT3=]*U!]?W4 K%:^+,"]J/6>"\$.!I  SJN_
M^\N__>N_$7(VMI&$UM&B6=-Q\[25EOB_D^(.!Q4\81L\NW-T3(=0A>JV9&<D
MRC-URP,CA_ CA] (ME,]=I@D?GBG? FH?/@DV",^5#>H:VL\=*ATN/"H*)51
M)J()T= .>B=F;U*9-A6Z;\(%R&LQ^3.)A:)X1YRY5*$/KIH)^"E5P+(,P[#
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M!SWX01"&4(0C3)MQYD8<->A*A=B)CJNL$YU8D3 U\2%<M'Q1K!J&1UH):9;
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MFHG$0P8ZC"]U)9KHS(V4$[1@O5;;!9+,BO0[@ 8)AA5 @%,@B4NT/&%8 0#
M@9P# %234T U@!48NB.D @%H$(B8!Q5@@3W=AWRH @00!A@( /#35$>-3RT
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M"BH  $ ,.@P;@VPRK0M  "KH ,TBQ-&KA0#<]O8;MMA)\MD!U=U'43YA' "
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MC"![96-X._4Y:I42[K(,W4=5JD[7-FM6P,8!9("3&"NWNNU9:?&,E@'>I)6
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M!JTW$Z'-:$0;*BM*%"G"9?N@U8L&=1FTJLNB*;/*=>NRK:&4A5H6-FRQL)M
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M^QFY4"' ?="'%&RPEE Y8!FXA=2!:)# 6RF)BJ- 6S&QBF@(H3A(CAJ*!Q3
MCFM!A4LI5;FP]D'!D\BQ&/0W&>A,SS30C10PHRHRM7"+>!DJ]*0+)N,+)(3)
MIWI"@'G"+,,ZJ\.Z(P(BB!FSLKN,-P.-B^F,K\(BKR([MY*B%FTKMV-*1HN-
M%;$SY *C#ZDKM7E+U>A*QB*A3](-NP&/JAD.KJE*#B&04-@'=P@/):T'3#L\
MVM.. J2'1;+25DPCS+.K53K%-5!293C%2T.<RJ,D8:./P!$\P>HLKOPDQB0:
MS!JML 2;_[:!O?GP)$G,,P'IO!?11$1+$,C:#\=3S)\IT /=AV+ MFPJINAZ
MOB$9'4;U)4>=G49E$LZ)MF$*KUVZU"$Q3=+A-C;)IE[@$MK<G4A9/T@IGD Y
M'GB:!#C(!(39!TC!'OP*%.D9OJ?PMVV!J0IB1^TD%8K0L&%)J8&PQWI8P()X
MN ECE@5;L&;!"(/<!T8P"9"H0)!X"O5DQP0\ O1$2&0Y*/A12(VP"54).99R
ML']:E?$I*(T(5G7,OP);BD(UU'G=H)D3,!?2BF7P($EQBZ)J(:/2UV5@(8&=
M%\*H%Z<*F(3=!"J+*BFD0M3PT!'=JB/R4(61(H]!BZM2.]K(B\MB&+O6((VV
M4RNYNHVYNC,UF[.[ [4M>LI XCVG5,R3#8VJF(\]4A%68D.B$;S'^=+94-(J
M';;(;+7/("'2"T1(%%H'D2ST4-)W"!%?BU-"; ]@L]-#[!KY2*4,,1O4LDS(
M+!S7:BTMQ:,W/1M0 Q#>RR/>NA!:PA#>X#RP5:/'>4KAJHZV88]2DE<#151>
MS#;J$T;.D3;3_(4YP9)B.J;K8K;0C%31S))C/#X@,2]N(J]& $?>]!--D"?=
MK)Y,N*]XBM6_P+=(@;=UR_^OFJN'YZP@Z91!J9"! ,3' 9(Q4$&($'2H[M0'
M_42?7X6)3K$?%QL(M)#6_5E/##2Q]$&(JOC @1L(##N5AES7D1N5ET@53ZE/
M81F(=^T>E\,4<Z37[L6<'$1/JP@JCR3)$1+"=GDAO5#)%LH+Z*FAEY2Z^!V,
MQ3B,J/HA*KQ?AGG8LBM1SI"8,532JM@R,LM8H_0,L%H[+B*9*N(BU3 9F"DN
M,_2[O'K#RG%%.[*M_?C9O^/*Y0@<1-H;W-./]8"+\SB%=Y$9PZHC1%(#)=6'
MO%L:K-D.-EP.0<H-X2RUGJ6UX+*\,BT\MT7%04*/R(D127L:.2T0V#N0L^T;
M&9[_+,3IK<AZ&\<RK/U(D"5.$;5M4\2[LT53 XVDUR%Y7.9;1NEJU,7=)6J[
MMDYUMN@#IDX-GF;*IMKI$O3BS78"L'0+)^*Y'GE*@[]HSD/Q+V5@-TK(6Q];
M!ER-*:5079 @SUY5 W8\J 2$,)HX N^,E3B(KSY)"#AX)Q0\B,Z B"# (0'6
MA!D#@E/0!X DB1R  WI1AC&PP)+(J(!2 U  JE/FUH( !6*02(+8!%_6"4]>
MEQ)9L1$LSYC8N ):*?I19("K%@,K7>\M%WJHEQOT('W0@@ (X*OH,6-#"R+\
M0:LP210Z7R7[UWG1K[Y02<+H%X-]*OK-LBL;X*Y+C:W"_Q@D*@V.28W74%$L
MO(J2W82,95$J"MF053.114,[*PX[HU&UF8Y$.Y$CU8U%FZ7FJ H V:U".Y$^
M31RU630E9=+>^%G#(C5*RZ,[^-$'N1JY1+U.$R4U..%B.*P3?E+\L#7;&MN)
M9B3VB"4G?C7#:3TWI40]FZ,*$1N]\ZP['>)"HIM;*X\W7)$$<;S<XYE"\N V
MZF"J?"Q5\]YD<^-;3$WC<]0Q8;;O.F.^G2[FPU1C(I+=<1/9P3[;:03F#*="
MEM5)>(/E(1[1;3= !D=X.^0?@PI&EH&8LQ3\0]86G,<7.S%]1!9F24$J72 @
M8%"< U,@*,!]H(3T.6%W( @XL/^*&D3(WXU6DPC@O]B'>;#65EZ(X,,*22GM
M^?P4VA:($WX72?'E$XSLW76@V'U'B)"IEXO.3,F4::;F;]&'80@#%0"  (@!
M'- $X?NQ>:"" ^AF[PR+'M,7N!!?DM2O(92+E!R4=^$3P'AGF4P,*J-?0<$A
MANG0@?$R+&P8S+!O?)88L@K@<,:,UT +/\F8LRM#!KZSDM4BS"M9E6D]H?Z[
ME4F<OT.C+R(<[VR0W+B[3;(9PF1$("7I=P$1)5V&S]-3.6UA"I\\6,-:2 2:
MX: 7.-I@0<KB1^QJ4M1:R9I+RKJ;,64/P6)ALBU2U)H-LG2/UNN0O(D/W.N9
MJL;*3;S_+46$1 0Q),#SWN+CU%UD7->YDK2N<K=^MDPE$NYJDC&IA-$\)E^<
MG3<!/UTT$^GY$WS3S32P+^5!%'=SIW@*%'), VR4/U@\W=551];5E!QX2('Z
M;656WFDAUJI8B)]]UO\F"$<?'^1\]'W8;<WV3H0\SWV0!)*XY'GH-XF;!!$3
M=(@(X \T@FZF!(R@;6+=98)@]-!V]$$'EF<I2(><Y-A]9G^S%JG(A.0.%WV0
M!.<^@!NX 1@      IM3BWS8@@!0Z;0(R;?PYA0"[W)N(7^=H7Q9LGUIPJ<+
M@QC09"E#C"M+F [=R8?M*G^&6+$[HL\@40,,X!"7#;GX9]*0_Z$34H:/^0R_
M8$I-IND 1YB%_5&SP9>J( 8R_(Q_9Y>KVK6%U4B$.<7-MJL].IPX>/@0(6F-
M) 90^XTO'1&1CJP"<2UO7+N![X]N_L9!VH2!'J&4O[N\("' J XGW7>#O_"]
M8CTKE?"C 9NL":SCT,O#N8^G)"0[3*VK@;VJJ;W"ZI BO[R(%F(_JJ4NJADG
M+JPQU7"0]HP,.0X!\=Z]54W/D=35[%3HFK8D81WH"^LF45Q<3))/'>,@X4WF
M(:=VTTW=U 0X9S?>I(0WJ%5RU,U7[<AGKC^G*&P$:$B*"$'8Y8D9*PK[=##*
M[HDX0 M@H6P@^-F%H-*!N/R".&%B*/\(]&3E AP&:U7/&7" @",(>^3L3W%A
M:$U>\Z'\UE<#UM>)SA] 8(&5A^A5AM!/4"X(J"#N76VY7O?U2=&'6@" &$AV
MJQB&+<@!ZEZN?+CN[-Z*'D,7$SH7H O)<$Y?])T+H-OV]A78P'A)^%6&;08"
M:GQ"]\8Z+H,,J]NZ^C:BRV [(Y*8B@W@Z3; C0&(3='V$=ND"<ZF4/L6UAM(
M<!-"4 L/0M2D<!_%. ,W+=RG;Y,:CAU':E*C*0Y'>A<[UCN(4.3"90OI082#
M<*$:FS9!(KPY<B&EGC+W-9P)9XU-A?5LKCFUCUX<.$'A:$*Z\^<^F?3@1 W9
M<2A!KI0T=G3_B)&KV8Y;XRA4EG:?LJ,(<TK52;>23;I6I]K5"8<NW[%_XP2-
M4_)OWKQQ3/Z%F)-NSC4'&2/-Z5+NWK\')2^VV;4STL,EH]8U3!?Q:36?50]&
MW)<IU[J6-6.M;?LV[MRZB?GR]:MW[]^]<0D';OPX<ES'E?M&;IRY\^BYC%-*
M?KRZ<^7"L4?/#IS[\>G@NSNGU&B,^3&-HA/+NHQ8IDF4Y,=7DRD-I?OS-:71
MI"E^?I-H0DP:DV2B"5BZ*;C@@CC(( ,",L3PX(010CCA@SFH 02'&P+A88<<
MZL#AASIL".*')*;HX0\I'N$1B7$\=>*'1@Q$"1!& %6B4\1\V&.*_Q_*2$^*
M S6"0PYP/#4& CG(,(,#,R"90PXI#HFBC?M0<N) F:@(1#3ZX C$E22J8:,^
M:J0Q8H@H_N#AAF2L^.&;<Z:1XIT<MKBA@P_ZB2&$?DJ( "4,&GHHHHEV- \,
M 0"!E3Z:*#HI;OEL$8",M=6ST%N;FK7IIISJD]4^ T6SJ4PR12.3,EE!4X];
MRS2T#*W*T+H,*,IL88 :H=@*2C&^;@(L*,,64VRQFB!K4"@6*3LLLYI "XIA
MTMIA$54'723M0LI4.Y R)_D'[D$63435'1X9U)-"4)4;YKD5.>220$_5E&Y,
M!^%;4$Z@1$.,3IH,!'!0Z2[5&&1H$858*/_Z%).34I.113 <[=*EE&N9D76P
MP PA1I8RCUW$U[^3P:'5:!V':Q#$'0%<\4(O0_9958D19I-@JHUETF(\\;18
M5SJ11E=-(!FFF,TUUZ2732>I%A)=$L/FFDF619U35%:QUMK.)\UUM&1-6TU5
M3GC-);9G3Y.6(*5M*]C=>+Y QUW<Y-G=&W?*51)=W<W=_3=PQ0$^>.!R-U=W
M>I.<UX@CXXVD##'_V8=?)OGM-\D; AJX'^4&#N@VZ+<]:&&$%CYXP.@9A@A$
ME2'N66>>0+18HNRKRSXBBDK6TZ%3R@Q+3+,RI<GAP!SJJ"7Q<!GD.RA:D1@F
M(TZ"^50F,N2 @Y3_4EI/8ELKZD#6F-/C2...0"BTC":^^S[RZK/7B>*7\<MO
M9I <!AHAZOC[B4 ,%F82.@ #"*E%   ';X'4,,*@@@.L  <=Z\@P)*$D8<1@
M@4IZRB)B4$"8/$42:HC&/!2(.DEU)!]4.,!*.A@#&!S @2.!QC#0L Q],(*%
M.)!(--H1AA7$( >GRHH^!C*,2%0P!C@(Q:SJ 0T/*B,988"!$3<!C64H0Q)B
M:!0.Q" &->"JBYM01BB YZQF->N+T))6LIRE1H,4RPX&>6.RV@61>9UD(.@[
MB5-H@I"#@(M91"D70BY"%930<9 *B51/S(41BG2+(A]\BF=<(QAP=84C__KH
MB4WPHBV/8.TT7#F73D02F_/! 2]M4<UA8@.S2[(F4VG:Y%;L,K"CN.0T&"/;
M+#VC2( A96*L$4Q=$%.SCT'&9%1+3#!#(IN:=>8QBIF,UX*2,(C<S#6U/%O8
M&%/*G<2FE\P,IFA0Z1JY)$PQ6&N-55!SMJA,!9I4$2 \1X(W\E1'<-!!3M_F
MR1RZD4<YV+EG=L#SB[CETV_5 2@N"DJX[]S-$8M[J"^P4QOX:$X_]]$$?2B!
M'\Q-0G,"8EL\W=8G0&'(=*EK'?U !+^4LG1.'I+3AEZD#^[A1@T;*E.9@G!
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MY%J0](F?W "%&%O_R,#_()\$_@0[Q$  .-M/Z(,B"-9/$) !+40%<F"\:0$
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MV8?!G4)0'<]()V@LGF-8YS8MF<.VQHYM7DE8YWM2["RJ,.%)K%"_9V>0!E\
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M+Y3//AFLO&^^^7!@S\LOP:R-G1@," "'-- ((P8 _QZ(9I]Y8 #@@!\D41.
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M09-W8UR+/Q-+0J>5E:H5T4R4C^4.CP@&CIG_TD!/(S,XS67@HNO\T*[\1;$
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MA2]G1-[T,*$$L84Q:J%'@EZ#$OJCQEB#'CK8> +JF2VP-8BA/R8%A5:#'L:
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ML2E$@N:A:6= EY\"0/2G$?3C 0[_I1U>) AF;!C$( &^O^'_PPC<I!=61S4
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M5O6(9&=6^I#1$ XY/*1/(S@\0%"D.1S4"P(Y/!I-HQX=1,P#BO_*H$-%8LQ
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MI!CQ/Q.E8\R$ %8'H:2S#@% <T'1#G09%&/Q  ]D+GCXA^M@ &7*=D>EEP;
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M4U/<8Z/E[83CM).)LC[>/3[5,P/'LG0O,>O.G70K^(+!,I8/W(8F""U0^Q-
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MLSF'K8]M'<P?R/ N<0)KNY)< _TU3*105O0HX%P'-_YXY)/O%;**;[31L<Q
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M:,=WS$?6@))\B92%NPT$80%I8J)1"K'-&ZGK8S3MPR&?4[? 0C'->S(4S+D
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M)9=J6QIM\:0/1!])C#+E\";@4!W6 Q,V_ _??)87=;GOA(@L"JK&DWN?:^-
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M0SSB$I]XP8?U1[?A+ZUN.XTM4VOQ\L(49*/1AZXIHX^-*&08].V+0"*4DGF
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MW!,ZG"XE2Y]57!6:EQ1BH152X15JH?ULX1="813V4 [5WBP=FN1Q',$-R]J
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M-$1!#$-R2,0-F$=M\,)$A*5R),3)P4%9WD#_2-##;D1$<3A'@FS"@^A';,C
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M)=N6=>.=12\Z$H-WGJ.T?:L'LB.Y8N_UOBO?V2,TVP$.XMWVBN\UDUN\V9N
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MQQJ+K#&)7YM8$\E6 V4TCB=[;3;44,-,MM)>L\WDT5[#+64$8RLM9>UBBZU
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M1[:GE(.[#M"&PZ'N<">2UE%.>>0C.$3^33@E$EN <!.' M%HEM.QD&ZD!C?
M17)#'I1F3+1TN="E@2S/RY(D2(>#- PK>#M,7>7"5"5NADX3R> "F+:PB908
MR0COE,3H<+")>>#O)#]RYTEV3 $G/Z&+36'8)TOTP8LPH#,:BUA=00\:@X^
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MU)?>@TLAS>?F#U][4D+RSSG<+P/GHSSJCSX?<2GQ=4YKJSP\$+N0DT.\BST
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MFG&?3*\;=2C^^"O C?7B@HE:[Z\\%((%+^(."S.I+& LCC BPS <I@XS>++
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M)2_)C1E$D8 6;EJ$/WP&;OI[P%&B>R;42"*O[VAG7RX5)>Y">OY$VPS93V3
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MY@K7_XB"$V'9!%@J$<B\YO*X$^T'.*+! 7 B=@,D1BP,5PO0%NPVD\-1QC?
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MT?5&;;3G_57;P//Z&YQX]^*.'&_(_^OKV;3"^H_<W=Z&(9(M8DM",MD^NI9
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MT\T>M$$ -".7<P#-R:V:M$HSHW752_X0)1S8YR7:[4% \W]4L MM DPH@Y_
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M-)/N% $5,!#][O7WOG^\SW_/><YY[GWNO9]S/MJZ,%DYQ^Q[L'L_ ?^O(
M @!  0!8   /  $ ( @ A " 4  0%@#" ^   !P"@", <!0 C@7 \0 D ("$
M ) ( !(%0&(!2#P  P!@(  , H!! 3!8  8/P $ . @ AP#@4  <%H##_]L-
MP$, > 0 CP+@L0#\O^8?-@0"0$  * @ ^V\& 0$@( @$A(" 4! 0%@+"0^
M"!P"@2,@<!0$CH7 \1 D (*$0) ("!(%06(A2#P$ X!@(! , H)!03!8" 8/
MP0$@. @$AX#@4! <%H+#0_  "!X"P2,@>!0$CX7@__'X=S8$ 4 @ "@$ /N/
M%@($0( @"! " 4(A0%@$"(^  Q!P" *.0,!1"#@6 <<CD  $$H) (A!(% *)
M12#Q" P @8$@, @$!H7 8!$8/ ('0. @"!P"@4,A<%@$#H_  Q!X" */0.!1
M"#P6@?\GP3_%(2@  @5 H0#8?XJ@0  4"(("(5 @% J$18'P*#@ !8>@X @4
M'(6"8U%P/ H)0"$A*"0"A42AD%@4$H_" % 8" J#0&%0* P6A<&C<  4#H+"
M(5 X% J'1>'P*#P A8>@\ @4'H7"8U'X?^K_,QN"!2"P !06@/UG!A8$P((@
M6! ""T)A05@L"(^% [!P"!:.P,)16#@6"\=CD0 L$H)%(K!(%!:)Q2+Q6 P
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M,*21=IVU9WW\5, \#]5V)!+-VD4KS16-VRU^(JR#?T_D+%KHXS$J6J<W-=@
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M,Z7)EOO;PKB2$'#L:IZXJ]Z7 >#)H[PERR-A>G/#0.)//I*MY(FH4"9=K#O
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MRW/GJXAD.?0YKD*1.,:L[4K3I!&2M5/2&OZU<OXZ!6V>^72T1L6Q\CB%Q\'
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M)";T4!K?8S9F5JQF6Z9E5MK?\3V/>_RGG0'3IW45\2*XE >(A-%I*&J.53%
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M(_,S &[@V*2H?4:&2CRN7E!%F11$]4Z.54 B05A%51QM\J[OG^!'#)+/Y6)
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M8:+C?$ &4R)#*'$EC*+A4$:G>0;D4P* YQ1B5R1B;^83/HKN!H)NMV0+  P
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MAH[WOM5?S0=8HA F4%),D(D7.U55Z3,-,PO_3JILS<SL35"2Y?)'D=JT1PR
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M2J^A1.ZB!_2=#HL\BB+@^%2YMFJ;FV\\PW-7(EKV<I=NZ$$O=,N!X.(A[E=
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M!Q3I'/,I_KTF)$'R\BI.<,:#V"2BFM7B_Q!;+L-;+P(&YL^C"$ZN&O\"1=4
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MS!"-J\==]<K!U">!'+?N]D2/A']\0SMA0=1Z0XSGF3(-"1'9MQP0B*-J8'G
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M<$-%] ]Q>8Y#4IWNJ\"4 3_0K)*B"D)^@IYV24P1<@,IO(B0F01,L(UV43?
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M1!/Y*:H\0:)Y,K];-;:BSID!-L="]<#A2245R::5D#0H*XX"XW%6&U-1!AS
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MEX)92.;H+'E7?MKGC,2(9MK3CJ0.;)%0;SQ8V]QC6>2C#OE5EA%%0"G)8 %
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M(Z8E7AH@T(C!<69@&!]B!(81PU#,C1AA!$HDR% @#C%A+C9\&",&QQ@&5L1
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M:RCGG%%%@QZT@1A8UN,MM^0.+Q#+RQ')9!T#-L1-(GJ(=1YH$>\<1"T^6$C
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M2R8^F (U)V09)V1ZZJ0"920:IL$:E/-%G:$YS-6 )U5)L)&'3DA/=80J#/1
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MH2 3:J+%IZ,RRI(J!5F8,Y_@]"SKEE)/E&?)24H06%W*!6A TC1#^&_0PG:
M4H>+*AEG<3!YFC/Q&7^2!BCA)E!5EX8EXX+B_^&7'=%[L?0PSUE6Y#B+AY%.
M%B@Q(#2FG02(6C2IO29"D>D3U?(185!]&),D9;I<K=1;/3H3MB@]8^0\$!$>
M$BDJH3DI- 2-@I(&)\IL]N-^W>,XJJ,4ZF8G&TAP3K45*2$8\=EJWW0YV)*
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MJ/NW-IM HC,Z?JL2IW-"%/(W:ANW'.R2+B$> +NYIS.V?E.Z)ZPYHXL!2=#
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M O>!P7W@<!\DW > (T!P! 2.@,$1<#@""4< <!0(CH+ 43 X"@Y'(>$H  Z
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M/%<#FTQ3U"RY*F513T$3R>RP-5-+CH==IGX+!Y(B=X4OVUTNW68D#^?? (S
M%49J<4;+RH9]9[\03%OIU92--.F/=CZ.%+(@?^J-])^,#GJ,#C\.C^(@QR)&
M9%Z-M9\@H\*1*+:Q"N1HC"5R'HE<7!E)0XX1(I#K;.-_)9&3U$-^941]5.,M
M$6.K;&F8Z.;1'A-_TB?NVR8XO[7MC42L)5%TOOPZ,V*]HEF.B>LA&6_QPK,<
M*\/Y%;LE+F[1Z[\6!$(61&,5;\HK*-^6OS68G$J:&KN?>OEV&EMQ&L]V&C]R
MFKA\FF1LFMTS.5X<1[0,!RY:6',PY<+$KUA-_O@X(_IV]HO0+$%.5 USOPW
MA"_E\:UDI_Y\/K:?-5GEU ?O3]S+ERC/HV_:&3[0MR@>?M1^(TK#TU/3UL3X
M[9SI&,HR Z46.:>5,6?B.:>,.V]G,*^K./^C_&L1&['HRGP=^IQKY)RG[&R
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MH;--4;["+N=!L=SU#A4ME2-6OS4Z<*.Y>Y.#><O*>FL-W+B(W+IZW[JMWWH
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MHZWRK,RZ(UC0R5VX27E,;L>(P\L(3<HDSE\<KD,6:C<R9E-H3K(HC3Q8;NQ
M"6A^Q,X(3<P00C<@(\J6I>S@#,<\XB"([F$&C79.C@AQH^ID @'-#C)<Q>R2
M\.N4P2K8C B;0B)TL"G@8NO:!>,:*KL8$.MFXS>0T&3NRZR:*-,&#]CBJ],V
M"?3:,-2^(T2H Z1^*$!D#-4T[Z?<<*,*8M9HJFG *-9@;?(&T8P&\4)H:FKX
M;/#ZD(KHB+U\C>[@B_D2Z0 ,((^D2A+T* "@ 486A%$.99+4IA1-\111,155
M$14U06TBIQ7_AZ$5,R$6/V$8)FD8/D$3;%$7;[$7>3%!9A$6A3$85[$8C7%M
M;H!R2BP ,#$& (!QTL!*]@&/ZD895V06&848T,0F-$&+=!$TO'$8P!$TQ+$;
MR7$<OS$=GP84RO%^#.2FV%%#NC$6Q?$=X]% AN9 8G' W-$;D\$<G483D@$<
M_W&,_)$@ =(;E:$<\3$ Q\1C^LOST*K4'HJ[<*QVPD/0HDOB" +CPNO.'.Y2
MFD+'>JF&5FNY(DX2+R6Z(NW*+B5C'H;MLJMKR,ZZIFX$M^QAL&/E=C!2/(X^
M;@XYJ!#MK$,$23(EU:JZ@F<'FP?CG(<%:672=.,V;*?JK&8W],.N_]@L!!/P
MO@ZMF51PK=3L.$"2+EA2T/1B\]2NBJPFJ-1C/*QFU>!.9R(E+LFJN]8+U0RO
M\]Z(8["H\$ M]"#1BG[#.'#M\FP*$&]-,14Q,0>Q\1ZD:9@H4HIJU68(:*K&
M\V"P9RC1$EU,;9XM45C/(:E*&<3 ,TD3%%EL43(!#5 S-1/I?F 33/"K9)8H
M] :"D[IP,(8P!-ME9/[L)@P( 9DCS[Z-T-*NRRS.BD 2R-:*"8ELY2XF(3"&
MTHA, D].ZF 28G[L X^R"L4-"5&(OAC#-F1"Y4+D)^,,##6&.Y P,8@29+BN
MY7S.S 2O/#?EZ9R0I6;P8;S#XA2"!7&P)_]Q#N<2D.BX#%G>;+P\3=/J\'6B
MB-/.*C#K PU!YD$]!O$D5+]HB  Q;<8@4C"#J"YI*//& S%AC:<6<3$7,8P8
M;$5AS29 E)/8HT$IZC+KRT2!K> *I/449?0*:38KR30!4$AMA!B\2E&T\36-
MM'7NYQ.;-$@^:B\';W:*D@7+\P%S1@HY[<8.RJ1^,PEK)^WD\BKR,V1FT#D:
MK5W::F0F9LU\;:&FBR-3+D%;D,PZ;F*LQCAT V1FCKL<;C]W!B70;C@O+O$B
M[DSW#%"Q\V&0!4 ^:"ZQ<#T'H^.$+DP/[F'ZU&*\PWF"K,Z^]$MGL+<NK+WX
ML"Y)C41/%2Y3%2[__9 R/U2E#L["@LKS9LB\R L-U=)!)]/4_O Q*:_ =HIH
M\A$R\;&,'I-8'7-"S*I6;755;1-G2N9K<#/:U(9)Q63TL#5**\<TMW4V8Y%1
M6O-;N?5PGK1<8^0.*W1&:PP%70)>$L@LW9, 70V4T'(_Y]5?ZG.A%L("PQ-3
MSE,'X94XU(H)J8OIJ@@RZ(,!8^X$.8)4?^P((\X"(W8C40A3+!5HM-0WL7(W
M>FPZ.[+.TE+&MA(++S;GF"Y2YQ4->:SI@JY2;4-E4C8'JRX!:_;A)N;AH&XZ
MY=3OK,B-A T2RTM76\J\.&IH.;3"]HL/B;:^J"CSBJA56^8JI3:C:$8Y_PH1
M1B%/00YSP18,1A=S:>Z2B4S5I,@K$ODLCCBIWZ3-V401J]#UD(@T;@TEVQ9E
M2>G6CI0!%"8E;R=2,WW-V-BCNCPVR5Y085/.4+.+ M.)=J!23X4NE-:JH9KG
M.G>VZG;39H7.S+##T"X2ZF82!#VNX8ZS*(GR[MISK:YLY6BE3U-2R<IS*U_R
M!8NRS"9T4ET5TK(L9WWL+OLS V.00-$L02DM@89W=/O#A7 V!7GWR_KSST9B
M9RZM/>0+<#&SHM(VV/).>UW&+MG#U92#.3K35S^/0Q?O5.LPAS9S96Y-11TS
M\E3TIKP6:8(5$2</,$_MU^+(65?J\RRSA@IN-/]9,ZK\EG7P-F^'[T?3@%P+
M6$[N)TD;F/!\[53[5@+Y-2)&,BTE5LH24$!9RE,A;6!_SKI*4 *],-%@5PB?
MDRNW4B\\,M&0HV"Q].C>X^O"--(<:CPF4($<L,@ZI"DO!CX/"B6HD(-/MJT(
MBF?$#$2$MP*_[B5]$PHA+NB0U\@D N*($(E;SHCGL\OT0T$W,L[:2F(!K*)0
MY*>:UHP',, BZFH#,XW[<HT"+\+,@V? EWIA9U9=RD3/:&D6I#%1U#$%.5FE
M!HUT36INY@WW\M)T"/3LCO.J%=I"<8"#M('-50R<#UTQS_5.TY*[=1A"TV]5
M!CO>#E>E:@I!D%$W]XK_* [E&NY+1QB5/RA,$7#/X,Q7F#=$FFLPC)#1LO++
M6'CE*I4CT?,'"PV+T9+/N&OGFE*!?HR&G;/1EDZ4-E-+F;ET4]=3:]B9=7B%
MLQ19YO.DX).A"-7EAC<_%5>A2/7/AK.Y/!>8K:R**V4PL%B8BTKQB*CM(+)C
M3+349G6?U:@ ]?D19\CPW!A:\4N(NJ9,4>9\0R19Y[?R=(TQ =%%::UK(1II
MD&A\UY5_0T8N+U.HGB. MTHT)\%'/1EN3#,9_-9 Q+634]I<I]"3\W(RU[9'
M2M8]N&,,_8P(6S9/]Z,BSPQ>HI/POG+;;K+E<)EW:3B#6V,JLS/+H)@_D,4'
MHA\6T.C3B9998R#%BBW20W(C!'M#J!VU=(OWZFHP>J_852,7OXRC+'0.7C;U
M37?W7Q]MF)^WA-<.TPAU31LQE8&W!5F25I^NT/*YI+@&CCW4-O5#L?L7C?TK
MBL27D1G4901I0HTJH/67+CV4I11Q:R_D12^ZP9!UM"^/C(9F+J.5:=-0@OGR
M-E^'1Q,XID?,-#.Y7#>9MFN;&%!:E"?XGUEJ.O\&8B2HS-'*D+TXQ'G(4TU]
MF2D%=#S7[@*+\@4E5TSC$V.)%SS#,JS-66,E*T#.#H=H):Y_3H&XK2-]<IH9
MBBB%&70QU08-%0U3,.,P<-)&Y GG&SM1.6)=CLBB,D!%MN32^E&3F0[AF2N1
MEXD/K3 UV&D9?'H[::$)<_-,!.XDG/-&5'U9+7_7UFE!%&W3,#[2%T0]6L B
M&J/-R/%LXEB'=;3K=T7%ME1_QF@#%S[J&-. [2X">+9U&ZR@ 4E;FH%[W)*@
MU));6[R(5JJVC"E/]IH;VH4;/..H<J@#&W8I"@%]S%(D32N1K.S"[[R1\+M3
M=^K"E"HO]E'+XX9_^'?_@>SL_,S,AO,X"?RA=.,*#6W*>0,]I9FL3'!ITR 9
M:SH[VDS2(&ZZ%.,&HHH!=WI5D\.GL[/D():[!%:M8;:K09";B=##(9QL6?O)
M1^2,+\JG>O6[/A2S\1*?)_1D[GF&8H9#.9L@!KFBSVAJ3IQ% 9'683S75'Q]
M'SN)1N:>/3JS 2\-F8-')Z%OASS9+RFWE;W9+VFS]?"4)^O,K":(TTRK;7"E
M=GH2Q*^'E>%,\ @-\.</PR\&E UB,B$,Q"\3S/+;8X 8NIKGE"/\T),[K%K,
MR4,$K>,+%0AG1- L_7H,>Y=!]DARC3#@[^<&9. &8@#]V/UUP;WA%P?>#X+;
M_[> X:4O$[9B&;QD"](@K0F>8,9C$LY&8X&X>,6M3J5NQZID$N*3!-&YO7/N
MYX*H>9W3@FFV83.8)\F#XR9&)C.2CO:#E*?U+:4U>S?S9R2,UQ N?#LI59=6
MLT4F(NM+PE&7K?E#BTX[P5J<?ML7HRG:(,](Q:7FPB%;O:!],'E=T^O(6C.A
MR)T][NW(I>5^JD*Y@'7Y#25LI"DEI]^;N=.NT,+T ^<]!L3OS'# W"6!Y $]
M8FX@#-( ]L2/+L1/$]#@W9NC2MH&A>HY"9-M2KQLC U;9 GJ3-5K*S@DEFT2
MR7JS3\$# ;F=D."\K8^N**K$<<Y$#&) $C9N&'#@\?\G(?++3R^X7=F"G^&+
M9CB&8>%+'B%(/A/*SCRX7>.YTF,:BE1]:N6\)*K6:ITAMBZAD(,/]CB$^?O5
M&\$O'2VYD'JP^J/.&'OC^+?/OMC@7STZ/ V#W=&(C=2ZII\!HIXR@<J402N(
M<*!"@0P7(B26*1-$B,HD4I3X::)%B1@U>LQ4T6/(CQ>)9>P(DN/'D!P5)A1X
M4."^A"X1UCM(4R;-@C,)*IQ9D&!#F?N*&CV*-*G2I4R;.BU*;)*RIU2K9CJP
MP@".JIH,!#@P]>B!  8F%15SX$ ,HVC#5GT+-^[2:'+KVKW+%"+>MY.\&A!3
M%0W9M4>AD0V0Z:S7&T9Q -C_"SFRY,F4J[ZLN3.ST8++#-)3]EE?YL^DET%;
M1B^:LLZ@<4+['!2:0&(WQ&2*(4:UZ7JW):FN& ,-:&5B8A!;K2R,<>#$/L<
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M&HD@F1KZR3_Y''+P(/]T:J^FCG;JBBF/$%SI/IQN:JH^ 2LZZ*B..$,IP(L
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M3"V'^ZL'P8GMFQ;O:RQYE(3QXPDC:1:">RTYVL+RLBUF68GWF9;Y43 X2;H
MPJ?V8B9/XZ!1/*J=D3H%5,4)8D4':AK%V*^O L"KPHRL4L7(:"\2H\!;#)VB
MZQ4)$\7XFB%P&J%F_,H0,K:\6HT;)$$2-$&P3$OCL!.J%(W5&,+$L@@TD &9
MZQS(PS>2R,L;E 23^;:CR(0V]#9Z.X@;5 ;Q0[AA6(9):,,P,+:5T(0SH\NU
MBXC"3(,PB $QD SJN@&ZC %O6P]BP$&+6,P;V (<\#PQ,3B$((8NG*,V3+DM
MF GC_PLW*X--K2 &,;C,&T #8IB605.&R$2#VT@MCL#,H #,;PL#Z= *P/2V
MS,R9PZPR3>B*W+D\91B&C8N!T\R)20@#94B#-CQ-GXB&-OR)C:-#Y-1.OFP8
M>;-!'+@!<?,1P&3,VVA#8N#&$BR*)#N(-D0XW'1#A2 &26 \Z]J)YGQ/>B,&
MQ@.W&R!$UNP-QIR$B9R[*P$_UP,I)%$F>'L61LQ'RTDHH-H(LP@[!\N?7 -*
MLZ-*H'P)6@O0L/(+IXQ%!UJ4RA#*IL2J!22FK)+%_Q,F1U$Z#+*THO+$9:)*
MFUDP8,RF:E)+)H4;8E2.;C. &%"!&]"$)KU2V@ /?**J_?^;1MJ+G8V[3!R0
M#'^#%S%4IZ&0"320.1C)35&Y"\S,!-*D-QM$.%DY,QR0!(2;!,;33#B5%9/<
MS9\8T#:<A#3P-F)8!F+H3AR44X+(!)G;A\0SU# XQ-Q"DC/S0<I .)78O)K
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MW) ( QE@$7(=B-"T9QRI!X ,8QGPTP)BW?!0T"VH#]Y .(.RH@KQ/HA(*'D
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MZ%9=#&DL-XE?0('J6IPWH%K686-A:=5!PV")Z'<'T=,E18B%N=-*FEPJQC#
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MZ&4HBM;S,<US8J7'_HF'NO$O.&GDC/J6Q. 8UM*6"T'T(E,TG1%#_-[(6<!
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M.AD5%@BUZMATG:1E2M'@\M+3RK'VV4A"9@EN<TAK_[W+1-?(TW"MC*C$"AC
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M-X-/:EC=NX#0XYIR 690<; JPXP)]%#(,F;('2WCL\<+<UDL0ZV=9#L TFE
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M0AP[:6O&-<(\'O0YSTL0"I55G>QH/3&I]<V$3 BHTLHW.QVSW@2OB>L<WD;
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M%,O$@\L:.YT^@D@RL0U;S]2Q(8MA5G03H].C-1$YK#(Z6U$*7 2)CX (D B
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M8%:+!GO<LS43"B@QF*F+9CAT(H+ 02MJ(U!!IM8SIE%H.":CEAN3)Z"N=8=
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M1JS$_2.1-'T]5L8R0.P3.##3 14&5B",82!&PA@P8@2(<6-2)HMB8C14"",
MC!49<83!05'90),G4:94N9)E2Y?_+V'&E#ES7T$QPS01TZ2,&"AB)6G"))9)
MY3)ZRY0IJ\<S&K&%*B)"]!@C$SU-80(@!'"#V-*ERI#22RJV'K2@9]&F5;N6
M;5N97I4F3;H46MRY<?<!S5NR9+2R^^CM\QMMWS+!^^KI0ZP86F+$ATLV-JMO
MF;[!>??IJW>YGL#$?R/_I7>Y<N9H@1$3UDS9L]F^CPO#'OUXM>/9G0U[MCR:
M]6/#?LT:UFS6+V"!OSNOSKPY<&_ T2QW7DQX<VS7F9$K[EP\-F?%T4U6+M[;
M-F;-A*%#%\][NO33A',[3BXXL?K6W:6O%MX=M6C/V(\3C#?Y"%O..,WH&ZBR
MW'C[K3_H_Z3;KKS2K'.O.OD@T^VYVP8*K#'%D!/H0<<<-#"U?:XK+#KUM!/1
M)+TZ:^P_VGXS;CK63ELN.,1X^H08G(#4),AA0 E2F4R&(L9'))E,DDB<DDQ&
M2$VDA!+)*8<L4D@MA\1RRBJWQ G,,8=29L@DKZQ2IRZK+%+),IND<DHXX81&
M+*.4.4JLQNR2"ZFQDN)3KJ3"BJO00.4Z[4\]C6H4-;24"0 H' XPX   T'!+
M)4TF4>RD>C*19 PTT! C#(,6TNBA ,30:Q*$&(H!@(P,"("KI'[22]-=>>VU
MUTD."#952Q>:Q->:B)E)F1M6. "BCK**@2\QJ!6#I&.QS5;;;0NS';2NK_J,
MJRZYI/_C<2X#<_QP.1!7E'"R^$#\3S'4]J-L-\+,BM"S IO;+$((&^,7Q0CM
MS9&Q"Z,CKCH/ZVMPH.3$4RXY"8T+;M[,NE,Q0,R <BPTC?O=MST6GU.N.<.$
M*^NOB57[J\8+9=3W,9@QH\WE@<<S3+K9^KU78P9%A) ^^\S#T+KG-ENQ:'7;
MTS!IZ4)3[++4Y%.LI-4&L]?=V#I,CT.#0:-O,I#1P\RLP+9#+>0*6<SMXX(=
M?FPV\78>VD7&T#SR3227=!)+-YG4^\F_@Y0RR;XST1M)+='L"2>]^P8SR!]S
M2KS)RP_/''.^Z=Q\33FS!))+I):I"RG3!Z4L+CVA00I<1L7_&DVN.V''<ZP_
ME1E7+K4FN6$@,=#@*9, LATF\9<FB>& A!Q2P=E6"4I55C$2YTE7;K'/7GOM
MAZ+)^DQN<!ZB&)(5R"P9MT]?_?6WO0O<LN("-_ZD!KH+9P1/[.NOQ;!KL33]
MK6:WJZ%L1FA#D=D\-C2L#:AK"<),@=(VGGK$(%-URQ=U9M0PHFV'-0$S#P8!
M-)A^77!M*N(.!T]D&,E4C'_2R0W=X+.N^)CF:5SKF<%,V"#+[ 9C,;K9/JQ%
M(T_Y##\8)-!P[)8)JGP'8@%ZC[T>DR/:1+$Z)F2-SX3FP2:>;(?X$9EC8*,N
MB.&H,U!;3@QMIAV_Q,LX_RJ:W=9C_Z+\S#!?,_K? 3&T0MN0)B]=\F.80$<X
MS37NCX4CW"'_2*<O 7)REBO3E!27-\XA3I)TDMPB"YFG/.%I*609E%@&93NE
MZ*YUY )+[@;E)W'-#RZY00L.B"(0,1A+( >XWJXT4967H.$A&<G(K!)"/9X0
M@Y<KX @,H,<^92Z3F3(YWEF(<0.)J,!6PVCF-;&9S9<@:BZZ"Q1<!E4N<,T0
M.#;"T%].^"YY(<Q&0!N.$B?B2S&(+!,8B0'U$E3/B62";OKH'3',8IR/G7$?
M][Q.<:X6-CW^YXE-;&%J[.5.-.ZG.GS134/-HT1:;F=D'T3-,&[@RQN(01,"
M"<V1[#E22?_DB3!I$*D,T$",%CF%*F6490SJ>" @QH!A)N6:RBZ&1 \&ICC]
M4D8,)I$U>)GS85F\F;J0:%/R(*@W2-S/#%-V+ZO"S8D<4HX>J7,Q#Z),C?/"
MEW_X,[ 6X><Z*:OC"M6UU!(A9D<X#(PR&,DE+5U2=(6$).<<:;E(>JY)?5O2
M8/=624H:MG&!;>P@ =NXPVXNDJ1+Y2E+N91H@(4RH!046/2T25"*UBB*HH>=
M"#5:;]UR)K,<""P'<@!K'FL8DW E2_"*$XN@81*\+55&0CK2-/@V$^72YG&Q
M:9&2#J1W:3A6]\ZR+  <9%;+1>YUL<L^N+QO?JC\RE[JQZ?^M1/_9V:3VP:#
MAB.&$2:AZ)%.\M)0D4Q4Y(#T<"GU)!%2HNA#&3*0!#'2L(62)$835+D/P;(F
MD'MV"&,GLAEUKH,_NO6OG ;T:5'7%9O2E&MN"O*487I7W+/5K#S<*8E+&6$1
M1MP@#-9=2DBI-XE)C&2>@+%6129A+1EP-AKYO6=D"A/$FP$GB,5!GX<4=)@9
M/H=_: 2?L?"W0A4JE*-F3*&!%EJPV)RG;AI+*!M=N-8H]HRN<+RH5>D3U K9
M\#ZE05!Q&GJQ+9_HA_X24 CW2.(6<49X.AF3D/SVY[[N)$U>*F29Q 3(-A7.
M;X:$$B61]*3'!JY)DJ;TYR*)24,3.K%+_^+O43J[.DT"RD]'N9UJ3X>4O5SV
ME(<RK6E9*Y-2I212 ?55+FV-%EX"8 4 2.9 "I1=86]/#,LS0*;0$( #_)I7
M2(+4).+KVU@/F]K59DLJY1=.;=//,[,32-:$)F>(<D>')V3C@Q;S%VC\$W__
M658RB8&1SBBQ)/2@2'#"4.,!"\@^""H)!1.#G J7MZ<0W;!/YUR=%*T7/]]1
MX0/W2*\ MK! 4T;/R00RB3 X5R %]IWLPB"#6'KJ2-7A92QK0D'M9 *F,9#$
M&O?!2W:B1N8 *K/.BB;6_<T-:_H@AG_S-R,8[4LY'>/A>6IF\(<E3$<_<^+"
M2*;PL!7Q;N6)&?\&F>A>Z$R1YQ+,6GWV7%$#W9%_5Y/BPO!\474G$!J/M9*?
M$;GIT 72<)!V.Z ]QUC"=BZQA6T<XSB'R4#'77!X;]PI53DNTIG:4;,KW5U.
M(VK[S2]VF64UMR%U@/*9!"/%F\2CT)(\AJC@!M?SE+51WZMA'( H3L$!4D_O
M*^AJ2GX_2?WM<8_;NWP++WV"'UY,BA>P*=U!0BOXSE@$\V74,Q,!-*(2B7%6
MR=0C>=8L$"^CW[O#(!4Q:,"! 4<,F]<H>)Z$65MV?NJS".(/*%,6?X**OK$V
MHBLY,$<^OR7F(@E938DB3@P.MD X,((H_$5HEL-:DJ4DAB$&QD P_(G_?&X
M!\JG'H((Z>(CB+Q,0SH&/L C-=3F,,KHR?"(PL8(HRXC;E+F.*#(AW*JR@!$
M.4PFK&"N/])KCZI#X""JZ<CJ0'!#:?I#:N;CI\P+?\KI1#K,1LSK!G4NK*A(
M1')+KP;M[1P-"N6.2_Z*3B:KTR:M\ 9G</@J)WQ$<OQ,LLCPTB@)T'S$T< 0
M33X-3SQ)+/@+4$SGLTR-U AEDRX+=?JD=O1D+=" ]8"BGC0O6W+IMH)"&=(
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M*96N]I3RPK+$8BV4Z# YCEMRR6[Q=HJQ2S';@AAPP",,H&ZIN(N[!9PR];+
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MJY,Z52YX+R^6XJ,QFB\6Q:)5YKX_32Y!"7#30@S>P"0.H$^Q16S_'WS:4^(
M:.E5LN(PHQW:J;W;+U5ORW9^_A:HE]A@EJHW];'L['B%@INF\*D7XZ\N,.)J
MG/,@93DQ NQJ"FP8"./>-CT:YMTR,O%=$7+ -*/YX'5<XW' F%-&E$%1C<4Q
MH"MY>81:9"IL0,I8CHI6>[$JL([ $+/_!$I1&6HV[#..,$,Z;Z"DWB,@,09
M^62D.OC-_R-YP-<UA>RHPD!G&B,3WD-^6?%$7J]\1F,80E(=B3%#E&$\M7D
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MJ_<^IGEEZ,M'BP^_O#)H]>DK6T8/@/3I!U]_Z,''4((*+LA@@A7A( :$!]R
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M ,=FSV&A:WIFG1%6QS;5R<URK)/"V&P'A\J9V0I/HS7_5$V(68O<U*P6N65
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M>CLY0SI$#!_E;2@30JI77\,@($/4-0EF?/&18!1F'_[11#@U-:%X;P$H))F
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M1$0UF!AA^/^FB3 U(,BG'QSF'\J'-4+2*/N  _(1 RE25080 $<U"?YJ )J
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M=3PU1WW'C@6NVH&43C;P=03E)^D0QP4/X&Y87/KS^8 (V:;C7*M1,S?PZ(G
MI9ZA-7^\ZJ6A'5LN['+B[G"43,?11\/#8.(\G$9>#0WO/.EB1UTA\&;+U0KK
MXWI*GR;P7DOP[WI9N#8G:MO?Z+NV]BJ*O8[Q*G7KDEW9Z4MKK5#K&7<G&#?%
M45F^8]%," .,Q\ )9$ZHHBUL@OH+A#CS9; HHOUE]!/_[.60&S$8@Q#;K'KA
M4S /864X@$DXH@=)<B['C'G]""BO#!S 4W6Y#-).>(ZOET*UCA?FN' IL%1S
MMD*>Q&*?O!P>Z$O!N:-^;IP.%X;.GOCM].8::T-.^7PM6"*T:M!=[TX9$&%2
M="+L#ME>-4-W)2UIQ-A:#S29XPPY+F)_0WRF41Y%>?U.)D]O:CQ/LBAA7.,B
M=5\7=!B]9ZK,RH<%XCXA6+RYSD4L-B(EY.JQ87H,:_9F0^")'MEJ^6("]=J[
M]!A:O:$7%'^FM?)PB40?J'%G/N5SZQ?_I^LCY9T X!*':[[NMG/WWWGBTOG1
ME1/'ZU\IQG6F* #:\7T/;#6E_\PTE19=3&;/%$V,LM,8&(F'C\TJZOBNK688
M&-6/*)?2I,:/(-?1T(< 2%?[:!S<3W[G8&<6 UNR#8E?CMLC SVB[N\;:EM=
M:L!VW*%2+[V?FB6_BI0CP>E*^:&Y]S'D3:V0:7/76W:,G(\.\;13\VG>L62+
MG6B/\=<M:6A2JU2 T+=L7[U]T.I%$ZAO'[U] O<1-%@P6CUH#!U.;&A1&<:%
MR_0A!*F/XD:)!Z/M^UB084*$*4?2HXCR(\2+#PFBY+B/9,2#$&%"K <S(4V"
M!RW&C/D0I$.9*7>^1%GPY--]' ]ZW%D0I-2=2H7V?&E5XLR1"V-"1#LPXLV+
M%J.IU?\*$BG$M1F)>ARJ$*?(BULK@L7Z=%DF8H4_&596.)-BPXXU#8,L.7(R
MR,00,YX\&93CQ9<[@SZ<6+3GTL0B#P.%6E-ERII7PWXM>?1IU9M3HV[,F+1C
M9;[I^5ZFK)YOW]"4 4?NFSAP>LN< Q<N79GTYM650X<&?3CU@SIK@@\O?KP^
MQA S:1JO?CW[?<,F?6\O?S[]^O;OX\^O?S__L> 5MY<&&C5-<L-Z:."PCV&9
M9#)))OU!&*&$$U)8H847AE<<<<IXQYU5RW$(8DTAZL014SRMY))0% 4U%D59
M111C0SQQQ.)+:PEVE7\R ?6B5G3!Z):*&&F%$E<Q@C700C7_LA58BTBB9%)=
M.QWY%%5*LN565$.V6!%;'\&EU98E+4GD2"N=Z!)--?Z5%8IB/L7C4RHNE&)-
M#7%U$U@-X=013FCY:&)&+?KTT$1Z!G6F12W:.)6:9W6TED9HKIBB17L2A=&E
M097%8I5[BBDI2GC"U155!?$)*DHLAJE0F$]N"J6;+IWJU91+N@8;9XOIIEAC
MF(5VVFV?B3999[V:5MAFCB$&F6W![N88;JS=1FVNUCH;&VK02JM)9P(!!U=Q
MSY%+G;GBFBM<<?HHQRYP["H3C7+'"0>-NNJ2F-Q:&/(+D2;F]1NPP ,3G!]Z
MXA76WB1BU(1&&NN)\3!X"1=<L<47_V-\,7?';5@<B!\75Q.YSF5%%TM[H>6E
MCELI":928#J:Z,F'KJ332@/A:2=78+G4*LP_53HJ1D(?]=290D\ZDU%C%:W0
MS9""):B?' UDT4"-3LUT3UPZ6N>3:UV-4-)C]67764KWM2*>-.5,D%E)2EET
MU2N]7.39<:9:9U>ONFRWEWR^?":1?>M%]Y1.#1U1J49[R3*<,[+\=ITPUCUJ
M0BQAWNC;#H%I):U"85K51"K'>-7?/G[5$=\.W3@,MZ8!F^ROM %KK&? (A9;
M:ZK1MJWLI#7V6&NS9::MLZ]_ACOMM$4;G,?,'?>;,NX6)V]SR$V7O;G1<;?=
M]< 11]QS\?_UIU@:#DXB,;_#9+)2QN_#'W]]]!Q C'C$'$!^A@;83[_]:,1
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MT6_["A9(8@ME#2C\FNL,+J%GD"O[MIEG;$=P),= P9:B[1+ <H=P5(3'<*'
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M!%6B_T3_&A&%3,^,!8)L 1G.ID?*$09Y1:8(!ILF%0"E1R9P > N1H&@;0Q
M>.<2%V#HWD 0N6=$YH/00S4>#?HUA"7[R#%RD9#15@S,UQ/YRQ:@\4HPMKF%
MYF1 KC''V&+'P*OJPRZ_RCY$KB^?N4JTR/FA<31,0AC?@%! KBE#*E2\J372
M!#96S95?!)#O1(&T,DA,XZ/D(VU1FHD8QODXB+-!*D21H: 2PQ:@05P4]60;
M^D'H7FG$@"3@\4KI7IC(]DH D&V/,]C$7M%X)+.9U#Q2A8EDD#X.R9I Q95T
M!'W*V\AAYU9Y(/"9551IN<;E7*OT-4 ;J.L0W?(8=(6ZMVA!?YFTB"N]1JB
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M]D,FO?\#7NO>/35\Q$TFSOR8\)^Z6]TSR1U\#5HA!T3N:KV5P*/P"MU<)(B
M?@+OJF'-NH[4&GB^^QZP.===6D&-5,YMM:K-=#STUH=)3$1-8L@W=!'"_N@
MGLS_1I-S $YP@3:W7]&]MT<O8IS"OW]P!96(_9MSL(15ER7967AW4))=.;$D
M3@;[GW7R+TJLI,/$Z^G61'D,$.E(14_40 U>[ #=YTX014]J+ +#Y'M^KL6
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MP'"D1Q0G,V//K\!F1$E2D\)0+G8>+.58ZG=>!0#1Z?Y"[C6+I,,2LC02\.E
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M5SL, %63A*'V=AJ23[<6-LFYA=-1>1XUQA RAC<U>D 0.3M*H1*73I#M %2
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MJ'MI"1Y!*AX*8UX%$U_6QD_F421Q>8GY(8X_A09[N0^FN!^H*&&@$6\=9#)
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MMY/(^W@TZ*VT4X&W<SQ5)UA2$2I 5T:I=*I&5ZVVRV>5.W,GES:2963_K/:
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M&3<@-6E'3")DW98DD\D^DF[5L]%B#?FV<FYJ&),X9CD_E<N_78YT,LB3,M-
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MMS( 8= $W4YU3=J_GAC+P&8F;C Z XBAF-=T""Z!4&W1]V14>WLO]/SNI.B
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MGS'E'C4IBE&B! BR):BLAFG,6>KPBF<-94@VE?]!+*,QP@]O*<,Y@5/!"*,
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M<<8+2V/"1#]"*M"2WAD.O2Z9LHN)R(L"^EZ8^J,^54JL01.<$?G  C/MG0]
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M&*\KFGA,\UOG>\M"T^FQV0>>*[CQFW;\M>^7Z(#J[2C$"WC(*,FN2I08S;?
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MHQH@O&R)_KI91>S2,X'0#"/<Z531K%@>C"B*>@:JB4C MS;(M6YIV5D&&L)
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M.5U+]1 6N_ @>%Q=F#?EL\R..Y]5K#QK U1'?VN+DA_)4MV@1A' \ %JP #
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M#=E)(81-Q+5+4T@:#(4:69[FA]2)$XICL(6D29QV[ MJ3$^&S)X8F)VY_)\
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M]#-/F]L$],[TZPS4I)<^BNG0VIGW#"S!.*J2QY0.&Y?Y!*'C%H 0F=="IA+
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M2).1_X91!J.*0!+)29.F_*BD)[7<Z$#_7I1Q)@[M8ZXXF$*S3T4A/>-QJ,4
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M#CTEPP1AI4P;L3 (_V1.SZ+K4(:U+DHYYCT<_E*%-%(@#)/SO=DU+:D%ZB8
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M0(5WZRD4_9"I,F0JI90E+.$55]2KBOQ0([G"C $G]J_ <0J)AAK/H,1F'-!
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M,QD]"FB0<J>=W,UC;/GHI;[7G\Q(L&]STR!4ZA06P54FABH2'5[.E9I,*:6
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M?>S'?PS(@2S(@QS( 0$ .U!+ P04    " !<@EM8B'^;93%;  !"6P  $0
M &EM9S0S.3 S,C,T7S8N9VEF1'=55!M<$VT*%'?WX@X%@EMQ=P@NQ8*[4Z#!
MW36X2Z 4=[<B*1X<6JRX%BBTM+G??^_#G:<S:]::V;/WG'/6J*@IBXG;L*'T
MO?H%^'\&! #    4 ( # $@ -P# #01P@P'<4  W',"-!(   ! 0  (#0%
M" X (0$0   "!$#   @4 ($#($@ # "  0$P,  &!<#@ !@2@   $$   @Q
M0 $(. "!_"\W  D$(,$ )!2 A .0_SG_U08" 6 @  H$P/^+ ;D!0&X@D!L,
MY(8"N>% ;B00! ""@$ 0& B" D%P( @)A " $" 0 @9"H$ (' A! F$ ( P(
MA(&!,"@0!@?"D$ $ (@  A%@( (*1,"!""00"0 B@4 D&(B$ I%P(/(_'/^U
M#00#P&  % R _P<+S T <P/!W& P-Q3,#0=S(\$@ !@$!(/ 8! 4#(*#04@P
M! "& ,$0,!@"!4/@8 @2# . 84 P# R&0<$P.!B&!", 8 00C "#$5 P @Y&
M(,%( !@)!"/!8"04C(2#D?]1\!_C0"@ # 5 H0#X?XQ N0%0;B"4&PSEAD*Y
MX5!N)!0$@(* 4! 8"H)"07 H" F% * 0(!0"AD*@4 @<"D%"80 H# B%@:$P
M*!0&A\*04 0 B@!"$6 H @I%P*$()!0)@"*!4"08BH1"D7 H\C_V_Q,;" >
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MC13'ZNNHH_L31Q0C#8/BAA(2JWO(O#BAOT0^/JCR!$2ARL@R>NI^+& H18D
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M=7#>RX9%!/DXAW^:HB\?+-4N'TG5)C1,-9NFQTN8[J3?<_Y6*T!ONO/;GW*
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MAMN@P#TO,F'P!::)TOFHCVYTI8!;3CS=(L))\T%#2&S:JVYDX990,7ETV&>
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MXC)XGR31$O()C4S"AHTP"2]SUF&T(L>GWEB[)D?[1VYX?98$IY!5/>M5=5X
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MSQ%R\24SC4E<(J:U43^%MK9FW82S-DK"6L9(OPBL:[>0-%E2GUCS]>JN-,;
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M]#L'%8\)]9%02%6FPXMBE(FK DWF3':D1?-NAL%Y$/W2!*D63HU7(;)8B0A
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MPQN=%KH"R1DM"">X;KM$I'&W>XZ_#0*\\_N%&QESYXXV$#R_9Z(>&+FHC7J
M9F , AQWT;M)_ADN_\U7"2*[54V^*K&Z3Z\L1+RRZV&[$0^2<6<&8)3-4AQ3
M4G1\UWH%<V  (?PA5 C\ KJM);*V=[PF-&$3YWCJ#N(^QV#&QR7#3P2MK#NV
MTR*EP;D^_Q:S98 )>W3(-R4-R!MH9<UG7;4P$BN5W/N2W60,A)S+Y^JU:]EW
M:9O-P<)M* %CM!S7<F#)B6'-@\LF$XL8*#>STXP%EES.;4(3")1Q_R6:!7*
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M+  & ,#  !@4 $, 8&@ # MH   :P( &** ! 6A  QJP  P @ $#,%  !@'
MH $8[']O [!@ !8*P"( 6#0 ^Y_S7VXP&  % Q!@ /J_&!@$ (/ 8! 4#$*
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M\D)0&Y6<M]I5=76E\'JEQEI!((7$2-@3<0]:;4&M]NZ5AD;&EQ+$)<6U>8F
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M'V8__CG\?M/G\V!&>9<T_"-XZ(\8]F8T>O$>]J>][$_[]S\AD?=AW ^+AO>
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M'Z'%06ZC"\OK#<.>$?O N8]Z7IFTXOMJ40MAY,7(5A/-/[JZ/N]>?:."5N,
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MZ;"Z3[>@J]AP8R=7*. X:S27#S<<".-TRI]4!,ER<O]VZF^\EM+7ON-1"BG
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M135;0K7KLI!QO(J1=+?%;F!TZ_ *OS)SB&$F\H,JOFDMG(J<7F(CT,"<XM)
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M8M=R*J=^M=-[+W11?X<K=/(CB89%J2)\4-@HRH S!B!LY&-KN%98-QA&\"5
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MTRU[89M$*4))P0MK:3NTXD*X*AT>+$1F$1E)^YZU61Y,&;Y"8B6.^SZ+6:7
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M2_] $[+\L9)3G@#Y7-Y*J7WHNU(3"\#UU$GX!(H<R!';)NI1*V<"2?.#'>>
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M&GI;-M8()NM.DD-8V/$:3(%0JI$ZW8K,?\.K'AO=B5'_5_,27^)!-TPQOOZ
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M-7U9JATD<<3<AVS.[N#>86%0:I#:X@AET,C,!_U3+/:F@FI&*?(IDQ"#&,1
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MT1JM6*0D1&+OA[S,V;K#D:XE,XZQ>;8G-L8%7N1E,-" A69H)D!M']$13,(
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M$G8ZIP=8%)9Q'>2V1E/BF@WYL&1)GI60^%$!;\)5%[JL8>,ZAUPWTL   N
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MWAV2V)[JHWB(8M@NPNMAWU RTR,M1<0FCFJ;>>"5JJ\@3$3DBUEKTK6R3,@
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MYF8;+7(V_B,_C;.QP4N'63K%:O%E0]-XPSN?V;9_C)'">[PK)J<HV28:/!A
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MU'(TJ4G*3+00KI@Z2LM#G[)Z_TJBA!1[#K'2TN +LHX^.JY--]^$LR0Q;CA
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MDL> %DRJ)F;Y"(MI%&XSNV"IF -3)]QZGH8#KQ[TP3:YN6S4'7IX(Z&8A!L
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M18/8$ ,GK.N%=5HHJ["3P8'K>M]C?@E7;69:!@Q,:Y8Z@B5L(ZF'(MU'%QU
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M]&;!M4<N9C"J-47/E9&0-$U5K98J]>W UE,D,Q Q[D\VE&S'Q;?.<U--)NK
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M0A)UQR 3MS,!Y11RRPDC*F\(UPME_##QE-*U#8S20$8UN1'(_+/QH,O[% 7
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M0/*_I"1HPFFT"L/&J\YDCERVO+TFH.F 'CC9H_Y7:DL [ 7JK[[KO?[K/3J
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MJ=$ED+1*DCJ'G_\=Z"<!3&SK> 13G/ .M)(]C9RD=#HC=72.L]28=L>I.[^
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MUH\\N4;W@Q1?FDZ:=TE!FBSO,Y11DG[]EY4?A)]>A0,1Q!ZJ<J=>E702-D^
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M/XTDA#M6BGIF2W_7;TQX89-@  %0GLHAGMCA<@W&<L<D&NC9OWWLQ[9R P$
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M.!%PL6;5HH$5"3VTU3B&UE.1 I3^0X(8$['(ND\L/#)/?"Y'"R466\[J%R"
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M%A@#^%1//,W_TR2,AAB8#K+9AS< 3U\1G'P,-IM ' 08@_AQ12U*2##LI.&
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MVX;^,$<F!$"A[T.)-S57.WJ(!Y4F[+/;'H"0WX9< _"GT[<R-+IPK$T:D*U
M-&YM$,/!HNMMLO27JSIS(_K8**V6PP0F:?IU)'GHZOJNHS8W#P0&PD"&0\,%
MZDI)7&!RE'IR3&1,83&RE[>IHPVF+QZ7K;!N^V]I1[.VS_9P=LKT9H+*;L=;
M8+JQS/K%J( _7\R&Z\8R-*NY9[>@7XHR0/L*W( 8<#LF:PUTR+>^I[4]BR),
MR'EWA,'4X)TTC_I0TSO"$BW"+W>OFPUZ/EYXH#JZ7C+&>S8./'S3$L/$;T?
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M\UJ.>RQN*Y$/ JEON_I2(R81+3QC0P Q4?3(T1!SL$-*$"PT(2BC4C) TBC
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M)S3,XEXU DU3*S*B81@6ZHB4KV*AU$O-A -O11/@@V45+2+J 4W-0C/,"\T
M;398MB>& :*.B!X8BC92BU>$K:'R))#Z*3@VMBD\U#CZ9&9GU452I6-+PE+E
MYC8K3^$N8Z%LKB;$H*$0 RR[;Q@VKJ%ZE @3,U>7!VB0%2B_1T%[P@+UX>[R
MPFS;SVZ9 CL0U3B.=+^8$2S,!B\B0QFH@E?F=F^P,2T*#WQL9FE[PIC\[WNZ
MKS5P8CN9]&XO5R6FME-G,7W0XALUY#(8%WS&$$PS<1_D31-@(&4QEW4M@FE;
M%X$6_!#=@!%V:U?8;'>)R")?(!5W>]=,?/\7>&>%<\_/8H-72U[7>)/7W=S(
MX?8M*YL7))8!#5+4(=-B!8Z4)&[MUH S<V<$4B56)+3W)S07;Y77?,TM6L6-
M&LL.-CQC<&^F3EJ##IVE"[-P83_"[*H29(A!'U2S(R8.5*"$6'U449L-#61
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MUCI[9N\Y9Q\M'4T964<$-A[63\#_"Q    4 $   "@#  (   ! $ $(!0 0
MB ( ,0 (   ! 2!0  0!@*  $ P !@# 0  8% !# & H  P#0 ( 2!  "04@
M$0 D"H#$ -   !H$0$,!: 0 C0*@,?^=#<"  !@H (, 8%  S'_)?]@@$  *
M B!  -1_-1 0  *"0$ H"(@  5$@( 8$ 8 @(! $"H(@0! 4"((!P0 @& @$
M@X)@"! ,!8)A0$@ " D"(:$@) *$1(&0&! : $*#0&@H"(T H5$@- :$ 8 P
M(! &"L(@0!@4"/-?'_^-#8("H%   @I _=<6% B  D%0(!0*1$"!*"@0 X4
MH! 0% *%0A!0" H*P4!A "@,!(5!H3 $%(:"PC!0) "*!$&14"@2 46BH$@,
M% V HD%0-!2*1D#1*"@: \4 H!@0% .%8A!0# J*^8^"_Q@'(0!0! "! *#^
M8P0!!"" ( 00B@ B$$ 4 HA!0  (" @!@2(@" 0$A8!@$#   @9"P* (& (!
M0R%@& 02@$""$$@H HE (%$() :!!B#0( 0:BD C$&@4 HU!8  (# B!@2(P
M" 0&A<#\Q_Y_8H-0 "@*@$ !4/^)@0("4$ 0"@A% 1$H( H%Q* @ !0$A()
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M,N1 YB1;Z_Y/<3:&L-M2G5O6N"G>=0YN,RSTM^VRT8Y6=9KYM?<^B6"NJAS
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MZK79%<V$^PB67-@VM;Z8&Y9NCC&=@W$VDO+D40R<">H%BH'M(?<R,*ZY;*M
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M(L;2L+([=L^M'7_U]6BMFG]8$7M<=YRBLI'24'W6V'5K\N&,5U<-;&FJC+\
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M(D-!K/"/";C^*46A5>[YQ;'-JGP^4[NJ=YFZ@OF9V*-O^^HVLKG@FK*X_G7
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M1R(\)L1AQ/^('D5H\Y%I::6-"Y'!&I%'1PX],2'XZ\V$!&62_C%G/:0*%(]
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MK[>=1QB[0:2I\5J O9:U7?:4_1G?+KQVKQ>WB:&.71S%444UT.*5 609E@)
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M/-=S;AT];3EY%T;2):(?P/\S! "@   + #@ ( "B ""* $11@"@6$,4!H@3
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M&2H(N$Q0HBB1/Q:0Y1*4O33Q.5'&G/IF1:<S?ZQI8=RQXU@TJ1C016,'D'#
M.3.J0G$&!X1*5';BZ3A.YC1S!@]$DVCSFO2&1%CT*MOKG13DR;8RG"@F2E'S
M)Y5R [$3;N(S6Z"'$@MI 7E4Z/AF3N+T<8I#2>>J ==C_G(T/<,4A5:*VU*.
M*\:@YXI*0B13 CFS_U ,RI3*9OP2S);A:@[   + _FAK., N4(U*XX9N1L6R
MZDS4=/*42BRUN_S/5<54(4DLY%2SR)*LAN F;=0C$W9DD"HP_VB*='T6!BOI
M=%F-+JT\Z$!5U%&JL#:'U%(9D+?>ZRIYE3LK<S\N[Z+RAP:UU&8R(08 4SJ*
M9UO#,RE?CC]P\S"Y%5^"Y!_/<4P!4E%+LKNXSDY92$;#T5&'!+ TB+.05+NF
M-4(7=C75Y:R.[#BCE9HDI"!,;LCF[R.42.B2@Z_F$T9,$!I6"RS3,4@G\\MZ
M95UK$ U6 !/&KNR>8S G%N,0<E(!"U[(\4/1*4*]ZYI(D$76- %WLEZGE#O]
M3TFQB3XF4 ;&H"PT@1A>-NP61$C:20MKD5?]%2$Q5LDN%:(84DB5JF9A=!O!
M%6E7L(T4)0?V8UK.]6;08 =CH#3^2\YE=P,;\S*K%'4_RPECO#%<AW)  '5L
MP;8<<8R@0I8@@_(A/;  +96P^"=B 6MY+%(#D4RP()=AK6Q0<;,KP\E  2IR
MU"!OU<F&J.L'AP0J-E6=O'9%/H5&P31(\]49<V5#@3/#)"5]R%2M&/=D9!1(
M_V_$[*2L/O=GD<[%WI$U Y55]U;++'=WKS439F!?J&N>%F=?HG<,S*=ITR -
MFI8F- %#B>%IY\XH,V[K%$9A6O4A/:@QNY%$&_?&+E/*]K1X^7$@61*NM,M:
M%H5#UO^I;6V&(=  #;"C[D+U-MK5,+]UZ-S48TG6=T>,21TD1LTV3%U4>/WV
MK@H&=G?U=LK&'YL1/+,UGCBK6?TO $MP'M^*Y08H!ZH1GOJI8!:H%+="RH17
M0G@L1]ND0'-K)AU8("%E>ZG,3R]W6&&30OU7,CA,4@;3(3=S#PV4(FNQ31^X
M1JM*80]W@]@73K5K<>,IMS+71;/X-;-QJ12G>JF71Q[H@:27>G% >G$ "J%0
M%L5 >R?A)<+WCB%O1= W#N_P%;.V84\0<Z&3/&]+=Y?L-@<9H:B$(A7E2M/H
MB /3(8 W:(]7:Z?E(-WI33,N5@=PDN7%J9P57YLXBZ4U3Z7_-' VL#X3ER>W
MQ86A9W#C]VR%4@45^"DS88QT\YWRH^X:1VM?K'-DY2/(#C_:38WDL4?#YJ82
MRI/OQ#3EY6;H-NN4(:BX!$L^HVN62C.Z#>L<]C4G=BE[V%L;V'5W\F3[]FYA
MN4W/])?K-Z"(UGWAHVDU@7NW5Q:Y5XX_LXW;>''..(W9F)_]>7K;&'MEL6F[
M]R7$]X[#[_0R5UD!:&!-+%BYN)39I7#+L9;]-%I;3YL@F5<P(A-H-SJ*9Y"K
ME427F8BK;H<_]GTL!&153C(U^4&;^)W->5#PBI8-=XM/M&6 ]5]^2<F0ZX/1
MBX.%]CM=I#C(T*+AE4H,^L.VZU_$_[*,)=E1]L'ZUK%OP5:Q6A<B)VDW8Y?G
MKA-=._I7^@L'_ZM+,4,3RD=[?B<&@LI<+(,I(C(YF0IY1RAW*5E]KSI)&Q.7
M(Y,R)7@$Q5/EINQ1#U,_S_E5\63GF,0(/P]J(1MJ-6&RGP*9K@^?S3BSIY>?
MUUB@U;AZW_B*9!$-[!DJ-*&.QTQ\T:Z%O%"%Q+!(7;AS5_=U+BA?\[HE_<:B
M<*NC<X6_5L!4;R":=6,GYG6!0[F<WQ0$)]J>X/>D$3A^??4 &9D#P5E!&AJ1
MWP@YB2[+"&N1RZE(7C@VB<NK;S,@IQALQV 8=I>=F_<ZK5$>#5E%N *+>O(I
M3EIT794D:O_#;S080A.6<$"UHP<B)F+B*4 J,]+5K>&Z'FX !S"46"YC,*/,
MY5HL>0F[-8'5K@,Y82'J29<Z5^D4K*GU5D_80AI3@ZIZFB(7"2T&"5D<4,0C
M20>$^ 1BLJ&"GNLY%G$@>LT8- %ZL]>XGS=[<3),M+FT>U%;?)^6[0Z[C!3&
M7;HS!?DCKNS7DE,9BVL,%+K@/P2*MV\%#2:.TQ+<>T*JZ4!<E(6V9$\SIYN1
M8&/.3B_Z5XF,PSOH?N*\1LGSXGY.C@3QOI7$5-C*PG6SJ$+\9.=F>JS8FT$&
MH[.Z213C(\@*4 J4>,,HA>8#B)4[',OK-&\FI+T\,X G#7Q(,C3_ 5@D8Q(Z
MS#+4IQF-MH&G,Z?Y,;;]2:<3N:+F%W+_R6 _=\./E-*K7.<BG6T !$7&9$)B
MAT/,DSU@G#*^D?9>=K)/V\!O_)[%  K?^"-\_+,!.HVS'8UC,8YCL:F3/,FA
M5O(D+VS1I=>-JR"M>\Z/]%D6Q0*M^]-%)5,HXZ,FA;@9N*A%:8[,F:(L7&+(
MUL]%M$\P?'UD/5H:<M_Y=4TY64W!\D:D)]B[V+>:<KIG^UI_53[.:@;_^^2N
MNK]9\*&D#VBB!"J>N+WW=JL=2N1E=':@V<L_FB) (UVI(Q,,8#(RP:<L0\)A
M^6,+?>1I])G%^.*+]RUMED@!V[P32)"W_U9683,(#Q6C 5$25?I;1A)#R.-$
MV$9[F)-#E+U 8IQ/T,[QH+V.T;Z>J_V-W;B?S]BS?US;-99+P;VT:0(..G*R
M4Z_)_[ _ME#*#S?1"0>Q[)3>MT==*T,XB4?%H;Z5$?F/,QP<HWZ1"/GB_WJ6
MR<MSJ5O>X7>E>=BZ*QFW\X?\9K53Q5:5?\Z$E04_);J=?WVV9V@V!/0\.A:>
M2=FJJ"E]H":Y;GN4PBEA KRC4=U4W?J5/ /5)R.))6.:=6I!)J%>W%$\T4F<
MF]O+G/G,:7BV"[".#%G85=CZRU8=D\MA2?Q"TENA(*?[PZ:\O61>!44GUR1$
MEM+CLO .DT2.C/\218J!LJ>=G@%BC)@<. ;BP"'CH(R$"QLB; @1X4.&#A/F
M$',0QQB-:29-TI0)I"9BF8@I.XFRGC*5^Y3M@U9OWS)],O4MJP<S)\N5T>@M
M:ZDLQTJ=,/<9/8HTJ=*E3)LZ?0HUJM2I5*LF/8A468Q,5KLBK<<5IUBB.UN*
M=3ETYUBU.M'6G G7YMF69F&ZO4L7[5R\>NWF7>LW;>"Z9?FNO;NW94^X]!;;
MM-G8Y^.XRR+W=%SYLF2X?*.)U:P9+DP<Q&02MIL8,=FV?UE3G@P9<V3*8[C.
MSGN:96:VO/D2[KMW[YB%:>A.2@-\<%JX@ N+S32FN>K4P0,?KNLU.]3_TMJ[
M>_\^51, ')F491(#8)+4-S%<[DL3XRBQ YJ2FI_T.O/MM,FKUV/,&&:3649@
M: /*=EEJN?7'8&L*!D@@A #:9): ^H&V&6XNP84;<SHER%^%C067AB;YQ=88
MBA+"IA^$ETVG86XS[;4,-)75J)9O+N6TCS[1*&732<N<9!(QQ&B"Y$>94/+&
M)&.D(9! %^5 T404081EEE@>-*648CS9T224A(EDD2@)&=D^/>W3V#[$B'%2
M:^#-26>==EJ5B0KD$0/? >[=R91YOYWUF4^_Q2C88=?QM!F*F#D(W'1Z3=JA
MH0TF*JE9>KF885J+L4G9; =N)FJ+8G&JWZ&DV2(HF4ICG#1J@G[M%NF"#EHW
MV(FA]C2&)@7ZM.BM:TEXJ([^N30)0G#6$\T8ZEV***$PN7B<L(BAZNBOQ +J
M%5?<?@ON4FC<<!4.4DURPX_[3'+ 49FTMU0FL3:JZVS-?4BOBB*R:F&IV;I8
MF+"HL89IL=(1AB&&NVZF**Z\M46=PZN-,8S!!&MX*HL:ZY=:J OCJ)<^]V9\
M(;"HK702/<JD2D],IL$T68_,-K:RC2HK8R22(FDRB1I0#F30<!)=N=#061K-
MD-$243F<0%"FT1'42FJ"PTVSTA/_;M9:;]W4NS$ <, -%7/=$C&K'6SLK)!Y
MN*A_!"L8(LIO8?SVQ8D.#+? $=,XV5J/;AA;H0G/%N&H(.?65C1BU"=WK?V]
M#:*#K'ZLHJ.U\>MOR8ME;GBEGOE&65 +:4)31YZ1Y7C T\$$W>=O%9Z?MH%3
M^"O9V]F.^W<%)?4N35#!A[6;!G#W+C1+3>+ZI6X/6SEEB%]7\H0_ 1[]OX%#
M^[AS9RL':;$R6:9ZL)D6K.-?&T968MW463C@BBTJ5\^\^0'6(N><@D:A@356
MYGB+(L?\$IFQ*1HTB9!/B)0D3;R!$IF VA@>^$"@46EH5BJ:EAY202L]"S?J
MRIT'/ZB=_R&5)W>"VLW5]#>B\45K>VT[V_E.-[+LV6UO;F&;XR %M[58SW\\
M+)4/934S]LV(+&RSRZN8M[#)8:R&]C-<WTYHF<59BRXW:MX.-T:O'ZX*:T)[
MU7N>)2WQ$69^13F._&!7*+9IIDR9<!$(E6*\-\H1*F*X@<N,4D>HG 0-,=#$
MCF*  _,<H#A*4<8DY,>BS-G/AY0)CF$&ASG-Y<MYGK*4@W9UK)E-+V]QL]7=
M6BB^8WEO4FD@1G/^AK:Y4"XNBZ*D)O]EEFQ-SHE5+)CL)'DXE*D$9/]AH6;4
MA#7/V 0:*.$?SHXT$ITU$$H/_-F4KF2EH2%O57.LIC6/TB;[X/^.'KZRF"@;
M1S>U?"INWUR>7O2GK^5LC$(AXN$306D8^-E,B/-"9[TB&9M.=I(T@W.?%7&9
MR!XJ;)WZZ176JB=)?JERBQXC:.6HMI#2."E6- RG,B8#'5#5<XN1;,PD$D*:
MZUC36]<LJ? 6=Q(Q&& ,=#Q #%X:'S?=X*5BZ)J$8#<BNXURA:KS9! G^:OD
M>1-OUK%015?GR'!R+U+E=$WG](F=7JD3H<U;I,):LDF8K FJY%,,[ [ES[!*
M+)1$H8MD4&C/R #G*(#[49I<$A,?Z>,NQTRF,IFYD?J$RJ1\)2$.U),4,=24
M;,I@W/,^Z4)-[31U6LWIPW(XP[$RM7S_V7MA#+L7LE7B%*T<U:+K*J-4X9!S
M6HGLYS\+=%K.[DJ*%T4H[&B)14@R%(M"*X[IM*5(S@JU6L"QIRP56=A7Z>^:
MW.FK->%C@  <( "#G4H'C?*3IM3CD+%+*PPK:[!X]B:TO26<=3M+S_MUBKNC
M-*=B94C6GAJ++VD8QBQ;A"@<SK"J,%QJVZ[8T"2V[9:O=1]1'XL8!)VD8?3S
M28%P$L#_60TGQ, !1XT+8:VE 0!_.HHF#% ?KBUC&*A[WE@!EEC$^@>(\+NA
MB!V6MMZ8=ZJ'Q>R*X;E8Q F47JR%K/;"]S9*C>^;,D%I&H.:1=72LK^.[6TF
M%B*4:H45D>Z\_U'K#-BOT.2V31FMG34K'.$WFD<2(_R6/J:IQOUXTL4L9"R,
MS=PO#FD78I*UJ$]9&&+RMI.=TA%E?NG1J_@:QLP=#M":54)@>5*UR8[:+EHP
MMSDA@Q:ID6U.?]=6: ;A9"9N(890$IGE3 ,J#,U%"CT.0%*ME9#(0@3RY$J%
ML$FJZ*LJY',,T:8W[0;8DM0;F4Y/G$IYQB^AI+KT*NG<V+ "E8#8XC5HWH2#
M'.#GM^[;%VY!HQM6P_,A/$O#KF&YDD;BRT+K*HZ(DTAJGT ';UB68Z@U339B
M@**0YZY3-*AKN,WNYY0IY'&KQ8A=S5ZWQ>03)W@7FCR ^WMZ(K+AF__/C*@T
M9"*3\,,,]*#L60/;4XRGDG>4?S@7DJ7P=3#4U8Y'^U@4Z\TU$<J+,G!0C$.A
M>^7@P8I2HA$#P&X-+ ,<]F:;JMXS7];$W\MJM$.3:C7O;:  DG..ND<K*CKV
MA -_IW*T79;,B($8XCTUT6-K+^HYUK0++BS/2*<YW<0,G" /=FEIC>_W).1)
MTQRGAPV=F"HGFI%,+IPFK-WAD;*<L ?HM%$R$8!VTPEYG(1U._\=XB >/4!)
M-3$H12YB]++YQCS'+F4?K\EHU:H1FABKYPW/;T[R-#!D%!R]\#T6@*J^<I#M
MT-G%"_M_PO)-RKC8WF_?%3Z6&_""_Y:@INK_6/@ZOLP+,CR!E7?K@ZL/Q:C_
MO*Z7;V@RKW@?E,_+,N#TEC"&-XUR41NO/U9O5K')*(@I?^B?'_(;FQVTFEC(
M0,#8:%G3;4S_.C!I3?A35H[[E3.Y9KEQ#RBZMQ0WX'=T\F7XE5J/=E,!AVA'
M%6LC!VAD,4[+ WT=5C[2 W'O!66!MCQJUA(E<FUAIF@6IVK%)G%!IH!:!&X7
M!X$-<B&'MV]EQW]697,7=QF65C  J(-200R 5%QN$@,W$#Q;LV$$]V?(QWU=
MMUA[PST\]':2ACHV)EO@5ETE>#VA!7G1PG4^<6MBH0\Y8!*Y,7>*QFS QH2B
M=V@G2(5GQW5EZ%K^;K01"S$)%EA>Q(<L8P!#6TATI2(6=Z>&<F%-/[B#=Y)'
MXA(#ST4G8+&&319QB&:%2Q9V4 A@YZ=S'U9DTI=BR<=5N9:$E6-0^*1Z)$@L
MC*);\N9:0E1\DH5SC/8?(F-=T9>)ZA>!Z^-=M%</&_=__X.HBW\'-@2( S%@
M /1A.[\78ZR8A2DV?&)W3]XU7I]D>9@W8[_F/K<$6SZ7C.=$( 8#&LK@1>A5
M>9AW;XG79MX8+$G7;W3(BB[1?@FA'M'#4T!$%PB&8+RE2F[8B![%4JMQ3;VW
MB]Z!$4SQCX#R;J^'1<M8A5<W8Q?G2G%FCD%'41989Y.W8Q4XBY_W9\<(*0HG
M?9KX4VXG?W+C@9T4DK96D7FSB&PX9<(F6P'774*%?UU%=H=1-876CS69%77T
M4@28B^&R<%4UC4JD709'66/4/O>XAT"'/4G87U2T40A2?3IF;T3YDZ5R>4;D
M*W?F6R;X75+&E387>Y"H@-4(<?^EUQ.B(P-JH!,4\A@Q<5 T06DJ020X8U=+
M AU3]Q+I)7EST4!)%8@V62>\5T@'$ ;<\F7>8W CR7S>UUE?&7&-I'59>8E(
M2$G?LY)A.955*)2&68/@U0B9\%FQM5V#-F^/E%MMDSJ558D=V8BRV&@8Z6K3
M06*MN((-I@P8LI-^N8/1U15Q8A\(EA6Y6$($99E&N2H#MX1G@Y6;B9BL&4;6
MT5W%YG23^)&@QXK=EWZ!](1_\5YREIVMIH7>)8M,=7\1F7//]U$R, 8'1"1'
M<B0A$340]$ :(9\@=4$Y, P8")FRX3Q.8GM7AIMSH@PS-0EP!0T]> ""6"?>
MQG'*N7'_NO);0N6=>\9OE*F"3): 4%<K-Z*=B!=U2T=O!\F'T(<6I52A(&9G
MU%AU*&B$>F91S1>:B[2(X::!T#:.&UE]EE:<B/B?.QH5F7 #+I4&P:,),Q5S
M1X$N@-1NW"0RP &B13>1Y1F:^"5MNE62_>&1Z7>$!>>AZ>AF2/6D126#0S$&
MQ!"#T_>18T:*.(9$ ->,F$6)+2EPNN82#6817X(#,R 1%90T1',T>TH<!(J7
M8B@J?NB1^\BCWT$,-P V0?@U,8 &7J8>LU5%@T9+' B5ZZ<B]2B-EKE#)4AW
MTEB-9B@I&I=FUKF)<?:)*HA3(.J(4ZF0JHJ4;S%V_,=.WE1$_T=E?,1':)-*
M7RA8J+2I(4-XJ,/*%/4@!I- #&@  /5!# : '&G@)^MR  ,J!C&5%0LG<A?2
MB0DEG22)?B=YB@HXH<FHB5,$?/MVJV<:IK&TD&-!#+TR5Z%E5&8F=#H15D_I
MIFB&BV\7?]Q90]RHI]#DITLS$$\")L?Q$91P=Q0!KXSG?:^7(4ZB,'<T1PA*
MK%8Q"1AQ SA02N"R#".$:_8EL@'#JYGYC9 7J##9I3PUG1!Y,:&H4(G%B!=7
M(IF#A3NW<RQKKOGZE#8&9Z#T-Q@#BBG9//FZLYB"<C1YL4O+%)^F'GQT%(ZZ
M#P1(?H&7%&"A>':H7L7(B4DIHL*R@O^+R6Q,&:Z7^:"^JJ*!0T1CMZ O0AWJ
MN!%_E7F5%%[[FJ7.>+//.+*S]EZB>EYO6Q=8TWY< C00U!%J\!')9"3%=%%X
M41/[ !UI0!$#:G3WER)QH0EC4#FWB3N<R[110;'@TG8ERHR8B9)9F4ZRNGI-
MVJE#V[>B66IEVIHD67ECUI"7PXF3=S(MZIS'V9P/4JO(6%Y(>+>D.J7S)HY;
MB[?1TQBTATZ?"[WD!VK[@ ./BD=B ',D%0.$Q%9<<9KF2B@S.F5'>8*QBZ*K
MVJL.YZ4M.'K2>5ZI)KMP]Z1\01(\LS(0ZX@.]U_.:)K9)Z=ZAJ_Z1(&HIS]C
MT0C6%B?&XSO_!$1^/?(C;#E AQ$;U:()8L 0>1:3EKN'D(N'!V:HT0MAA5E)
M8#EQZD.\WG2-9G$_),.V#MN1Z3<M352RX:9ODBK#D;D@)%ILOSL4-@I$KUFY
MSE&[7*5\L-ABNSJ^0+: N AZ.)@8(+QW. ,*9E(5 EBD1E$06I%A4VN]1_&Q
M,;&)H'.VKENB6">^7QF\/&O"BE6O<$>&T*F2ENFM92$6_HK"X_J +>N .I:W
M04R1K&%&/3(]0V)@T0,-7#B*S\%2/B&Y#$&YJ+M*A.HO>@?%QC6ZJ$@][X0]
M:@RE+FN\4N8^C?>W>QLC))S$YNN@=Y9?UB-5@_*SP2:5P8N&::2SU3VT2K[+
M5/T$5I#FJO>8G!^#=.E+FR+#&I6<:?-A #%P #!P -,[%8 YM=PK6%JAO3*'
M,YG@O3>;K<3I@>[(*%I)@_75= D9SN#CR8T5@\Y6BB@4QYNJO^$YRFD7>4+;
M*3S,KT)LF(:C*)&CLG@K@\U">'*3QN T(T/)6RT!46M'#+V:HAG5.+Y93:%K
MS-6T#)B@2:;XB)'VOL:HIIGL<[Y4SC'*SW7X<PTJI0I9J]$HG @Y&QHIO$3\
MI<;YO2%+;UL9P$9K?B^DQ E8MT%K>8(Z$T[,>/\3G66_>!XW4,'P(A6:L+U'
ML3M8C+U;813UX,Q'H0^^LH=M[(U2::,2N*_,P400.L!F%M:F6*F]BX036%2F
MAKRR>:$G[:DC:'5B:[J]#$FSN+Y(A=+2(Y9?I#!LO<2,!QV;Y":-G!"4@,YT
M/1=^F!_^1]0F-8?- 9;X:;,P&*<E>8P,!XYHNK.@2LYP3(.AK,'GJQD@*&8R
MB+*S6Z//><>G2HMY:,/Y:];+&&7**'LSRU&T]QJ>^]@?I ]2?1Y&T4<\> !=
MO ]0VQ)23;60&ZW7VG,#/<<M*:E89[9U?=LE2+:M>\JBN%&I/-N=+,\J/,:6
MDA@-&;:Q@Z$KFZ93E4K_+$VE+#;"I5P@QX&SZ&@Q]"<:S#()5+(0K[+3F*0/
ME("'E7--,M?;6;'%Q+0U\*>\XCV9_?QBGGS"N+;5R?BZMWVVCJFZ&5W#+YG=
MRT QT<#1BV&F>SRN9[C&&=S1I3QD71F-NQRNK>J&!.4F,SFI!VY<4LW41G$#
MQMT4T/!2:# )0I[<-Y LY,+<8O N!<A-6'.I853=_$79=HVVJ"R69/RJLOU=
MTVB$U F^3IF7KF;EE+JZ9NC>Y?S>0P7>(BH69H37O(N&'+RD-=<2<8@0;03C
MU:$): !H#N>?.(X4A;@NU@HNYJ''>HS6M-NEBCZ4_-&UP5RV9IC:LMF@_]T\
M_Y\<5.5-*C-1L^]KCBZZ5*VMYA-.MM#3/@R-X7!,W4]%H6-^6HS7%^\:)Y0"
MZ"6U.UHA!F@0 !:K%,N !H)5$-:+;&@PA.?Q5TM16/'U?>,MXR$)P.C'I(66
M*T3[T;1:LF\]:#F+*:&4U_6-<U^;H6KKUC#+4#)*NENIQ**8.0_2$6U;S\AI
MJE1TT/<[)"UQ9!?LT?_6.AKCV+5N%&A@+D:1!DB>-0P>BYGRE:.^H?$;UN.L
M[4BT1.P;YMK\6&<>Y>%E$[6QX2GJE'+J-[<$U&SH;PW8A"O-4 77W2B/WBC9
MX=7HIE0#QKCA[\2%Y.S1=W&T-?20S3!9>*O]Z*X]\?].F"AC.-O6B<[>7M;B
M>^9$3^:I;LXO_-/S+)[VG*7@C,9OR.PIR=9^?6!\[&I^<1R;%&G#P1#ET?/<
M%*3;4DW\2-1C8$=&,0F$+KI?ONYQ1HJ^7'>OB_?@O,X,6L#_B]IOWL^BWB#T
M4+,]#5YT#3Y '-,OK=E?W[6IF<+DFK4_-\!V$4B=-/-\Q9MD\[%+>,;7O>6K
MWO*TG?B,F=6ISLNKCTGD1K;W#$4F&T9/'NVP6^6+[^Y(;(/_;>GX5V(;_>Q'
M9TAX!\.6[\D!G@:383?K>*?(L>COQE*^0<G^/BX[ A]HT7^  @V1?6][?=HV
MMLI-]N& '2$_!MMQK)\S#NO_$O^[T/X\;5BRRE!*'.DPU65Z:!6>N7OY+DK6
ML \0]:+16[9/F4&$!Q4FW+>,WL"!!975@U9OX46* @GJ<QCQX4>/$3E^7#8R
M&C$Q$C,>W-?2Y4N8,67.I%G3YDV<.77NY#FS7D^@-.EE^GFPI,.C()4FC981
MXL.,3$F./,K1Y,:.!!$BY;AUJE2P5K,^#3N6Y%>Q4(U^52JR:E:)!C-6Q*AP
MI5RZ<I^Z%9NVZ<*W?0._94OVJMNE@@]CO3LX,5S%<.=:9#@1(N6+"3'?G5BQ
MXMM]D]+HPZS9\^:\G5%37)9I#.F#6 \3&R/#]HQ,#:\&UI3F;,2@P6^R%%[<
M^'&;_XT.Q& >XX",&#=BX$ ^<])6CD[1$N;+?7M;K(\C%P[???'@W>,-=]3>
M??5IC'0GGZ9?6G7JQN23.MXWAFAJN>Z;S[[)[()O0/A,*[ RO.QKT$ "ZY,P
MJJ[L@A! U2"TJSL&-=1+-LBDVDN\DHC)09G,B*MN119;=+&F:,20KKD#<GMQ
M)F4T\4L_L2KC;$&FVL/J0\=&1(^K$'<,";SNF 11/<K, D[ "Q=,$;ME!DQQ
M,_/*XE%*D*)4LCRVCMS1R[]T@XO(\\Y,3Z7/*O3*2"7'F*0I_  L$L0&7=N'
MKB8A4F82'&0H=(PK57-MQ(%N#(H81R.5M*5,Q! ##4LOQ?_!TC1NK">3*CW,
MD*$DS?+N2/W 0Q4Q1D%4]4TAU]M.L##C^_' !*NLJ%567SU*F30T$;,C-TW]
MKLM936W0+0K+4M#6/.L1D;SUVBSU3&JU$A##9[N%<"!E<"CJKDG+-??<E]
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M67W!2W'<[OQ2F\^;>"DF+VBGG5+3(E[G&56OHBV^;0N-Y//3KXF& P"#.:[
M "EW%'5+#%R93YNIF^5J[#;G9W2#4_S*6I4T,Y-VQ7*^-\?)+@R7>EGQF"8S
MY]-D>D+IS/Q@&J]>P[VJ"##"$[X,83!*Z)3V&S,F.0C:""/#635]\#3JNQ$Q
MX+"7J)1HN)&A,*;E$YRK8R(8LSU<X[DW2ZE=XBSW<RO?0KX>,K3V4: L03+=
M>[HH:[2$6S79LR_@6XO/:K45C"\EN:@83$ Y>SAZ*R6+<3%E.)%ZF/^/"YQ"
MF,B$27BT3)"$1QL]2?DRF(&JTXJSAYHU=L.WPU.8')LB2!I#C"*5>OHJE@-#
M&TPW5'$=]GI!-8.R&UR_I4G"Y9LW?X,0=9J[L%(H_N,(/W&[GJ.,C0BQOY*!
M56H:$.(^*@R.3#"JF%"& ) $1YDL&(0+P*.Q]S.W 0.NV;HQ$KR\?QNDKQ@^
MK2,O)IH@% L+4GQ# !R\-)NO6(2KHPN_]-N]%-0?Q..Z?6$/=Z- XO*12ES&
MZB&W8V-#$51%^<*V&G2HRTBF#9&RV6,UT*([:'Q&7'$BB'LXEDO"<GR]UK,7
M600DXXL\(=(6'CHV?ADRDKF8:M.:X=D2LP+_"_F@,C$XD2<)(>EBQIQ @QB8
M"3&@CA<),1/[K/PZ0&2[Q5RKM6'$17QC*>[H(CGA+;WJ*&3*)=JK1?LZ1P@*
MIPP:-O4CP-YC#!>SJ">"QS_LKE?,NYNR/%A<"DOK*;0@R"EDB1 #%9\Y(=)8
MIHW<.8HD*ZD*&U7,C"3*L64+&=URO;K;OW8;M&BB,24T-/TKJ43BGS5KQQFR
M-7D$P(V"FW&<2.GY"Z0\0&JDJS_[NT8Y"&C0F3'@&Q#B0I[LB5.+"8,<2* 8
M"J:CJK[9-T4ZQZV$*4+[PN!+,ZWTRM0YR\:\$@(\I(GZOY-$J'"4F"1B.QF:
M.;T31G+<#&X,)-JI_[B<R1Q >\J3V#:]R\O/$[<;"  #D($*/!?(6:',:<,"
M4CR!LT5^:[J(+#=@'(MM:IK_^D:O/+_U6S+#2SIQS$7\.,Q^BT-<$L73 \LF
M'$>C\S_E^1]/O,6*Q ]]6, 86T?9D1G1J!(+=,W@2(,8<"R8P &%?)%):# \
M$R7I9,JH@[/!61:8Q,U34DRR+"VP\L8D%,6W $E#G+.QC,<P'!:I1$YZ&;8
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MOR([%KQ%F44OS!83S+"@*\^Z<'3NECMJ>97?&M:R7()J:75Y#LW;UFP22ZG
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M96!B!=Z*)<MTM52B K!'P*3(,&B:2I#2 QI.G>I26_4[TG3_RYG***M1*Z9
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M:C9A]UR+NXHJ-*26R<VMHI$/&O"9*/X5SIA<MF'+;>7D*](#&LA &,!E&.#
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MP.R\#HVA3[GN@>>Z;B>-($-SF$//]\;+A4S2D8^O$)U:P&CZ]VH11J2!#."
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MDT;1HT$(.4QC FH2 #C()%Y3FB@>$YK1U%=#I%E-:PI*:]?4YC8WXT3-$,,
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M<&EE!.SD?F+V 0+&<-4<70QWZOK3L:Z@GZ9]'Q/J:<"([O>!C1H' + [:<1
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M(R0A*&$ %(S_"40K#/ &@B#'Z24.1D'QY-L&0D,,0 SJ(4/(L=$\XS$+Y@W
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M&:3TRI9/*AL(&3PU^!HS*+Q/0EJN]SLTA*V@/9I?!T\&MCI""N;U#N!HCRG
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MJO\# &%L96,M,C R,S$R,S$N>'-D4$L! A0#%     @ 7();6+1A+XIB%
MB[$  !               ( !93,% &%L96,M97@Q,%\Q,2YH=&U02P$"% ,4
M    " !<@EM84V23&)VM   5Y@4 #P              @ 'U1P4 86QE8RUE
M>#$P7S,N:'1M4$L! A0#%     @ 7();6.[@"W@T2P  D7\"  \
M     ( !O_4% &%L96,M97@Q,%\T+FAT;5!+ 0(4 Q0    ( %R"6UBE<4?0
MDCL  )P$ @ -              "  2!!!@!A;&5C+65X,3DN:'1M4$L! A0#
M%     @ 7();6-KTIEVN P  /!H   \              ( !W7P& &%L96,M
M97@R,U\Q+FAT;5!+ 0(4 Q0    ( %R"6U@.EQ",CP@  #$\   /
M      "  ;B !@!A;&5C+65X,S%?,2YH=&U02P$"% ,4    " !<@EM8=EO*
M&I@(   V/   #P              @ %TB08 86QE8RUE>#,Q7S(N:'1M4$L!
M A0#%     @ 7();6%&,,;8+!0  "2    \              ( !.9(& &%L
M96,M97@S,E\Q+FAT;5!+ 0(4 Q0    ( %R"6U@'9DPV%P4  ' @   /
M          "  7&7!@!A;&5C+65X,S)?,BYH=&U02P$"% ,4    " !<@EM8
MKP5,M-L5  !.?@  #@              @ &UG 8 86QE8RUE>#1?,RYH=&U0
M2P$"% ,4    " !<@EM8[M]D<RH:  !HQ@  #0              @ &\L@8
M86QE8RUE>#DW+FAT;5!+ 0(4 Q0    ( %R"6UCR8G4\KF$! +IA 0 1
M          "  1'-!@!I;6<T,SDP,S(S-%\P+F=I9E!+ 0(4 Q0    ( %R"
M6UCZD8"Q\+X! /"^ 0 1              "  >XN" !I;6<T,SDP,S(S-%\Q
M+F=I9E!+ 0(4 Q0    ( %R"6UBTW PTYX,  #Z^   2              "
M 0WN"0!I;6<T,SDP,S(S-%\Q,"YJ<&=02P$"% ,4    " !<@EM84.F\VN)>
M 0#N7@$ $@              @ $D<@H :6UG-#,Y,#,R,S1?,3$N9VEF4$L!
M A0#%     @ 7();6)'-=OVG)@$ K"8! !(              ( !-M$+ &EM
M9S0S.3 S,C,T7S$R+F=I9E!+ 0(4 Q0    ( %R"6UB!U5*R"#T  +=&   2
M              "  0WX# !I;6<T,SDP,S(S-%\Q,RYJ<&=02P$"% ,4
M" !<@EM8K4D@IXF*  "YB@  $@              @ %%-0T :6UG-#,Y,#,R
M,S1?,30N9VEF4$L! A0#%     @ 7();6!N]G:*5S@  ILX  !(
M     ( !_K\- &EM9S0S.3 S,C,T7S$U+F=I9E!+ 0(4 Q0    ( %R"6UB1
M^BSMYY8  /F6   2              "  <..#@!I;6<T,SDP,S(S-%\Q-BYG
M:6902P$"% ,4    " !<@EM8/L@\26&<   "]P  $@              @ ':
M)0\ :6UG-#,Y,#,R,S1?,3<N:G!G4$L! A0#%     @ 7();6%9"5XI.1@
M7T8  !(              ( !:\(/ &EM9S0S.3 S,C,T7S$X+F=I9E!+ 0(4
M Q0    ( %R"6UC^=U67T8L! -B+ 0 1              "  >D($ !I;6<T
M,SDP,S(S-%\R+F=I9E!+ 0(4 Q0    ( %R"6UA5!W".?9@! (J8 0 1
M          "  >F4$0!I;6<T,SDP,S(S-%\S+F=I9E!+ 0(4 Q0    ( %R"
M6UB_:I8=#LP  "7,   1              "  94M$P!I;6<T,SDP,S(S-%\T
M+F=I9E!+ 0(4 Q0    ( %R"6UA.K5"]UF0" ,1D @ 1              "
M =+Y$P!I;6<T,SDP,S(S-%\U+F=I9E!+ 0(4 Q0    ( %R"6UB(?YME,5L
M $);   1              "  ==>%@!I;6<T,SDP,S(S-%\V+F=I9E!+ 0(4
M Q0    ( %R"6UAVXLT0^E4! /Y5 0 1              "  3>Z%@!I;6<T
M,SDP,S(S-%\W+F=I9E!+ 0(4 Q0    ( %R"6UAB%ZYZ75L  '1;   1
M          "  6 0& !I;6<T,SDP,S(S-%\X+F=I9E!+ 0(4 Q0    ( %R"
M6UB2'-I1LJT  ,ZM   1              "  >QK& !I;6<T,SDP,S(S-%\Y
:+F=I9E!+!08     (  @ ,\'  #-&1D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>alec-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alec="http://alector.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alec-20231231.xsd" xlink:type="simple"/>
    <context id="C_0b316b30-6fe6-45ed-a034-7a7078c020a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_11e15bef-5569-498f-9263-fd8668b4e72c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-22</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="C_0af91d08-2797-49ba-a679-a9d25bb3512d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:AdimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cce98dde-1d02-4f46-a623-794fa3f11385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_be19a186-b61e-4093-842b-37a052d70447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_063d5b29-5b06-4630-b2ef-ae848097335d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_56217c44-9068-48a9-bd55-ca120578b623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_21a83cdc-0b37-49af-9a68-60f9ffb64987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb09fe55-8ca8-43e2-8bb6-54b263316207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7b15d294-93bc-4f21-877c-2a47962db58d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_340e1b04-fc2d-4614-bea3-759221ffd38e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b63dbca3-4067-43b5-ab54-c12f0d45646c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_d6321c67-3454-46af-9d81-b479594892c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0a89ff33-c725-4439-ad8e-bf3568d41b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_90f3186a-3a7c-4ce6-bbc4-af5ab058188b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ec43ac9d-d355-4fa2-9bd9-cf8e37006808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b5b6de0c-0735-4356-9282-a70e9141c22d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_fc9dc938-5e3b-488d-998b-8e76468ef770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_34b1db7c-6e16-43d3-bd5b-68502507a278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dbfb3835-28fe-4139-9939-85de4a95d6c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_fd74e1af-61b1-488d-8031-e66435e39cdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fcade9bc-91eb-4e33-86f9-9e6dd66a7393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_939b60bd-dbba-49f8-810d-9f58546ab346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2ba9b64f-d373-4d84-929c-816017c4d96c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5eeb6d5e-07f7-4d7a-9ae5-040a3397c88c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_79cee874-ca87-430e-8f98-93d2c63bf411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e1505fa-8544-4458-96c7-53104f4fe63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_ef477b10-b2f5-419c-9069-8dd0afc677f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_95c548cd-02a1-4c12-93cb-ea44937aa4a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_536c635f-d92f-46c9-b598-60cb1e600887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_331414b3-e237-427f-b014-b2fbd7be148d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_799c46d0-304e-442b-87b3-67e31110ef56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f0628b57-6af6-4f3a-a678-5f72c4012bd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf80a4f5-ee57-4865-a16e-612cda395dcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_3bb5d2cb-8240-469c-b215-b0ef522ac46c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe95f1f3-8845-4196-a35b-577d8188b3b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_cd9b5156-4a31-481b-b713-37aa7a33df0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3aa9e816-d1a0-4625-9af0-5128da3a9209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18e12969-87bd-493d-8d25-859c9cbffa99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="C_7151cd96-2161-4092-af10-bd88188169e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1cbc65c-39be-40d5-94a2-085b20c52e97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8df4e45d-5ccf-4447-ac9d-b88b2629cca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_6938cb01-3217-495c-940e-68f940751ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0c6c34c3-6684-47c0-932c-32afe31b92fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_ce453676-bced-4bc7-adfc-3a7dc2104ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="C_72e522a3-5366-4e26-836a-dbe1abd68f5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_baab8074-6a4c-411b-b481-b273fda9f214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="C_618c715a-60ae-467c-8c7b-117bc9bc8695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f5380031-3260-4626-aa94-6be4667cd0d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_53a5db9e-db92-4bd5-a460-a20781d98b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CertificateOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c758acc5-763d-4c36-99d6-c281cf90a70f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18a6ec65-ac34-40f3-95e7-bfa2ffab6462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab5bd7aa-9449-45ef-913b-7842f838798d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_781e8b1b-18da-4c56-a6df-8621e45c8fde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e123b7a5-e275-4b05-8fa9-5b78e2f38cf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17714c29-f0b8-4a31-9e58-2bb7319ace3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c2ced522-2924-4199-8e43-04ab2c397ba4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0e7b91da-0112-404f-9acb-f761639a66b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="C_5221b583-972a-4325-9c52-a770e32fec78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5faa559f-1d59-40e4-a7d3-52eebb14274c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d28c5140-6e95-49fb-9fb1-c9575190d7b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">alec:ChangeInEstimateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e3cdfe83-caeb-4047-a450-8e67619a35be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_762e850e-ccde-406e-bb94-80d9fd84a94a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_a780de0c-7437-4cda-82c1-96d14ee7da1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb621957-f8bc-47e9-9219-b82401bc112f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a10ce102-5713-4bf0-a2c5-da99484f0103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:UnderwritingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e5a08e1c-7661-4242-afc0-5a1579c71846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:UnderwritingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-17</instant>
        </period>
    </context>
    <context id="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c39aa66-67a0-4bc2-bb2d-dfaf63ec336a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f68b6d3e-af72-4397-a93c-d21976f8b5eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5787191-0ee2-419a-98e0-6bb30e57cb15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e332595b-2812-42e7-8164-9333c6cb735f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_875c92eb-4727-4d07-8257-01fde8082811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cd35894d-35dd-488a-bba1-d0a7f771501b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4aa98c31-3185-40ce-8dd2-7ce79a8cd6e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_c1f0c7a7-e180-4765-8b37-912035434a8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_d4fbee25-c222-4832-b8a1-0ed2b6aff01f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_52035361-b24c-4755-ad7a-e82a0d8ebc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_666e3ab2-8e5f-48ca-8ffa-0360410c200c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0a79701-f609-4f39-8ea8-fa90332bbbba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2023-03-28</instant>
        </period>
    </context>
    <context id="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eba99dec-98b2-45c0-9d27-7d9f74ea5672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8f63097f-fc67-43ad-b6f8-799a51185227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_906aea5b-0c93-441f-993c-a2359ebc1e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2d7c568c-73b0-4659-933e-e70332ce56ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f0b6fc05-c1a0-4504-91f0-023a1f8c2514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a6997d26-1cd1-493e-9c86-be8ab9f39310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e926ae33-adab-44c6-9813-d90466e7d1d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_324a6c7e-62a2-4eaf-a1db-f175723903c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db20ea7a-0049-46f5-a310-e578628c49ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7f97232c-f60b-4a4b-b51b-6d2e65356471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_52dc5672-fc66-4cee-a898-4ecac0b3d0bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c4cbf91d-96bc-43ff-ae3a-304b48be2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="C_f69c2b26-8b9d-489b-a357-6baf4bc970c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_cbbafbf6-6ed4-4a1e-81cd-8fc78087cc1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d58b91a6-8565-488e-b02e-ec025dddbb45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d3eeb729-bc22-498d-881c-1db3ed88b394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_fddc05c2-32c9-4c4e-b1bc-8af85e42859f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88135be7-53d0-4cfa-bfc7-18676d65fe75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_16787d87-ace1-4e09-9ce1-9264b6480e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_44344e5d-5a1c-404e-8607-c5de69163711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_958166bd-8c6f-438a-9963-ca72620d9960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fdbff2fe-671a-4c39-9142-ff03f354ebbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24dffb2c-e6de-4b86-a1a9-787450030b02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_85f03d7f-58f4-427b-a31f-ee0c4a55e9ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d33b68e-2d8d-4bba-8c12-cc5befb5c40e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_60750fab-7364-4d16-b450-a83cad11cc9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5b536d9-fa13-474e-a41d-356bbdb5ca40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d2bb0f40-e78b-430e-9753-abc94b48fdb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_67c1d049-46bc-4a4e-bfb5-f558c76ed8e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b2f18b21-9cde-4c57-b478-19cc995431ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_acc458ea-fb09-43a4-ace2-5afee4642294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a7296cb0-df0b-44d4-8629-0d1f54c91d3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ac7c560-3741-425b-922a-fa6377eceda5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b441b445-cd74-4873-a003-e91cd23b0590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54cb7dea-1f14-46b8-a85c-4dea206dca63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:AdimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b020fee9-3aeb-4b54-9981-194d9a106693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1ef725d3-1855-48f2-ad32-868fd7a56f60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0ea8a13b-a850-4902-bc14-e2a26e047915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_19b8748c-94f6-4009-ae46-72a683ffb30c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0b4d8d2-f8bb-40b4-9f9f-b389737a0383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_758a9e1c-3654-4bc4-a4b7-e7f816f49088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a87639f8-76eb-442c-be84-1c45bb446983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99484b82-1134-42a5-ab27-b25e9ac34512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_eb3c4f20-3132-4502-b703-ab8173a141fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dc034315-cf03-4581-b437-e478d0086352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70243292-8d4b-4f56-b852-1e89e77c7444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a26230e7-fd18-41d7-8d63-f51a79aa854b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_2576a651-9ed1-4183-b092-abc05d49d737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6ad7b64a-0330-47d7-be46-238226e3cd18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f007740c-c40f-4489-8fb4-025d2bc6fa15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_0473103a-2c31-4a58-83e1-238b77fc08f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_46e9ae40-b4f7-48d6-998a-fdae75e33340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a3c0dae0-748f-402b-8e0c-a163a0ca3e35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AlectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_7db9d754-8d91-4ea6-9ab3-778ba4a2b5f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Employees">
        <measure>alec:Employees</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_f6e80797-f1a0-4a3f-b7ac-8a6d73737f9e">0001653087</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_d66bfc5f-9520-4474-a1d5-a87a8fdf835d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend
      contextRef="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160"
      id="F_212f573b-a35a-4193-8109-9d7f4ed630b3">true</us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_2243f1f8-6c2e-4253-84c7-bee7a5b60294">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_8f6db90f-54b3-4b0b-85ee-d8cd007a1398">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      id="F_59739cf5-7c7b-4790-81b7-25249697bc0e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      id="F_24681dae-d59f-43a3-ad73-dee32de8893e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_60750fab-7364-4d16-b450-a83cad11cc9e"
      id="F_94e46f7d-4030-4cdd-937b-79e7aa9936e8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_23bad412-c194-449a-a60e-538e93d13a94">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7e0bc482-fc9e-4c88-be3e-00731abac25d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_bbfcd3ff-cb28-4742-87a2-1743549de7c0">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_76a14c40-1ad1-4c2f-9f98-bdae00bdc32a">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7cdf628a-1470-4e56-b684-c7f373265c56">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_23e49932-075e-4808-849d-0323614d039c">001-38792</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_175e5d43-d313-45d3-9cc7-e9dd1a1e6d64">Alector, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_0e3abff1-bd69-4555-9df8-2631972b39ec">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_846d2315-632e-4c8c-a68a-cb6a80c7a1b5">001-38792</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_16a72581-0332-4581-b942-ecef2c91a013">82-2933343</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_bc13c219-323b-4075-9a84-5694465a3c2f">131 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_6ceb05ba-761c-463d-961d-31054bd12502">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_0c034698-0684-47f6-81c6-0cfc9da0e783">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_441d0c45-f743-48cc-8247-5425b51f9389">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_1b16f006-acc8-4688-b7f6-f54b97602971">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_6dd6265a-e091-4edc-9d0d-da87ef335dc0">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_034353ad-33f8-40f4-9005-9f5ffe3559d4">231-5660</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_dbb56710-bbb0-4377-b18a-f3e5fa77426d">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_a6901e52-1095-495b-b32e-dfcd86ad70e8">ALEC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_ca6bac6a-da7b-418f-9297-b5e6fc6b8cb8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_3b1cbbd3-5ef5-4f23-9f4f-404abd5d0861">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_bb4b5d34-7011-4703-8adb-84803959c0ad">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_5b50d448-cee2-4cd5-b761-9914f9cf3279">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_0f75bff1-da7c-4b72-b984-b52cc44df192">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_648b7a45-3a3b-41f5-afa5-9df471f9e9cb">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_6a221e1e-b513-4536-8d29-1e1d3a70f021">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_37f073c1-e45f-43ca-9baf-477547e09778">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_eabcf272-d632-46f5-95b1-9ff1ee28853c">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_1f82a363-f36a-4b82-b311-2cd4aa0daf42">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_809c3285-1e73-441d-a4f4-24de23900c91">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_8df4e45d-5ccf-4447-ac9d-b88b2629cca6"
      decimals="-5"
      id="F_fdf79698-5a0f-4bbf-8318-5cc7e577aac7"
      unitRef="U_USD">383800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0e7b91da-0112-404f-9acb-f761639a66b5"
      decimals="0"
      id="F_95d0c87d-cc0a-4435-a179-1ea151034e40"
      unitRef="U_shares">95749259</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_29a48823-5326-492e-9ce4-5f6fbf1c9450">&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the registrant&#x2019;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s 2023 fiscal year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_24556ad3-bc7c-4b6b-b0a9-fcd71bd32add">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_1b5bbe73-4967-4369-b729-8a94ec6f34e2">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_cce2a5d4-08af-44b7-9235-262479330bc8">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_4e12ccd7-99bb-41a7-a3bc-ac850754db01"
      unitRef="U_USD">74555000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_fa26a672-f2a6-47a2-a539-60099c3748ed"
      unitRef="U_USD">154323000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_9ac761dd-5a7e-4610-8f35-d982ee50ce30"
      unitRef="U_USD">474306000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_7a331e5d-9f62-4e6b-840c-75b9203133ce"
      unitRef="U_USD">558528000</us-gaap:MarketableSecuritiesCurrent>
    <alec:CollaborationReceivable
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_f34a99df-0d07-4869-8adb-406e1cef19ff"
      unitRef="U_USD">0</alec:CollaborationReceivable>
    <alec:CollaborationReceivable
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_7fd0664b-7cba-4009-b24b-92d676116e09"
      unitRef="U_USD">2587000</alec:CollaborationReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_3faa984d-f0de-4997-acbd-737decaf4579"
      unitRef="U_USD">16946000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_787e0788-554d-4f4d-9345-d01e1bbb52bf"
      unitRef="U_USD">10997000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_817f4965-18a1-4dc6-a1a2-f0ad4a931a91"
      unitRef="U_USD">565807000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_316f383d-4c8e-4485-bfdb-136e9b083a26"
      unitRef="U_USD">726435000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_6b082b5c-d039-476e-a7ad-bec295f633ab"
      unitRef="U_USD">21861000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_887f511a-d9dc-444b-bfed-bc8c71f0800c"
      unitRef="U_USD">25521000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_b85e34b6-cfa4-4d80-98a0-06db67f0e03b"
      unitRef="U_USD">25195000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_79fda727-e307-4832-b82a-f0fae4f00912"
      unitRef="U_USD">27811000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_ff4290cb-d73a-4485-9f85-d4e8c01c3fa0"
      unitRef="U_USD">1546000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_251fcf61-3de5-46f6-b889-f7e5153d2974"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a44fc565-b9da-4a52-9a77-8a8e573a5c90"
      unitRef="U_USD">7418000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_23689ab0-1fb0-4e53-bb5d-00313f5b8da9"
      unitRef="U_USD">6409000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_bc05f178-17c3-41a2-b2af-29abd0b94be5"
      unitRef="U_USD">621827000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_9192f934-dd78-413f-bd0b-8aac9d7365c2"
      unitRef="U_USD">787648000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_b87b9e89-13c0-4aed-aef8-f3ea877c2183"
      unitRef="U_USD">3775000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_c9fdb16c-7a95-4cbb-9699-7ccdbe5b71c5"
      unitRef="U_USD">4189000</us-gaap:AccountsPayableCurrent>
    <alec:AccruedClinicalSupplyCost
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_f0f0c43b-2492-4a42-a8da-c6ce27a03980"
      unitRef="U_USD">5215000</alec:AccruedClinicalSupplyCost>
    <alec:AccruedClinicalSupplyCost
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_9853de11-a791-494d-aa60-86cc9093d2da"
      unitRef="U_USD">5559000</alec:AccruedClinicalSupplyCost>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_30ac3b0a-9590-4250-bf39-362987ee7544"
      unitRef="U_USD">30378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_2506f646-05dd-4073-a539-684ed9a26c26"
      unitRef="U_USD">27771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_55b9ccff-7590-4896-ba6f-ca76d83e91a2"
      unitRef="U_USD">82975000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_a346d3bb-7694-4e26-ab76-3b2eea0a1660"
      unitRef="U_USD">48231000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <alec:CollaborationPayable
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_23f51ff8-49bb-425b-af76-25990c2f2566"
      unitRef="U_USD">7703000</alec:CollaborationPayable>
    <alec:CollaborationPayable
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_59940351-d522-4f1d-a014-e1f29e63c102"
      unitRef="U_USD">0</alec:CollaborationPayable>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_9165586b-a096-4b50-9ba3-976dda0c7a45"
      unitRef="U_USD">39440000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_55b6f756-d60f-489d-8ed7-52ac0b525d96"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_5c63b528-c964-4584-be33-fef8db61cd67"
      unitRef="U_USD">8462000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_608d4442-bcf4-4068-aef4-8b21ec1e1304"
      unitRef="U_USD">8059000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_e0e87293-adf9-4254-a656-e7fcab78fc9a"
      unitRef="U_USD">177948000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_b682690c-04e3-454a-a064-6e7adf34936a"
      unitRef="U_USD">93809000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_35477d85-30ea-45e8-b7d0-048fa4386f4b"
      unitRef="U_USD">210845000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_aa7fea58-c97c-424d-9f24-03ba916c7d3a"
      unitRef="U_USD">443370000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a3716784-4774-4abd-8e61-65adb54066f0"
      unitRef="U_USD">67047000</us-gaap:ContractWithCustomerRefundLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_d4efef2b-9885-444f-8d53-2967d5850aa3"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerRefundLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_2c900572-3cca-4471-b106-9637fae13fb4"
      unitRef="U_USD">30456000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_4714a6ae-96d7-455d-9c3e-075e6fa3ebdc"
      unitRef="U_USD">35268000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_3cdba768-ff11-40fc-a7c8-2a1ea5f14af7"
      unitRef="U_USD">1373000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3f183b6a-69f4-4a73-9761-94b8e3e49c37"
      unitRef="U_USD">759000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_65b55762-bea9-41af-85ef-d0277188515a"
      unitRef="U_USD">487669000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_2ee70bfb-83e4-44c1-847b-46e6cb0dedeb"
      unitRef="U_USD">573206000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="4"
      id="F_f7773acb-c880-4bcd-908e-7d97498ca59b"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="4"
      id="F_b0eda075-565b-4156-bc7d-0571e92cba92"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="0"
      id="F_22bb368b-79d8-4137-8ebd-a62be00afd59"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="0"
      id="F_7eb2c3ef-8026-4fa1-ba9a-32c0fc4c80ff"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="0"
      id="F_eb732526-17ce-40a6-84c0-422a544bd316"
      unitRef="U_shares">84879693</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="0"
      id="F_843e8bde-f4de-45a4-88df-9b980c0fdaf2"
      unitRef="U_shares">84879693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="0"
      id="F_cb1c2c7f-3caa-40e1-b416-e9878dc4b925"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="0"
      id="F_7430ada1-1048-4dfd-aa72-fe8025e2463c"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_692db0c7-d617-44c0-8aee-486fc16b772a"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_bff35057-3a12-478f-bc4b-0bed91b62567"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_f441331f-511c-4dd1-a342-16d9b56f5c2d"
      unitRef="U_USD">844044000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3310a614-5b4f-460d-a39b-6354bfdb66ca"
      unitRef="U_USD">798696000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_7c67c580-99a3-4fb2-a19e-f4a7211c7ef2"
      unitRef="U_USD">184000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_2df049db-8049-4162-9e75-3568ca8ff0dc"
      unitRef="U_USD">-4575000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_fe258f4b-c30d-412d-87c3-d7f1e9d4b2c5"
      unitRef="U_USD">-710078000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3b4bda11-bc3f-492b-9693-205397dfc6cb"
      unitRef="U_USD">-579687000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_1beb8619-0bd9-4814-956b-c4db8b7c3fe3"
      unitRef="U_USD">134158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_1c6496f6-3a47-44f4-84fe-55e80208de73"
      unitRef="U_USD">214442000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_22330cdb-074b-462d-9f5e-7eabcff6d83d"
      unitRef="U_USD">621827000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_753281ac-3a1a-41e2-b209-e3633ecf96b2"
      unitRef="U_USD">787648000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_cb37ec45-8068-4830-9d00-202fbcd15250"
      unitRef="U_USD">97062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_146d3bdb-aae3-4d0f-a7aa-e964235dd578"
      unitRef="U_USD">133617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_07629a50-fa60-4b52-aa7e-059d65d8d51c"
      unitRef="U_USD">207085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_b9843e3a-724f-4dba-bf96-f5fe7c776ab5"
      unitRef="U_USD">192115000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_1f0dce83-5a0f-4270-8e64-e0087a2f8390"
      unitRef="U_USD">210418000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_739c4e06-f713-44b1-a5fe-7797362a584f"
      unitRef="U_USD">189407000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_e5955004-b947-4ad9-bd5b-db808b446a39"
      unitRef="U_USD">56687000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_760ad245-4381-4e77-8aef-1be5521e8a14"
      unitRef="U_USD">61033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_f4e1200b-d2ad-4109-a8fc-c2ef5f638eb7"
      unitRef="U_USD">55038000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_9fd820b7-a17f-4ee1-bc72-ada20c50d3de"
      unitRef="U_USD">248802000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_6ca26822-ca5b-4867-8ee3-2aa0586ebd2c"
      unitRef="U_USD">271451000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_3523ebcd-c6df-43fd-a033-369d67911dbd"
      unitRef="U_USD">244445000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_7e18115b-cbb0-480d-b7c9-8fdc2349d3e8"
      unitRef="U_USD">-151740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f097d312-a649-4f25-9d4d-3ffabece2641"
      unitRef="U_USD">-137834000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4e31a27e-65ff-46b3-b681-7200073b02f6"
      unitRef="U_USD">-37360000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_5f1e3129-4f2a-4951-906f-d60b16aef6b0"
      unitRef="U_USD">26561000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_e74aedfc-d04f-4748-9211-08f455f2e1ed"
      unitRef="U_USD">7778000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_99b04500-226c-4fc3-8b10-1e24676c0d9b"
      unitRef="U_USD">1031000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_cab72aad-c851-4c00-a540-159863aae049"
      unitRef="U_USD">-125179000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_9c23c6ef-9ef4-478c-99a6-d0e167296e69"
      unitRef="U_USD">-130056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_1b91055b-8cd1-4850-aa64-0df58c0a7f92"
      unitRef="U_USD">-36329000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_0fbc1f1a-9fc6-4600-8fe5-04e79e25ad2d"
      unitRef="U_USD">5212000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_a7a55848-7caf-47dd-ac43-57e766f9b682"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_bf1888aa-85c1-43b0-b3af-052d1b285104"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_658ed8ef-dd9c-45b4-9d61-b6dd27a90e12"
      unitRef="U_USD">-130391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_7eb6a1a6-432a-4f0f-b8c6-58493eecc3e4"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_56463d9d-8906-46ae-978a-ceff580a11b4"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_dd556dd2-6967-476c-a6c9-844d2edd801f"
      unitRef="U_USD">4759000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f2fb5434-9dc1-486b-9a30-23ca64dd4ea6"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_3ba29a9e-82c0-404a-9022-1ee10d123204"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_3143f2c8-b13a-45c4-9e84-7c402e1579c2"
      unitRef="U_USD">-125632000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_2d638ac4-37ac-4b55-8321-564145dda3a2"
      unitRef="U_USD">-136942000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_115e2f9a-47da-4879-b576-96793c1a023b"
      unitRef="U_USD">-37886000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="2"
      id="F_e9fd1469-76de-4a9b-8fb2-4e8d7d454563"
      unitRef="U_USDollarShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="2"
      id="F_561b2ed0-9c2a-459a-a59b-612351a4b8c4"
      unitRef="U_USDollarShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="2"
      id="F_33fa8c86-a003-4424-8fd0-cc253b2d2832"
      unitRef="U_USDollarShare">-1.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="2"
      id="F_7dbd2cbe-f489-4e7d-a5aa-a6e7ede87502"
      unitRef="U_USDollarShare">-1.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="2"
      id="F_c37496d4-415e-411f-a25c-6ebf185c91ac"
      unitRef="U_USDollarShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="2"
      id="F_2efb31e9-0a67-41a3-b9d6-d51fcf440b37"
      unitRef="U_USDollarShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="0"
      id="F_982323ac-219a-449b-81bf-734843c3bdc6"
      unitRef="U_shares">83733730</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="0"
      id="F_a4d17398-c219-48e2-bef3-9a5543b5e411"
      unitRef="U_shares">83733730</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="0"
      id="F_47c6b958-7ff3-43c4-9efb-b6e2424898be"
      unitRef="U_shares">82467587</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="0"
      id="F_6703d295-e2ab-4400-9857-3ce25e46690c"
      unitRef="U_shares">82467587</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="0"
      id="F_e4093381-38f9-47ab-9844-0d79e554c33a"
      unitRef="U_shares">80416936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="0"
      id="F_5ea5fb0d-4e97-488a-a0c4-5c74e4786c6d"
      unitRef="U_shares">80416936</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6938cb01-3217-495c-940e-68f940751ad7"
      decimals="INF"
      id="F_89a71f4c-b3a4-416c-ab2d-cf73933e6088"
      unitRef="U_shares">79316261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6938cb01-3217-495c-940e-68f940751ad7"
      decimals="-3"
      id="F_bbe0c3f2-e702-458f-9aef-12a0dabd11f6"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b020fee9-3aeb-4b54-9981-194d9a106693"
      decimals="-3"
      id="F_bb260673-91c2-4304-bcc7-5a34e50843a7"
      unitRef="U_USD">676956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0b316b30-6fe6-45ed-a034-7a7078c020a5"
      decimals="-3"
      id="F_a9af1ebb-5632-4a43-bed4-7fd1589694fd"
      unitRef="U_USD">614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc9dc938-5e3b-488d-998b-8e76468ef770"
      decimals="-3"
      id="F_4c5396a9-321a-4938-9e20-4f2589e3a264"
      unitRef="U_USD">-410048000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_db20ea7a-0049-46f5-a310-e578628c49ec"
      decimals="-3"
      id="F_2ec6ecb1-6eca-42e1-b18a-9314cd481185"
      unitRef="U_USD">267530000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346"
      decimals="INF"
      id="F_a2375c45-5d93-4aa8-8702-bf4330bf339b"
      unitRef="U_shares">2395223</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf"
      decimals="-3"
      id="F_75dee3d5-56f6-453c-ac21-949cdc15a643"
      unitRef="U_USD">28530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_f436230b-41d6-4d56-b6fd-cb82f3f26a12"
      unitRef="U_USD">28530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346"
      decimals="INF"
      id="F_c522a70d-316d-40ec-a668-f81dea3b11ff"
      unitRef="U_shares">156420</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346"
      decimals="INF"
      id="F_d88a084c-a91e-48da-a6d5-066e458cb2aa"
      unitRef="U_shares">136331</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf"
      decimals="-3"
      id="F_17c5a9e5-4200-4a49-884e-0bac0fadb952"
      unitRef="U_USD">1765000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_e51ec8bd-7e41-407e-9cf2-e8d973a1e753"
      unitRef="U_USD">1765000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_939b60bd-dbba-49f8-810d-9f58546ab346"
      decimals="INF"
      id="F_4d14fab2-c0f3-429c-8abe-9f220d8fdc1e"
      unitRef="U_shares">18043</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_fd74e1af-61b1-488d-8031-e66435e39cdf"
      decimals="-3"
      id="F_f7713203-5e9a-4e9a-a978-3a2c84c9dfa3"
      unitRef="U_USD">40785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4fa00289-46fd-4946-8c48-de58d9239c37"
      unitRef="U_USD">40785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_e332595b-2812-42e7-8164-9333c6cb735f"
      decimals="-3"
      id="F_4a997ceb-1e3b-430c-842f-c6d77c0b6b1b"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_c4fb746f-00ae-4f12-9e57-5e0241c5be7a"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_67c1d049-46bc-4a4e-bfb5-f558c76ed8e0"
      decimals="-3"
      id="F_677e9c46-f466-46c6-8435-553a8a0d001f"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_674ceacd-909e-442a-884b-7031e81a335a"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e3cdfe83-caeb-4047-a450-8e67619a35be"
      decimals="INF"
      id="F_b42bbe16-0611-468b-94f0-ebd618548039"
      unitRef="U_shares">81986192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e3cdfe83-caeb-4047-a450-8e67619a35be"
      decimals="-3"
      id="F_e60de40e-fe72-4d81-a408-6e9029d9fc31"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f5380031-3260-4626-aa94-6be4667cd0d5"
      decimals="-3"
      id="F_d87774d0-05f7-49dd-a869-055366e4e726"
      unitRef="U_USD">748036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a7296cb0-df0b-44d4-8629-0d1f54c91d3d"
      decimals="-3"
      id="F_60d0e700-2431-44a2-9249-6fbad4090e2c"
      unitRef="U_USD">-943000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_875c92eb-4727-4d07-8257-01fde8082811"
      decimals="-3"
      id="F_a0c77875-ccc9-4e89-b933-10eceaac29e0"
      unitRef="U_USD">-446377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695"
      decimals="-3"
      id="F_260e0f74-eb82-458b-a752-c52f0353b834"
      unitRef="U_USD">300724000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b"
      decimals="INF"
      id="F_5454935f-9866-42e3-8cf1-584b9d6efb3d"
      unitRef="U_shares">298238</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37"
      decimals="-3"
      id="F_43eae9d1-8d57-491c-b33b-e55aa5b08986"
      unitRef="U_USD">3059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_0de19483-3749-4730-87db-67a7e83f714a"
      unitRef="U_USD">3059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b"
      decimals="INF"
      id="F_c9de6e14-7a64-4329-bcd4-0b3f4dbacfe8"
      unitRef="U_shares">414578</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_fc8af8e4-7a34-4648-8989-7c4c2ffb686b"
      decimals="INF"
      id="F_ed78956a-5231-49cc-89b6-2209079b1b58"
      unitRef="U_shares">196710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37"
      decimals="-3"
      id="F_17d41d98-4652-4e29-b69f-fc259123ca00"
      unitRef="U_USD">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_0d8edbfb-8149-4813-b45f-1c742083b039"
      unitRef="U_USD">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d6969ea4-3c96-4bd2-9c4d-c2c0bc14aa37"
      decimals="-3"
      id="F_2795bec0-3641-406a-bb05-4a0770fffd40"
      unitRef="U_USD">46146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_a5292a7b-366b-484c-9ca2-3ede713d0071"
      unitRef="U_USD">46146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_fdbff2fe-671a-4c39-9142-ff03f354ebbc"
      decimals="-3"
      id="F_689a7ca8-860e-47b0-ac4d-a520e3ef88fa"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_296ccc15-58c3-4d57-b21e-b590eda438b4"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d7c568c-73b0-4659-933e-e70332ce56ef"
      decimals="-3"
      id="F_89d4e29d-4c70-4cd7-aa08-e9d85fa5ab8a"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_a8dfd9ed-cccb-46fd-aa0a-7f4677fc7ec5"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_24dffb2c-e6de-4b86-a1a9-787450030b02"
      decimals="INF"
      id="F_d60486b5-f0e4-4073-a2a6-798aa3a4ccfe"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_24dffb2c-e6de-4b86-a1a9-787450030b02"
      decimals="-3"
      id="F_789aba50-31a6-4323-9e02-9024bf20b0c0"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7db9d754-8d91-4ea6-9ab3-778ba4a2b5f8"
      decimals="-3"
      id="F_c5f667ea-6605-4264-8d55-910ec23a1950"
      unitRef="U_USD">798696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_799c46d0-304e-442b-87b3-67e31110ef56"
      decimals="-3"
      id="F_dc683075-6ecf-48b6-9065-9fcb40945b82"
      unitRef="U_USD">-4575000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e123b7a5-e275-4b05-8fa9-5b78e2f38cf9"
      decimals="-3"
      id="F_b99d8b9e-38ca-414c-8fbb-29bf09388634"
      unitRef="U_USD">-579687000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3438ecb6-87bb-4a73-ae19-334db6d3bba9"
      unitRef="U_USD">214442000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a"
      decimals="INF"
      id="F_2603f8db-afc4-44b9-b6a6-cbcb88255d00"
      unitRef="U_shares">132191</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a"
      decimals="-3"
      id="F_a733172a-7684-40d5-a5c0-243bc0083bd3"
      unitRef="U_USD">1079000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_3a9dc9a4-d893-46a5-ac54-094261fa7ecb"
      unitRef="U_USD">1079000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a"
      decimals="INF"
      id="F_48a8391d-1800-4530-af01-9c6f352e2859"
      unitRef="U_shares">1584449</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_7eabd4ca-c26e-4676-a7b0-8070998bc68a"
      decimals="INF"
      id="F_e2829e5e-67ff-4fbf-b23e-5cd96809b56a"
      unitRef="U_shares">267335</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a"
      decimals="-3"
      id="F_b289fd92-0960-4a3d-b23a-4503e84a32c2"
      unitRef="U_USD">1471000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_4f52371f-b28c-428b-b67f-cc31c0ddfb7d"
      unitRef="U_USD">1471000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_72e522a3-5366-4e26-836a-dbe1abd68f5a"
      decimals="-3"
      id="F_cec69ce9-cafc-4887-8ad1-5cac9d29743e"
      unitRef="U_USD">42798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_885f81f2-d0a2-480d-825c-8af6e6481b92"
      unitRef="U_USD">42798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_17714c29-f0b8-4a31-9e58-2bb7319ace3f"
      decimals="-3"
      id="F_21ecc3e3-e0c4-4bcd-b766-0acbf275f9c4"
      unitRef="U_USD">4759000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_1543d6c3-789d-4835-bf58-54696072614b"
      unitRef="U_USD">4759000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_5221b583-972a-4325-9c52-a770e32fec78"
      decimals="-3"
      id="F_9aab59ef-e720-4b46-bb89-199045171604"
      unitRef="U_USD">-130391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_5bd324c0-02a1-4d2b-981f-9909c7a70551"
      unitRef="U_USD">-130391000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99"
      decimals="INF"
      id="F_7f9c4712-a522-411c-9067-0e2d5431ef56"
      unitRef="U_shares">84879693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b3cc2280-cd10-4f24-8d2c-4e968ce64c99"
      decimals="-3"
      id="F_070afa72-a2ad-4abc-aebe-055d1ed7c9fd"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8f63097f-fc67-43ad-b6f8-799a51185227"
      decimals="-3"
      id="F_cab15996-0e3e-42d6-9ee6-ed8cbe8c36b4"
      unitRef="U_USD">844044000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0af91d08-2797-49ba-a679-a9d25bb3512d"
      decimals="-3"
      id="F_527cd34e-3f65-4601-8c4b-eb5b024bc347"
      unitRef="U_USD">184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7b15d294-93bc-4f21-877c-2a47962db58d"
      decimals="-3"
      id="F_a9fe204b-f121-473f-bc8f-3a5fe3e78bf5"
      unitRef="U_USD">-710078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_595a6bab-6d15-455b-aa1a-1f8e1c31ae55"
      unitRef="U_USD">134158000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_9ccdf488-4ff9-4c4b-bb1e-ac8217d81f1f"
      unitRef="U_USD">-130391000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f8066da3-e6d3-4aa2-b307-1f4108aa3588"
      unitRef="U_USD">-133310000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_0499cd6b-b02f-46b3-a9d8-1eaa6c20d789"
      unitRef="U_USD">-36329000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_0b667dc5-d4f8-4bf5-9c34-2c733aa85f1d"
      unitRef="U_USD">5725000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f1e41235-3da4-4f83-9357-5292e1fa5633"
      unitRef="U_USD">5714000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_f5a1ffc3-b9fb-404e-8106-671d026e6e9b"
      unitRef="U_USD">6329000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_8de54e2b-8ced-4cbd-9a63-bc27a04ac4fd"
      unitRef="U_USD">42798000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_34dbe482-15b1-4881-b6ef-1e8dc5f51016"
      unitRef="U_USD">46146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_79b23249-cb06-440f-91df-3c5d3fb615ca"
      unitRef="U_USD">40785000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_79493c60-4f4e-4a50-adea-636492db52b8"
      unitRef="U_USD">15318000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_cf1b9d42-9e96-4d04-88f6-5a17ebdd2df2"
      unitRef="U_USD">1163000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_38746072-38ba-4e40-928f-8b0e9c97487c"
      unitRef="U_USD">-2099000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_58212fc5-1b73-449f-8d32-2680e59eae78"
      unitRef="U_USD">3123000</alec:AmortizationRightOfUseAsset>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_ddcaa4c3-9f41-486c-9b19-0758ed3ac9f9"
      unitRef="U_USD">2758000</alec:AmortizationRightOfUseAsset>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4aa9a7e2-51c8-44ba-9aae-93fe56c0f358"
      unitRef="U_USD">1986000</alec:AmortizationRightOfUseAsset>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_ce99ee9d-df15-498c-b058-becd08bc1d70"
      unitRef="U_USD">-48000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_4e933801-3a7a-4af1-b4be-8a93d0e529f8"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_bbc44363-58e4-418c-918b-c1999f2055cb"
      unitRef="U_USD">0</us-gaap:GainLossOnDispositionOfAssets1>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_da22529d-38c9-4552-a9bf-f87a5a220b79"
      unitRef="U_USD">-2587000</alec:IncreaseDecreaseInCollaborationReceivable>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_894b68b3-f761-4319-b7e3-f89808c67f94"
      unitRef="U_USD">-4804000</alec:IncreaseDecreaseInCollaborationReceivable>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_d0214440-0c3b-466c-aa47-2827d667c427"
      unitRef="U_USD">7391000</alec:IncreaseDecreaseInCollaborationReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_4500530e-acae-41d1-b1c9-16b7a39dac27"
      unitRef="U_USD">5949000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_43abb429-5f34-4a1b-8fee-9f564bc15002"
      unitRef="U_USD">3926000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_2936eb32-d429-4a02-8f74-386756a8acbc"
      unitRef="U_USD">-1132000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_b1c823c6-af64-4a94-a008-1fddf65a1d71"
      unitRef="U_USD">1009000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_7ed627dd-08a1-4f4a-8871-3dea06c82381"
      unitRef="U_USD">835000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_0d7e827e-5c48-4204-a258-24d66c5f9e5e"
      unitRef="U_USD">2957000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_ab81c89f-53b9-499d-8722-934605e60d63"
      unitRef="U_USD">-377000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_ebb7dd95-73dc-401a-8939-39c4e524f620"
      unitRef="U_USD">-572000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4065c572-ecf5-4490-ab4d-14ce27e948d3"
      unitRef="U_USD">1917000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_63029f4f-0170-4699-a401-4c3d5bcf817f"
      unitRef="U_USD">2546000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_d6601855-508f-4614-9b3f-8f575edda85c"
      unitRef="U_USD">-2655000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_7815497c-1d1a-411c-bd74-4afcdfe150a2"
      unitRef="U_USD">2391000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <alec:IncreaseDecreaseInPayableToCollaborationPartner
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_8cb013db-a5d8-435e-8272-ff36e41dab5d"
      unitRef="U_USD">7703000</alec:IncreaseDecreaseInPayableToCollaborationPartner>
    <alec:IncreaseDecreaseInPayableToCollaborationPartner
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_7dc09f2c-c422-4819-b1d1-f4144b05a793"
      unitRef="U_USD">0</alec:IncreaseDecreaseInPayableToCollaborationPartner>
    <alec:IncreaseDecreaseInPayableToCollaborationPartner
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_630143e9-447d-4d39-8234-1d5493f4ae1e"
      unitRef="U_USD">0</alec:IncreaseDecreaseInPayableToCollaborationPartner>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_b00b539d-fdee-4246-83c4-035d886de26c"
      unitRef="U_USD">-66782000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f6b81cfc-2d90-4f4a-8607-6e4b41d1777d"
      unitRef="U_USD">66383000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_d6379ab3-86af-46b1-9eda-6fd2edd4d42c"
      unitRef="U_USD">292915000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_28437145-e24f-4824-94de-48b0dd1d9dc2"
      unitRef="U_USD">24512000</alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner>
    <alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_21565a69-731c-44f6-b355-a6e855f17772"
      unitRef="U_USD">0</alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner>
    <alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_0a038bd4-3b20-4d0a-901e-7f61d084fb1b"
      unitRef="U_USD">0</alec:IncreaseDecreaseInRefundLiabilityToCollaborationPartner>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_d71657a7-86c9-4e54-8d05-18666cf21bb7"
      unitRef="U_USD">-4968000</alec:IncreaseDecreaseInLeaseLiabilities>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_6cf4d983-8ac0-4a28-95a6-e0c2a27105c2"
      unitRef="U_USD">-4274000</alec:IncreaseDecreaseInLeaseLiabilities>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_63b627eb-ce9e-4daa-b99b-539a86977e95"
      unitRef="U_USD">-4012000</alec:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_1de63a8a-b433-4f16-95b5-484cce9b944a"
      unitRef="U_USD">614000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_d05a9e15-9b83-4c14-957b-4836e9f7fa7c"
      unitRef="U_USD">601000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4add56ea-f099-4e1b-9938-7da3132bb9e6"
      unitRef="U_USD">-314000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_d62bd23e-0473-4d43-9b9e-047e4fe72d22"
      unitRef="U_USD">-184162000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_8c71b4ab-7661-4b7a-a597-5cfb9a557473"
      unitRef="U_USD">-20329000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_49400022-d30c-420a-8224-e2b00410e213"
      unitRef="U_USD">298551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_da4d1564-4e1f-4cfb-9a66-c877002117ff"
      unitRef="U_USD">2381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_17865ea7-a3fc-4c93-9a27-bc01ba5d012a"
      unitRef="U_USD">4117000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_d63ab3c2-6e10-4f07-a568-3c2360c721c7"
      unitRef="U_USD">3247000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_253592e8-c68a-466b-9053-bec97ca92d4a"
      unitRef="U_USD">551729000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_c0e51c80-23d2-4c22-b833-7ef9f1a1651a"
      unitRef="U_USD">556898000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_4ff1df14-493e-44d9-84a4-98ff26db7ed5"
      unitRef="U_USD">343402000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_f8a28599-a1fa-44c1-bfaa-16c44a1ba579"
      unitRef="U_USD">652523000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_faf4f04c-6b82-4302-bce5-9fa74e6d7aab"
      unitRef="U_USD">402001000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_aa35b5d2-e6ae-4f2d-b942-88b896dbf8b1"
      unitRef="U_USD">286290000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_ee320d33-aea3-445a-8cc0-82e34ad480ea"
      unitRef="U_USD">3505000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_fd8566eb-8b43-417d-8bc0-c7b5ebef000d"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_db9ee585-e032-48c5-a4dd-db33a589349d"
      unitRef="U_USD">10696000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_19dbb324-87ae-4333-9d3f-e733569fd920"
      unitRef="U_USD">101918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_bcbdd5bd-947a-46c2-a0e9-41c67cee55ce"
      unitRef="U_USD">-159014000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_8e855c9f-d6df-4fd6-aca2-5b2b732ddc76"
      unitRef="U_USD">-49663000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_47ca048d-3bbb-4578-8e81-9632b4427e17"
      unitRef="U_USD">1079000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_ef019227-8362-413d-a0b6-19dbeb27da56"
      unitRef="U_USD">3059000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_9a317aec-f5f1-43e9-9308-6051b741b82a"
      unitRef="U_USD">28530000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_7652a356-a523-4c60-8f26-71c78457308d"
      unitRef="U_USD">1471000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_fff3cb2b-7c98-4603-a91f-5a5f0a8c3301"
      unitRef="U_USD">1455000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_52e49340-546f-46d6-a07b-d1c192d66d67"
      unitRef="U_USD">1765000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_80973364-0207-4b81-a282-7a733f0efaf7"
      unitRef="U_USD">2550000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_d1f7053f-d33d-4ef2-863e-2a3691712ecb"
      unitRef="U_USD">4514000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_448c638f-df0e-4ff0-a547-5a03dcdeb14b"
      unitRef="U_USD">30295000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_59a5efa7-43b8-4705-b7e8-76da9088bd13"
      unitRef="U_USD">-79694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_538393e1-ebc1-464c-b162-0dc7875bfbb5"
      unitRef="U_USD">-174829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_c2197cca-c8f2-416e-a1dd-218aff3d2121"
      unitRef="U_USD">279183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_049c6ca2-d3d5-425b-ad5b-08b213bdb8ca"
      unitRef="U_USD">155795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695"
      decimals="-3"
      id="F_e61865fc-0293-4fb9-9bd9-ba632ba83e27"
      unitRef="U_USD">330624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_db20ea7a-0049-46f5-a310-e578628c49ec"
      decimals="-3"
      id="F_08c0ac35-3388-45f0-8bf7-82e0efed7224"
      unitRef="U_USD">51441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_6eca9342-398a-48aa-9c32-a3cca1b6594e"
      unitRef="U_USD">76101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_f3e779e5-8c07-4a0f-8eea-e994b241c832"
      unitRef="U_USD">155795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695"
      decimals="-3"
      id="F_0def6870-8814-4035-8155-258a2eade9ba"
      unitRef="U_USD">330624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_a33a5fff-9e9e-4845-a9e9-9e2451344843"
      unitRef="U_USD">172000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_61b31a2d-5cab-4738-8551-5f6ee34c1797"
      unitRef="U_USD">493000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_7a5b8379-822b-428c-aeea-bd1aa6a2a018"
      unitRef="U_USD">705000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_067ae176-3211-4f4f-b1a2-725efa44204f">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company  &lt;/span&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_cb6b64c9-61d9-4ec0-bc3d-59835ddd520e">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash relates to a letter of credit established for a lease entered into in June 2018.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are included in other comprehensive income and reported as a separate component of stockholders&#x2019; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, certificates of deposit, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#x2019;s financial instruments approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_94e46f7d-4030-4cdd-937b-79e7aa9936e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each performance obligation is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;estimates. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing price of the Company&#x2019;s common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur for all awards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are the result of transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits within the provision for taxes in the consolidated statements of operations. The Company accrued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest and penalties for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee 401(k) Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the Code) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#x2019;s contributions to the plan are discretionary. For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, 2022, and 2021, the Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_e4509f94-f937-4c2b-b286-344c85dd26b0">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_6449e70b-2b97-4914-b03b-36946703b473">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_ef9b94cf-37a3-4d16-a2bb-ea5991896068">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_34600bd0-81af-4447-b6a6-35c8dce80ce4">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash relates to a letter of credit established for a lease entered into in June 2018.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_df8cfb06-c58c-45a0-8916-2fcbac684c49">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_c76b3522-47dc-4a63-aad1-caf579cd613f"
      unitRef="U_USD">74555000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_2ac91760-30c5-40c5-b17e-293be8c24cfb"
      unitRef="U_USD">154323000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_be2815d6-86d4-453b-ab6f-541925cc3449"
      unitRef="U_USD">1546000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_07c741ec-2c74-48b0-a1e3-2ccd46928b71"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_5a9fa028-3f41-485e-9448-43649321307e"
      unitRef="U_USD">76101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_c96ac5b1-66bd-4e42-80c0-f8158029d55e"
      unitRef="U_USD">155795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_9859be16-07f0-4be0-ad8a-3ffc4f3a3d0f">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;are included in other comprehensive income and reported as a separate component of stockholders&#x2019; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, certificates of deposit, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-6"
      id="F_68c1b1cd-f633-4272-b052-2e9ecc220cdd"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_5007a151-c732-43ae-bd5c-4d20a27d07c7">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#x2019;s financial instruments approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_ad53a419-270b-46dc-93c7-ddabe5ff0488">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_94e46f7d-4030-4cdd-937b-79e7aa9936e8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d4fbee25-c222-4832-b8a1-0ed2b6aff01f"
      id="F_f3e6532d-389d-4c38-9b8b-7e60f52eee7d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_def8c72c-9cf2-49c7-a7af-d58500ae5dcf">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7a7f91cd-01ea-44f3-9753-9721a828e500">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-6"
      id="F_3fdde6bf-01fc-46f2-8662-8469bbd28a5d"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-6"
      id="F_5ea0053d-9267-49ab-9941-47a6910efe97"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_c69f94f2-1ada-4542-8def-1cc2e8036fb2">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each performance obligation is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_d5a02afe-0e9f-4f57-95f0-fbb2a429dd50">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;estimates. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_e32b1df1-2e01-493d-97c1-87427b7872a2">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing price of the Company&#x2019;s common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur for all awards.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_c7c5b459-5ee2-400f-97f7-4336251ffa21">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are the result of transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_8aab1f09-d55b-44de-99a5-72d669b579ff">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits within the provision for taxes in the consolidated statements of operations. The Company accrued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest and penalties for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_6f5cda2c-7ae5-41c4-92c7-a4dd26571a48"
      unitRef="U_USD">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PostemploymentBenefitPlansPolicy
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_5a4c3e52-8d2f-437b-824f-b48f14061516">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee 401(k) Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the Code) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#x2019;s contributions to the plan are discretionary. For the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, 2022, and 2021, the Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="2"
      id="F_60fe571a-ea15-48a9-94cb-475298e88bb9"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_8b778e06-b2a5-4bb4-ab02-692057b21770"
      unitRef="U_USD">1100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-5"
      id="F_a0b4fe8e-47b7-4be3-ba00-9c73d44bc98a"
      unitRef="U_USD">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-5"
      id="F_2101c9d0-b44a-464f-9d4a-b950db5a13a1"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_be805052-491a-4de0-adec-51c7a3eb13db">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_dac47de6-75bf-4f08-ac7c-b874b3685626">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_55d1b004-c7a6-4a64-a093-d560ac9d0ec6">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;544,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;655,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the remaining contractual maturities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of investments were less than one year and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;investment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;were after one year through two years. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. For the year ended December 31, 2023 and 2021, the Company sold marketable securities for the total proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for an immaterial realized loss and gain based on the specific identification method. The Company did not sell any marketable securities for the years ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_4ab2cd1f-1adb-46f2-afe4-ce29589d0337">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.9399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;178,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;544,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;501,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;655,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8"
      decimals="-3"
      id="F_d8e4d053-8693-4ac6-bf0c-0137d2fa747c"
      unitRef="U_USD">67101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8"
      decimals="-3"
      id="F_92566bf1-8bc1-41bb-83a9-1858280c3812"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8"
      decimals="-3"
      id="F_19d82f43-1ca8-48c3-81df-27bf350856a9"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e182d36e-185b-4b5e-ae5b-376f53a27ec8"
      decimals="-3"
      id="F_f8f2e8b0-28f9-49c0-a32d-ef06244ae4e0"
      unitRef="U_USD">67101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471"
      decimals="-3"
      id="F_e44150f2-bb0e-4bfc-8f1d-8bf887465ca3"
      unitRef="U_USD">178232000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471"
      decimals="-3"
      id="F_cd1f64bf-71f0-4bf6-8d55-0c9dbd42f065"
      unitRef="U_USD">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471"
      decimals="-3"
      id="F_85b58a64-fb85-4b19-b332-439c41cfb4f3"
      unitRef="U_USD">112000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f97232c-f60b-4a4b-b51b-6d2e65356471"
      decimals="-3"
      id="F_b540933f-3993-4454-837e-777c5d839a16"
      unitRef="U_USD">178206000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72"
      decimals="-3"
      id="F_2182e88d-bd1b-43c3-ba20-9bda1601cea2"
      unitRef="U_USD">29086000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72"
      decimals="-3"
      id="F_32462008-ad86-4d59-b397-efb49ccb62cf"
      unitRef="U_USD">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72"
      decimals="-3"
      id="F_caf0db5c-a348-402f-8a4a-a51238f37dd6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_53a5db9e-db92-4bd5-a460-a20781d98b72"
      decimals="-3"
      id="F_bcf733d2-1634-44ec-8de5-9e40d1ea26cb"
      unitRef="U_USD">29149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340"
      decimals="-3"
      id="F_80179b07-43a5-4787-98e8-7f254c52996a"
      unitRef="U_USD">140082000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340"
      decimals="-3"
      id="F_efa54071-4ff7-407b-8ff4-b9917f857e36"
      unitRef="U_USD">85000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340"
      decimals="-3"
      id="F_461a831a-54c0-42b4-89ec-3a8f0a393a88"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_46e9ae40-b4f7-48d6-998a-fdae75e33340"
      decimals="-3"
      id="F_c23e0ac0-429a-4403-aae1-bced7a2b9c0d"
      unitRef="U_USD">140133000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e"
      decimals="-3"
      id="F_0ae67773-76b7-4899-a760-589e7426d49b"
      unitRef="U_USD">129474000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e"
      decimals="-3"
      id="F_8caa9bd8-764b-40d3-ad7b-24722b60b5af"
      unitRef="U_USD">173000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e"
      decimals="-3"
      id="F_258e02d6-dd4b-43dd-b618-f5a565ffa392"
      unitRef="U_USD">78000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_624f949e-17a4-4e4d-aeb5-56efa8974e6e"
      decimals="-3"
      id="F_ce22a0de-af9f-4286-8b2c-a38d111a1cbd"
      unitRef="U_USD">129569000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b"
      decimals="-3"
      id="F_dc291efb-fb7a-43f9-a54d-d6a853691870"
      unitRef="U_USD">543975000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b"
      decimals="-3"
      id="F_97cd7dbc-837f-4891-9e68-07348372b9e7"
      unitRef="U_USD">407000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b"
      decimals="-3"
      id="F_c1eceaa7-b8b4-403b-aed4-8bc6d843da2a"
      unitRef="U_USD">224000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a780de0c-7437-4cda-82c1-96d14ee7da1b"
      decimals="-3"
      id="F_ec258786-f8f0-4089-b7cb-4ef2e816e948"
      unitRef="U_USD">544158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12"
      decimals="-3"
      id="F_af61037f-847e-46eb-84cf-aae9522b04cc"
      unitRef="U_USD">74848000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12"
      decimals="-3"
      id="F_8c5b3c56-7709-4e09-b43c-484368a29519"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12"
      decimals="-3"
      id="F_6d4c5df0-3a5d-426e-a26a-a25d32e67f58"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d58feb5a-c636-4e06-a7ab-b5b17ad3fb12"
      decimals="-3"
      id="F_0934a569-6801-47e4-82b2-3962dae198ec"
      unitRef="U_USD">74848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d"
      decimals="-3"
      id="F_0e345f2e-91b4-42e5-b649-62249127df6d"
      unitRef="U_USD">506372000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d"
      decimals="-3"
      id="F_ee710cd1-532b-4743-ae48-c46faee09848"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d"
      decimals="-3"
      id="F_1a3f87d4-e116-41df-aefe-a153243c4da2"
      unitRef="U_USD">4569000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ab5bd7aa-9449-45ef-913b-7842f838798d"
      decimals="-3"
      id="F_c94754f1-6832-49c1-8d51-a33859952519"
      unitRef="U_USD">501810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb"
      decimals="-3"
      id="F_0da221c3-d4e5-4fc3-bf8a-f7f90de5d162"
      unitRef="U_USD">44438000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb"
      decimals="-3"
      id="F_5219443a-54fb-419c-9d91-69c33c5c98cb"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb"
      decimals="-3"
      id="F_ce52de30-9202-4da8-baea-3742a461359c"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f046ab04-15c7-4369-aa49-cd5e43cd49cb"
      decimals="-3"
      id="F_495a6bfb-25d3-482f-ba74-fe035a565275"
      unitRef="U_USD">44432000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6"
      decimals="-3"
      id="F_ecb36fbd-c546-48d6-a401-57d054afba7b"
      unitRef="U_USD">29352000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6"
      decimals="-3"
      id="F_34ee1e27-d734-4894-b711-bfe7bcfaac2d"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6"
      decimals="-3"
      id="F_5929663f-4bcc-467e-bb59-0ce1e010203b"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_73cd82b7-2461-4bb6-a3f8-16aa8581e5f6"
      decimals="-3"
      id="F_ce28f990-104c-4826-9efb-a80f96c34033"
      unitRef="U_USD">29346000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8"
      decimals="-3"
      id="F_afb72212-68cb-487c-90a4-3a63984e0eb5"
      unitRef="U_USD">655010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8"
      decimals="-3"
      id="F_0202a6ed-706e-4e9e-b4f7-be9d15d0c53c"
      unitRef="U_USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8"
      decimals="-3"
      id="F_9f00a9e1-ffc7-4877-9344-a7a2ad9d8661"
      unitRef="U_USD">4587000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9dd84d0b-3664-4491-991d-d0c679a6b1c8"
      decimals="-3"
      id="F_62b4cdd2-9bf4-43c5-9b56-51e3447d6182"
      unitRef="U_USD">650436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_f1f95814-0433-4c02-a571-98bfbc146b79"
      unitRef="U_USD">503100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <alec:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_fc605ad2-118d-4376-b7c0-a9585d125485"
      unitRef="U_USD">41100000</alec:AvailableForSaleSecuritiesDebtMaturitiesOverOneYearThroughTwoYearsFairvalue>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_878223b6-4c85-4d7e-8fbb-31bdcca50c6d"
      unitRef="U_USD">3500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-5"
      id="F_7a6c0eff-8a4f-40cb-9717-0ae158efb066"
      unitRef="U_USD">10700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_430ec06c-3606-4fbf-905a-809cc966ff2c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.     Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of December 31, 2023, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into customary indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for certain losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded a liability related to such indemnification agreements as of December 31, 2023. As permitted under Delaware law, the Company has entered into indemnification agreements with its directors and officers that requires it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by law. The Company also has directors&#x2019; and officers&#x2019; insurance.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <alec:IndemnificationAgreementLiability
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="INF"
      id="F_578aaf34-1e1b-4471-92ea-802f2f9c3fd4"
      unitRef="U_USD">0</alec:IndemnificationAgreementLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_6910cd3a-782b-49b7-be68-179d29561daf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.     Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;GSK&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab, and AL101 (GSK Agreement). The GSK Agreement became effective on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the GSK Agreement, the Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in upfront payments, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was received in August 2021 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and other non-orphan indications. GSK will also conduct the initial Phase 2 trial for AL101 in Alzheimer&#x2019;s disease. Development costs will be shared &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% by GSK and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% by the Company, except that subject to the GSK Amendment (defined below), the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company and GSK amended the GSK Agreement (GSK Amendment). Under the terms of the GSK Amendment, the Company is responsible for funding and sharing in GSK&#x2019;s and the Company&#x2019;s development costs up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the conduct of the initial Phase 2 trial for AL101 in Alzheimer&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;disease. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed the GSK Amendment in accordance with ASC 606 and concluded that the GSK Amendment was a contract modification to the GSK Agreement. Accordingly, the transaction price as of May 2023, was updated from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;571.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the difference of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as refund liability to collaboration partner for the expected cost reimbursement to GSK. The refund liability is an estimate of variable consideration calculated as the difference between the Company&#x2019;s maximum funding of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the Company&#x2019;s cost budget estimated using the expected value method. The Company determined that the modified performance obligation for the AL101 Alzheimer&#x2019;s disease program is performing development activities to support the initial Phase 2 trial, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the modification date relating to the performance obligation which was satisfied in prior periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three months ended September 30, 2023, as a result of the planned closure of the latozinemab Phase 2 trial and concurrent agreement by the Company to cost-share additional R&amp;amp;D, the Company determined there was a modification of the GSK Agreement, resulting in a decrease of the scope of the performance obligation associated with the latozinemab FTD-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;C9orf72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Phase 2 trial and an increase in the amount of R&amp;amp;D cost-shared by the Company in future periods. The impact of this additional cost share was accounted for as a refund liability, which reduced the transaction price for the GSK Agreement by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The refund liability is an estimate of variable consideration. The Company determined that the modified performance obligation for the latozinemab FTD-C9orf72 indication is performing the first Phase 2 development activities, including license rights and know-how. The Company updated the cost-based input measure of progress for the modified performance obligation and recorded a cumulative catch-up adjustment to revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the modification date relating to the performance obligation that was satisfied in prior periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of latozinemab and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to latozinemab FTD-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GRN&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The transaction price at inception included fixed consideration consisting of the upfront payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The transaction price as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was decreased to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;569.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million due to the estimated refund liabilities created from the contract modifications. The Company reassessed the estimated refund liabilities to collaboration partner as of December 31, 2023 to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of latozinemab and AL101 and estimated research and development costs to be incurred by the Company in each of the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management&#x2019;s assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GRN&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collaboration revenue under the GSK Agreement during the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, the entire amount of which was included in deferred revenue at the beginning of the period. The deferred revenue related to the GSK Agreement was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, the Company recognized a reduction of research and development expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, under the GSK Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;AbbVie&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in upfront payments, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector concluded that further development of AL003, the asset being developed under that program, was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. Accordingly, the Company is no longer developing that program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. If AbbVie exercises its option for the AL002 program, AbbVie would take over development of the product candidate, and the program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. Alternatively, following AbbVie&#x2019;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, the Company and AbbVie amended the AbbVie Agreement (AbbVie Amendment), which resulted in the Company receiving a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment in March 2023 for the dosing of the first patient in a long-term extension (LTE) trial. In addition, under the terms of the AbbVie Amendment, the Company was eligible to earn up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to support the enrollment of additional patients to replace discontinuations. The performance obligations to conduct the LTE trial and enroll additional patients are not considered distinct from the AL002 program performance obligation. The Company received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the enrollment of additional patients from AbbVie in the third quarter of 2023 and received the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the fourth quarter of 2023. The transaction price as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; included fixed consideration consisting of the upfront payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;205.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million LTE milestone payment, and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment for enrollment of additional patients.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which was included in deferred revenue at the beginning of the period. Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The deferred revenue related to the AbbVie Agreement was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, respectively. The deferred revenue is expected to be recognized over the research and development period of the AL002 program through the completion of the ongoing Phase 2 and the Phase 2 LTE clinical trials.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <alec:CollaborationAndLicenseAgreementEffectiveDate
      contextRef="C_d58b91a6-8565-488e-b02e-ec025dddbb45"
      id="F_894bdc0a-cfbe-476f-9890-7632c0d9abc7">2021-08-17</alec:CollaborationAndLicenseAgreementEffectiveDate>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_99484b82-1134-42a5-ab27-b25e9ac34512"
      decimals="-6"
      id="F_a828e820-3370-47d5-ae83-1f5a06b5030b"
      unitRef="U_USD">700000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_d58b91a6-8565-488e-b02e-ec025dddbb45"
      decimals="-6"
      id="F_470ba5f8-8f17-4200-a3c2-74c8d21f85e5"
      unitRef="U_USD">500000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_f007740c-c40f-4489-8fb4-025d2bc6fa15"
      decimals="-6"
      id="F_5fe48808-7ef7-47c2-89a8-7efc74574f4b"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable
      contextRef="C_cd35894d-35dd-488a-bba1-d0a7f771501b"
      decimals="-8"
      id="F_0f09668e-a0b7-493d-b389-c37bc134e774"
      unitRef="U_USD">1500000000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable>
    <alec:PercentageOfDevelopmentCost
      contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c"
      decimals="2"
      id="F_fc162dcc-44ea-4135-b283-a85ead5f7955"
      unitRef="U_pure">0.60</alec:PercentageOfDevelopmentCost>
    <alec:PercentageOfDevelopmentCost
      contextRef="C_a3c0dae0-748f-402b-8e0c-a163a0ca3e35"
      decimals="2"
      id="F_72aabac8-c882-45c3-bcaa-4db3646effcd"
      unitRef="U_pure">0.40</alec:PercentageOfDevelopmentCost>
    <alec:CompanyMaximumFunding
      contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d"
      decimals="-5"
      id="F_fc39b075-0114-4b63-ad7f-f756b05741f2"
      unitRef="U_USD">140500000</alec:CompanyMaximumFunding>
    <alec:TransactionsPrice
      contextRef="C_b63dbca3-4067-43b5-ab54-c12f0d45646c"
      decimals="-6"
      id="F_bc046671-54f8-415b-8772-da08c615ca66"
      unitRef="U_USD">700000000</alec:TransactionsPrice>
    <alec:TransactionsPrice
      contextRef="C_0c6c34c3-6684-47c0-932c-32afe31b92fb"
      decimals="-5"
      id="F_797aaa32-05a5-43c3-b1fe-c304a85d51fa"
      unitRef="U_USD">571600000</alec:TransactionsPrice>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="C_fe95f1f3-8845-4196-a35b-577d8188b3b5"
      decimals="-5"
      id="F_a02787ce-8e1c-44d9-b3cd-fe698972f988"
      unitRef="U_USD">128400000</us-gaap:ContractWithCustomerRefundLiability>
    <alec:CompanyMaximumFunding
      contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d"
      decimals="-5"
      id="F_ed3b3188-c44b-4e0f-9db8-c82d065b5ee4"
      unitRef="U_USD">140500000</alec:CompanyMaximumFunding>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_5b34c8be-a3ff-4f6b-a5ca-33885b1be64d"
      decimals="-5"
      id="F_fecb209b-ee2a-4c5c-ae3b-7ebfb7d4845e"
      unitRef="U_USD">26900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <alec:ReductionInTransactionPrice
      contextRef="C_4e1505fa-8544-4458-96c7-53104f4fe63f"
      decimals="-5"
      id="F_da629269-a443-44f0-b158-340516816328"
      unitRef="U_USD">4200000</alec:ReductionInTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_eba99dec-98b2-45c0-9d27-7d9f74ea5672"
      decimals="-5"
      id="F_68d9cfdc-9a7c-43eb-84f0-0dcb95b4c3bb"
      unitRef="U_USD">4900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c"
      decimals="-6"
      id="F_72eab347-0817-4479-a99a-29590036ba2e"
      unitRef="U_USD">700000000</alec:CollaborativeArrangementUpfrontPayments>
    <alec:TransactionsPrice
      contextRef="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4"
      decimals="-5"
      id="F_53e9608b-4ced-4f49-992b-bbd513e9c8a0"
      unitRef="U_USD">569000000</alec:TransactionsPrice>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="C_d28c5140-6e95-49fb-9fb1-c9575190d7b4"
      decimals="-5"
      id="F_90aeab9c-becb-4d2c-a89c-b60b3005ff29"
      unitRef="U_USD">106500000</us-gaap:ContractWithCustomerRefundLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c"
      decimals="-5"
      id="F_bae43c79-41e9-4d24-8aae-870ebbf28d37"
      unitRef="U_USD">66600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c5787191-0ee2-419a-98e0-6bb30e57cb15"
      decimals="-5"
      id="F_391b344d-5128-4eb5-8e98-95b8711be736"
      unitRef="U_USD">62900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_1e4ce16a-1c4e-4c58-b395-a14509909bf4"
      decimals="-5"
      id="F_d51efe6b-6891-4bac-87be-656cfd524738"
      unitRef="U_USD">247400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_dc034315-cf03-4581-b437-e478d0086352"
      decimals="-5"
      id="F_01e39f59-eba3-4919-a102-374efaf7cb01"
      unitRef="U_USD">444900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2ba9b64f-d373-4d84-929c-816017c4d96c"
      decimals="-5"
      id="F_2dc2375f-a006-490f-9d54-40fddc002ab0"
      unitRef="U_USD">21800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c5787191-0ee2-419a-98e0-6bb30e57cb15"
      decimals="-5"
      id="F_2fbddcfe-df11-4937-91ca-1f8de6f0da4a"
      unitRef="U_USD">14700000</us-gaap:ResearchAndDevelopmentExpense>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9"
      decimals="-5"
      id="F_f7295bd1-c7ad-4a77-b1c0-4b3b3a43dc1f"
      unitRef="U_USD">205000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9"
      decimals="-5"
      id="F_45f77712-f606-4bf0-8180-1ff53b07f23b"
      unitRef="U_USD">5000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_c1f0c7a7-e180-4765-8b37-912035434a8f"
      decimals="-5"
      id="F_0e170a36-a929-454f-85c9-d839a5f3d2d7"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram
      contextRef="C_dbfb3835-28fe-4139-9939-85de4a95d6c9"
      decimals="-5"
      id="F_06c24adb-6191-43e0-b521-3f6a16bf77cb"
      unitRef="U_USD">250000000</alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable
      contextRef="C_f69c2b26-8b9d-489b-a357-6baf4bc970c6"
      decimals="-5"
      id="F_9690e958-133d-4ec1-a7d3-a083cf09dbad"
      unitRef="U_USD">225000000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_cf80a4f5-ee57-4865-a16e-612cda395dcc"
      decimals="-5"
      id="F_06f1ea26-de03-458b-a2d6-07116241e31c"
      unitRef="U_USD">17800000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable
      contextRef="C_5eeb6d5e-07f7-4d7a-9ae5-040a3397c88c"
      decimals="-5"
      id="F_221ee0d0-8f44-45a5-a743-9bd0a74d8e1d"
      unitRef="U_USD">12500000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_19b8748c-94f6-4009-ae46-72a683ffb30c"
      decimals="-5"
      id="F_a07abf71-8d95-47a4-a60c-8a8a758e6e23"
      unitRef="U_USD">5700000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable
      contextRef="C_7151cd96-2161-4092-af10-bd88188169e1"
      decimals="-5"
      id="F_23b14fd5-b799-4b1e-a710-81b549d9ee26"
      unitRef="U_USD">6800000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivable>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa"
      decimals="-5"
      id="F_74425371-1699-4e8a-9edd-480d6f9d6f2a"
      unitRef="U_USD">205000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa"
      decimals="-5"
      id="F_0f30db99-8427-4319-88eb-2282b78dab82"
      unitRef="U_USD">17800000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients
      contextRef="C_7151cd96-2161-4092-af10-bd88188169e1"
      decimals="-5"
      id="F_ae54ea44-1a97-46c2-aad7-300d69c6bf43"
      unitRef="U_USD">12500000</alec:CollaborativeArrangementMilestonePaymentsForEnrollmentOfAdditionalPatients>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_4376117b-bb1e-48ea-a7cd-9467af82b1aa"
      decimals="-5"
      id="F_07b06e8f-0a7c-435f-a5a2-01417c02e55e"
      unitRef="U_USD">30500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_95c548cd-02a1-4c12-93cb-ea44937aa4a8"
      decimals="-5"
      id="F_515e87ae-0611-4d26-bfee-65a59e8c26f7"
      unitRef="U_USD">10900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_85f03d7f-58f4-427b-a31f-ee0c4a55e9ed"
      decimals="-5"
      id="F_feafd067-1e21-478b-a8f8-0ca28e56a974"
      unitRef="U_USD">70700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_e926ae33-adab-44c6-9813-d90466e7d1d6"
      decimals="-5"
      id="F_371db0b9-e291-4bdc-877f-fd9c23694bdc"
      unitRef="U_USD">14900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_7151cd96-2161-4092-af10-bd88188169e1"
      decimals="-5"
      id="F_a6b046a4-f5ad-46c4-a0c9-3f8858daa631"
      unitRef="U_USD">46400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_79cee874-ca87-430e-8f98-93d2c63bf411"
      decimals="-5"
      id="F_9e61967c-04e9-4a36-9e29-ed39e8205b73"
      unitRef="U_USD">46700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_cb2ceb58-993f-4c64-971f-3a45bbb0805a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.       Balance Sheet Components&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.333%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_3cf6f6ed-166e-49d1-a2eb-69243a54220d">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.333%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.503%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_758a9e1c-3654-4bc4-a4b7-e7f816f49088"
      decimals="-3"
      id="F_5c7897be-12ed-415f-9b04-cd135d251916"
      unitRef="U_USD">2372000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b2f18b21-9cde-4c57-b478-19cc995431ea"
      decimals="-3"
      id="F_95f2529e-f5fb-4aae-befb-88cc708cc202"
      unitRef="U_USD">2310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f5b536d9-fa13-474e-a41d-356bbdb5ca40"
      decimals="-3"
      id="F_6728873e-7f16-44d7-a5e3-068bd859c3f8"
      unitRef="U_USD">2430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f68b6d3e-af72-4397-a93c-d21976f8b5eb"
      decimals="-3"
      id="F_bb53466a-6cfe-45c8-9cd9-57ec71e4fdea"
      unitRef="U_USD">2430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fddc05c2-32c9-4c4e-b1bc-8af85e42859f"
      decimals="-3"
      id="F_451fa208-dd18-413a-acb3-56eeb89768a2"
      unitRef="U_USD">18493000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6d33b68e-2d8d-4bba-8c12-cc5befb5c40e"
      decimals="-3"
      id="F_beaf7c1b-c34e-449d-9657-5f1ab3e47a85"
      unitRef="U_USD">17165000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2576a651-9ed1-4183-b092-abc05d49d737"
      decimals="-3"
      id="F_5f2d33a9-6e5d-46a3-bf1e-a9654182e564"
      unitRef="U_USD">26616000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f0628b57-6af6-4f3a-a678-5f72c4012bd8"
      decimals="-3"
      id="F_830d65ec-7e82-441a-a9f8-9d5ba885252f"
      unitRef="U_USD">26228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a744f03b-fdcd-4316-8068-2d334121371a"
      unitRef="U_USD">49911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3985ab15-d9c9-469a-8706-dd1205229d79"
      unitRef="U_USD">48133000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_33f87e00-6e7f-4d85-9975-c12c78b55835"
      unitRef="U_USD">28050000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_b7c2eb27-ba74-4355-b7c9-91b2ff7377f5"
      unitRef="U_USD">22612000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a0676479-5ce0-4395-9a22-6f213ac2c0cc"
      unitRef="U_USD">21861000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_98b88ff3-444b-47e5-9a48-b73eba727d04"
      unitRef="U_USD">25521000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_bc9dcf3c-2386-4a95-a26b-0f4bdc997085">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <alec:AccruedResearchAndDevelopmentCosts
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_d6c90006-3cd1-48ce-998d-52e539d4e8b2"
      unitRef="U_USD">13539000</alec:AccruedResearchAndDevelopmentCosts>
    <alec:AccruedResearchAndDevelopmentCosts
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_ea6bcf5e-7f14-4363-84b2-7bd7d3563658"
      unitRef="U_USD">12321000</alec:AccruedResearchAndDevelopmentCosts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_13cdf8a2-a8e1-49b1-9ae1-7c06879c3dfa"
      unitRef="U_USD">15297000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_fd0912bb-2bc6-40ec-81ff-10e37c72b2fd"
      unitRef="U_USD">12758000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_c9584ed5-0707-4e46-8caa-3cf79a476fb6"
      unitRef="U_USD">1119000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_292ddcce-d126-4e4a-bcef-a317b7226815"
      unitRef="U_USD">1983000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_344ad03e-4877-4a2c-a32c-384e973fe458"
      unitRef="U_USD">423000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_77eeb080-14be-4029-9cc2-f0c0c1284dad"
      unitRef="U_USD">709000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_65c71b88-21f6-4644-a2b8-03126e1a01f9"
      unitRef="U_USD">30378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_be175ab1-2187-4938-9854-84bce9db0e10"
      unitRef="U_USD">27771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_76903a84-9baf-44d9-9bda-ab53e7d26324">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.      Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2018, the Company signed a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in office and laboratory space in South San Francisco which serves as the Company&#x2019;s headquarters (the Headquarters). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with an option to renew for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The landlord paid for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company signed a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space in Newark, California. The lease term ends on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 6, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with an option to extend for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The landlord is obligated to pay for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of tenant improvements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;measurement of the lease liabilities for the leases excludes the options to extend the term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#x2019;s leases consist of operating expenses for the spaces.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2019, the Company entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of the Headquarters, which was amended to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in December 2020. This Sublease expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the Company entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of the Headquarters, which was amended in May 2022 to include an additional space of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet. The 7,100 square feet of space subleased expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the additional space of 13,150 expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In October 2023, the Company entered into a second amendment to sublease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of the Headquarters. This sublease will expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;November 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, the Company entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,300&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of the Headquarters. This sublease will expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The sublessee pays its proportionate share of operating expenses for the space.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.91%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income and reimbursement of variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the weighted-average remaining lease term for operating leases was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and the weighted-average discount rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. Cash paid for amounts included in the measurement of lease liabilities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, 2022, and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following are the lease payments owed under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <alec:AreaOfPropertyInLease
      contextRef="C_4aa98c31-3185-40ce-8dd2-7ce79a8cd6e4"
      decimals="0"
      id="F_52f2f1f9-9134-4d6a-bbaa-70de9b7d6cd7"
      unitRef="U_sqft">105000</alec:AreaOfPropertyInLease>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_53d34142-8702-4156-a042-b2693ebb016c">The lease expires in 2029 with an option to renew for a period of ten years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <alec:LeaseExpirationYear
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7a358262-0d14-4257-9fb3-cb9034a11bae">2029</alec:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      id="F_c5f4b335-f768-436d-842e-ecfbce3522d3">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_acc458ea-fb09-43a4-ace2-5afee4642294"
      decimals="-5"
      id="F_d1fe80a5-d87a-40ec-b74d-f0123fe19940"
      unitRef="U_USD">15700000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_a592cf4d-5bd2-49f3-b156-93e62c8123f1"
      unitRef="U_USD">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_56217c44-9068-48a9-bd55-ca120578b623"
      id="F_d042c5df-1e07-4909-924e-8431fed8f88f">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4"
      decimals="0"
      id="F_1db2aee0-0eab-4898-a64d-ce0edf9ab4ad"
      unitRef="U_sqft">18700</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f"
      id="F_40d930f7-a3d2-4caa-b7cd-d4bb60378ead">2028-02-06</us-gaap:LeaseExpirationDate1>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="C_4eef05e8-f717-4531-bf0e-d08a2bb002f4"
      id="F_7c33028d-69c5-48bc-bc3c-6040d40fa9ab">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_d90f94b7-29f1-4a51-a99a-1a15f28c7d0f"
      decimals="-5"
      id="F_bff9ff4a-c71c-4dd0-8112-1e05fbbeb0ce"
      unitRef="U_USD">400000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <alec:AreaOfPropertyInSubleaseAgreement
      contextRef="C_d3eeb729-bc22-498d-881c-1db3ed88b394"
      decimals="0"
      id="F_78da1d95-2b6f-4d21-9493-df4c5a317c3d"
      unitRef="U_sqft">25000</alec:AreaOfPropertyInSubleaseAgreement>
    <alec:AreaOfPropertyInLease
      contextRef="C_e0b4d8d2-f8bb-40b4-9f9f-b389737a0383"
      decimals="0"
      id="F_731c68a2-fa14-4b19-a4de-c733e70f1c3b"
      unitRef="U_sqft">23600</alec:AreaOfPropertyInLease>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_340e1b04-fc2d-4614-bea3-759221ffd38e"
      id="F_ad8ddee3-5a1a-4fa2-9677-dab8a9da534c">2021-11</alec:SubleaseExpirationMonthAndYear>
    <alec:AreaOfPropertyInSubleaseAgreement
      contextRef="C_762e850e-ccde-406e-bb94-80d9fd84a94a"
      decimals="0"
      id="F_24705bf3-888c-45da-81a0-d26dc8634e01"
      unitRef="U_sqft">7100</alec:AreaOfPropertyInSubleaseAgreement>
    <alec:AdditionalAreaOfPropertyInLease
      contextRef="C_536c635f-d92f-46c9-b598-60cb1e600887"
      decimals="0"
      id="F_ccff41ee-5bce-4a32-a046-39c7bdce5972"
      unitRef="U_sqft">13150</alec:AdditionalAreaOfPropertyInLease>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_cd300ca0-d7c3-41f0-bc1c-51337ae1c160"
      id="F_70d92b72-f4a7-420d-b9c8-c11e455abbdb">2022-12</alec:SubleaseExpirationMonthAndYear>
    <alec:AdditionalAreaSubleaseExpirationMonthAndYear
      contextRef="C_e1cbc65c-39be-40d5-94a2-085b20c52e97"
      id="F_d9e1f96e-b5f3-4559-902e-2be2889a57df">2023-11</alec:AdditionalAreaSubleaseExpirationMonthAndYear>
    <alec:AdditionalAreaOfPropertyInLease
      contextRef="C_fcade9bc-91eb-4e33-86f9-9e6dd66a7393"
      decimals="0"
      id="F_d35bcc1f-a4ff-457e-9ff6-31f4bd0a8165"
      unitRef="U_sqft">13250</alec:AdditionalAreaOfPropertyInLease>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_18e12969-87bd-493d-8d25-859c9cbffa99"
      id="F_751e73a7-cb2f-4cfe-808e-c49eaec68888">2024-11</alec:SubleaseExpirationMonthAndYear>
    <alec:AreaOfPropertyInSubleaseAgreement
      contextRef="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53"
      decimals="0"
      id="F_6c38c6ec-0efc-4e23-adf9-7b96b9b8536e"
      unitRef="U_sqft">9300</alec:AreaOfPropertyInSubleaseAgreement>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_7670ce5a-d097-4cf5-b9b1-1c19a64bad53"
      id="F_37e97f10-2923-4ff5-bdae-4735d552da31">2025-02</alec:SubleaseExpirationMonthAndYear>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_0b6a2d95-c49f-405d-bc8b-10a3ccb93377">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.91%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.74%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.957%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income and reimbursement of variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_359f2657-f92d-4b63-9532-0056e144ce85"
      unitRef="U_USD">6626000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_7817613e-98f4-43c4-9376-edba9abe1b24"
      unitRef="U_USD">6638000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_76d1e43b-2dc9-4beb-a0bb-e6261bc274ff"
      unitRef="U_USD">6204000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_2569333e-f406-4387-b85c-108b903be4a4"
      unitRef="U_USD">3149000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f88ff287-9f52-44f9-b8be-51a9a45fa3e9"
      unitRef="U_USD">2785000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_1febc256-e6f4-4f30-b2bd-7fc758d82538"
      unitRef="U_USD">3046000</us-gaap:VariableLeaseCost>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_edb274a5-3163-4649-acc9-a86d6627a964"
      unitRef="U_USD">2482000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_2c3091aa-f43f-4a2d-9f69-c7966027f818"
      unitRef="U_USD">1872000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_3659c93c-8dd0-46c0-975a-26ac59198316"
      unitRef="U_USD">2141000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <us-gaap:LeaseCost
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_ad0bc337-076c-46ab-8478-08705de1899e"
      unitRef="U_USD">7293000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_0d690518-e084-4ab3-aed2-f04476941a2e"
      unitRef="U_USD">7551000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_a4c77a8b-c012-4320-b773-d158a3af03c6"
      unitRef="U_USD">7109000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      id="F_c61c54be-0ff5-4522-9928-4e4ca68d11bd">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="3"
      id="F_8f6edc5a-19d3-4679-9c64-dbed4b7c4fce"
      unitRef="U_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_5432ed7e-28a7-47a8-86de-2470e38fcfb7"
      unitRef="U_USD">8400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-5"
      id="F_e717465f-27c7-41f2-80a0-47f8f50540bd"
      unitRef="U_USD">8200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-5"
      id="F_07876fb8-9bd2-4cdf-925b-dbeb6c4d1f35"
      unitRef="U_USD">7900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_166a2b71-2e10-49c4-bc73-ef42d8533228">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following are the lease payments owed under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_2b415f72-b9b9-4d10-afcc-ce96214ae2ba"
      unitRef="U_USD">8855000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a8c537a4-f357-4024-896b-f676d4acdeb5"
      unitRef="U_USD">9161000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_af4f04f7-4817-4d33-8bd6-a2f4190469d7"
      unitRef="U_USD">9477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_66c687e5-4b99-452d-8020-e3f46ece59cf"
      unitRef="U_USD">9804000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_1e867a85-6d07-4abe-99cb-54c00e7e69b7"
      unitRef="U_USD">8969000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_d4f90432-6168-4765-88d2-8004439b0b0a"
      unitRef="U_USD">2209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_6c462149-ddb9-4834-802c-e144c091904c"
      unitRef="U_USD">48475000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_dfb0db10-d4b3-4df0-adcc-16bb558ce122"
      unitRef="U_USD">9557000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_0d25b719-2bf6-48d8-b718-4c784377c16c"
      unitRef="U_USD">38918000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7ad8c8a5-1f74-4fff-8712-455b0bd9c304">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.       Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated grant-date fair value of all the Company&#x2019;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.022%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#x2019;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Equity Incentive Plan and 2022 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#x2019;s employees, directors, and consultants. The Company&#x2019;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or more of the outstanding shares, the exercise price of each share shall be at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value and the term of the award shall not exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The stock options generally vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period with one forty-eighth of the shares vesting each month or over a four-year period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% vesting at the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2023, the Company added &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,144,785&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,018,705&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock under the 2019 Plan, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,579,341&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were available for issuance of future awards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,630,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,407,389&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were available for issuance of future awards under the Inducement Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Option activity is shown below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,996,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,628,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;132,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,057,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,467,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31,&lt;br/&gt;&#160;&#160;&#160;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, 2022, and 2021, respectively. The weighted-average grant-date fair value per share of options granted was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized stock-based compensation related to unvested stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which the Company expects to recognize over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity for the RSUs is shown below.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the Company&#x2019;s stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;model &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to be amortized over an estimated weighted average service period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,539,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;414,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,142,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,584,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,092,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which the Company expects to recognize over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591,397&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in unrecognized compensation expense related to the 2019 ESPP expected to be recognized over five months.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_3d4074a4-78bf-4850-823a-161d249f9c88">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a6997d26-1cd1-493e-9c86-be8ab9f39310"
      decimals="-3"
      id="F_d9371c98-d392-4917-bcda-53f5176d1bf8"
      unitRef="U_USD">22407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_21a83cdc-0b37-49af-9a68-60f9ffb64987"
      decimals="-3"
      id="F_a9c64394-f107-44df-b49f-84d02a98ca9f"
      unitRef="U_USD">24895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88135be7-53d0-4cfa-bfc7-18676d65fe75"
      decimals="-3"
      id="F_cf34ee28-476b-4af2-95fc-83d3d106ab70"
      unitRef="U_USD">21443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d2bb0f40-e78b-430e-9753-abc94b48fdb0"
      decimals="-3"
      id="F_b389493e-0ab3-4b1d-b2fe-66e5790befe4"
      unitRef="U_USD">20391000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_70243292-8d4b-4f56-b852-1e89e77c7444"
      decimals="-3"
      id="F_d85be3f5-50c2-4a08-b72f-5705e2e86aef"
      unitRef="U_USD">21251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_44344e5d-5a1c-404e-8607-c5de69163711"
      decimals="-3"
      id="F_c2ba09ab-ff75-436c-ad65-b680a25f31b0"
      unitRef="U_USD">19342000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_b0d5987b-0dfe-42e0-8e37-0b7ba8941bcf"
      unitRef="U_USD">42798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_76e0683d-f25c-40a7-b662-f87258c34072"
      unitRef="U_USD">46146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_1b8dcac8-16e8-4771-88ad-383459fdc7f4"
      unitRef="U_USD">40785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_c20ad7d3-6143-445c-a305-27fff31c85e8">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated grant-date fair value of all the Company&#x2019;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.022%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.793%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_52035361-b24c-4755-ad7a-e82a0d8ebc06"
      id="F_e71bbef9-8ff6-4894-8270-41777d39eb6e">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5faa559f-1d59-40e4-a7d3-52eebb14274c"
      id="F_a63e3016-0ca3-4257-824f-e0c33db8d22b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ef477b10-b2f5-419c-9069-8dd0afc677f6"
      id="F_a47ff1ab-a858-474a-b3e8-e2317f116a17">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a10ce102-5713-4bf0-a2c5-da99484f0103"
      id="F_3bb86d5c-a534-4e6b-a48f-e54e82c41d90">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6ac7c560-3741-425b-922a-fa6377eceda5"
      id="F_dc96d455-b615-46e5-8ed3-562e320ad116">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3aa9e816-d1a0-4625-9af0-5128da3a9209"
      id="F_b875a4be-8c0c-4402-8662-6514d6e4a9bc">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"
      decimals="2"
      id="F_e57c6547-fd79-499a-88e4-c07bdae11bd4"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"
      decimals="2"
      id="F_3e658f85-6d94-49a9-b164-8bbdc97a1f78"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"
      decimals="2"
      id="F_7147aee6-f6a5-4c6a-9fb8-0cbb1416136d"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"
      decimals="2"
      id="F_f6d13b8a-2a4c-4d2f-8adb-75fb9287c031"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f"
      decimals="2"
      id="F_2eeec05e-3cc6-403e-a488-d633b77f4b49"
      unitRef="U_pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f"
      decimals="2"
      id="F_0564cccc-8f74-4557-9452-77b75ca0ce5c"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"
      decimals="3"
      id="F_25ad1593-d703-4e7c-abda-a1620622255f"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"
      decimals="3"
      id="F_ba352a2e-c3e8-49a1-a0a5-4386bc2f4394"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"
      decimals="3"
      id="F_28add35c-ceb7-43a5-bfc4-962624680c2e"
      unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"
      decimals="3"
      id="F_a366774e-8b2c-4aab-aa4f-1867448b08cd"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f"
      decimals="3"
      id="F_59caf9c3-c559-41a4-8811-b28bde935e1f"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f"
      decimals="3"
      id="F_36569415-07da-4648-89f6-8bd231dd107b"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c98a4b8b-bbb8-4d34-a4d1-271f6c9b119b"
      decimals="2"
      id="F_67f118be-89d5-4995-9d85-345ef811774f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4c4c8bef-a2c0-4cee-9b79-01b5420fa464"
      decimals="2"
      id="F_edc95fc4-b148-40ea-8f25-930cac41e903"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c758acc5-763d-4c36-99d6-c281cf90a70f"
      decimals="2"
      id="F_7f7f4795-2d62-4434-8fe6-c0ee9458bb7c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <alec:PercentageOfStockOwnedByIndividual
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      decimals="2"
      id="F_a14863f8-d714-41ff-89c8-6831783adbff"
      unitRef="U_pure">0.10</alec:PercentageOfStockOwnedByIndividual>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      decimals="2"
      id="F_57fc2588-32ee-41d7-84cc-ee29a8644826"
      unitRef="U_pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      id="F_4ae5b1cc-15a9-4a87-bc65-3a36d61dadb0">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_ce453676-bced-4bc7-adfc-3a7dc2104ba3"
      id="F_b9f103fb-a0c5-4d75-ace4-4dedb773d407">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      id="F_591f2fa3-a532-4734-9c8d-7707cf55e6ed">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      decimals="2"
      id="F_df539d5a-9488-480e-9a74-e8c34aefb07f"
      unitRef="U_pure">0.25</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod
      contextRef="C_baab8074-6a4c-411b-b481-b273fda9f214"
      id="F_a5b51a69-e8a0-47c8-8177-e1e8e707ae85">P1Y</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b5b6de0c-0735-4356-9282-a70e9141c22d"
      decimals="INF"
      id="F_15249694-9da6-4bde-a964-9ca14a80ea65"
      unitRef="U_shares">4144785</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="INF"
      id="F_500ae604-5792-4b6e-aa8b-747ea6107654"
      unitRef="U_shares">23018705</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="INF"
      id="F_70f566c9-b685-46c2-9fe6-84f6cc373afd"
      unitRef="U_shares">6579341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0ea8a13b-a850-4902-bc14-e2a26e047915"
      decimals="INF"
      id="F_e1f7074b-8cbd-4f45-a801-fc13272058fc"
      unitRef="U_shares">1630000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_11e15bef-5569-498f-9263-fd8668b4e72c"
      decimals="INF"
      id="F_13aff6b6-eaa0-4b49-9462-27ecf1cfd0d8"
      unitRef="U_shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_324a6c7e-62a2-4eaf-a1db-f175723903c8"
      decimals="0"
      id="F_44ec9075-56f6-4bf8-b50c-368f22614fed"
      unitRef="U_shares">1407389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_a31533b7-ef61-46b9-9310-1a6ff8c2c1e6">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Option activity is shown below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,996,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;298,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,628,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;132,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,057,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,467,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31,&lt;br/&gt;&#160;&#160;&#160;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9"
      decimals="0"
      id="F_4bde0e80-e9d0-46d7-9bc8-7c2aceb07745"
      unitRef="U_shares">11644070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9"
      decimals="2"
      id="F_5267021b-ffa9-49eb-bce0-8b1d5ae1fa0a"
      unitRef="U_USDollarShare">16.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="0"
      id="F_9e875346-d0d2-4c2e-b85e-5f59417fa233"
      unitRef="U_shares">4996366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="2"
      id="F_5ea514d8-224c-43ea-bd19-0dfbec1eae2a"
      unitRef="U_USDollarShare">12.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="0"
      id="F_a585ee61-b1cf-4afc-8453-f9b540f6ed5e"
      unitRef="U_shares">298239</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="2"
      id="F_9c26fc4a-082e-46af-90af-f2af25de3e67"
      unitRef="U_USDollarShare">10.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="0"
      id="F_2219b036-8c25-4690-8210-95b9ecfcacd9"
      unitRef="U_shares">2628925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="2"
      id="F_53b0d008-a6f8-4e4b-888e-dfe204a610c3"
      unitRef="U_USDollarShare">18.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd"
      decimals="0"
      id="F_32ac6b07-f732-44f7-b4ec-568afe18340f"
      unitRef="U_shares">13713272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd"
      decimals="2"
      id="F_c3eafcec-ef3a-41eb-8830-224e90022460"
      unitRef="U_USDollarShare">14.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="0"
      id="F_fb35172c-ae81-4fd0-b60c-801d4e54d5e4"
      unitRef="U_shares">572538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="2"
      id="F_fc31a705-474e-4a13-8777-c3967b0508e9"
      unitRef="U_USDollarShare">6.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="0"
      id="F_0cb011f0-c081-4d95-b9a7-0bab7e008cc0"
      unitRef="U_shares">132192</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="2"
      id="F_732c39e8-6f6d-4fd4-ab7c-6c3766029356"
      unitRef="U_USDollarShare">8.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="0"
      id="F_d37bc6cb-4ecc-485d-ad57-ae3f7b249338"
      unitRef="U_shares">2057381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="2"
      id="F_125cdc61-8f42-4f96-9b8c-0d524464fae3"
      unitRef="U_USDollarShare">14.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="0"
      id="F_d1b1c8c3-05a7-4eae-bf75-d6c4524f7742"
      unitRef="U_shares">12096237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="2"
      id="F_9360d1bd-c9e0-40e2-b1d2-0ec5741c04e5"
      unitRef="U_USDollarShare">14.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      id="F_b94bfa86-dc4c-49ac-a299-d99562db1281">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="-3"
      id="F_f0692fbe-3ddb-40e9-bf81-550db86196b9"
      unitRef="U_USD">676000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="0"
      id="F_f1c39194-0e59-465f-881d-37dd7a7f9183"
      unitRef="U_shares">8467987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="2"
      id="F_9d9afe53-47b8-4a70-aaa9-709150165afc"
      unitRef="U_USDollarShare">14.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      id="F_c3741878-4b21-4534-bb06-d3138585575c">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="-3"
      id="F_e8ba0c04-d791-429b-a614-8374f7d1b53a"
      unitRef="U_USD">62000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="0"
      id="F_d0967323-2f79-47c7-8ce6-dccb02a2242f"
      unitRef="U_shares">12096237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="2"
      id="F_e5890d10-30ef-4265-aa87-4dc2a246d20d"
      unitRef="U_USDollarShare">14.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      id="F_937088a3-2e40-41a7-9fba-7e66f58fe9df">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="-3"
      id="F_885ea291-db9a-47ac-851b-78d5566f6ec3"
      unitRef="U_USD">676000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="-5"
      id="F_afcc776a-0712-400a-894d-c955165af361"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_8e75b2f4-4239-442d-88e3-f9885bf64bfd"
      decimals="-5"
      id="F_44be298f-fcc7-4553-b453-3195d8eb5327"
      unitRef="U_USD">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_6c1e2dfd-0dce-4f5a-8831-16f4616768e9"
      decimals="-5"
      id="F_4f623c0b-03d0-49ad-92b9-bc4dc3f58c23"
      unitRef="U_USD">37100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      decimals="2"
      id="F_aaffc3c9-35ab-424b-bce7-982d835078dd"
      unitRef="U_USDollarShare">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_91f1eafb-13c1-4e74-9bd9-2643413ab6fc"
      decimals="2"
      id="F_1881b278-8cd2-4d09-834b-fc9b90842500"
      unitRef="U_USDollarShare">8.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_18a6ec65-ac34-40f3-95e7-bfa2ffab6462"
      decimals="2"
      id="F_5eca23d4-e5b7-4c08-a2b1-05d305fa58c8"
      unitRef="U_USDollarShare">14.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_09823be7-67ec-450c-9c79-dcfb89cd3bdd"
      decimals="-5"
      id="F_8f07f965-9b03-43e3-aded-38ff7fb20653"
      unitRef="U_USD">32700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ae1394c7-4aed-4dda-8a2a-c51c62d3da1e"
      id="F_72bc0670-7242-4018-90ab-ac0221db2c9a">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_fcd8a87e-0a2b-4881-8d93-48685b0c6528">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity for the RSUs is shown below.&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,539,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;414,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,142,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,584,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units as of&lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,092,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue
      contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde"
      decimals="-5"
      id="F_d1b23363-4ab5-4f05-ad36-3d666ff3e260"
      unitRef="U_USD">6600000</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde"
      id="F_36e9de4c-5187-4f93-941c-22f2ca58ca7c">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0"
      decimals="0"
      id="F_45509eb7-98ef-4074-8b80-1fc53e998ae8"
      unitRef="U_shares">1373874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_17dd9f30-445c-4242-aa65-4afa4e70a2e0"
      decimals="2"
      id="F_a6b95ee8-a302-49fb-a885-2f295dec4eb8"
      unitRef="U_USDollarShare">18.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="0"
      id="F_c8e8b702-af49-473a-bfe3-8733ed612653"
      unitRef="U_shares">2539014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="2"
      id="F_4427e129-3741-492e-930e-47c488b00865"
      unitRef="U_USDollarShare">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="0"
      id="F_e5866d90-e8e7-45a5-afe4-b1c4b29eb1a2"
      unitRef="U_shares">414577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="2"
      id="F_aad39f61-f654-4d48-91f1-af84975f7fb5"
      unitRef="U_USDollarShare">18.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="0"
      id="F_f0313a14-5be5-447c-8145-34c5188adae9"
      unitRef="U_shares">453693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_16787d87-ace1-4e09-9ce1-9264b6480e93"
      decimals="2"
      id="F_cdbbec87-8b5d-474a-88b2-d7e482911b17"
      unitRef="U_USDollarShare">16.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6ad7b64a-0330-47d7-be46-238226e3cd18"
      decimals="0"
      id="F_91da485e-3a9c-4bdf-93f1-db10c27b5b9c"
      unitRef="U_shares">3044618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6ad7b64a-0330-47d7-be46-238226e3cd18"
      decimals="2"
      id="F_b05a0046-a799-4a09-8d26-e4c763d5aa56"
      unitRef="U_USDollarShare">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="0"
      id="F_ad14e123-f550-4a7b-995a-1a62b0136408"
      unitRef="U_shares">5142444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="2"
      id="F_239a0e6d-f194-4d9f-874f-6f9bc15bed17"
      unitRef="U_USDollarShare">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="0"
      id="F_c1a7a1cc-72c8-4a97-895f-2590fe2ee99d"
      unitRef="U_shares">1584448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="2"
      id="F_ce7da579-0cf4-404a-b3ed-aa9e9230f7e1"
      unitRef="U_USDollarShare">10.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="0"
      id="F_ff683623-1055-49bf-8435-8959105b3576"
      unitRef="U_shares">510513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_34b1db7c-6e16-43d3-bd5b-68502507a278"
      decimals="2"
      id="F_b8a3ca39-bbe0-4afd-b5d3-3d02bfafd37c"
      unitRef="U_USDollarShare">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe"
      decimals="0"
      id="F_329d428a-3d80-44f8-9d78-fb1b7c55ebe1"
      unitRef="U_shares">6092101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3c7af153-fc49-4dc7-9ef8-8a72160b5efe"
      decimals="2"
      id="F_a4fd32f3-d439-4d1d-bc2e-13903cd6649f"
      unitRef="U_USDollarShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_cbbafbf6-6ed4-4a1e-81cd-8fc78087cc1b"
      decimals="-5"
      id="F_743b9d24-b706-43e5-b41a-2a1ef9cb11d2"
      unitRef="U_USD">41500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_781e8b1b-18da-4c56-a6df-8621e45c8fde"
      id="F_e131c88c-5373-44fe-b74d-828bd25dc5a7">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <alec:SubsequentOfferingPeriod
      contextRef="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b"
      id="F_0d4b7a1d-421a-49e0-b62f-fc4335800a6d">P6M</alec:SubsequentOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="C_8ebbb4a4-6c80-43b9-a218-49a973d3e21b"
      decimals="2"
      id="F_62ae0bfc-b7ba-4b45-970c-01353afc63ae"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_063d5b29-5b06-4630-b2ef-ae848097335d"
      decimals="0"
      id="F_26ae0800-6fa6-4718-98fb-9b12e26f52f5"
      unitRef="U_shares">591397</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_fb621957-f8bc-47e9-9219-b82401bc112f"
      decimals="-5"
      id="F_a36f1b09-157c-4c30-9b0b-745683e844cd"
      unitRef="U_USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_3ac1e8bd-195b-4e2f-8ba9-50596e0b5d22">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.       Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The federal and state income tax provision for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.509%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits, net of uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&#x2019;s deferred tax assets and liabilities consist of (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.569%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.256%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.256%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Refund liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal and state net operating loss (NOL) carryforwards of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of taxable income. State NOL carryforwards will begin to expire as early as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, if not utilized, or have an indefinite life. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company also had federal and California tax credit carryforward of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The federal tax credits will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2041 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;while the California tax credits have no expiration date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#x2019;s ability to utilize NOL carryforwards may be limited as the result of such an &#x201c;ownership change.&#x201d; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the unrecognized tax benefits for uncertain tax positions as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company accrued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest and penalties for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, the Company recorded an uncertain tax position of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The income tax provision for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, included changes to reserves related to prior year uncertain tax provisions of an increase of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and decrease of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The income tax provision for the years ended December 31, 2022, included changes to reserves of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_af71143c-7f8d-4f5b-9ee2-3fe1e9889925">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The federal and state income tax provision for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.509%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_5c893011-286a-4400-aedc-ff2bcd19d0d4"
      unitRef="U_USD">4178000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_584f3e08-f0c2-44c3-b8a9-2e957f238443"
      unitRef="U_USD">2209000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_9b4b2135-af23-4912-af7b-daec3a0eb09f"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_7fb86099-a868-4036-a58a-2f86f6a47151"
      unitRef="U_USD">1034000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_12bbb2b2-2a97-4e6f-a273-cf2506f94a24"
      unitRef="U_USD">1045000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_c1f1c4ce-e83e-4023-8645-2dc732e13601"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_976ad369-ba03-4e8c-9354-ce1143895dff"
      unitRef="U_USD">5212000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f28f6c77-1730-4a30-b847-b6037cb26a45"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_e178c1f1-296d-47f1-ab07-95675739d4e9"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_f3891a55-8cd2-4444-a504-677030f4ed98">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits, net of uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_5f948a70-f8d2-46ac-9673-0fda707b958f"
      unitRef="U_USD">-26188000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_f8b6e810-cc1d-4177-a434-d1f3ae69b17f"
      unitRef="U_USD">-27205000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_9c8753e6-3afe-4cee-81cd-1590df2f6ffe"
      unitRef="U_USD">-7627000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_203dc7d0-24f0-4dcf-8f0e-03c5dec7f346"
      unitRef="U_USD">-431000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_43a70cab-d261-483a-b58b-3d8c7281c2fb"
      unitRef="U_USD">-344000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_b3b757cc-2c14-4a17-b569-5b17b4c9554c"
      unitRef="U_USD">398000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_cf4e8231-5830-4970-a36e-25eba37f6d37"
      unitRef="U_USD">14460000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_0a2644f7-f3b8-49ac-bc81-f301b6c84b01"
      unitRef="U_USD">15138000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_cfe5ee43-90c4-4821-bc6c-e179bf60340d"
      unitRef="U_USD">7042000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <alec:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_3d6ffa4b-21b4-4be5-b3cf-77e3a5a41f90"
      unitRef="U_USD">612000</alec:IncomeTaxReconciliationUncertainTaxPositions>
    <alec:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_0cf674ba-90e9-434f-b055-6d01257be7d6"
      unitRef="U_USD">2687000</alec:IncomeTaxReconciliationUncertainTaxPositions>
    <alec:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_3314d3d5-7ccd-4b48-b2d9-cd13a82ff7a7"
      unitRef="U_USD">0</alec:IncomeTaxReconciliationUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_0541edaa-c682-4d4a-8bfb-a8cd2f758044"
      unitRef="U_USD">4842000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_16e90e7e-082f-4f0d-9b6b-f1d22f29ed0c"
      unitRef="U_USD">4919000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_7a44266e-b61d-4797-b7f6-693be1da699e"
      unitRef="U_USD">-2368000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_a51411f6-e689-481d-b5d7-b96eb6ab9b05"
      unitRef="U_USD">40661000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_6f6be071-bb8f-4bd3-8318-9a805af3302d"
      unitRef="U_USD">38421000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_17bfd310-257b-4376-9d4a-efcb5720e9d2"
      unitRef="U_USD">16800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_3dd7cd25-d1ff-4146-8b2a-6fbdd32a8fd9"
      unitRef="U_USD">176000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_b8db7dae-1e76-4f9d-88df-ce10d6fbcf2e"
      unitRef="U_USD">-86000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_43a42ce9-cdf5-4460-ae4f-4dd9c7aff67b"
      unitRef="U_USD">-161000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_49fbc02b-5b1b-428f-aa16-691663715002"
      unitRef="U_USD">5212000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_6309b11e-c8ec-4997-86d0-4df1eedfde0a"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="-3"
      id="F_e0d73495-3177-4ec8-9dc5-7365b3a792fa"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_ed2e7f8c-edd0-4479-9329-76a315d3df6f">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&#x2019;s deferred tax assets and liabilities consist of (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.569%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.256%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.256%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Refund liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;164,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_ccc1fe73-8840-43ab-91c1-db1f4e6f8da3"
      unitRef="U_USD">12448000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_a24b11a8-4453-4bfc-ab41-9ab03041a587"
      unitRef="U_USD">20963000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_cf82c8cc-7a99-4452-9301-2d1a7071d89a"
      unitRef="U_USD">931000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_75fe4d04-7234-4a31-9b86-6529d44aae02"
      unitRef="U_USD">806000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_b36ae368-cde4-4bf3-bcbf-daa2b7169af7"
      unitRef="U_USD">26682000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3a4117e1-d3e1-4cf9-93e0-3409f6ae3cc1"
      unitRef="U_USD">26319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_b40deffa-575d-4f63-99f4-015cf332a187"
      unitRef="U_USD">15311000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_1246c3ba-3c5a-4ace-9276-65d3d86a757b"
      unitRef="U_USD">13351000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_1fce968f-daec-4c6b-a73e-ccb4cd8f905d"
      unitRef="U_USD">63004000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_127d006b-1225-4ff2-ba15-f1cdf81afe25"
      unitRef="U_USD">67673000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <alec:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_1d1d27fa-30f7-4e12-919c-599d07e4a942"
      unitRef="U_USD">9030000</alec:DeferredTaxAssetsLeaseLiabilities>
    <alec:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_32820d41-71d5-4e2a-a383-5291a3fb3389"
      unitRef="U_USD">10055000</alec:DeferredTaxAssetsLeaseLiabilities>
    <alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_71657bf4-cf31-468e-8f65-734f978b0ca8"
      unitRef="U_USD">62305000</alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_75a8cb70-51f1-4f33-9633-bb6ec606634b"
      unitRef="U_USD">35150000</alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <alec:DeferredTaxAssetsRefundLiability
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_ada38543-67de-4d4f-9c00-12461b404177"
      unitRef="U_USD">24707000</alec:DeferredTaxAssetsRefundLiability>
    <alec:DeferredTaxAssetsRefundLiability
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_3429d53d-401a-449a-b61b-d6cb2c630d25"
      unitRef="U_USD">0</alec:DeferredTaxAssetsRefundLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_d143fa75-ea34-47f8-8f35-9eba036bc8ce"
      unitRef="U_USD">521000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_bd44ae9e-0401-4e67-bbbe-3a8f04abc772"
      unitRef="U_USD">1608000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a1e971aa-34c8-4eca-940d-adb5cfdf8c2b"
      unitRef="U_USD">214939000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_778d7cb6-11c7-4e07-a2fd-c71c1298ae35"
      unitRef="U_USD">175925000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_ef2d38b6-fa29-4b99-86fc-66e38a6380d6"
      unitRef="U_USD">204550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_45d6b27a-a52b-499c-b24f-1985afea3fb8"
      unitRef="U_USD">164316000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_e3a4e553-cd6a-4787-82d4-d1ddb0665232"
      unitRef="U_USD">10389000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_9113c251-75f5-4c16-8a3d-18ea2b71f195"
      unitRef="U_USD">11609000</us-gaap:DeferredTaxAssetsNet>
    <alec:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_0b954c45-b4b6-4c30-a80a-6cd8f1e524ff"
      unitRef="U_USD">4544000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <alec:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_fcb30d16-5e35-40b7-a433-ae6fdbbda96c"
      unitRef="U_USD">5155000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <alec:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_2aee303c-fd98-4cf3-ac7d-a8f32ffdfc74"
      unitRef="U_USD">5845000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
    <alec:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_dcacf778-eb5f-4855-a337-c3825e0c6633"
      unitRef="U_USD">6454000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_2fbfb0b9-cffd-473e-af93-07364d0ca07d"
      unitRef="U_USD">10389000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_8acaea28-2f77-442f-841d-2423671081c4"
      unitRef="U_USD">11609000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_a1ce4303-d243-46ba-a8cc-f0709b3639ba"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_fd5d271b-ebd5-49a6-83ae-bfcd1b1e797d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_69442b42-0daa-45e6-8771-9db18cebf564"
      unitRef="U_USD">40200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_958166bd-8c6f-438a-9963-ca72620d9960"
      decimals="0"
      id="F_374aad23-a28d-4100-ba5f-f0ee94c0560c"
      unitRef="U_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f0b6fc05-c1a0-4504-91f0-023a1f8c2514"
      decimals="-5"
      id="F_84c3f9e5-c438-419a-b3ec-4abda3a36199"
      unitRef="U_USD">202200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="C_6c39aa66-67a0-4bc2-bb2d-dfaf63ec336a"
      decimals="2"
      id="F_71be9af3-3e3b-407d-9999-d702f510e054"
      unitRef="U_pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <alec:OperatingLossCarryforwardsBeginningExpirationYear
      contextRef="C_fb09fe55-8ca8-43e2-8bb6-54b263316207"
      id="F_21c53523-136f-489a-b16a-d382223368c0">2030</alec:OperatingLossCarryforwardsBeginningExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_958166bd-8c6f-438a-9963-ca72620d9960"
      decimals="-5"
      id="F_edf00e51-9673-4002-a9ef-a759c771a7f8"
      unitRef="U_USD">27100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_906aea5b-0c93-441f-993c-a2359ebc1e69"
      decimals="-5"
      id="F_cb4651d7-c3e5-49b6-8b37-3a43c6eac7ea"
      unitRef="U_USD">19300000</us-gaap:TaxCreditCarryforwardAmount>
    <alec:TaxCreditBeginningExpirationYear
      contextRef="C_cce98dde-1d02-4f46-a623-794fa3f11385"
      id="F_26059e8d-21de-4269-8eb4-1afffd02b0b3">2041</alec:TaxCreditBeginningExpirationYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_808a1ccf-b5b8-4ddd-8941-2ed115fcbb81">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022, and 2021 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_618c715a-60ae-467c-8c7b-117bc9bc8695"
      decimals="-3"
      id="F_7f6919fc-48ed-4332-bd31-e2d0fc3e841b"
      unitRef="U_USD">6939000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_1dd5aee9-9a3b-46b4-acce-ad33a1048a99"
      unitRef="U_USD">8199000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_cd9b5156-4a31-481b-b713-37aa7a33df0b"
      decimals="-3"
      id="F_4d70bf1a-a02b-4d46-b3c0-1912b25ab5be"
      unitRef="U_USD">15138000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_f933ec57-05dd-4bc0-b86c-8b41e24cbda4"
      unitRef="U_USD">594000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_bf9d970a-9983-473c-80af-0f79cfdb8686"
      unitRef="U_USD">2588000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-3"
      id="F_006d27a1-e176-4592-ab83-4f49243236da"
      unitRef="U_USD">3071000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-3"
      id="F_baf2ccbd-f3a5-4d9c-851d-d317117ce8ef"
      unitRef="U_USD">20203000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_a36d2b98-9ad7-4d5c-8fda-b4e7eb0f279b"
      unitRef="U_USD">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_860a356d-773c-4ffd-af09-0d78fd5f9968"
      unitRef="U_USD">5100000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-5"
      id="F_305071be-25f8-444a-9a42-26d6bbbd26ef"
      unitRef="U_USD">8200000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_fb88892c-387d-4fc4-a721-7b6effcb06bb"
      unitRef="U_USD">2600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_46cd614a-a385-4a02-b3b4-95a3f4eefe79"
      unitRef="U_USD">600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <alec:ReversalReservesOnUncertainTaxProvisions
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="-3"
      id="F_cf6d61b6-6c27-47c3-ad59-3e6a282f0181"
      unitRef="U_USD">0</alec:ReversalReservesOnUncertainTaxProvisions>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_bcbdd19d-eca8-472c-87b2-543a9002068d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.    Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#x2019;s development of antibodies optimized by Adimab in its AL003 program, which was terminated in June 2022. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies, the term of which was extended effective August 2022 (2019 Adimab Agreement). In December 2021, the Company signed another&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab Agreement expired and the Company did not exercise any option to carry forward any of the results. Tillman Gerngross, Ph.D, the Executive Chairman of the board of directors of Adimab is a co-founder and former director of Alector. Dr. Gerngross resigned as a member of the Company&#x2019;s board of directors, effective June 15, 2023. For the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur any expenses related to Adimab. For the years ended December 31, 2022, and 2021, the Company incurred expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued liabilities due to Adimab as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of any covered product candidates.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_d6321c67-3454-46af-9d81-b479594892c1"
      decimals="-3"
      id="F_22a3a975-5093-4dbe-bec1-f7baffca9eb6"
      unitRef="U_USD">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_1ef725d3-1855-48f2-ad32-868fd7a56f60"
      decimals="-5"
      id="F_83924d49-c748-480e-bd83-fc743b172102"
      unitRef="U_USD">200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_eb3c4f20-3132-4502-b703-ab8173a141fb"
      decimals="-5"
      id="F_aed9f82e-d6ea-4652-9e7e-3161305c657d"
      unitRef="U_USD">1000000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_e4f0eef7-e506-4530-aa5b-49d9c2e5fad8"
      decimals="-3"
      id="F_76de3884-676b-4159-9882-fc06a2211843"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_54cb7dea-1f14-46b8-a85c-4dea206dca63"
      decimals="-3"
      id="F_f831a205-ef98-443c-a4d6-aca2b8a10775"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_07a39965-c852-4478-81e7-bf2e5f1034ee">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11.     Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;&#160;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,092,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares committed under 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,348,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,925,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,088,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_85843a4b-f449-480b-9c95-91613d8c8d2e">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.645%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;&#160;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,092,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,096,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares committed under 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,348,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,925,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,088,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b441b445-cd74-4873-a003-e91cd23b0590"
      decimals="0"
      id="F_8f36b8e6-8660-441e-854b-7689df154a47"
      unitRef="U_shares">6092101</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_666e3ab2-8e5f-48ca-8ffa-0360410c200c"
      decimals="0"
      id="F_fbac6a61-ae95-4e80-bdcb-dea375cd3a4c"
      unitRef="U_shares">3044618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be19a186-b61e-4093-842b-37a052d70447"
      decimals="0"
      id="F_04f97d04-14a1-4f4c-b1c1-e9e952d627fe"
      unitRef="U_shares">1373874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c2ced522-2924-4199-8e43-04ab2c397ba4"
      decimals="0"
      id="F_af8e79ba-acba-4704-a2fe-6b6691375b62"
      unitRef="U_shares">12096237</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0a89ff33-c725-4439-ad8e-bf3568d41b8b"
      decimals="0"
      id="F_470e6e5c-dddf-4d7f-b0c3-4fbd1a12ae84"
      unitRef="U_shares">13713272</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ec43ac9d-d355-4fa2-9bd9-cf8e37006808"
      decimals="0"
      id="F_d2c6a884-02ec-4697-859f-0f6dfc09e36a"
      unitRef="U_shares">11644070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_52dc5672-fc66-4cee-a898-4ecac0b3d0bc"
      decimals="0"
      id="F_bc24859a-f601-4274-bfba-ef87f8989989"
      unitRef="U_shares">160356</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_90f3186a-3a7c-4ce6-bbc4-af5ab058188b"
      decimals="0"
      id="F_5d67a4ff-b12a-4253-9051-f06b9b9238f7"
      unitRef="U_shares">167133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3bb5d2cb-8240-469c-b215-b0ef522ac46c"
      decimals="0"
      id="F_023ea247-76dd-4fca-b847-72a2a49b5254"
      unitRef="U_shares">70406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="0"
      id="F_e068c4a6-fd25-4c44-90ab-f21c2484c842"
      unitRef="U_shares">18348694</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7b0589ed-f3ae-4fad-ac98-c221d8f17608"
      decimals="0"
      id="F_c83fae40-3529-4412-811a-20a517d144c2"
      unitRef="U_shares">16925023</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0473103a-2c31-4a58-83e1-238b77fc08f4"
      decimals="0"
      id="F_6d62760c-8333-430b-8a4d-f69a0c1c1125"
      unitRef="U_shares">13088350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_c82f8732-c50e-416f-a3d0-14e95ba8841f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.     Restructuring&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 28, 2023, the Company committed to a plan to reduce its workforce by approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to better align the Company&#x2019;s resources with its previously announced strategic prioritization of its late-stage progranulin and TREM2 immuno-neurology programs. The Company initiated a reduction in force impacting approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; employees across the organization effective March 29, 2023. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company incurred restructuring costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, primarily consisting of one-time charges related to the reduction in force, including personnel expenses such as salaries, one-time severance payments, and other benefits, which were included in operating expenses. Accrued liabilities associated with restructuring costs were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <alec:PercentageOfReductionInWorkforce
      contextRef="C_c0a79701-f609-4f39-8ea8-fa90332bbbba"
      decimals="2"
      id="F_03f3cd3e-b2d1-48e0-814d-1d4e1c7ff828"
      unitRef="U_pure">0.11</alec:PercentageOfReductionInWorkforce>
    <alec:NumberOfReductionInWorkforce
      contextRef="C_c4cbf91d-96bc-43ff-ae3a-304b48be2025"
      decimals="0"
      id="F_962306b4-1956-458a-a328-879460dda14a"
      unitRef="U_Employees">30</alec:NumberOfReductionInWorkforce>
    <us-gaap:RestructuringCharges
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      decimals="-5"
      id="F_00dc3abe-097f-40ee-9a74-496f69e18d0f"
      unitRef="U_USD">1700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve
      contextRef="C_331414b3-e237-427f-b014-b2fbd7be148d"
      decimals="-5"
      id="F_b4dccc74-9bcf-4bb5-82f2-b689160fd479"
      unitRef="U_USD">100000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_17eedfd5-6e27-419a-8fa7-463cd5c2f78c"
      id="F_7d6e7f34-0662-4884-98cb-08ff341ff60e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13.     Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 17, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company entered into an underwriting agreement with Cantor Fitzgerald &amp;amp; Co. (Cantor), relating to the issuance and sale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,869,566&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock at a price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; paid by Cantor. The Company also granted Cantor an option exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of the underwriting agreement to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,630,434&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. Aggregate gross proceeds from the offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering closed on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 19, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The option to purchase additional shares was not exercised by Cantor&lt;/span&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      id="F_898c754e-5974-46b2-9323-2434aef21382">2024-01-17</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      decimals="INF"
      id="F_9281cfb7-de61-4573-a3f0-d7fedf1220c8"
      unitRef="U_shares">10869566</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e5a08e1c-7661-4242-afc0-5a1579c71846"
      decimals="INF"
      id="F_3c5d5fb5-ea48-46b6-860a-7f13a95e4777"
      unitRef="U_USDollarShare">6.57</us-gaap:SaleOfStockPricePerShare>
    <alec:SaleOfStockOptionTerm
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      id="F_2178ea3d-8ad8-4c98-b74a-1de7f1e5ee08">P30D</alec:SaleOfStockOptionTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_a26230e7-fd18-41d7-8d63-f51a79aa854b"
      decimals="INF"
      id="F_9afda212-2338-476b-968f-825528bc1742"
      unitRef="U_shares">1630434</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      decimals="-5"
      id="F_582042ca-2d84-4079-8127-57f7c29b6b3c"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <alec:AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      decimals="-5"
      id="F_4d7be343-2bbc-478c-9d73-fd7f5d73cca0"
      unitRef="U_USD">3900000</alec:AmountOnUnderwritingDiscountsAndCommissionsAndOfferingExpenses>
    <alec:SaleOfStockClosingDate
      contextRef="C_cf866f8c-b3b1-42e3-83a6-a2fc0a8f97a2"
      id="F_4155abf3-8183-49b3-b8bf-63049460bc6b">2024-01-19</alec:SaleOfStockClosingDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983"
      id="F_56e2aac4-a0a2-4993-afc8-8ad09a3d06b6">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983"
      id="F_3eccdb5b-00cf-4251-96eb-73886f1fcddf">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983"
      id="F_10ef04ec-6e15-4b71-892c-89c05a58883f">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_a87639f8-76eb-442c-be84-1c45bb446983"
      id="F_6690e603-1e1d-486e-b0f8-6cea73c83e8a">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
